0000950170-24-12223910-Q Sarepta Therapeutics, Inc. 20241106202411061601291601291601290 0000950170-24-122239 10-Q 90 20240930 20241106 20241106 Sarepta Therapeutics, Inc. 0000873303 2834 930797222 DE 1231 10-Q 34 001-14895 241430778 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 Sarepta Therapuetics, Inc. 20120712 AVI BIOPHARMA INC 19980930 ANTIVIRALS INC 19970123 10-Q 1 srpt-20240930.htm 10-Q 10-Q Q3000087330312/31falsehttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberseven months0000873303us-gaap:CommonStockMember2023-04-012023-06-300000873303us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000873303srpt:RebatesMember2023-09-300000873303srpt:ElevidysMembercountry:US2023-01-012023-09-300000873303us-gaap:CommonStockMember2024-03-310000873303srpt:SupplyAgreementMember2024-07-012024-09-300000873303us-gaap:CommonStockMember2023-06-300000873303us-gaap:SalesRevenueNetMembersrpt:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-3000008733032023-09-300000873303us-gaap:FairValueInputsLevel3Membersrpt:StrategicEquityInvestmentsMember2024-09-300000873303us-gaap:FairValueInputsLevel2Membersrpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember2024-09-300000873303us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300000873303srpt:SupplyAgreementMembersrpt:RoyaltyRevenueMember2024-01-012024-09-300000873303srpt:ChargebacksMember2024-01-012024-09-300000873303us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2024-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000873303srpt:RebatesMember2022-12-3100008733032024-04-012024-06-300000873303srpt:PmoProductsMember2024-01-012024-09-300000873303us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000873303srpt:ElevidysMember2024-01-012024-09-300000873303srpt:ChargebacksMember2023-09-300000873303us-gaap:SalesRevenueNetMembersrpt:NoIndividualMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000873303us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2024-09-300000873303srpt:RebatesMember2023-12-310000873303us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000873303us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2024-09-300000873303us-gaap:CommonStockMember2024-07-012024-09-300000873303srpt:SupplyAgreementMembersrpt:ContractManufacturingRevenueMember2024-01-012024-09-300000873303srpt:CustomerFourMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310000873303us-gaap:AdditionalPaidInCapitalMember2024-06-300000873303us-gaap:RetainedEarningsMember2024-07-012024-09-300000873303us-gaap:CommonStockMember2024-04-012024-06-300000873303us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2023-12-310000873303srpt:SupplyAgreementMember2024-01-012024-09-300000873303srpt:CashDepositsAndMoneyMarketFundsMember2024-09-300000873303us-gaap:SalesRevenueNetMembersrpt:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300000873303srpt:CorporateBondsMember2024-09-300000873303us-gaap:FairValueInputsLevel1Member2023-12-310000873303srpt:RocheMemberus-gaap:CollaborativeArrangementMember2024-09-3000008733032024-07-012024-09-300000873303srpt:BedfordMassachusettsMember2024-01-012024-09-300000873303us-gaap:CommonStockMember2024-09-300000873303srpt:RocheMemberus-gaap:CollaborativeArrangementMember2023-07-012023-09-300000873303us-gaap:FairValueInputsLevel3Member2022-12-310000873303srpt:RebatesMember2024-09-300000873303srpt:OtherAccrualsMember2024-01-012024-09-300000873303srpt:MsRodinoKlapacMember2024-07-012024-09-300000873303us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000873303us-gaap:CorporateBondSecuritiesMember2023-12-310000873303us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000873303srpt:PmoProductsMembercountry:US2024-07-012024-09-300000873303srpt:RocheMemberus-gaap:CollaborativeArrangementMembersrpt:ElevidysMember2023-07-012023-09-300000873303srpt:BedfordMassachusettsMember2022-04-2200008733032023-12-310000873303srpt:TwoThousandSeventeenCappedCallsPartialSettlementMember2022-09-142022-09-140000873303us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300000873303srpt:CashDepositsAndMoneyMarketFundsMember2023-12-310000873303srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember2023-12-310000873303srpt:PromptPayMember2024-09-300000873303srpt:PrincipalMember2024-09-300000873303srpt:SupplyAgreementMembersrpt:RoyaltyRevenueMember2024-07-012024-09-300000873303us-gaap:FairValueInputsLevel3Membersrpt:CorporateBondsMember2023-12-310000873303srpt:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000873303us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000873303us-gaap:CashAndCashEquivalentsMember2024-09-300000873303srpt:RocheMemberus-gaap:CollaborativeArrangementMember2023-01-012023-09-300000873303srpt:TwoThousandTwentyFourNotesRepurchaseMember2024-01-012024-09-300000873303us-gaap:CollaborativeArrangementMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000873303srpt:EquityIncentivePlansMember2024-01-012024-09-300000873303us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembersrpt:CustomerThreeMember2023-01-012023-12-310000873303srpt:EquityIncentivePlansMember2023-01-012023-09-300000873303us-gaap:ConvertibleDebtSecuritiesMember2023-01-012023-09-300000873303us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000873303srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember2017-11-1400008733032024-09-3000008733032023-01-012023-09-300000873303us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000873303us-gaap:ConvertibleDebtSecuritiesMember2024-01-012024-09-300000873303us-gaap:FairValueInputsLevel1Membersrpt:CorporateBondsMember2023-12-310000873303srpt:PmoProductsMembercountry:US2023-01-012023-09-300000873303srpt:StrategicEquityInvestmentsMemberus-gaap:FairValueInputsLevel1Member2024-09-300000873303us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000873303us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000873303srpt:RebatesMember2024-01-012024-09-300000873303us-gaap:CashAndCashEquivalentsMember2023-12-310000873303srpt:BedfordMassachusettsMember2022-05-310000873303us-gaap:EmployeeStockOptionMember2024-07-012024-09-300000873303us-gaap:MoneyMarketFundsMember2023-12-310000873303srpt:RocheMemberus-gaap:CollaborativeArrangementMember2024-07-012024-09-300000873303us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300000873303srpt:OtherAccrualsMember2023-09-300000873303us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2024-09-300000873303us-gaap:FairValueInputsLevel3Member2023-09-300000873303us-gaap:RetainedEarningsMember2024-06-300000873303us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000873303srpt:PromptPayMember2022-12-310000873303us-gaap:SalesRevenueNetMembersrpt:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000873303us-gaap:CertificatesOfDepositMember2024-09-300000873303us-gaap:FairValueInputsLevel3Membersrpt:DerivativeAssetMember2024-09-3000008733032023-07-012023-09-300000873303srpt:BedfordMassachusettsMember2022-04-222022-04-220000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310000873303us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-09-300000873303srpt:TwoThousandAndTwentySevenSeniorConvertibleNotesMember2024-09-300000873303us-gaap:FairValueInputsLevel2Membersrpt:StrategicEquityInvestmentsMember2024-09-300000873303srpt:RebatesMember2023-01-012023-09-300000873303us-gaap:CertificatesOfDepositMember2023-12-310000873303srpt:OtherAccrualsMember2024-09-300000873303us-gaap:SalesRevenueNetMembersrpt:NoIndividualMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300000873303us-gaap:CommonStockMember2024-06-300000873303srpt:RestrictedStockAndRestrictedStockUnitsRSUsMember2024-07-012024-09-300000873303srpt:BedfordMassachusettsMember2024-08-012024-08-310000873303srpt:RocheMemberus-gaap:CollaborativeArrangementMembersrpt:ElevidysMember2023-01-012023-09-300000873303us-gaap:SalesRevenueNetMembersrpt:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300000873303srpt:TwoThousandSeventeenCappedCallTransactionsMember2024-01-012024-09-300000873303srpt:RestrictedStockAndRestrictedStockUnitsRSUsMember2023-01-012023-09-300000873303us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310000873303srpt:StrategicEquityInvestmentsMember2023-12-310000873303srpt:PmoProductsMembercountry:US2024-01-012024-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-04-012023-06-30000087330320232023-12-310000873303us-gaap:CollaborativeArrangementMember2024-07-012024-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-06-300000873303us-gaap:FairValueInputsLevel3Member2024-09-300000873303us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2023-12-310000873303us-gaap:CollaborativeArrangementMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000873303us-gaap:AdditionalPaidInCapitalMember2023-12-310000873303us-gaap:FairValueInputsLevel2Member2023-12-310000873303us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembersrpt:CustomerThreeMember2024-01-012024-09-300000873303us-gaap:RetainedEarningsMember2024-01-012024-03-310000873303srpt:DerivativeAssetMember2024-09-300000873303us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000873303us-gaap:CollaborativeArrangementMember2023-01-012023-09-300000873303srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember2024-06-300000873303us-gaap:RetainedEarningsMember2024-09-300000873303us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300000873303srpt:SupplyAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000873303srpt:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310000873303us-gaap:CommonStockMember2023-12-310000873303srpt:RestOfWorldMembersrpt:PmoProductsMember2024-07-012024-09-300000873303srpt:ConvertibleDebtAndTermLoanAndRevolverAndMortgageLoansMember2023-12-310000873303us-gaap:FairValueInputsLevel3Membersrpt:StrategicEquityInvestmentsMember2023-12-310000873303srpt:CorporateBondsMember2023-12-310000873303us-gaap:CommercialPaperMember2023-12-310000873303srpt:StrategicEquityInvestmentsMember2024-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300000873303us-gaap:CommonStockMember2023-07-012023-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300000873303srpt:FirstInstallmentsMember2024-01-012024-03-310000873303srpt:BedfordMassachusettsMember2024-09-300000873303us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000873303srpt:RestOfWorldMembersrpt:PmoProductsMember2024-01-012024-09-300000873303us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-12-3100008733032024-01-012024-03-310000873303srpt:BedfordMassachusettsMember2023-05-012023-05-3100008733032022-12-310000873303srpt:NonCurrentInvestmentsMember2024-09-300000873303us-gaap:RetainedEarningsMember2022-12-310000873303srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember2017-11-132017-11-1400008733032023-03-310000873303us-gaap:FairValueInputsLevel2Member2024-09-300000873303us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2024-09-300000873303us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2023-12-310000873303srpt:PromptPayMember2023-12-310000873303us-gaap:RetainedEarningsMember2023-06-300000873303us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-310000873303srpt:InterestMember2024-09-300000873303us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310000873303us-gaap:CommonStockMember2022-12-310000873303us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000873303us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2024-09-300000873303srpt:ChargebacksMember2022-12-310000873303us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2024-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-07-012023-09-300000873303srpt:RestOfWorldMembersrpt:PmoProductsMember2023-01-012023-09-300000873303srpt:ElevidysMember2024-07-012024-09-300000873303us-gaap:RetainedEarningsMember2023-07-012023-09-300000873303us-gaap:CommercialPaperMember2024-09-300000873303us-gaap:FairValueInputsLevel1Membersrpt:CorporateBondsMember2024-09-300000873303srpt:PromptPayMember2023-09-300000873303us-gaap:CommercialPaperMember2023-12-310000873303srpt:RocheMemberus-gaap:CollaborativeArrangementMember2023-12-310000873303us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300000873303us-gaap:CollaborativeArrangementMember2024-01-012024-09-300000873303us-gaap:RetainedEarningsMember2023-03-310000873303srpt:ElevidysMembercountry:US2024-01-012024-09-300000873303srpt:TwoThousandAndTwentySevenSeniorConvertibleNotesMember2023-12-310000873303srpt:TwoThousandTwentyFourNotesRepurchaseMember2024-09-300000873303srpt:ConvertibleDebtAndTermLoanAndRevolverAndMortgageLoansMember2024-09-300000873303srpt:PmoProductsMember2023-01-012023-09-300000873303us-gaap:CertificatesOfDepositMember2024-09-300000873303us-gaap:RetainedEarningsMember2023-12-310000873303us-gaap:SalesRevenueNetMembersrpt:NoIndividualMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-3000008733032023-01-012023-03-310000873303srpt:ThermoFisherScientificIncorporationMembersrpt:RocheAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000873303us-gaap:SalesRevenueNetMembersrpt:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300000873303srpt:LacertaTherapeuticsIncMember2023-09-300000873303us-gaap:CommonStockMember2023-03-310000873303us-gaap:ShortTermInvestmentsMember2023-12-310000873303us-gaap:FairValueInputsLevel1Member2024-09-300000873303us-gaap:FairValueInputsLevel2Membersrpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember2024-01-012024-09-300000873303us-gaap:FairValueInputsLevel3Membersrpt:CorporateBondsMember2024-09-300000873303srpt:ElevidysMembercountry:US2023-07-012023-09-300000873303srpt:PmoProductsMember2023-07-012023-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310000873303us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000873303us-gaap:ShortTermInvestmentsMember2024-09-300000873303us-gaap:FairValueInputsLevel2Membersrpt:StrategicEquityInvestmentsMember2023-12-310000873303srpt:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310000873303us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2023-12-310000873303us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000873303srpt:FirstInstallmentsMember2023-01-012023-03-310000873303us-gaap:FairValueInputsLevel3Member2023-12-310000873303srpt:LacertaTherapeuticsIncMember2024-09-300000873303srpt:ChargebacksMember2024-09-300000873303srpt:StrategicEquityInvestmentsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000873303srpt:SupplyAgreementMembersrpt:ThermoFisherScientificIncorporationMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-07-182024-07-180000873303us-gaap:CorporateBondSecuritiesMember2024-09-3000008733032024-01-012024-09-300000873303srpt:SupplyAgreementMembersrpt:ThermoFisherScientificIncorporationMember2024-01-012024-09-300000873303us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000873303srpt:ElevidysMember2023-01-012023-09-300000873303srpt:ChargebacksMember2023-01-012023-09-300000873303srpt:ElevidysMember2023-07-012023-09-300000873303srpt:PromptPayMember2023-01-012023-09-300000873303us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000873303srpt:RestOfWorldMembersrpt:PmoProductsMember2023-07-012023-09-300000873303us-gaap:RetainedEarningsMember2023-01-012023-03-310000873303us-gaap:FairValueInputsLevel2Membersrpt:CorporateBondsMember2024-09-300000873303srpt:PromptPayMember2024-01-012024-09-300000873303us-gaap:FairValueInputsLevel3Member2023-01-012023-09-3000008733032024-06-3000008733032024-03-310000873303srpt:BedfordMassachusettsMember2022-05-312022-05-310000873303srpt:ChargebacksMember2023-12-310000873303us-gaap:FairValueInputsLevel2Membersrpt:CorporateBondsMember2023-12-310000873303srpt:OtherAccrualsMember2023-12-310000873303srpt:OtherAccrualsMember2023-01-012023-09-300000873303us-gaap:RetainedEarningsMember2023-04-012023-06-300000873303srpt:ThermoFisherScientificIncorporationMembersrpt:RocheAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000873303srpt:EmployeeStockPurchasePlanMember2024-01-012024-09-300000873303us-gaap:RetainedEarningsMember2024-04-012024-06-300000873303us-gaap:AdditionalPaidInCapitalMember2023-06-300000873303srpt:DerivativeAssetMemberus-gaap:FairValueInputsLevel1Member2024-09-300000873303us-

gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300000873303srpt:EmployeeStockPurchasePlanMember2024-07-012024-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-07-012024-09-300000873303us-gaap:MoneyMarketFundsMember2024-09-300000873303srpt:MsRodinoKlapacMember2024-09-300000873303srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember2024-09-300000873303us-gaap:FairValueInputsLevel2Membersrpt:DerivativeAssetMember2024-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-300000873303srpt:RestrictedStockAndRestrictedStockUnitsRSUsMember2023-07-012023-09-300000873303us-gaap:AdditionalPaidInCapitalMember2024-03-310000873303us-gaap:CommonStockMember2024-01-012024-03-310000873303us-gaap:CommonStockMember2023-01-012023-03-310000873303srpt:PmoProductsMembercountry:US2023-07-012023-09-300000873303us-gaap:AdditionalPaidInCapitalMember2022-12-310000873303us-gaap:CommonStockMembersrpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember2023-03-022023-03-020000873303us-gaap:CertificatesOfDepositMember2023-12-310000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-03-310000873303srpt:TwoThousandTwentyFourNotesRepurchaseMember2022-09-142022-09-140000873303us-gaap:FairValueInputsLevel3Member2024-01-012024-09-300000873303us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-30000087330320 24-11-010000873303srpt:EmployeeStockPurchasePlanMember2023-07-012023-09-300000873303us-gaap:SalesRevenueNetMembersrpt:CustomersExceedMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000873303us-gaap:CorporateBondSecuritiesMember2023-12-310000873303us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000873303us-gaap:SalesRevenueNetMembersrpt:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300000873303us-gaap:CorporateBondSecuritiesMember2024-09-300000873303us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2024-09-300000873303us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000873303srpt:TwoThousandSeventeenCappedCallsPartialSettlementMember2023-03-022023-03-020000873303us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000873303srpt:ElevidysMembercountry:US2024-07-012024-09-30000087330320 23-01-012023-12-310000873303srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember2023-03-020000873303us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000873303srpt:PmoProductsMember2024-07-012024-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-04-012024-06-300000873303srpt:TwoThousandTwentyFourNotesRepurchaseMember2022-09-140000873303us-gaap:CommercialPaperMember2024-09-300000873303us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2023-12-310000873303us-gaap:CommonStockMember2023-09-300000873303srpt:RestrictedStockAndRestrictedStockUnitsRSUsMember2024-01-012024-09-300000873303srpt:OtherAccrualsMember2022-12-310000873303us-gaap:RetainedEarningsMember2024-03-310000873303us-gaap:AdditionalPaidInCapitalMember2024-09-300000873303us-gaap:AdditionalPaidInCapitalMember2023-09-300000873303us-gaap:SalesRevenueNetMembersrpt:NoIndividualMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000873303srpt:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300000873303srpt:EmployeeStockPurchasePlanMember2023-01-012023-09-300000873303us-gaap:CollaborativeArrangementMembersrt:MaximumMember2024-01-012024-09-300000873303srpt:SupplyAgreementMembersrpt:ContractManufacturingRevenueMember2024-07-012024-09-300000873303srpt:RocheMemberus-gaap:CollaborativeArrangementMember2024-01-012024-09-300000873303us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-03-310000873303us-gaap:AdditionalPaidInCapitalMember2023-03-310000873303us-gaap:SalesRevenueNetMembersrpt:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300000873303us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000873303us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300000873303us-gaap:RetainedEarningsMember2023-09-300000873303us-gaap:SalesRevenueNetMembersrpt:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-30000087330320 23-04-012023-06-30xbrli:pureutr:sqftxbrli:sharessrpt:Segmentiso4217:USDxbrli:sharesiso4217:USD Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 Â SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Â Delaware 93-0797222 (State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.) Â Â Â 215 First Street, Suite 415Cambridge, MA 02142 (Address of principal executive offices) (Zip Code) Registrantâ€™s telephone number, including area code: (617) 274-4000 Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading Symbol Name of exchange on which registered Common Stock, $0.0001 par value per share SRPT The Nasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Large accelerated filer â˜’ Accelerated filer â˜ Â Â Â Â Non-accelerated filer â˜ Smaller reporting company â˜ Â Â Â Â Â Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ Â Indicate the number of shares outstanding of each of the issuerâ€™s classes of common stock, as of the latest practicable date. Common Stock with $0.0001 par value 95,519,650 (Class) (Outstanding as of November 1, 2024) Â Â Â SAREPTA THERAPEUTICS, INC. FORM 10-Q INDEX Â Page PART I â€” FINANCIAL INFORMATION Â Â Â Â Â Â Â Item 1. Financial Statements (unaudited) Â 3 Â Â Â Â Â Condensed Consolidated Balance Sheets â€” As of September 30, 2024 and December 31, 2023 Â 3 Â Â Â Â Â Â Condensed Consolidated Statements of Comprehensive Income (Loss) â€” For the Three and Nine Months Ended September 30, 2024 and 2023 Â 4 Â Â Â Â Â Â Â Condensed Consolidated Statements of Stockholdersâ€™ Equity â€” For the Three and Nine Months Ended September 30, 2024 and 2023 Â 5 Â Â Â Â Â Condensed Consolidated Statements of Cash Flows â€” For the Nine Months Ended September 30, 2024 and 2023 Â 7 Â Â Â Â Â Notes to Condensed Consolidated Financial Statements Â 8 Â Â Â Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â 24 Â Â Â Â Â Item 3. Quantitative and Qualitative Disclosures about Market Risk Â 39 Â Â Â Â Â Item 4. Controls and Procedures Â 40 Â Â Â Â Â PART II â€” OTHER INFORMATION Â Â Â Â Â Â Item 1. Legal Proceedings Â 41 Â Â Â Â Â Item 1A. Risk Factors Â 41 Â Â Â Â Â Item 2. Â Unregistered Sales of Equity Securities and Use of Proceeds Â 78 Â Â Â Â Â Item 3. Defaults Upon Senior Securities Â 78 Â Â Â Â Â Item 4. Mine Safety Disclosures Â 78 Â Â Â Â Â Item 5. Other Information Â 78 Â Â Â Â Â Item 6. Exhibits Â 78 Â Â Â Â Â Exhibits Â 79 Â Â Â Â Â Signatures Â 80 Â Â 2 Â PART I â€” FINANCIAL INFORMATION Â Â Item 1. Financial Statements SAREPTA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands, except share and per share amounts) Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Assets Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 197,855 Â Â $ 428,430 Â Short-term investments Â Â 1,000,534 Â Â Â 1,247,820 Â Accounts receivable, net Â Â 434,524 Â Â Â 400,327 Â Inventory Â Â 565,924 Â Â Â 322,859 Â Manufacturing-related deposits and prepaids Â Â 321,055 Â Â Â 102,181 Â Other current assets Â Â 165,477 Â Â Â 77,714 Â Total current assets Â Â 2,685,369 Â Â Â 2,579,331 Â Property and equipment, net Â Â 305,788 Â Â Â 227,154 Â Right of use assets Â Â 140,898 Â Â Â 129,952 Â Non-current inventory Â Â 202,550 Â Â Â 191,368 Â Non-current investments Â Â 181,770 Â Â Â â€” Â Other non-current assets Â Â 83,559 Â Â Â 136,771 Â Total assets Â $ 3,599,934 Â Â $ 3,264,576 Â Â Â Â Â Â Â Â Liabilities and Stockholdersâ€™ Equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 118,774 Â Â $ 164,918 Â Accrued expenses Â Â 344,830 Â Â Â 314,997 Â Deferred revenue, current portion Â Â 127,001 Â Â Â 50,416 Â Current portion of long-term debt Â Â 91,595 Â Â Â 105,483 Â Other current liabilities Â Â 17,289 Â Â Â 17,845 Â Total current liabilities Â Â 699,489 Â Â Â 653,659 Â Long-term debt Â Â 1,135,965 Â Â Â 1,132,515 Â Lease liabilities, net of current portion Â Â 170,009 Â Â Â 140,965 Â Deferred revenue, net of current portion Â Â 325,000 Â Â Â 437,000 Â Contingent consideration Â Â 47,400 Â Â Â 38,100 Â Other non-current liabilities Â Â 1,000 Â Â Â 3,000 Â Total liabilities Â Â 2,378,863 Â Â Â 2,405,239 Â Commitments and contingencies (Note 16) Â Â Â Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Preferred stock, $0.0001Â par value, 3,333,333Â shares authorized; noneÂ issued andÂ Â Â outstanding Â Â â€” Â Â Â â€” Â Common stock, $0.0001Â par value, 198,000,000Â shares authorized; 95,493,005Â Â Â and 93,731,831Â issued and outstanding at September 30, 2024, and December 31, Â Â Â 2023, respectively Â Â 10 Â Â Â 9 Â Additional paid-in capital Â Â 5,588,839 Â Â Â 5,304,623 Â Accumulated other comprehensive income, net of tax Â Â 2,245 Â Â Â 918 Â Accumulated deficit Â Â (4,370,023) Â Â (4,446,213) Total stockholdersâ€™ equity Â Â 1,221,071 Â Â Â 859,337 Â Total liabilities and stockholdersâ€™ equity Â $ 3,599,934 Â Â $ 3,264,576 Â See accompanying notes to unaudited condensed consolidated financial statements. 3 Â SAREPTA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited, in thousands, except per share amounts) Â Â For the Three Months EndedÂ September 30, Â Â For the Nine Months EndedÂ September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues: Â Â Â Â Â Â Â Â

investment discount, net Â Â (33,474) Â Â (32,847) Non-cash termination charges Â Â 62,747 Â Â Â â€” Â Non-cash change in the fair value of derivatives Â Â 8,565 Â Â Â 1,200 Â Impairment of strategic investments Â Â â€” Â Â Â 27,821 Â Loss on debt extinguishment Â Â â€” Â Â Â 387,329 Â Gain from sale of Priority Review Voucher Â Â â€” Â Â Â (102,000) Other Â Â 1,822 Â Â Â 324 Â Changes in operating assets and liabilities, net: Â Â Â Â Â Â Increase in accounts receivable Â Â (34,197) Â Â (104,227) (Increase) decrease in manufacturing-related deposits and prepaids Â Â (235,544) Â Â 7,897 Â Increase in inventory Â Â (233,511) Â Â (53,610) Increase in other assets Â Â (39,380) Â Â (2,886) Decrease in deferred revenue Â Â (35,415) Â Â (66,750) Decrease in accounts payable, accrued expenses, lease liabilities and other liabilities Â Â (13,565) Â Â (111,223) Net cash used in operating activities Â Â (297,833) Â Â (446,336) Â Â Â Â Â Â Cash flows from investing activities: Â Â Â Â Â Â Purchase of property and equipment Â Â (98,874) Â Â (57,067) Purchase of available-for-sale securities Â Â (936,684) Â Â (1,475,404) Maturity and sale of available-for-sale securities Â Â 1,037,001 Â Â Â 1,340,265 Â Purchase of intangible assets Â Â (10,000) Â Â (11,239) Proceeds from sale of Priority Review Voucher Â Â â€” Â Â Â 102,000 Â Net cash used in investing activities Â Â (8,557) Â Â (101,445) Â Â Â Â Â Â Cash flows from financing activities: Â Â Â Â Â Â Proceeds from exercise of stock options and purchase of stock under the Employee StockÂ Â Â Purchase Program Â Â 75,815 Â Â Â 49,303 Â Partial settlement of capped call share options for 2024 Notes Â Â â€” Â Â Â 80,645 Â Debt conversion costs for 2024 Notes Â Â â€” Â Â Â (6,887) Net cash provided by financing activities Â Â 75,815 Â Â Â 123,061 Â Â Â Â Â Â Â Decrease in cash, cash equivalents and restricted cash Â Â (230,575) Â Â (424,720) Â Â Â Â Â Â Cash, cash equivalents and restricted cash: Â Â Â Â Â Â Beginning of period Â Â 444,009 Â Â Â 985,801 Â End of period Â $ 213,434 Â Â $ 561,081 Â Â Â Â Â Â Â Reconciliation of cash, cash equivalents and restricted cash: Â Â Â Â Â Â Cash and cash equivalents Â $ 197,855 Â Â $ 541,932 Â Restricted cash in other assets Â Â 15,579 Â Â Â 19,149 Â Total cash, cash equivalents and restricted cash Â $ 213,434 Â Â $ 561,081 Â Â Â Â Â Â Â Supplemental disclosure of cash flow information: Â Â Â Â Â Â Cash paid during the period for income taxes Â $ 11,614 Â Â $ 9,569 Â Cash paid during the period for interest Â $ 15,169 Â Â $ 15,129 Â Supplemental schedule of non-cash activities: Â Â Â Â Â Â Modification of 2017 Capped Calls (defined below) Â $ 43,887 Â Â $ â€” Â Intangible assets and property and equipment included in accounts payable and accrued expenses Â $ 33,841 Â Â $ 16,059 Â Lease liabilities arising from obtaining right of use assets Â $ 20,367 Â Â $ 79,846 Â Common stock issued for conversion or exchange of 2024 Notes Â $ 14,185 Â Â $ 693,377 Â Proceeds from exercise of stock options not yet received Â $ 475 Â Â $ â€” Â Capitalized stock-based compensation and depreciation as inventory Â $ 20,736 Â Â $ â€” Â Â Â Â Â Â Â Â See accompanying notes to unaudited condensed consolidated financial statements. 7 Â SAREPTA THERAPEUTICS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Â Â 1. ORGANIZATION AND NATURE OF BUSINESS Sarepta Therapeutics, Inc. (together with its wholly-owned subsidiaries, â€œSareptaâ€ or the â€œCompanyâ€) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying its proprietary, highly-differentiated and innovative technologies, and through collaborations with its strategic partners, the Company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (â€œDuchenneâ€) and is developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (â€œLGMDsâ€) and other neuromuscular and central nervous system disorders.The Company's products in the U.S., EXONDYS 51 (eteplirsen) Injection (â€œEXONDYS 51â€), VYONDYS 53 (golodirsen) Injection (â€œVYONDYS 53â€) and AMONDYS 45 (casimersen) Injection (â€œAMONDYS 45â€), were granted accelerated approval by the U.S. Food and Drug Administration (the â€œFDAâ€) on September 19, 2016, December 12, 2019 and February 25, 2021, respectively. Indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping, respectively, EXONDYS 51, VYONDYS 53 and AMONDYS 45 (collectively, the â€œPMO Productsâ€) use the Companyâ€™s phosphorodiamidate morpholino oligomer (â€œPMOâ€) chemistry and exon-skipping technology to skip exon 51, exon 53 and exon 45 of the dystrophin gene. Exon skipping is intended to promote the production of an internally truncated but functional dystrophin protein. ELEVIDYS (delandistrogene moxeparvovec-rokl), approved by the FDA on June 20, 2024, is an adeno-associated virus-(â€œAAVâ€) based gene therapy for the treatment of ambulatory patients at least four years old with Duchenne with a confirmed mutation in the Duchenne gene. ELEVIDYS is also approved for non-ambulatory patients under the accelerated approval pathway. ELEVIDYS was previously granted accelerated approval by the FDA on June 22, 2023 for the treatment of ambulatory patients aged four through five years with Duchenne with a confirmed mutation in the Duchenne gene. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.As of September 30, 2024, the Company had approximately $1,395.8 million of cash, cash equivalents, restricted cash and investments, consisting of $197.9 million of cash and cash equivalents, $1,182.3 million of investments and $15.6 million of restricted cash. The Company believes that its balance of cash, cash equivalents and investments as of the date of the issuance of this report is sufficient to fund its current operational plan for at least the next twelve months, though it may pursue additional cash resources through public or private debt and equity financings, seek funded research and development arrangements and additional government contracts and establish collaborations with or license its technology to other companies. Â 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESBasis of PresentationThe accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€), reflect the accounts of Sarepta and its wholly-owned subsidiaries. All intercompany transactions between and among its consolidated subsidiaries have been eliminated. Management has determined that the Company operates in one segment: discovering, developing, manufacturing and delivering therapies to patients with rare diseases. In the opinion of the Companyâ€™s management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with U.S. GAAP, but that is not required for interim reporting purposes, has been omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes for the year ended December 31, 2023 which are contained in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on February 28, 2024. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year. Estimates and UncertaintiesThe preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. 8 Â Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist of cash held at financial institutions, cash equivalents, investments and accounts receivable, net, from customers. As of September 30, 2024, the Companyâ€™s cash was concentrated at three financial institutions, which potentially exposes the Company to credit risks. However, the Company does not believe that there is significant risk of non-performance by the financial institutions. The Company also purchases commercial paper, government and government agency bonds, corporate bonds and certificates of deposit issued by highly rated corporations, financial institutions and governments and limits the amount of credit exposure to any one issuer. These amounts may at times exceed federally insured limits. The Company has not experienced any credit losses related to these financial instruments and does not believe to be exposed to any significant credit risk related to these instruments. As of September 30, 2024, three entities accounted for 37%, 27% and 20% of accounts receivable, net, respectively. As of December 31, 2023, four entities accounted for 40%, 19%, 19% and 12% of accounts receivable, net, respectively. As of September 30, 2024, the Company believes its largest customers are of high credit quality and has not experienced any material credit losses related to such customers.Significant Accounting PoliciesFor details about the Company's accounting policies, please read Note 2, Summary of Significant Accounting Policies and Recent Accounting Pronouncements of the Annual Report on Form 10-K for the year ended December 31, 2023.There have not been any material changes to the Company's accounting policies or recent accounting pronouncements that could have a material impact through September 30, 2024. 3. LICENSE AND COLLABORATION AGREEMENTSF. Hoffman-La Roche Ltd.For the three and nine months ended September 30, 2023, the Company recognized $22.5 million and $66.8 million, respectively, of collaboration revenue associated with the license, collaboration and option agreement (the â€œRoche Agreementâ€) with F. Hoffman-La Roche Ltd. (â€œRocheâ€) related to the amortization of the single, combined performance obligation, with no such activity for the corresponding periods ended September 30, 2024. Under the Roche Agreement, the Company has granted Roche options to acquire ex-U.S. rights to certain future Duchenne development programs (the â€œOptionsâ€) in exchange for separate option exercise payments, milestone and royalty considerations, and cost-sharing provisions. These Options were accounted for as material rights related to individual programs and recorded in deferred revenue at the inception of the Roche Agreement. The value assigned to the material rights is included in deferred revenue until such rights expire or are exercised. On February 12, 2024, Roche declined to exercise its optional rights related to one external, early stage development program, which resulted in the immediate recognition of $48.0 million of collaboration revenue for the nine months ended September 30, 2024. As of September 30, 2024 and December 31, 2023, the Company had total deferred revenue of $452.0 million and $487.4 million, primarily related to the separate material rights for the Options associated with the Roche Agreement, of which $127.0 million and $50.4 million were classified as current, respectively. The costs associated with co-development activities performed under the Roche Agreement are included in operating expenses, with any reimbursement of costs by Roche reflected as a reduction of such expenses when the related expense is incurred. For the three and nine months ended September 30, 2024, costs reimbursable by Roche and reflected as a reduction to operating expenses were $61.5 million and $101.1 million, respectively. For the three and nine months ended September 30, 2023, costs reimbursable by Roche and reflected as a reduction to operating expenses were $34.9 million and $83.4 million, respectively. As of September 30, 2024 and December 31, 2023, there were $66.4 million and $29.8 million, respectively, of collaboration and other receivables included in other current assets on the unaudited condensed consolidated balance sheets.In accordance with the Roche Agreement, the Company agreed to enter into a supply agreement with Roche in order to supply them with clinical and commercial batches of ELEVIDYS (the â€œSupply Agreementâ€). While the Supply Agreement is in the process of being negotiated, the Company has delivered batches of commercial ELEVIDYS supply to Roche that were agreed upon on a purchase order-by-purchase order basis. Contract manufacturing revenue and royalty revenue are included in collaboration and other revenue in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). The following table summarizes certain Roche activity for the three and nine months ended September 30, 2024: Â Â For the Three Months Ended September 30, 2024 Â Â For the Nine Months Ended September 30, 2024 Â Â (in thousands) Â Contract manufacturing revenue $ 27,891 Â Â $ 33,698 Â Royalty revenue $ 9,510 Â Â $ 12,066 Â Cost of sales (inventory costs related to products sold to Roche) $ 13,725 Â Â $ 15,379 Â Â 9 Â There was no similar activity for the same periods of 2023.Research and Option AgreementsThe Company has research and option agreements with third parties in order to develop various technologies and biologics that may be used in the administration of the Companyâ€™s genetic therapeutics. The agreements generally provide for research services related to pre-clinical development programs and options to license the technology for clinical development. Prior to the options under these agreements being executed, the Company may be required to make up to $34.8 million in research milestone payments. Under these agreements, there are $116.8 million in potential option payments to be made by the Company upon the determination to exercise the options. Additionally, if the options for each agreement are executed, the Company would incur additional contingent obligations and may be required to make development, regulatory, and sales milestone payments and royalty payments based on the net sales of the developed products upon commercialization. For the nine months ended September 30, 2023, the Company recognized $7.5 million of up-front payments related to an exercised option as research and development expense, with no similar activity for the three months ended September 30, 2023. For the three and nine months ended September 30, 2023, the Company recognized $3.8 million of research milestone expense as research and development expense. During the three and nine months ended September 30, 2024, the Company did not exercise any options, nor did any additional research milestone payments become probable of occurring.Milestone ObligationsThe Company has license and collaboration agreements in place for which it could be obligated to pay, in addition to the payment of up-front fees upon execution of the agreements, certain milestone payments as a product candidate proceeds from the submission of an investigational new drug application through approval for commercial sale and beyond. As of September 30, 2024, the Company may be obligated to make up to $2.7 billion of future development, regulatory, commercial and up-front royalty payments associated with its collaboration and license agreements. These obligations exclude potential future option and milestone payments for options that have yet to be exercised within research and option agreements entered into by the Company as of September 30, 2024, which are discussed above. For the three and nine months ended September 30, 2023, the Company recognized up-front, development milestone and other expenses of $3.8 million and $11.9 million, respectively, as research and development expense in the accompanying unaudited condensed consolidated statements of comprehensive income (loss), with no similar activity for the three and nine months ended September 30, 2024. 4. FAIR VALUE MEASUREMENTSThe Company has certain financial assets and liabilities that are recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.â€¢Level 1 â€“ quoted prices for identical instruments in active markets;â€¢Level 2 â€“ quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; andâ€¢Level 3 â€“ valuations derived from valuation techniques in which one or more significant value drivers are unobservable. 10 Â During the nine months ended September 30, 2024, there were no transfers into or out of Level 3. The tables below present information about the Companyâ€™s financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques it utilizes to determine such fair value: Â Â Â Fair Value Measurement as of September 30, 2024 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â (in thousands) Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 21,951 Â Â $ 21,951 Â Â Â $ â€” Â Â $ â€” Â Commercial paper Â Â 34,995 Â Â Â â€” Â Â Â 34,995 Â Â Â â€” Â Government and government agency bonds Â Â 900,407 Â Â Â 13,494 Â Â Â 886,913 Â Â Â â€” Â Corporate bonds Â Â 233,245 Â Â Â â€” Â Â Â 233,245 Â Â Â â€” Â Strategic investments Â Â 4,723 Â Â Â 3,723 Â Â Â â€” Â Â Â 1,000 Â Certificates of deposit Â Â 17,988 Â Â Â â€” Â Â Â 17,988 Â Â Â â€” Â Derivative assets Â Â 44,622 Â Â Â â€” Â Â Â 44,622 Â Â Â â€” Â Total assets Â $ 1,257,931 Â Â $ 39,168 Â Â $ 1,217,763 Â $ 1,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent consideration Â $ 47,400 Â Â $ â€” Â Â $ â€” Â Â $ 47,400 Â Total liabilities Â $ 47,400 Â Â $ â€” Â Â $ â€” Â $ 47,400 Â Â Â Fair Value Measurement as of December 31, 2023 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â (in thousands) Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 63,919 Â Â $ 63,919 Â Â $ â€” Â Â $ â€” Â Commercial paper Â Â 113,362 Â Â Â â€” Â Â Â 113,362 Â Â Â â€” Â Government and government agency bonds Â Â 1,001,137 Â Â Â â€” Â Â Â 1,001,137 Â Â Â â€” Â Corporate bonds Â Â 130,380 Â Â Â â€” Â Â Â 130,380 Â Â Â â€” Â Strategic investments Â Â 6,527 Â Â Â 5,527 Â Â Â â€” Â Â Â 1,000 Â Certificates of deposit Â Â 56,621 Â Â Â â€” Â Â Â 56,621 Â Â Â â€” Â Total assets Â $ 1,371,946 Â Â $ 69,446 Â Â $ 1,301,500 Â $ 1,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent consideration Â $ 38,100 Â Â $ â€” Â Â $ â€” Â Â $ 38,100 Â Total liabilities Â $ 38,100 Â Â $ â€” Â Â $ â€” Â $ 38,100 Â Â The Companyâ€™s assets with a fair value categorized as Level 1 within the fair value hierarchy include money market funds, certain government and government agency bonds and the Company's strategic investment in a biotechnology company listed on the Nasdaq Global Market.Â The Company's assets with a fair value categorized as Level 2 within the fair value hierarchy consist of commercial paper, government and government agency bonds, corporate bonds, certificates of deposit and the derivative assets associated with capped call options (the â€œ2017 Capped Callsâ€) for the Company's $570.0 million aggregate principal amount of senior convertible notes due on November 15, 2024 (the â€œ2024 Notesâ€). The Company's commercial paper, government and government agency bonds, corporate bonds and certificates of deposit have been initially valued at the transaction price and subsequently valued at the end of each reporting period utilizing third-party pricing services. The Company uses observable market inputs to determine value, which primarily consist of reportable trades. Certain short-term investments with maturities of less than three months at the date of acquisition are presented as cash equivalents on the unaudited condensed consolidated balance sheets as of September 30, 2024.Â The fair value of the derivative assets related to the 2017 Capped Calls was determined using an option pricing model with Monte Carlo simulations. The significant inputs to the model are the Companyâ€™s share price, estimated volatility and corresponding risk free rate. At the end of each reporting period, the fair value is adjusted to reflect the most current assumptions through earnings. The fair value of the derivative assets from the effective date of the 2017 Capped Calls modification on September 16, 2024 to September 30, 2024 increased by $0.7 million. The increase was recorded within other income (expense), net in the unaudited condensed consolidated statements of comprehensive income (loss). For additional information related to the 2017 Capped Calls, please refer to Note 10, Indebtedness. 11 Â The Companyâ€™s assets with a fair value categorized as Level 3 within the fair value hierarchy consist of a strategic investment in a private biotechnology company whose fair value measurement was based upon significant inputs not observable in the market and therefore represented a Level 3 measurement. At the end of each

reporting period, the fair value of the Company's strategic investments that are not publicly traded securities are adjusted if the issuers issue similar or identical securities or when there is a triggering event for impairment. There were no valuation measurement events related to the fair value of the Company's Level 3 strategic investments during the nine months ended September 30, 2024, as no impairment indicators were identified nor were similar securities issued. During the three months ended September 30, 2023, the Company recorded an impairment loss of $27.5 million related to the Company's strategic investment in Series A preferred stock of Lacerta Therapeutics, Inc. (â€œLacertaâ€) after comparing the fair value of the Lacerta strategic investment to its carrying value. The impairment loss for the three and nine months ended September 30, 2023 is included in other (expense) income, net within the unaudited condensed consolidated statements of comprehensive income (loss). The Companyâ€™s contingent consideration liability with a fair value categorized as Level 3 within the fair value hierarchy relates to the regulatory-related contingent payments to Myonexus Therapeutics, Inc. (â€œMyonexusâ€) selling shareholders as well as to an academic institution under a separate license agreement that meet the definition of a derivative. For more information related to Myonexus, please read Note 3, License and Collaboration Agreements to the financial statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. The contingent consideration liability was estimated using an income approach based on the probability-weighted expected cash flows that incorporated industry-based probability adjusted assumptions relating to the achievement of the milestone and thus the likelihood of making the payments. This fair value measurement was based upon significant inputs not observable in the market and therefore represented a Level 3 measurement. Significant changes, which increase or decrease the probabilities of achieving the milestone or shorten or lengthen the time required to achieve the milestone, would result in a corresponding increase or decrease in the fair value of the liability. At the end of each reporting period, the fair value is adjusted to reflect the most current assumptions through earnings.The following table represents a roll-forward of the fair value of Level 3 financial liabilities for the periods indicated: Â Â As of September 30, 2024 Â Â As of September 30, 2023 Â Â Â (in thousands) Â Fair value, as of beginning of year Â $ 38,100 Â Â $ 36,900 Â Change in estimated fair value Â Â 9,500 Â Â Â 2,000 Â Liabilities terminated Â Â (200) Â Â (800) Fair value, as of end of period Â $ 47,400 Â Â $ 38,100 Â For the three and nine months ended September 30, 2024, the Company recorded a net decrease of $0.8 million and a net increase of $9.3 million, respectively, to account for the change in fair value of the Company's existing contingent consideration liabilities and any liabilities terminated. These changes, which are recorded through earnings, were a result of updates made to certain inputs and assumptions impacting the probability-weighted expected cash flows, principally the probability of success of the underlying programs and the discount rate utilized to determine the present value of future payments to be made, partially offset by the termination of a license agreement with an academic institution that included an embedded derivative during the three months ended September 30, 2024. For the three and nine months ended September 30, 2023, net increases of $2.0 million and $1.2 million were recorded to account for the change in fair value and a termination of one of the Company's license agreements with an existing contingent consideration liability. As of September 30, 2024, the contingent consideration was recorded as a long-term liability on the Company's unaudited condensed consolidated balance sheets. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, net and accounts payable approximated fair value because of the immediate or short-term maturity of these financial instruments. For fair value information related to the Company's debt facilities, please read Note 10, Indebtedness. 5. CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIESThe following table summarizes the Companyâ€™s financial assets with maturities of less than 90 days from the date of purchase included in cash equivalents in the unaudited condensed consolidated balance sheets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Money market funds Â $ 21,951 Â Â $ 63,919 Â Commercial paper Â Â 2,330 Â Â Â 53,680 Â Corporate bonds Â Â 2,001 Â Â Â â€” Â Total Â $ 26,282 Â Â $ 117,599 Â Â 12 Â Â It is the Companyâ€™s policy to mitigate credit risk in its financial assets by maintaining a well-diversified portfolio that limits the amount of exposure as to maturity and investment type. The weighted average maturity of the Company's available-for-sale securities was approximately seven and five months as of September 30, 2024 and December 31, 2023, respectively.The following tables summarize the Companyâ€™s cash, cash equivalents, short-term investments and non-current investments for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair MarketValue Â Â Â (in thousands) Â Cash and money market funds Â $ 193,524 Â Â $ â€” Â Â $ â€” Â Â $ 193,524 Â Commercial paper Â Â 34,995 Â Â Â â€” Â Â Â â€” Â Â Â 34,995 Â Government and government agency bonds Â Â 898,726 Â Â Â 1,704 Â Â Â (23) Â Â 900,407 Â Corporate bonds Â Â 232,654 Â Â Â 603 Â Â Â (12) Â Â 233,245 Â Certificates of deposit Â Â 17,988 Â Â Â â€” Â Â Â â€” Â Â Â 17,988 Â Total cash, cash equivalents and investments Â $ 1,377,887 Â Â $ 2,307 Â Â $ (35) Â $ 1,380,159 Â As reported: Â Â Â Â Â Â Â Â Â Â Â Â Cash and cash equivalents Â $ 197,854 Â Â $ 1 Â Â $ â€” Â Â $ 197,855 Â Short-term investments Â Â 998,884 Â Â Â 1,667 Â Â Â (17) Â Â 1,000,534 Â Non-current investments Â Â 181,149 Â Â Â 639 Â Â Â (18) Â Â 181,770 Â Total cash, cash equivalents and investments Â $ 1,377,887 Â Â $ 2,307 Â Â $ (35) Â $ 1,380,159 Â Â Â Â As of December 31, 2023 Â Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair MarketValue Â Â Â (in thousands) Â Cash and money market funds Â $ 374,750 Â Â $ â€” Â Â $ â€” Â Â $ 374,750 Â Commercial paper Â Â 113,362 Â Â Â â€” Â Â Â â€” Â Â Â 113,362 Â Government and government agency bonds Â Â 1,000,302 Â Â Â 1,006 Â Â Â (171) Â Â 1,001,137 Â Corporate bonds Â Â 130,270 Â Â Â 118 Â Â Â (8) Â Â 130,380 Â Certificates of deposit Â Â 56,621 Â Â Â â€” Â Â Â 56,621 Â Total cash, cash equivalents and investments Â $ 1,675,305 Â Â $ 1,124 Â Â $ (179) Â $ 1,676,250 Â As reported: Â Â Â Â Â Â Â Â Â Â Â Â Cash and cash equivalents Â $ 428,430 Â Â $ â€” Â Â $ â€” Â Â $ 428,430 Â Short-term investments Â Â 1,246,875 Â Â Â 1,124 Â Â Â (179) Â Â 1,247,820 Â Total cash, cash equivalents and investments Â $ 1,675,305 Â Â $ 1,124 Â Â $ (179) Â $ 1,676,250 Â Â 6. PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUESNet product revenues, which includes revenues associated with the PMO Products and ELEVIDYS, consisted of the following: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â PMO Products Â Â Â Â Â Â Â Â Â Â Â United States Â $ 210,683 Â Â $ 198,069 Â Â $ 604,598 Â Â $ 602,415 Â Rest of World Â Â 38,105 Â Â Â 42,145 Â Â Â 108,565 Â Â Â 108,282 Â Total PMO product revenues, net Â $ 248,788 Â Â $ 240,214 Â Â $ 713,163 Â Â $ 710,697 Â ELEVIDYS Â Â Â Â Â Â Â Â Â Â Â United States Â Â 180,983 Â Â Â 69,108 Â Â Â 436,640 Â Â Â 69,108 Â Total ELEVIDYS product revenue, net Â $ 180,983 Â Â $ 69,108 Â Â $ 436,640 Â Â $ 69,108 Â Total product revenues, net Â $ 429,771 Â Â $ 309,322 Â Â $ 1,149,803 Â Â $ 779,805 Â Â 13 Â For the three and nine months ended September 30, 2024 and 2023, no individual country outside the U.S. exceeded 10% of total net product revenues.Â Â The following table summarizes the Company's net product revenues, by customer, for those customers that exceeded 10% for the periods indicated: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Product revenues, net Â Â Â Â Â Â Â Â Â Â Â Customer 1 Â Â 28 % Â Â 40 % Â Â 33 % Â Â 45 % Customer 2 Â Â 19 % Â Â 23 % Â Â 20 % Â Â 29 % Â As of September 30, 2024 and December 31, 2023, the Company's accounts receivable, net were $434.5 million and $400.3 million, respectively, both of which were related to product sales, net of discounts and allowances. As of September 30, 2024, the majority of the Companyâ€™s accounts receivable arose from product sales in the U.S. and all customers have standard payment terms that generally require payment within 65 to 90 days. Outside of the U.S., the majority of the Companyâ€™s customers have payment terms ranging between 90 and 150 days. Please refer to Note 2, Summary of Significant Accounting Policies for discussion of the credit risk associated with accounts receivable, net.Â The following tables summarize an analysis of the change in reserves for discounts and allowances for each of the periods indicated: Â Â Chargebacks Â Â Rebates Â Â Prompt Pay Â Â Other Accruals Â Â Total Â Â Â (in thousands) Â Balance, as of December 31, 2023 Â $ 27,486 Â Â $ 98,194 Â Â $ 3,831 Â Â $ 35,261 Â Â $ 164,772 Â Provision Â Â 72,832 Â Â Â 118,228 Â Â Â 13,442 Â Â Â 53,674 Â Â Â 258,176 Â Adjustments relating to prior periods Â Â 783 Â Â Â (8,716) Â Â â€” Â Â Â (88) Â Â (8,021) Payments/credits Â Â (77,808) Â Â (100,693) Â Â (12,191) Â Â (58,741) Â Â (249,433) Balance, as of September 30, 2024 Â $ 23,293 Â Â $ 107,013 Â Â $ 5,082 Â Â $ 30,106 Â Â $ 165,494 Â Â Â Â Â Â Chargebacks Â Â Rebates Â Â Prompt Pay Â Â Other Accruals Â Â Total Â Â Â (in thousands) Â Balance, as of December 31, 2022 Â $ 417 Â Â $ 67,493 Â Â $ 3,343 Â Â $ 23,445 Â Â $ 94,698 Â Provision Â Â 18,191 Â Â Â 94,025 Â Â Â 11,251 Â Â Â 52,500 Â Â Â 175,967 Â Adjustments relating to prior periods Â Â 110 Â Â Â (4,154) Â Â â€” Â Â Â â€” Â Â Â (4,044) Payments/credits Â Â (9,386) Â Â (73,317) Â Â (10,586) Â Â (40,048) Â Â (133,337) Balance, as of September 30, 2023 Â $ 9,332 Â Â $ 84,047 Â Â $ 4,008 Â Â $ 35,897 Â Â $ 133,284 Â Â The following table summarizes the total reserves above included in the Companyâ€™s unaudited condensed consolidated balance sheets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Reduction to accounts receivable, net Â $ 56,773 Â Â $ 64,697 Â Component of accrued expenses Â Â 108,721 Â Â Â 100,075 Â Total reserves Â $ 165,494 Â Â $ 164,772 Â Â 7. INVENTORYThe following table summarizes the components of the Companyâ€™s inventory for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Raw materials Â $ 208,320 Â Â $ 133,963 Â Work in progress Â Â 482,171 Â Â Â 318,458 Â Finished goods Â Â 77,983 Â Â Â 61,806 Â Total inventory Â $ 768,474 Â Â $ 514,227 Â Â 14 Â No material inventory reserves existed as of September 30, 2024 or December 31, 2023. The Company classifies inventory associated with its PMO Products as non-current inventory when consumption of the inventory is expected beyond the Company's normal PMO Product inventory operating cycle of two years. Non-current inventory consists of raw materials and work in progress associated with the PMO Products.The following table summarizes the balance sheet classification of the Company's inventory for each of the periods indicated: Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Balance sheet classification Â Â Â Â Â Â Inventory Â $ 565,924 Â Â $ 322,859 Â Non-current inventory Â Â 202,550 Â Â Â 191,368 Â Total inventory Â $ 768,474 Â Â $ 514,227 Â Â 8. OTHER ASSETSThe following table summarizes the Companyâ€™s other current assets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Collaboration and other receivables Â $ 66,404 Â Â $ 29,786 Â Derivative asset Â Â 44,622 Â Â Â â€” Â Prepaid maintenance services Â Â 13,326 Â Â Â 11,281 Â Prepaid clinical and pre-clinical expenses Â Â 12,034 Â Â Â 10,280 Â Tax-related receivables and prepaids Â Â 11,422 Â Â Â 6,862 Â Prepaid commercial expenses Â Â 3,982 Â Â Â 2,729 Â Interest receivable Â Â 3,637 Â Â Â 2,731 Â Prepaid insurance Â Â 2,198 Â Â Â 3,352 Â Other Â Â 7,852 Â Â Â 10,693 Â Total other current assets Â $ 165,477 Â Â $ 77,714 Â The following table summarizes the Companyâ€™s other non-current assets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Manufacturing-related deposits and prepaids Â $ 28,127 Â Â $ 74,204 Â Intangible assets, net Â Â 27,570 Â Â Â 29,620 Â Restricted cash* Â Â 15,579 Â Â Â 15,579 Â Strategic investments Â Â 4,723 Â Â Â 6,527 Â Prepaid maintenance services Â Â 3,907 Â Â Â 5,466 Â Other Â Â 3,653 Â Â Â 5,375 Â Total other non-current assets Â $ 83,559 Â Â $ 136,771 Â Â * The Company had approximately $15.6 million in restricted cash included in other non-current assets on the Companyâ€™s unaudited condensed consolidated balance sheets as of both September 30, 2024 and December 31, 2023. Restricted cash for both periods relates to (i) letters of credit established under the Companyâ€™s various property leases that serve as security for potential future default of lease payments, (ii) a letter of credit established under a certain commercial supply agreement and (iii) collateralized cash for the Companyâ€™s credit cards. The restricted cash is unavailable for withdrawal or use for general obligations. 15 Â 9. ACCRUED EXPENSESThe following table summarizes the Companyâ€™s accrued expenses for each of the periods indicated: Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Product revenue related reserves Â $ 108,721 Â Â $ 100,075 Â Accrued contract manufacturing costs Â Â 75,909 Â Â Â 33,024 Â Accrued employee compensation costs Â Â 57,107 Â Â Â 78,732 Â Accrued clinical and pre-clinical costs Â Â 40,514 Â Â Â 34,669 Â Accrued professional fees Â Â 21,486 Â Â Â 17,187 Â Accrued income taxes Â Â 14,696 Â Â Â 13,766 Â Accrued royalties Â Â 12,185 Â Â Â 12,070 Â Accrued fixed assets Â Â 4,821 Â Â Â 3,231 Â Accrued research expenses Â Â 2,882 Â Â Â 2,441 Â Accrued interest Â Â 1,118 Â Â Â 4,395 Â Other Â Â 5,391 Â Â Â 15,407 Â Total accrued expenses Â $ 344,830 Â Â $ 314,997 Â Â 10. INDEBTEDNESS2024 Convertible Notes and 2017 Capped Call TransactionsOn November 14, 2017, the Company issued $570.0 million aggregate principal amount of senior convertible notes due on November 15, 2024 and, simultaneously, entered into capped call transactions with counterparties intended to minimize the impact of potential dilution upon conversion of the 2024 Notes. On September 14, 2022, the Company entered into separate, privately negotiated transactions to repurchase a portion of the outstanding 2024 Notes. The holders exchanged $150.6 million in aggregate principal value of 2024 Notes held by them for an aggregate payment of $248.6 million for full settlement of the principal value and accrued interest on such date. As a result of the repurchases, the Company entered into agreements with the 2017 Capped Calls counterparties to terminate a corresponding portion of the 2017 Capped Calls and received $26.3 million in cash.On March 2, 2023, the Company entered into separate, privately negotiated exchange agreements with certain holders of the outstanding 2024 Notes. The holders exchanged $313.5 million in aggregate principal value of the 2024 Notes held by them for 4.5 million shares of the Companyâ€™s common stock. As a result of the exchange, the Company entered into agreements with the counterparties to the 2017 Capped Calls to terminate a portion of the 2017 Capped Calls and received approximately $80.6 million in cash.In June 2024, certain existing holders elected to convert $14.2 million in aggregate principal amount of the 2024 Notes into approximately 0.2 million shares of the Companyâ€™s common stock. As the conversions were completed under the original terms of the 2024 Notes, there is no gain or loss impact on the accompanying unaudited condensed consolidated statements of comprehensive income (loss). The capped call options related to the shares underlying the conversion are required to be settled at the scheduled maturity date of the 2024 Notes.In May 2024, the Company informed holders of the 2024 Notes of its election to settle the 2024 Notes in shares, which, pursuant to the terms of the 2017 Capped Call agreements, would require the Company to settle the 2017 Capped Calls in shares. On September 16, 2024 (the â€œEffective Dateâ€), the Company entered into supplements with each of the counterparties to modify the terms of each of the 2017 Capped Calls to require settlement in cash rather than in shares. As a result of the modification, the Company reassessed the classification of the 2017 Capped Calls and concluded that these instruments, which were initially classified within equity, should be reclassified as derivative assets. Accordingly, the Company reclassified the fair value of the 2017 Capped Calls, from stockholdersâ€™ equity to derivative assets on the Effective Date, with subsequent changes in fair value recorded to earnings through the settlement date. The fair value on the Effective Date of $43.9 million was reclassified from stockholdersâ€™ equity (additional paid-in capital) to derivative assets and recorded to other current assets on the unaudited condensed consolidated balance sheets. The increase in the fair value of the derivative assets from the Effective Date to September 30, 2024 was $0.7 million and recorded to other income (expense), net in the unaudited condensed consolidated statements of comprehensive income (loss). The derivative assets, along with the 2024 Notes, will settle on November 15, 2024. For further information related to the fair value determination of the derivative assets, please read Note 4, Fair Value Measurements.For additional details about the 2024 Notes, please read Note 13, Indebtedness to the financial statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. 16 Â Total Debt ObligationsAs of September 30, 2024 and December 31, 2023, the Company recorded approximately $1,227.6 million and $1,238.0 million as debt on the unaudited condensed consolidated balance sheets, respectively, with the 2024 Notes balance recorded as a current liability for both periods.The following table summarizes the Companyâ€™s debt instruments for each of the periods indicated:Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â (in thousands) Â Principal amount of the 2024 Notes $ 91,640 Â Â $ 105,847 Â Principal amount of the 2027 Notes Â 1,150,000 Â Â Â 1,150,000 Â Unamortized discount - debt issuance costs of 2024 Notes Â (45) Â Â (364) Unamortized discount - debt issuance costs of 2027 Notes Â (14,035) Â Â (17,485) Total carrying value of debt instruments $ 1,227,560 Â Â $ 1,237,998 Â Â Â Â Â Â Â Â Fair value of 2024 Notes $ 171,154 Â Â $ 144,833 Â Fair value of 2027 Notes Â 1,307,930 Â Â Â 1,172,276 Â Total fair value of debt instruments $ 1,479,084 Â Â $ 1,317,109 Â Â For both of the three months ended September 30, 2024 and 2023, interest expense from debt instruments was $5.2 million, inclusive of $1.2 million of amortization of debt discounts. For the nine months ended September 30, 2024 and 2023, interest expense from debt facilities was $15.7 million and $16.8 million, inclusive of $3.7 million and $3.9 million of amortization of debt discounts, respectively. The fair value of the 1.25% convertible senior notes due on September 15, 2027 (â€œ2027 Notesâ€) and the 2024 Notes is based on open market trades and is classified as Level 1 in the fair value hierarchy. The following table summarizes the total principal and contractual interest payments due under the Companyâ€™s debt arrangements: Â Â As of September 30, 2024 Â Â Â Principal Â Â Interest Â Â Total Payments Â Â Â (in thousands) Â 2024 (October-December) Â $ 91,640 Â Â $ 711 Â Â $ 92,351 Â 2025 Â Â â€” Â Â Â 14,375 Â Â Â 14,375 Â 2026 Â Â â€” Â Â Â 14,375 Â Â Â 14,375 Â 2027 Â Â 1,150,000 Â Â Â 14,375 Â Â Â 1,164,375 Â Total payments Â $ 1,241,640 Â Â $ 43,836 Â Â $ 1,285,476 Â Â 11. STOCK-BASED COMPENSATIONThe following table summarizes the Companyâ€™s stock awards granted for each of the periods indicated: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Stock options Â Â 6,442 Â Â $ 55.16 Â Â Â 50,875 Â Â $ 66.53 Â Â Â 327,920 Â Â $ 67.39 Â Â Â 1,135,799 Â Â $ 72.23 Â Restricted stock units Â Â 135,092 Â Â $ 127.51 Â Â Â 27,539 Â Â $

118.05 Â Â Â 1,351,982 Â (1) $ 128.90 Â Â Â 1,137,202 Â (2) $ 153.02 Â Â (1) Included in restricted stock units (â€œRSUsâ€) for the nine months ended September 30, 2024 are 97,460 shares with performance conditions (â€œMarch 2024 PSUsâ€) which are related to the achievement of certain financial performance goals and regulatory approval of certain of the Company's product candidates. The expanded regulatory approval of ELEVIDYS in June 2024 resulted in the cliff-vesting of 44,300 of the 97,460 shares of the March 2024 PSUs during the nine months ended September 30, 2024. As of September 30, 2024, none of the performance conditions for the remaining 53,160 shares were probable of being achieved. Stock options and the 17 Â remaining RSUs granted during the three and nine months ended September 30, 2024 have only service-based criteria and vest over four years. (2) Included in the RSUs for the nine months ended September 30, 2023 are 502,225 shares with performance conditions (the â€œMarch 2023 PSUsâ€), which are related to regulatory approval of ELEVIDYS and achievement of a certain financial performance target, both of which were achieved in 2023. Vesting of the March 2023 PSUs is contingent on the fulfillment of remaining service conditions.Â During the year ended December 31, 2022, the Company granted 38,500 RSUs with performance conditions (the â€œMarch 2022 PSUsâ€), which are related to regulatory approval of certain of the Company's product candidates. As a result of the expanded regulatory approval of ELEVIDYS in June 2024, a portion of the March 2022 PSUs became eligible for vesting. Vesting of the March 2022 PSUs is contingent on the fulfillment of remaining service conditions. As of September 30, 2024, none of the remaining performance conditions were probable of being achieved.Stock-based Compensation ExpenseFor the three months ended September 30, 2024 and 2023, total stock-based compensation expense was $43.5 million and $48.1 million, respectively. For the nine months ended September 30, 2024 and 2023, total stock-based compensation expense was $134.6 million and $136.7 million, respectively.Â The following table summarizes stock-based compensation expense by grant type and by function included within the unaudited condensed consolidated statements of comprehensive income (loss):Â Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â (in thousands) Â Stock options Â $ 15,158 Â Â $ 17,471 Â Â $ 46,954 Â Â $ 62,436 Â Restricted stock units Â Â 31,926 Â Â Â 28,924 Â Â Â 97,261 Â Â Â 70,101 Â Employee Stock Purchase Program Â Â 1,912 Â Â Â 1,666 Â Â Â 5,640 Â Â Â 4,151 Â Subtotal Â $ 48,996 Â Â $ 48,061 Â Â $ 149,855 Â Â $ 136,688 Â Capitalized stock-based compensation costs* Â Â (5,546) Â Â â€” Â Â Â (15,231) Â Â â€” Â Total stock-based compensation expense included in expenses Â $ 43,450 Â Â $ 48,061 Â Â $ 134,624 Â Â $ 136,688 Â Research and development Â Â 18,034 Â Â Â 22,325 Â Â Â 54,113 Â Â Â 60,315 Â Selling, general and administrative Â Â 25,416 Â Â Â 25,736 Â Â Â 80,511 Â Â Â 76,373 Â Total stock-based compensation expense included in expenses Â $ 43,450 Â Â $ 48,061 Â Â $ 134,624 Â Â $ 136,688 Â *Prior to the nine months ended September 30, 2024, capitalized stock-based compensation costs were not material. 12. OTHER INCOME (LOSS), NETThe following table summarizes other income (loss), net for each of the periods indicated:Â Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â (in thousands) Â Accretion of investment discount, net Â $ 10,749 Â Â $ 12,984 Â Â $ 34,319 Â Â $ 35,809 Â Interest income Â Â 7,584 Â Â Â 9,838 Â Â Â 22,753 Â Â Â 27,532 Â Interest expense Â Â (4,918) Â Â (5,229) Â Â (13,916) Â Â (16,776) Change in fair value of derivatives* Â Â 1,535 Â Â Â (2,000) Â Â (8,565) Â Â (1,200) Impairment of strategic investments Â Â â€” Â Â Â (27,500) Â Â â€” Â Â Â (27,821) Other, net Â Â (3,140) Â Â (425) Â Â Â (1,960) Â Â Â (235) Other income (expense), net Â $ 11,810 Â Â $ (12,332) Â $ 32,631 Â Â $ 17,309 Â Gain from sale of Priority Review Voucher Â Â â€” Â Â Â â€” Â Â Â 102,000 Â Loss on debt extinguishment Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (387,329) Total other income (loss), net Â $ 11,810 Â Â $ (12,332) Â $ 32,631 Â Â $ (268,020) Â 18 Â *Related to the change in fair value of the contingent consideration derivative liabilities and the 2017 Capped Calls derivative assets. For more information, please read Note 4, Fair Value Measurements and Note 10, Indebtedness. 13. LEASESÂ The Company has real estate operating leases in Cambridge, Andover, Burlington and Bedford, Massachusetts, Dublin and Columbus, Ohio, and Durham, North Carolina that provide for scheduled annual rent increases over the lease term. The Company has also identified leases embedded in certain of its manufacturing and supply agreements as the Company determined that it controls the use of the facilities and related equipment therein. For more information related to the lease embedded in manufacturing and supply agreements with Catalent, Inc. (â€œCatalentâ€), please refer to Note 21, Commitments and Contingencies of the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Bedford, Massachusetts On April 22, 2022, the Company entered into a lease agreement (the â€œBedford Leaseâ€) for 288,000 square feet of to-be-constructed research and development and manufacturing space in Bedford, Massachusetts. The term of the Bedford Lease commences upon the landlordâ€™s completion of the initial construction of the core and shell of the building, at which time the Company will obtain control of the premises and commence internal construction activities. The Company has two options to extend the lease for a period of ten years each, exercisable under certain conditions and at a market rate determined in accordance with the lease agreement.In May 2022, in connection with the execution of the Bedford Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $8.4 million, which was included in the other non-current assets of the Companyâ€™s unaudited condensed consolidated balance sheets. Such letter of credit shall be reduced to approximately $5.6 million at the commencement of the fourth rent year, provided certain conditions set forth in the Bedford Lease are satisfied.Undiscounted minimum rent payments due over the term of the lease aggregate to $307.4 million. Additionally, the Company is responsible for reimbursing the landlord for the Companyâ€™s share of the propertyâ€™s operating expenses and property taxes. The Bedford Lease also provides for a tenant improvement allowance from the landlord of up to $72.0 million to be used towards costs incurred by the Company in the design and construction of the premises. The Company recorded the $72.0 million tenant improvement allowance as a reduction to right-of-use (â€œROUâ€) assets and lease liabilities in May 2023 as the Company obtained control of the premises. In August 2024, the Company entered into an amendment to the Bedford Lease to extend the term in which the tenant improvement allowance could be reimbursed from the landlord (the â€œBedford Amendmentâ€). The Bedford Amendment extended the reimbursement period associated with the tenant improvement allowance through December 2, 2025. The Company also agreed to reimburse the landlord for certain costs incurred in order to fund the extension of the reimbursement period associated with the tenant improvement allowance, totaling $2.9 million. The Bedford Amendment was accounted for as a modification to the Bedford Lease.As of September 30, 2024, the Company had a lease liability and ROU asset of $131.7 million and $92.0 million, respectively, on its unaudited condensed consolidated balance sheets related to the Bedford Lease. Tenant improvement costs incurred by the Company that had been reimbursed by the landlord totaled $29.5 million through September 30, 2024 and were recorded as an increase to lease liabilities when received within the Company's unaudited condensed consolidated balance sheets. Â Â 14. INCOME TAXESÂ During the three and nine months ended September 30, 2024, the Company recorded an income tax provision of $0.4 million and $12.8 million, representing an effective tax rate of 1.2% and 14.4%, respectively. The income tax provision primarily relates to the current tax provision on taxable profits, including in certain states which restrict the amount of net operating loss carryforwards which may be utilized to offset taxable income. On a periodic basis, the Company reassesses the valuation allowance on its deferred tax assets, weighing positive and negative evidence to assess the recoverability of such deferred tax assets. In assessing the Companyâ€™s ability to realize its net deferred tax assets, the Company considered various factors, including future reversals of existing taxable temporary differences, projected future taxable income, potential carryback claims and tax planning strategies to determine whether it is more likely than not that some portion or all of its net deferred tax assets will not be realized. Based upon these factors, the Company has determined that the uncertainty regarding the realization of these assets is sufficient to warrant the need to maintain a full valuation allowance against its net deferred tax assets as of September 30, 2024. It is possible that with continued positive performance of the business in future periods, there may be sufficient positive evidence to release a portion or all of the Companyâ€™s valuation allowance. The release of the valuation allowance, as well as the exact timing and the amount of such release, continue to be subject to, among other things, the Companyâ€™s level of profitability, revenue growth, and expectations regarding future profitability. Release of the valuation allowance 19 Â would result in a benefit to income tax expense for the period the release is recorded, which could have a material impact on net earnings. The total deferred tax asset balance subject to the valuation allowance was approximately $897.0 million as of September 30, 2024. The Company will continue to monitor the need for a full or partial valuation allowance on a quarterly basis. During the three and nine months ended September 30, 2023, the Company recorded an income tax provision of $7.8 million and $21.2 million, respectively, representing an effective tax rate of (23.4%) and (3.8%), respectively. For tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize the costs over five years for research activities performed in the U.S. and 15 years for research activities performed outside the U.S. The requirement to capitalize research and development costs for tax purposes resulted in the Company having taxable profits and recording federal and state tax expense of $4.1 million and $17.1 million, respectively. The state tax expense of $17.1 million is primarily related to state taxable income, partially offset by net operating loss carryforwards. 15. EARNINGS (LOSS) PER SHAREBasic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed by dividing net income by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding.Â The following table sets forth the computation of basic and diluted earnings (loss) per common share: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands, except per share amounts) Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Net income (loss) - basic Â $ 33,611 Â Â $ (40,937) Â $ 76,190 Â Â $ (581,632) Add: interest expense, net of tax, on the Company'sÂ Â Â Â convertible debt Â Â 413 Â Â Â â€” Â Â Â 1,182 Â Â Â â€” Â Net income (loss) - diluted Â $ 34,024 Â Â $ (40,937) Â $ 77,372 Â Â $ (581,632) Denominator: Â Â Â Â Â Â Â Â Â Â Â Weighted-average common shares outstanding, basic Â Â 95,390 Â Â Â 88,889 Â Â Â 94,669 Â Â Â 88,609 Â Effect of dilutive securities: Â Â Â Â Â Â Â Â Â Â Â Common stock issuable under the Company'sÂ Â Â Â Â equity incentive plans Â Â 3,810 Â Â Â â€” Â Â Â 3,529 Â Â Â â€” Â Common stock issuable under the Company'sÂ Â Â Â Â convertible debt Â Â 1,248 Â Â Â â€” Â Â Â 1,374 Â Â Â â€” Â Weighted-average common shares outstanding, diluted Â 100,448 Â Â Â 88,889 Â Â Â 99,572 Â Â Â 88,609 Â Earnings (loss) per common share, basic Â $ 0.35 Â Â $ (0.46) Â $ 0.80 Â Â $ (6.56) Earnings (loss) per common share, diluted Â $ 0.34 Â Â $ (0.46) Â $ 0.78 Â Â $ (6.56) Â The following table summarizes potential shares of common stock that were excluded from the computation of diluted earnings per share as they were anti-dilutive:Â Â Â As of September 30, 2024 Â Â As of September 30, 2023 Â Â Â (in thousands) Â Â Common stock issuable under the Company's equity incentive plans Â Â 2,464 Â (1) Â 12,111 Â (2) Common stock issuable under the Company's convertible debt Â Â 8,100 Â Â Â 9,542 Â Â Total number of potentially issuable common stock Â Â 10,564 Â Â Â 21,653 Â Â Â 20 Â (1) As of September 30, 2024, the anti-dilutive common stock issuable under the Company's equity incentive plans excludes 1.2 million shares that are dilutive but have performance or market conditions that were not met as of the end of the period.(2) As of September 30, 2023, the anti-dilutive common stock issuable under the Company's equity incentive plans includes 1.1 million shares that have performance or market conditions that were not met as of the end of the period because these were anti-dilutive as the Company was in a net loss position at the end of the period. 16. COMMITMENTS AND CONTINGENCIESManufacturing ObligationsThe following table summarizes the aggregate non-cancelable contractual obligations arising from the Companyâ€™s manufacturing obligations: Â Â Â As ofSeptember 30, 2024 Â Â Â (in thousands) Â 2024 (October-December) Â $ 600,021 Â 2025 Â Â 312,338 Â 2026 Â Â 119,238 Â 2027 Â Â 82,217 Â 2028 Â Â 72,306 Â Total manufacturing commitments* Â $ 1,186,120 Â Â * Total manufacturing commitments include the Catalent manufacturing and supply agreement, for which the Company has ROU assets and lease liabilities recorded on the unaudited condensed consolidated balance sheets as of September 30, 2024. Â Thermo Fisher Scientific, Inc. The Company entered into a development, commercial manufacturing, and supply agreement as related to the Company's adherent manufacturing process for its gene therapy programs in June 2018 and, subsequently, entered into the first, second and third amendments in May 2019, July 2020 and October 2021, respectively, with Brammer Bio MA, LLC, an affiliate of Thermo Fisher Scientific, Inc. (â€œThermoâ€) (collectively, the â€œThermo Agreementâ€). In March 2023, the Company executed a fourth amendment (the â€œThermo Amendmentâ€) that modified the terms of the Thermo Agreement. The Thermo Amendment removed the previous minimum batch purchase commitment of $54.7 million per annum and associated fee for the remaining term of the Thermo Agreement. In connection with the elimination of such commitment and fee, the Thermo Amendment implemented a fee of up to $60.0 million, to be paid in three installments of $20.0 million each by March 1, 2024, December 31, 2024 and December 31, 2025, respectively. During the three months ended March 31, 2024, the Company paid the first $20.0 million installment due March 1, 2024, considered a nonrefundable advance payment. On July 18, 2024, the Company issued a termination notice to Thermo to terminate the Thermo Agreement. The termination was effective as of August 21, 2024. The aggregate net impact of the termination was $55.4 million of research and development expense in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). As the Company had yet to obtain regulatory approval to produce commercial supply of ELEVIDYS at Thermo manufacturing facilities, the Company recorded the charges incurred as research and development expenses in the three months ended September 30, 2024. Included in the net impact noted above are non-cash charges due to the termination of $62.7 million, related to the remaining unamortized nonrefundable advance payments. Additionally, there were unbilled service and material costs ordered by the Company as of the termination date of $29.2 million that were expensed as research and development expense during the three months ended September 30, 2024. As related to the termination, for both the three and nine months ended September 30, 2024, costs reimbursable by Roche under the Roche Agreement and reflected as a reduction to research and development expenses were $36.5 million. For more information related to the Companyâ€™s manufacturing and supply agreements, please read Note 21, Commitments and Contingencies to the financial statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023.Litigation In the normal course of business, the Company from time to time is named as a party to various legal claims, actions and complaints, which have included and may include matters involving securities, employment, intellectual property, arising from the use 21 Â of therapeutics utilizing its technology, or others. The Company records a loss contingency reserve for a legal proceeding when it considers the potential loss probable, and it can reasonably estimate the amount of the loss or determine a probable range of loss. The Company provides disclosure when it considers a loss reasonably possible or when it determines that a loss in excess of a reserve is reasonably possible. The Company provides an estimate of such reasonably possible losses or an aggregate range of such reasonably possible losses, unless the Company believes that such an estimate cannot be made. The Company has not recorded any material accruals for loss contingencies, and in management's opinion, no material range of loss is estimable for the matters described below as of September 30, 2024.On September 15, 2020, REGENXBIO INC. (â€œRegenxâ€) and the Trustees of the University of Pennsylvania (â€œU-Pennâ€) filed a lawsuit against the Company and Sarepta Therapeutics Three, LLC, in the U.S. District Court for the District of Delaware. The plaintiffs assert patent infringement of U.S. Patent No. 10,526,617 (â€œthe â€˜617 Patentâ€) under 35 U.S.C.Â§Â§ 271(a)-(c) based on Sareptaâ€™s alleged direct or indirect manufacture and use of the patented cultured host cell technology allegedly used to make AAV gene therapy products, including SRP-9001 (approved June 22, 2023 in the U.S. as ELEVIDYSÂ®). Specifically, the Complaint essentially includes the allegation that Sareptaâ€™s use, and the use by its contract manufacturers on its behalf, of a host cell containing a recombinant acid molecule that encodes a capsid protein having at least 95% amino acid identity to AAVrh10 infringes the â€˜617 Patent asserted by Regenx. Plaintiffs seek injunctive relief, a judgment of infringement and willful infringement, damages that are no less than a reasonable royalty (treble damages), attorneysâ€™ fees and costs, and such other relief as the court deems just and proper. On January 5, 2024, the Court granted Sareptaâ€™s motion for summary judgment on the grounds that the asserted claims of Regenxâ€™s â€˜617 Patent are invalid because they cover patent ineligible subject matter under 35 U.S.C. Â§ 101. On January 12, 2024, the Court entered judgment and closed the case. Plaintiffs have appealed to the U.S. Court of Appeals for the Federal Circuit. On June 20, 2023, Regenx and U-Penn commenced a second patent infringement lawsuit against Sarepta and its contract manufacturer, Catalent asserting patent alleged infringement of U. S. Patent No. 11,680,274 (â€œthe â€™274 Patentâ€). In the second lawsuit, Regenx and U-Penn allege that Sarepta and Catalentâ€™s manufacture, use and commercial launch of ELEVIDYSÂ® (SRP-9001) infringe the â€™274 Patent. Sarepta answered the complaint on August 10, 2023, and a case schedule was set with a trial commencing on November 17, 2025. On February 21, 2024, Sarepta submitted a petition for Inter Partes Review (â€œIPRâ€) for filing with the Patent Trial and Appeal Board (â€œPTABâ€) at the USPTO. The petition seeks to invalidate the â€˜274 Patent. On March 20, 2024, the district court stayed the litigation pending the PTABâ€™s determination on the IPR. On August 22, 2024, the PTAB instituted inter partes review of all challenged claims of the â€˜274 Patent on all asserted grounds.On July 13, 2021, Nippon Shinyaku Co., Ltd. (â€œNippon Shinyakuâ€ or â€œNSâ€) filed a lawsuit against the Company in the U.S. District Court for the District of Delaware. NS asserted a claim for breach of contract arising from Sarepta filing seven petitions for Inter Partes Review (â€œIPR Petitionsâ€) with the PTAB at the USPTO in which Sarepta sought to invalidate certain NS patents concerning exon 53 skipping technology (U.S. Patent Nos. 9,708,361, 10,385,092, 10,407,461, 10,487,106, 10,647,741, 10,662,217, and 10,683,322, respectively, and collectively the â€œNS Patentsâ€). In addition, NS asserted claims for patent infringement and willful infringement of each of the NS Patents allegedly arising from Sareptaâ€™s activities, including the sale of, its exon 53 skipping product, VYONDYS 53 (golodirsen). NS further sought a determination of non-infringement by NS alleged to arise from

NSâ€™s activities, including the sale of, its exon 53 skipping product, Viltepso (viltolarsen) and invalidity of certain patents licensed to the Company from the University of Western Australia (â€œUWAâ€) (U.S. Patent Nos. 9,994,851, 10,227,590, and 10,266,827, collectively the â€œUWA Patentsâ€). In its complaint, NS sought legal fees and costs, an unspecified amount of monetary relief (treble damages) attributed to Sareptaâ€™s alleged infringement, and such other relief as the court deems just and proper. In January 2022, the PTAB granted institution of all claims of all NS Patents in response to Sareptaâ€™s IPR Petitions and determined that Sarepta demonstrated a reasonable likelihood of success in proving that the NS Patents are unpatentable. NS filed a motion for preliminary injunction solely seeking Sareptaâ€™s withdrawal of the IPR Petitions, which was ultimately granted after the U.S. Court of Appeals for the Federal Circuit reversed and remanded to the district court on February 8, 2022. Sarepta subsequently withdrew the IPRs, which were terminated on June 14, 2022. On December 27, 2021, the district court partially granted and denied the motion to dismiss by Sarepta and ordered NS to file a Second Amended Complaint (â€œSACâ€), which it did on January 14, 2022. In the SAC, NS maintained all claims of the original complaint of July 13, 2021, except a determination of non-infringement of the UWA Patents. On January 28, 2022, Sarepta filed its answer to the SAC, with defenses and counterclaims against NS and NS Pharma Inc. that include infringement of the UWA Patents allegedly arising from their activities concerning, including the sale of, its exon 53 skipping product, Viltepso (viltolarsen) and breach of contract. Sarepta also sought a determination of invalidity of the NS Patents. In its counterclaim complaint, Sarepta sought an award of relief in its defenses to NSâ€™ allegations, a judgment of breach of contract, a determination of invalidity of the NS Patents, a judgment of infringement and willful infringement of the UWA Patents, legal fees and costs, an unspecified amount of monetary relief (treble damages) attributable to NSâ€™ alleged infringement, and such other relief as the court deems just and proper. UWA has since been joined as a Plaintiff in Sareptaâ€™s counterclaims against NS. On August 14, 2023, the Court granted cross motions to amend the pleadings, allowing Sarepta to add a counterclaim against NS for inequitable conduct, and NS to add counterclaims against Sarepta for inequitable conduct and Walker Process fraud. The parties have since stipulated to the dismissal of NS's claim of infringement of its 22 Â â€™361 Patent and certain claims of the â€™322 Patent, and NSâ€™s breach of contract claim. The Court bifurcated the Walker Process fraud claim on April 18, 2024, and granted Sarepta's motion for summary judgement of infringement of the '851 Patent and NSâ€™s motion for partial summary judgment of infringement of certain NS patents on May 1, 2024. A trial is scheduled to commence on December 16, 2024. On or about June 5, 2023, Sarepta initiated a patent infringement lawsuit against Nippon Shinyaku in Japan, alleging that NSâ€™s production, sales and offers to sell Viltepso infringe Sareptaâ€™s Japanese Patent No. 6406782. NS filed its preliminary answer on July 13, 2023. A technical presentation session occurred on July 26, 2024.On July 26, 2024, Genzyme Corporation filed a lawsuit against Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC, in the U.S. District Court for the District of Delaware. The complaint asserts infringement of United States Patent Nos. 9,051,542 (the â€œâ€™542 Patentâ€) and 7,704,721 (the â€œâ€™721 Patentâ€) arising from Sareptaâ€™s alleged manufacture and sale of ELEVIDYSÂ® (delandistrogene moxeparvovec-rokl). In its complaint, Genzyme seeks, inter alia, damages for the alleged infringement, including increased damages up to three times the amount found or assessed, together with prejudgment and post-judgment interest and costs. Â 23 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. The purpose of Management's Discussion and Analysis of Financial Condition and Results of Operations is to provide an understanding of the financial condition, changes in financial condition and results of operations of Sarepta Therapeutics, Inc. This section should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q and the section contained in our Annual Report on Form 10-K for the year ended December 31, 2023 under the caption â€œPart II-Item 7 â€“ Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€. This Quarterly Report on Form 10-Q contains certain forward-looking statements, which are often identified by words such as â€œbelieve,â€ â€œanticipate,â€ â€œexpect,â€ â€œintend,â€ â€œplan,â€ â€œwill,â€ â€œmay,â€ â€œestimate,â€ â€œcould,â€ â€œcontinue,â€ â€œongoing,â€ â€œpredict,â€ â€œpotential,â€ â€œlikely,â€ â€œseekâ€ and other similar expressions, as well as variations or negatives of these words. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements include, but are not limited to: â€¢our belief that our proprietary technology platforms and collaborations can be used to develop potential therapeutic candidates to treat a broad range of diseases; â€¢our expectation that our partnerships with manufacturers will support our clinical and commercial manufacturing capacity for our Duchenne muscular dystrophy (â€œDuchenneâ€) gene therapy programs and Limb-girdle muscular dystrophy (â€œLGMDâ€) programs, while also acting as a manufacturing platform for potential future gene therapy programs, and our belief that our current network of manufacturing partners is able to fulfill the requirements of our commercial plan; â€¢our expectation that our partnership with Catalent, Inc. (â€œCatalentâ€) will support our clinical and commercial manufacturing demand for our SRP-9001 Duchenne program and LGMD programs, while also acting as a manufacturing platform for potential future gene therapy programs; â€¢our expectation that Aldevron LLC (â€œAldevronâ€) will provide Good Manufacturing Processes (â€œGMPâ€)-grade plasmid for our SRP-9001 Duchenne program and LGMD programs, as well as plasmid source material for future gene therapy programs; â€¢the possible impact of regulations and regulatory decisions by the Food and Drug Administration (the â€œFDAâ€) and other regulatory agencies on our business as well as the development of our product candidates and our financial and contractual obligations; â€¢estimated timelines and milestones for the remainder of 2024 and beyond; â€¢our engagement with regulatory authorities outside of the U.S. including the European Medicines Agency (the â€œEMAâ€); â€¢our plan to continue building out our network for commercial distribution in jurisdictions in which our products are approved; â€¢our plan to expand our pipeline through internal research and development and through strategic transactions; â€¢the timely completion and satisfactory outcome of our post-marketing requirements and commitments, including verification of a clinical benefit for our products in confirmatory trials; â€¢our ability to further secure long-term supply of our commercial products and our product candidates to satisfy our planned commercial, early access programs (â€œEAPâ€) and clinical needs; â€¢the possible impact of any competing products on the commercial success of our products and our product candidates and our ability to compete against such products; â€¢our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our plans and ability to file and progress to issue additional patent applications to enhance and protect our new and existing technologies and programs; â€¢our estimates regarding our cash runway and statements about our future capital needs; â€¢our estimates regarding future revenues, research and development expenses, other expenses, capital requirements and payments to third parties; â€¢our expectation regarding the impact of environmental laws and regulations on our business; and our beliefs and expectations regarding milestone, royalty or other payments that could be due to third parties under existing agreements. 24 Â Â We undertake no obligation to update any of the forward-looking statements contained in this Quarterly Report on Form 10-Q after the date of this report, except as required by law or the rules and regulations of the U.S. Securities and Exchange Commission (the â€œSECâ€). We caution readers not to place undue reliance on forward-looking statements. Our actual results could differ materially from those discussed in this Quarterly Report on Form 10-Q. The forward-looking statements contained in this Quarterly Report on Form 10-Q, and other written and oral forward-looking statements made by us from time to time, are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including the risks, uncertainties and assumptions identified under the heading â€œRisk Factorsâ€ in this Quarterly Report on Form 10-Q. Overview We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, highly differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne and are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne, LGMDs, and other neuromuscular and central nervous system related disorders. We commercialized four products, all of which were granted accelerated approval or traditional approval by the FDA: â€¢The PMO Products: oEXONDYS 51 (eteplirsen) Injection (â€œEXONDYS 51â€), granted accelerated approval by the FDA on September 19, 2016, is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping. EXONDYS 51 uses our phosphorodiamidate morpholino oligomer (â€œPMOâ€) chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene. oVYONDYS 53 (golodirsen) Injection (â€œVYONDYS 53â€), granted accelerated approval by the FDA on December 12, 2019, is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. VYONDYS 53 uses our PMO chemistry and exon-skipping technology to skip exon 53 of the dystrophin gene. oAMONDYS 45 (casimersen) Injection (â€œAMONDYS 45â€), granted accelerated approval by the FDA on February 25, 2021, is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping. AMONDYS 45 uses our PMO chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene. â€¢ELEVIDYS (delandistrogene moxeparvovec-rokl), approved by the FDA on June 20, 2024, is an adeno-associated virus-based (â€œAAVâ€) gene therapy for the treatment of ambulatory patients at least four years old with Duchenne with a confirmed mutation in the Duchenne gene. ELEVIDYS is also approved for non-ambulatory patients under the accelerated approval pathway. ELEVIDYS was previously granted accelerated approval by the FDA on June 22, 2023 for the treatment of ambulatory patients aged four through five years with Duchenne with a confirmed mutation in the Duchenne gene. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. We are in the process of conducting various clinical trials for our approved products, including studies that are required to comply with our post-marketing FDA requirements/commitments to verify and describe the clinical benefit of these products. A summary description of our key product candidates, including those in collaboration with our strategic partners, is as follows: â€¢SRP-9003 (LGMD, gene therapy program). We are developing gene therapy programs for various forms of LGMDs. The most advanced of our LGMD product candidates, SRP-9003, is designed to transfer a gene that codes for and restores beta-sarcoglycan protein with the goal of restoring the dystrophin associated protein complex. It utilizes the AAVrh.74 vector system, the same vector used in our SRP-9001 gene therapy program. A Phase 1/2a trial of SRP-9003 was commenced in the fourth quarter of 2018. In February 2019, we announced positive two-month biopsy data from the first three-patient low-dose cohort dosed in the SRP-9003 trial, and in October 2019, we announced positive nine-month functional data from these three patients. We have dosed one additional cohort of three patients at a higher dose per the study protocol. In June 2020, we announced safety and expression results from three clinical trial participants in the high-dose cohort measured at 60 days, and one-year functional data from three clinical trial participants in the low-dose cohort. In September 2020, we announced six-month functional data from three clinical 25 Â trial participants in the high-dose cohort, and eighteen-month functional data from three clinical trial participants in the low-dose cohort. In March 2021, we announced 24-month functional and expression data from the three clinical trial participants in the low-dose cohort and twelve-month functional data from the three clinical trial participants in the high-dose cohort. In March 2022, we announced 36-month functional data from three clinical trial participants in the low-dose cohort and 24-month functional data from two clinical trial participants in the high-dose cohort. In January 2024, we announced that we had begun screening in Study SRP-9003-301, a Phase 3, multi-national, open-label study of SRP-9003. â€¢SRP-5051 uses our next-generation chemistry platform, cell-penetrating peptide-conjugated PPMO, and our exon-skipping technology to skip exon 51 of the dystrophin gene. SRP-5051, a peptide conjugated PMO, is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. In 2019, we commenced Study 5051-201. In November 2024, we announced that we discontinued development of SRP-5051 and our PPMO program for treatment of Duchenne. Our pipeline includes more than 40 programs in various stages of pre-clinical and clinical development, reflecting our multifaceted approach and expertise in precision genetic medicine to make a profound difference in the lives of patients suffering from rare diseases. Manufacturing, Supply and Distribution We have developed proprietary state-of-the-art Chemistry, Manufacturing and Controls (â€œCMCâ€) capabilities that allow manufacturing and testing of our products and product candidates to support both clinical development and commercialization. We continue to refine and optimize our manufacturing processes and test methods. We have entered into certain manufacturing and supply arrangements with third-party suppliers which will in part utilize these capabilities to support production of certain of our product candidates and their components. We have also opened facilities over the past several years that significantly enhanced our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabilities to produce our products and product candidates for commercial and/or clinical use. For our current and future manufacturing needs, we have entered into supply agreements with specialized contract manufacturing organizations (each a â€œCMOâ€) to produce custom raw materials, the active pharmaceutical ingredients (â€œAPIsâ€), drug product and finished goods for our products and product candidates for both commercial and clinical use. All of our CMO partners have extensive technical expertise, GMP experience and experience manufacturing our specific technology. For our commercial Duchenne PMO program, we have worked with our existing CMOs to increase production capacity from mid-scale to large-scale. While there is a limited number of companies that can produce raw materials and APIs in the quantities and with the quality and purity that we require for our commercial products, based on our diligence to date, we believe our current network of CMOs is able to fulfill these requirements, and is capable of expanding capacity as needed. Additionally, we have evaluated, and will continue to evaluate further relationships with additional suppliers to increase overall capacity as well as further reduce risks associated with relying on a limited number of suppliers for manufacturing. Our gene therapy manufacturing capabilities have been greatly enhanced through partnerships with Aldevron and Catalent. We have adopted a hybrid development and manufacturing strategy in which we have built internal expertise relative to all aspects of AAV-based manufacturing, including gene therapy and gene editing, while closely partnering with experienced manufacturing partners to expedite development and commercialization of our gene therapy programs. We have secured manufacturing capacity at Catalent to support our clinical and commercial manufacturing demand for ELEVIDYS and our LGMD programs, while also acting as a manufacturing platform for potential future gene therapy programs. The collaboration integrates process development, clinical and commercial production and testing. Aldevron provides GMP-grade plasmid for ELEVIDYS and is expected to provide plasmid source material for our LGMD programs and future gene therapy programs. Manufacturers and suppliers of our commercial products and product candidates are subject to the current GMP (â€œcGMPâ€) requirements and other rules and regulations prescribed by FDA and other foreign regulatory authorities. We depend on our third-party partners for continued compliance with cGMP requirements and applicable foreign standards. Our PMO commercial products are distributed in the U.S. through a limited network of home infusion specialty pharmacy providers that deliver the medication to patients and a specialty distributor that distributes our products to hospitals and hospital outpatient clinics. With respect to the pre-commercial distribution of our products to patients outside of the U.S., we have contracted with third party distributors and service providers to distribute our products in certain countries through our EAPs. We plan to continue building out our network for commercial distribution in jurisdictions in which our products are approved. The U.S. distribution model for ELEVIDYS employs multiple distribution partners that include third-party logistics providers, as well as a limited network of specialty pharmacy providers that provide the medication to hospitals for infusion. 26 Â Cash, Cash Equivalents, Restricted Cash and Investments As of September 30, 2024, we had approximately $1,395.8 million of cash, cash equivalents, restricted cash and investments, consisting of $197.9 million of cash and cash equivalents, $1,182.3 million of investments, and $15.6 million of restricted cash. We believe that our balance of cash, cash equivalents and investments is sufficient to fund our current operational plan for at least the next twelve months. The likelihood of our long-term success must be considered in light of the expenses, difficulties and delays frequently encountered in the development and commercialization of new pharmaceutical products, competitive factors in the marketplace, the risks associated with government sponsored reimbursement programs and the complex regulatory environment in which we operate. Critical Accounting Policies and Estimates The discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements included elsewhere in this report. The preparation of our unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the U.S. requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities for the periods presented. Some of these judgments can be subjective and complex and, consequently, actual results may differ from these estimates. We believe that the estimates and judgments upon which we rely are reasonable based upon historical experience and information available to us at the time that we make these estimates and judgments. To the extent there are material differences between these estimates and actual results, our unaudited condensed consolidated financial statements will be affected. Although we believe that our judgments and estimates are appropriate, actual results may differ from these estimates. We believe the following accounting policies to be most critical to the judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements: â€¢inventory; and â€¢income tax. There have not been significant changes to our critical accounting policies and significant estimates as detailed in our Annual Report on Form 10-K for the year ended December 31, 2023, apart from additional monitoring of our valuation allowance, as noted below. Income Taxes We follow the asset and liability method of accounting for income taxes, which requires the recognition of deferred tax assets and liabilities for expected future tax consequences attributable to differences

between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is recorded to reduce the net deferred tax asset to zero when it is more likely than not that the net deferred tax asset will not be realized. As of September 30, 2024, we continued to maintain a full valuation allowance against all of our deferred tax assets, with the exception of deferred tax assets in certain foreign jurisdictions, based on management's evaluation of all available evidence, including our earnings history. We will continue to monitor the realizability of our deferred tax assets in future periods. We may release all or a portion of the valuation allowance in the near-term; however, the release of the valuation allowance, as well as the exact timing and the amount of such release, continue to be subject to, among other things, our level of profitability, revenue growth and expectations regarding future profitability. If and when we determine the valuation allowance should be released or reduced, the adjustment would result in a benefit to income tax expense for the period the release is recorded, which could have a material impact on net earnings. We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon an examination. The calculation of our tax liabilities (or amount of reduction in our deferred tax assets from net operating loss carryover and research credit carryover) resulting from uncertain tax positions can involve significant judgment. Further, the calculation may involve the application of complex tax regulations in a foreign jurisdiction. Any significant impact as a result of changes in underlying facts, law, tax rates, tax audit, or review could lead to adjustments to our deferred tax asset, income tax expense, our effective tax rate, and/or our cash flow. Although we believe that we have adequately provided for tax liabilities resulting from uncertain tax positions, the actual amounts paid, if any, could have a material impact on our results of operations. Interest and penalties associated with uncertain tax positions are classified as a component of income tax expense. 27 Â Results of Operations for the Three and Nine Months Ended September 30, 2024 and 2023 The following tables set forth selected unaudited condensed consolidated statements of income (loss) data for each of the periods indicated: Â Â Â For the Three Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands, except per share amounts) Â Â $ Â Â % Â Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Products, net Â $ 429,771 Â Â $ 309,322 Â Â $ 120,449 Â Â Â 39 % Collaboration and other Â Â 37,401 Â Â Â 22,495 Â Â Â 14,906 Â Â Â 66 % Total revenues Â Â 467,172 Â Â Â 331,817 Â Â Â 135,355 Â Â Â 41 % Cost and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of sales (excluding amortization of in-licensed rights) Â Â 91,691 Â Â Â 37,026 Â Â Â 54,665 Â Â Â 148 % Research and development Â Â 224,483 Â Â Â 194,301 Â Â Â 30,182 Â Â Â 16 % Selling, general and administrative Â Â 128,200 Â Â Â 120,893 Â Â Â 7,307 Â Â Â 6 % Amortization of in-licensed rights Â Â 602 Â Â Â 439 Â Â Â 163 Â Â Â 37 % Total cost and expenses Â Â 444,976 Â Â Â 352,659 Â Â Â 92,317 Â Â Â 26 % Operating income (loss) Â Â 22,196 Â Â Â (20,842) Â Â 43,038 Â Â NM* Â Other income (loss), net: Â Â Â Â Â Â Â Â Â Â Â Â Other income (expense), net Â Â 11,810 Â Â Â (12,332) Â Â 24,142 Â Â NM* Â Total other income (loss), net Â Â 11,810 Â Â Â (12,332) Â Â 24,142 Â Â NM* Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income (loss) before income tax expense Â Â 34,006 Â Â Â (33,174) Â Â 67,180 Â Â NM* Â Income tax expense Â Â 395 Â Â Â 7,763 Â Â Â (7,368) Â Â (95)% Net income (loss) Â $ 33,611 Â Â $ (40,937) Â $ 74,548 Â Â NM* Â Â Â Â Â Â Â Â Â Â Â Â Â Â Earnings (loss) per share: Â Â Â Â Â Â Â Â Â Â Â Â Basic Â $ 0.35 Â Â $ (0.46) Â $ 0.81 Â Â NM* Â Diluted Â $ 0.34 Â Â $ (0.46) Â $ 0.80 Â Â NM* Â Â 28 Â Â Â For the Nine Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands, except per share amounts) Â Â $ Â Â % Â Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Products, net Â $ 1,149,803 Â Â $ 779,805 Â Â $ 369,998 Â Â Â 47 % Collaboration and other Â Â 93,764 Â Â Â 66,750 Â Â Â 27,014 Â Â Â 40 % Total revenues Â Â 1,243,567 Â Â Â 846,555 Â Â Â 397,012 Â Â Â 47 % Cost and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of sales (excluding amortization of in-licensed rights) Â Â 186,795 Â Â Â 106,167 Â Â Â 80,628 Â Â Â 76 % Research and development Â Â 604,569 Â Â Â 681,870 Â Â Â (77,301) Â Â (11)% Selling, general and administrative Â Â 393,999 Â Â Â 350,171 Â Â Â 43,828 Â Â Â 13 % Amortization of in-licensed rights Â Â 1,804 Â Â Â 796 Â Â Â 1,008 Â Â Â 127 % Total cost and expenses Â Â 1,187,167 Â Â Â 1,139,004 Â Â Â 48,163 Â Â Â 4 % Operating income (loss) Â Â 56,400 Â Â Â (292,449) Â Â 348,849 Â Â NM* Â Other income (loss), net: Â Â Â Â Â Â Â Â Â Â Â Â Other income, net Â Â 32,631 Â Â Â 17,309 Â Â Â 15,322 Â Â Â 89 % Gain from sale of Priority Review Voucher Â Â â€” Â Â 102,000 Â Â Â (102,000) Â Â (100)% Loss on debt extinguishment Â Â â€” Â Â Â (387,329) Â Â 387,329 Â Â Â (100)% Total other income (loss), net Â Â 32,631 Â Â Â (268,020) Â Â 300,651 Â Â NM* Â Â Â Â Â Â Â Â Â Â Â Â Â Â Income (loss) before income tax expense Â Â 89,031 Â Â Â (560,469) Â Â 649,500 Â Â NM* Â Income tax expense Â Â 12,841 Â Â Â 21,163 Â Â Â (8,322) Â Â (39)% Net income (loss) Â $ 76,190 Â Â $ (581,632) Â $ 657,822 Â Â NM* Â Â Â Â Â Â Â Â Â Â Â Â Â Â Earnings (loss) per share: Â Â Â Â Â Â Â Â Â Â Â Â Basic Â $ 0.80 Â Â $ (6.56) Â $ 7.36 Â Â NM* Â Diluted Â $ 0.78 Â Â $ (6.56) Â $ 7.34 Â Â NM* Â Â * NM: not meaningful Revenues Revenues from product sales are recorded at the time of sale at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, governmental chargebacks including Public Health Services chargebacks, prompt pay discounts, patient assistance programs and distribution fees. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if no payments are required of us) or a current liability (if a payment is required of us). Our estimates take into consideration current contractual and statutory requirements. Actual amounts of consideration ultimately received or paid may differ from our estimates. The following tables summarize the components of our net product revenues, by product, for each of the periods indicated: Â Â Â For the Three Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â PMO Products Â $ 248,788 Â Â $ 240,214 Â Â $ 8,574 Â Â Â 4 % ELEVIDYS Â Â 180,983 Â Â Â 69,108 Â Â Â 111,875 Â Â Â 162 % Products, net Â $ 429,771 Â Â $ 309,322 Â Â $ 120,449 Â Â Â 39 % Â Â Â For the Nine Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â PMO Products Â $ 713,163 Â Â $ 710,697 Â Â $ 2,466 Â Â Â (â€”) % ELEVIDYS Â Â 436,640 Â Â Â 69,108 Â Â Â 367,532 Â Â NM* Â Products, net Â $ 1,149,803 Â Â $ 779,805 Â Â $ 369,998 Â Â Â 47 % Â 29 Â * NM: not meaningful Â Net product revenues for our products for the three and nine months ended September 30, 2024 increased by $120.4 million and $370.0 million, respectively, compared with the three and nine months ended September 30, 2023. The increases primarily reflect additional net product revenues of $111.9 million and $367.5 million, respectively, associated with sales of ELEVIDYS during the three and nine months ended September 30, 2024 due to an increase in demand following its June 2023 FDA approval and launch and expanded label in June 2024. Â The following tables summarize the components of our collaboration and other revenues for the periods indicated: Â Â Â For the Three Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â Contract manufacturing Â $ 27,891 Â Â $ â€” Â Â $ 27,891 Â Â NM* Â Royalty revenue Â Â 9,510 Â Â Â â€” Â Â Â 9,510 Â Â NM* Â Amortization of performance obligations** Â Â â€” Â Â Â 22,495 Â Â Â (22,495) Â Â (100)% Total collaboration and other Â $ 37,401 Â Â $ 22,495 Â Â $ 14,906 Â Â Â 66 % Â Â Â For the Nine Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â Amortization of performance obligations** Â $ 48,000 Â Â $ 66,750 Â Â $ (18,750) Â Â (28)% Contract manufacturing Â Â 33,698 Â Â Â â€” Â Â Â 33,698 Â Â NM* Â Royalty revenue Â Â 12,066 Â Â Â â€” Â Â Â 12,066 Â Â NM* Â Total collaboration and other Â $ 93,764 Â Â $ 66,750 Â Â $ 27,014 Â Â Â 40 % * NM: not meaningful ** Related to the recognition of previously deferred revenue under the Roche collaboration agreement as the Company satisfies its performance obligations under the contract. For more information, please read Note 3, License and Collaboration Agreements. Collaboration and other revenues primarily relate to our collaboration arrangement with F. Hoffman-La Roche Ltd. (â€œRocheâ€). For the three months ended September 30, 2024 and 2023, we recognized $37.4 million and $22.5 million of collaboration and other revenues, respectively. In accordance with the Collaboration Agreement with Roche (the â€œCollaboration Agreementâ€), the parties agreed to enter into a supply agreement in order for us to supply Roche with clinical and commercial batches of ELEVIDYS (the â€œSupply Agreementâ€). While the Supply Agreement is in the process of being negotiated, we delivered batches of commercial ELEVIDYS supply to Roche that were agreed upon on a purchase order-by-purchase order basis. For the three months ended September 30, 2024, we recognized $27.9 million of contract manufacturing revenue, which is related to these Roche shipments, with no similar activity during the three months ended September 30, 2023. In addition, we recognized $9.5 million of royalty revenue from sales of ELEVIDYS by Roche, with no similar activity for the three months ended September 30, 2023. This was partially offset by the amortization of the single, combined performance obligation under the Collaboration Agreement during the three months ended September 30, 2023, which was fully amortized as of December 31, 2023. Please refer to Note 3, License and Collaboration Agreements for further discussion of the Collaboration Agreement. For the nine months ended September 30, 2024 and 2023, we recognized $93.8 million and $66.8 million of collaboration and other revenues, respectively. The increase is primarily due to $33.7 million of contract manufacturing revenue related to shipments of ELEVIDYS to Roche and $12.1 million of royalty revenue from sales of ELEVIDYS by Roche recognized in the nine months ended September 30, 2024, with no similar activity for the nine months ended September 30, 2023. This was partially offset by an $18.8 million decrease in collaboration revenue recognized in the nine months ended September 30, 2024. This decrease was due to the amortization of the single, combined performance obligation under the Collaboration Agreement recognized during the nine months ended September 30, 2023, which was fully amortized as of December 31, 2023, partially offset by Rocheâ€™s declined option to acquire the ex-US rights to a certain external, early stage Duchenne development program during the nine months ended September 30, 2024. 30 Â Cost of sales (excluding amortization of in-licensed rights) Our cost of sales (excluding amortization of in-licensed rights) consists of inventory costs that relate to sales of our products and the related overhead costs and royalty payments primarily to BioMarin Pharmaceuticals, Inc. (â€œBioMarinâ€) and the University of Western Australia (â€œUWAâ€) for our PMO Products and to Nationwide Childrenâ€™s Hospital (â€œNationwideâ€) for ELEVIDYS. Prior to receiving regulatory approval for our products, we expensed manufacturing and material costs as research and development expenses. For the PMO Products, all previously expensed manufacturing costs had been fully consumed prior to the three and nine months ended September 30, 2024 and 2023. For ELEVIDYS sold in the three and nine months ended September 30, 2024, a portion of related manufacturing costs incurred had previously been expensed as research and development expenses, as such costs were incurred prior to FDA approval of the product. For ELEVIDYS sold in the three and nine months ended September 30, 2023, the majority of related manufacturing costs incurred had previously been expensed as research and development expenses, as such costs were incurred prior to FDA approval of the product. If product related costs had not previously been expensed as research and development expenses prior to receiving FDA approval, the incremental inventory costs related to ELEVIDYS sold, including products sold to Roche under the Collaboration Agreement, would have been approximately $29.1 million and $68.8 million for the three and nine months ended September 30, 2024, respectively. The following table summarizes the components of our cost of sales (excluding amortization of in-licensed rights) for each of the periods indicated: Â Â For the Three Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â Inventory costs related to products sold (excluding products sold to Roche**) Â $ 65,781 Â Â $ 26,525 Â Â $ 39,256 Â Â Â 148 % Inventory costs related to products sold to Roche** Â Â 13,725 Â Â Â â€” Â Â Â 13,725 Â Â NM* Â Royalty payments Â Â 12,185 Â Â Â 10,501 Â Â Â 1,684 Â Â Â 16 % Total cost of sales (excluding amortization of in-licensed rights) Â $ 91,691 Â Â $ 37,026 Â Â $ 54,665 Â Â Â 148 % Â Â Â For the Nine Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â Inventory costs related to products sold (excluding products sold to Roche**) Â $ 140,294 Â Â $ 78,700 Â Â $ 61,594 Â Â Â 78 % Royalty payments Â Â 31,122 Â Â Â 27,467 Â Â Â 3,655 Â Â Â 13 % Inventory costs related to products sold to Roche** Â Â 15,379 Â Â Â â€” Â Â Â 15,379 Â Â NM* Â Total cost of sales (excluding amortization of in-licensed rights) Â $ 186,795 Â Â $ 106,167 Â Â $ 80,628 Â Â Â 76 % * NM: not meaningful ** See above for further details regarding product supply sold to Roche via contract manufacturing under our Collaboration Agreement. Â The cost of sales (excluding amortization of in-licensed rights) for the three and nine months ended September 30, 2024 increased by $54.7 million and $80.6 million, respectively, compared with the same periods in 2023. The changes primarily reflect an increase in cost of sales related to ELEVIDYS due to an increase in demand following its June 2023 FDA approval and expanded label in June 2024, as well as increases in the write-offs of certain batches of our products not meeting our quality specifications. For the three and nine months ended September 30, 2024, we recognized $13.7 million and $15.4 million, respectively, of cost of sales related to products sold to Roche under the Collaboration Agreement, with no similar activity for the same periods in 2023. Research and development expenses Research and development expenses consist of costs associated with research activities as well as those associated with our product development efforts, conducting pre-clinical trials, clinical trials and manufacturing activities. Direct research and development expenses associated with our programs include clinical trial site costs, clinical manufacturing costs, costs incurred for consultants, up-front fees and milestones paid to third parties in connection with technologies that have not reached technological feasibility and do not have an alternative future use, and other external services, such as data management and statistical analysis support, and materials and supplies used in support of clinical programs. Indirect costs of our programs include salaries, stock-based compensation and allocation of our facility- and technology-related costs. Research and development expenses represent a substantial percentage of our total operating expenses. We do not maintain or evaluate and, therefore, do not allocate internal research and development costs on a project-by-project basis. As a result, a 31 Â significant portion of our research and development expenses are not tracked on a project-by-project basis, as the costs may benefit multiple projects. The following tables summarize our research and development expenses by project for each of the periods indicated: Â Â For the Three Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â SRP-9001 Â $ 148,081 Â Â $ 45,478 Â Â $ 102,603 Â Â NM* Â LGMD platform Â Â 16,502 Â Â Â 13,390 Â Â Â 3,112 Â Â Â 23 % Eteplirsen (exon 51) Â Â 9,859 Â Â Â 24,616 Â Â Â (14,757) Â Â (60)% Other gene therapies Â Â 8,457 Â Â Â 7,069 Â Â Â 1,388 Â Â Â 20 % PPMO platform Â Â 6,156 Â Â Â 22,100 Â Â Â (15,944) Â Â (72)% Gene editing Â Â 3,878 Â Â Â 3,216 Â Â Â 662 Â Â Â 21 % Golodirsen (exon 53) Â Â 1,703 Â Â Â 3,569 Â Â Â (1,866) Â Â (52)% Casimersen (exon 45) Â Â 1,571 Â Â Â 4,414 Â Â Â (2,843) Â Â (64)% Other projects Â Â 451 Â Â Â 8,930 Â Â Â (8,479) Â Â (95)% Internal research and development expenses Â Â 89,149 Â Â Â 96,254 Â Â Â (7,105) Â Â (7)% Roche collaboration reimbursement Â Â (61,324) Â Â (34,735) Â Â (26,589) Â Â 77 % Total research and development expenses Â $ 224,483 Â Â $ 194,301 Â Â $ 30,182 Â Â Â 16 % Â Â Â For the Nine Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â SRP-9001 Â $ 260,935 Â Â $ 238,578 Â Â $ 22,357 Â Â Â 9 % LGMD platform Â Â 54,420 Â Â Â 42,198 Â Â Â 12,222 Â Â Â 29 % Eteplirsen (exon 51) Â Â 48,681 Â Â Â 76,588 Â Â Â (27,907) Â Â (36)% Other gene therapies Â Â 24,986 Â Â Â 18,553 Â Â Â 6,433 Â Â Â 35 % PPMO platform Â Â 24,488 Â Â Â 54,641 Â Â Â (30,153) Â Â (55)% Casimersen (exon 45) Â Â 12,629 Â Â Â 17,444 Â Â Â (4,815) Â Â (28)% Gene editing Â Â 11,869 Â Â Â 9,364 Â Â Â 2,505 Â Â Â 27 % Golodirsen (exon 53) Â Â 6,685 Â Â Â 11,974 Â Â Â (5,289) Â Â (44)% Other projects Â Â 8,556 Â Â Â 22,870 Â Â Â (14,314) Â Â (63)% Internal research and development expenses Â Â 251,835 Â Â Â 272,390 Â Â Â (20,555) Â Â (8)% Roche collaboration reimbursement Â Â (100,515) Â Â (82,730) Â Â (17,785) Â Â 21 % Total research and development expenses Â $ 604,569 Â Â $ 681,870 Â Â $ (77,301) Â Â (11)% * NM: not meaningful The following tables summarize our research and development expenses by category for each of the periods indicated: Â Â For the Three Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â Manufacturing expenses* Â $ 136,612 Â Â $ 63,083 Â Â $ 73,529 Â Â Â 117 % Clinical trial expenses Â Â 41,723 Â Â Â 51,180 Â Â Â (9,457) Â Â (18)% Compensation and other personnel expenses Â Â 39,266 Â Â Â 38,731 Â Â Â 535 Â Â Â 1 % Facility- and technology-related expenses Â Â 23,529 Â Â Â 22,821 Â Â Â 708 Â Â Â 3 % Stock-based compensation Â Â 18,034 Â Â Â 22,325 Â Â Â (4,291) Â Â (19)% Professional services Â Â 7,976 Â Â Â 6,130 Â Â Â 1,846 Â Â Â 30 % Pre-clinical expenses Â Â 774 Â Â Â 2,738 Â Â Â (1,964) Â Â (72)% Research and other Â Â 17,893 Â Â Â 22,028 Â Â Â (4,135) Â Â (19)% Roche collaboration reimbursement Â Â (61,324) Â Â (34,735) Â Â (26,589) Â Â 77 % Total research and development expenses Â $ 224,483 Â Â $ 194,301 Â Â $ 30,182 Â Â Â 16 % Â 32 Â Â *Beginning in the period ended March 31, 2024, we implemented an updated manufacturing absorption methodology that allocates the absorption of indirect manufacturing costs to their respective originating categories. Research and development expenses by category, specifically, manufacturing expenses, compensation and other personnel expenses, facility- and technology-related expenses and professional services, have been reclassified for the period ended September 30, 2023 for comparability. This reallocation has no impact on the total research and development expenses recognized. Â Research and development expenses for the three months ended September 30, 2024 increased by $30.2 million, or 16%, compared with the three months ended September 30, 2023. The increase was primarily driven by the following: â€¢$73.5 million increase in manufacturing expenses primarily due to $91.9 million of costs associated with the termination of the development, commercial manufacturing and supply agreement (the â€œThermo Agreementâ€) related to Brammer Bio MA, LLC, an affiliate of Thermo Fisher Scientific, Inc. (â€œThermoâ€) in August 2024, partially offset by a decrease in activity for our PPMO platform and a decrease in clinical batches for our Eteplirsen program. Please refer to Note 16, Commitments and Contingencies for further discussion of the Thermo Agreement; â€¢$9.5 million decrease in clinical trial expenses primarily due to a decrease in activity for our PPMO

platform and a ramp-down of the ESSENCE studies for AMONDYS 45 and VYONDYS 53; â€¢$4.3 million decrease in stock-based compensation expense primarily due to an increase in indirect manufacturing costs absorption offset as a result of ELEVIDYS approval in June 2023 and expanded label in June 2024, partially offset by changes in headcount; â€¢$1.8 million increase in professional services primarily due to an increase in reliance on third-party research and development contractors for clinical programs; â€¢$2.0 million decrease in pre-clinical expenses primarily due to a decrease in toxicology study activity in our PPMO platform; â€¢$4.1 million decrease in research and other expenses primarily due to milestone achievements in certain research and license agreements during the three months ended September 30, 2023, with no similar milestone activity for the three months ended September 30, 2024; and â€¢$26.6 million increase in the offset to expense associated with a collaboration reimbursement from Roche, primarily due to reimbursable costs associated with the termination of the Thermo Agreement during the three months ended September 30, 2024, with no similar activity for the three months ended September 30, 2023. This was partially offset by a decrease in clinical supply costs due to timing for our SRP-9001 gene therapy programs. Â Â Â For the Nine Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â Manufacturing expenses* Â $ 256,971 Â Â $ 290,176 Â Â $ (33,205) Â Â (11)% Clinical trial expenses Â Â 125,731 Â Â Â 134,580 Â Â Â (8,849) Â Â (7)% Compensation and other personnel expenses Â Â 118,208 Â Â Â 120,696 Â Â Â (2,488) Â Â (2)% Facility- and technology-related expenses Â Â 66,924 Â Â Â 65,458 Â Â Â 1,466 Â Â Â 2 % Stock-based compensation Â Â 54,113 Â Â Â 60,315 Â Â Â (6,202) Â Â (10)% Professional services Â Â 22,256 Â Â Â 19,815 Â Â Â 2,441 Â Â Â 12 % Pre-clinical expenses Â Â 5,666 Â Â Â 8,927 Â Â Â (3,261) Â Â (37)% Research and other Â Â 55,215 Â Â Â 64,633 Â Â Â (9,418) Â Â (15)% Roche collaboration reimbursement Â Â (100,515) Â Â (82,730) Â Â (17,785) Â Â 21 % Total research and development expenses Â $ 604,569 Â Â $ 681,870 Â Â $ (77,301) Â Â (11)% Â 33 Â Â *Beginning in the period ended March 31, 2024, we implemented an updated manufacturing absorption methodology that allocates the absorption of indirect manufacturing costs to their respective originating categories. Research and development expenses by category, specifically, manufacturing expenses, compensation and other personnel expenses, facility- and technology-related expenses and professional services, have been reclassified for the period ended September 30, 2023 for comparability. This reallocation has no impact on the total research and development expenses recognized. Â Research and development expenses for the nine months ended September 30, 2024 decreased by $77.3 million, or 11%, compared with the nine months ended September 30, 2023. The decrease was primarily driven by the following: â€¢$33.2 million decrease in manufacturing expenses primarily due to the capitalization of commercial batches of ELEVIDYS manufactured upon its approval in June 2023, a decrease in clinical batches for our Eteplirsen program and a decrease in activity for our PPMO platform, partially offset by $91.9 million of costs associated with the termination of the Thermo Agreement. Please refer to Note 16, Commitments and Contingencies for further discussion of the Thermo Agreement; â€¢$8.8 million decrease in clinical trial expenses primarily due to a ramp-down of the ESSENCE studies for AMONDYS 45 and VYONDYS 53 and our EMBARK study, partially offset by an increased patient enrollment and site activation for our EXPEDITION and EMERGENE studies during the nine months ended September 30, 2024; â€¢$2.5 million decrease in compensation and other personnel expenses primarily due to an increase in indirect manufacturing costs absorption offset as a result of ELEVIDYS approval in June 2023 and expanded label in June 2024, partially offset by changes in headcount; â€¢$1.5 million increase in facility- and technology-related expenses primarily due to our continuing expansion efforts, partially offset by an increase in indirect manufacturing costs absorption offset as a result of ELEVIDYS approval in June 2023 and expanded label in June 2024; â€¢$6.2 million decrease in stock-based compensation expense primarily due to an increase in indirect manufacturing costs absorption offset as a result of ELEVIDYS approval in June 2023 and expanded label in June 2024, partially offset by the achievement of performance conditions related to certain restricted stock units with performance conditions (â€œPSUsâ€) during the nine months ended September 30, 2024 and changes in headcount; â€¢$2.4 million increase in professional services primarily due to an increase in reliance on third-party research and development contractors for clinical programs, partially offset by a decrease in regulatory-related consulting services subsequent to ELEVIDYS approval in June 2023 and expanded label in June 2024; â€¢$3.3 million decrease in pre-clinical expenses primarily due to a decrease in toxicology study activity in our PPMO platform, partially offset by an increase in toxicology study activity in our LGMD gene therapy programs; â€¢$9.4 million decrease in research and other expenses primarily due to timing of achievement of certain up-front and milestone payments, partially offset by an increase in sponsored research with certain institutions during the nine months ended September 30, 2024; and â€¢$17.8 million increase in the offset to expense associated with a collaboration reimbursement from Roche due to reimbursable costs associated with the termination of the Thermo Agreement during the nine months ended September 30, 2024, with no similar activity for the nine months ended September 30, 2023. This was partially offset by a decrease in clinical supply costs due to timing for our SRP-9001 gene therapy programs. Selling, general and administrative expenses Selling, general and administrative expenses consist of salaries, benefits, stock-based compensation and related costs for personnel in our executive, finance, legal, information technology, business development, human resources, commercial and other general and administrative functions. Other general and administrative expenses include an allocation of our facility- and technology-related costs and professional fees for legal, consulting and accounting services. 34 Â The following tables summarize our selling, general and administrative expenses by category for each of the periods indicated: Â Â For the Three Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â Professional services Â $ 41,643 Â Â $ 39,162 Â Â $ 2,481 Â Â Â 6 % Compensation and other personnel expenses Â Â 40,545 Â Â Â 37,618 Â Â Â 2,927 Â Â Â 8 % Stock-based compensation Â Â 25,416 Â Â Â 25,736 Â Â Â (320) Â Â (1)% Facility- and technology-related expenses Â Â 13,531 Â Â Â 11,923 Â Â Â 1,608 Â Â Â 13 % Other Â Â 7,267 Â Â Â 6,601 Â Â Â 666 Â Â Â 10 % Roche collaboration reimbursement Â Â (202) Â Â (147) Â Â (55) Â Â 37 % Total selling, general and administrative expenses Â $ 128,200 Â Â $ 120,893 Â Â $ 7,307 Â Â Â 6 % Â Selling, general and administrative expenses for the three months ended September 30, 2024 increased by $7.3 million, or 6%, compared with the three months ended September 30, 2023. This increase was primarily driven by the following: â€¢$2.5 million increase in professional service expenses primarily related to the continued efforts to commercialize ELEVIDYS, partially offset by lower expenses related to ongoing litigation matters; â€¢$2.9 million increase in compensation and other personnel expenses primarily due to changes in headcount; and â€¢$1.6 million increase in facility- and technology-related expenses primarily due to our continuing expansion efforts. Â Â Â For the Nine Months EndedSeptember 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â Professional services Â $ 125,341 Â Â $ 112,050 Â Â $ 13,291 Â Â Â 12 % Compensation and other personnel expenses Â Â 122,725 Â Â Â 114,414 Â Â Â 8,311 Â Â Â 7 % Stock-based compensation Â Â 80,511 Â Â Â 76,373 Â Â Â 4,138 Â Â Â 5 % Facility- and technology-related expenses Â Â 38,026 Â Â Â 32,189 Â Â Â 5,837 Â Â Â 18 % Other Â Â 28,005 Â Â Â 15,777 Â Â Â 12,228 Â Â Â 78 % Roche collaboration reimbursement Â Â (609) Â Â (632) Â Â 23 Â Â Â (4)% Total selling, general and administrative expenses Â $ 393,999 Â Â $ 350,171 Â Â $ 43,828 Â Â Â 13 % Â Selling, general and administrative expenses for the nine months ended September 30, 2024 increased by $43.8 million, or 13%, compared with the nine months ended September 30, 2023. This increase was primarily driven by the following: â€¢$13.3 million increase in professional service expenses primarily related to the continued efforts to commercialize ELEVIDYS and ongoing litigation matters; â€¢$8.3 million increase in compensation and other personnel expenses primarily due to changes in headcount; â€¢$4.1 million increase in stock-based compensation expense primarily related to the achievement of performance conditions related to certain PSUs during the nine months ended September 30, 2024; â€¢ $5.8 million increase in facility- and technology-related expenses primarily due to our continuing expansion efforts; and â€¢$12.2 million increase in other expenses primarily due to the timing of charitable contribution activity. Amortization of in-licensed rights Amortization of in-licensed rights relates to the agreements we entered into with UWA, Nationwide, BioMarin, and Parent Project Muscular Dystrophy in April 2013, December 2016, July 2017 and May 2018, respectively. Each in-licensed right is being amortized on a straight-line basis over the remaining life of the relevant patent from the date the related fee was incurred, either the regulatory approval of or the first commercial sale of the applicable product. For the three and nine months ended September 30, 2024, we recorded amortization of in-licensed rights of approximately $0.6 million and $1.8 million, respectively. For the three and nine months ended September 30, 2023, we recorded amortization of in-licensed rights of approximately $0.4 million and $0.8 million, respectively. 35 Â Other income (expense), net Other income (expense), net primarily consists of interest expense on our debt instruments, interest income on our cash, cash equivalents and investments, amortization of investment premium or accretion of investment discount, unrealized gain or loss from our investment in our strategic investments, the changes in the fair value of the derivative assets associated with the capped call options for our $570.0 million aggregate principal amount of senior convertible notes due on November 15, 2024 (the â€œ2024 Notesâ€) and the changes in the fair value of contingent consideration related to regulatory-related contingent payments meeting the definition of a derivative liability. Our cash equivalents and investments consist of money market funds, corporate bonds, commercial paper, government and government agency debt securities and certificates of deposit. For the three months ended September 30, 2024, other income, net, was $11.8 million and for the three months ended September 30, 2023, other expense, net was $12.3 million. The change is primarily due to the impairment of a strategic investment during the three months ended September 30, 2023, with no similar activity during the three months ended September 30, 2024. For the nine months ended September 30, 2024 and 2023, other income, net was $32.6 million and $17.3 million, respectively. The change is primarily due to the impairment of a strategic investment during the nine months ended September 30, 2023, with no similar activity during the nine months ended September 30, 2024. This change was partially offset by a decrease in interest income due to the investment mix of our investment portfolio and an increase in the fair value of derivatives, primarily related to contingent consideration. Income tax expense Income tax expense for the three and nine months ended September 30, 2024 was approximately $0.4 million and $12.8 million, respectively. Income tax expense for the three and nine months ended September 30, 2023 was approximately $7.8 million and $21.2 million, respectively. Income tax expense for the three and nine months ended September 30, 2024 and 2023 relates to state, federal and foreign income taxes for which available tax losses or credits were not available to offset. As of September 30, 2024, we continued to maintain a full valuation allowance against our deferred tax assets, with the exception of deferred tax assets in certain foreign jurisdictions. We continue to monitor the available evidence relative to recovery of our deferred tax assets and whether such evidence would be sufficient to conclude that it is more likely than not that such deferred tax assets may be partially or fully recoverable. If we were to remove our valuation allowance in part or full, any such adjustment could have a material impact on our effective tax rate in the applicable period and beyond. Liquidity and Capital Resources There have been no material changes to our obligations under lease arrangements as reported in our Annual Report on Form 10-K for the year ended December 31, 2023. The following table summarizes our financial condition for each of the periods indicated: Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â Financial assets: Â Â Â Â Â Â Â Â Â Â Â Cash and cash equivalents Â $ 197,855 Â Â $ 428,430 Â Â $ (230,575) Â Â (54)% Short-term investments Â Â 1,000,534 Â Â Â 1,247,820 Â Â Â (247,286) Â Â (20)% Non-current investments Â Â 181,770 Â Â Â â€” Â Â Â 181,770 Â Â NM* Â Restricted cash Â Â 15,579 Â Â Â 15,579 Â Â Â â€” Â Â Â (â€”)% Total cash, cash equivalents and investments Â $ 1,395,738 Â Â $ 1,691,829 Â Â $ (296,091) Â Â (18)% Â Â Â Â Â Â Â Â Â Â Â Borrowings: Â Â Â Â Â Â Â Â Â Â Â Convertible debt Â $ 1,227,560 Â Â $ 1,237,998 Â Â $ (10,438) Â Â (1)% Total borrowings Â $ 1,227,560 Â Â $ 1,237,998 Â Â $ (10,438) Â Â (1)% Â Â Â Â Â Â Â Â Â Â Â Working capital Â Â Â Â Â Â Â Â Â Â Â Current assets Â $ 2,685,369 Â Â $ 2,579,331 Â Â $ 106,038 Â Â Â 4 % Current liabilities Â Â 699,489 Â Â Â 653,659 Â Â Â 45,830 Â Â Â 7 % Total working capital Â $ 1,985,880 Â Â $ 1,925,672 Â Â $ 60,208 Â Â Â 3 % Â * NM: not meaningful 36 Â Â For the periods ended September 30, 2024 and December 31, 2023, our principal sources of liquidity were primarily derived from sales of our products, net proceeds from sale of the ELEVIDYS Priority Review Voucher, net proceeds from our offering of 1.25% convertible senior notes due on September 15, 2027 (â€œ2027 Notesâ€), proceeds from the partial settlement of capped call options associated with the exchange of a portion of the 2024 Notes for shares of our common stock and our collaboration arrangement with Roche. Our principal uses of cash are research and development expenses, manufacturing costs, selling, general and administrative expenses, investments, capital expenditures, business development transactions, settlement of long-term debt and other working capital requirements. The changes in our working capital primarily reflect the use of cash in operating activities. While our contractual obligations, commitments and debt service requirements over the next several years are significant, we intend to continue to fund our short-term financing needs and working capital requirements from cash flows of operating activities as well as cash on hand and such sources are anticipated to be adequate to fund working capital requirements for at least twelve months from the date these unaudited condensed consolidated financial statements were issued. Beyond September 30, 2025, our cash requirements will depend extensively on our ability to advance our research, development and commercialization of product candidates. We may seek additional financings primarily from, but not limited to, the sale and issuance of equity and debt securities, the licensing or sale of our technologies, and entering into additional government contracts and/or funded research and development agreements. Our future expenditures and long-term capital requirements may be substantial and will depend on many factors, including but not limited to the following: â€¢our ability to continue to generate revenues from sales of commercial products and potential future products; â€¢the timing and costs associated with our expansion efforts; â€¢the timing and costs of building out our manufacturing capabilities; â€¢the timing of payments related to our future inventory commitments and manufacturing obligations; â€¢the timing and costs associated with our existing lease obligations and new obligations expected to be entered into in future years; â€ ¢the timing and costs associated with our clinical trials and pre-clinical trials; â€¢the attainment of milestones and our obligations to make milestone payments to Myonexus Therapeutics, Inc.'s selling shareholders, BioMarin, Nationwide, UWA and other institutions; â€¢obligations to holders of our convertible notes; and â€¢the costs of filing, prosecuting, defending and enforcing patent claims and our other intellectual property rights. We cannot provide assurances that financing will be available when and as needed or that, if available, the financings will be on favorable or acceptable terms. If we are unable to obtain additional financing when and if we require, this would have a material adverse effect on our business and the results of operations. To the extent we issue additional equity securities, our existing stockholders could experience substantial dilution. We believe that existing cash and cash equivalents, along with future cash generated from operations will be sufficient to meet the capital requirements of our operations for the next 12 months and foreseeable future. We have entered into long-term contractual arrangements from time to time for our facilities, the provision of goods and services, and issuance of debt securities, among others. Additional information regarding our obligations under debt, lease and manufacturing arrangements are provided in Note 10, Indebtedness, Note 13, Leases and Note 16, Commitments and Contingencies to the unaudited condensed consolidated financial statements contained in Item 1. There have been no material changes to our obligations under leasing arrangements as reported in our Annual Report on Form 10-K for the year ended December 31, 2023. 37 Â For products and product candidates that are currently approved or are in various research and development stages, we may be obligated to make up to $2.7 billion of future development, regulatory, up-front royalty and sales milestone payments associated with our license and collaboration agreements. Payments under these agreements generally become due and payable upon the achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones is not probable, and payment is not required as of September 30, 2024, such contingencies have not been recorded in our unaudited condensed consolidated financial statements. Amounts related to contingent milestone payments are not yet considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones. Cash Flows The following table summarizes our cash flow activity for each of the periods indicated: Â Â Â For the Nine Months Ended Â Â Â Â Â Â Â Â Â September 30, Â Â Â Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â Change Â Â Â (in thousands) Â Â $ Â Â % Â Cash (used in) provided by Â Â Â Â Â Â Â Â Â Â Â Operating activities Â $ (297,833) Â $ (446,336) Â $ 148,503 Â Â Â (33)% Investing activities Â Â (8,557) Â Â (101,445) Â Â 92,888 Â Â Â (92)% Financing activities Â Â 75,815 Â Â Â 123,061 Â Â Â (47,246) Â Â (38)% Decrease in cash, cash equivalents and restricted cash Â $ (230,575) Â $ (424,720) Â $ 194,145 Â Â Â (46)% Operating Activities Cash used in operating activities, which consists of our net income (loss) adjusted for non-cash items and changes in net operating assets and liabilities, totaled $297.8 million and $446.3 million for the nine months ended September 30, 2024 and 2023, respectively. Cash used in operating activities for the nine months ended September 30, 2024 was primarily driven by the net income of $76.2 million, adjusted for the following non-cash items: â€¢$134.6 million in stock-based compensation expense; â€¢$62.7 million in non-cash termination charges as a result of the Thermo Agreement termination; â€¢$27.3 million in depreciation and amortization expense; â€¢$12.3 million reduction in the carrying amount of the right of use assets; â€¢$8.6 million charge related to the change in the fair value of derivatives; and â€¢$5.6 million in other items. These amounts were partially offset by $33.5 million in accretion of investment discount, net. The net cash outflow from changes in our operating assets and liabilities was primarily driven by the following: â€¢$235.5 million increase in manufacturing-related deposits and prepaids primarily due to an increase in prepaid raw materials and batch fees with Catalent; â€¢ $233.5 million increase in inventory primarily due to capitalized inventory related to ELEVIDYS; â€¢$39.4 million increase in other assets primarily due to an increase in the collaboration receivable related to Roche; â€¢$35.4 million decrease in deferred revenue primarily related to the collaboration with Roche; â€¢$34.2 million increase in accounts receivable due to an

increase in payment terms for product sales related to the PMO Products; and â€¢$13.6 million decrease in accounts payable, accrued expenses, lease liabilities and other liabilities, primarily due to the timing and invoicing of payments with our contract research organizations and contract manufacturing organizations. Cash used in operating activities for the nine months ended September 30, 2023 was primarily driven by the net loss of $581.6 million, adjusted for the following non-cash items: â€¢$387.3 million in loss on debt extinguishment related to the exchange of 2024 Notes; 38 Â â€¢$136.7 million in stock-based compensation expense; â€¢$33.0 million in depreciation and amortization expense; â€¢$27.8 million in impairments associated with our strategic investments; and â€¢$16.1 million in other non-cash items. These amounts were partially offset by the gain of $102.0 million recorded from the sale of the ELEVIDYS Priority Review Voucher and $32.8 million in accretion of investment discount, net. The net cash outflow from changes in our operating assets and liabilities was primarily driven by the following: â€¢$111.2 million decrease in accounts payable, accrued expenses, lease liabilities and other liabilities, primarily due to the $54.0 million shortfall payment to Thermo made during the nine months ended September 30, 2023, payments to Catalent for raw materials and the overall timing and invoicing of payments; â€¢$104.2 million increase in accounts receivable due to sales of ELEVIDYS and an increase in the demand of our PMO Products; â€¢$66.8 million decrease in deferred revenue related to the collaboration with Roche; and â€¢$53.6 million increase in inventory due to the addition of capitalized inventory after the approval of ELEVIDYS in June 2023. These amounts were partially offset by a $7.9 million decrease in manufacturing-related deposits and prepaids primarily due to the timing and usage of manufacturing prepaids. Investing Activities Cash used in investing activities was $8.6 million and $101.4 million for the nine months ended September 30, 2024 and 2023, respectively. Cash used in investing activities for the nine months ended September 30, 2024 primarily consisted of $936.7 million of purchases of available-for-sale securities, $98.9 million of purchases of property and equipment and $10.0 million of purchases of intangible assets, partially offset by $1,037.0 million from the maturity and sale of available-for-sale securities. Cash used in investing activities for the nine months ended September 30, 2023 primarily consisted of $1,475.4 million of purchases of available-for-sale securities, $57.1 million of purchases of property and equipment and $11.2 million of purchases of intangible assets, partially offset by $102.0 million of net proceeds related to the sale of the ELEVIDYS Priority Review Voucher and $1,340.3 million from the maturity of available-for-sale securities. Financing Activities Cash provided by financing activities was $75.8 million and $123.1 million for the nine months ended September 30, 2024 and 2023, respectively. Cash provided by financing activities for the nine months ended September 30, 2024 consisted of $75.8 million in proceeds from exercise of options and purchase of stock under our Employee Stock Purchase Program. Cash provided by financing activities for the nine months ended September 30, 2023 consisted of $80.6 million in partial settlement of capped call share options for the 2024 Notes and $49.3 million in proceeds from exercise of options and purchase of stock under our Employee Stock Purchase Program, partially offset by $6.9 million in third-party debt conversion costs related to the exchange of 2024 Notes. Item 3. Quantitative and Qualitative Disclosures about Market Risk Our current investment policy is to maintain a diversified investment portfolio consisting of money market investments, commercial paper, certificates of deposit, government and government agency bonds and high-grade corporate bonds with maturities of 24 months or less. Our cash is primarily deposited in and invested through highly rated financial institutions in the U.S. As of September 30, 2024, we had approximately $1,395.8 million of cash, cash equivalents, restricted cash and investments, comprised of $197.9 million of cash and cash equivalents, $1,182.3 million of investments, and $15.6 million of restricted cash. The Company only holds debt securities classified as available-for-sale. The fair value of cash equivalents and short-term investments is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 10 basis point adverse movement across all maturities. As of September 30, 2024, we estimate that 39 Â such hypothetical 10 basis point adverse movement would result in a hypothetical loss in fair value of approximately $0.6 million to our interest rate sensitive instruments. Â Our $1,150.0 million aggregate principal amount of our 2027 Notes has a fixed interest rate of 1.25% per annum, payable semi-annually in cash on each March 15 and September 15 and our $91.6 million aggregate principal amount of our 2024 Notes has a fixed interest rate of 1.5% per annum, payable semi-annually in cash on each May 15 and November 15, and therefore are not subject to fluctuations in market interest rates. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures We carried out an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q for the period ended September 30, 2024, under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of our disclosure controls and procedures pursuant to paragraph (b) of Rules 13a-15 and 15d-15 under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). The purpose of this evaluation was to determine whether as of the evaluation date our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in our filings with the SEC under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms and (ii) is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on that evaluation, management has concluded that as of September 30, 2024, our disclosure controls and procedures were effective. Changes in Internal Control over Financial Reporting During the quarterly period ended September 30, 2024, there were no changes in our internal controls over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting. Â 40 Â PART II OTHER INFORMATION Item 1. Legal Proceedings For material legal proceedings, please read Note 16, Commitments and Contingencies to our unaudited condensed consolidated financial statements included in this report. Item 1A. Risk Factors. Set forth below and elsewhere in this report and in other documents we file with the SEC are descriptions of risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements contained in this report. Because of the following factors, as well as other variables affecting our operating results, past financial performance should not be considered a reliable indicator of future performance and investors should not use historical trends to anticipate results or trends in future periods. The risks and uncertainties described below are not the only ones facing us. Other events that we do not currently anticipate or that we currently deem immaterial also affect our results of operations and financial condition. Risks Related to Our Business We are highly dependent on the commercial success of our products in the U.S. We may not be able to meet expectations with respect to sales of our products or maintain or attain profitability and positive cash-flow from operations, as applicable. The FDA granted accelerated approval for EXONDYS 51, VYONDYS 53, AMONDYS 45 and ELEVIDYS, as therapeutic treatments for Duchenne in patients who have a confirmed mutation in the dystrophin gene that is amenable to exon 51, exon 53, exon 45 skipping, and ambulatory patients with Duchenne with a confirmed mutation in the Duchenne gene, respectively. EXONDYS 51 has been approved for marketing only in the U.S., Israel, Kuwait and Libya, AMONDYS 45 in the U.S., Kuwait, and Libya and VYONDYS 53 in the U.S., Kuwait and Libya and ELEVIDYS in the U.S, and our partner for ELEVIDYS, Roche, has received certain approvals for ELEVIDYS in territories outside of the United States. Our commercial PMO products are also available in additional countries through our EAP. The commercial success of our products continues to depend on, and the commercial success of any future products would depend on, a number of factors attributable to one of our products or the products of our competitors, including, but not limited to: â€¢the effectiveness of our sales, managed markets, marketing efforts and support for our products; â€¢the generation and dissemination of new data analyses and the consistency of any new data with prior results, whether they support a favorable safety, efficacy and effectiveness profile of our products and any potential impact on our FDA accelerated approval status and/or FDA package insert for our products; â€¢the effectiveness of our ongoing commercialization activities, including negotiating and entering into any additional commercial, supply and distribution contracts, ongoing manufacturing efforts and hiring any additional personnel as needed to support commercial efforts; â€¢our ability to timely comply with FDA post-marketing requirements and commitments, including through successfully conducting additional studies that confirm clinical efficacy, effectiveness and safety of our products and acceptance of the same by the FDA and medical community since continued approval may be contingent upon verification of a clinical benefit in confirmatory trials, particularly in light of FDA's expanded expedited withdrawal procedures as set forth in the Food and Drug Omnibus Reform Act of 2022 (â€œFDORAâ€); â€¢the occurrence of any side effects, adverse reactions or misuse, or any unfavorable publicity in these areas; â€¢the generation of evidence describing payers, patients and/or societal value of our products; â€¢whether we can consistently manufacture our products and product candidates at acceptable costs; â€¢the rate and consistency with which our products are prescribed by physicians, which depends on physiciansâ€™ views on the safety, effectiveness and efficacy of our products; â€¢our ability to secure and maintain adequate reimbursement for our products, including the duration of the prior-authorization as well as the number and duration of re-authorization processes required for patients who initially obtained coverage by third parties, including by government payors, managed care organizations and private health insurers; â€¢our ability to obtain and maintain patent protection for our products, to preserve our trade secrets, to prevent third parties from infringing on our proprietary rights and to operate without infringing on the proprietary rights of third parties; 41 Â â€¢the development, commercialization or pricing of competing products or therapies for the treatment of Duchenne, or its symptoms, and the existence of competing clinical trials; â€¢our ability to increase awareness of the importance of genetic testing and knowing/understanding Duchenne mutations, and identifying and addressing procedural barriers to obtaining therapy; â€¢our ability to remain compliant with evolving laws and regulations that apply to us and our commercial activities; â€¢the actual market-size, ability to identify patients and the demographics of patients eligible for our products, which may be different than expected; â€¢the sufficiency of our drug supply to meet commercial and clinical demands and standards, which are negatively impacted by various factors, including when our projections on the potential number of amenable patients and their average weight are inaccurate; the potential impacts of the COVID-19 pandemic; if regulatory requirements increase our drug supply needs; if our current drug supply is destroyed or negatively impacted at our manufacturing sites, storage sites or in transit; failure to meet cGMP requirements; or if we encounter delays expanding the number of patients on our products and portions of our productsâ€™ supply expire before sale; â€¢our ability to obtain regulatory approvals to commercialize our product candidates, and to commercialize our products in markets outside of the U.S.; â€¢the process leading to a patientâ€™s first infusion of our products and any future commercial products may be slower for certain patients. For example, the time to first infusion may take longer if a patient chooses to put in an intravenous port, which eases access to the vein. In addition, the capacity of any infusion centers responsible for the administration of ELEVIDYS may impact timing. Delays in the process prior to infusion could negatively impact the sales of our products, including any future gene therapy products; and â€¢the exercise by Roche of its option to obtain an exclusive license to commercialize one or more of our Duchenne products beyond ELEVIDYS outside of the U.S. and Rocheâ€™s subsequent commercialization efforts. We experience significant fluctuations in sales of our products from period to period and, ultimately, we may never generate sufficient revenues from our products to maintain profitability or sustain our anticipated levels of operations. Even though EXONDYS 51, VYONDYS 53, AMONDYS 45 and ELEVIDYS have received accelerated approval from the FDA, they face future post-approval development and regulatory requirements, which present additional challenges for us to successfully navigate. The accelerated approvals for EXONDYS 51, VYONDYS 53 and AMONDYS 45 granted by the FDA were based on an increase in the surrogate biomarker of dystrophin in skeletal muscles observed in some patients treated with these products. The accelerated approval for ELEVIDYS in non-ambulatory patients granted by the FDA was based on an effect on the surrogate endpoint of expression ELEVIDYS micro-dystrophin, of the protein produced by ELEVIDYS. These products are subject to ongoing FDA requirements governing labeling, packaging, storage, advertising, promotion and recordkeeping, and we are required to submit additional safety, efficacy and other post-marketing information to the FDA. Under the accelerated approval pathway, continued approval may be contingent upon verification of a clinical benefit in confirmatory trials. These post-approval requirements and commitments may not be feasible and/or could impose significant burdens and costs on us; could negatively impact our development, manufacturing and supply of our products; and could negatively impact our financial results. Failure to meet post-approval commitments and requirements, including completion of enrollment and in particular, any failure to obtain positive safety and efficacy data from our ongoing and planned studies of our products, would lead to negative regulatory action from the FDA and/or withdrawal of regulatory approval of EXONDYS 51, VYONDYS 53, AMONDYS 45 or ELEVIDYS. The recently enacted FDORA has expanded FDA's expedited withdrawal procedures for drugs approved via the accelerated approval pathway if a sponsor fails to conduct any required post-approval study with due diligence. Manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. Drug product manufacturers are required to continuously monitor and report adverse events from clinical trials and commercial use of the product. If we or a regulatory agency discover previously unknown adverse events or events of unanticipated severity or frequency, a regulatory agency may require labeling changes, implementation of risk evaluation and mitigation strategy program, or additional post-marketing studies or clinical trials. If we or a regulatory agency discover previously unknown problems with a product, such as problems with a facility where the API or drug product is manufactured or tested, a regulatory agency may impose restrictions on that product and/or the manufacturer, including removal of specific product lots from the market, withdrawal of the product from the market, suspension of manufacturing or suspension of clinical trials using the same manufacturing materials. Sponsors of drugs approved under FDA accelerated approval provisions also are required to submit to the FDA, at least 30 days before initial use, all promotional materials intended for use after the first 120 days following marketing approval. If we or the manufacturing facilities for our products fail to comply with applicable regulatory requirements, a regulatory agency may: â€¢issue warning letters or untitled letters; 42 Â â€¢seek an injunction or impose civil or criminal penalties or monetary fines; â€¢suspend or withdraw or alter the conditions of our marketing approval; â€¢mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners; â€¢suspend any ongoing clinical trials; â€¢require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance; â€¢refuse to approve pending applications or supplements to applications submitted by us; â€¢suspend or impose restrictions on operations, including costly new manufacturing requirements; â€¢seize or detain products, refuse to permit the import or export of products or require us to initiate a product recall; or â€¢refuse to allow us to enter into supply contracts, including government contracts. We are subject to uncertainty relating to reimbursement policies which, if not favorable, could hinder or prevent the commercial success of our products and/or product candidates. Our ability to successfully maintain and/or increase sales of our products in the U.S. depends in part on the coverage and reimbursement levels set by governmental authorities, private health insurers and other third-party payors. Third party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. We may not be able to obtain or maintain adequate third-party coverage or reimbursement for our products, and/or we may be required to provide discounts or rebates on our products in order to obtain or maintain adequate coverage. We expect that private insurers will continue to consider the efficacy, effectiveness, cost-effectiveness and safety of our products, including any new data and analyses that we are able to collect and make available in a compliant manner, in determining whether to approve reimbursement for our products and at what levels. If there are considerable delays in the generation of new evidence or if any new data and information we collect is not favorable, third party insurers may make coverage decisions that negatively impact sales of our products. We continue to have discussions with payors, some of which may eventually deny coverage. We may not receive approval for reimbursement of our products from additional insurers on a satisfactory rate or basis, in which case our business would be materially adversely affected. In addition, obtaining these approvals can be a time consuming and expensive process. Our business would be materially adversely affected if we are not able to maintain favorable coverage decisions and/or fail to receive additional favorable coverage decisions from third party insurers, in particular during re-authorization processes for patients that have already initiated therapy. Our business could also be adversely affected if government health programs, private health insurers, including managed care organizations, or other reimbursement bodies or payors limit the indications for which our products will be reimbursed or fail to recognize approval or accelerated approval and surrogate endpoints as clinically meaningful. Furthermore, we cannot predict to what extent an economic recession, changes in fiscal policy or general increase in unemployment rates may disrupt global healthcare systems and access to our products or result in a widespread loss of individual health insurance coverage due to unemployment or trends in employee attrition, a shift from commercial payor coverage to government payor coverage, or an increase in demand for patient assistance and/or free drug programs, any of which would adversely affect access to our products and our net sales. In some foreign countries, particularly Canada and the countries of Europe, Latin America and Asia Pacific, the pricing and reimbursement of prescription pharmaceuticals is subject to strict governmental control. In these countries, pricing and reimbursement negotiations with governmental authorities can take 12 to 24 months or longer after the receipt of regulatory approval and product launch. In order to obtain favorable reimbursement for the indications sought or pricing approval in some countries, we may be required to collect additional data, including conducting additional studies. Furthermore, several countries around the world have implemented government measures to either freeze or reduce pricing of pharmaceutical products. If reimbursement for our products is unavailable in any country in which reimbursement is sought, limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed. In addition, many foreign countries reference to other countriesâ€™ official public list price, hence an unsatisfactory price level in one country could consequently impinge negatively upon overall revenue. We expect to experience pricing pressures in connection

with the sale of our current and future products due to a number of factors, including current and future healthcare reforms and initiatives by government health programs and private insurers (including managed care plans) to reduce healthcare costs, the scrutiny of pharmaceutical pricing, the ongoing debates on reducing government spending and additional legislative proposals. These healthcare reform efforts or any future legislation or regulatory actions aimed at 43 Â controlling and reducing healthcare costs, including through measures designed to limit reimbursement, restrict access or impose unfavorable pricing modifications on pharmaceutical products, could impact our and our partnersâ€™ ability to obtain or maintain reimbursement for our products at satisfactory levels, or at all, which could materially harm our business and financial results. Additionally, ELEVIDYS and our gene therapy product candidates represent novel approaches to treatment that will call for new levels of innovation in both pricing, reimbursement, payment and drug access strategies. Current reimbursement models may not accommodate the unique factors of our gene therapy product and product candidates, including high up-front costs, lack of long-term efficacy and safety data and fees associated with complex administration, dosing and patient monitoring requirements. Hence, it may be necessary to restructure approaches to payment, pricing strategies and traditional payment models to support these therapies. The downward pressure on healthcare costs in general has become intense. As a result, increasingly high barriers are being erected to the entry of new products. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our products and product candidates will be harmed. The manner and level at which reimbursement is provided for services related to our products and product candidates (e.g., for administration of our products to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and limit our ability to market or sell our products. Healthcare policy reform and other governmental and private payor initiatives may have an adverse effect upon, and could prevent commercial success of our products and product candidates. The U.S. government and individual states continue to aggressively pursue healthcare reform, which includes ongoing attempts to manage utilization as well as control and/or lower the cost of prescription drugs and biologics. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results, and we cannot predict how future federal or state legislative, judicial or administrative changes relating to healthcare policy will affect our business. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs to limit the growth of government-paid and private insurance healthcare costs, including proposed or implemented reforms involving price controls, waivers from Medicaid drug rebate law requirements, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs and implementing new requirements for, or eliminating caps on, rebates paid on products under government healthcare programs. We anticipate that the Biden Administration and Congress, state legislatures and the private sector will continue to consider and may adopt healthcare policies intended to curb rising healthcare costs, and specifically prescription drug costs. These cost containment measures may include, among other possible actions, implementation or modification of: â€¢controls on government funded reimbursement for drugs; â€¢caps or mandatory discounts under certain government sponsored programs; â€¢caps on drug reimbursement under commercial insurance; â€¢challenges to the pricing of drugs or limits or prohibitions on reimbursement for specific products through other means; â€¢reform of drug importation laws; â€¢delegation of decision making to state Medicaid agencies and waiver of reimbursement requirements; â€¢expansion of use of managed care systems in which healthcare providers contract to provide comprehensive healthcare for a fixed cost per person; and â€¢prohibition on direct-to-consumer advertising or drug marketing practices. In recent years, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Additionally, in its 2024 decision in Loper Bright Enterprises v. Raimondo, the U.S. Supreme Court overruled the â€œChevron doctrine,â€ which gives deference to regulatory agenciesâ€™ statutory interpretations in litigation against federal government agencies, such as the FDA, CMS and other federal agencies where the law is ambiguous. This Supreme Court decision may lead to challenges of longstanding decisions and policies of these agencies, which could lead to uncertainties in the industry and disrupt the federal agencyâ€™s operations. 44 Â We are unable to predict what additional legislation, regulations or policies, if any, relating to the healthcare industry or third party coverage and reimbursement may be enacted in the future or what effect such legislation, regulations or policies would have on our business. Any cost containment measures, including those listed above, or other healthcare system reforms that are adopted, could significantly decrease the available coverage and the price we might establish for our products and product candidates, which would have an adverse effect on our net revenues and operating results. Our products may not be widely adopted by patients, payors or healthcare providers, which would adversely impact our potential profitability and future business prospects. The commercial success of our products, particularly in the U.S., depends upon the level of market adoption by patients, payors and healthcare providers. If our products do not achieve an adequate level of market adoption for any reason, or if market adoption does not persist, our potential profitability and our future business prospects will be severely adversely impacted. The degree of market acceptance of our products depends on a number of factors, including: â€¢our ability to demonstrate to the medical and payor community, including specialists who may purchase or prescribe our products, the clinical efficacy, effectiveness and safety of our products as the prescription products of choice for their respective indications; â€¢the effectiveness of our sales and marketing organizations and distribution networks; â€¢the ability of patients or providers to be adequately reimbursed for our products in a timely manner from government and private payors; â€¢the ability to timely demonstrate to the satisfaction of payors real world effectiveness and the economic, humanistic, societal and clinical benefits of our products; â€¢the burden or efficiency of payer prior authorization processes and the ability of families and physicians to navigate them; â€¢the actual and perceived efficacy and safety profile of our products, particularly if unanticipated adverse events related to our productsâ€™ treatment arise and create safety concerns among potential patients or prescribers or if new data and analyses we obtain for our products do not support, or are interpreted by some parties to not support, the efficacy of our products; and â€¢the efficacy and safety of our other exon-skipping and gene therapy product candidates and third partiesâ€™ competitive therapies. Further, the potential commercial success of our product candidates as well as ELEVIDYS will depend on additional factors, including the capacity of any infusion centers responsible for the administration of our product candidates and ELEVIDYS. ELEVIDYS and our gene therapy product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events. Failure of other gene therapy programs, negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of ELEVIDYS or our gene therapy product candidates and harm our ability to conduct our business or obtain regulatory approvals for ELEVIDYS or our gene therapy product candidates. Gene therapy remains a newly applied technology, with only a few gene therapy products approved to date in the U.S., the EU or elsewhere, including ELEVIDYS. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians who specialize in the treatment of genetic diseases targeted by our product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. In addition, ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional regulations or prohibiting the processes we may use. Federal and state agencies, congressional committees and foreign governments have expressed their intentions to further regulate biotechnology. More restrictive regulations or claims that our products or product candidates are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be. More restrictive government regulations or negative public opinion would harm our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our gene therapy product candidates or 45 Â demand ELEVIDYS or any other products we may develop. For example, earlier gene therapy trials led to several well-publicized adverse events, including death, and recent gene therapy trials have failed to demonstrate efficacy. Lack of efficacy and/or serious adverse events related to clinical trials we, our strategic partners or other companies conduct, even if such adverse events are not ultimately attributable to the relevant product candidates or products, and/or failed commercialization of gene therapy products may result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. We may not be able to expand the global footprint of our products outside of the U.S. EXONDYS 51 has been approved for marketing only in the U.S., Israel, Libya and Kuwait, AMONDYS 45 in the U.S., Libya and Kuwait, VYONDYS 53 in the U.S., Libya and Kuwait and ELEVIDYS in the U.S. We may not receive approval to commercialize these products in additional countries. Our partner for ELEVIDYS, Roche, has received certain approvals for ELEVIDYS in territories outside of the United States. In November 2016, we submitted a MAA for eteplirsen to the EMA and the application was validated in December 2016. As we announced on June 1, 2018, the CHMP of the EMA adopted a negative opinion for eteplirsen. In September 2018, the CHMP of the EMA confirmed its negative opinion for eteplirsen, and the European Commission adopted the CHMP opinion in December 2018. During 2019, we sought follow-up EMA scientific advice for eteplirsen. Once data from our ongoing studies are available, we plan to evaluate future engagement with the EMA on potential next steps. In order to market any product in a country outside of the U.S., we must comply with numerous and varying regulatory requirements for approval in those countries regarding demonstration of evidence of the productâ€™s safety and efficacy and governing, among other things, labeling, distribution, advertising, and promotion, as well as pricing and reimbursement of the product. Obtaining marketing approval in a country outside of the U.S. is an extensive, lengthy, expensive and uncertain process, and the regulatory authority may reject an application or delay, limit or deny approval of any of our products for many reasons, including: â€¢we may not be able to demonstrate to the satisfaction of regulatory authorities outside the U.S. the risk benefit of our products; â€¢the results of clinical trials may not meet the level of statistical or clinical significance required for approval by regulatory authorities outside the U.S.; â€¢regulatory authorities outside the U.S. may disagree with the adequacy (number, design, size, controls, conduct or implementation) of our clinical trials prior to granting approval, and we may not be able to generate the required data on a timely basis, or at all; â€¢regulatory authorities outside the U.S. may conclude that data we submit to them fail to demonstrate an appropriate level of safety or efficacy of our products, or that our productsâ€™ respective clinical benefits outweigh their safety risks; â€¢regulatory authorities outside the U.S. may not accept data generated at our clinical trial sites or require us to generate additional data or information; â€¢regulatory authorities outside the U.S. may impose limitations or restrictions on the approved labeling of our products, thus limiting intended users or providing an additional hurdle for market acceptance of the product; â€¢regulatory authorities outside the U.S. may identify deficiencies in the manufacturing processes, or may require us to change our manufacturing process or specifications; and â€¢regulatory authorities outside the U.S. may adopt new or revised approval policies and regulations. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ significantly from that required to obtain approval in the U.S. In particular, in many foreign countries, it is required that a product receives pricing and reimbursement approval before the product can be distributed commercially. Many foreign countries undertake cost-containment measures that could affect pricing or reimbursement of our products. This can result in substantial delays, and the price that is ultimately approved in some countries may be lower than the price for which we expect to offer our products. Marketing approval in one country does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country may have a negative effect on the approval process in others. Failure to obtain marketing approval in other countries or any delay or setback in obtaining such approval would impair our ability to develop foreign markets for our products and could adversely affect our business and financial condition. In addition, failure to obtain approval in one country or area may affect sales under the EAP in other countries or areas. Even if we are successful in obtaining regulatory approval of our products 46 Â in additional countries, our revenue earning capacity will depend on commercial and medical infrastructure, pricing and reimbursement negotiations and decisions with third party payors, including government payors. In addition, we have granted Roche an exclusive option to obtain an exclusive license to commercialize certain products, including eteplirsen, golodirsen and casimersen, outside of the U.S. If this option is exercised, Roche will have sole control over and decision-making authority with respect to the commercialization of such products outside the U.S. Historical revenues from eteplirsen, golodirsen and casimersen through our EAP outside the U.S. may not continue and we may not be able to continue to distribute our products through our EAP. We established a global EAP for our products in some countries where these products currently have not been approved. While we generate revenue from the distribution of these products through our EAP, we cannot predict whether historical revenues from this program will continue, whether we will be able to continue to distribute our products through our EAP, or whether revenues will exceed revenues historically generated from sales through our EAP. Reimbursement through national EAPs may cease to be available if authorization for an EAP expires or is terminated. For example, healthcare providers in EAP jurisdictions may not be convinced that their patients benefit sufficiently from our products or alternatively, may prefer to wait until such time as our products are approved by a regulatory authority in their country before prescribing any of our products. Even if a healthcare provider is interested in obtaining access to our products for its patient through the EAP, the patient may not be able to obtain access to our products if funding for the drug is not secured. Our business and financial results have not yet been materially adversely affected by the ongoing conflict between Russia and Ukraine, or the conflict in the Middle-East. As our revenue from countries outside of the United States increases, our access to patients in those regions through our EAP and our ability to generate revenue from commercial sales of our products in Russia, Ukraine or the Middle-East may be adversely affected. The United States and other nations have raised the possibility of sanctions on companies that do business with Russia or its allies, including Belarus. We also may be adversely impacted by sanctions imposed on third parties with which we do business, such as third-party distributors and service providers of our EAP. Any failure to maintain revenues from sales of our products through our EAP and/or to generate revenues from commercial sales of these products exceeding historical sales due to issues under our EAP or due to global instability, like that resulting from the ongoing conflict between Russia and Ukraine or the instability in the Middle-East, could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Failure to obtain or maintain regulatory exclusivity for our products could result in our inability to protect our products from competition and our business may be adversely impacted. If a competitor obtains an authorization to market the same or substantially same product before a product of ours is authorized in a given country and is granted regulatory exclusivity, then our product may not be authorized for sale as a result of the competitorâ€™s regulatory exclusivity and as a result, our investment in the development of that product may not be returned. In addition to any patent protection, we rely on various forms of regulatory exclusivity to protect our products. During the development of our products, we anticipate any one form of regulatory exclusivities becoming available upon approval of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country. Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenues for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations. We are not guaranteed to receive or maintain regulatory exclusivity for our current or future products, and if our products that are granted orphan status were to lose their status as orphan drugs or the data or marketing exclusivity provided for orphan drugs, our business and operations could be adversely affected. Due to the nature of our products and product candidate pipeline, in addition to new chemical entity (â€œNCEâ€) exclusivity and new biologic exclusivity, orphan drug exclusivity is especially important for our products that are eligible for orphan drug designation. For eligible products, we plan to rely on orphan drug exclusivity to maintain a competitive position. If we do not have adequate patent protection for our products, then the relative importance of obtaining regulatory exclusivity is even greater. While orphan status for any of our products, if granted or maintained, would provide market exclusivity for the time periods specified above upon approval, we would not be able to exclude other companies from obtaining regulatory approval of products using the same or similar active ingredient for the same indication during or beyond the exclusivity period applicable to our product on the basis of orphan drug status (e.g., seven years in the U.S.). For example, the exclusivity period for EXONDYS 51 ended in September 2023. Orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. A recent decision in 2021 by the U.S. Court of Appeals for the Eleventh Circuit in Catalyst Pharmaceuticals, Inc. vs. Becerra regarding interpretation of the Orphan Drug Actâ€™s exclusivity provisions as applied to drugs and 47 Â biologics approved for orphan indications narrower than the productâ€™s orphan designation has the potential to significantly broaden the scope of orphan exclusivity for such products. Depending on how FDA applies the Catalyst decision, it could impact our ability to obtain or seek to work around orphan exclusivity and might affect our ability to retain orphan exclusivity that the FDA previously has recognized for our products. Legislation has been introduced to amend the Orphan Drug Act in a way that may prevent these effects of the

Catalyst decision, but it is unclear if or when such legislation could be enacted. In addition, we may face risks with maintaining regulatory exclusivities for our products, and our protection may be circumvented, even if maintained. For instance, orphan drug exclusivity in the U.S. may be rescinded if (i) an alternative, competing product demonstrates clinical superiority to our product with orphan exclusivity; or (ii) we are unable to assure the availability of sufficient quantities of our orphan products to meet the needs of patients. Moreover, competitors may receive approval of different drugs or biologics for indications for which our prior approved orphan products have exclusivity. Orphan drug exclusivity in Europe may be modified for several reasons, including a significant change to the orphan medicinal product designations or status criteria after-market authorization of the orphan product (e.g., product profitability exceeds the criteria for orphan drug designation), problems with the production or supply of the orphan drug, or a competitor drug, although similar, is safer, more effective or otherwise clinically superior than the initial orphan drug. Thus, other companies may have received, or could receive, approval to market a product candidate that is granted orphan drug exclusivity for the same drug or similar drug and same orphan indication as any of our product candidates for which we plan to file an NDA, BLA or MAA. If that were to happen, our prior approved orphan products may face competition and any pending NDA, BLA or MAA for our product candidate for that indication may not be approved until the competing companyâ€™s period of exclusivity has expired in the U.S. or the EU, as applicable. For example, in September 2021, the FDA issued guidance concerning its position on interpreting when gene therapy products would be considered the â€œsameâ€ or â€œdifferentâ€ for purposes of orphan drug exclusivity. The guidance states that if two gene therapy products have or use different vectors, the FDA generally intends to consider them to be â€œdifferentâ€ drugs. Further, according to the guidance, the FDA generally intends to consider vectors from the same viral group (e.g., adeno-associated virus 2 (AAV2) vs. adeno-associated virus 5 (AAV5)) to be different, when the differences between the vectors impact factors such as tropism, immune response avoidance, or potential insertional mutagenesis. However, there is considerable uncertainty as to the interpretation of these guidelines. As illustrated by this guidance, orphan drug exclusivity as applied to gene therapy products is an evolving area subject to change and interpretation by the FDA and therefore, we cannot be certain as to how the FDA will apply those rules to ELEVIDYS or our gene therapy product candidates. If we are unable to successfully maintain and further develop internal commercialization capabilities, sales of our products may be negatively impacted. We have hired and trained a commercial team and put in the organizational infrastructure we believe we need to support the commercial success of our products in the U.S. Factors that may inhibit our efforts to maintain and further develop commercial capabilities include: â€¢an inability to retain an adequate number of effective commercial personnel; â€¢an inability to train sales personnel, who may have limited experience with our company or our products, to deliver a consistent message regarding our products and be effective in educating physicians on how to prescribe our products; â€¢an inability to equip sales personnel with compliant and effective materials, including medical and sales literature to help them educate physicians and our healthcare providers regarding our products and their proper administration and educate payors on the safety, efficacy and effectiveness profile of our products to support favorable coverage decisions; â€¢unforeseen costs and expenses associated with maintaining and further developing an independent sales and marketing organization; and â€¢an inability to develop effective commercial, sales and marketing infrastructure to support new product launches. If we are not successful in maintaining an effective commercial, sales and marketing infrastructure, we will encounter difficulty in achieving, maintaining or increasing projected sales of our products in the U.S., which would adversely affect our business and financial condition. 48 Â The patient population suffering from Duchenne, LGMDs, and CMT 1A is small and has not been established with precision. If the actual number of patients is smaller than we estimate, our revenue and ability to achieve profitability may be adversely affected. Duchenne, LGMD, and CMT 1A are rare, fatal genetic disorders. Duchenne affects an estimated one in approximately every 3,500 to 5,000 males born worldwide, of which up to 13% are estimated to be amenable to exon 51 skipping, up to 8% are estimated to be amenable to exon 53 skipping and up to 8% are estimated to be amenable to exon 45 skipping. LGMDs as a class affect an estimated range of approximately one in every 14,500 to one in every 123,000 individuals. CMT is a group of peripheral nerve disorders affecting approximately one in every 2,500 individuals. CMT type 1A affects approximately 50,000 patients in the U.S. Our estimates of the size of these patient populations are based on limited number of published studies as well as internal analyses. Various factors may decrease the market size of our products and product candidates, including the severity of the disease, patient demographics and the response of patientsâ€™ immune systems to our products and product candidates. If the results of these studies or our analysis of them do not accurately reflect the relevant patient population, our assessment of the market may be inaccurate, making it difficult or impossible for us to meet our revenue goals, or to obtain and maintain profitability. We face intense competition and rapid technological change, which may result in other companies discovering, developing or commercializing competitive products. The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. We are aware of many pharmaceutical and biotechnology companies that are actively engaged in research and development in areas in which our products and product candidates are aimed. Some of these competitors are developing or testing product candidates that now, or may in the future, compete directly with our products or product candidates. For example, we face competition in the field of Duchenne by third parties who are developing or who had once developed: (i) exon skipping product candidates, such as Wave (notably for exons 51 and 53), Nippon Shinyaku (notably for exon 44 and exon 53, for which it has received accelerated FDA approval for its product Viltepso (viltolarsen)), Daiichi (notably for exon 45), Dyne Therapeutics pursuing antibody-oligonucleotide conjugates for exons 44, 45, 51, and 53, Avidity Biosciences pursuing antibody-oligonucleotide conjugates for exons 44, 45 and 51, PepGen (notably for exon 51), SQY Therapeutics and BioMarin (BMN-351 for exon 51), Entrada; (ii) gene therapies, such as Genethon and Solid (also in partnership with Ultragenyx), and Regenxbio; (iii) gene editing, including CRISPR/Cas 9 approaches, such as Exonics Therapeutics (acquired by Vertex Pharmaceuticals), GenAssist, CRISPR Therapeutics, and Precision Biosciences; (iv) other disease modifying approaches, such as PTC Therapeutics, which has a small molecule candidate, ataluren, that targets nonsense mutations; and (v) other approaches that may be palliative in nature or potentially complementary with our products and product candidates and that are or were once being developed including but not limited to, Santhera (Reveragen), Fibrogen, Capricor Therapeutics (in partnership with Nippon Shinyaku), BioPhytis, Percheron Therapeutics, Italfarmaco (approved product Givinostat), Dystrogen and Edgewise Therapeutics. Although BioMarin announced on May 31, 2016 its intent to discontinue clinical and regulatory development of drisapersen as well as its other clinical stage candidates, BMN 044, BMN 045 and BMN 053, then-currently in Phase 2 studies for distinct forms of Duchenne, it further announced its intent to continue to explore the development of next generation oligonucleotides for the treatment of Duchenne. Indeed, BioMarin is conducting clinical trials for BMN-351, an oligonucleotide therapy. In addition, while Wave announced its intention to discontinue development of suvodirsen and suspend development of WVE-N531, it is conducting clinical trials for its exon 53 oligonucleotide, WVE-N531. In addition, we are aware of many pharmaceutical and biotechnology companies that are actively engaged in research and development using platform technologies that may be viewed as competing with ours beyond and including those companies mentioned immediately above, such as Alnylam Pharmaceuticals, Inc., Arbutus (formerly Tekmira Pharmaceuticals Corp.), Deciphera Pharmaceuticals, Ionis Pharmaceuticals, Inc., Roche Innovation Center Copenhagen (formerly Santaris Pharma A/S), Shire plc (now Takeda), Biogen, Moderna Therapeutics, Avidity, Dyne Therapeutics, Stoke Therapeutics, Ultragenyx, Sanofi and PepGen. Additionally, several companies and institutions have entered into collaborations or other agreements for the development of product candidates, including mRNA, gene therapy and gene editing (CRIPSR and AAV, among others) and small molecule therapies that are potential competitors for therapies being developed in the muscular dystrophy, neuromuscular and rare disease space, including, but not limited to, Astellas Pharma, Biogen Inc., Arrowhead Pharmaceuticals, Ionis, Alexion Pharmaceuticals, Inc., Sanofi, Shire (now Takeda), Eli Lilly, Alnylam Pharmaceuticals, Inc., Moderna Therapeutics, Inc., Akashi, Capricor Therapeutics (in partnership with Nippon Shinyaku), Oxford University, Exonics Therapeutics (acquired by Vertex Pharmaceuticals), and Editas Medicine. If any of our competitors are successful in obtaining regulatory approval for any of their product candidates, it may limit our ability to enter into the market, gain market share or maintain market share in the Duchenne space or other diseases targeted by our platform technologies, products and product candidate pipeline. 49 Â It is possible that our competitors will succeed in developing technologies that, in addition to limiting the market size for our products or product candidates, impact the regulatory approval and post-marketing process for our products and product candidates, are more effective than our products or product candidates or would render our technologies obsolete or noncompetitive. Our competitors may, among other things, relative to our products or product candidates: â€¢develop safer or more effective products; â€¢implement more effective approaches to sales and marketing; â€¢develop less costly products; â€¢have lower cost of goods; â€¢receive more favorable reimbursement coverage; â€¢obtain preferred formulary status; â€¢obtain regulatory approval more quickly; â€¢have access to more manufacturing capacity; â€¢develop products that are more convenient and easier to administer; â€¢form more advantageous strategic alliances; or â€¢establish superior intellectual property positions. Â Further, development and commercialization of ELEVIDYS and any expansion of its currently approved label, and development of our gene therapy product candidates, may compete with or supersede our current approved products, which may impact future revenues from sales of our current approved products. Our gene therapy product candidates are being developed for potential treatment of overlapping patient populations with our current approved products, and we have not determined if our gene therapy product candidates will be used in patients in combination with our existing approved products or in separate treatment regiments. Â Our revenue could face competitive pressures for any of the above reasons. Moreover, if competing products are marketed in a territory in which we also have the authority to market our products, our sales may diminish, or our business could be otherwise materially adversely affected. Â Future sales of ELEVIDYS may decrease sales growth, or reduce sales, of our PMO Products, which could negatively impact our operating results, including through potential inventory write-offs. Substantial overlap may exist between the addressable patient population for ELEVIDYS and the patient populations eligible for treatment with our PMO Products. In the future, ELEVIDYS may be used in combination with our PMO Products or may be adopted as a separate treatment regimen. Accordingly, ELEVIDYS may compete with our PMO Products. As a result, successful commercialization of ELEVIDYS may reduce sales of our PMO Products, potentially resulting in significant accounting charges relating to write-off of inventory if such inventory becomes in excess, obsolete or unusable. We have entered into multiple collaborations and strategic transactions, including our collaboration with Roche, and may seek or engage in future strategic collaborations, alliances, acquisitions or licensing agreements or other relationships that complement or expand our business. We may not be able to complete such transactions, and such transactions, if executed, may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. In order to achieve our long-term business objectives, we actively evaluate various strategic opportunities on an ongoing basis, including licensing or acquiring products, technologies or businesses. We may face competition from other companies in pursuing such opportunities. This competition is most intense for approved drugs and late-stage drug candidates, which have the lowest risk in terms of probability of success but would have a higher risk and more immediate effect on our financial performance. Our ability to complete transactions may also be limited by applicable antitrust and trade regulation laws and regulations in the relevant U.S. and foreign jurisdictions in which we or the operations or assets we seek to acquire carry on business. 50 Â We have entered into multiple collaborations, including with Roche, Nationwide, Duke University, University of Florida, Dyno Therapeutics, and Hansa Biopharma. We may not realize the anticipated benefits of such collaborations, and the anticipated benefits of any future collaborations or strategic relationships, each of which involves numerous risks, including: â€¢collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration; â€¢collaborators may not pursue development and commercialization of our products or product candidates based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities; â€¢collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; â€¢collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates, or otherwise undermine or devalue the efforts of our collaboration; â€¢collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; â€¢disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our products or product candidates, or that result in costly litigation or arbitration that diverts management attention and resources; â€¢collaborations may be terminated and, if terminated, may eliminate our rights to commercialize certain product candidates or may result in a need for additional capital; â€¢failure to successfully develop the acquired or licensed drugs or technology or to achieve strategic objectives, including successfully developing and commercializing the drugs, drug candidates or technologies that we acquire or license; â€¢entry into markets in which we have no or limited direct prior experience or where competitors in such markets have stronger market positions; â€¢disruption of our ongoing business, distraction of our management and employees from other opportunities and challenges and retention of key employees; â€¢potential failure of the due diligence processes to identify significant problems, liabilities or other shortcomings or challenges of an acquired company, or acquired or licensed product or technology, including but not limited to, problems, liabilities or other shortcomings or challenges with respect to intellectual property, product quality, safety, accounting practices, employee, customer or third-party relations and other known and unknown liabilities; â€¢liability for activities of the acquired company or licensor before the acquisition or license, including intellectual property infringement claims, violations of laws, commercial disputes, tax liabilities, and other known and unknown liabilities; â€¢exposure to litigation or other claims in connection with, or inheritance of claims or litigation risk as a result of an acquisition or license, including but not limited to, claims from terminated employees, customers, former equity holders or other third-parties; â€¢difficulty in integrating the products, product candidates, technologies, business operations and personnel of an acquired asset or company; and â€¢difficulties in the integration of the acquired companyâ€™s departments, systems, including accounting, human resource and other administrative systems, technologies, books and records, and procedures, as well as in maintaining uniform standards, controls, including internal control over financial reporting required by the Sarbanes-Oxley Act of 2002 and related procedures and policies. For example, we will have limited influence and control over the development and commercialization activities of Roche in the territories in which it leads development and commercialization of ELEVIDYS, and if the exclusive option is exercised, in the territories in which it may lead commercialization of certain other products or product candidates. Rocheâ€™s development and commercialization activities in the territories where it is the lead party may adversely impact our own efforts in the U.S. Failure by Roche to meet its obligations under the collaboration agreement, to apply sufficient efforts at developing and commercializing collaboration products, or to comply with applicable legal or regulatory requirements, may materially adversely affect our business and our results of operations. In addition, to the extent we rely on Roche to commercialize any products for which we obtain regulatory approval, we will receive less revenues than if we commercialized these products ourselves. 51 Â Even if we achieve the long-term benefits associated with strategic transactions, our expenses and short-term costs may increase materially and adversely affect our liquidity and short-term net income (loss). Future licenses or acquisitions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, the creation of contingent liabilities, impairment or expenses related to goodwill, and impairment or amortization expenses related to other intangible assets, which could harm our financial condition. For example, in February 2020, we issued and sold 2,522,227 shares of common stock to Roche Finance in connection with the entry into the collaboration agreement with Roche. Risks Related to the Development of our Product Candidates We may find it difficult to enroll patients in our clinical trials, which could delay or prevent clinical trials of our product candidates. Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on the speed at which we can recruit eligible patients to participate in testing our product candidates. We have experienced delays in some of our clinical trials, and we may experience similar delays in the future. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our technology, delays in our ability to expand the labels of any of our approved products or termination of the clinical trials altogether. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a study, to complete our clinical trials within the expected timeframe. Patient enrollment can be impacted by factors including, but not limited to: â€¢design and complexity and/or commitment of participation required in the study protocol; â€¢size of the patient population; â€¢diagnostic capabilities within patient population; â€¢eligibility criteria for the study in question; â€¢clinical supply availability; â€¢delays in participating site identification, qualification and subsequent activation to enroll; â€¢perceived risks and benefits of the product candidate under study, including as a result of adverse effects observed in similar or competing therapies; â€¢proximity and availability of clinical trial sites for prospective patients; â€¢availability of competing therapies and clinical trials; â€¢competition of site efforts to facilitate timely enrollment in clinical trials; â€¢participating site motivation; â€¢patient referral practices of physicians; â€¢activities of patient advocacy groups; â€¢ability to monitor patients adequately during and after treatment; and â€¢severity of the disease under investigation. In particular, each of the conditions for which we plan to evaluate our product candidates are rare genetic diseases with limited patient pools from which to draw for

clinical trials. Further, because newborn screening for these diseases is not widely adopted, and it can be difficult to diagnose these diseases in the absence of a genetic screen, we may have difficulty finding patients who are eligible to participate in our studies. The eligibility criteria of our clinical trials will further limit the pool of available study participants. Additionally, the process of finding and diagnosing patients may prove costly. The treating physicians in our clinical trials may also use their medical discretion in advising patients enrolled in our clinical trials to withdraw from our studies to try alternative therapies. In addition, the resurgence COVID-19 infection rates may impact patient ability and willingness to travel to clinical trial sites as a result of quarantines and other restrictions, which may negatively impact enrollment in our clinical trials. We may not be able to initiate or continue clinical trials if we cannot enroll the required eligible patients per protocol to participate in the clinical trials required by the FDA or the EMA or other regulatory agencies. Our ability to successfully initiate, 52 Â enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including: â€¢difficulty in establishing or managing relationships with contract research organizations (â€œCROsâ€) and physicians; â€¢different standards for the conduct of clinical trials; â€¢our inability to locate qualified local consultants, physicians and partners; â€¢the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment; â€¢ability to procure and deliver necessary clinical trial materials needed to perform the study; and â€¢inability to implement adequate training at participating sites remotely when in person training cannot be completed. If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business. Failures or delays in the commencement or completion of ongoing and planned clinical trials of our product candidates negatively impact commercialization efforts; result in increased costs; and delay, prevent or limit our ability to gain regulatory approval of product candidates and to generate revenues and continue our business. Successful completion of clinical trials at each applicable stage of development is a prerequisite to submitting a marketing application to the regulatory agencies and, consequently, the ultimate approval and commercial marketing of any of our product candidates for the indications in which we develop them. We do not know whether any of our clinical trials will begin or be completed, and results announced, as planned or expected, if at all, as the commencement and completion of clinical trials and announcement of results is often delayed or prevented for a number of reasons, including, among others: â€¢denial by the regulatory agencies of permission to proceed with our planned clinical trials or any other clinical trials we may initiate, or placement of a clinical trial on hold; â€¢delays in filing or receiving approvals of additional INDs that may be required; â€¢negative and/or unanticipated results from our ongoing non-clinical trials or clinical trials; â€¢challenges in identifying, recruiting, enrolling and retaining patients to participate in clinical trials; â€¢challenges with subject compliance within clinical trials; â€¢timely and effectively contract with (under reasonable terms), manage and work with investigators, institutions, hospitals and the CROs/ vendors involved in the clinical trial; â€¢negotiate contracts and other related documents with clinical trial parties and institutional review boards, such as informed consents, CRO agreements and site agreements, which can be subject to extensive negotiations that could cause significant delays in the clinical trial process, with terms possibly varying significantly among different trial sites and CROs and possibly subjecting the Company to various risks; â€¢inadequate quantity or quality of supplies of a product candidate or other materials necessary to conduct clinical trials, for example as a result of delays in defining and implementing the manufacturing process for materials used in pivotal trials or for the manufacture of larger quantities or other delays or issues arising in the manufacturing of sufficient supply of finished drug product; â€¢difficulties obtaining institutional review board (â€œIRBâ€) approval, and equivalent (Ethics Committees or ECs) approval for sites outside the U.S., to conduct a clinical trial at a prospective site or sites; â€¢ensure adherence to trial designs and protocols agreed upon and approved by regulatory authorities and applicable legal and regulatory guidelines; â€¢delays or problems in analyzing data, or the need for additional analysis or data or the need to enroll additional patients; â€¢the occurrence of serious adverse events or unexpected drug-related side effects experienced by patients in a clinical trial or unexpected results in ongoing non-clinical trials; â€¢delays in validating endpoints utilized in a clinical trial; â€¢delays in validating outcome assessments needed in a clinical trial; 53 Â â€¢our inability to have formal meetings with the regulatory agencies or to interact with them on a regular basis; â€¢our inability to satisfy the requirements of the regulatory agencies to commence clinical trials, such as developing potency assays and lot release specifications that correlate with the activity or response of the product candidate or other CMC requirements; â€¢the regulatory agencies disagreeing with our clinical trial design and our interpretation of data from clinical trials, or changing the requirements for approval even after the regulatory authority has reviewed and commented on the design for our clinical trials; â€¢reports from non-clinical or clinical testing of competing therapies that raise safety or efficacy concerns; and â€¢the recruitment and retention of employees, consultants or contractors with the required level of expertise. Any inability to complete successfully pre-clinical and clinical development could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, manufacturing or formulation changes to our product candidates often require additional studies to demonstrate comparability of the modified product candidates to earlier versions. Clinical study delays also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which impairs our ability to successfully commercialize our product candidates and harms our business and results of operations. Clinical development is lengthy and uncertain. Clinical trials of our novel gene therapy candidates may be delayed, including as a result of the resurgence in COVID-19, or other similar, pandemics and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which could have a material adverse impact on our business. Clinical testing is expensive and complex and can take many years to complete, and its outcome is inherently uncertain. We may not be able to initiate, may experience delays in, or may have to discontinue clinical trials for our product candidates as a result of numerous unforeseen events, including: â€¢the FDA, other regulators, IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site for any number of reasons, including concerns regarding safety and aspects of the clinical trial design; â€¢we may experience delays in reaching, or fail to reach, agreement on favorable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; â€¢the outcome of our pre-clinical studies and our early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; â€¢we may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful; â€¢clinical trials of any product candidates may fail to show safety or efficacy, or produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical studies or clinical trials, or we may decide to abandon product development programs; â€¢differences in trial design between early stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials; â€¢pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many product candidates believed to have performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval; and â€¢regulators may elect to impose a clinical hold, or we or our investigators, IRBs, or ethics committees may elect to suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable benefit risk ratio. For example, in the past we have received clinical holds from the FDA. Although these holds have generally not materially affected our development timelines, there is no assurance that any future hold would not have a material adverse effect. A clinical hold, or any of the above factors, may be out of our control and could materially impair our development timelines, expenses and results of operations. In addition, the impact of COVID-19 has caused disruptions and may cause future delays in some of our clinical trials. Responses to a resurgence of infection rates of COVID-19 or other similar pandemics by healthcare providers and regulatory agencies could delay the commencement of clinical trials, site initiation, protocol compliance, or the completion of clinical trials, including the completion of post-marketing requirements and commitments, slow down enrollment, and make the ongoing collection of data for patients enrolled in studies more difficult or intermittent. 54 Â Results from pre-clinical and earlyâ€‘stage clinical trials may not be indicative of safety or efficacy in lateâ€‘stage clinical trials, and pre-clinical and clinical trials may fail to demonstrate acceptable levels of safety, efficacy, and quality of our product candidates, which could prevent or significantly delay their regulatory approval. To obtain the requisite regulatory approvals to market and sell any of our product candidates, we must demonstrate, through extensive pre-clinical and clinical trials, that the product candidate is safe and effective in humans. Ongoing and future pre-clinical and clinical trials of our product candidates may not show sufficient safety, efficacy or adequate quality to obtain or maintain regulatory approvals. For example, although we believe the data for SRP-9003 collected to date are positive, the additional data we collect may not be consistent with the pre-clinical and/or early clinical data or show a safe benefit that warrants further development or pursuit of a regulatory approval. Furthermore, success in pre-clinical and early clinical trials does not ensure that the subsequent trials will be successful, nor does it predict final results of a confirmatory trial. Some of our clinical trials were conducted with small patient populations and were not blinded or placebo-controlled, making it difficult to predict whether the favorable results that we observed in such trials will be repeated in larger and more advanced clinical trials. For example, our most recent announcements for SRP-9003 include: in March 2022, we announced 24-month functional data from two clinical trial participants in the high-dose cohort, and 36-month functional data from three clinical trial participants in the low-dose cohort for SRP-9003. These data are based on small patient samples, and, given the heterogeneity of LGMD patients and potential lot-to-lot variability, the data may not be predictive of future results. In addition, we cannot assure that the results of additional data or data from any future trial will yield results that are consistent with the data presented, that we will be able to demonstrate the safety and efficacy of these product candidates, that later trial results will support further development, or even if such later results are favorable, that we will be able to successfully complete the development of, obtain accelerated, conditional or standard regulatory approval for, or successfully commercialize any of such product candidates. Similarly, we cannot provide assurances that data from our ongoing and planned studies with respect to our commercially approved products and product candidates will be positive and consistent or that the interpretation by regulators, such as the FDA or EMA, of the data we collect for our products or product candidates will be consistent with our interpretations.Â Our product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval of product candidates, limit the commercial potential or result in significant negative consequences following any potential marketing approval. Â Our product candidates may cause undesirable side effects. In addition to side effects caused by our product candidates, the administration process or related procedures also can cause adverse side effects. If any such adverse events occur in our trials, we may decide, or the FDA, the EMA or other regulatory authorities could order us, to halt, delay or amend pre-clinical development or clinical development of our product candidates or we may be unable to receive regulatory approval of our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates and may harm our business, financial condition and prospects significantly. If there are significant delays in obtaining or we are unable to obtain or maintain required regulatory approvals, we will not be able to commercialize our product candidates in a timely manner or at all, which could impair our ability to generate sufficient revenue and have a successful business. The research, testing, manufacturing, labeling, approval, commercialization, marketing, selling and distribution of drug products are subject to extensive regulation by applicable local, regional and national regulatory authorities and regulations may differ from jurisdiction to jurisdiction. In the U.S., approvals and oversight from federal (e.g., FDA), state and other regulatory authorities are required for these activities. Sale and marketing of our product candidates in the U.S. or other countries is not permitted until we obtain the required approvals from the applicable regulatory authorities. Of the large number of drugs in development in the biopharmaceutical industry, only a small percentage result in the submission of a marketing application to the FDA or an MAA to the EMA (or NCA of an EU member state) and even fewer are approved for commercialization. 55 Â Our ability to obtain the government or regulatory approvals required to commercialize any of our product candidates in any jurisdiction, including in the U.S. or the EU, cannot be assured, may be significantly delayed or may never be achieved for various reasons including the following: â€¢Our non-clinical, clinical, chemistry, manufacturing and controls and other data and analyses from past, current and future studies for any of our product candidates may not be sufficient to meet regulatory requirements for marketing application approvals. The regulatory authorities could disagree with our interpretations and conclusions regarding data we provide in connection with NDA, BLA or MAA submissions for one or more of our product candidates, and may delay, reject or refuse to accept for review, or approve any submission we make or identify additional requirements for product approval to be submitted upon completion, if ever. In addition, in the U.S., an FDA advisory committee could determine that our data are insufficient to provide a positive recommendation for approval of any NDA or BLA we submit to the FDA. Even if we meet FDA requirements and an advisory committee votes to recommend approval of an NDA or BLA submission, the FDA could still disagree with the advisory committeeâ€™s recommendation and deny approval of a product candidate based on their review. â€¢The regulatory approval process for product candidates targeting orphan diseases, such as Duchenne, that use new technologies and processes, such as antisense oligonucleotide therapies, gene therapy and other alternative approaches or endpoints for the determination of efficacy is uncertain due to, among other factors, evolving interpretations of a new therapeutic class, the broad discretion of regulatory authorities, lack of precedent, small safety databases, varying levels of applicable expertise of regulators or their advisory committees, scientific developments, changes in the competitor landscape, shifting political priorities and changes in applicable laws, rules or regulations and interpretations of the same. As a result of uncertainty in the approval process for products intended to treat serious rare diseases, we may not be able to anticipate, prepare for or satisfy requests or requirements from regulatory authorities, including completing and submitting planned NDAs, BLAs and MAAs for our product candidates, in a timely manner, or at all. Examples of such requests or requirements could include, but are not limited to, conducting additional or redesigned trials and procedures (e.g., additional safety data, patient muscle biopsies, dystrophin analyses and the use of assays), repeating or completing additional analysis of our data, or providing additional supportive data. In addition, in the U.S., an FDA advisory committee or regulators may disagree with our data analysis, interpretations and conclusions at any point in the approval process, which could negatively impact the approval of our NDA or BLA or result in a decision by the Company not to proceed with an NDA or BLA submission for a product candidate based on feedback from regulators. â€¢We may not have the resources required to meet regulatory requirements and successfully navigate what is generally a lengthy, expensive and extensive approval process for commercialization of drug product candidates. Any failure on our part to respond to these requirements in a timely and satisfactory manner could significantly delay or negatively impact confirmatory study timelines and/or the development plans we have for PMO, PPMO, gene therapy-based product candidates or other product candidates. Responding to requests from regulators and meeting requirements for clinical trials, submissions and approvals may require substantial personnel, financial or other resources, which, as a small biopharmaceutical company, we may not be able to obtain in a timely manner or at all. In addition, our ability to respond to requests from regulatory authorities that involve our agents, third party vendors and associates may be complicated by our own limitations and those of the parties we work with. It may be difficult or impossible for us to conform to regulatory guidance or successfully execute our product development plans in response to regulatory guidance, including guidance related to clinical trial design with respect to any NDA, BLA or MAA submissions. Even if our product candidates demonstrate safety and efficacy in clinical studies, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory advisory group or authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical studies and the review process. Regulatory agencies also may approve a treatment candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. Furthermore, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our treatment candidates. Finally, some of our product candidates may require diagnostic tests to ensure we appropriately select patients suitable for treatment. If we are unable to successfully develop diagnostic tests for these product candidates, experience significant delays in doing so, or are unable to obtain required regulatory clearances or approvals for any diagnostic tests, the commercialization of our product candidates may be delayed or prevented. Even if we receive the required regulatory clearance or approvals for certain diagnostic tests, the commercial success of any of our product candidates that require such tests will be dependent upon the continued availability of such tests. 56 Â We are investing significant resources in the development of novel gene therapy product candidates. Only a few gene therapy products have been approved in the U.S. and EU. If we are unable to show the safety and efficacy of these product candidates, experience delays in doing so or are unable to successfully commercialize at least one of these drugs, our business would be materially harmed. We are investing significant resources in the development of our gene therapy product candidates. We

believe that a significant portion of the long-term value attributed to our company by investors is based on the commercial potential of these product candidates. There can be no assurance that any development problems we experience in the future related to our gene therapy programs will not cause significant delays or unanticipated costs, or that such development problems can be solved. Development problems and delays in one program may delay the development of other programs. Early results from ongoing clinical trials may differ materially from final results from such clinical trials. The results from pre-clinical and early clinical studies do not always accurately predict results in later, large-scale clinical trials. We may also experience delays in developing a sustainable, reproducible and commercial-scale manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical trials or commercializing our products on a timely or profitable basis, if at all. In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Currently, only a few gene therapy products have been approved in the Western world. Given the few precedents of approved gene therapy products, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our gene therapy product candidates in the U.S., the EU or other jurisdictions. Approvals by the EMA and the EC may not be indicative of what the FDA may require for approval. Regulatory requirements governing gene therapy products have evolved and may continue to change in the future. Within the FDA, the Center for Biologics Evaluation and Research (â€œCBERâ€) regulates gene therapy products. Within the CBER, the review of gene therapy and related products is consolidated in the Office of Cellular, Tissue and Gene Therapies, and the FDA has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its reviews. The CBER works closely with the National Institutes of Health (the â€œNIHâ€). The FDA and the NIH have published guidance documents with respect to the development and submission of gene therapy protocols. For example, on January 28, 2020, the FDA issued final guidance documents that updated draft guidance documents that were originally released in July 2018 to reflect recent advances in the field, and to set forth the framework for the development, review and approval of gene therapies. These final guidance documents pertain to the development of gene therapies for the treatment of specific disease categories, including rare diseases, and to manufacturing and long-term follow up issues relevant to gene therapy, among other topics. The FDA also issued a new guidance document in September 2021 describing the FDAâ€™s approach for determining whether two gene therapy products were the same or different for the purpose of assessing orphan drug exclusivity, as well as a final guidance document in January 2024 on human gene therapy product incorporating human genome editing. FDA also issued a draft guidance in December 2023 that provides recommendations for developing a potency assurance strategy for gene therapy products. In addition, the FDA can put an IND on hold if the information in an IND is not sufficient to assess the risks in pediatric patients. These regulatory review agencies, committees and advisory groups and the new requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional or larger studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates or lead to significant post-approval studies, limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable requirements and guidelines, failure of which may lead to delayed or discontinued development of our product candidates. If the anticipated or actual timing of marketing approvals for our gene therapy product candidates, or the market acceptance of these product candidates, if approved, including treatment reimbursement levels agreed to by third-party payors, do not meet the expectations of investors or public market analysts, the market price of our common stock would likely decline. 57 Â Because we are developing product candidates for the treatment of certain diseases in which there is little clinical experience and we are using new endpoints or methodologies, there is increased risk that the FDA, the EMA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our partners, which could delay, limit or prevent full or accelerated regulatory approval. During the FDA review process, we will need to identify success criteria and endpoints such that the FDA will be able to determine the clinical efficacy and safety profile of our product candidates. As we are developing novel treatments for diseases in which there is little clinical experience with new endpoints and methodologies, such as gene therapy, there is heightened risk that the FDA, the EMA or other regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results (reflecting a tangible benefit to patients). In addition, the resulting clinical data and results may be difficult to analyze. Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoints to a degree of statistical significance. Achieving appropriate statistical power may be challenging for some of the ultra-rare genetically defined diseases we are targeting in our programs, especially if the acceptance of descriptive data is not yet established. In addition, different methodologies, assumptions and applications we utilize to assess particular safety or efficacy parameters may yield different statistical results. Even if we believe the data collected from clinical trials of our product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Pre-clinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our partners, which could delay, limit or prevent full or accelerated regulatory approval. If our study data do not consistently or sufficiently demonstrate the safety or efficacy of any of our product candidates, the regulatory approvals for such product candidates could be significantly delayed as we work to meet approval requirements, or, if we are not able to meet these requirements, such approvals could be withheld or withdrawn. Fast track product, breakthrough therapy, priority review, or Regenerative Medicine Advanced Therapy (â€œRMATâ€) designation by the FDA, or access to the Priority Medicine scheme (â€œPRIMEâ€) by the EMA, for our product candidates, if granted, may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval. We may seek fast track, breakthrough therapy designation, RMAT designation, PRIME scheme access or priority review designation for our product candidates if supported by the results of clinical trials. A fast track product designation is designed to facilitate the clinical development and expedite the review of drugs intended to treat a serious or life-threatening condition which demonstrate the potential to address an unmet medical need. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A RMAT designation is designed to accelerate approval for regenerative advanced therapies such as our gene therapy product candidates. Priority review designation is intended to speed the FDA marketing application review timeframe for drugs that treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. PRIME is a scheme provided by the EMA to enhance support for the development of medicines that target an unmet medical need. For drugs and biologics that have been designated as fast track products or breakthrough therapies, or granted access to the PRIME scheme, interaction and communication between the regulatory agency and the sponsor of the trial can help to identify the most efficient path for clinical development. Sponsors of drugs with fast track products or breakthrough therapies may also be able to submit marketing applications on a rolling basis, meaning that the FDA may review portions of a marketing application before the sponsor submits the complete application to the FDA, if the sponsor pays the user fee upon submission of the first portion of the marketing application. For products that receive a priority review designation, the FDA's marketing application review goal is shortened to six months, as opposed to ten months under standard review. This review goal is based on the date the FDA accepts the marketing application for review. This application validation period typically adds approximately two months to the timeline for review and decision from the date of submission. RMAT designations will accelerate approval and will include all the benefits of fast track and breakthrough therapy designations, including early interactions with the FDA, but the exact mechanisms have not yet been announced by FDA. Designation as a fast track product, breakthrough therapy, RMAT, PRIME, or priority review product is within the discretion of the regulatory agency. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a fast track product, breakthrough therapy, RMAT, PRIME, or priority review product, the agency may disagree and instead determine not to make such designation. In any event, the receipt of such a designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional regulatory procedures and does not assure ultimate marketing approval by the agency. In addition, regarding fast track products and breakthrough therapies, the 58 Â FDA may later decide that the products no longer meet the conditions for qualification as either a fast track product, RMAT, or a breakthrough therapy or, for priority review products, decide that period for FDA review or approval will not be shortened. We may not be able to advance all of our programs, and we may use our financial and human resources to pursue particular programs and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success. Our pipeline includes more than 40 programs in various stages of development for a broad range of diseases and disorders. We plan to expand our pipeline through internal research and development and through strategic transactions. Because we have limited resources, we may not be able to advance all of our programs. We may also forego or delay pursuit of opportunities with certain programs or for indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.Â Risks Related to Third Parties If we are unable to maintain our agreements with third parties to distribute our products to patients, our results of operations and business could be adversely affected. We rely on third parties to commercially distribute our products to patients in the U.S. We have contracted with a third-party logistics company to warehouse our products and with distributors and specialty pharmacies to sell and distribute our products to patients. A specialty pharmacy is a pharmacy that specializes in the dispensing of medications for complex or chronic conditions that require a high level of patient education and ongoing management. This distribution network requires significant coordination with our sales and marketing and finance organizations. In addition, failure to coordinate financial systems could negatively impact our ability to accurately report product revenue from our products. If we are unable to effectively manage the distribution process, the sales of our products, as well as any future products we may commercialize, could be delayed or severely compromised and our results of operations may be harmed. In addition, the use of third parties involves certain risks, including, but not limited to, risks that these organizations will: â€¢not provide us with accurate or timely information regarding their inventories, the number of patients who are using our products or serious adverse events and/or product complaints regarding our products; â€¢not effectively sell or support our products; â€¢reduce or discontinue their efforts to sell or support our products; â€¢not devote the resources necessary to sell our products in the volumes and within the time frame we expect; â€¢be unable to satisfy financial obligations to us or others; or â€¢cease operations. Any such events may result in decreased product sales, lower product revenue, loss of revenue, and/or reputational damage, which would harm our results of operations and business. With respect to the pre-commercial distribution of our products to patients outside of the U.S., we have contracted with third party distributors and service providers to distribute our products in certain countries through our EAP. We will need to continue building out our network for commercial distribution in jurisdictions in which our products are approved, which will also require third party contracts. The use of distributors and service providers involves certain risks, including, but not limited to, risks that these organizations will not comply with applicable laws and regulations, or not provide us with accurate or timely information regarding serious adverse events and/or product complaints regarding our products. Any such events may result in regulatory actions that may include suspension or termination of the distribution and sale of our products in a certain country, loss of revenue, and/or reputational damage, which could harm our results of operations and business. 59 Â We rely on third parties to conduct some aspects of our early stage research and pre-clinical and clinical development. The inadequate performance by or loss of any of these third parties could affect the development and commercialization of our product candidate development. We have relied upon, and plan to continue to rely upon, third parties to conduct some aspects of our early stage research and pre-clinical and clinical development with respect to certain of our product candidates, including our follow-on exon-skipping product candidates, PPMO, gene therapy and gene editing product candidates. Our third-party collaborators may not commit sufficient resources or adequately develop our programs for these candidates. If our third-party collaborators fail to commit sufficient resources to any of our product candidates or to carry out their contractual duties or obligations, our programs related to any particular product candidate could be delayed, terminated, or unsuccessful. Furthermore, if we fail to make required payments to these third-party collaborators, including up-front, milestone, reimbursement or royalty payments, or to observe other obligations in our agreements with them, these third parties may not be required to perform their obligations under our respective agreements with them and may have the right to terminate such agreements. In addition, if our strategic partners experience regulatory delays for the development of their clinical product candidates, including clinical holds, our opportunities to commercialize products may be delayed. We also have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data completeness for our ongoing pre-clinical and clinical programs. We rely on these parties for execution of our pre-clinical and clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on collaborators and CROs does not relieve us of our regulatory responsibilities. The individuals at our third-party collaborators and CROs who conduct work on our behalf, including their sub-contractors, are not always our employees, and although we participate in the planning of our early stage research and pre-clinical and clinical programs, we cannot control whether or not they devote sufficient time and resources or exercise appropriate oversight of these programs, except for remedies available to us under our agreements with such third parties. If our collaborators and CROs do not successfully carry out their contractual duties or obligations or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our pre-clinical and clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Our reliance on third parties requires us to share our proprietary information, which increases the possibility that a competitor will discover them or that our proprietary information will be misappropriated or inadvertently disclosed. Our reliance on third-party collaborators requires us to disclose our proprietary information to these parties, which could increase the risk that a competitor will discover this information or that this information will be misappropriated or disclosed without our intent to do so. If any of these events were to occur, then our ability to obtain patent protection or other intellectual property rights could be irrevocably jeopardized, and costly, distracting litigation could ensue. Furthermore, if these third parties cease to continue operations and we are not able to quickly find a replacement provider or we lose information or items associated with our products or product candidates, our development programs may be delayed. Although we carefully manage our relationships with our third-party collaborators and CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. Some of the third parties we rely for early-stage research and pre-clinical development are located in China. There has been increased governmental focus in the United States on the role of Chinese companies in the life sciences industry. This focus has included U.S. legislative proposals, such as the proposed BIOSECURE Act, which is pending before the U.S. Senate. If enacted, the BIOSECURE Act would, among other things, prohibit U.S. federal agencies from entering into or renewing any contract with any entity that uses biotechnology equipment or services produced or provided by a â€œbiotechnology company of concernâ€ to perform that contract with the government. If adopted, the BIOSECURE Act could cause us to seek to exit some or all of our arrangements with China-based service providers determined to be â€œbiotechnology companies of concernâ€ and transition these services to alternative companies. 60 Â Risks Related to Manufacturing We currently rely on third parties to manufacture our products and to produce our product candidates; our dependence on these parties, including failure on our part to accurately anticipate product demand and timely secure manufacturing capacity to meet commercial, EAP, clinical and pre-clinical product demand may impair the availability of product for commercial supply or to successfully support various programs, including research and development and the potential commercialization of additional product candidates in our pipeline. We rely on, and expect to continue relying on for the foreseeable future, a limited number of third parties to manufacture and supply materials (including raw materials and subunits), API and drug product and to provide labeling and packaging of vials and storage of our products and product candidates. The limited number of third parties with facilities and capabilities suited for the manufacturing process of our products and product candidates creates a risk that we may not be able to obtain materials and APIs in the quantity and

purity that we require. As of the date of this Quarterly Report, we have dual sourcing for the APIs and drug product for all three of our PMO commercial products and one source for ELEVIDYS drug substance and drug product manufacturing. In addition, the process for adding new manufacturing capacity is lengthy and often causes delays in development efforts. Any interruption of the development or operation of those facilities due to, among other reasons, events such as the ongoing COVID-19 pandemic, order delays for equipment or materials, equipment malfunctions, quality control and quality assurance issues, regulatory delays and possible negative effects of such delays on supply chains and expected timelines for product availability, production yield issues, shortages of qualified personnel, discontinuation of a facility or business or failure or damage to a facility by natural disasters, such as earthquakes or fires, could result in the cancellation of shipments, loss of product in the manufacturing process or a shortfall in supply of our products, product candidates or materials. Any delay or interruption in the supply of finished products could hinder our ability to distribute our products to meet commercial demand or execute our commercialization plans on the timing that we expect, which could result in the loss of potential revenues, adversely affect our ability to gain market acceptance, or otherwise adversely affect our business, financial condition and prospects. If these third parties cease providing quality manufacturing and related services to us, and we are not able to engage appropriate replacements in a timely manner, our ability to manufacture our products or product candidates in sufficient quality and quantity required for our planned commercial, pre-clinical and clinical or EAPs, our various product research, development and commercialization efforts would be adversely affected. Furthermore, any problems in our manufacturing process or the facilities with which we contract make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. We, through our third-party manufacturers, seek to produce or produce supply of our products and product candidates. In light of the limited number of third parties with the expertise to produce our products and product candidates, the lead time needed to manufacture them, and the availability of underlying materials, we may not be able to, in a timely manner or at all, establish or maintain sufficient commercial and other manufacturing arrangements on the commercially reasonable terms necessary to provide adequate supply of our products and product candidates. Furthermore, we may not be able to obtain the significant financial capital that may be required in connection with such arrangements. Even after successfully engaging third parties to execute the manufacturing process for our products and product candidates, such parties may not comply with the terms and timelines they have agreed to for various reasons, some of which may be out of their or our control, which impacts our ability to execute our business plans on expected or required timelines in connection with the commercialization of our products and the continued development of our product candidates. When we enter into long-term manufacturing agreements that contain exclusivity provisions and /or substantial termination penalties, we constrain our operational flexibility. We also rely on a third party to design, manufacture, obtain and maintain regulatory approval for companion diagnostic tests for ELEVIDYS. Any delay or failure by us or our collaborators to develop or obtain regulatory approval of the companion diagnostic tests could harm our business, possibly materially. The operations at one of our partner sites could also be disturbed by man-made or natural disasters, public health pandemics or epidemics or other business interrupts such as potential supply chain disruptions caused by the ongoing conflict between Russia and Ukraine. In addition, the need to prioritize rated orders issued by the Federal Emergency Management Agency pursuant to the U.S. Defense Production Act could impact the manufacturing, supply chain and distribution of our products and product candidates. 61 Â Products intended for use in gene therapies are novel, complex and difficult to manufacture. We could experience production problems or inaccurately forecast demand, which could result in delays in commercialization or development of other gene therapy programs, limit the supply of our product candidates or future approved products or otherwise harm our business. We currently have development, manufacturing and testing agreements with third parties to manufacture supplies of ELEVIDYS and our gene therapy product candidates. Several factors could cause production interruptions, including talent acquisition/retention, equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of suppliers. The physical and chemical properties of biologics such as ours generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, we employ multiple steps to control our manufacturing process to assure that the process works and the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in delay in product release, product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory. We may encounter problems achieving adequate quantities and quality of clinical and/or commercial-grade materials that meet FDA, EMA or other applicable foreign standards or specifications with consistent and acceptable production yields and costs. Lot failures or product recalls could cause us to delay clinical trials or product launches, or may result in an inability to fulfill demand for commercial supply of ELEVIDYS, or other future gene therapy products, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. In addition, the FDA, the EMA and other foreign regulatory authorities may require us to submit samples of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other foreign regulatory authorities may require that we not distribute a lot until the competent authority authorizes its release. As our product candidates advance to later stage clinical trials, it is customary that various CMC aspects of the development program, such as manufacturing, formulation and other processes, and route of administration, may be altered to optimize the candidates and processes for scale-up necessary for later stage clinical trials and potential approval and commercialization. These changes may not produce the intended optimization, including production of drug substance and drug product of a quality and in a quantity sufficient for Phase 3 clinical stage development or for commercialization, which may cause delays in the initiation or completion of clinical trials and greater costs. We may also need to conduct additional studies to demonstrate comparability between newly manufactured drug substance and/or drug product for commercialization relative to previously manufactured drug substance and/or drug product for clinical trials. Demonstrating comparability may require us to incur additional costs or delay initiation or completion of clinical trials and, if unsuccessful, could require us to complete additional pre-clinical studies or clinical trials. We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to operate our manufacturing process which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements. In addition, if our third-party manufacturers are unable to satisfy requirements related to the manufacturing ELEVIDYS, our ability to meet commercial demand may be adversely impacted, which could result in the loss of potential revenues, adversely affect our ability to gain market acceptance of ELEVIDYS, or otherwise adversely affect our business, financial condition and prospects. ELEVIDYS is our first gene therapy product. We may not be able to accurately estimate commercial demand for this new type of product. If commercial demand for ELEVIDYS is greater than we estimate, we and our manufacturers may be unable to fulfill all orders for ELEVIDYS in a timely manner, which may adversely affect our business, financial condition and prospects. Currently the capacity to produce our viral vectors or gene therapy product candidates at commercial levels is limited and the availability of sufficient GMP compliance capacity may result in delays in our development plans or increased capital expenditures, and the development and sales of any gene therapy products, if approved, may be materially harmed. The third parties we use in the manufacturing process for our products and product candidates may fail to comply with cGMP regulations. Our contract manufacturers are required to produce our materials, APIs and drug products under cGMP. We and our contract manufacturers are subject to periodic inspections by the FDA, EMA and corresponding state and foreign authorities to ensure strict compliance with cGMP and other applicable government regulations. In addition, before we can begin to commercially manufacture our product candidates in third-party or our own facilities, we must obtain regulatory approval from the FDA, which includes a review of the manufacturing process and facility. A manufacturing authorization also must be obtained from the appropriate EU regulatory authorities and may be required by other foreign regulatory authorities. The timeframe required to obtain such approval or authorization is uncertain. In order to obtain approval, we need to demonstrate that all of our processes, methods and equipment are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. In complying with cGMP, we are 62 Â obligated to expend time, money and effort in production, record keeping and quality control to seek to assure that the product meets applicable specifications and other requirements. We do not have direct operational control over a third-party manufacturerâ€™s compliance with regulations and requirements. In addition, changes in cGMP could negatively impact the ability of our contract manufacturers to complete the manufacturing process of our products and product candidates in a compliant manner on the schedule we require for commercial and clinical trial use, respectively. Failure to achieve and maintain compliance with cGMP and other applicable government regulations, including failure to detect or control anticipated or unanticipated manufacturing errors, results in product recalls, clinical holds, delayed or withheld approvals, patient injury or death. Failure by our contract manufacturers to adhere to applicable cGMP and other applicable government regulations, or our contract manufacturers experiencing manufacturing problems, may result in significant negative consequences, including product seizures or recalls, postponement or cancellation of clinical trials, loss or delay of product approval, fines and sanctions, loss of revenue, termination of the development of a product candidate, reputational damage, shipment delays, inventory shortages, inventory write-offs and other product-related charges and increased manufacturing costs. If we experience any of these consequences, the success of our commercialization of our products and/or our development efforts for our product candidates could be significantly delayed, fail or otherwise be negatively impacted. We may not be able to successfully optimize manufacturing of our product candidates in sufficient quality and quantity or within targeted timelines, or be able to secure ownership of intellectual property rights developed in this process, which could negatively impact the commercial success of our products and/or the development of our product candidates. Our focus remains on optimizing manufacturing for our follow-on exon skipping product candidates and other programs, including PPMO and gene therapy. We may not be able to successfully increase manufacturing capacity for the production of materials, APIs and drug products, whether in collaboration with third party manufacturers or on our own, in a manner that is safe, compliant with cGMP conditions or other applicable legal or regulatory requirements, in a cost-effective manner, in a time frame required to meet our timeline for commercialization, clinical trials and other business plans, or at all. Challenges complying with cGMP requirements and other quality issues arise during efforts to increase manufacturing capacity and scale up production. We experience such issues in connection with manufacturing, packaging and storage of our products and product candidates, and during shipping and storage of the APIs or finished drug product. In addition, in order to release our products for commercial use and demonstrate stability of product candidates for use in clinical trials (and any subsequent drug products for commercial use), our manufacturing processes and analytical methods must be validated in accordance with regulatory guidelines. Failure to successfully validate, or maintain validation of, our manufacturing processes and analytical methods or demonstrate adequate purity, stability or comparability of our products or product candidates in a timely or cost-effective manner, or at all, may undermine our commercial efforts. Failure to successfully validate our manufacturing processes and analytical methods or to demonstrate adequate purity, stability or comparability, will negatively impact the commercial availability of our products and the continued development and/or regulatory approval of our product candidates, which could significantly harm our business. During our work with our third-party manufacturers to increase and optimize manufacturing capacity, they may make proprietary improvements in the manufacturing processes for our products or product candidates. We may not own or be able to secure ownership of such improvements or may have to share the intellectual property rights to those improvements. Additionally, we may need additional processes, technologies and validation studies, which could be costly and which we may not be able to develop or acquire from third parties. Failure to secure the intellectual property rights required for the manufacturing process needed for large-scale clinical trials or the continued development of our product candidates could cause significant delays in our business plans or otherwise negatively impact the continued development of our product candidates. Risks Related to our Intellectual Property Our success, competitive position and future revenue depend in part on our ability and the abilities of our licensors and other collaborators to obtain, maintain and defend the patent protection for our products, product candidates, and platform technologies, to preserve our trade secrets, and to prevent third parties from infringing on our proprietary rights. We currently directly hold various issued patents and patent applications, or have exclusive license or option rights to issued patents and patent applications, in each case in the U.S. as well as other countries that protect our products, product candidates and platform technologies. We anticipate filing additional patent applications both in the U.S. and in other countries. Our success will depend, in significant part, on our ability to obtain, maintain and defend our U.S. and foreign patents covering our products, product candidates and platform technologies as well as preserving our trade secrets for these assets. The patent process is subject to numerous risks and uncertainties, and we can provide no assurance that we will be successful in obtaining, maintaining, or defending our patents. 63 Â Even when our patent claims are allowed, the claims may not issue, or in the event of issuance, may not be sufficient to protect our products, product candidates or platform technologies or may be challenged in post-grant proceedings by third parties. The patent positions of pharmaceutical, biotechnology and other life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. This uncertainty is heightened for our PMO- and PPMO based products and product candidates and gene therapy-based products and product candidates for which there has not been a significant number of patent litigations involving such technologies. Congress periodically considers changes to patent law, and that such changes could have adverse effects. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date in the U.S. and tests used for determining the patentability of patent claims in all technologies are in flux. The USPTO and patent offices in other jurisdictions have often required that patent applications directed to pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations exemplified in the patent application, thereby limiting the scope of protection against competitive challenges. Accordingly, even if we or our licensors are able to obtain patents, the patents might be substantially narrower than anticipated. Thus, there is no assurance as to the degree and range of protections any of our patents, if issued, may afford us or whether patents will be issued. Patents which may be issued to us may be subjected to further governmental review that may ultimately result in the reduction of their scope of protection, and pending patent applications may have their requested breadth of protection significantly limited before being issued, if issued at all. The pharmaceutical, biotechnology and other life sciences patent situation outside the U.S. can be even more uncertain. As a matter of public policy, there might be significant pressure on governmental bodies to limit the scope of patent protection or impose compulsory licenses for disease treatments that prove successful, particularly as a tactic to impose a price control. Additionally, competitors may leverage such pressure to enhance their ability to exploit these laws to create, develop and market competing products. We may be able to assert that certain activities engaged in by our competitors infringe on our current or future patent rights. To the extent that we enforce our patents, an alleged infringer may deny infringement and/or counter-claim that our patents are not valid or enforceable, and if successful, could negatively impact our patent estate. We may not be able to successfully defend patents necessary to prevent competitors from developing, manufacturing, or commercializing competing product candidates or products. To the extent we assert infringement of a patent that covers a competing product candidate or product as well as our own product candidate(s) or product(s), or such a patent is otherwise challenged without our initiation, the patent protection for our own product candidate(s) or product(s) could be materially adversely affected should an infringing competitor be successful in challenging the validity, enforceability, or scope of our patent(s). Our patent rights might be challenged, invalidated, circumvented or otherwise not provide any competitive advantage. Defending our patent positions may require significant financial resources and could negatively impact other Company objectives. Even if we successfully enforce our patent rights against a competitor, we may not be able to recover adequate damages or obtain other desired relief. Under the Hatch-Waxman Act, one or more motivated third parties may file an ANDA, seeking approval of a generic copy of an innovator product approved under the NDA pathway such as our PMO Products, or an NDA under Section 505(b)(2), for a new or improved version of the original innovator products. In certain circumstances, motivated third parties may file such an ANDA or NDA under Section 505(b)(2) as early as the so-called â€œNCE-1â€ date that is one year before the expiry of the five-year period of NCE exclusivity or more generally four years after NDA approval. The third parties are allowed to rely on the safety and efficacy data of the innovatorâ€™s product, may not need to conduct clinical trials and can market a competing version of a product after the expiration or loss of patent exclusivity or the expiration or loss of regulatory exclusivity and often charge significantly lower prices. Upon the expiration or loss of patent protection or the expiration or loss of regulatory exclusivity for a product, the major portion of revenues for that product may be dramatically reduced in a very short period of time. If we are not successful in defending our patents and regulatory exclusivities, we will not derive the expected benefit from them. As such, a third party could be positioned to market an ANDA or Section 505(b)(2) product that competes with one of our products prior to the expiry of our patents if the third party successfully challenges the validity, enforceability, or scope of our patents protecting the product. The patent landscape is continually evolving, and we may be able to assert that certain activities engaged in by third parties infringe our current or future patent rights. There has been, and we believe that there will continue to be, significant litigation in the biopharmaceutical and pharmaceutical industries regarding patent and other intellectual property rights. As such, the patents and patent applications that we own, license, have optioned, and rely on for exclusivity for our product candidates may be challenged. Uncertainty over intellectual

property in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes, which is inherently costly and unpredictable. Litigation, interferences, oppositions, inter partes reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, enforceability, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our product candidates or products. We may also face challenges to our 64 Â patent and regulatory exclusivities covering our products by third parties, including manufacturers of generics and/or biosimilars who may choose to launch or attempt to launch their products before the expiration of our patents or regulatory exclusivity. Litigation, interferences, oppositions, inter partes reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcomes of such proceedings could adversely affect the validity, enforceability, and scope of our patents or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed products or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from developing, manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from our products. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. Our business prospects will be impaired if third parties successfully assert that our products, product candidates, or platform technologies infringe proprietary rights of such third parties. Similar to us, competitors continually seek intellectual property protection for their technology. Several of our development programs, particularly gene therapy programs, focus on therapeutic areas that have been the subject of extensive research and development by third parties for many years and have been protected with third party patent rights. Due to the amount of intellectual property in our various fields of technology, we cannot be certain that we do not infringe intellectual property rights of competitors or other third parties or that we will not infringe intellectual property rights of competitors or other third parties granted or created in the future. Moreover, activities we conduct or those conducted on our behalf in connection with the development of our product candidates may not be protected from infringement under the so-called Safe Harbor provision of 35 U.S.C. Â§ 271(e)(1) and thus may be found to infringe the patent rights of third parties. Our competitors or other third parties might have obtained, or could obtain in the future, patents that threaten, limit, interfere with or eliminate our ability to make, use and sell our products, product candidates or platform technologies in important commercial markets. Due to the nature of our various partnerships, collaborators, licensors, CROs, CMOs and the like, we may be subjected to claims of infringement arising from activities conducted by these third parties in connection with our product candidates, whether or not such activities are authorized by us. In addition, we may have contractual obligations to indemnify these partners from claims of infringement or declaratory relief. As a result, we may be subject to substantial unforeseen costs, distraction, and financial liability if a third party making such a claim was successful in obtaining a final judgment of infringement and validity. In order to maintain or obtain freedom to operate for our products and product candidates, we may incur significant expenses, including those associated with entering into agreements with third parties that require milestone and royalty payments. Additionally, if we were to challenge the patent rights of our competitors or otherwise defend against allegations of infringement, misappropriation, breach of contract or related claims, we could incur substantial costs and ultimately might not be successful. If our products, product candidates, or platform technologies are alleged to infringe or are determined to infringe enforceable proprietary rights of others, we could incur substantial costs and may have to: â€¢obtain rights or licenses from others, which might not be available on commercially reasonable terms or at all; â€¢abandon development of an infringing product candidate, or cease commercialization of an infringing product; â€¢redesign our products, product candidates or processes to avoid infringement; â€¢pay damages; and/or â€¢defend litigation or administrative proceedings which might be costly whether we win or lose, and which could result in a substantial diversion of financial and management resources. 65 Â Any of these events could result in product and product candidate development delays or cessation, and as such substantially harm our potential earnings, financial condition and operations. The patent landscape of our product candidates and products is continually evolving and multiple parties, including both commercial entities and academic institutions, may have rights to claims or may be pursuing additional claims that could provide these parties a basis to assert that our products, product candidates or platform technologies infringe on the intellectual property rights of such parties. There has been, and we believe that there will continue to be, significant litigation in the biopharmaceutical and pharmaceutical industries regarding patent and other intellectual property rights. Risks Related to our Business Operations Failure to comply with healthcare and other regulations is subject to substantial penalties and our business, operations and financial condition could be adversely affected. As a manufacturer of pharmaceuticals, within the U.S., certain federal and state healthcare laws and regulations apply to or affect our business. These laws may constrain the business or financial arrangements and relationships through which we conduct business, including how we conduct research regarding, market, sell, and distribute our products. The laws and regulations include: â€¢federal healthcare anti-kickback law, which prohibit, among other things, persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid; â€¢federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, information or claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent; â€¢the Federal Food, Drug and Cosmetic Act, which among other things, strictly regulates drug product and medical device marketing, prohibits manufacturers from marketing such products for off-label use and regulates the distribution of samples; â€¢federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; â€¢federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; â€¢the so-called â€œfederal sunshineâ€ law, which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with teaching hospitals, physicians and certain non-physician practitioners as well as physician ownership interests to the federal government for re-disclosure to the public; and â€¢state law equivalents of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third party payor, including commercial insurers, state laws regulating interactions between pharmaceutical manufactures and healthcare providers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts. The number and complexity of both federal and state laws continues to increase, and additional governmental resources are being used to enforce these laws and to prosecute companies and individuals who are believed to be violating them. We anticipate that government scrutiny of pharmaceutical sales and marketing practices and other activities will continue for the foreseeable future and subject us to the risk of government investigations and enforcement actions. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations, and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices are non-compliant. We have implemented a compliance program, which is based on industry best practices and is designed to ensure that our activities comply with all applicable laws, regulations and industry standards. While our compliance program is intended to detect and prevent potential non-compliance, we cannot be certain that compliance will be assured. If our operations are found to be in violation of any of the laws described above or any other laws, rules or regulations that apply to us, we will be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Responding to government investigations, defending any claims raised, and any resulting fines, restitution, damages and penalties, settlement payments or administrative actions, as well as any related actions brought by stockholders or other third parties, could have a material impact on our reputation, business and financial condition and divert the attention of our management from operating our business. Even if we successfully defend against an action against us for violation of a law, the action and our defense could nonetheless cause us to incur significant legal expenses and divert our managementâ€™s attention from the operation of our business. 66 Â Moreover, achieving and sustaining compliance with applicable federal and state privacy, security, fraud and reporting laws may prove costly. Â Government pricing requirements, such as those under the Medicaid Drug Rebate Program, other federal government programs, and state price transparency laws, and their related reporting and payment obligations require strict adherence; our failure to adhere to such requirements could subject us to penalties, sanctions, and fines that could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. Â We participate in the Medicaid Drug Rebate Program, the PHS 340B drug pricing program, the U.S. Department of Veterans Affairs, Federal Supply Schedule (â€œFSSâ€) pricing program, and the Tricare Retail Pharmacy program, and have obligations to report the average sales price for certain drug products to the Medicare program. Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts, which can change and evolve over time. Requirements are subject to change. Â If we become aware that our reporting for a prior quarter or other time period was incorrect or has changed as a result of recalculation of pricing data, we generally are obligated to resubmit the corrected data and provide refunds or other reconciliations. Price recalculations may affect the ceiling price at which we are required to offer our products to certain customers under the PHS 340B drug pricing program and increase our general costs. Â Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, if we fail to submit the required price data on a timely basis, or if we are found to have charged certain customers more than the statutorily mandated ceiling price. The Centers for Medicare & Medicaid Services (â€œCMSâ€) also could decide to terminate our Medicaid Drug Rebate agreement. Our failure to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program and other governmental programs could negatively impact our financial results. Â Several states have passed or are considering legislation that requires or purports to require companies to report pricing information, including proprietary pricing information. Such reporting requirements are not always clearly defined and failure to appropriately disclose in accordance with these requirements may lead to the imposition of penalties. If we, our collaborators, or any third-party manufacturers engaged by us or our collaborators fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business. We, our collaborators, and any third-party manufacturers we engage are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the generation, handling, use, storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and wastes, as well as laws and regulations relating to occupational health and safety, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials. Our operations involve the use of hazardous materials, including organic and inorganic solvents and reagents. Although we believe that our activities conform in all material respects with such environmental laws, there can be no assurance that violations of these laws will not occur in the future as a result of human error, accident, equipment failure or other causes. Liability under environmental, health and safety laws can be joint and several and without regard to fault or negligence. The failure to comply with past, present or future laws could result in the imposition of substantial fines and penalties, remediation costs, property damage and personal injury claims, loss of permits or a cessation of operations, and any of these events could harm our business and financial condition. We expect that our operations will be affected by other new environmental, health and workplace safety laws on an ongoing basis, and although we cannot predict the ultimate impact of any such new laws, they may impose greater compliance costs or result in increased risks or penalties, which could harm our business. Further, with respect to the operations of any current or future collaborators or third party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our product or product candidates, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product or product candidates. Â Comprehensive tax reform in the U.S. and future guidance could adversely affect our business and financial condition. The Tax Cuts and Jobs Act (the â€œTCJAâ€) was enacted on December 22, 2017 in the U.S. The TCJA contains significant changes to corporate taxation, including reduction of the U.S. corporate tax rate from 35% to 21%, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, limitation of the tax deduction for interest expense, immediate deductions for certain new investments instead of 67 Â deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. On March 27, 2020, President Trump signed into law the â€œCoronavirus Aid, Relief, and Economic Security Actâ€ or the CARES Act, which included certain changes in tax law intended to stimulate the U.S. economy in light of the COVID-19 outbreak, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. We continue to monitor changes in tax laws in the U.S. and the impact of proposed and enacted legislation in the international jurisdictions in which the company operates, which could materially impact our tax provision, cash tax liability and effective tax rate. The COVID-19 pandemic has resulted, and may continue to result in disruptions to our commercialization, clinical trials, manufacturing and other business operations, which could have a material adverse effect on our business, financial condition, operating results, cash flows and prospects. Â The COVID-19 pandemic has presented a substantial public health and economic challenge around the world. The rapid spread of COVID-19 and resurgences in infection rates have led to the implementation of various public health safety measures, as well as reported adverse impacts on healthcare resources, facilities and providers across the United States and in other countries. In response to the pandemic, healthcare providers have reallocated, and may need to further, reallocate limited resources and personnel capacity to focus on the treatment of patients with COVID-19 and implement limitations on access to hospitals and other medical institutions due to concerns about the spread of COVID-19 in such settings. These responses may be extended by the duration of the outbreak, periodic spikes in infection rates due to new strains of the virus, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact. These actions have and may in the future negatively impact commercialization, clinical trials, manufacturing and other business operations, including: Â â€¢Commercial: The response to COVID-19 by healthcare providers has made it difficult for some patients, especially those dependent on a hospital setting, to receive infusions or initiate treatment with our commercial products. In addition, as a result of the pandemic, some patients may choose to delay or stop treatment to avoid a visit to a hospital or a visit of a third party in their homes to minimize the risk of infection. In some cases, at home infusions have been delayed due to outbreaks of COVID-19 among trained personnel and staffing shortages at times during periodic spikes in infection rates. These challenges may continue for the foreseeable future, which is expected to reduce our revenue and cash flows. â€¢Clinical trials: The impact of COVID-19 has caused disruptions and delays in some of our clinical trials, and may in the future disrupt or delay our clinical trials. Missing data could undermine data integrity and probability of success. A resurgence of COVID-19 could delay the commencement of trials, site initiation, compliance in the trials, the completion of trials, including the completion of post-marketing requirements and commitments, slow down enrollment, and make the ongoing collection of data for patients enrolled in studies more difficult or intermittent. Quarantines and other travel limitations (whether voluntary or required) were implemented in many countries during the pandemic, and any future mitigation measures may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, which may negatively impact the execution of clinical trials. Significant delays or disruptions to our clinical trials could adversely affect our ability to timely initiate studies, conduct successful studies, obtain or maintain regulatory approvals, or commercialize our product candidates. â€¢Operations: Remote working increases our vulnerability to cybersecurity breaches. Further, if the spread of the COVID-19 pandemic continues and our operations are adversely impacted, including due to an outbreak in a facility, we risk a delay, default and/or nonperformance under existing agreements. Â Any of the foregoing factors could have a material adverse impact on our business, financial condition, operating results, cash flows and prospects. The extent to which COVID-19 impacts our operations and those of our third-party partners will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including resurgences of COVID-19, additional or modified government actions, new information which emerges concerning the severity of COVID-19 and the actions taken to contain the virus or treat its impact, among others. In particular, the speed of the continued spread of COVID-19 globally, and the magnitude of interventions to contain the spread of the virus, will determine the impact of the pandemic on our operations. Our ability to use net operating loss carryforwards and other tax attributes to offset future taxable income may be limited by provisions of the Internal Revenue Code, and it is possible that certain transactions or a combination of certain transactions may result in material additional limitations on our ability to use our net operating losses. We have incurred substantial losses during our history and expect to incur more as we pursue our business strategy. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset a portion of future taxable income, if any, subject to expiration of such carryforwards in the case of carryforwards generated prior to January 1, 2018. In general, under Section 382 of the

Internal Revenue Code, a corporation that undergoes an â€œownership changeâ€ is subject to limitations on its ability to utilize its pre-change net operating losses and certain other tax assets (including R&D tax credits) to offset future taxable income. In general, 68 Â an ownership change occurs if the aggregate stock ownership of certain stockholders increases by more than 50 percentage points over such stockholdersâ€™ lowest percentage ownership during the testing period, which is generally three years. An ownership change could limit our ability to utilize our net operating loss and tax credit carryforwards for taxable years including or following such â€œownership change.â€ Such limitations may result in expiration of a portion of the net operating loss carryforwards incurred prior to 2018 before utilization and may be substantial. If such change has occurred or does occur, the tax benefits related to the net operating loss carryforwards and certain other tax assets may be limited or lost. Moreover, proposed U.S. Treasury Regulations promulgated under Section 382 of the Code could, if finalized, significantly impact a corporationâ€™s ability to use its pre-change net operating loss carryforwards or other attributes following an ownership change. Limitations imposed on the ability to use net operating losses and tax credits to offset future taxable income could require us to pay U.S. federal income taxes earlier than we estimated or than would have otherwise been required if such limitations were not in effect and could cause such net operating losses and tax credits to expire unused, in each case reducing or eliminating the benefit of such net operating losses and tax credits and potentially adversely affecting our financial position. Similar rules and limitations may apply for state income tax purposes. At the state level, there may also be periods during which the use of net operating loss carryforwards or other attributes is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. These net operating losses have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. The Inflation Reduction Act of 2022, among other things implements a corporate book minimum tax (â€œBMTâ€) 15% rate that could apply to consolidated groups of companies with adjusted financial statement income in excess of $1.0 billion over a three-year period. The BMT has various limitations, including a more restrictive limit on availability of net operating loss carryforwards, which if applied to us, could impact its cash tax liability and ability to utilize tax attributes. In addition, many of the jurisdictions in which we operate have or are expected to adopt changes to tax laws as a result of the Base Erosion and Profit Shifting final proposals from the Organization for Economic Co-operation and Development and specific country anti-avoidance initiatives. In addition, the current proposal of the BMT may result in increases in tax imposed by non-U.S. jurisdictions. Such tax law changes and anti-avoidance initiatives increase uncertainty and may adversely affect our tax provision, cash tax liability and effective tax rate. Our employees, principal investigators, consultants and strategic partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and strategic partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the U.S. and abroad, report financial information or data accurately or disclose unauthorized activities to us. We adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. Failure to retain our key personnel or an inability to attract and retain additional qualified personnel would cause our future growth and our ability to compete to suffer. We are highly dependent on the efforts and abilities of the principal members of our senior management. Additionally, we have scientific personnel with significant and unique expertise in RNA-targeted therapeutics and gene therapy technologies. The loss of the services of any one of the principal members of our managerial team or staff may prevent us from achieving our business objectives. The competition for qualified personnel in the biotechnology field is intense, and our future success depends upon our ability to attract, retain, motivate and support such personnel. The COVID-19 pandemic has exacerbated workforce competition and workforce shortages. In order to develop and commercialize our products successfully, we will be required to retain key management and scientific employees. In certain instances, we may also need to expand or replace our workforce and our management ranks. In addition, we rely on certain consultants and advisors, including scientific and clinical advisors, to assist us in the formulation and advancement of our research and development programs. Our consultants and advisors may be employed by other entities or have commitments under consulting or advisory contracts with third parties that limit their availability to us, or both. If we are unable to attract, assimilate or retain such key personnel, our ability to advance our programs would be adversely affected. Turnover rates of key employees has varied substantially in recent years. Over the last few years, we have had several executive management changes. Leadership transitions can be inherently difficult to manage and may cause uncertainty or a disruption to our business or may increase the likelihood of turnover in other key officers and employees. If we lose the services of one or more 69 Â of our senior management or key employees, or if one or more of them decides to join a competitor or otherwise to compete with us, our business could be harmed. Risks Related to our Financial Condition and Capital Requirements We have previously incurred operating losses and we may not maintain profitability. We generated an operating income of $56.4 million for the nine months ended September 30, 2024. Our accumulated deficit was $4.4 billion as of September 30, 2024. Although we currently have four commercially approved products in the U.S., we believe that it will take us some time to attain positive cash flow from operations. Since our products and product candidates target small patient populations, the per-patient drug pricing must be high in order to recover our development and manufacturing costs, fund adequate patient support programs, fund additional research and achieve profitability. We may be unable to maintain or obtain sufficient sales volumes at a price high enough to justify our product development efforts and our sales, marketing and manufacturing expenses. We have generally incurred expenses related to research and development of our technologies and product candidates and from general and administrative expenses that we have incurred while building our business infrastructure. We anticipate that our expenses will increase substantially if and/or as we: â€¢continue the commercialization of our products in the U.S.; â€¢expand the global footprint of our products outside of the U.S.; â€¢establish our sales, marketing and distribution capabilities; â€¢continue our research, pre-clinical and clinical development of our product candidates; â€¢respond to and satisfy requests and requirements from regulatory authorities in connection with development and potential approval of our product candidates; â€¢initiate additional clinical trials for our product candidates; â€¢seek marketing approvals for our product candidates that successfully complete clinical trials; â€¢acquire or in-license other product candidates; â€¢maintain, expand and protect our intellectual property portfolio; â€¢increase manufacturing capabilities, including capital expenditures related to our real estate facilities and entering into manufacturing agreements; â€¢hire additional clinical, quality control and scientific personnel; and â€¢add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts. As a result, we expect to continue to incur significant operating losses at least through 2023. Because of the numerous risks and uncertainties associated with developing biopharmaceutical products, we are unable to predict the extent of any future losses or when, or if, we will become profitable. We may need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. We may require additional capital from time to time in the future in order to meet FDA post-marketing approval requirements and market and sell our products as well as to continue the development of product candidates in our pipeline, to prepare for potential commercialization of additional product candidates in our pipeline, to expand our product portfolio and to continue or enhance our business development efforts. The actual amount of funds that we may need and the sufficiency of the capital we have or are able to raise will be determined by many factors, some of which are in our control and others that are beyond our control. While we are currently well capitalized, we may use available capital resources sooner than we expect under our current operating plan. In addition, our operating plan may change. We may need or choose to seek additional funds sooner than planned, through equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances, funded research and development arrangements and licensing arrangements or a combination of these approaches. In any event, we expect to require additional capital to expand future development efforts, obtain regulatory 70 Â approval for, and to commercialize, our product candidates. Raising funds in the current economic environment may present additional challenges. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or in light of specific strategic considerations. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. In the event we receive negative data from our key clinical programs or encounter other major setbacks in our development, manufacturing or regulatory activities or in our commercialization efforts, our stock price is likely to decline, which would make a future financing more difficult. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders. The issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities may dilute all of our stockholders. The incurrence of indebtedness may result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product, if approved, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights. We may seek additional capital through a combination of private and public equity offerings, debt financings, collaborations and strategic and licensing arrangements. To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, the ownership interest of our stockholders in our company may be diluted. In addition, the terms of any such securities may include liquidation or other preferences that materially adversely affect the rights of our stockholders. Debt financing, if available, may increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaboration, strategic partnerships and licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, our intellectual property, future revenue streams or grant licenses on terms that are not favorable to us. The estimates and judgments we make, or the assumptions on which we rely, in preparing our consolidated financial statements and condensed consolidated financial statements could prove inaccurate. Our consolidated financial statements and condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. Such estimates and judgments include revenue recognition, inventory, valuation of stock-based awards, research and development expenses and income tax. We base our estimates on historical experience, facts and circumstances known to us and on various other assumptions that we believe to be reasonable under the circumstances. We cannot provide assurances, however, that our estimates, or the assumptions underlying them, will not change over time or otherwise prove inaccurate. If this is the case, we may be required to restate our consolidated financial statements or condensed consolidated financial statements, which could, in turn, subject us to securities class action litigation. Defending against such potential litigation relating to a restatement of our consolidated financial statements or condensed consolidated financial statements would be expensive and would require significant attention and resources of our management. Moreover, our insurance to cover our obligations with respect to the ultimate resolution of any such litigation may be inadequate. As a result of these factors, any such potential litigation could have a material adverse effect on our financial results and cause our stock price to decline, which could in turn subject us to securities class action litigation. 71 Â Risks Related to Our Common Stock Our stock price is volatile and may fluctuate due to factors beyond our control. The market prices for and trading volumes of securities of biotechnology companies, including our securities, has historically been volatile. Our stock has had significant swings in trading prices, in particular in connection with our public communications regarding feedback received from regulatory authorities. For example, over the last 12 months, as of the date of this report, our stock has increased as much as 30% in a single day or decreased as much as 8% in a single day. The market has from time to time experienced significant price and volume fluctuations unrelated to the operating performance of particular companies. The market price of our common stock may fluctuate significantly due to a variety of factors, including but not limited to: â€¢the commercial performance of our products in the U.S.; â€¢the timing of our submissions to regulatory authorities and regulatory decisions and developments; â€¢positive or negative clinical trial results or regulatory interpretations of data collected in clinical trials conducted by us, our strategic partners, our competitors or other companies with investigational drugs targeting the same, similar or related diseases to those targeted by us; â€¢delays in beginning and completing pre-clinical and clinical trials for potential product candidates; â€¢delays in entering or failing to enter into strategic relationships with respect to development and/or commercialization of our products or product candidates or entry into strategic relationships on terms that are not deemed to be favorable to us; â€¢technological innovations, product development or additional commercial product introductions by ourselves or competitors; â€¢changes in applicable government regulations or regulatory requirements in the approval process; â€¢developments concerning proprietary rights, including patents and patent litigation matters, such as developments in the interferences declared by the USPTO, including in the near term any outcomes of ongoing interference proceedings and over the longer term the outcomes from any related appeals; â€¢public concern relating to the commercial value, efficacy or safety of any of our products; â€¢our ability to obtain funds, through the issuance of equity or equity linked securities or incurrence of debt, or other corporate transactions; â€¢comments by securities analysts; â€¢developments in litigation against us; â€¢changes in senior management; or â€¢general market conditions in our industry or in the economy as a whole. Broad market and industry factors may seriously affect the market price of a companyâ€™s stock, including ours, regardless of actual operating performance. For example, the trading prices of biopharmaceutical companies have been highly volatile as a result of inflation and increased interest rates and overall market volatility. In addition, our operations and performance may be affected by political or civil unrest or military action, including the ongoing conflict between Russia and Ukraine. Additionally, in the past, following periods of volatility in the overall market and the market price of a particular companyâ€™s securities, securities class action litigation has often been instituted against these companies. Such litigation could result in substantial costs and a diversion of our managementâ€™s attention and resources. Our revenues and operating results could fluctuate significantly, which may adversely affect our stock price. Our revenues and operating results may vary significantly from year-to-year and quarter-to-quarter as well as in comparison to the corresponding quarter of the preceding year. Variations may result from one or more factors, including, without limitation: â€¢timing of purchase orders; â€¢changes in coverage and reimbursement policies of health plans and other health insurers, especially in relation to those products that are currently manufactured, under development or identified for future development by us; â€¢re-authorizations processes that may be required for patients who initially obtained coverage by third parties, including government payors, managed care organizations and private health insurers; 72 Â â€¢transition from temporary billing codes established by the CMS to permanent medical codes; â€¢timing of approval of applications filed with the FDA; â€¢timing of product launches and market acceptance of products launched; â€¢changes in the amounts spent to research, develop, acquire, license or promote new and existing products; â€¢results of clinical trial programs; â€¢serious or unexpected health or safety concerns with our product or product candidates and any resulting clinical holds; â€¢introduction of new products by others that render one or more of our products obsolete or noncompetitive; â€¢the ability to maintain selling prices and gross margins on our products; â€¢increases in the cost of raw materials contained within our products and product candidates; â€¢manufacturing and supply interruptions, including product rejections or recalls due to failure to comply with manufacturing specifications; â€¢timing of revenue recognition relating to our distribution agreements; â€¢the ability to protect our intellectual property from being acquired by other entities; â€¢the ability to avoid infringing the intellectual property of others; â€¢the impact of the COVID-19 or similar pandemics; and â€¢the addition or loss of customers. In addition, in one or more future periods, our results of operations may fall below the expectations of securities analysts and investors. In that event, the market price of our common stock could decline. Provisions of our certificate of incorporation, bylaws and Delaware law might deter acquisition bids for us that might be considered favorable and prevent or frustrate any attempt to replace or remove the then-current management and board of directors. Certain provisions of our certificate of incorporation and bylaws may make it more difficult for a third party to acquire control of us or effect a

change in our board of directors and management. These provisions include: â€¢when the board is comprised of six or more directors, classification of our board of directors into two classes, with one class elected each year; â€¢directors may only be removed for cause by the affirmative vote of a majority of the voting power of all the then-outstanding shares of voting stock; â€¢prohibition of cumulative voting of shares in the election of directors; â€¢right of the board of directors to elect directors to fill a vacancy created by the expansion of the board of directors or the resignation, death, disqualification or removal of a director; â€¢express authorization of the board of directors to make, alter or repeal our bylaws; â€¢prohibition on stockholder action by written consent; â€¢advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at stockholder meetings; â€¢the ability of our board of directors to authorize the issuance of undesignated preferred stock, the terms and rights of which may be established and shares of which may be issued without stockholder approval, including rights superior to the rights of the holders of common stock; and â€¢a super-majority (66 2/3%) of the voting power of all of the then-outstanding shares of capital stock are required to amend, rescind, alter or repeal our bylaws and certain provisions of our certificate of incorporation. In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in 73 Â our certificate of incorporation and our bylaws and in the Delaware General Corporation Law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors. A significant number of shares of our common stock are issuable pursuant to outstanding stock awards, and we expect to issue additional stock awards and shares of common stock to attract and retain employees, directors and consultants. We may also issue shares of common stock to finance our operations and in connection with our strategic goals. The vesting and exercise of these awards and sales of shares will dilute the interests of existing security holders and may depress the price of our common stock. Currently, our Amended and Restated Certificate of Incorporation authorizes the issuance of up to 198.0 million shares of common stock. As of September 30, 2024, there were approximately 95.5 million shares of common stock outstanding and outstanding awards to purchase 11.7 million shares of common stock under various incentive stock plans. Additionally, as of September 30, 2024, there were approximately 3.4 million shares of common stock available for future issuance under our 2018 Equity Incentive Plan, approximately 0.2 million shares of common stock available for issuance under our Amended and Restated 2013 Employee Stock Purchase Plan, and approximately 1.1 million shares of common stock available for issuance under our 2024 Employment Commencement Incentive Plan. We may issue additional shares to grant equity awards to our employees, officers, directors and consultants under our 2018 Equity Incentive Plan, our 2013 Employee Stock Purchase Plan or our 2024 Employment Commencement Incentive Plan. We may also issue additional common stock and warrants from time to time to finance our operations and in connection with strategic transactions, such as acquisitions and licensing. For example, in February 2020, we issued and sold 2,522,227 shares of common stock to Roche Finance in connection with the entry into the collaboration agreement with Roche. The issuance of additional shares of common stock or warrants to purchase common stock and the perception that such issuances may occur or exercise of outstanding warrants or stock options may have a dilutive impact on other stockholders and could have a material negative effect on the market price of our common stock. Future sales of our common stock in the public market could cause our share price to fall. Sales of a substantial number of our common stock in the public market, including sales by members of our management or board of directors, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity or equity-related securities. Risks Related to Our Convertible Senior Notes Servicing our 1.50% notes due 2024 (the â€œ2024 Notesâ€) and 1.25% notes due 2027 (the â€œ2027 Notesâ€, and together with the 2024 Notes, the â€œNotesâ€) requires a significant amount of cash, and we may not have sufficient cash flow to pay our debt. In 2017, we issued $570.0 million aggregate principal amount of Notes, pursuant to that certain indenture, dated as of November 14, 2019, between us, as issuer, and U.S. Bank National Association, as trustee. In September 2022, we issued $1,150.0 million aggregate principal amount of 2027 Notes, pursuant to that certain indenture dated as of September 16, 2022, between us, as issuer, and U.S. Bank National Association, as trustee, including $20.0 million of 2027 Notes issued to the Michael A. Chambers Living Trust in a private placement. In September 2022, we entered into separate, privately negotiated transactions to repurchase a portion of the outstanding 2024 Notes and, in March 2023, we entered into separate, privately negotiated exchange agreements with holders of $313.5 million in aggregate principal value of outstanding 2024 Notes pursuant to which these 2024 Notes were exchanged for shares of our common stock. Our ability to make scheduled payments of the principal of, to pay interest on, or to refinance our indebtedness, including the Notes, depends on our future performance, which is subject to many factors, including, economic, financial, competitive and other, beyond our control. We do not expect our business to be able to generate cash flow from operations in the foreseeable future, sufficient to service our debt and make necessary capital expenditures and we may therefore be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance the 2027 Notes will depend on the capital markets and our financial condition at such times. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, and limit our flexibility in planning for and reacting to changes in our business. We may not have the ability to raise the funds necessary to repurchase the Notes as required upon a fundamental change, and our future debt may contain limitations on our ability to repurchase the Notes. 74 Â Holders of the Notes will have the right to require us to repurchase their Notes for cash upon the occurrence of a fundamental change at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any. A fundamental change may also constitute an event of default or prepayment under, and result in the acceleration of the maturity of, our then-existing indebtedness. We cannot assure you that we will have sufficient financial resources, or will be able to arrange financing, to pay the fundamental change repurchase price in cash with respect to any Notes surrendered by holders for repurchase upon a fundamental change. In addition, restrictions under our then existing credit facilities or other indebtedness, if any, may not allow us to repurchase the Notes upon a fundamental change. Our failure to repurchase the Notes upon a fundamental change when required would result in an event of default with respect to the Notes which could, in turn, constitute a default under the terms of our other indebtedness, if any. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes. Capped call transactions entered into in connection with the Notes may impact the value of our common stock. In connection with the Notes, we entered into capped call transactions (the â€œCapped Call Transactionsâ€) with certain financial institutions. The Capped Call Transactions are expected to generally reduce the potential dilution upon conversion of the Notes into shares of our common stock. In connection with establishing their initial hedges of the Capped Call Transactions, these financial institutions or their respective affiliates may have entered into various derivative transactions with respect to our common stock and/or purchased our common stock. The financial institutions, or their respective affiliates, may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions prior to the maturity of the Notes. This activity may have an impact on the value of our common stock. General Risks Unfavorable global economic conditions could harm our business, financial condition or results of operations. Our results of operations could be harmed by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn, including the impact of increased interest rates and inflation (such as the recent rise in inflation in the United States), could result in a variety of risks to our business, including weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could strain our manufacturers, possibly resulting in manufacturing disruption, or cause delays in payments for our services by third-party payors or our future collaborators. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could harm our business. We may be subject to product liability claims and our insurance may not be adequate to cover damages. The current and future use of our product candidates by us and our collaborators in clinical trials, expanded access programs, the sale of our products, or the use of our products under emergency use vehicles may expose us to liability claims inherent to the manufacture, clinical testing, marketing and sale of medical products. These claims might be made directly by consumers or healthcare providers or indirectly by pharmaceutical companies, our collaborators or others selling such products. Regardless of merit or eventual outcome, we may experience financial losses in the future due to such product liability claims. We have obtained commercial general liability insurance coverage for our clinical trials and the sale of commercial products. However, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against all losses. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. Violation of the General Data Protection Regulation or UK GDPR could subject us to significant fines. The GDPR and UK GDPR increase our obligations with respect to clinical trials conducted in the member states of the EEA and the UK by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR and the UK GDPR increase the scrutiny that clinical trial sites located in the EEA and UK should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the U.S. The GDPR and UK GDPR impose substantial fines for breaches of data protection requirements, which can be up to four percent of global revenue or 20 million Euros (Â£17.5 million in the U.K.), whichever is greater, and they also confer a private right of action on data subjects for breaches of data protection requirements. Compliance with these directives is a rigorous and time-intensive process that requires review and updates that may increase our cost of doing business, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm in connection with our European and U.K. activities. Â 75 Â We have expanded, and may continue to expand, our organization and may experience difficulties in managing this growth, which could disrupt our operations. To support the expansion of our business activities, we have expanded, and may continue to expand, our full-time employee base, as well as our consultant and contractor base. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. Our ability to manage our growth properly and maintain compliance with all applicable rules and regulations will require us to continue to improve our operational, legal, financial and management controls, as well as our reporting systems and procedures. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our sales and operations are subject to the risks of doing business internationally. We are increasing our presence in international markets, including emerging markets, subjecting us to many risks that could adversely affect our business and revenues, such as: â€¢the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; â€¢uncertainties regarding the collectability of accounts receivable; â€¢fluctuations in foreign currency exchange rates that may adversely impact our revenues, net income and value of certain of our investments; â€¢difficulties in staffing and managing international operations; â€¢the imposition of governmental controls; â€¢less favorable intellectual property or other applicable laws; â€¢increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; â€¢the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; â€¢compliance with complex import and export control laws; â€¢restrictions on direct investments by foreign entities and trade restrictions; and â€¢changes in tax laws and tariffs. In addition, our international operations are subject to regulation under U.S. law. For example, the Foreign Corrupt Practices Act (â€œFCPAâ€) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the healthcare professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results. We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively. In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of our suppliers, as well as personally identifiable information of the patients using our commercially approved products, clinical trial participants and employees. Similarly, our third-party providers possess certain of our sensitive data. The secure maintenance of this information is critical to our operations and business strategy. Our ongoing operating activities also depend on functioning computer systems. Despite our security measures, our information technology and infrastructure are subject to 76 Â attacks or breaches. Any such breach could result in a material compromise of our networks, and the information stored there could be accessed, publicly disclosed, lost, stolen, or rendered, permanently or temporarily, inaccessible. Furthermore, we may not promptly discover a system intrusion. Attacks could have a material impact on our business, operations or financial results. Any such access, disclosure or other loss of information, including our data being breached at third party providers, could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, disrupt our operations and damage our reputation, which could adversely affect our business. We also may need to pay â€œransomwareâ€ to re-access our systems. In addition, privacy and data protection laws may be interpreted and applied differently from country to country and may create inconsistent or conflicting requirements, which increase the costs incurred by us in complying with such laws. The European Unionâ€™s GDPR, and the UK GDPR in the U.K., purport to have a broad territorial scope, include a broad array of requirements for handling personal data including the public disclosure of significant data breaches, and impose substantial penalties for non-compliance of up to the greater of â‚¬20 million (Â£17.5 million in the U.K.) or 4% of global annual revenue for the preceding financial year. Our efforts to comply with GDPR, UK GDPR and other privacy and data protection laws imposes significant costs and challenges that are likely to increase over time, and we are exposed to substantial penalties or litigation related to violations of existing or future data privacy laws and regulations Additionally, the California Consumer Privacy Act (â€œCPAâ€), includes significant privacy obligations applicable to many businesses that do business in California. The CPA requires disclosures to California consumers, imposes rules around collecting or using information about minors, and affords consumers with privacy rights such as the right to know whether the data is sold or disclosed and to whom, the right to request that a company delete personal information collected, the right to correct inaccurate information, the right to limit the use of sensitive information, the right to opt-out of the sale of personal information or sharing of personal information for cross-context behavioral advertising, and the right to non-discrimination in terms of price or service when a consumer exercises a privacy right. Failure to comply with these requirements is subject to civil sanctions, including fines and penalties. The CPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. We will need to continually evaluate and potentially update our privacy program to ensure compliance with the CPA, GDPR, UK GDPR, and other applicable privacy laws and will incur additional costs and expenses in our effort to comply. We may incur substantial costs in connection with litigation and other disputes. In the ordinary course of business we may, and in some cases have, become involved in lawsuits and other disputes such as securities claims, intellectual property challenges, including interferences declared by the USPTO, and employee matters. It is possible that we may not prevail in claims made against us in such disputes even after expending significant amounts of money and company resources in defending our positions in such lawsuits and disputes. The outcome of such lawsuits and disputes is inherently uncertain and may have a negative impact on our business, financial condition and results of operations. The increasing use of social media platforms presents new risks and challenges. Social media is increasingly being used to communicate about our products, technologies and programs, and the diseases our product and product candidates are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend ourselves or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product and/or product candidates.

There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business. We or the third parties upon whom we depend may be adversely affected by natural disasters and/or terrorism attacks, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. Natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage, terrorism attack or other event occurred that prevented us from using all or a significant portion of our office, manufacturing and/or lab spaces, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. 77 Â The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None. Â Item 3. Defaults Upon Senior Securities. None. Â Item 4. Mine Safety Disclosures. None. Â Item 5. Other Information. During the three months ended September 30, 2024, Louise Rodino-Klapac entered into and adopted a written plan for the sale of our securities that is intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information (a â€œRule 10b5-1 trading planâ€). Ms. Rodino-Klapacâ€™s 10b5-1 trading plan has an adoption date of August 9, 2024 and an end date of November 15, 2025, covering 28,875 options to purchase shares of common stock with a strike price of $76.36 and 24,988 shares of common stock. Â Item 6. Exhibits. The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q. 78 Â EXHIBIT INDEX Â Â Â Â Â Incorporated by Reference toFilings Indicated Â ExhibitNumber Â Exhibit Description Â Form Â FileNo. Â Exhibit Â FilingDate Â ProvidedHerewith Â Â Â Â Â

Registrantâ€™s internal control over financial reporting. November 6, 2024 /s/ IAN M. ESTEPAN Â Ian M. Estepan Executive Vice President, Chief Financial Officer (Principal Financial and Accounting Officer) Â Â EX-32.1 6 srpt-ex32_1.htm EX-32.1 EX-32.1 Â EXHIBIT 32.1 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) I, Douglas S. Ingram, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that this Quarterly Report of Sarepta Therapeutics, Inc. on Form 10-Q for the quarterly period ended September 30, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Sarepta Therapeutics, Inc. November 6, 2024 /s/ DOUGLAS S. INGRAM Douglas S. Ingram President and Chief Executive Officer (Principal Executive Officer) A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Sarepta Therapeutics, Inc. and will be retained by Sarepta Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by Sarepta Therapeutics, Inc. for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Sarepta Therapeutics, Inc. specifically incorporates it by reference. Â EX-32.2 7 srpt-ex32_2.htm EX-32.2 EX-32.2 Â EXHIBIT 32.2 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) I, Ian M. Estepan, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that this Quarterly Report of Sarepta Therapeutics, Inc. on Form 10-Q for the quarterly period ended September 30, 2024, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Sarepta Therapeutics, Inc. Â November 6, 2024 /s/ IAN M. ESTEPAN Ian M. Estepan Executive Vice President, Chief Financial Officer (Principal Financial and Accounting Officer) A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Sarepta Therapeutics, Inc. and will be retained by Sarepta Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by Sarepta Therapeutics, Inc. for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Sarepta Therapeutics, Inc. specifically incorporates it by reference. Â EX-101.SCH 8 srpt-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - GAIN FROM SALE OF PRIORITY REVIEW VOUCHER link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - INDEBTEDNESS link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - OTHER INCOME (LOSS), NET link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - EARNINGS (LOSS) PER SHARE link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - INDEBTEDNESS (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - OTHER INCOME (LOSS), NET (Tables) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Organization and Nature of Business - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - License and Collaboration Agreements - Summary of Activity Related to Supply Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Gain from Sale of Priority Review Voucher - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured and Carried at Fair Value (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Fair Value Measurements - Summary of Fair Value of Level 3 Financial Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Company Financial Assets with Maturities of Less Than 90 Days Included in Cash Equivalents (Detail) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Company Cash, Cash Equivalents and Short-term Investments (Detail) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Product Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summarizes the concentration of the three largest customers (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Change in Reserves for Discounts and Allowances (Detail) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Total Reserves Included in Consolidated Balance Sheets (Detail) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Inventory - Summary of Components of Inventory (Detail) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Inventory - Summarizes the Balance Sheet Classification (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - OTHER ASSETS (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Other Assets - Summary of Other Current Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Other Assets - Summary of Other Non-current Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Indebtedness - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - Indebtedness - Summary of Debt Facilities (Detail) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - Indebtedness - Summarizes Total Gross Payments Due under Company's Debt Arrangements (Detail) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - Stock-Based Compensation - Summary of Stock Awards Granted (Detail) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - Stock-Based Compensation - Summary of Stock Awards Granted (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Grant Type Included within Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - Other Income (Loss), Net - Summary of Other Income (Loss) (Detail) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - Other Income (Loss), Net - (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - Leases (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 996085 - Disclosure - INCOME TAXES (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 996095 - Disclosure - Earning (Loss) Per Share - Basic and Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 996105 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 996115 - Disclosure - Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 996125 - Disclosure - Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 996135 - Disclosure - Commitments and Contingencies - Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations (Detail) link:presentationLink link:calculationLink link:definitionLink 996145 - Disclosure - Commitments and Contingencies (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 996155 - Disclosure - SUBSEQUENT EVENTS (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Maturity and sale of available-for-sale securities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total Platform Operator, Crypto Asset [Table] Statement [Line Items] Statement [Line Items] Debt Instrument [Axis] Debt Instrument Research, option and milestone expense. Research, Option And Milestone Expense Research, option and milestone expense Increase in accounts receivable Increase (Decrease) in Accounts Receivable Cash, cash equivalents and investments, Amortized cost Cash Cash Equivalents And Investments Amortized Cost Basis Cash cash equivalents and investments amortized cost basis. Cash, cash equivalents and investments, Amortized cost Issuance Of Common Stock For Conversion Of 2024 Notes Value Issuance Of Common Stock For Conversion Of 2024 Notes Value Issuance of common stock for conversion of 2024 Notes Entity Address, Postal Zip Code Entity Address, Postal Zip Code Summary of Company Cash, Cash Equivalents and Short-Term Investments and non-current investments Cash, Cash Equivalents and Investments [Table Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Proceeds from sale of Priority Review Voucher Proceeds from Sale of Intangible Assets Prepaid research expenses, current. Prepaid Research Expenses Current Prepaid research expenses Costs and Expenses [Abstract] Cost and expenses: Revenues [Abstract] Revenues: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid during the period for interest Roche Supply Agreement [Member] Supply agreement. Supply Agreement [Member] Share-based payment arrangement, Cost not yet recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Number of Operating Segments Number of operating segments Share-Based Payment Arrangement, Tranche One [Member] Unvested Tranche Member Schedule Of Inventory Table Text Block Schedule Of Inventory Table Text Block Schedule of Components of Inventory Effective tax rate Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total Effective Income Tax Rate Reconciliation, Tax Credit, Percent Effective tax rate Cash, Cash Equivalents, and Marketable Securities [Text Block] CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES Shares, Outstanding Balance (in shares) Balance (in shares) Gain (Loss) on Disposition of Intangible Assets Gain from sale of Priority Review Voucher Gain from sale of Priority Review Voucher Other Other Noncash Income (Expense) Other Other Noncash Income (Expense), Total Fair Value Hierarchy and NAV [Axis] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Reduction to right of use assets and lease liabilities Reduction To Right Of Use Assets And Lease Liabilities Reduction To Right Of Use Assets And Lease Liabilities Long-Term Debt, Type [Domain] Share-Based Payment Arrangement, Amount Capitalized Capitalized stock-based compensation costs Total carrying value of debt instruments Long-Term Debt, Current Maturities Current portion of long-term debt Investments Investments Investments, Total Prepaid maintenance services Prepaid maintenance services Prepaid maintenance services Payment for option exercise Payment For Option Exercise Payment for option exercise. LEASES Lessee, Operating Leases [Text Block] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Liabilities Terminated Liabilities Terminated Liabilities Terminated Product and Service [Axis] Depreciation, Depletion and Amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Manufacturing-related deposits and prepaid expense current. Manufacturing Related Deposits And Prepaid Expense Current Manufacturing-related deposits and prepaids Cash deposits and money market funds. Cash Deposits And Money Market Funds [Member] Cash and Money Market Funds [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Common stock issuable under the Company's convertible debt Common stock issuable under the Company's convertible debt Concentration Risk Benchmark [Axis] Prepaid Taxes Prepaid income tax Title and Position [Axis] Inventory, Work in Process, Net of Reserves Work in progress Cash cash equivalents restricted cash and investments. Cash Cash Equivalents Restricted Cash And Investments Cash cash equivalents restricted cash and investments Accrued clinical and preclinical costs current. Accrued Clinical And Preclinical Costs Current Accrued clinical and pre-clinical costs Prepaid medical affairs expenses. Prepaid Medical Affairs Expenses Prepaid medical affairs expenses Entity Central Index Key Entity Central Index Key Cash Equivalents, at Carrying Value Cash equivalents Cash Equivalents, at Carrying Value, Total Chargebacks. Chargebacks [Member] Chargebacks [Member] Common stock, shares issued Common Stock, Shares, Issued Common Stock, Shares, Issued, Total Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Other Noncurrent Assets [Member] Remaining lease term Lessee, Operating Lease, Remaining Lease Term 2026 Long-Term Debt, Maturity, Year Four Share-Based Payment Arrangement, Expense, after Tax Subtotal Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Total fair value of debt instruments Debt Instrument, Fair Value Disclosure Debt Instrument Fair Value Debt Instrument, Fair Value Disclosure, Total Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under employee stock purchase plan Rebates. Rebates [Member] Rebates [Member] Income (loss) before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (loss) before income tax expense Summary of change in reserves for discounts and

allowances. Summary Of Change In Reserves For Discounts And Allowances Table [Text Block] Summary of Change in Reserves for Discounts and Allowances Accounts receivable payment term. Accounts Receivable Payment Term Accounts receivable payment term Increase decrease in accumulated deficit. Increase Decrease In Accumulated Deficit Decrease in accumulated deficit PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES [Text Block] PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES [Text Block] Convertible debt and term loan and revolver and mortgage loans. Convertible Debt And Term Loan And Revolver And Mortgage Loans [Member] Convertible Debt, The Term Loan, The Revolver and The Mortgage Loans [Member] Concentration Risk Type [Domain] Concentration Risk Type Rest of World [Member] Rest of World [Member] Customer [Axis] Customer Concentration Risk [Member] Customer Concentration Risk [Member] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Accounting standard update two thousand and sixteen to two thousand and eighteen. Accounting Standard Update Two Thousand And Sixteen To Two Thousand And Eighteen [Member] ASU 2020-06 Commitments and contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Customer two. Customer Two [Member] Customer Two [Member] 2017 Capped Calls Partial Settlement [Member] Two Thousand Seventeen Capped Calls Partial Settlement [Member] Two Thousand Seventeen Capped Calls Partial Settlement [Member] Total Roche supply agreement revenue Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Collaboration and other Amortization of Debt Issuance Costs Amortization of Debt Issuance Costs Cover [Abstract] Subsequent Event [Line Items] Bio Marin Pharmaceutical Incorporation. Bio Marin Pharmaceutical Incorporation [Member] BioMarin Pharmaceutical, Inc. [Member] Equity Incentive Plans [Member] Equity Incentive Plans [Member] Equity Incentive Plans [Member] Earnings Per Share, Basic, Total Earnings Per Share, Basic Earnings (loss) per common share, basic Basic Collaboration Receivable. Collaboration Receivable Collaboration Receivable Cash and cash equivalents, Gross unrealized gains Cash And Cash Equivalents Gross Unrealized Gain Before Tax Cash and cash equivalents gross unrealized gain before tax. Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Available for sale debt securities, Gross unrealized gains Available for sale debt securities, Gross unrealized losses Contract with Customer, Liability, Current Deferred revenue, current portion Modification of 2017 Capped Calls Modification of Capped Calls Modification of Capped Calls Schedule of Cash and Cash Equivalents [Table Text Block] Summary of Company Financial Assets with Maturities of Less Than 90 Days Included in Cash Equivalents Share-Based Payment Arrangement, Expense Total stock-based compensation expense Stock-based compensation expense Implemented fee Amendment Implemented Fee Total carrying value of debt instruments Aggregate long-term debt Long-Term Debt Conversion of shares excluded from computation of diluted EPS Conversion of shares excluded from computation of diluted EPS Conversion of shares excluded from computation of diluted EPS Non-cash termination charges Gain (Loss) on Contract Termination Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Assets, Current [Abstract] Current assets: UNITED STATES U.S. [Member] United States [Member] Investment Type [Axis] Investment Type Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Product and Service [Domain] Accumulated other comprehensive income, net of tax Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Debt Instrument [Line Items] Debt Instrument [Line Items] Increase (decrease) in additional paid in capital. Increase Decrease In Additional Paid In Capital Decrease in additional paid-in-capital Customer Four [Member] Customer Four [Member] Property, Plant and Equipment, Net Property and equipment, net Property, Plant and Equipment, Net, Total Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Prepaid commercial. Prepaid Commercial Prepaid commercial expenses SummaryOfInventoryBalanceSheetClassificationTableTextBlock Summary of Inventory Balance Sheet Classification [Table Text Block] Summary of Inventory Balance Sheet Classification Contract with Customer, Liability, Noncurrent Deferred revenue, net of current portion Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Non-cash contract termination cost Non-Cash Contract Termination Cost Non-cash contract termination cost. Other Income and Expenses [Abstract] Vesting [Axis] Common Stock, Par or Stated Value Per Share Common stock, par value Accrued Royalties, Current Accrued royalties Unrealized gains on investments, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Contract with Customer, Liability Deferred Revenue Contract with Customer, Liability, Total Statement of Cash Flows [Abstract] Counterparty Name [Axis] Counterparty Name Convertible Debt Securities [Member] Convertible Debt Securities [Member] Antidilutive Securities, Name [Domain] Accrued contract manufacturing expense current. Accrued Contract Manufacturing Expense Current Accrued contract manufacturing costs Schedule of Other Assets, Noncurrent [Table Text Block] Summary of Other Non-current Assets Accrued Income Taxes, Total Accrued Income Taxes Accrued income taxes Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date. Long Term Debt Maturities Repayments Of Principal After Year Four 2027 Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts Notes And Loans Receivable [Line Items] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Equity Components [Axis] Equity Components Partial settlement of capped call Partial settlement of capped call share options for 2024 Notes Partial settlement of capped call share options for 2024 Notes Partial settlement of capped call share options for 2024 Notes Entity Address, Address Line One Entity Address, Address Line One Two Thousand And Nineteen Term Loan Member Two Thousand And Nineteen Term Loan [Member] 2019 Term Loan [Member] Nationwide license agreement. Nationwide License Agreement [Member] Nationwide License Agreement [Member] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Basic and Diluted Net Loss Per Share 2022 Capped Call Transactions [Member] 2022 Capped Call Transactions [Member] Employee-related Liabilities, Current Accrued employee compensation costs Employee-related Liabilities, Current, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Grants, Restricted stock units Expanded Grants, Stock options Cash cash equivalents and investments. Cash Cash Equivalents And Investments Cash, cash equivalents and investments, Fair value Cash, cash equivalents and investments, Fair value Subsequent Event Type [Axis] Nonoperating Income (Expense) Total other income (loss), net Non-US [Member] Outside of U.S. [Member] Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Effect of dilutive securities* Amendment Flag Amendment Flag Current Federal Tax Expense (Benefit) Federal tax expense Operating Lease, Liability, Noncurrent Lease liabilities, net of current portion Remaining expense associated Remaining expense associated in share Remaining expense associated in share Debt Instrument, Convertible, Carrying Amount of Equity Component Aggregate principal amount converted into equity Inventory, Finished Goods, Net of Reserves Finished goods Debt Instrument, Name [Domain] Debt Instrument, Name Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Net income (loss) Lessee, Lease, Description [Table] Inventory, Noncurrent, Total Inventory, Noncurrent Non-current inventory Other non-current assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercise of options for common stock, shares Research and Development Expense [Member] Research and Development Expense [Member] Research and Development Expense Customer [Domain] Contractual Obligation, to be Paid, Year Two 2026 Equity Component [Domain] Equity Component Statistical Measurement [Domain] Statistical Measurement Prompt pay. Prompt Pay [Member] Prompt Pay [Member] Gain from sale of intangible asset. Gain From Sale Of Intangible Asset [Line Items] Gain From Sale Of Intangible Asset [Line Items] Interest expense debt Interest Expense, Debt Interest expense reduced Interest Expense, Debt, Total Other income (expense), net Other income (expense), net Other Nonoperating Income (Expense) Other, net Recognized over approximately the next year Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest Unrealized gains from available-for-sale securities, net of tax Collateralized Letter of Credit Cash Deposit Collateralized Letter of Credit Cash Deposit Collateralized Letter of Credit Cash Deposit Cash and cash equivalents gross unrealized loss before tax. Cash And Cash Equivalents Gross Unrealized Loss Before Tax Cash and cash equivalents, Gross unrealized losses Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Reconciliation of cash, cash equivalents and restricted cash: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net income (loss) Schedule of Other Current Assets [Table Text Block] Summary of Other Current Assets Deferred Revenue, Current Deferred Revenue, Current Deferred Revenue, Current, Total Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Proceeds from Stock Options Exercised Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program Lease discount rate Lessee, Operating Lease, Discount Rate Loans Payable, Noncurrent Long-term debt Total carrying value of debt facilities Payments credits reserves for discounts and allowances. Payments Credits Reserves For Discounts And Allowances Payments/credits Payables and Accruals [Abstract] Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under employee stock purchase plan, shares Non-current investments [Member] Non-current investments [Member] Non-current investments [Member] Short-Term Investments Short-term investments Short-term Investments, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Grants, Stock options Stock options granted to CEO Debt Conversion Costs Debt Conversion Costs Debt conversion costs for 2024 Notes Debt conversion costs for 2024 Notes Restricted cash Restricted Cash, Noncurrent Restricted cash in other assets Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Total other comprehensive income Other Comprehensive Income (Loss), Net of Tax Collaborative Arrangement Disclosure [Text Block] LICENSE AND COLLABORATION AGREEMENTS Cumulative Effect, Period of Adoption, Adjustment [Member] Cumulative Effect of Accounting Change [Member] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Common stock, shares outstanding Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance installments date Installments Date of implemented fee Weighted average maturity period of available for sale securities. Weighted Average Maturity Period Of Available For Sale Securities Weighted average maturity period of available-for-sale securities Issuance Of Common Stock For Conversion Of 2024 Notes Shares Issuance Of Common Stock For Conversion Of 2024 Notes Shares Issuance of common stock for conversion of 2024 Notes, Shares Payments to Acquire Debt Securities, Available-for-Sale Purchase of available-for-sale securities Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Revenue Benchmark [Member] Sales Revenue Net [Member] Customers Exceed [Member] Customers Exceed [Member] Schedule of Certain Activity Related to Revenue with Supply Agreement Schedule Of Certain Activity Related To Revenue With Supply Agreement [Table Text Block] Schedule of certain activity related to revenue with supply agreement. Antidilutive Securities [Axis] Corporate Bond Securities [Member] Corporate Bond [Member] Other Non-Current Assets Amortized Cost Other Non-Current Assets Amortized Cost Other Non-Current Assets Amortized Cost Entity Interactive Data Current Entity Interactive Data Current Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Summary of Fair Value of Level 3 Financial Assets Cost of Sales [Member] Cost of Sales [Member] Accounting Standards Update [Domain] Accounting Standards Update Document Quarterly Report Document Quarterly Report Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] Summary of Fair Value of Level 3 Financial Liabilities Significant Accounting Policies [Policy Text Block] Significant Accounting Policies [Policy Text Block] Significant Accounting Policies Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Statement of Financial Position Location, Balance [Axis] Statistical Measurement [Axis] Statistical Measurement Cost of sales Cost of Goods and Services Sold Cost of Goods and Services Sold, Total Operating lease cost Operating Lease, Cost Columbus Ohio Columbus Ohio [Member] Debt Instrument, Periodic Payment, Principal Debt Instrument, Periodic Payment, Principal Assets, Fair Value Disclosure Total assets Fair value, at the beginning of the period Fair value, at the end of the period Assets, Fair Value Disclosure, Total FDA Member. F D A [Member] F D A Summary of reserves for discounts and allowances included in consolidated balance sheets. Summary Of Reserves For Discounts And Allowances Included In Consolidated Balance Sheets Table [Text Block] Summary of Total Reserves Included in Consolidated Balance Sheets PMO Products [Member] PMO Products [Member] Disaggregation of Revenue [Table Text Block] Summary of Product Revenues Michael A Director [Member] Commercial Paper [Member] Commercial Paper [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Restricted stock units No Individual [Member] No Individual [Member] Customer one. Customer One [Member] Customer One [Member] Ms. Rodino Klapac [Member] Ms. Rodino Klapac [Member] Milestone payment to be paid by company upon specified research milestone achievement. Milestone Payment To Be Paid By Company Upon Specified Research Milestone Achievement Contingent research milestone payments Statement of Income Location, Balance [Axis] Income Statement Location Assets Total assets Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Vesting PSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Schedule of Activity Related to Supply Agreement Schedule of Principal Transactions Revenue [Table Text Block] Reduction in the carrying amounts of the right of use assets. Reduction In The Carrying Amounts Of The Right Of Use Assets Reduction in the carrying amounts of the right of use assets PRV P R V [Member] P R V Entity Address, City or Town Entity Address, City or Town Impairment of equity investments Income (Loss) from Equity Method Investments Contractual Obligation To Be Paid After Year Three Year Contractual Obligation To Be Paid After Year Three Year Thereafter Schedule of Maturities of Long-Term Debt [Table Text Block] Summarizes Total Gross Payments Due under Company's Debt Arrangements Cash and cash equivalents amortized cost basis. Cash And Cash Equivalents Amortized Cost Basis Cash and cash equivalents, Amortized cost Cash and cash equivalents, Amortized cost Accrued research expenses. Accrued Research Expenses Accrued research expenses Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Summary of Stock-Based Compensation Expense by Grant Type Included within Consolidated Statements of Operations and Comprehensive Loss Provision for reserves for discounts and allowances. Provision For Reserves For Discounts And Allowances Provision Debt Instrument, Face Amount Debt instrument, face amount Total payments Principal amount Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Thermo fisher scientific, inc. Thermo Fisher Scientific Incorporation [Member] Thermo Fisher Scientific, Inc. [Member] Development milestone and settlement upfront fee recognized as research and development expense. Development Milestone And Settlement Upfront Fee Recognized As Research And Development Expense Development Milestone and Upfront Fee Recognized as Research and Development Expense Accounting Standards Update 2020-06 [Member] ASU 2020-06 Share-Based Payment Arrangement [Text Block] STOCK-BASED COMPENSATION Current State and Local Tax Expense (Benefit) State tax expense Lysogene S.A. [Member] Lysogene S A [Member] Lysogene S,A. Prepaid Expense and Other Assets, Current [Abstract] Fair Value Disclosures [Abstract] 2027 Convertible Notes [Member] Two Thousand And Twenty Seven Senior Convertible Notes [Member] Two Thousand And Twenty Seven Senior Convertible Notes [Member] Chief Executive Officer [Member] Chief Executive Officer Stock Issued During Period, Value, Stock Options Exercised Exercise of options for common stock Reduction In Carrying Value Of Convertible Notes Reduction In Carrying Value Of Convertible Notes Reduction in carrying value of convertible notes Lessee, Lease, Description [Line Items] Liabilities, Current [Abstract] Current liabilities: Other Assets Disclosure [Text Block] OTHER ASSETS Accounts Receivable [Member] Accounts Receivable [Member] Income Taxes Paid, Net, Total Income Taxes Paid, Net Cash paid during the period for income taxes Cash and Cash Equivalents [Member] Cash and Cash Equivalents [Member] Document Type Document Type Henogen SA. Henogen SA [Member] Henogen SA [Member] Accounting Standards Update [Axis] Accounting Standards Update US Government Agencies Debt Securities [Member] Government and Government Agency Bonds [Member] Title of 12(b) Security Title of 12(b) Security Cash and cash equivalents, Fair value Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Statement of Financial Position Location, Balance [Domain] Debt Instrument, Redemption, Period [Axis] Gain (loss) from sale of intangible assets. Gain Loss From Sale Of Intangible Assets Disclosure [Text Block] GAIN FROM SALE OF PRIORITY REVIEW VOUCHER Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Issuance of Common Stock for Exchange of 2024 Notes Shares Issuance of Common Stock for Exchange of 2024 Notes Shares Issuance of common stock for exchange of 2024 Notes, shares Research and Development Expense Research and development expense Research and Development Expense, Total Impairment of strategic investments Equity Method Investment, Other-than-Temporary Impairment Impairment of equity investment Impairment of investment in private companies Roche Agreement [Member] Roche Agreement [Member] Roche Agreement. Cost of goods sold excluding amortization. Cost Of Goods Sold Excluding Amortization Cost of sales (excluding amortization of in-licensed rights) Product Information [Line Items] Subsequent Event

Type [Domain] Share-Based Payment Arrangement, Activity [Table Text Block] Summary of Stock Awards Granted Schedule of product revenues concentration risk. Schedule Of Product Revenues Concentration Risk [Table Text Block] Schedule of Product revenue Concentration risks Principal Transaction Revenue [Line Items] Prepaid maintenance services, current. Prepaid Maintenance Services Current Prepaid maintenance services Payments for (Proceeds from) Tenant Allowance Tenant improvement allowance Reserves for reduction to accounts receivable. Reserves For Reduction To Accounts Receivable Reduction to accounts receivable Payments for Rent Undiscounted rent payment Derivative asset Derivative Asset[Member] DerivativeAsset[Member] Financial Instruments [Domain] Financial Instruments APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition Stock-based compensation Gain from sale of intangible asset. Gain From Sale Of Intangible Asset [Table] Gain From Sale Of Intangible Asset [Table] Restricted stock and restricted stock units. Restricted Stock And Restricted Stock Units R S Us [Member] Restricted stock units Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Investments [Domain] Investments Category of Item Purchased [Axis] Accounts Receivable Payment Terms Accounts Receivable Payment Terms Payment Terms Revenue from Contract with Customer, Excluding Assessed Tax Products, net Revenue from Contract with Customer, Excluding Assessed Tax, Total Product revenues, net Income Tax Disclosure [Text Block] INCOME TAXES Selling, General and Administrative Expense Selling, general and administrative Selling, General and Administrative Expense, Total Increase (decrease) in carrying amount of convertible notes. Increase Decrease In Convertible Notes Increase in convertible notes Finite-Lived Intangible Assets, Net Intangible assets, net Finite-Lived Intangible Assets, Net, Total Finite-Lived Intangible Assets, Net, Beginning Balance Finite-Lived Intangible Assets, Net, Ending Balance Other Accrued Liabilities, Current Other Entity Address, Address Line Two Entity Address, Address Line Two Strategic Equity Investments [Member] Strategic Equity Investments [Member] Liabilities and Equity [Abstract] Liabilities and Stockholdersâ€™ Equity Noncash or Part Noncash Acquisition, Fixed Assets Acquired Intangible assets and property and equipment included in accounts payable and accrued expenses Document Period End Date Document Period End Date Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Employee Benefits and Share-Based Compensation Stock-based compensation Grants Contractual Obligation, to be Paid, Year Four 2028 Contract Manufacturing Revenue [Member] Contract Manufacturing Revenue [Member] Contract Manufacturing Revenue [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total number of potentially issuable common stock Debt Conversion, Converted Instrument, Amount Common stock issued for exchange of 2024 Notes Issuance Of Common Stock For Conversion For Notes Shares Issuance Of Common Stock For Conversion For Notes Shares Issuance of common stock for exchange of 2024 Notes, shares Issuance of common stock for exchange of 2024 Notes, shares Accrued Liabilities, Current Accrued expenses Total accrued expenses Leasehold improvement receivable current. Leasehold Improvement Receivable Current Leasehold improvement receivable Letter of Credit Reduce Letter of Credit Reduce Letter of Credit Reduce Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Income tax expense Provision for Income tax Income tax expense Trading Symbol Trading Symbol Equity, Attributable to Parent Balance Balance Total stockholdersâ€™ equity Two Thousand Twenty Four Notes Induced Conversion [Member] Two Thousand Twenty Four Notes Induced Conversion [Member] 2024 Notes Induced Conversion [Member] Cash, cash equivalents and investments, Gross unrealized gains Cash Cash Equivalents And Investments Gross Unrealized Gain Before Tax Cash cash equivalents and investments gross unrealized gain before tax. Cash, cash equivalents and investments, Gross unrealized gains Payment for full settlement of the principal value and accrued interest Debt Instrument, Periodic Payment Debt Instrument, Periodic Payment, Total Other Liabilities, Noncurrent Other non-current liabilities Other Liabilities, Noncurrent, Total Restricted Stock Units (RSUs) [Member] Restricted Stock Units [Member] Decrease in deferred revenue Net decrease in deferred revenue Increase (Decrease) in Deferred Revenue Non-cash interest expense Noncash Interest Expense Noncash interest expense. Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock-Based Compensation Expense by Function Included within Condensed Consolidated Statements of Operations and Comprehensive Loss Geographical [Axis] Geographical Phantom Share Units (PSUs) [Member] Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Available for sale debt securities, Gross unrealized losses Leases [Abstract] Derivative asset Derivative Asset, Current Area of Land Area of lease Use of Estimates, Policy [Policy Text Block] Estimates and Uncertainties Principal [Member] Principal [Member] Collaborative Arrangement [Member] Collaborative Arrangement Concentration Risk, Percentage Concentration of credit risk percentage First installments First Installments [Member] Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] FAIR VALUE MEASUREMENTS Scenario [Axis] Modification of 2017 Capped Calls Modification of 2017 Capped Calls Modification of 2017 Capped Calls Security Exchange Name Security Exchange Name Deposit Liabilities, Accrued Interest Eliminated accrued interest Counterparty Name [Domain] Counterparty Name Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree Contractual Obligation, to be Paid, Year Three 2027 Two thousand and twenty four senior convertible notes. Two Thousand And Twenty Four Senior Convertible Notes [Member] 2024 Convertible Notes [Member] Corporate Bonds Corporate Bonds [Member] Corporate Bonds [Member] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption Accrued Interest Accrued Interest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Stock options Subsequent Event [Member] Subsequent Event [Member] Maximum [Member] Maximum [Member] Liabilities and Equity Total liabilities and stockholdersâ€™ equity Loss on debt extinguishment Loss on debt extinguishment Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt, Total Operating Lease, Right-of-Use Asset Right of use assets Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Earnings (loss) per common share, diluted Diluted Liabilities Total liabilities Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Assets, Current Total current assets Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Forecast [Member] Forecast [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Share based compensation granted under plan vest period Debt Conversion Description [Axis] Capitalized stock-based compensation and depreciation as inventory Capitalized stock-based compensation and depreciation as inventory Capitalized stock-based compensation and depreciation as inventory Entity Filer Category Entity Filer Category Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Changes in operating assets and liabilities, net: Debt Instrument, Redemption, Period [Domain] Net income (loss) - diluted Net Income (Loss) Available to Common Stockholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted, Total Other Assets, Miscellaneous, Current Other Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] ORGANIZATION AND NATURE OF BUSINESS Nonoperating Income (Expense) [Abstract] Other income (loss), net: Royalty revenue Royalty Revenue Royalty Revenue Current Fiscal Year End Date Current Fiscal Year End Date Lacerta Therapeutics, Inc. Lacerta Therapeutics Inc [Member] Lacerta Therapeutics Inc [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Interest on Convertible Debt, Net of Tax Add: interest expense, net of tax, on the Company's convertible debt Add: interest expense, net of tax, on the Company's convertible debt Non-cash change in the fair value of derivatives Non-Cash Change In The Fair Value Of Derivatives Non-Cash Change In The Fair Value Of Derivatives Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Share-based Payment Arrangement, Noncash Expense, Total Entity Registrant Name Entity Registrant Name Business Combination, Contingent Consideration, Liability Contingent consideration Contingent consideration Business Combination, Contingent Consideration, Liability, Total Commitments and Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Earnings Per Share [Text Block] EARNINGS (LOSS) PER SHARE Debt Instrument, Maturity Date Debt instrument, maturity date Entity Emerging Growth Company Entity Emerging Growth Company Money Market Funds [Member] Money Market Funds [Member] Payments to Acquire Intangible Assets Purchase of intangible assets Purchase of intangible assets Other Liabilities, Current Other current liabilities Other Liabilities, Current, Total Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares outstanding - basic Weighted Average Number of Shares Outstanding, Basic, Total Basic Vesting [Domain] Common Stock, Shares Authorized Common stock, shares authorized Schedule of Long-Term Debt Instruments [Table Text Block] Summary of Debt Facilities 2024 Notes Repurchase [Member] Two Thousand Twenty Four Notes Repurchase [Member] Two Thousand Twenty Four Notes Repurchase [Member] Concentration Risk Type [Axis] Concentration Risk Type Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Debt Disclosure [Abstract] Strategic investments noncurrent. Strategic Investments Noncurrent Strategic investments Amortization of Intangible Assets Amortization of in-licensed rights Amortization of Intangible Assets, Total Financial Instrument [Axis] Financial Instrument Impairment Loss Impairment Loss Impairment Loss Long-Term Purchase Commitment, Category of Item Purchased [Domain] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Accumulated Other Comprehensive (Loss) Income [Member] Restricted Cash and Investments, Noncurrent Restricted cash and investments Restricted Cash and Investments, Noncurrent, Total Restricted cash September 20, 2025 [Member] September Twenty Two Thousand Twenty Five [Member] September Twenty Two Thousand Twenty Five [Member] Share-Based Payment Arrangement [Abstract] (Increase) decrease in manufacturing-related deposits and prepaids Increase Decrease In Manufacturing-Related Deposits And Prepaids Increase Decrease In Manufacturing-Related Deposits And Prepaids Net (increase) decrease in manufacturing-related deposits and prepaids Nationwide Children Hospital. Nationwide Children Hospital [Member] NationWide Children Hospital [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Receivables, Net, Current [Abstract] Issuance of common stock for exchange of notes shares Issuance of common stock for exchange of notes shares Issuance of common stock for exchange of 2024 Notes, shares Goodwill, Impairment Loss Manufacturing related deposits and prepaids Manufacturing related deposits and prepaids Manufacturing-related deposits and prepaids Debt Securities, Available-for-Sale Available for sale debt securities, Fair value Debt Securities, Available-for-sale, Total Accounting Policies [Abstract] Other Assets, Miscellaneous, Noncurrent Other Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Income Tax Disclosure [Abstract] Long-Term Purchase Commitment, Amount Purchase commitment Inventory, Raw Materials, Net of Reserves Raw materials Equity, Attributable to Parent [Abstract] Stockholdersâ€™ equity: Receivable [Domain] Receivable Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental schedule of non-cash activities: Research milestone expense Research Milestone Expense Research Milestone Expense Employee stock purchase plan. Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan Statement [Table] Statement [Table] Weighted Average Number of Shares Outstanding, Basic [Abstract] Weighted average number of shares of common stock used in computing earnings (loss) per share: Subsequent Event [Table] Proceeds from sale of rare pediatric disease priority review voucher, Net of commission. Proceeds From Sale Of Rare Pediatric Disease Priority Review Voucher Net Of Commission Proceeds from sale of rare pediatric disease priority review voucher, Net of commission Preferred Stock, Shares Authorized Preferred stock, shares authorized Securities Act File Number Entity File Number Vest of restricted stock units Restricted Stock Units Vested Restricted Stock Units Vested Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Decrease in cash, cash equivalents and restricted cash Decrease in accounts payable, accrued expenses, lease liabilities and other liabilities Increase decrease in accounts payable and accrued expenses and other liabilities. Increase Decrease In Accounts Payable And Accrued Expenses And Other Liabilities Earnings Per Share [Abstract] Interest Receivable Interest receivable 2024 (October-December) Long-Term Debt, Maturity, Remainder of Fiscal Year Inventory Disclosure [Abstract] Contractual Obligation, Fiscal Year Maturity [Table Text Block] Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations Statement of Financial Position [Abstract] Interest Expense, Operating and Nonoperating Interest expense Interest Expense, Total Accrued Fixed Assets Accrued Fixed Assets Accrued fixed assets Other, net Other Nonrecurring (Income) Expense Other Nonrecurring (Income) Expense, Total Other, net Operating Income (Loss) Operating (loss) income Long-Term Debt, Maturity, Year One 2025 Entity Shell Company Entity Shell Company Accrued Professional Fees, Current Accrued professional fees Entity Tax Identification Number Entity Tax Identification Number Assets [Abstract] Assets Entity Current Reporting Status Entity Current Reporting Status Proceeds from exercise of stock options not yet received Proceeds from exercise of stock options not yet received Accrued product revenue related reserve current. Accrued Product Revenue Related Reserve Current Product revenue related reserves Total Total [Member] Total [Member] Long-Term Debt, Type [Axis] Subsequent Events [Abstract] Inventory Disclosure [Text Block] INVENTORY Geographical [Domain] Geographical Document Fiscal Year Focus Document Fiscal Year Focus Cash, Cash Equivalents, and Short-Term Investments Cash, cash equivalents and investments Cash, Cash Equivalents, and Short-term Investments, Total Certificates of Deposit [Member] Certificates of Deposit [Member] Preferred Stock, Value, Issued Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance 2017 Capped Call Transactions [Member] Two Thousand Seventeen Capped Call Transactions [Member] Two Thousand Seventeen Capped Call Transactions [Member] Revenue, Product and Service Benchmark [Member] Product Revenues [Member] Receivable Type [Axis] Other Accruals [Member] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations End of period Beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Long-Term Investments, Total Long-Term Investments Non-current investments Business Acquisition [Axis] Business Acquisition City Area Code City Area Code Principal Transaction Revenue [Table] Contractual Obligation, to be Paid, Year One 2025 Other accruals. Other Accruals [Member] Other Accruals [Member] Liabilities, Current Total current liabilities Change in fair value of derivatives Liabilities, Fair Value Adjustment Fair value of contingent consideration liability Change in the fair value of contingent consideration Inventory, Net Inventory Total inventory Inventory Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Statutory tax rate Accretion of Investment Discount, Net Accretion of Investment Discount, Net Accretion of investment discount, net ELEVIDYS [Member] ELEVIDYS [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Equity Investment Agreement [Member] Equity Investment Agreement [Member] Equity investment agreement. Cash cash equivalents and investments gross unrealized loss before tax. Cash Cash Equivalents And Investments Gross Unrealized Loss Before Tax Cash, cash equivalents and investments, Gross unrealized losses Cash, cash equivalents and investments, Gross unrealized losses Commitments and Contingencies Disclosure [Abstract] Debt Issuance Costs, Net Unamortized discount - debt issuance costs Debt Issuance Costs, Net, Total Debt Securities, Available-for-Sale, Amortized Cost Available for sale debt securities, Amortized cost Available for sale debt securities, Amortized cost Adjustments To Product Revenue Reserves Relating To Sales In Prior Years Adjustments To Product Revenue Reserves Relating To Sales In Prior Years Adjustments relating to prior periods Debt Instrument, Interest Rate, Stated Percentage Debt instrument, interest rate per annum Retained Earnings [Member] Accumulated Deficit [Member] Earnings Per Share, Basic [Abstract] Earnings (loss) per share: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Schedule of Other Nonoperating Income (Expense) [Table Text Block] Summary of Other Income (Loss) Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Assets and Liabilities Measured and Carried at Fair Value Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share Document Transition Report Document Transition Report Customer three. Customer Three [Member] Customer Three [Member] Increase in other assets Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Operating Assets, Total 2024 (October-December) Contractual Obligation, to be Paid, Remainder of Fiscal Year Antidilutive Security, Excluded EPS Calculation [Table] Inventory current and noncurrent net. Inventory Current and Noncurrent Net Total inventory Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract] Cash, cash equivalents and restricted cash: Minimum [Member] Minimum [Member] Two Thousand Twenty Seven Notes [Member] Two Thousand Twenty Seven Notes [Member] 2027 Notes [Member] Common Stock [Member] Common Stock [Member] Restricted cash Restricted Cash Restricted Cash, Total Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Long-Term Debt, Maturity, Year Two 2026 Roche. Roche [Member] Roche Holding A.G. [Member] Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCRUED EXPENSES Share based compensation expense included in costs and expenses. Share Based Compensation Expense Included In Costs And Expenses Total stock-based compensation expense included in expenses Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Accounts Receivable And Reserves For Product Sales [Text Block] Accounts receivable and reserves for product sales. PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES Debt Securities, Available-for-Sale, Current Available for sale debt securities

current, Fair value Debt Securities, Available-for-sale, Current, Total Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income (loss) to cash flows from operating activities: Short-Term Investments [Member] Short-term Investments [Member] Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Statement of Income Location, Balance [Domain] Income Statement Location Other Assets, Noncurrent Other non-current assets Total other non-current assets Other Assets, Current Other current assets Total other current assets Goodwill and Intangible Assets Disclosure [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Other investing activity. Other Investing Activity Other Accounts and Financing Receivables [Table] Schedule Of Accounts Notes Loans And Financing Receivable [Table] Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Manufacturing related deposits and prepaid expense non current. Manufacturing Related Deposits And Prepaid Expense Non Current Manufacturing-related deposits and prepaids Scenario [Domain] Prepaid clinical and preclinical expenses current. Prepaid Clinical And Preclinical Expenses Current Prepaid clinical and pre-clinical expenses Value Added Tax Receivable Tax-related receivables and prepaids Title and Position [Domain] Revenue, Product and Service [Extensible Enumeration] Type of Revenue [Extensible List] Nationwide children's hospital. Nationwide Childrens Hospital [Member] Nationwide Children?s Hospital [Member] Manufacturing commitments agreement Member Manufacturing Commitments Agreement [Member] Manufacturing Commitments Agreement [Member] Common stock, $0.0001 par value, 198,000,000 shares authorized; 95,493,005 and 93,731,831 issued and outstanding at September 30, 2024, and December 31, 2023, respectively Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Investment Income, Interest Interest income Prepaid Insurance Prepaid insurance Catalent and Thermo Member Catalent And Thermo [Member] Catalent and Thermo [Member] Cash and Cash Equivalent [Table] Schedule Of Cash And Cash Equivalents [Table] Long-Term Debt, Maturity, Year Three 2027 Operating lease liability Operating Lease, Liability, Total Operating Lease, Liability Debt Conversion, Name [Domain] Schedule of Accrued Liabilities [Table Text Block] Summary of Accrued Expenses Commitments and contingencies (Note 16) Commitments and Contingencies Collaboration receivable current. Collaboration Receivable Current Collaboration receivable Collaboration and other receivables Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares outstanding - diluted Diluted Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Research and Development Expense (Excluding Acquired in Process Cost) Research and development Research and Development Expense (Excluding Acquired in Process Cost), Total Accounts Receivable, after Allowance for Credit Loss, Current Total accounts receivable, net Accounts receivable, net Lessee, Operating Lease, Renewal Term Leases, term of contract extend Increase in inventory Increase (Decrease) in Inventories Increase (Decrease) in Inventories, Total Interest [Member] Interest [Member] Dilutive Securities, Shares Dilutive Securities, Shares Dilutive securities Prepaid Expense and Other Assets, Noncurrent [Abstract] Concentration Risk Benchmark [Domain] Entity Small Business Entity Small Business Debt Disclosure [Text Block] INDEBTEDNESS Billed Contracts Receivable Product sales receivable, net of discounts and allowances Revenues Total revenues Revenues Remaining shares associated with performance condition Remaining Shares Associated With Performance Condition Remaining Shares Associated With Performance Condition Other Nonoperating Income and Expense [Text Block] OTHER INCOME (LOSS), NET Contractual Obligation Total manufacturing commitments Bedford Massachusetts Bedford Massachusetts [Member] Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Royalty Revenue [Member] Royalty Revenue [Member] Royalty Revenue [Member] Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Common stock issuable under the Company's equity incentive plans Common stock issuable under the Company's equity incentive plans Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Lease liabilities arising from obtaining right of use assets Accretion of investment discount, net Amortization of Discounts Premiums Investments Cash Equivalent And Investments Amortization of Discounts Premiums Investments Cash Equivalent And Investments Nature of Operation, Product Information, Concentration of Risk [Table] Reserves for component of accrued expenses. Reserves For Component Of Accrued Expenses Component of accrued expenses Deferred tax asset valuation allowance Deferred Tax Assets, Valuation Allowance Fair value convertible note exchange Fair value convertible note exchange Fair value convertible note exchange Fair Value, Inputs, Level 3 [Member] Level 3 [Member] Subsequent Events [Text Block] SUBSEQUENT EVENTS Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Costs and Expenses Total cost and expenses Fair value at the beginning of the year Liabilities, Fair Value Disclosure Total liabilities Fair value at the beginning of the period Fair value at the end of the period Liabilities, Fair Value Disclosure, Total Change in fair value of derivatives* Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Accounts Receivable, Allowance for Credit Loss, Current Ending balance Beginning balance Total reserves Up-front and development milestone expenses. Up Front And Development Milestone Expenses Up-front and development milestone expenses XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Entity Registrant Name SAREPTA THERAPEUTICS, INC. Â Entity Central Index Key 0000873303 Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Shell Company false Â Entity File Number 001-14895 Â Entity Tax Identification Number 93-0797222 Â Entity Incorporation, State or Country Code DE Â Entity Address, Address Line One 215 First Street Â Entity Address, Address Line Two Suite 415 Â Entity Address, City or Town Cambridge Â Entity Address, State or Province MA Â Entity Address, Postal Zip Code 02142 Â City Area Code 617 Â Local Phone Number 274-4000 Â Title of 12(b) Security Common Stock, $0.0001 par value per share Â Trading Symbol SRPT Â Security Exchange Name NASDAQ Â Document Quarterly Report true Â Document Transition Report false Â Entity Common Stock, Shares Outstanding Â 95,519,650 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 197,855 $ 428,430 Short-term investments 1,000,534 1,247,820 Accounts receivable, net 434,524 400,327 Inventory 565,924 322,859 Manufacturing-related deposits and prepaids 321,055 102,181 Other current assets 165,477 77,714 Total current assets 2,685,369 2,579,331 Property and equipment, net 305,788 227,154 Right of use assets 140,898 129,952 Non-current inventory 202,550 191,368 Non-current investments 181,770 0 Other non-current assets 83,559 136,771 Total assets 3,599,934 3,264,576 Current liabilities: Â Â Accounts payable 118,774 164,918 Accrued expenses 344,830 314,997 Deferred revenue, current portion 127,001 50,416 Current portion of long-term debt 91,595 105,483 Other current liabilities 17,289 17,845 Total current liabilities 699,489 653,659 Long-term debt 1,135,965 1,132,515 Lease liabilities, net of current portion 170,009 140,965 Deferred revenue, net of current portion 325,000 437,000 Contingent consideration 47,400 38,100 Other non-current liabilities 1,000 3,000 Total liabilities 2,378,863 2,405,239 Commitments and contingencies (Note 16) Stockholdersâ€™ equity: Â Â Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding 0 0 Common stock, $0.0001 par value, 198,000,000 shares authorized; 95,493,005 and 93,731,831 issued and outstanding at September 30, 2024, and December 31, 2023, respectively 10 9 Additional paid-in capital 5,588,839 5,304,623 Accumulated other comprehensive income, net of tax 2,245 918 Accumulated deficit (4,370,023) (4,446,213) Total stockholdersâ€™ equity 1,221,071 859,337 Total liabilities and stockholdersâ€™ equity $ 3,599,934 $ 3,264,576 X - DefinitionManufacturing related deposits and prepaids + ReferencesNo definition available. + Details Name: srpt_ManufacturingRelatedDepositsAndPrepaids Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification

-Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period

Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermLoansPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value $ 0.0001 $ 0.0001 Preferred stock, shares authorized 3,333,333 3,333,333 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value $ 0.0001 $ 0.0001 Common stock, shares authorized 198,000,000 198,000,000 Common stock, shares issued 95,493,005 93,731,831 Common stock, shares outstanding 95,493,005 93,731,831 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues: Â Â Â Â Products, net $ 429,771 $ 309,322 $ 1,149,803 $ 779,805 Type of Revenue [Extensible List] us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember us-gaap:ProductMember Collaboration and other $ 37,401 $ 22,495 $ 93,764 $ 66,750 Total revenues 467,172 331,817 1,243,567 846,555 Cost and expenses: Â Â Â Â Cost of sales (excluding amortization of in-licensed rights) 91,691 37,026 186,795 106,167 Research and development 224,483 194,301 604,569 681,870 Selling, general and administrative 128,200 120,893 393,999 350,171 Amortization of in-licensed rights 602 439 1,804 796 Total cost and expenses 444,976 352,659 1,187,167 1,139,004 Operating (loss) income 22,196 (20,842) 56,400 (292,449) Other income (loss), net: Â Â Â Â Other income (expense), net 11,810 (12,332) 32,631 17,309 Gain from sale of Priority Review Voucher 0 0 0 102,000 Loss on debt extinguishment 0 0 0 (387,329) Total other income (loss), net 11,810 (12,332) 32,631 (268,020) Income (loss) before income tax expense 34,006 (33,174) 89,031 (560,469) Income tax expense 395 7,763 12,841 21,163 Net income (loss) 33,611 (40,937) 76,190 (581,632) Other comprehensive income: Â Â Â Â Unrealized gains on investments, net of tax 3,275 417 1,327 1,026 Total other comprehensive income 3,275 417 1,327 1,026 Comprehensive income (loss) $ 36,886 $ (40,520) $ 77,517 $ (580,606) Earnings (loss) per share: Â Â Â Â Basic $ 0.35 $ (0.46) $ 0.8 $ (6.56) Diluted $ 0.34 $ (0.46) $ 0.78 $ (6.56) Weighted average number of shares of common stock used in computing earnings (loss) per share: Â Â Â Â Basic 95,390 88,889 94,669 88,609 Diluted 100,448 88,889 99,572 88,609 X - DefinitionCost of goods sold excluding amortization. + ReferencesNo definition available. + Details Name: srpt_CostOfGoodsSoldExcludingAmortization Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-

gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details Name: us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIndicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources. + ReferencesNo definition available. + Details Name: us-gaap_TypeOfRevenueExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands Total Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Other Comprehensive (Loss) Income [Member] Accumulated Deficit [Member] Balance at Dec. 31, 2022 $ 384,950 $ 9 $ 4,296,841 $ (1,664) $ (3,910,236) Balance (in shares) at Dec. 31, 2022 Â 87,950 Â Â Â Exercise of options for common stock 22,808 Â 22,808 Â Â Exercise of options for common stock, shares Â 267 Â Â Â Vest of restricted stock units Â 390 Â Â Â Issuance of common stock under employee stock purchase plan 5,229 Â 5,229 Â Â Issuance of common stock under employee stock purchase plan, shares Â 77 Â Â Â Stock-based compensation 41,250 Â 41,250 Â Â Issuance Of Common Stock For Conversion Of 2024 Notes Value 693,377 Â 693,377 Â Â Issuance of common stock for conversion of 2024 Notes, Shares Â 4,456 Â Â Â Partial settlement of capped call share options for 2024 Notes 80,645 Â 80,645 Â Â Unrealized gains from available-for-sale securities, net of tax 1,245 Â Â 1,245 Â Â Net Income (Loss) (516,755) Â Â Â (516,755) Balance at Mar. 31, 2023 712,749 $ 9 5,140,150 (419) (4,426,991) Balance (in shares) at Mar. 31, 2023 Â 93,140 Â Â Â Balance at Dec. 31, 2022 384,950 $ 9 4,296,841 (1,664) (3,910,236) Balance (in shares) at Dec. 31, 2022 Â 87,950 Â Â Â Partial settlement of capped call share options for 2024 Notes 80,645 Â Â Â Â Net Income (Loss) (581,632) Â Â Â Â Balance at Sep. 30, 2023 764,357 $ 9 5,256,854 (638) (4,491,868) Balance (in shares) at Sep. 30, 2023 Â 93,537 Â Â Â Balance at Mar. 31, 2023 712,749 $ 9 5,140,150 (419) (4,426,991) Balance (in shares) at Mar. 31, 2023 Â 93,140 Â Â Â Exercise of options for common stock 5,861 Â 5,861 Â Â Exercise of options for common stock, shares Â 80 Â Â Â Vest of restricted stock units Â 54 Â Â Â Stock-based compensation 47,377 Â 47,377 Â Â Unrealized gains from available-for-sale securities, net of tax (636) Â Â (636) Â Net Income (Loss) (23,940) Â Â Â (23,940) Balance at Jun. 30, 2023 741,411 $ 9 5,193,388 (1,055) (4,450,931) Balance (in shares) at Jun. 30, 2023 Â 93,274 Â Â Â Exercise of options for common stock 9,873 Â 9,873 Â Â Exercise of options for common stock, shares Â 142 Â Â Â Vest of restricted stock units Â 45 Â Â Â Issuance of common stock under employee stock purchase plan 5,532 Â 5,532 Â Â Issuance of common stock under employee stock purchase plan, shares Â 76 Â Â Â Stock-based compensation 48,061 Â 48,061 Â Â Unrealized gains from available-for-sale securities, net of tax 417 Â Â 417 Â Net Income (Loss) (40,937) Â Â Â (40,937) Balance at Sep. 30, 2023 764,357 $ 9 5,256,854 (638) (4,491,868) Balance (in shares) at Sep. 30, 2023 Â 93,537 Â Â Â Balance at Dec. 31, 2023 859,337 $ 9 5,304,623 918 (4,446,213) Balance (in shares) at Dec. 31, 2023 Â 93,732 Â Â Â Exercise of options for common stock 15,579 Â 15,579 Â Â Exercise of options for common stock, shares Â 207 Â Â Â Vest of restricted stock units Â 461 Â Â Â Issuance of common stock under employee stock purchase plan 6,561 Â 6,561 Â Â Issuance of common stock under employee stock purchase plan, shares Â 90 Â Â Â Stock-based compensation 45,205 Â 45,205 Â Â Unrealized gains from available-for-sale

securities, net of tax (1,609) Â Â (1,609) Â Net Income (Loss) 36,119 Â Â Â 36,119 Balance at Mar. 31, 2024 961,192 $ 9 5,371,968 (691) (4,410,094) Balance (in shares) at Mar. 31, 2024 Â 94,490 Â Â Â Balance at Dec. 31, 2023 859,337 $ 9 5,304,623 918 (4,446,213) Balance (in shares) at Dec. 31, 2023 Â 93,732 Â Â Â Partial settlement of capped call share options for 2024 Notes 0 Â Â Â Â Net Income (Loss) 76,190 Â Â Â Â Balance at Sep. 30, 2024 1,221,071 $ 10 5,588,839 2,245 (4,370,023) Balance (in shares) at Sep. 30, 2024 Â 95,493 Â Â Â Balance at Mar. 31, 2024 961,192 $ 9 5,371,968 (691) (4,410,094) Balance (in shares) at Mar. 31, 2024 Â 94,490 Â Â Â Exercise of options for common stock 39,918 $ 1 39,917 Exercise of options for common stock, shares Â 468 Â Â Â Vest of restricted stock units Â 131 Â Â Â Stock-based compensation 55,654 Â 55,654 Â Â Issuance Of Common Stock For Conversion Of 2024 Notes Value 14,184 Â 14,184 Â Â Issuance of common stock for conversion of 2024 Notes, Shares Â 194 Â Â Â Unrealized gains from available-for-sale securities, net of tax (339) Â Â (339) Â Net Income (Loss) 6,460 Â Â Â 6,460 Balance at Jun. 30, 2024 1,077,069 $ 10 5,481,723 (1,030) (4,403,634) Balance (in shares) at Jun. 30, 2024 Â 95,283 Â Â Â Exercise of options for common stock 8,588 Â 8,588 Exercise of options for common stock, shares Â 118 Â Â Â Vest of restricted stock units Â 39 Â Â Â Issuance of common stock under employee stock purchase plan 5,644 Â 5,644 Â Â Issuance of common stock under employee stock purchase plan, shares Â 53 Â Â Â Stock-based compensation 48,996 Â 48,996 Â Â Issuance Of Common Stock For Conversion Of 2024 Notes Value 1 Â 1 Â Â Modification of 2017 Capped Calls 43,887 Â 43,887 Â Â Unrealized gains from available-for-sale securities, net of tax 3,275 Â Â 3,275 Â Net Income (Loss) 33,611 Â Â Â 33,611 Balance at Sep. 30, 2024 $ 1,221,071 $ 10 $ 5,588,839 $ 2,245 $ (4,370,023) Balance (in shares) at Sep. 30, 2024 Â 95,493 Â Â Â X - DefinitionIssuance Of Common Stock For Conversion Of 2024 Notes Shares + ReferencesNo definition available. + Details Name: srpt_IssuanceOfCommonStockForConversionOf2024NotesShares Namespace Prefix: srpt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionIssuance Of Common Stock For Conversion Of 2024 Notes Value + ReferencesNo definition available. + Details Name: srpt_IssuanceOfCommonStockForConversionOf2024NotesValue Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionModification of Capped Calls + ReferencesNo definition available. + Details Name: srpt_ModificationOfCappedCalls Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPartial settlement of capped call share options for 2024 Notes + ReferencesNo definition available. + Details Name: srpt_PartialSettlementOfCappedCallShareOptionsFor2024Notes Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRestricted Stock Units Vested + ReferencesNo definition available. + Details Name: srpt_RestrictedStockUnitsVested Namespace Prefix: srpt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting

Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net income (loss) $ 76,190 $ (581,632) Adjustments to reconcile net income (loss) to cash flows from operating activities: Â Â Depreciation and amortization 27,269 33,025 Reduction in the carrying amounts of the right of use assets 12,289 10,636 Non-cash interest expense 3,747 3,919 Stock-based compensation 134,624 136,688 Accretion of investment discount, net (33,474) (32,847) Non-cash termination charges 62,747 0 Non-cash change in the fair value of derivatives 8,565 1,200 Impairment of equity investments 0 27,821 Loss on debt extinguishment 0 387,329 Gain from sale of Priority Review Voucher 0 (102,000) Other 1,822 324 Changes in operating assets and liabilities, net: Â Â Increase in accounts receivable (34,197) (104,227) (Increase) decrease in manufacturing-related deposits and prepaids (235,544) 7,897 Increase in inventory (233,511) (53,610) Increase in other assets (39,380) (2,886) Decrease in deferred revenue (35,415) (66,750) Decrease in accounts payable, accrued expenses, lease liabilities and other liabilities (13,565) (111,223) Net cash used in operating activities (297,833) (446,336) Cash flows from investing activities: Â Â Purchase of property and equipment (98,874) (57,067) Purchase of available-for-sale securities (936,684) (1,475,404) Maturity and sale of available-for-sale securities 1,037,001 1,340,265 Purchase of intangible assets (10,000) (11,239) Proceeds from sale of Priority Review Voucher 0 102,000 Net cash provided by investing activities (8,557) (101,445) Cash flows from financing activities: Â Â Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program 75,815 49,303 Partial settlement of capped call share options for 2024 Notes 0 80,645 Debt conversion costs for 2024 Notes 0 (6,887) Net cash provided by financing activities 75,815 123,061 Decrease in cash, cash equivalents and restricted cash (230,575) (424,720) Cash, cash equivalents and restricted cash: Â Â Beginning of period 444,009 985,801 End of period 213,434 561,081 Reconciliation of cash, cash equivalents and restricted cash: Â Â Cash and cash equivalents 197,855 541,932 Restricted cash in other assets 15,579 [1] 19,149 Total cash, cash equivalents and restricted cash 213,434 561,081 Supplemental disclosure of cash flow information: Â Â Cash paid during the period for income taxes 11,614 9,569 Cash paid during the period for interest 15,169 15,129 Supplemental schedule of non-cash activities: Â Â Modification of 2017 Capped Calls 43,887 0 Intangible assets and property and equipment included in accounts payable and accrued expenses 33,841 16,059 Lease liabilities arising from obtaining right of use assets 20,367 79,846 Common stock issued for exchange of 2024 Notes 14,185 693,377 Proceeds from exercise of stock options not yet received 475 0 Capitalized stock-based compensation and depreciation as inventory $ 20,736 $ 0 [1] * The Company had approximately $15.6 million in restricted cash included in other non-current assets on the Companyâ€™s unaudited condensed consolidated balance sheets as of both September 30, 2024 and December 31, 2023. Restricted cash for both periods relates to (i) letters of credit established under the Companyâ€™s various property leases that serve as security for potential future default of lease payments, (ii) a letter of credit established under a certain commercial supply agreement and (iii) collateralized cash for the Companyâ€™s credit cards. The restricted cash is unavailable for withdrawal or use for general obligations. X - DefinitionAccretion of Investment Discount, Net + ReferencesNo definition available. + Details Name: srpt_AccretionOfInvestmentDiscountNet Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCapitalized stock-based compensation and depreciation as inventory + ReferencesNo definition available. + Details Name: srpt_CapitalizedStockBasedCompensationAndDepreciationAsInventory Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDebt Conversion Costs + ReferencesNo definition available. + Details Name: srpt_DebtConversionCosts Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease decrease in accounts payable and accrued expenses and other liabilities. + ReferencesNo definition available. + Details Name: srpt_IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherLiabilities Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease Decrease In Manufacturing-Related Deposits And Prepaids + ReferencesNo definition available. + Details Name: srpt_IncreaseDecreaseInManufacturingRelatedDepositsAndPrepaids Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionModification of 2017 Capped Calls + ReferencesNo definition available. + Details Name: srpt_ModificationOf2017CappedCalls Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon-Cash Change In The Fair Value Of Derivatives + ReferencesNo definition available. + Details Name: srpt_NonCashChangeInTheFairValueOfDerivatives Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash interest expense. + ReferencesNo definition available. + Details Name: srpt_NoncashInterestExpense Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPartial settlement of capped call share options for 2024 Notes + ReferencesNo definition available. + Details Name: srpt_PartialSettlementOfCappedCallShareOptionsFor2024Notes Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from exercise of stock options not yet received + ReferencesNo definition available. + Details Name: srpt_ProceedsFromExerciseOfStockOptionsNotYetReceived Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionReduction in the carrying amounts of the right of use assets. + ReferencesNo definition available. + Details Name: srpt_ReductionInTheCarryingAmountsOfTheRightOfUseAssets Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnContractTermination Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Â Â Net Income (Loss) $ 33,611 $ 6,460 $ 36,119 $ (40,937) $ (23,940) $ (516,755) $ 76,190 $ (581,632) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 17 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 shares Trading Arrangements, by Individual Â Material Terms of Trading Arrangement Item 5. Other Information. During the three months ended September 30, 2024, Louise Rodino-Klapac entered into and adopted a written plan for the sale of our securities that is intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information (a â€œRule 10b5-1 trading planâ€). Ms. Rodino-Klapacâ€™s 10b5-1 trading plan has an adoption date of August 9, 2024 and an end date of November 15, 2025, covering 28,875 options to purchase shares of common stock with a strike price of $76.36 and 24,988 shares of common stock. Ms. Rodino Klapac [Member] Â Trading Arrangements, by Individual Â Name Louise Rodino-Klapac Rule 10b5-1 Arrangement Adopted true Non-Rule 10b5-1 Arrangement Adopted false Adoption Date August 9, 2024 Expiration Date November 15, 2025 Aggregate Available 28,875 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrExpirationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd_IndividualAxis=srpt_MsRodinoKlapacMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 18 R9.htm IDEA: XBRL DOCUMENT v3.24.3 ORGANIZATION AND NATURE OF BUSINESS 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â ORGANIZATION AND NATURE OF BUSINESS 1. ORGANIZATION AND NATURE OF BUSINESS Sarepta Therapeutics, Inc. (together with its wholly-owned subsidiaries, â€œSareptaâ€ or the â€œCompanyâ€) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying its proprietary, highly-differentiated and innovative technologies, and through collaborations with its strategic partners, the

Company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (â€œDuchenneâ€) and is developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (â€œLGMDsâ€) and other neuromuscular and central nervous system disorders.The Company's products in the U.S., EXONDYS 51 (eteplirsen) Injection (â€œEXONDYS 51â€), VYONDYS 53 (golodirsen) Injection (â€œVYONDYS 53â€) and AMONDYS 45 (casimersen) Injection (â€œAMONDYS 45â€), were granted accelerated approval by the U.S. Food and Drug Administration (the â€œFDAâ€) on September 19, 2016, December 12, 2019 and February 25, 2021, respectively. Indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping, respectively, EXONDYS 51, VYONDYS 53 and AMONDYS 45 (collectively, the â€œPMO Productsâ€) use the Companyâ€™s phosphorodiamidate morpholino oligomer (â€œPMOâ€) chemistry and exon-skipping technology to skip exon 51, exon 53 and exon 45 of the dystrophin gene. Exon skipping is intended to promote the production of an internally truncated but functional dystrophin protein. ELEVIDYS (delandistrogene moxeparvovec-rokl), approved by the FDA on June 20, 2024, is an adeno-associated virus-(â€œAAVâ€) based gene therapy for the treatment of ambulatory patients at least four years old with Duchenne with a confirmed mutation in the Duchenne gene. ELEVIDYS is also approved for non-ambulatory patients under the accelerated approval pathway. ELEVIDYS was previously granted accelerated approval by the FDA on June 22, 2023 for the treatment of ambulatory patients aged four through five years with Duchenne with a confirmed mutation in the Duchenne gene. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.As of September 30, 2024, the Company had approximately $1,395.8 million of cash, cash equivalents, restricted cash and investments, consisting of $197.9 million of cash and cash equivalents, $1,182.3 million of investments and $15.6 million of restricted cash. The Company believes that its balance of cash, cash equivalents and investments as of the date of the issuance of this report is sufficient to fund its current operational plan for at least the next twelve months, though it may pursue additional cash resources through public or private debt and equity financings, seek funded research and development arrangements and additional government contracts and establish collaborations with or license its technology to other companies. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R10.htm IDEA: XBRL DOCUMENT v3.24.3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESBasis of PresentationThe accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€), reflect the accounts of Sarepta and its wholly-owned subsidiaries. All intercompany transactions between and among its consolidated subsidiaries have been eliminated. Management has determined that the Company operates in one segment: discovering, developing, manufacturing and delivering therapies to patients with rare diseases. In the opinion of the Companyâ€™s management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with U.S. GAAP, but that is not required for interim reporting purposes, has been omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes for the year ended December 31, 2023 which are contained in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on February 28, 2024. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year. Estimates and UncertaintiesThe preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist of cash held at financial institutions, cash equivalents, investments and accounts receivable, net, from customers. As of September 30, 2024, the Companyâ€™s cash was concentrated at three financial institutions, which potentially exposes the Company to credit risks. However, the Company does not believe that there is significant risk of non-performance by the financial institutions. The Company also purchases commercial paper, government and government agency bonds, corporate bonds and certificates of deposit issued by highly rated corporations, financial institutions and governments and limits the amount of credit exposure to any one issuer. These amounts may at times exceed federally insured limits. The Company has not experienced any credit losses related to these financial instruments and does not believe to be exposed to any significant credit risk related to these instruments. As of September 30, 2024, three entities accounted for 37%, 27% and 20% of accounts receivable, net, respectively. As of December 31, 2023, four entities accounted for 40%, 19%, 19% and 12% of accounts receivable, net, respectively. As of September 30, 2024, the Company believes its largest customers are of high credit quality and has not experienced any material credit losses related to such customers.Significant Accounting PoliciesFor details about the Company's accounting policies, please read Note 2, Summary of Significant Accounting Policies and Recent Accounting Pronouncements of the Annual Report on Form 10-K for the year ended December 31, 2023.There have not been any material changes to the Company's accounting policies or recent accounting pronouncements that could have a material impact through September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R11.htm IDEA: XBRL DOCUMENT v3.24.3 LICENSE AND COLLABORATION AGREEMENTS 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â LICENSE AND COLLABORATION AGREEMENTS 3. LICENSE AND COLLABORATION AGREEMENTSF. Hoffman-La Roche Ltd.For the three and nine months ended September 30, 2023, the Company recognized $22.5 million and $66.8 million, respectively, of collaboration revenue associated with the license, collaboration and option agreement (the â€œRoche Agreementâ€) with F. Hoffman-La Roche Ltd. (â€œRocheâ€) related to the amortization of the single, combined performance obligation, with no such activity for the corresponding periods ended September 30, 2024. Under the Roche Agreement, the Company has granted Roche options to acquire ex-U.S. rights to certain future Duchenne development programs (the â€œOptionsâ€) in exchange for separate option exercise payments, milestone and royalty considerations, and cost-sharing provisions. These Options were accounted for as material rights related to individual programs and recorded in deferred revenue at the inception of the Roche Agreement. The value assigned to the material rights is included in deferred revenue until such rights expire or are exercised. On February 12, 2024, Roche declined to exercise its optional rights related to one external, early stage development program, which resulted in the immediate recognition of $48.0 million of collaboration revenue for the nine months ended September 30, 2024. As of September 30, 2024 and December 31, 2023, the Company had total deferred revenue of $452.0 million and $487.4 million, primarily related to the separate material rights for the Options associated with the Roche Agreement, of which $127.0 million and $50.4 million were classified as current, respectively. The costs associated with co-development activities performed under the Roche Agreement are included in operating expenses, with any reimbursement of costs by Roche reflected as a reduction of such expenses when the related expense is incurred. For the three and nine months ended September 30, 2024, costs reimbursable by Roche and reflected as a reduction to operating expenses were $61.5 million and $101.1 million, respectively. For the three and nine months ended September 30, 2023, costs reimbursable by Roche and reflected as a reduction to operating expenses were $34.9 million and $83.4 million, respectively. As of September 30, 2024 and December 31, 2023, there were $66.4 million and $29.8 million, respectively, of collaboration and other receivables included in other current assets on the unaudited condensed consolidated balance sheets.In accordance with the Roche Agreement, the Company agreed to enter into a supply agreement with Roche in order to supply them with clinical and commercial batches of ELEVIDYS (the â€œSupply Agreementâ€). While the Supply Agreement is in the process of being negotiated, the Company has delivered batches of commercial ELEVIDYS supply to Roche that were agreed upon on a purchase order-by-purchase order basis. Contract manufacturing revenue and royalty revenue are included in collaboration and other revenue in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). The following table summarizes certain Roche activity for the three and nine months ended September 30, 2024: Â Â For the Three Months Ended September 30, 2024 Â Â For the Nine Months Ended September 30, 2024 Â Â (in thousands) Â Contract manufacturing revenue $ 27,891 Â Â $ 33,698 Â Royalty revenue $ 9,510 Â Â $ 12,066 Â Cost of sales (inventory costs related to products sold to Roche) $ 13,725 Â Â $ 15,379 Â Â There was no similar activity for the same periods of 2023.Research and Option AgreementsThe Company has research and option agreements with third parties in order to develop various technologies and biologics that may be used in the administration of the Companyâ€™s genetic therapeutics. The agreements generally provide for research services related to pre-clinical development programs and options to license the technology for clinical development. Prior to the options under these agreements being executed, the Company may be required to make up to $34.8 million in research milestone payments. Under these agreements, there are $116.8 million in potential option payments to be made by the Company upon the determination to exercise the options. Additionally, if the options for each agreement are executed, the Company would incur additional contingent obligations and may be required to make development, regulatory, and sales milestone payments and royalty payments based on the net sales of the developed products upon commercialization. For the nine months ended September 30, 2023, the Company recognized $7.5 million of up-front payments related to an exercised option as research and development expense, with no similar activity for the three months ended September 30, 2023. For the three and nine months ended September 30, 2023, the Company recognized $3.8 million of research milestone expense as research and development expense. During the three and nine months ended September 30, 2024, the Company did not exercise any options, nor did any additional research milestone payments become probable of occurring.Milestone ObligationsThe Company has license and collaboration agreements in place for which it could be obligated to pay, in addition to the payment of up-front fees upon execution of the agreements, certain milestone payments as a product candidate proceeds from the submission of an investigational new drug application through approval for commercial sale and beyond. As of September 30, 2024, the Company may be obligated to make up to $2.7 billion of future development, regulatory, commercial and up-front royalty payments associated with its collaboration and license agreements. These obligations exclude potential future option and milestone payments for options that have yet to be exercised within research and option agreements entered into by the Company as of September 30, 2024, which are discussed above. For the three and nine months ended September 30, 2023, the Company recognized up-front, development milestone and other expenses of $3.8 million and $11.9 million, respectively, as research and development expense in the accompanying unaudited condensed consolidated statements of comprehensive income (loss), with no similar activity for the three and nine months ended September 30, 2024. X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R12.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â FAIR VALUE MEASUREMENTS 4. FAIR VALUE MEASUREMENTSThe Company has certain financial assets and liabilities that are recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.â€¢Level 1 â€“ quoted prices for identical instruments in active markets;â€¢Level 2 â€“ quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; andâ€¢Level 3 â€“ valuations derived from valuation techniques in which one or more significant value drivers are unobservable.During the nine months ended September 30, 2024, there were no transfers into or out of Level 3. The tables below present information about the Companyâ€™s financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques it utilizes to determine such fair value: Â Â Â Fair Value Measurement as of September 30, 2024 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â (in thousands) Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 21,951 Â Â $ 21,951 Â Â $ â€” Â Â $ â€” Â Commercial paper Â Â 34,995 Â Â Â â€” Â Â Â 34,995 Â Â Â â€” Â Government and government agency bonds Â Â 900,407 Â Â Â 13,494 Â Â Â 886,913 Â Â Â â€” Â Corporate bonds Â Â 233,245 Â Â Â â€” Â Â Â 233,245 Â Â Â â€” Â Strategic investments Â Â 4,723 Â Â Â 3,723 Â Â Â â€” Â Â Â 1,000 Â Certificates of deposit Â Â 17,988 Â Â Â â€” Â Â Â 17,988 Â Â Â â€” Â Derivative assets Â Â 44,622 Â Â Â â€” Â Â Â 44,622 Â Â Â â€” Â Total assets Â $ 1,257,931 Â Â $ 39,168 Â Â $ 1,217,763 Â $ 1,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent consideration Â $ 47,400 Â Â $ â€” Â Â $ â€” Â Â $ 47,400 Â Total liabilities Â $ 47,400 Â Â $ â€” Â Â $ â€” Â $ 47,400 Â Â Â Â Â Fair Value Measurement as of December 31, 2023 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â (in thousands) Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 63,919 Â Â $ 63,919 Â Â $ â€” Â Â $ â€” Â Commercial paper Â Â 113,362 Â Â Â â€” Â Â Â 113,362 Â Â Â â€” Â Government and government agency bonds Â Â 1,001,137 Â Â Â â€” Â Â Â 1,001,137 Â Â Â â€” Â Corporate bonds Â Â 130,380 Â Â Â â€” Â Â Â 130,380 Â Â Â â€” Â Strategic investments Â Â 6,527 Â Â Â 5,527 Â Â Â â€” Â Â Â 1,000 Â Certificates of deposit Â Â 56,621 Â Â Â â€” Â Â Â 56,621 Â Â Â â€” Â Total assets Â $ 1,371,946 Â Â $ 69,446 Â Â $ 1,301,500 Â $ 1,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent consideration Â $ 38,100 Â Â $ â€” Â Â $ â€” Â Â $ 38,100 Â Total liabilities Â $ 38,100 Â Â $ â€” Â Â $ â€” Â $ 38,100 Â Â The Companyâ€™s assets with a fair value categorized as Level 1 within the fair value hierarchy include money market funds, certain government and government agency bonds and the Company's strategic investment in a biotechnology company listed on the Nasdaq Global Market.Â The Company's assets with a fair value categorized as Level 2 within the fair value hierarchy consist of commercial paper, government and government agency bonds, corporate bonds, certificates of deposit and the derivative assets associated with capped call options (the â€œ2017 Capped Callsâ€) for the Company's $570.0 million aggregate principal amount of senior convertible notes due on November 15, 2024 (the â€œ2024 Notesâ€). The Company's commercial paper, government and government agency bonds, corporate bonds and certificates of deposit have been initially valued at the transaction price and subsequently valued at the end of each reporting period utilizing third-party pricing services. The Company uses observable market inputs to determine value, which primarily consist of reportable trades. Certain short-term investments with maturities of less than three months at the date of acquisition are presented as cash equivalents on the unaudited condensed consolidated balance sheets as of September 30, 2024.Â The fair value of the derivative assets related to the 2017 Capped Calls was determined using an option pricing model with Monte Carlo simulations. The significant inputs to the model are the Companyâ€™s share price, estimated volatility and corresponding risk free rate. At the end of each reporting period, the fair value is adjusted to reflect the most current assumptions through earnings. The fair value of the derivative assets from the effective date of the 2017 Capped Calls modification on September 16, 2024 to September 30, 2024 increased by $0.7 million. The increase was recorded within other income (expense), net in the unaudited condensed consolidated statements of comprehensive income (loss). For additional information related to the 2017 Capped Calls, please refer to Note 10, Indebtedness.The Companyâ€™s assets with a fair value

categorized as Level 3 within the fair value hierarchy consist of a strategic investment in a private biotechnology company whose fair value measurement was based upon significant inputs not observable in the market and therefore represented a Level 3 measurement. At the end of each reporting period, the fair value of the Company's strategic investments that are not publicly traded securities are adjusted if the issuers issue similar or identical securities or when there is a triggering event for impairment. There were no valuation measurement events related to the fair value of the Company's Level 3 strategic investments during the nine months ended September 30, 2024, as no impairment indicators were identified nor were similar securities issued. During the three months ended September 30, 2023, the Company recorded an impairment loss of $27.5 million related to the Company's strategic investment in Series A preferred stock of Lacerta Therapeutics, Inc. (â€œLacertaâ€) after comparing the fair value of the Lacerta strategic investment to its carrying value. The impairment loss for the three and nine months ended September 30, 2023 is included in other (expense) income, net within the unaudited condensed consolidated statements of comprehensive income (loss). The Companyâ€™s contingent consideration liability with a fair value categorized as Level 3 within the fair value hierarchy relates to the regulatory-related contingent payments to Myonexus Therapeutics, Inc. (â€œMyonexusâ€) selling shareholders as well as to an academic institution under a separate license agreement that meet the definition of a derivative. For more information related to Myonexus, please read Note 3, License and Collaboration Agreements to the financial statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. The contingent consideration liability was estimated using an income approach based on the probability-weighted expected cash flows that incorporated industry-based probability adjusted assumptions relating to the achievement of the milestone and thus the likelihood of making the payments. This fair value measurement was based upon significant inputs not observable in the market and therefore represented a Level 3 measurement. Significant changes, which increase or decrease the probabilities of achieving the milestone or shorten or lengthen the time required to achieve the milestone, would result in a corresponding increase or decrease in the fair value of the liability. At the end of each reporting period, the fair value is adjusted to reflect the most current assumptions through earnings.The following table represents a roll-forward of the fair value of Level 3 financial liabilities for the periods indicated: Â Â As of September 30, 2024 Â Â As of September 30, 2023 Â Â Â (in thousands) Â Fair value, as of beginning of year Â $ 38,100 Â Â $ 36,900 Â Change in estimated fair value Â Â 9,500 Â Â Â 2,000 Â Liabilities terminated Â Â (200) Â Â (800) Fair value, as of end of period Â $ 47,400 Â Â $ 38,100 Â For the three and nine months ended September 30, 2024, the Company recorded a net decrease of $0.8 million and a net increase of $9.3 million, respectively, to account for the change in fair value of the Company's existing contingent consideration liabilities and any liabilities terminated. These changes, which are recorded through earnings, were a result of updates made to certain inputs and assumptions impacting the probability-weighted expected cash flows, principally the probability of success of the underlying programs and the discount rate utilized to determine the present value of future payments to be made, partially offset by the termination of a license agreement with an academic institution that included an embedded derivative during the three months ended September 30, 2024. For the three and nine months ended September 30, 2023, net increases of $2.0 million and $1.2 million were recorded to account for the change in fair value and a termination of one of the Company's license agreements with an existing contingent consideration liability. As of September 30, 2024, the contingent consideration was recorded as a long-term liability on the Company's unaudited condensed consolidated balance sheets. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, net and accounts payable approximated fair value because of the immediate or short-term maturity of these financial instruments. For fair value information related to the Company's debt facilities, please read Note 10, Indebtedness. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/820/tableOfContent + Details Name: us-gaap_FairValueMeasurementInputsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R13.htm IDEA: XBRL DOCUMENT v3.24.3 CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES 9 Months Ended Sep. 30, 2024 Cash and Cash Equivalents [Abstract] Â CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES 5. CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIESThe following table summarizes the Companyâ€™s financial assets with maturities of less than 90 days from the date of purchase included in cash equivalents in the unaudited condensed consolidated balance sheets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Money market funds Â $ 21,951 Â Â $ 63,919 Â Commercial paper Â Â 2,330 Â Â Â 53,680 Â Corporate bonds Â Â 2,001 Â Â Â â€” Â Total Â $ 26,282 Â Â $ 117,599 Â Â Â It is the Companyâ€™s policy to mitigate credit risk in its financial assets by maintaining a well-diversified portfolio that limits the amount of exposure as to maturity and investment type. The weighted average maturity of the Company's available-for-sale securities was approximately seven and five months as of September 30, 2024 and December 31, 2023, respectively.The following tables summarize the Companyâ€™s cash, cash equivalents, short-term investments and non-current investments for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair MarketValue Â Â Â (in thousands) Â Cash and money market funds Â $ 193,524 Â Â $ â€” Â Â $ â€” Â Â $ 193,524 Â Commercial paper Â Â 34,995 Â Â Â â€” Â Â Â â€” Â Â Â 34,995 Â Government and government agency bonds Â Â 898,726 Â Â Â 1,704 Â Â Â (23) Â Â 900,407 Â Corporate bonds Â Â 232,654 Â Â Â 603 Â Â Â (12) Â Â 233,245 Â Certificates of deposit Â Â 17,988 Â Â Â â€” Â Â Â â€” Â Â Â 17,988 Â Total cash, cash equivalents and investments Â $ 1,377,887 Â Â $ 2,307 Â Â $ (35) Â $ 1,380,159 Â As reported: Â Â Â Â Â Â Â Â Â Â Â Â Cash and cash equivalents Â $ 197,854 Â Â $ 1 Â Â $ â€” Â Â $ 197,855 Â Short-term investments Â Â 998,884 Â Â Â 1,667 Â Â Â (17) Â Â 1,000,534 Â Non-current investments Â Â 181,149 Â Â Â 639 Â Â Â (18) Â Â 181,770 Â Total cash, cash equivalents and investments Â $ 1,377,887 Â Â $ 2,307 Â Â $ (35) Â $ 1,380,159 Â Â Â Â As of December 31, 2023 Â Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair MarketValue Â Â Â (in thousands) Â Cash and money market funds Â $ 374,750 Â Â $ â€” Â Â $ â€” Â Â $ 374,750 Â Commercial paper Â Â 113,362 Â Â Â â€” Â Â Â â€” Â Â Â 113,362 Â Government and government agency bonds Â Â 1,000,302 Â Â Â 1,006 Â Â Â (171) Â Â 1,001,137 Â Corporate bonds Â Â 130,270 Â Â Â 118 Â Â Â (8) Â Â 130,380 Â Certificates of deposit Â Â 56,621 Â Â Â â€” Â Â Â â€” Â Â Â 56,621 Â Total cash, cash equivalents and investments Â $ 1,675,305 Â Â $ 1,124 Â Â $ (179) Â $ 1,676,250 Â As reported: Â Â Â Â Â Â Â Â Â Â Â Â Cash and cash equivalents Â $ 428,430 Â Â $ â€” Â Â $ â€” Â Â $ 428,430 Â Short-term investments Â Â 1,246,875 Â Â Â 1,124 Â Â Â (179) Â Â 1,247,820 Â Total cash, cash equivalents and investments Â $ 1,675,305 Â Â $ 1,124 Â Â $ (179) Â $ 1,676,250 Â X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent + Details Name: us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R14.htm IDEA: XBRL DOCUMENT v3.24.3 PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES 9 Months Ended Sep. 30, 2024 Receivables, Net, Current [Abstract] Â PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES 6. PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUESNet product revenues, which includes revenues associated with the PMO Products and ELEVIDYS, consisted of the following: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â PMO Products Â Â Â Â Â Â Â Â Â Â Â Â United States Â $ 210,683 Â Â $ 198,069 Â Â $ 604,598 Â Â $ 602,415 Â Rest of World Â Â 38,105 Â Â Â 42,145 Â Â Â 108,565 Â Â Â 108,282 Â Total PMO product revenues, net Â $ 248,788 Â Â $ 240,214 Â Â $ 713,163 Â Â $ 710,697 Â ELEVIDYS Â Â Â Â Â Â Â Â Â Â Â Â United States Â Â 180,983 Â Â Â 69,108 Â Â Â 436,640 Â Â Â 69,108 Â Total ELEVIDYS product revenue, net Â $ 180,983 Â Â $ 69,108 Â Â $ 436,640 Â Â $ 69,108 Â Total product revenues, net Â $ 429,771 Â Â $ 309,322 Â Â $ 1,149,803 Â Â $ 779,805 Â Â For the three and nine months ended September 30, 2024 and 2023, no individual country outside the U.S. exceeded 10% of total net product revenues.Â Â The following table summarizes the Company's net product revenues, by customer, for those customers that exceeded 10% for the periods indicated: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Product revenues, net Â Â Â Â Â Â Â Â Â Â Â Â Customer 1 Â Â 28 % Â Â 40 % Â Â 33 % Â Â 45 % Customer 2 Â Â 19 % Â Â 23 % Â Â 20 % Â Â 29 % Â As of September 30, 2024 and December 31, 2023, the Company's accounts receivable, net were $434.5 million and $400.3 million, respectively, both of which were related to product sales, net of discounts and allowances. As of September 30, 2024, the majority of the Companyâ€™s accounts receivable arose from product sales in the U.S. and all customers have standard payment terms that generally require payment within 65 to 90 days. Outside of the U.S., the majority of the Companyâ€™s customers have payment terms ranging between 90 and 150 days. Please refer to Note 2, Summary of Significant Accounting Policies for discussion of the credit risk associated with accounts receivable, net.Â The following tables summarize an analysis of the change in reserves for discounts and allowances for each of the periods indicated: Â Â Chargebacks Â Â Rebates Â Â Prompt Pay Â Â Other Accruals Â Â Total Â Â Â Â (in thousands) Â Balance, as of December 31, 2023 Â $ 27,486 Â Â $ 98,194 Â Â $ 3,831 Â Â $ 35,261 Â Â $ 164,772 Â Provision Â Â 72,832 Â Â Â 118,228 Â Â Â 13,442 Â Â Â 53,674 Â Â Â 258,176 Â Adjustments relating to prior periods Â Â 783 Â Â Â (8,716) Â Â â€” Â Â Â (88) Â Â (8,021) Payments/credits Â Â (77,808) Â Â (100,693) Â Â (12,191) Â Â (58,741) Â Â (249,433) Balance, as of September 30, 2024 Â $ 23,293 Â Â $ 107,013 Â Â $ 5,082 Â Â $ 30,106 Â Â $ 165,494 Â Â Â Â Â Â Chargebacks Â Â Rebates Â Â Prompt Pay Â Â Other Accruals Â Â Total Â Â Â Â (in thousands) Â Balance, as of December 31, 2022 Â $ 417 Â Â $ 67,493 Â Â $ 3,343 Â Â $ 23,445 Â Â $ 94,698 Â Provision Â Â 18,191 Â Â Â 94,025 Â Â Â 11,251 Â Â Â 52,500 Â Â Â 175,967 Â Adjustments relating to prior periods Â Â 110 Â Â Â (4,154) Â Â â€” Â Â Â â€” Â Â Â (4,044) Payments/credits Â Â (9,386) Â Â (73,317) Â Â (10,586) Â Â (40,048) Â Â (133,337) Balance, as of September 30, 2023 Â $ 9,332 Â Â $ 84,047 Â Â $ 4,008 Â Â $ 35,897 Â Â $ 133,284 Â Â The following table summarizes the total reserves above included in the Companyâ€™s unaudited condensed consolidated balance sheets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Reduction to accounts receivable, net Â $ 56,773 Â Â $ 64,697 Â Component of accrued expenses Â Â 108,721 Â Â Â 100,075 Â Total reserves Â $ 165,494 Â Â $ 164,772 Â X - DefinitionPRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES [Text Block] + ReferencesNo definition available. + Details Name: srpt_ProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTextBlock Namespace Prefix: srpt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesNetCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R15.htm IDEA: XBRL DOCUMENT v3.24.3 INVENTORY 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â INVENTORY 7. INVENTORYThe following table summarizes the components of the Companyâ€™s inventory for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Raw materials Â $ 208,320 Â Â $ 133,963 Â Work in progress Â Â 482,171 Â Â Â 318,458 Â Finished goods Â Â 77,983 Â Â Â 61,806 Â Total inventory Â $ 768,474 Â Â $ 514,227 Â Â No material inventory reserves existed as of September 30, 2024 or December 31, 2023. The Company classifies inventory associated with its PMO Products as non-current inventory when consumption of the inventory is expected beyond the Company's normal PMO Product inventory operating cycle of two years. Non-current inventory consists of raw materials and work in progress associated with the PMO Products.The following table summarizes the balance sheet classification of the Company's inventory for each of the periods indicated: Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Balance sheet classification Â Â Â Â Â Â Inventory Â $ 565,924 Â Â $ 322,859 Â Non-current inventory Â Â 202,550 Â Â Â 191,368 Â Total inventory Â $ 768,474 Â Â $ 514,227 Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R16.htm IDEA: XBRL DOCUMENT v3.24.3 OTHER ASSETS 9 Months Ended Sep. 30, 2024 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Â OTHER ASSETS 8. OTHER ASSETSThe following table summarizes the Companyâ€™s other current assets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Collaboration and other receivables Â $ 66,404 Â Â $ 29,786 Â Derivative asset Â Â 44,622 Â Â Â â€” Â Prepaid maintenance services Â Â 13,326 Â Â Â 11,281 Â Prepaid clinical and pre-clinical expenses Â Â 12,034 Â Â Â 10,280 Â Tax-related receivables and prepaids Â Â 11,422 Â Â Â 6,862 Â Prepaid commercial expenses Â Â 3,982 Â Â Â 2,729 Â Interest receivable Â Â 3,637 Â Â Â 2,731 Â Prepaid insurance Â Â 2,198 Â Â Â 3,352 Â Other Â Â 7,852 Â Â Â 10,693 Â Total other current assets Â $ 165,477 Â Â $ 77,714 Â The following table summarizes the Companyâ€™s other non-current assets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Manufacturing-related deposits and prepaids Â $ 28,127 Â Â $ 74,204 Â Intangible assets, net Â Â 27,570 Â Â Â 29,620 Â Restricted cash* Â Â 15,579 Â Â Â 15,579 Â Strategic investments Â Â 4,723 Â Â Â 6,527 Â Prepaid maintenance services Â Â 3,907 Â Â Â 5,466 Â Other Â Â 3,653 Â Â Â 5,375 Â Total other non-current assets Â $ 83,559 Â Â $ 136,771 Â Â * The Company had approximately $15.6 million in restricted cash included in other non-current assets on the Companyâ€™s unaudited condensed consolidated balance sheets as of both September 30, 2024 and December 31, 2023. Restricted cash for both periods relates to (i) letters of credit established under the Companyâ€™s various property leases that serve as security for potential future default of lease payments, (ii) a letter of credit established under a certain commercial supply agreement and (iii) collateralized cash for the Companyâ€™s credit cards. The restricted cash is unavailable for withdrawal or use for general obligations. X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets. + ReferencesNo definition available. + Details Name: us-gaap_OtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R17.htm IDEA: XBRL DOCUMENT v3.24.3 ACCRUED EXPENSES 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â ACCRUED EXPENSES 9. ACCRUED EXPENSESThe following table summarizes the Companyâ€™s accrued expenses for each of the periods indicated: Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Product revenue related reserves Â $ 108,721 Â Â $ 100,075 Â Accrued contract manufacturing costs Â Â 75,909 Â Â Â 33,024 Â Accrued employee compensation costs Â Â 57,107 Â Â Â 78,732 Â Accrued clinical and pre-clinical costs Â Â 40,514 Â Â Â 34,669 Â Accrued professional fees Â Â 21,486 Â Â Â 17,187 Â Accrued income taxes Â Â 14,696 Â Â Â 13,766 Â Accrued royalties Â Â 12,185 Â Â Â 12,070 Â Accrued fixed assets Â Â 4,821 Â Â Â 3,231 Â Accrued research expenses Â Â 2,882 Â Â Â 2,441 Â Accrued interest Â Â 1,118 Â Â Â 4,395 Â Other Â Â 5,391 Â Â Â 15,407 Â Total accrued expenses Â $ 344,830 Â Â $ 314,997 Â X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R18.htm IDEA: XBRL DOCUMENT v3.24.3 INDEBTEDNESS 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â INDEBTEDNESS 10. INDEBTEDNESS2024 Convertible Notes and 2017 Capped Call TransactionsOn November 14, 2017, the Company issued $570.0 million aggregate principal amount of senior convertible notes due on November 15, 2024 and,

simultaneously, entered into capped call transactions with counterparties intended to minimize the impact of potential dilution upon conversion of the 2024 Notes. On September 14, 2022, the Company entered into separate, privately negotiated transactions to repurchase a portion of the outstanding 2024 Notes. The holders exchanged $150.6 million in aggregate principal value of 2024 Notes held by them for an aggregate payment of $248.6 million for full settlement of the principal value and accrued interest on such date. As a result of the repurchases, the Company entered into agreements with the 2017 Capped Calls counterparties to terminate a corresponding portion of the 2017 Capped Calls and received $26.3 million in cash.On March 2, 2023, the Company entered into separate, privately negotiated exchange agreements with certain holders of the outstanding 2024 Notes. The holders exchanged $313.5 million in aggregate principal value of the 2024 Notes held by them for 4.5 million shares of the Companyâ€™s common stock. As a result of the exchange, the Company entered into agreements with the counterparties to the 2017 Capped Calls to terminate a portion of the 2017 Capped Calls and received approximately $80.6 million in cash.In June 2024, certain existing holders elected to convert $14.2 million in aggregate principal amount of the 2024 Notes into approximately 0.2 million shares of the Companyâ€™s common stock. As the conversions were completed under the original terms of the 2024 Notes, there is no gain or loss impact on the accompanying unaudited condensed consolidated statements of comprehensive income (loss). The capped call options related to the shares underlying the conversion are required to be settled at the scheduled maturity date of the 2024 Notes.In May 2024, the Company informed holders of the 2024 Notes of its election to settle the 2024 Notes in shares, which, pursuant to the terms of the 2017 Capped Call agreements, would require the Company to settle the 2017 Capped Calls in shares. On September 16, 2024 (the â€œEffective Dateâ€), the Company entered into supplements with each of the counterparties to modify the terms of each of the 2017 Capped Calls to require settlement in cash rather than in shares. As a result of the modification, the Company reassessed the classification of the 2017 Capped Calls and concluded that these instruments, which were initially classified within equity, should be reclassified as derivative assets. Accordingly, the Company reclassified the fair value of the 2017 Capped Calls, from stockholdersâ€™ equity to derivative assets on the Effective Date, with subsequent changes in fair value recorded to earnings through the settlement date. The fair value on the Effective Date of $43.9 million was reclassified from stockholdersâ€™ equity (additional paid-in capital) to derivative assets and recorded to other current assets on the unaudited condensed consolidated balance sheets. The increase in the fair value of the derivative assets from the Effective Date to September 30, 2024 was $0.7 million and recorded to other income (expense), net in the unaudited condensed consolidated statements of comprehensive income (loss). The derivative assets, along with the 2024 Notes, will settle on November 15, 2024. For further information related to the fair value determination of the derivative assets, please read Note 4, Fair Value Measurements.For additional details about the 2024 Notes, please read Note 13, Indebtedness to the financial statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023.Total Debt ObligationsAs of September 30, 2024 and December 31, 2023, the Company recorded approximately $1,227.6 million and $1,238.0 million as debt on the unaudited condensed consolidated balance sheets, respectively, with the 2024 Notes balance recorded as a current liability for both periods.The following table summarizes the Companyâ€™s debt instruments for each of the periods indicated:Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â (in thousands) Â Principal amount of the 2024 Notes $ 91,640 Â Â $ 105,847 Â Principal amount of the 2027 Notes Â 1,150,000 Â Â Â 1,150,000 Â Unamortized discount - debt issuance costs of 2024 Notes Â (45) Â Â (364) Unamortized discount - debt issuance costs of 2027 Notes Â (14,035) Â Â (17,485) Total carrying value of debt instruments $ 1,227,560 Â Â $ 1,237,998 Â Â Â Â Â Â Fair value of 2024 Notes $ 171,154 Â Â $ 144,833 Â Fair value of 2027 Notes Â 1,307,930 Â Â Â 1,172,276 Â Total fair value of debt instruments $ 1,479,084 Â Â $ 1,317,109 Â For both of the three months ended September 30, 2024 and 2023, interest expense from debt instruments was $5.2 million, inclusive of $1.2 million of amortization of debt discounts. For the nine months ended September 30, 2024 and 2023, interest expense from debt facilities was $15.7 million and $16.8 million, inclusive of $3.7 million and $3.9 million of amortization of debt discounts, respectively. The fair value of the 1.25% convertible senior notes due on September 15, 2027 (â€œ2027 Notesâ€) and the 2024 Notes is based on open market trades and is classified as Level 1 in the fair value hierarchy. The following table summarizes the total principal and contractual interest payments due under the Companyâ€™s debt arrangements: Â Â As of September 30, 2024 Â Â Â Principal Â Â Interest Â Â Total Payments Â Â Â (in thousands) Â 2024 (October-December) Â $ 91,640 Â Â $ 711 Â Â $ 92,351 Â 2025 Â Â â€” Â Â Â 14,375 Â Â Â 14,375 Â 2026 Â Â â€” Â Â Â 14,375 Â Â Â 14,375 Â 2027 Â Â 1,150,000 Â Â Â 14,375 Â Â Â 1,164,375 Â Total payments Â $ 1,241,640 Â Â $ 43,836 Â Â $ 1,285,476 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R19.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â STOCK-BASED COMPENSATION 11. STOCK-BASED COMPENSATIONThe following table summarizes the Companyâ€™s stock awards granted for each of the periods indicated: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Â Stock options Â Â 6,442 Â Â $ 55.16 Â Â Â 50,875 Â Â $ 66.53 Â Â Â 327,920 Â Â $ 67.39 Â Â Â 1,135,799 Â Â $ 72.23 Â Restricted stock units Â Â 135,092 Â Â $ 127.51 Â Â Â 27,539 Â Â $ 118.05 Â Â Â 1,351,982 Â (1) $ 128.90 Â Â Â 1,137,202 Â (2) $ 153.02 Â Â (1) Included in restricted stock units (â€œRSUsâ€) for the nine months ended September 30, 2024 are 97,460 shares with performance conditions (â€œMarch 2024 PSUsâ€) which are related to the achievement of certain financial performance goals and regulatory approval of certain of the Company's product candidates. The expanded regulatory approval of ELEVIDYS in June 2024 resulted in the cliff-vesting of 44,300 of the 97,460 shares of the March 2024 PSUs during the nine months ended September 30, 2024. As of September 30, 2024, none of the performance conditions for the remaining 53,160 shares were probable of being achieved. Stock options and the remaining RSUs granted during the three and nine months ended September 30, 2024 have only service-based criteria and vest over four years. (2) Included in the RSUs for the nine months ended September 30, 2023 are 502,225 shares with performance conditions (the â€œMarch 2023 PSUsâ€), which are related to regulatory approval of ELEVIDYS and achievement of a certain financial performance target, both of which were achieved in 2023. Vesting of the March 2023 PSUs is contingent on the fulfillment of remaining service conditions.Â During the year ended December 31, 2022, the Company granted 38,500 RSUs with performance conditions (the â€œMarch 2022 PSUsâ€), which are related to regulatory approval of certain of the Company's product candidates. As a result of the expanded regulatory approval of ELEVIDYS in June 2024, a portion of the March 2022 PSUs became eligible for vesting. Vesting of the March 2022 PSUs is contingent on the fulfillment of remaining service conditions. As of September 30, 2024, none of the remaining performance conditions were probable of being achieved.Stock-based Compensation ExpenseFor the three months ended September 30, 2024 and 2023, total stock-based compensation expense was $43.5 million and $48.1 million, respectively. For the nine months ended September 30, 2024 and 2023, total stock-based compensation expense was $134.6 million and $136.7 million, respectively.Â The following table summarizes stock-based compensation expense by grant type and by function included within the unaudited condensed consolidated statements of comprehensive income (loss):Â Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â (in thousands) Â Stock options Â $ 15,158 Â Â $ 17,471 Â Â $ 46,954 Â Â $ 62,436 Â Restricted stock units Â Â 31,926 Â Â Â 28,924 Â Â Â 97,261 Â Â Â 70,101 Â Employee Stock Purchase Program Â Â 1,912 Â Â Â 1,666 Â Â Â 5,640 Â Â Â 4,151 Â Subtotal Â $ 48,996 Â Â $ 48,061 Â Â $ 149,855 Â Â $ 136,688 Â Capitalized stock-based compensation costs* Â Â (5,546) Â Â â€” Â Â Â (15,231) Â Â â€” Â Â Total stock-based compensation expense included in expenses Â $ 43,450 Â Â $ 48,061 Â Â $ 134,624 Â Â $ 136,688 Â Research and development Â Â 18,034 Â Â Â 22,325 Â Â Â 54,113 Â Â Â 60,315 Â Selling, general and administrative Â Â 25,416 Â Â Â 25,736 Â Â Â 80,511 Â Â Â 76,373 Â Total stock-based compensation expense included in expenses Â $ 43,450 Â Â $ 48,061 Â Â $ 134,624 Â Â $ 136,688 Â Â *Prior to the nine months ended September 30, 2024, capitalized stock-based compensation costs were not material. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R20.htm IDEA: XBRL DOCUMENT v3.24.3 OTHER INCOME (LOSS), NET 9 Months Ended Sep. 30, 2024 Other Income and Expenses [Abstract] Â OTHER INCOME (LOSS), NET 12. OTHER INCOME (LOSS), NETThe following table summarizes other income (loss), net for each of the periods indicated:Â Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â (in thousands) Â Accretion of investment discount, net Â $ 10,749 Â Â $ 12,984 Â Â $ 34,319 Â Â $ 35,809 Â Interest income Â Â 7,584 Â Â Â 9,838 Â Â Â 22,753 Â Â Â 27,532 Â Interest expense Â Â (4,918) Â Â (5,229) Â Â (13,916) Â Â (16,776) Change in fair value of derivatives* Â Â 1,535 Â Â Â (2,000) Â Â (8,565) Â Â (1,200) Impairment of strategic investments Â Â â€” Â Â Â (27,500) Â Â â€” Â Â Â (27,821) Other, net Â Â (3,140) Â Â (425) Â Â (1,960) Â Â (235) Other income (expense), net Â $ 11,810 Â Â $ (12,332) Â $ 32,631 Â Â $ 17,309 Â Gain from sale of Priority Review Voucher Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 102,000 Â Loss on debt extinguishment Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (387,329) Total other income (loss), net Â $ 11,810 Â Â $ (12,332) Â $ 32,631 Â Â $ (268,020) Â *Related to the change in fair value of the contingent consideration derivative liabilities and the 2017 Capped Calls derivative assets. For more information, please read Note 4, Fair Value Measurements and Note 10, Indebtedness. X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.3 INCOME TAXES 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â INCOME TAXES 14. INCOME TAXESÂ During the three and nine months ended September 30, 2024, the Company recorded an income tax provision of $0.4 million and $12.8 million, representing an effective tax rate of 1.2% and 14.4%, respectively. The income tax provision primarily relates to the current tax provision on taxable profits, including in certain states which restrict the amount of net operating loss carryforwards which may be utilized to offset taxable income. On a periodic basis, the Company reassesses the valuation allowance on its deferred tax assets, weighing positive and negative evidence to assess the recoverability of such deferred tax assets. In assessing the Companyâ€™s ability to realize its net deferred tax assets, the Company considered various factors, including future reversals of existing taxable temporary differences, projected future taxable income, potential carryback claims and tax planning strategies to determine whether it is more likely than not that some portion or all of its net deferred tax assets will not be realized. Based upon these factors, the Company has determined that

the uncertainty regarding the realization of these assets is sufficient to warrant the need to maintain a full valuation allowance against its net deferred tax assets as of September 30, 2024. It is possible that with continued positive performance of the business in future periods, there may be sufficient positive evidence to release a portion or all of the Companyâ€™s valuation allowance. The release of the valuation allowance, as well as the exact timing and the amount of such release, continue to be subject to, among other things, the Companyâ€™s level of profitability, revenue growth, and expectations regarding future profitability. Release of the valuation allowance would result in a benefit to income tax expense for the period the release is recorded, which could have a material impact on net earnings. The total deferred tax asset balance subject to the valuation allowance was approximately $897.0 million as of September 30, 2024. The Company will continue to monitor the need for a full or partial valuation allowance on a quarterly basis.During the three and nine months ended September 30, 2023, the Company recorded an income tax provision of $7.8 million and $21.2 million, respectively, representing an effective tax rate of (23.4%) and (3.8%), respectively. For tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize the costs over five years for research activities performed in the U.S. and 15 years for research activities performed outside the U.S. The requirement to capitalize research and development costs for tax purposes resulted in the Company having taxable profits and recording federal and state tax expense of $4.1 million and $17.1 million, respectively. The state tax expense of $17.1 million is primarily related to state taxable income, partially offset by net operating loss carryforwards. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R22.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â LEASES 13. LEASESÂ The Company has real estate operating leases in Cambridge, Andover, Burlington and Bedford, Massachusetts, Dublin and Columbus, Ohio, and Durham, North Carolina that provide for scheduled annual rent increases over the lease term. The Company has also identified leases embedded in certain of its manufacturing and supply agreements as the Company determined that it controls the use of the facilities and related equipment therein. For more information related to the lease embedded in manufacturing and supply agreements with Catalent, Inc. (â€œCatalentâ€), please refer to Note 21, Commitments and Contingencies of the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Bedford, Massachusetts On April 22, 2022, the Company entered into a lease agreement (the â€œBedford Leaseâ€) for 288,000 square feet of to-be-constructed research and development and manufacturing space in Bedford, Massachusetts. The term of the Bedford Lease commences upon the landlordâ€™s completion of the initial construction of the core and shell of the building, at which time the Company will obtain control of the premises and commence internal construction activities. The Company has two options to extend the lease for a period of ten years each, exercisable under certain conditions and at a market rate determined in accordance with the lease agreement.In May 2022, in connection with the execution of the Bedford Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $8.4 million, which was included in the other non-current assets of the Companyâ€™s unaudited condensed consolidated balance sheets. Such letter of credit shall be reduced to approximately $5.6 million at the commencement of the fourth rent year, provided certain conditions set forth in the Bedford Lease are satisfied.Undiscounted minimum rent payments due over the term of the lease aggregate to $307.4 million. Additionally, the Company is responsible for reimbursing the landlord for the Companyâ€™s share of the propertyâ€™s operating expenses and property taxes. The Bedford Lease also provides for a tenant improvement allowance from the landlord of up to $72.0 million to be used towards costs incurred by the Company in the design and construction of the premises. The Company recorded the $72.0 million tenant improvement allowance as a reduction to right-of-use (â€œROUâ€) assets and lease liabilities in May 2023 as the Company obtained control of the premises. In August 2024, the Company entered into an amendment to the Bedford Lease to extend the term in which the tenant improvement allowance could be reimbursed from the landlord (the â€œBedford Amendmentâ€). The Bedford Amendment extended the reimbursement period associated with the tenant improvement allowance through December 2, 2025. The Company also agreed to reimburse the landlord for certain costs incurred in order to fund the extension of the reimbursement period associated with the tenant improvement allowance, totaling $2.9 million. The Bedford Amendment was accounted for as a modification to the Bedford Lease.As of September 30, 2024, the Company had a lease liability and ROU asset of $131.7 million and $92.0 million, respectively, on its unaudited condensed consolidated balance sheets related to the Bedford Lease. Tenant improvement costs incurred by the Company that had been reimbursed by the landlord totaled $29.5 million through September 30, 2024 and were recorded as an increase to lease liabilities when received within the Company's unaudited condensed consolidated balance sheets. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.3 EARNINGS (LOSS) PER SHARE 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â EARNINGS (LOSS) PER SHARE 15. EARNINGS (LOSS) PER SHAREBasic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed by dividing net income by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding.Â The following table sets forth the computation of basic and diluted earnings (loss) per common share: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands, except per share amounts) Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) - basic Â $ 33,611 Â Â $ (40,937) Â $ 76,190 Â Â $ (581,632) Add: interest expense, net of tax, on the Company'sÂ Â Â Â Â convertible debt Â Â 413 Â Â Â â€” Â Â Â 1,182 Â Â Â â€” Â Net income (loss) - diluted Â $ 34,024 Â Â $ (40,937) Â $ 77,372 Â Â $ (581,632) Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average common shares outstanding, basic Â Â 95,390 Â Â Â 88,889 Â Â Â 94,669 Â Â Â 88,609 Â Effect of dilutive securities: Â Â Â Â Â Â Â Â Â Â Â Â Common stock issuable under the Company'sÂ Â Â Â Â equity incentive plans Â Â 3,810 Â Â Â â€” Â Â Â 3,529 Â Â Â â€” Â Common stock issuable under the Company'sÂ Â Â Â Â convertible debt Â Â 1,248 Â Â Â â€” Â Â Â 1,374 Â Â Â â€” Â Weighted-average common shares outstanding, diluted Â Â 100,448 Â Â Â 88,889 Â Â Â 99,572 Â Â Â 88,609 Â Earnings (loss) per common share, basic Â $ 0.35 Â Â $ (0.46) Â $ 0.80 Â Â $ (6.56) Earnings (loss) per common share, diluted Â $ 0.34 Â Â $ (0.46) Â $ 0.78 Â Â $ (6.56) Â The following table summarizes potential shares of common stock that were excluded from the computation of diluted earnings per share as they were anti-dilutive:Â Â Â Â As of September 30, 2024 Â Â Â Â As of September 30, 2023 Â Â Â Â (in thousands) Â Â Common stock issuable under the Company's equity incentive plans Â Â 2,464 Â (1) Â 12,111 Â (2) Common stock issuable under the Company's convertible debt Â Â 8,100 Â Â Â 9,542 Â Â Total number of potentially issuable common stock Â Â 10,564 Â Â Â 21,653 Â Â Â (1) As of September 30, 2024, the anti-dilutive common stock issuable under the Company's equity incentive plans excludes 1.2 million shares that are dilutive but have performance or market conditions that were not met as of the end of the period.(2) As of September 30, 2023, the anti-dilutive common stock issuable under the Company's equity incentive plans includes 1.1 million shares that have performance or market conditions that were not met as of the end of the period because these were anti-dilutive as the Company was in a net loss position at the end of the period. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R24.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â COMMITMENTS AND CONTINGENCIES 16. COMMITMENTS AND CONTINGENCIESManufacturing ObligationsThe following table summarizes the aggregate non-cancelable contractual obligations arising from the Companyâ€™s manufacturing obligations: Â Â Â As ofSeptember 30, 2024 Â Â Â (in thousands) Â 2024 (October-December) Â $ 600,021 Â 2025 Â Â 312,338 Â 2026 Â Â 119,238 Â 2027 Â Â 82,217 Â 2028 Â Â 72,306 Â Total manufacturing commitments* Â $ 1,186,120 Â Â * Total manufacturing commitments include the Catalent manufacturing and supply agreement, for which the Company has ROU assets and lease liabilities recorded on the unaudited condensed consolidated balance sheets as of September 30, 2024. Â Thermo Fisher Scientific, Inc. The Company entered into a development, commercial manufacturing, and supply agreement as related to the Company's adherent manufacturing process for its gene therapy programs in June 2018 and, subsequently, entered into the first, second and third amendments in May 2019, July 2020 and October 2021, respectively, with Brammer Bio MA, LLC, an affiliate of Thermo Fisher Scientific, Inc. (â€œThermoâ€) (collectively, the â€œThermo Agreementâ€). In March 2023, the Company executed a fourth amendment (the â€œThermo Amendmentâ€) that modified the terms of the Thermo Agreement. The Thermo Amendment removed the previous minimum batch purchase commitment of $54.7 million per annum and associated fee for the remaining term of the Thermo Agreement. In connection with the elimination of such commitment and fee, the Thermo Amendment implemented a fee of up to $60.0 million, to be paid in three installments of $20.0 million each by March 1, 2024, December 31, 2024 and December 31, 2025, respectively. During the three months ended March 31, 2024, the Company paid the first $20.0 million installment due March 1, 2024, considered a nonrefundable advance payment. On July 18, 2024, the Company issued a termination notice to Thermo to terminate the Thermo Agreement. The termination was effective as of August 21, 2024. The aggregate net impact of the termination was $55.4 million of research and development expense in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). As the Company had yet to obtain regulatory approval to produce commercial supply of ELEVIDYS at Thermo manufacturing facilities, the Company recorded the charges incurred as research and development expenses in the three months ended September 30, 2024. Included in the net impact noted above are non-cash charges due to the termination of $62.7 million, related to the remaining unamortized nonrefundable advance payments. Additionally, there were unbilled service and material costs ordered by the Company as of the termination date of $29.2 million that were expensed as research and development expense during the three months ended September 30, 2024. As related to the termination, for both the three and nine months ended September 30, 2024, costs reimbursable by Roche under the Roche Agreement and reflected as a reduction to research and development expenses were $36.5 million. For more information related to the Companyâ€™s manufacturing and supply agreements, please read Note 21, Commitments and Contingencies to the financial statements included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023.Litigation In the normal course of business, the Company from time to time is named as a party to various legal claims, actions and complaints, which have included and may include matters involving securities, employment, intellectual property, arising from the use of therapeutics utilizing its technology, or others. The Company records a loss contingency reserve for a legal proceeding when it considers the potential loss probable, and it can reasonably estimate the amount of the loss or determine a probable range of loss. The Company provides disclosure when it considers a loss reasonably possible or when it determines that a loss in excess of a reserve is reasonably possible. The Company provides an estimate of such reasonably possible losses or an aggregate range of such reasonably possible losses, unless the Company believes that such an estimate cannot be made. The Company has not recorded any material accruals for loss contingencies, and in management's opinion, no material range of loss is estimable for the matters described below as of September 30, 2024.On September 15, 2020, REGENXBIO INC. (â€œRegenxâ€) and the Trustees of the University of Pennsylvania (â€œU-Pennâ€) filed a lawsuit against the Company and Sarepta Therapeutics Three, LLC, in the U.S. District Court for the District of Delaware. The plaintiffs assert patent infringement of U.S. Patent No. 10,526,617 (â€œthe â€˜617 Patentâ€) under 35 U.S.C.Â§Â§ 271(a)-(c) based on Sareptaâ€™s alleged direct or indirect manufacture and use of the patented cultured host cell technology allegedly used to make AAV gene therapy products, including SRP-9001 (approved June 22, 2023 in the U.S. as ELEVIDYSÂ®). Specifically, the Complaint essentially includes the allegation that Sareptaâ€™s use, and the use by its contract manufacturers on its behalf, of a host cell containing a recombinant acid molecule that encodes a capsid protein having at least 95% amino acid identity to AAVrh10 infringes the â€˜617 Patent asserted by Regenx. Plaintiffs seek injunctive relief, a judgment of infringement and willful infringement, damages that are no less than a reasonable royalty (treble damages), attorneysâ€™ fees and costs, and such other relief as the court deems just and proper. On January 5, 2024, the Court granted Sareptaâ€™s motion for summary judgment on the grounds that the asserted claims of Regenxâ€™s â€˜617 Patent are invalid because they cover patent ineligible subject matter under 35 U.S.C. Â§ 101. On January 12, 2024, the Court entered judgment and closed the case. Plaintiffs have appealed to the U.S. Court of Appeals for the Federal Circuit. On June 20, 2023, Regenx and U-Penn commenced a second patent infringement lawsuit against Sarepta and its contract manufacturer, Catalent asserting patent alleged infringement of U. S. Patent No. 11,680,274 (â€œthe â€™274 Patentâ€). In the second lawsuit, Regenx and U-Penn allege that Sarepta and Catalentâ€™s manufacture, use and commercial launch of ELEVIDYSÂ® (SRP-9001) infringe the â€™274 Patent. Sarepta answered the complaint on August 10, 2023, and a case schedule was set with a trial commencing on November 17, 2025. On February 21, 2024, Sarepta submitted a petition for Inter Partes Review (â€œIPRâ€) for filing with the Patent Trial and Appeal Board (â€œPTABâ€) at the USPTO. The petition seeks to invalidate the â€˜274 Patent. On March 20, 2024, the district court stayed the litigation pending the PTABâ€™s determination on the IPR. On August 22, 2024, the PTAB instituted inter partes review of all challenged claims of the â€˜274 Patent on all asserted grounds.On July 13, 2021, Nippon Shinyaku Co., Ltd. (â€œNippon Shinyakuâ€ or â€œNSâ€) filed a lawsuit against the Company in the U.S. District Court for the District of Delaware. NS asserted a claim for breach of contract arising from Sarepta filing seven petitions for Inter Partes Review (â€œIPR Petitionsâ€) with the PTAB at the USPTO in which Sarepta sought to invalidate certain NS patents concerning exon 53 skipping technology (U.S.

Patent Nos. 9,708,361, 10,385,092, 10,407,461, 10,487,106, 10,647,741, 10,662,217, and 10,683,322, respectively, and collectively the â€œNS Patentsâ€). In addition, NS asserted claims for patent infringement and willful infringement of each of the NS Patents allegedly arising from Sareptaâ€™s activities, including the sale of, its exon 53 skipping product, VYONDYS 53 (golodirsen). NS further sought a determination of non-infringement by NS alleged to arise from NSâ€™s activities, including the sale of, its exon 53 skipping product, Viltepso (viltolarsen) and invalidity of certain patents licensed to the Company from the University of Western Australia (â€œUWAâ€) (U.S. Patent Nos. 9,994,851, 10,227,590, and 10,266,827, collectively the â€œUWA Patentsâ€). In its complaint, NS sought legal fees and costs, an unspecified amount of monetary relief (treble damages) attributed to Sareptaâ€™s alleged infringement, and such other relief as the court deems just and proper. In January 2022, the PTAB granted institution of all claims of all NS Patents in response to Sareptaâ€™s IPR Petitions and determined that Sarepta demonstrated a reasonable likelihood of success in proving that the NS Patents are unpatentable. NS filed a motion for preliminary injunction solely seeking Sareptaâ€™s withdrawal of the IPR Petitions, which was ultimately granted after the U.S. Court of Appeals for the Federal Circuit reversed and remanded to the district court on February 8, 2022. Sarepta subsequently withdrew the IPRs, which were terminated on June 14, 2022. On December 27, 2021, the district court partially granted and denied the motion to dismiss by Sarepta and ordered NS to file a Second Amended Complaint (â€œSACâ€), which it did on January 14, 2022. In the SAC, NS maintained all claims of the original complaint of July 13, 2021, except a determination of non-infringement of the UWA Patents. On January 28, 2022, Sarepta filed its answer to the SAC, with defenses and counterclaims against NS and NS Pharma Inc. that include infringement of the UWA Patents allegedly arising from their activities concerning, including the sale of, its exon 53 skipping product, Viltepso (viltolarsen) and breach of contract. Sarepta also sought a determination of invalidity of the NS Patents. In its counterclaim complaint, Sarepta sought an award of relief in its defenses to NSâ€™ allegations, a judgment of breach of contract, a determination of invalidity of the NS Patents, a judgment of infringement and willful infringement of the UWA Patents, legal fees and costs, an unspecified amount of monetary relief (treble damages) attributable to NSâ€™ alleged infringement, and such other relief as the court deems just and proper. UWA has since been joined as a Plaintiff in Sareptaâ€™s counterclaims against NS. On August 14, 2023, the Court granted cross motions to amend the pleadings, allowing Sarepta to add a counterclaim against NS for inequitable conduct, and NS to add counterclaims against Sarepta for inequitable conduct and Walker Process fraud. The parties have since stipulated to the dismissal of NS's claim of infringement of its â€™361 Patent and certain claims of the â€™322 Patent, and NSâ€™s breach of contract claim. The Court bifurcated the Walker Process fraud claim on April 18, 2024, and granted Sarepta's motion for summary judgement of infringement of the '851 Patent and NSâ€™s motion for partial summary judgment of infringement of certain NS patents on May 1, 2024. A trial is scheduled to commence on December 16, 2024. On or about June 5, 2023, Sarepta initiated a patent infringement lawsuit against Nippon Shinyaku in Japan, alleging that NSâ€™s production, sales and offers to sell Viltepso infringe Sareptaâ€™s Japanese Patent No. 6406782. NS filed its preliminary answer on July 13, 2023. A technical presentation session occurred on July 26, 2024.On July 26, 2024, Genzyme Corporation filed a lawsuit against Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC, in the U.S. District Court for the District of Delaware. The complaint asserts infringement of United States Patent Nos. 9,051,542 (the â€œâ€™542 Patentâ€) and 7,704,721 (the â€œâ€™721 Patentâ€) arising from Sareptaâ€™s alleged manufacture and sale of ELEVIDYSÂ® (delandistrogene moxeparvovec-rokl). In its complaint, Genzyme seeks, inter alia, damages for the alleged infringement, including increased damages up to three times the amount found or assessed, together with prejudgment and post-judgment interest and costs. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R25.htm IDEA: XBRL DOCUMENT v3.24.3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of PresentationThe accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€), reflect the accounts of Sarepta and its wholly-owned subsidiaries. All intercompany transactions between and among its consolidated subsidiaries have been eliminated. Management has determined that the Company operates in one segment: discovering, developing, manufacturing and delivering therapies to patients with rare diseases. In the opinion of the Companyâ€™s management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with U.S. GAAP, but that is not required for interim reporting purposes, has been omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes for the year ended December 31, 2023 which are contained in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on February 28, 2024. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year. Estimates and Uncertainties Estimates and UncertaintiesThe preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Concentration of Credit Risk Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist of cash held at financial institutions, cash equivalents, investments and accounts receivable, net, from customers. As of September 30, 2024, the Companyâ€™s cash was concentrated at three financial institutions, which potentially exposes the Company to credit risks. However, the Company does not believe that there is significant risk of non-performance by the financial institutions. The Company also purchases commercial paper, government and government agency bonds, corporate bonds and certificates of deposit issued by highly rated corporations, financial institutions and governments and limits the amount of credit exposure to any one issuer. These amounts may at times exceed federally insured limits. The Company has not experienced any credit losses related to these financial instruments and does not believe to be exposed to any significant credit risk related to these instruments. As of September 30, 2024, three entities accounted for 37%, 27% and 20% of accounts receivable, net, respectively. As of December 31, 2023, four entities accounted for 40%, 19%, 19% and 12% of accounts receivable, net, respectively. As of September 30, 2024, the Company believes its largest customers are of high credit quality and has not experienced any material credit losses related to such customers. Significant Accounting Policies Significant Accounting PoliciesFor details about the Company's accounting policies, please read Note 2, Summary of Significant Accounting Policies and Recent Accounting Pronouncements of the Annual Report on Form 10-K for the year ended December 31, 2023.There have not been any material changes to the Company's accounting policies or recent accounting pronouncements that could have a material impact through September 30, 2024. X - DefinitionSignificant Accounting Policies [Policy Text Block] + ReferencesNo definition available. + Details Name: srpt_SignificantAccountingPoliciesPolicyTextBlock Namespace Prefix: srpt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R26.htm IDEA: XBRL DOCUMENT v3.24.3 LICENSE AND COLLABORATION AGREEMENTS (Tables) 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Schedule of Certain Activity Related to Revenue with Supply Agreement The following table summarizes certain Roche activity for the three and nine months ended September 30, 2024: Â Â For the Three Months Ended September 30, 2024 Â Â For the Nine Months Ended September 30, 2024 Â Â (in thousands) Â Contract manufacturing revenue $ 27,891 Â Â $ 33,698 Â Royalty revenue $ 9,510 Â Â $ 12,066 Â Cost of sales (inventory costs related to products sold to Roche) $ 13,725 Â Â $ 15,379 Â Â X - DefinitionSchedule of certain activity related to revenue with supply agreement. + ReferencesNo definition available. + Details Name: srpt_ScheduleOfCertainActivityRelatedToRevenueWithSupplyAgreementTableTextBlock Namespace Prefix: srpt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R27.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Assets and Liabilities Measured and Carried at Fair Value The tables below present information about the Companyâ€™s financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques it utilizes to determine such fair value: Â Â Â Fair Value Measurement as of September 30, 2024 Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â (in thousands) Â Assets Â Â Â Â Â Â Â Â Â Â Â Â Â Money market funds Â $ 21,951 Â Â $ 21,951 Â Â $ â€” Â Â $ â€” Â Commercial paper Â Â 34,995 Â Â Â â€” Â Â Â 34,995 Â Â Â â€” Â Government and government agency bonds Â Â 900,407 Â Â Â 13,494 Â Â Â 886,913 Â Â Â â€” Â Corporate bonds Â Â 233,245 Â Â Â â€” Â Â Â 233,245 Â Â Â â€” Â Strategic investments Â Â Â 4,723 Â Â Â 3,723 Â Â Â â€” Â Â Â 1,000 Â Certificates of deposit Â Â 17,988 Â Â Â â€” Â Â Â 17,988 Â Â Â â€” Â Derivative assets Â Â 44,622 Â Â Â â€” Â Â Â 44,622 Â Â Â â€” Â Total assets Â $ 1,257,931 Â Â Â $ 39,168 Â Â $ 1,217,763 Â $ 1,000 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent consideration Â $ 47,400 Â Â $ â€” Â Â $ â€” Â Â $ 47,400 Â Total liabilities Â $ 47,400 Â Â $ â€” Â Â $ â€” Â Â $ 47,400 Â Fair Value Measurement as of December 31, 2023 Â Â Â Â Total Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Â Â (in thousands) Â Assets Â Money market funds Â $ 63,919 Â Â $ 63,919 Â Â $ â€” Â Â $ â€” Â Commercial paper Â Â 113,362 Â Â Â â€” Â Â Â 113,362 Â Â Â â€” Â Government and government agency bonds Â Â 1,001,137 Â Â Â â€” Â Â Â 1,001,137 Â Â Â â€” Â Corporate bonds Â Â 130,380 Â Â Â â€” Â Â Â 130,380 Â Â Â â€” Â Strategic investments Â Â 6,527 Â Â Â 5,527 Â Â Â â€” Â Â Â 1,000 Â Certificates of deposit Â Â 56,621 Â Â Â â€” Â Â Â 56,621 Â Â Â â€” Â Total assets Â $ 1,371,946 Â Â Â $ 69,446 Â Â $ 1,301,500 Â $ 1,000 Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent consideration Â $ 38,100 Â Â $ â€” Â Â $ â€” Â Â $ 38,100 Â Total liabilities Â $ 38,100 Â Â $ â€” Â Â $ â€” Â Â $ 38,100 Â Summary of Fair Value of Level 3 Financial Liabilities The following table represents a roll-forward of the fair value of Level 3 financial liabilities for the periods indicated: Â Â As of September 30, 2024 Â Â As of September 30, 2023 Â Â Â (in thousands) Â Fair value, as of beginning of year Â $ 38,100 Â Â $ 36,900 Â Change in estimated fair value Â Â 9,500 Â Â Â 2,000 Â Liabilities terminated Â Â (200) Â Â (800) Fair value, as of end of period Â $ 47,400 Â Â $ 38,100 Â X - DefinitionTabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R28.htm IDEA: XBRL DOCUMENT v3.24.3 CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables) 9 Months Ended Sep. 30, 2024 Cash and Cash Equivalents [Abstract] Â Summary of Company Financial Assets with Maturities of Less Than 90 Days Included in Cash Equivalents The following table summarizes the Companyâ€™s financial assets with maturities of less than 90 days from the date of purchase included in cash equivalents in the unaudited condensed consolidated balance sheets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Money market funds Â $ 21,951 Â Â $ 63,919 Â Commercial paper Â Â 2,330 Â Â Â 53,680 Â Corporate bonds Â Â 2,001 Â Â Â â€” Â Total Â $ 26,282 Â Â $ 117,599 Â Â Â Summary of Company Cash, Cash Equivalents and Short-Term Investments and non-current investments The following tables summarize the Companyâ€™s cash, cash equivalents, short-term investments and non-current investments for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair MarketValue Â Â Â (in thousands) Â Cash and money market funds Â $ 193,524 Â Â $ â€” Â Â $ â€” Â Â $ 193,524 Â Commercial paper Â Â 34,995 Â Â Â â€” Â Â Â â€” Â Â Â 34,995 Â Government and government agency bonds Â Â 898,726 Â Â Â 1,704 Â Â Â (23) Â Â 900,407 Â Corporate bonds Â Â 232,654 Â Â Â 603 Â Â Â (12) Â Â 233,245 Â Certificates of deposit Â Â 17,988 Â Â Â â€” Â Â Â â€” Â Â Â 17,988 Â Total cash, cash equivalents and

investments Â $ 1,377,887 Â Â $ 2,307 Â Â $ (35) Â $ 1,380,159 Â As reported: Â Â Â Â Â Â Â Â Â Â Â Â Cash and cash equivalents Â $ 197,854 Â Â $ 1 Â Â $ â€” Â Â $ 197,855 Â Short-term investments Â Â 998,884 Â Â Â 1,667 Â Â Â (17) Â Â 1,000,534 Â Non-current investments Â Â 181,149 Â Â Â 639 Â Â Â (18) Â Â 181,770 Â Total cash, cash equivalents and investments Â $ 1,377,887 Â Â $ 2,307 Â Â $ (35) Â $ 1,380,159 Â Â Â Â As of December 31, 2023 Â Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair MarketValue Â Â Â (in thousands) Â Cash and money market funds Â $ 374,750 Â Â $ â€” Â Â $ â€” Â Â $ 374,750 Â Commercial paper Â Â 113,362 Â Â Â â€” Â Â Â â€” Â Â Â 113,362 Â Government and government agency bonds Â Â 1,000,302 Â Â Â 1,006 Â Â Â (171) Â Â 1,001,137 Â Corporate bonds Â Â 130,270 Â Â Â 118 Â Â Â (8) Â Â 130,380 Â Certificates of deposit Â Â 56,621 Â Â Â â€” Â Â Â â€” Â Â Â 56,621 Â Total cash, cash equivalents and investments Â $ 1,675,305 Â Â $ 1,124 Â Â $ (179) Â $ 1,676,250 Â As reported: Â Â Â Â Â Â Â Â Â Â Â Â Cash and cash equivalents Â $ 428,430 Â Â $ â€” Â Â $ â€” Â Â $ 428,430 Â Short-term investments Â Â 1,246,875 Â Â Â 1,124 Â Â Â (179) Â Â 1,247,820 Â Total cash, cash equivalents and investments Â $ 1,675,305 Â Â $ 1,124 Â Â $ (179) Â $ 1,676,250 Â X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash and cash equivalents. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash, cash equivalents, and investments. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R29.htm IDEA: XBRL DOCUMENT v3.24.3 PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES (Tables) 9 Months Ended Sep. 30, 2024 Receivables, Net, Current [Abstract] Â Summary of Product Revenues Net product revenues, which includes revenues associated with the PMO Products and ELEVIDYS, consisted of the following: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â PMO Products Â Â Â Â Â Â Â Â Â Â Â Â United States Â $ 210,683 Â Â $ 198,069 Â Â $ 604,598 Â Â $ 602,415 Â Rest of World Â Â 38,105 Â Â Â 42,145 Â Â Â 108,565 Â Â Â 108,282 Â Total PMO product revenues, net Â $ 248,788 Â Â $ 240,214 Â Â $ 713,163 Â Â $ 710,697 Â ELEVIDYS Â Â Â Â Â Â Â Â Â Â Â Â United States Â Â 180,983 Â Â Â 69,108 Â Â Â 436,640 Â Â Â 69,108 Â Total ELEVIDYS product revenue, net Â $ 180,983 Â Â $ 69,108 Â Â $ 436,640 Â Â $ 69,108 Â Total product revenues, net Â $ 429,771 Â Â $ 309,322 Â Â $ 1,149,803 Â Â $ 779,805 Â Â Schedule of Product revenue Concentration risks The following table summarizes the Company's net product revenues, by customer, for those customers that exceeded 10% for the periods indicated: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Product revenues, net Â Â Â Â Â Â Â Â Â Â Â Â Customer 1 Â Â 28 % Â Â 40 % Â Â 33 % Â Â 45 % Customer 2 Â Â 19 % Â Â 23 % Â Â 20 % Â Â 29 % Summary of Change in Reserves for Discounts and Allowances The following tables summarize an analysis of the change in reserves for discounts and allowances for each of the periods indicated: Â Â Chargebacks Â Â Rebates Â Â Prompt Pay Â Â Other Accruals Â Â Total Â Â Â (in thousands) Â Balance, as of December 31, 2023 Â $ 27,486 Â Â $ 98,194 Â Â $ 3,831 Â Â $ 35,261 Â Â $ 164,772 Â Provision Â Â $ 72,832 Â Â Â 118,228 Â Â Â 13,442 Â Â Â 53,674 Â Â Â 258,176 Â Adjustments relating to prior periods Â Â 783 Â Â Â (8,716) Â Â â€” Â Â Â (88) Â Â (8,021) Payments/credits Â Â (77,808) Â Â (100,693) Â Â (12,191) Â Â (58,741) Â Â (249,433) Balance, as of September 30, 2024 Â $ 23,293 Â Â $ 107,013 Â Â $ 5,082 Â Â $ 30,106 Â Â $ 165,494 Â Â Â Â Â Â Chargebacks Â Â Rebates Â Â Prompt Pay Â Â Other Accruals Â Â Total Â Â Â (in thousands) Â Balance, as of December 31, 2022 Â $ 417 Â Â $ 67,493 Â Â $ 3,343 Â Â $ 23,445 Â Â $ 94,698 Â Provision Â Â 18,191 Â Â Â 94,025 Â Â Â 11,251 Â Â Â 52,500 Â Â Â 175,967 Â Adjustments relating to prior periods Â Â 110 Â Â Â (4,154) Â Â â€” Â Â Â â€” Â Â Â (4,044) Payments/credits Â Â (9,386) Â Â (73,317) Â Â (10,586) Â Â (40,048) Â Â (133,337) Balance, as of September 30, 2023 Â $ 9,332 Â Â $ 84,047 Â Â $ 4,008 Â Â $ 35,897 Â Â $ 133,284 Â Summary of Total Reserves Included in Consolidated Balance Sheets The following table summarizes the total reserves above included in the Companyâ€™s unaudited condensed consolidated balance sheets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Reduction to accounts receivable, net Â $ 56,773 Â Â $ 64,697 Â Component of accrued expenses Â Â 108,721 Â Â Â 100,075 Â Total reserves Â $ 165,494 Â Â $ 164,772 Â X - DefinitionSchedule of product revenues concentration risk. + ReferencesNo definition available. + Details Name: srpt_ScheduleOfProductRevenuesConcentrationRiskTableTextBlock Namespace Prefix: srpt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSummary of change in reserves for discounts and allowances. + ReferencesNo definition available. + Details Name: srpt_SummaryOfChangeInReservesForDiscountsAndAllowancesTableTextBlock Namespace Prefix: srpt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSummary of reserves for discounts and allowances included in consolidated balance sheets. + ReferencesNo definition available. + Details Name: srpt_SummaryOfReservesForDiscountsAndAllowancesIncludedInConsolidatedBalanceSheetsTableTextBlock Namespace Prefix: srpt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesNetCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 39 R30.htm IDEA: XBRL DOCUMENT v3.24.3 INVENTORY (Tables) 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â Schedule of Components of Inventory The following table summarizes the components of the Companyâ€™s inventory for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Raw materials Â $ 208,320 Â Â $ 133,963 Â Work in progress Â Â 482,171 Â Â Â 318,458 Â Finished goods Â Â 77,983 Â Â Â 61,806 Â Total inventory Â $ 768,474 Â Â $ 514,227 Â Â Summary of Inventory Balance Sheet Classification The following table summarizes the balance sheet classification of the Company's inventory for each of the periods indicated: Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Balance sheet classification Â Â Â Â Â Â Inventory Â $ 565,924 Â Â $ 322,859 Â Non-current inventory Â Â 202,550 Â Â Â 191,368 Â Total inventory Â $ 768,474 Â Â $ 514,227 Â X - DefinitionSchedule Of Inventory Table Text Block + ReferencesNo definition available. + Details Name: srpt_ScheduleOfInventoryTableTextBlock Namespace Prefix: srpt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSummaryOfInventoryBalanceSheetClassificationTableTextBlock + ReferencesNo definition available. + Details Name: srpt_Summaryofinventorybalancesheetclassificationtabletextblock Namespace Prefix: srpt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R31.htm IDEA: XBRL DOCUMENT v3.24.3 OTHER ASSETS (Tables) 9 Months Ended Sep. 30, 2024 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Â Summary of Other Current Assets The following table summarizes the Companyâ€™s other current assets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Collaboration and other receivables Â $ 66,404 Â Â $ 29,786 Â Derivative asset Â Â 44,622 Â Â Â â€” Â Prepaid maintenance services Â Â 13,326 Â Â Â 11,281 Â Prepaid clinical and pre-clinical expenses Â Â 12,034 Â Â Â 10,280 Â Tax-related receivables and prepaids Â Â 11,422 Â Â Â 6,862 Â Prepaid commercial expenses Â Â 3,982 Â Â Â 2,729 Â Interest receivable Â Â 3,637 Â Â Â 2,731 Â Prepaid insurance Â Â 2,198 Â Â Â 3,352 Â Other Â Â 7,852 Â Â Â 10,693 Â Total other current assets Â $ 165,477 Â Â $ 77,714 Â Summary of Other Non-current Assets The following table summarizes the Companyâ€™s other non-current assets for each of the periods indicated:Â Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Manufacturing-related deposits and prepaids Â $ 28,127 Â Â $ 74,204 Â Intangible assets, net Â Â 27,570 Â Â Â 29,620 Â Restricted cash* Â Â 15,579 Â Â Â 15,579 Â Strategic investments Â Â 4,723 Â Â Â 6,527 Â Prepaid maintenance services Â Â 3,907 Â Â Â 5,466 Â Other Â Â 3,653 Â Â Â 5,375 Â Total other non-current assets Â $ 83,559 Â Â $ 136,771 Â Â * The Company had approximately $15.6 million in restricted cash included in other non-current assets on the Companyâ€™s unaudited condensed consolidated balance sheets as of both September 30, 2024 and December 31, 2023. Restricted cash for both periods relates to (i) letters of credit established under the Companyâ€™s various property leases that serve as security for potential future default of lease payments, (ii) a letter of credit established under a certain commercial supply agreement and (iii) collateralized cash for the Companyâ€™s credit cards. The restricted cash is unavailable for withdrawal or use for general obligations. X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of noncurrent assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amounts of other current assets. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R32.htm IDEA: XBRL DOCUMENT v3.24.3 ACCRUED EXPENSES (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Summary of Accrued Expenses The following table summarizes the Companyâ€™s accrued expenses for each of the periods indicated: Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Product revenue related reserves Â $ 108,721 Â Â $ 100,075 Â Accrued contract manufacturing costs Â Â 75,909 Â Â Â 33,024 Â Accrued employee compensation costs Â Â 57,107 Â Â Â 78,732 Â Accrued clinical and pre-clinical costs Â Â 40,514 Â Â Â 34,669 Â Accrued professional fees Â Â 21,486 Â Â Â 17,187 Â Accrued income taxes Â Â 14,696 Â Â Â 13,766 Â Accrued royalties Â Â 12,185 Â Â Â 12,070 Â Accrued fixed assets Â Â 4,821 Â Â Â 3,231 Â Accrued research expenses Â Â 2,882 Â Â Â 2,441 Â Accrued interest Â Â 1,118 Â Â Â 4,395 Â Other Â Â 5,391 Â Â Â 15,407 Â Total accrued expenses Â $ 344,830 Â Â $ 314,997 Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R33.htm IDEA: XBRL DOCUMENT v3.24.3 INDEBTEDNESS (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Summary of Debt Facilities The following table summarizes the Companyâ€™s debt instruments for each of the periods indicated:Â Â As of September 30, 2024 Â Â As of December 31, 2023 Â Â Â (in thousands) Â Principal amount of the 2024 Notes $ 91,640 Â Â $ 105,847 Â Principal amount of the 2027 Notes Â 1,150,000 Â Â Â 1,150,000 Â Unamortized discount - debt issuance costs of 2024 Notes Â (45) Â Â (364) Unamortized discount - debt issuance costs of 2027 Notes Â (14,035) Â Â (17,485) Total carrying value of debt instruments $ 1,227,560 Â Â $ 1,237,998 Â Â Â Â Â Â Fair value of 2024 Notes $ 171,154 Â Â $ 144,833 Â Fair value of 2027 Notes Â 1,307,930 Â Â Â 1,172,276 Â Total fair value of debt instruments $ 1,479,084 Â Â $ 1,317,109 Â Summarizes Total Gross Payments Due under Company's Debt Arrangements The following table summarizes the total principal and contractual interest payments due under the Companyâ€™s debt arrangements: Â Â As of September 30, 2024 Â Â Â Principal Â Â Interest Â Â Total Payments Â Â Â (in thousands) Â 2024 (October-December) Â $ 91,640 Â Â $ 711 Â Â $ 92,351 Â 2025 Â Â â€” Â Â Â 14,375 Â Â Â 14,375 Â 2026 Â Â â€” Â Â Â 14,375 Â Â Â 14,375 Â 2027 Â Â 1,150,000 Â Â Â 14,375 Â Â Â 1,164,375 Â Total payments Â $ 1,241,640 Â Â $ 43,836 Â Â $ 1,285,476 Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R34.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Summary of Stock Awards Granted The following table summarizes the Companyâ€™s stock awards granted for each of the periods indicated: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Â Grants Â Â WeightedAverageGrantDate FairValue Â Stock options Â Â 6,442 Â Â $ 55.16 Â Â Â 50,875 Â Â $ 66.53 Â Â Â 327,920 Â Â $ 67.39 Â Â Â 1,135,799 Â Â $ 72.23 Â Restricted stock units Â Â 135,092 Â Â $ 127.51 Â Â Â 27,539 Â Â $ 118.05 Â Â Â 1,351,982 Â (1) $ 128.90 Â Â Â 1,137,202 Â (2) $ 153.02 Â Â (1) Included in restricted stock units (â€œRSUsâ€) for the nine months ended September 30, 2024 are 97,460 shares with performance conditions (â€œMarch 2024 PSUsâ€) which are related to the achievement of certain financial performance goals and regulatory approval of certain of the Company's product candidates. The expanded regulatory approval of ELEVIDYS in June 2024 resulted in the cliff-vesting of 44,300 of the 97,460 shares of the March 2024 PSUs during the nine months ended September 30, 2024. As of September 30, 2024, none of the performance conditions for the remaining 53,160 shares were probable of being achieved. Stock options and the remaining RSUs granted during the three and nine months ended September 30, 2024 have only service-based criteria and vest over four years. (2) Included in the RSUs for the nine months ended September 30, 2023 are 502,225 shares with performance conditions (the â€œMarch 2023 PSUsâ€), which are related to regulatory approval of ELEVIDYS and achievement of a certain financial performance target, both of which were achieved in 2023. Vesting of the March 2023 PSUs is contingent on the fulfillment of remaining service conditions. Summary of Stock-Based Compensation Expense by Grant Type Included within Consolidated Statements of Operations and Comprehensive Loss The following table summarizes stock-based compensation expense by grant type and by function included within the unaudited condensed consolidated statements of comprehensive income (loss):Â Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Stock options Â $ 15,158 Â Â $ 17,471 Â Â $ 46,954 Â Â $ 62,436 Â Restricted stock units Â Â 31,926 Â Â Â 28,924 Â Â Â 97,261 Â Â Â 70,101 Â Employee Stock Purchase Program Â Â 1,912 Â Â Â 1,666 Â Â Â 5,640 Â Â Â 4,151 Â Subtotal Â $ 48,996 Â Â $ 48,061 Â Â $ 149,855 Â Â $ 136,688 Â

Capitalized stock-based compensation costs* Â Â (5,546) Â Â â€” Â Â Â (15,231) Â Â â€” Â Total stock-based compensation expense included in expenses Â $ 43,450 Â Â $ 48,061 Â Â $ 134,624 Â Â $ 136,688 Â Research and development Â Â 18,034 Â Â Â 22,325 Â Â Â 54,113 Â Â Â 60,315 Â Selling, general and administrative Â Â 25,416 Â Â Â 25,736 Â Â Â 80,511 Â Â Â 76,373 Â Total stock-based compensation expense included in expenses Â $ 43,450 Â Â $ 48,061 Â Â $ 134,624 Â Â $ 136,688 Â Â *Prior to the nine months ended September 30, 2024, capitalized stock-based compensation costs were not material. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R35.htm IDEA: XBRL DOCUMENT v3.24.3 OTHER INCOME (LOSS), NET (Tables) 9 Months Ended Sep. 30, 2024 Other Income and Expenses [Abstract] Â Summary of Other Income (Loss) The following table summarizes other income (loss), net for each of the periods indicated:Â Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â (in thousands) Â Accretion of investment discount, net Â $ 10,749 Â Â $ 12,984 Â Â $ 34,319 Â Â $ 35,809 Â Interest income Â Â 7,584 Â Â Â 9,838 Â Â Â 22,753 Â Â Â 27,532 Â Interest expense Â Â (4,918) Â Â (5,229) Â Â (13,916) Â Â (16,776) Change in fair value of derivatives* Â Â 1,535 Â Â Â (2,000) Â Â (8,565) Â Â (1,200) Impairment of strategic investments Â Â â€” Â Â Â (27,500) Â Â â€” Â Â Â (27,821) Other, net Â Â (3,140) Â Â (425) Â Â (1,960) Â Â (235) Other income (expense), net Â $ 11,810 Â Â $ (12,332) Â $ 32,631 Â Â $ 17,309 Â Gain from sale of Priority Review Voucher Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 102,000 Â Loss on debt extinguishment Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (387,329) Total other income (loss), net Â $ 11,810 Â Â $ (12,332) Â $ 32,631 Â Â $ (268,020) Â *Related to the change in fair value of the contingent consideration derivative liabilities and the 2017 Capped Calls derivative assets. For more information, please read Note 4, Fair Value Measurements and Note 10, Indebtedness. X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R36.htm IDEA: XBRL DOCUMENT v3.24.3 EARNINGS (LOSS) PER SHARE (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Basic and Diluted Net Loss Per Share The following table sets forth the computation of basic and diluted earnings (loss) per common share: Â Â For the Three Months Ended September 30, Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â Â (in thousands, except per share amounts) Â Numerator: Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss) - basic Â $ 33,611 Â Â $ (40,937) Â $ 76,190 Â Â $ (581,632) Add: interest expense, net of tax, on the Company'sÂ Â Â Â convertible debt Â Â 413 Â Â Â â€” Â Â Â 1,182 Â Â Â â€” Â Net income (loss) - diluted Â $ 34,024 Â Â $ (40,937) Â $ 77,372 Â Â $ (581,632) Denominator: Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average common shares outstanding, basic Â Â 95,390 Â Â Â 88,889 Â Â Â 94,669 Â Â Â 88,609 Â Effect of dilutive securities: Â Â Â Â Â Â Â Â Â Â Â Â Common stock issuable under the Company'sÂ Â Â Â equity incentive plans Â Â 3,810 Â Â Â â€” Â Â Â 3,529 Â Â Â â€” Â Common stock issuable under the Company'sÂ Â Â Â convertible debt Â Â 1,248 Â Â Â â€” Â Â Â 1,374 Â Â Â â€” Â Weighted-average common shares outstanding, diluted Â Â 100,448 Â Â Â 88,889 Â Â Â 99,572 Â Â Â 88,609 Â Earnings (loss) per common share, basic Â $ 0.35 Â Â $ (0.46) Â $ 0.80 Â Â $ (6.56) Earnings (loss) per common share, diluted Â $ 0.34 Â Â $ (0.46) Â $ 0.78 Â Â $ (6.56) Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share The following table summarizes potential shares of common stock that were excluded from the computation of diluted earnings per share as they were anti-dilutive:Â Â Â As of September 30, 2024 Â Â As of September 30, 2023 Â Â Â Â (in thousands) Â Â Common stock issuable under the Company's equity incentive plans Â Â 2,464 Â (1) Â 12,111 Â (2) Common stock issuable under the Company's convertible debt Â Â 8,100 Â Â Â 9,542 Â Â Total number of potentially issuable common stock Â Â 10,564 Â Â Â 21,653 Â Â Â (1) As of September 30, 2024, the anti-dilutive common stock issuable under the Company's equity incentive plans excludes 1.2 million shares that are dilutive but have performance or market conditions that were not met as of the end of the period.(2) As of September 30, 2023, the anti-dilutive common stock issuable under the Company's equity incentive plans includes 1.1 million shares that have performance or market conditions that were not met as of the end of the period because these were anti-dilutive as the Company was in a net loss position at the end of the period. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the effect of income (loss) on an entity's diluted earnings per share. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52 + Details Name: us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R37.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES (Tables) 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations The following table summarizes the aggregate non-cancelable contractual obligations arising from the Companyâ€™s manufacturing obligations: Â Â Â As ofSeptember 30, 2024 Â Â Â (in thousands) Â 2024 (October-December) Â $ 600,021 Â 2025 Â Â 312,338 Â 2026 Â Â 119,238 Â 2027 Â Â 82,217 Â 2028 Â Â 72,306 Â Total manufacturing commitments* Â $ 1,186,120 Â Â * Total manufacturing commitments include the Catalent manufacturing and supply agreement, for which the Company has ROU assets and lease liabilities recorded on the unaudited condensed consolidated balance sheets as of September 30, 2024. X - DefinitionTabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Subparagraph (a) -Publisher SECReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock Namespace Prefix: srt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Nature of Business - Additional Information (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Â Cash cash equivalents restricted cash and investments $ 1,395,800 Â Â Cash and cash equivalents 197,855 $ 428,430 $ 541,932 Short-term investments 1,000,534 1,247,820 Â Non-current investments 181,770 $ 0 Â Investments 1,182,300 Â Â Restricted cash $ 15,600 Â Â X - DefinitionCash cash equivalents restricted cash and investments. + ReferencesNo definition available. + Details Name: srpt_CashCashEquivalentsRestrictedCashAndInvestments Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 48 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) $ / shares Jun. 30, 2024 USD ($) Mar. 31, 2024 USD ($) Sep. 30, 2023 USD ($) $ / shares Jun. 30, 2023 USD ($) Mar. 31, 2023 USD ($) Sep. 30, 2024 USD ($) Segment $ / shares Sep. 30, 2023 USD ($) $ / shares Dec. 31, 2023 Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Number of operating segments | Segment Â Â Â Â Â Â 1 Â Â Interest expense reduced $ 5,200 Â Â $ 5,200 Â Â $ 15,700 $ 16,800 Â Net Income (Loss) $ 33,611 $ 6,460 $ 36,119 $ (40,937) $ (23,940) $ (516,755) $ 76,190 $ (581,632) Â Earnings (loss) per common share, diluted | $ / shares $ 0.34 Â Â $ (0.46) Â Â $ 0.78 $ (6.56) Â Customer One [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member] Â Â Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Concentration of credit risk percentage Â Â Â Â Â Â 37.00% Â 40.00% Customer Two [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member] Â Â Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Concentration of credit risk percentage Â Â Â Â Â Â 27.00% Â 19.00% Customer Three [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member] Â Â Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Concentration of credit risk percentage Â Â Â Â Â Â 20.00% Â 19.00% Customer Four [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member] Â Â Â Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Concentration of credit risk percentage Â Â Â Â Â Â 12.00% X - DefinitionSummary Of Significant Accounting Policies [Line Items] + ReferencesNo definition available. + Details Name: srpt_SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: srpt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-

18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: srt_MajorCustomersAxis=srpt_CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=srpt_CustomerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=srpt_CustomerThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=srpt_CustomerFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R40.htm IDEA: XBRL DOCUMENT v3.24.3 License and Collaboration Agreements - Additional Information (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Product revenues, net $ 429,771 $ 309,322 $ 1,149,803 $ 779,805 Â Total Roche supply agreement revenue 37,401 22,495 93,764 66,750 Â Development Milestone and Upfront Fee Recognized as Research and Development Expense 0 3,800 0 11,900 Â ELEVIDYS [Member] Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Product revenues, net 180,983 69,108 436,640 69,108 Â Collaborative Arrangement Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Payment for option exercise Â Â 116,800 Â Â Research, option and milestone expense 0 Â 0 Â Â Up-front and development milestone expenses Â Â Â 7,500 Â Collaborative Arrangement | Maximum [Member] Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Contingent research milestone payments Â Â 34,800 Â Â Development Milestone and Upfront Fee Recognized as Research and Development Expense Â Â 2,700,000 Â Â Collaborative Arrangement | Research and Development Expense [Member] Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Research and development expense Â 3,800 Â 3,800 Â Collaborative Arrangement | Roche Holding A.G. [Member] Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Product revenues, net Â 22,500 48,000 66,800 Â Deferred Revenue 452,000 Â 452,000 Â $ 487,400 Deferred Revenue, Current 127,000 Â 127,000 Â 50,400 Research and development expense 61,500 34,900 101,100 83,400 Â Collaboration Receivable $ 66,400 Â $ 66,400 Â $ 29,800 Collaborative Arrangement | Roche Holding A.G. [Member] | ELEVIDYS [Member] Â Â Â Â Â Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Â Â Â Â Â Total Roche supply agreement revenue Â $ 0 Â $ 0 Â X - DefinitionCollaboration Receivable. + ReferencesNo definition available. + Details Name: srpt_CollaborationReceivable Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDevelopment milestone and settlement upfront fee recognized as research and development expense. + ReferencesNo definition available. + Details Name: srpt_DevelopmentMilestoneAndSettlementUpfrontFeeRecognizedAsResearchAndDevelopmentExpense Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMilestone payment to be paid by company upon specified research milestone achievement. + ReferencesNo definition available. + Details Name:

srpt_MilestonePaymentToBePaidByCompanyUponSpecifiedResearchMilestoneAchievement Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment for option exercise. + ReferencesNo definition available. + Details Name: srpt_PaymentForOptionExercise Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionResearch, option and milestone expense. + ReferencesNo definition available. + Details Name: srpt_ResearchOptionAndMilestoneExpense Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUp-front and development milestone expenses. + ReferencesNo definition available. + Details Name: srpt_UpFrontAndDevelopmentMilestoneExpenses Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details Name: us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=srpt_ElevidysMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=srpt_RocheMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R41.htm IDEA: XBRL DOCUMENT v3.24.3 License and Collaboration Agreements - Summary of Activity Related to Supply Agreement (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Total Roche supply agreement revenue $ 37,401 $ 22,495 $ 93,764 $ 66,750 Roche Supply Agreement [Member] Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Cost of sales 13,725 Â 15,379 Â Roche Supply Agreement [Member] | Contract Manufacturing Revenue [Member] Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Total Roche supply agreement revenue 27,891 Â 33,698 Â Roche Supply Agreement [Member] | Royalty Revenue [Member] Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Royalty revenue $ 9,510 Â $ 12,066 Â X - DefinitionRoyalty Revenue + ReferencesNo definition available. + Details Name: srpt_RoyaltyRevenue Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details Name: us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=srpt_SupplyAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=srpt_ContractManufacturingRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=srpt_RoyaltyRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Assets and Liabilities Measured and Carried at Fair Value (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets $ 1,257,931 $ 1,371,946 Â Â Contingent consideration 47,400 38,100 Â Â Total liabilities 47,400 38,100 Â Â Money Market Funds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 21,951 63,919 Â Â Commercial Paper [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 34,995 113,362 Â Â Government and Government Agency Bonds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 900,407 1,001,137 Â Â Corporate Bonds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 233,245 130,380 Â Â Strategic Equity Investments [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 4,723 6,527 Â Â Certificates of Deposit [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 17,988 56,621 Â Â Derivative asset Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 44,622 Â Â Â Level 1 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 39,168 69,446 Â Â Contingent consideration 0 0 Â Â Total liabilities 0 0 Â Â Level 1 [Member] | Money Market Funds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 21,951 63,919 Â Â Level 1 [Member] | Commercial Paper [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 0 0 Â Â Level 1 [Member] | Government and Government Agency Bonds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 13,494 0 Â Â Level 1 [Member] | Corporate Bonds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 0 0 Â Â Level 1 [Member] | Strategic Equity Investments [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 3,723 5,527 Â Â Level 1 [Member] | Certificates of Deposit [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 0 0 Â Â Level 1 [Member] | Derivative asset Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets Â Â Â Level 2 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 1,217,763 1,301,500 Â Â Contingent consideration 0 0 Â Â Total liabilities 0 0 Â Â Level 2 [Member] | Money Market Funds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 0 0 Â Â Level 2 [Member] | Commercial Paper [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 34,995 113,362 Â Â Level 2 [Member] | Government and Government Agency Bonds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 886,913 1,001,137 Â Â Level 2 [Member] | Corporate Bonds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 233,245 130,380 Â Â Level 2 [Member] | Strategic Equity Investments [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 0 0 Â Â Level 2 [Member] | Certificates of Deposit [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 17,988 56,621 Â Â Level 2 [Member] | Derivative asset Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 44,622 Â Â Â Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 1,000 1,000 Â Â Contingent consideration 47,400 38,100 Â Â Total liabilities 47,400 38,100 $ 36,900 Level 3 [Member] | Money Market Funds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 0 0 Â Â Level 3 [Member] | Commercial Paper [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 0 0 Â Â Level 3 [Member] | Government and Government Agency Bonds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 0 0 Â Â Level 3 [Member] | Corporate Bonds [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 0 0 Â Â Level 3 [Member] | Strategic Equity Investments [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 1,000 1,000 Â Â Level 3 [Member] | Certificates of Deposit [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets 0 $ 0 Â Â Level 3 [Member] | Derivative asset Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total assets $ 0 Â Â Â X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. +

ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=srpt_CorporateBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=srpt_StrategicEquityInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=srpt_DerivativeAssetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Summary of Fair Value of Level 3 Financial Liabilities (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Fair value at the beginning of the year Â Â $ 38,100 Â Change in the fair value of contingent consideration $ 800 $ 2,000 9,300 $ 1,200 Fair value at the end of the period 47,400 Â 47,400 Â Fair Value, Inputs, Level 3 [Member] Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Fair value at the beginning of the year Â Â 38,100 36,900 Change in the fair value of contingent consideration Â Â 9,500 2,000 Liabilities Terminated Â Â (200) (800) Fair value at the end of the period $ 47,400 $ 38,100 $ 47,400 $ 38,100 X - DefinitionLiabilities Terminated + ReferencesNo definition available. + Details Name: srpt_LiabilitiesTerminated Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties. + ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesFairValueAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Nov. 14, 2017 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Impairment of equity investment Â $ 0 $ 27,500 $ 0 $ 27,821 Â Other income (expense), net Â 11,810 (12,332) 32,631 17,309 Â Debt instrument, face amount Â 1,285,476 Â 1,285,476 Â Â Fair value of contingent consideration liability Â 800 2,000 9,300 1,200 Â 2024 Convertible Notes [Member] Â Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Â Debt instrument, maturity date Nov. 15, 2024 Â Â Â Â Â Debt instrument, face amount $ 570,000 91,640 Â $ 91,640 Â $ 105,847 2024 Convertible Notes [Member] | Level 2 [Member] Â Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Â Debt instrument, maturity date Â Â Â Nov. 15, 2024 Â Â Debt instrument, face amount Â 570,000 Â $ 570,000 Â Â Two Thousand Seventeen Capped Call Transactions [Member] Â Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Â Other income (expense), net Â Â Â 700 Â Â Lacerta Therapeutics Inc [Member] Â Â Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Â Impairment Loss Â $ 0 $ 27,500 $ 0 $ 27,500 Â X - DefinitionImpairment Loss + ReferencesNo definition available. + Details Name: srpt_ImpairmentLoss Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1 + Details Name: us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties. + ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesFairValueAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=srpt_TwoThousandAndTwentyFourSeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=srpt_TwoThousandSeventeenCappedCallTransactionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=srpt_LacertaTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Cash, Cash Equivalents and Marketable Securities - Summary of Company Financial Assets with Maturities of Less Than 90 Days Included in Cash Equivalents (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Cash and Cash Equivalents [Line Items] Â Â Cash equivalents $ 26,282 $ 117,599 Money Market Funds [Member] Â Â Cash and Cash Equivalents [Line Items] Â Â Cash equivalents 21,951 63,919 Commercial Paper [Member] Â Â Cash and Cash Equivalents [Line Items] Â Â Cash equivalents 2,330 53,680 Corporate Bond [Member] Â Â Cash and Cash Equivalents [Line Items] Â Â Cash equivalents $ 2,001 $ 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Cash, Cash Equivalents and Marketable Securities - Summary of Company Cash, Cash Equivalents and Short-term Investments (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Cash and Cash Equivalents [Line Items] Â Â Â Cash and cash equivalents, Amortized cost $ 1,377,887 $ 1,675,305 Â Available for sale debt securities, Gross unrealized gains 2,307 1,124 Â Cash, cash equivalents and investments, Gross unrealized gains 2,307 1,124 Â Available for sale debt securities, Gross unrealized losses (35) (179) Â Cash, cash equivalents and investments, Gross unrealized losses (35) (179) Â Cash and cash equivalents, Fair value 197,855 428,430 $ 541,932 Cash, cash equivalents and investments, Fair value 1,380,159 1,676,250 Â Cash and Money Market Funds [Member] Â Â Â Cash and Cash Equivalents [Line Items] Â Â Â Cash and cash equivalents, Amortized cost 193,524 374,750 Â Cash and cash equivalents, Fair value 193,524 374,750 Â Commercial Paper [Member] Â Â Â Cash and Cash Equivalents [Line Items] Â Â Â Cash and cash equivalents, Amortized cost 34,995 113,362 Â Available for sale debt securities, Fair value 34,995 113,362 Â Government and Government Agency Bonds [Member] Â Â Â Cash and Cash Equivalents [Line Items] Â Â Â Cash and cash equivalents, Amortized cost 898,726 1,000,302 Â Available for sale debt securities, Gross unrealized gains 1,704 1,006 Â Available for sale debt securities, Gross unrealized losses (23) (171) Â Available for sale debt securities, Fair value 900,407 1,001,137 Â Corporate Bond [Member] Â Â Â Cash and Cash Equivalents [Line Items] Â Â Â Cash and cash equivalents, Amortized cost 232,654 130,270 Â Available for sale debt securities, Gross unrealized gains 603 118 Â Available for sale debt securities, Gross unrealized losses (12) (8) Â Available for sale debt securities, Fair value 233,245 130,380 Â Certificates of

Deposit [Member] Â Â Â Cash and Cash Equivalents [Line Items] Â Â Â Cash and cash equivalents, Amortized cost 17,988 56,621 Â Available for sale debt securities, Fair value 17,988 56,621 Â Cash and Cash Equivalents [Member] Â Â Â Cash and Cash Equivalents [Line Items] Â Â Â Cash, cash equivalents and investments, Amortized cost 197,854 428,430 Â Cash and cash equivalents, Gross unrealized gains 1 Â Â Cash and cash equivalents, Fair value 197,855 428,430 Â Short-term Investments [Member] Â Â Â Cash and Cash Equivalents [Line Items] Â Â Â Available for sale debt securities, Amortized cost 998,884 1,246,875 Â Available for sale debt securities, Gross unrealized gains 1,667 1,124 Â Available for sale debt securities, Gross unrealized losses (17) (179) Â Available for sale debt securities current, Fair value 1,000,534 $ 1,247,820 Â Non-current investments [Member] Â Â Â Cash and Cash Equivalents [Line Items] Â Â Â Other Non-Current Assets Amortized Cost 181,149 Â Â Available for sale debt securities, Gross unrealized gains 639 Â Â Available for sale debt securities, Gross unrealized losses (18) Â Â Available for sale debt securities, Fair value $ 181,770 Â Â X - DefinitionCash and cash equivalents amortized cost basis. + ReferencesNo definition available. + Details Name: srpt_CashAndCashEquivalentsAmortizedCostBasis Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash and cash equivalents gross unrealized gain before tax. + ReferencesNo definition available. + Details Name: srpt_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash cash equivalents and investments. + ReferencesNo definition available. + Details Name: srpt_CashCashEquivalentsAndInvestments Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash cash equivalents and investments amortized cost basis. + ReferencesNo definition available. + Details Name: srpt_CashCashEquivalentsAndInvestmentsAmortizedCostBasis Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash cash equivalents and investments gross unrealized gain before tax. + ReferencesNo definition available. + Details Name: srpt_CashCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash cash equivalents and investments gross unrealized loss before tax. + ReferencesNo definition available. + Details Name: srpt_CashCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionOther Non-Current Assets Amortized Cost + ReferencesNo definition available. + Details Name: srpt_OtherNonCurrentAssetsAmortizedCost Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=srpt_CashDepositsAndMoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=srpt_NonCurrentInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail) 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Cash and Cash Equivalents [Line Items] Â Â Weighted average maturity period of available-for-sale securities 7 months 5 months X - DefinitionWeighted average maturity period of available for sale securities. + ReferencesNo definition available. + Details Name: srpt_WeightedAverageMaturityPeriodOfAvailableForSaleSecurities Namespace Prefix: srpt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 57 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Product Revenues (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Product Information [Line Items] Â Â Â Â Products, net $ 429,771 $ 309,322 $ 1,149,803 $ 779,805 PMO Products [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Products, net 248,788 240,214 713,163 710,697 PMO Products [Member] | United States [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Products, net 210,683 198,069 604,598 602,415 PMO Products [Member] | Rest of World [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Products, net 38,105 42,145 108,565 108,282 ELEVIDYS [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Products, net 180,983 69,108 436,640 69,108 ELEVIDYS [Member] | United States [Member] Â Â Â Â Product Information [Line Items] Â Â Â Â Products, net $ 180,983 $ 69,108 $ 436,640 $ 69,108 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ProductInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=srpt_PmoProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srpt_RestOfWorldMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=srpt_ElevidysMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues (Additional Information) (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Products, net $ 429,771 $ 309,322 $ 1,149,803 $ 779,805 Â Revenues 467,172 $ 331,817 1,243,567 $ 846,555 Â Product sales receivable, net of discounts and allowances $ 434,500 Â $ 434,500 Â $ 400,300 Payment Terms Â Â As of September 30, 2024, the majority of the Companyâ€™s accounts receivable arose from product sales in the U.S. and all customers have standard payment terms that generally require payment within 65 to 90 days. Outside of the U.S., the majority of the Companyâ€™s customers have payment terms ranging between 90 and 150 days. Â Â Sales Revenue Net [Member] | Customer Concentration Risk [Member] | Customer One [Member] Â Â Â Â Â Concentration of credit risk percentage 28.00% 40.00% 33.00% 45.00% Â Sales Revenue Net [Member] | Customer Concentration Risk [Member] | Customer Two [Member] Â Â Â Â Â Concentration of credit risk percentage 19.00% 23.00% 20.00% 29.00% Â Sales Revenue Net [Member] | Customer Concentration Risk [Member] | No Individual [Member] Â Â Â Â Â Concentration of credit risk percentage 10.00% 10.00% 10.00% 10.00% Â Sales Revenue Net [Member] | Customer Concentration Risk [Member] | Customers Exceed [Member] Â Â Â Â Â Concentration of credit risk percentage Â Â 10.00% Â Â Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member] Â Â Â Â Â Concentration of credit risk percentage Â Â 37.00% Â 40.00% Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member] Â Â Â Â Â Concentration of credit risk percentage Â Â 27.00% Â 19.00% Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Three [Member] Â Â Â Â Â Concentration of credit risk percentage Â Â 20.00% Â 19.00% X - DefinitionAccounts Receivable Payment Terms + ReferencesNo definition available. + Details Name: srpt_AccountsReceivablePaymentTerms Namespace Prefix: srpt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -

Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-2 + Details Name: us-gaap_BilledContractReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=srpt_CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=srpt_CustomerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=srpt_NoIndividualMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=srpt_CustomersExceedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=srpt_CustomerThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summarizes the concentration of the three largest customers (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member] 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Customer One [Member] Â Â Â Â Principal Transaction Revenue [Line Items] Â Â Â Â Concentration Risk, Percentage 28.00% 40.00% 33.00% 45.00% Customer Two [Member] Â Â Â Â Principal Transaction Revenue [Line Items] Â Â Â Â Concentration Risk, Percentage 19.00% 23.00% 20.00% 29.00% X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479048/940-320-50-1 + Details Name: us-gaap_PrincipleTransactionRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=srpt_CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=srpt_CustomerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Change in Reserves for Discounts and Allowances (Detail) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Accounts Notes And Loans Receivable [Line Items] Â Â Beginning balance $ 164,772 $ 94,698 Provision 258,176 175,967 Adjustments relating to prior periods (8,021) (4,044) Payments/credits (249,433) (133,337) Ending balance 165,494 133,284 Chargebacks [Member] Â Â Accounts Notes And Loans Receivable [Line Items] Â Â Beginning balance 27,486 417 Provision 72,832 18,191 Adjustments relating to prior periods 783 110 Payments/credits (77,808) (9,386) Ending balance 23,293 9,332 Rebates [Member] Â Â Accounts Notes And Loans Receivable [Line Items] Â Â Beginning balance 98,194 67,493 Provision 118,228 94,025 Adjustments relating to prior periods (8,716) (4,154) Payments/credits (100,693) (73,317) Ending balance 107,013 84,047 Prompt Pay [Member] Â Â Accounts Notes And Loans Receivable [Line Items] Â Â Beginning balance 3,831 3,343 Provision 13,442 11,251 Adjustments relating to prior periods 0 0 Payments/credits (12,191) (10,586) Ending balance 5,082 4,008 Other Accruals [Member] Â Â Accounts Notes And Loans Receivable [Line Items] Â Â Beginning balance 35,261 23,445 Provision 53,674 52,500 Adjustments relating to prior periods (88) 0 Payments/credits (58,741) (40,048) Ending balance $ 30,106 $ 35,897 X - DefinitionAdjustments To Product Revenue Reserves Relating To Sales In Prior Years + ReferencesNo definition available. + Details Name: srpt_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments credits reserves for discounts and allowances. + ReferencesNo definition available. + Details Name: srpt_PaymentsCreditsReservesForDiscountsAndAllowances Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProvision for reserves for discounts and allowances. + ReferencesNo definition available. + Details Name: srpt_ProvisionForReservesForDiscountsAndAllowances Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=srpt_ChargebacksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=srpt_RebatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=srpt_PromptPayMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=srpt_OtherAccrualsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Total Reserves Included in Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Receivables, Net, Current [Abstract] Â Â Â Â Reduction to accounts receivable $ 56,773 $ 64,697 Â Â Component of accrued expenses 108,721 100,075 Â Â Total reserves $ 165,494 $ 164,772 $ 133,284 $ 94,698 X - DefinitionReserves for component of accrued expenses. + ReferencesNo definition available. + Details Name: srpt_ReservesForComponentOfAccruedExpenses Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReserves for reduction to accounts receivable. + ReferencesNo definition available. + Details Name: srpt_ReservesForReductionToAccountsReceivable Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesNetCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 62 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory - Summary of Components of Inventory (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Raw materials $ 208,320 $ 133,963 Work in progress 482,171 318,458 Finished goods 77,983 61,806 Total inventory $ 768,474 $ 514,227 X - DefinitionInventory current and noncurrent net. + ReferencesNo definition available. + Details Name: srpt_InventoryCurrentAndNoncurrentNet Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 63 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory - Summarizes the Balance Sheet Classification (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Inventory $ 565,924 $ 322,859 Non-current inventory 202,550 191,368 Total inventory $ 768,474 $ 514,227 X - DefinitionInventory current and noncurrent net. + ReferencesNo definition available. + Details Name: srpt_InventoryCurrentAndNoncurrentNet Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 64 R55.htm IDEA: XBRL DOCUMENT v3.24.3 OTHER ASSETS (Additional Information) (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Prepaid Expense and Other Assets, Current [Abstract] Â Â Â Restricted cash in other assets $ 15,579 [1] $ 15,579 [1] $ 19,149 [1] * The Company had approximately $15.6 million in restricted cash included in other non-current assets on the Companyâ€™s unaudited condensed consolidated balance sheets as of both September 30, 2024 and December 31, 2023. Restricted cash for both periods relates to (i) letters of credit established under the Companyâ€™s various property leases that serve as security for potential future default of lease payments, (ii) a letter of credit established under a certain commercial supply agreement and (iii) collateralized cash for the Companyâ€™s credit cards. The restricted cash is unavailable for withdrawal or use for general obligations. X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 65 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Other Assets - Summary of Other Current Assets (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Prepaid Expense and Other Assets, Current [Abstract] Â Â Collaboration and other receivables $ 66,404 $ 29,786 Derivative asset 44,622 0 Prepaid maintenance services 13,326 11,281 Prepaid clinical and pre-clinical expenses 12,034 10,280 Tax-related receivables and prepaids 11,422 6,862 Prepaid commercial expenses 3,982 2,729 Interest receivable 3,637 2,731 Prepaid insurance 2,198 3,352 Other 7,852 10,693 Total other current assets $ 165,477 $ 77,714 X - DefinitionCollaboration receivable current. + ReferencesNo definition available. + Details Name: srpt_CollaborationReceivableCurrent Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrepaid clinical and preclinical expenses current. + ReferencesNo definition available. + Details Name: srpt_PrepaidClinicalAndPreclinicalExpensesCurrent Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrepaid commercial. + ReferencesNo definition available. + Details Name: srpt_PrepaidCommercial Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrepaid maintenance services, current. + ReferencesNo definition available. + Details Name: srpt_PrepaidMaintenanceServicesCurrent Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 + Details Name: us-gaap_DerivativeAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherAssetsMiscellaneousCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ValueAddedTaxReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 66 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Other Assets - Summary of Other Non-current Assets (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Prepaid Expense and Other Assets, Noncurrent [Abstract] Â Â Â Manufacturing-related deposits and prepaids $ 28,127 $ 74,204 Â Intangible assets, net 27,570 29,620 Â Restricted cash 15,579 [1] 15,579 [1] $ 19,149 Strategic investments 4,723 6,527 Â Prepaid maintenance services 3,907 5,466 Â Other 3,653 5,375 Â Total other non-current assets $ 83,559 $ 136,771 Â [1] * The Company had approximately $15.6 million in restricted cash included in other non-current assets on the Companyâ€™s unaudited condensed consolidated balance sheets as of both September 30, 2024 and December 31, 2023. Restricted cash for both periods relates to (i) letters of credit established under the Companyâ€™s various property leases that serve as security for potential future default of lease payments, (ii) a letter of credit established under a certain commercial supply agreement and (iii) collateralized cash for the Companyâ€™s credit cards. The restricted cash is unavailable for withdrawal or use for general obligations. X - DefinitionManufacturing related deposits and prepaid expense non current. + ReferencesNo definition available. + Details Name: srpt_ManufacturingRelatedDepositsAndPrepaidExpenseNonCurrent Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrepaid maintenance services + ReferencesNo definition available. + Details Name: srpt_PrepaidMaintenanceServices Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionStrategic investments noncurrent. + ReferencesNo definition available. + Details Name: srpt_StrategicInvestmentsNoncurrent Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherAssetsMiscellaneousNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-

gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 67 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Â Product revenue related reserves $ 108,721 $ 100,075 Accrued contract manufacturing costs 75,909 33,024 Accrued employee compensation costs 57,107 78,732 Accrued clinical and pre-clinical costs 40,514 34,669 Accrued professional fees 21,486 17,187 Accrued income taxes 14,696 13,766 Accrued royalties 12,185 12,070 Accrued fixed assets 4,821 3,231 Accrued research expenses 2,882 2,441 Accrued interest 1,118 4,395 Other 5,391 15,407 Total accrued expenses $ 344,830 $ 314,997 X - DefinitionAccrued clinical and preclinical costs current. + ReferencesNo definition available. + Details Name: srpt_AccruedClinicalAndPreclinicalCostsCurrent Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued contract manufacturing expense current. + ReferencesNo definition available. + Details Name: srpt_AccruedContractManufacturingExpenseCurrent Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Fixed Assets + ReferencesNo definition available. + Details Name: srpt_AccruedFixedAssets Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Interest + ReferencesNo definition available. + Details Name: srpt_AccruedInterest Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued product revenue related reserve current. + ReferencesNo definition available. + Details Name: srpt_AccruedProductRevenueRelatedReserveCurrent Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued research expenses. + ReferencesNo definition available. + Details Name: srpt_AccruedResearchExpenses Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 68 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Indebtedness - Additional Information (Detail) - USD ($) $ in Thousands, shares in Millions 3 Months Ended 9 Months Ended Mar. 02, 2023 Sep. 14, 2022 Nov. 14, 2017 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 Dec. 31, 2023 Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Debt instrument, face amount Â Â Â $ 1,285,476 Â Â Â $ 1,285,476 Â Â Â Other current assets Â Â Â 165,477 Â Â 165,477 Â Â Â $ 77,714 Other income (expense), net Â Â Â 11,810 $ (12,332) Â 32,631 $ 17,309 Â Â Partial settlement of capped call share options for 2024 Notes Â Â Â Â Â $ 80,645 0 80,645 Â Â Loss on debt extinguishment Â Â Â 0 0 Â 0 (387,329) Â Â Debt conversion costs for 2024 Notes Â Â Â Â Â Â 0 6,887 Â Â Interest expense debt Â Â Â 5,200 5,200 Â 15,700 16,800 Â Â Long-term debt Â Â Â 1,135,965 Â Â 1,135,965 Â Â 1,132,515 Aggregate long-term debt Â Â Â 1,227,560 Â Â 1,227,560 Â Â 1,237,998 Amortization of Debt Issuance Costs Â Â Â 1,200 $ 1,200 Â 3,700 $ 3,900 Â Â Convertible Debt, The Term Loan, The Revolver and The Mortgage Loans [Member] Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Long-term debt Â Â Â 1,227,600 Â Â 1,227,600 Â Â 1,238,000 2024 Convertible Notes [Member] Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Debt instrument, face amount Â Â Â $ 570,000 91,640 Â Â 91,640 Â Â 105,847 Issuance of common stock for exchange of 2024 Notes, shares 4.5 Â Â Â Â Â Â Â 0.2 Â Aggregate principal amount converted into equity Â Â Â Â Â Â Â Â $ 14,200 Â Debt instrument, maturity date Â Â Nov. 15, 2024 Â Â Â Â Â Â Â 2024 Convertible Notes [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Periodic Payment, Principal $ 313,500 Â Â Â Â Â Â Â Â Â Â 2027 Convertible Notes [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Debt instrument, face amount Â Â Â 1,150,000 Â Â 1,150,000 Â Â $ 1,150,000 2017 Capped Call Transactions [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Other income (expense), net Â Â Â Â Â Â 700 Â Â Â 2017 Capped Calls Partial Settlement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Partial settlement of capped call share options for 2024 Notes $ 80,600 $ 26,300 Â Â Â Â Â Â Â Â Â Â 2024 Notes Repurchase [Member] Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Debt instrument, face amount Â 150,600 Â Â Â Â Â Â Â Â Â Â Other current assets Â Â Â $ 43,900 Â Â 43,900 Â Â Â Other income (expense), net Â Â Â Â Â Â $ 700 Â Â Â Payment for full settlement of the principal value and accrued interest Â $ 248,600 Â Â Â Â Â Â Â Â Â X - DefinitionDebt Conversion Costs + ReferencesNo definition available. + Details Name: srpt_DebtConversionCosts Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance of Common Stock for Exchange of 2024 Notes Shares + ReferencesNo definition available. + Details Name: srpt_IssuanceOfCommonStockForExchangeOf2024NotesShares Namespace Prefix: srpt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPartial settlement of capped call share options for 2024 Notes + ReferencesNo definition available. + Details Name: srpt_PartialSettlementOfCappedCallShareOptionsFor2024Notes Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe carrying amount of the equity component of convertible debt which may be settled in cash upon conversion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period

Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of the required periodic payments including both interest and principal payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentPeriodicPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the required periodic payments applied to principal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermLoansPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=srpt_ConvertibleDebtAndTermLoanAndRevolverAndMortgageLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=srpt_TwoThousandAndTwentyFourSeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=srpt_TwoThousandAndTwentySevenSeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=srpt_TwoThousandSeventeenCappedCallTransactionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=srpt_TwoThousandSeventeenCappedCallsPartialSettlementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=srpt_TwoThousandTwentyFourNotesRepurchaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Indebtedness - Summary of Debt Facilities (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Nov. 14, 2017 Debt Instrument [Line Items] Â Â Â Principal amount $ 1,285,476 Â Â Total carrying value of debt instruments 1,227,560 $ 1,237,998 Â Total carrying value of debt instruments 91,595 105,483 Â Total fair value of debt instruments 1,479,084 1,317,109 Â 2024 Convertible Notes [Member] Â Â Â Debt Instrument [Line Items] Â Â Â Principal amount 91,640 105,847 $ 570,000 Unamortized discount - debt issuance costs (45) (364) Â Total fair value of debt instruments 171,154 144,833 Â 2027 Convertible Notes [Member] Â Â Â Debt Instrument [Line Items] Â Â Â Principal amount 1,150,000 1,150,000 Â Unamortized discount - debt issuance costs (14,035) (17,485) Â Total fair value of debt instruments $ 1,307,930 $ 1,172,276 Â X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DebtInstrumentFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -

SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=srpt_TwoThousandAndTwentyFourSeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=srpt_TwoThousandAndTwentySevenSeniorConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Indebtedness - Summarizes Total Gross Payments Due under Company's Debt Arrangements (Detail) $ in Thousands Sep. 30, 2024 USD ($) Debt Instrument [Line Items] Â 2024 (October-December) $ 92,351 2025 14,375 2026 14,375 2027 1,164,375 Total payments 1,285,476 Principal [Member] Â Debt Instrument [Line Items] Â 2024 (October-December) 91,640 2025 0 2026 0 2027 1,150,000 Total payments 1,241,640 Interest [Member] Â Debt Instrument [Line Items] Â 2024 (October-December) 711 2025 14,375 2026 14,375 2027 14,375 Total payments $ 43,836 X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtConversionByUniqueDescriptionAxis=srpt_PrincipalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtConversionByUniqueDescriptionAxis=srpt_InterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Stock Awards Granted (Detail) - $ / shares 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2022 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Grants, Stock options 6,442 50,875 327,920 1,135,799 Â Weighted Average Grant Date Fair Value, Stock options $ 55.16 $ 66.53 $ 67.39 $ 72.23 Â Grants, Restricted stock units 135,092 27,539 1,351,982 [1] 1,137,202 [2] Â Weighted Average Grant Date Fair Value, Restricted stock units $ 127.51 $ 118.05 $ 128.9 $ 153.02 Â Restricted Stock Units [Member] Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Grants, Stock options Â Â 97,460 502,225 38,500 [1] Included in restricted stock units (â€œRSUsâ€) for the nine months ended September 30, 2024 are 97,460 shares with performance conditions (â€œMarch 2024 PSUsâ€) which are related to the achievement of certain financial performance goals and regulatory approval of certain of the Company's product candidates. The expanded regulatory approval of ELEVIDYS in June 2024 resulted in the cliff-vesting of 44,300 of the 97,460 shares of the March 2024 PSUs during the nine months ended September 30, 2024. As of September 30, 2024, none of the performance conditions for the remaining 53,160 shares were probable of being achieved. Stock options and the remaining RSUs granted during the three and nine months ended September 30, 2024 have only service-based criteria and vest over four years. [2] Included in the RSUs for the nine months ended September 30, 2023 are 502,225 shares with performance conditions (the â€œMarch 2023 PSUsâ€), which are related to regulatory approval of ELEVIDYS and achievement of a certain financial performance target, both of which were achieved in 2023. Vesting of the March 2023 PSUs is contingent on the fulfillment of remaining service conditions. X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Stock Awards Granted (Parenthetical) (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2022 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Grants, Stock options 6,442 50,875 327,920 1,135,799 Â Expanded Grants, Stock options 135,092 27,539 1,351,982 [1] 1,137,202 [2] Â Stock-based compensation expense $ 43.5 $ 48.1 $ 134.6 $ 136.7 Â Restricted Stock Units [Member] Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Grants, Stock options Â Â 97,460 502,225 38,500 Remaining shares associated with performance condition Â Â 53,160 Â Â Vesting PSUs 44,300 Â 97,460 Â Â [1] Included in restricted stock units (â€œRSUsâ€) for the nine months ended September 30, 2024 are 97,460 shares with performance conditions (â€œMarch 2024 PSUsâ€) which are related to the achievement of certain financial performance goals and regulatory approval of certain of the Company's product candidates. The expanded regulatory approval of ELEVIDYS in June 2024 resulted in the cliff-vesting of 44,300 of the 97,460 shares of the March 2024 PSUs during the nine months ended September 30, 2024. As of September 30, 2024, none of the performance conditions for the remaining 53,160 shares were probable of being achieved. Stock options and the remaining RSUs granted during the three and nine months ended September 30, 2024 have only service-based criteria and vest over four years. [2] Included in the RSUs for the nine months ended September 30, 2023 are 502,225 shares with performance conditions (the â€œMarch 2023 PSUsâ€), which are related to regulatory approval of ELEVIDYS and achievement of a certain financial performance target, both of which were achieved in 2023. Vesting of the March 2023 PSUs is contingent on the fulfillment of remaining service conditions. X - DefinitionRemaining Shares Associated With Performance Condition + ReferencesNo definition available. + Details Name: srpt_RemainingSharesAssociatedWithPerformanceCondition Namespace Prefix: srpt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2022 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Stock-based compensation expense $ 43.5 $ 48.1 $ 134.6 $ 136.7 Â Grants, Stock options 6,442 50,875 327,920 1,135,799 Â Restricted Stock Units (RSUs) [Member] Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Grants, Stock options Â Â 97,460 502,225 38,500 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Grant Type Included within Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Â Â Â Â Â Total stock-based compensation expense $ 43,500 $ 48,100 $ 134,600 $ 136,700 Total stock-based compensation expense included in expenses 43,450 48,061 134,624 136,688 Subtotal 48,996 48,061 149,855 136,688 Capitalized stock-based compensation costs [1] (5,546) 0 (15,231) 0 Research and Development Expense Â Â Â Â Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Â Â Â Â Â Total stock-based compensation expense included in expenses 18,034 22,325 54,113 60,315 Selling, General and Administrative Â Â Â Â Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Â Â Â Â Â Total stock-based compensation expense included in expenses 25,416 25,736 80,511 76,373 Employee Stock Option Â Â Â Â Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Â Â Â Â Â Total stock-based compensation expense included in expenses 15,158 17,471 46,954 62,436 Restricted stock units Â Â Â Â Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Â Â Â Â Â Total stock-based compensation expense included in expenses 31,926 28,924 97,261 70,101 Employee Stock Purchase Plan Â Â Â Â Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Â Â Â Â Â Total stock-based compensation expense included in expenses $ 1,912 $ 1,666 $ 5,640 $ 4,151 [1] Prior to the nine months ended September 30, 2024, capitalized stock-based compensation costs were not material. X - DefinitionShare based compensation expense included in costs and expenses. + ReferencesNo definition available. + Details Name: srpt_ShareBasedCompensationExpenseIncludedInCostsAndExpenses Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after tax, of expense for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost capitalized for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=srpt_RestrictedStockAndRestrictedStockUnitsRSUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=srpt_EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Other Income (Loss), Net - Summary of Other Income (Loss) (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Nonoperating Income (Expense) [Abstract] Â Â Â Â Accretion of investment discount, net $ 10,749 $ 12,984 $ 34,319 $ 35,809 Interest income 7,584 9,838 22,753 27,532 Interest expense (4,918) (5,229) (13,916) (16,776) Change in fair value of derivatives* [1] 1,535 (2,000) (8,565) (1,200) Impairment of strategic investments 0 (27,500) 0 (27,821) Other, net (3,140) (425) (1,960) (235) Other income (expense), net 11,810 (12,332) 32,631 17,309 Gain from sale of Priority Review Voucher 0 0 0 102,000 Loss on debt extinguishment 0 0 0 (387,329) Total other income (loss), net $ 11,810 $ (12,332) $ 32,631 $ (268,020) [1] Related to the change in fair value of the contingent consideration derivative liabilities and the 2017 Capped Calls derivative assets. For more information, please read Note 4, Fair Value Measurements and Note 10, Indebtedness. X - DefinitionAmortization of Discounts Premiums Investments Cash Equivalent And Investments + ReferencesNo definition available. + Details Name: srpt_AmortizationOfDiscountsPremiumsInvestmentsCashEquivalentAndInvestments Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 25 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480238/815-25-50-1 + Details Name: us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1 + Details Name: us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization)

of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of other expense (income) that is infrequent in occurrence or unusual in nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483613/220-20-50-1 + Details Name: us-gaap_OtherNonrecurringIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 76 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Additional Information) (Details) $ in Thousands 1 Months Ended 9 Months Ended May 31, 2022 USD ($) Apr. 22, 2022 USD ($) ftÂ² Aug. 31, 2024 USD ($) May 31, 2023 USD ($) Sep. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Right of use assets Â Â Â Â Â $ 140,898 $ 129,952 Bedford Massachusetts [Member] Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Area of lease | ftÂ² Â 288,000 Â Â Â Â Leases, term of contract extend Â 10 years Â Â Â Â Letter of Credit Reduce $ 5,600 Â Â Â Â Â Collateralized Letter of Credit Cash Deposit $ 8,400 Â Â Â Â Â Undiscounted rent payment Â $ 307,400 Â Â Â Â Tenant improvement allowance Â $ 72,000 $ 2,900 Â 29,500 Â Reduction to right of use assets and lease liabilities Â Â Â $ 72,000 Â Â Right of use assets Â Â Â Â Â 92,000 Â Operating lease liability Â Â Â Â Â $ 131,700 Â X - DefinitionCollateralized Letter of Credit Cash Deposit + ReferencesNo definition available. + Details Name: srpt_CollateralizedLetterOfCreditCashDeposit Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLetter of Credit Reduce + ReferencesNo definition available. + Details Name: srpt_LetterOfCreditReduce Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionReduction To Right Of Use Assets And Lease Liabilities + ReferencesNo definition available. + Details Name: srpt_ReductionToRightOfUseAssetsAndLeaseLiabilities Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionArea of land held. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfLand Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNet cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromTenantAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash payments to lessor's for use of assets under operating leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForRent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=srpt_BedfordMassachusettsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R68.htm IDEA: XBRL DOCUMENT v3.24.3 INCOME TAXES (Additional Information) (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Provision for Income tax $ 395 $ 7,763 $ 12,841 $ 21,163 Effective tax rate 1.20% (23.40%) 14.40% (3.80%) Deferred tax asset valuation allowance $ 897,000 Â $ 897,000 Â Federal tax expense Â $ 4,100 Â $ 4,100 State tax expense Â $ 17,100 Â $ 17,100 X - DefinitionAmount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_CurrentFederalTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 78 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Earning (Loss) Per Share - Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Earnings Per Share [Abstract] Â Â Â Â Â Â Â Â Net Income (Loss) $ 33,611 $ 6,460 $ 36,119 $ (40,937) $ (23,940) $ (516,755) $ 76,190 $ (581,632) Add: interest expense, net of tax, on the Company's convertible debt 413 Â Â 0 Â Â 1,182 0 Net income (loss) - diluted $ 34,024 Â Â $ (40,937) Â Â $ 77,372 $ (581,632) Weighted-average common shares outstanding - basic 95,390 Â Â 88,889 Â Â 94,669 88,609 Common stock issuable under the Company's equity incentive plans 3,810 Â Â 0 Â Â 3,529 0 Common stock issuable under the Company's convertible debt 1,248 Â Â 0 Â Â 1,374 0 Weighted-average common shares outstanding - diluted 100,448 Â Â 88,889 Â Â 99,572 88,609 Earnings (loss) per common share, basic $ 0.35 Â Â $ (0.46) Â Â $ 0.8 $ (6.56) Earnings (loss) per common share, diluted $ 0.34 Â Â $ (0.46) Â Â $ 0.78 $ (6.56) X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_InterestOnConvertibleDebtNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting

Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 79 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share - Basic and Diluted Net Loss Per Share (Parenthetical) (Detail) - shares shares in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total number of potentially issuable common stock 10,564 21,653 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 80 R71.htm IDEA: XBRL DOCUMENT v3.24.3 Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Details) - shares shares in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total number of potentially issuable common stock 10,564 21,653 Equity Incentive Plans [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total number of potentially issuable common stock 2,464 [1] 12,111 [2] Convertible Debt Securities [Member] Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Total number of potentially issuable common stock 8,100 9,542 [1] As of September 30, 2024, the anti-dilutive common stock issuable under the Company's equity incentive plans excludes 1.2 million shares that are dilutive but have performance or market conditions that were not met as of the end of the period. [2] As of September 30, 2023, the anti-dilutive common stock issuable under the Company's equity incentive plans includes 1.1 million shares that have performance or market conditions that were not met as of the end of the period because these were anti-dilutive as the Company was in a net loss position at the end of the period. X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srpt_EquityIncentivePlansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R72.htm IDEA: XBRL DOCUMENT v3.24.3 Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Parenthetical) (Details) - shares shares in Millions Sep. 30, 2024 Sep. 30, 2023 Earnings Per Share [Abstract] Â Â Dilutive Securities, Shares 1.2 1.1 X - DefinitionDilutive Securities, Shares + ReferencesNo definition available. + Details Name: srpt_DilutiveSecuritiesShares Namespace Prefix: srpt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 82 R73.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations (Detail) $ in Thousands Sep. 30, 2024 USD ($) Commitments And Contingencies [Line Items] Â 2024 (October-December) $ 600,021 2025 312,338 2026 119,238 2027 82,217 2028 72,306 Total manufacturing commitments $ 1,186,120 [1] [1] Total manufacturing commitments include the Catalent manufacturing and supply agreement, for which the Company has ROU assets and lease liabilities recorded on the unaudited condensed consolidated balance sheets as of September 30, 2024. X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: srpt_CommitmentsAndContingenciesLineItems Namespace Prefix: srpt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_ContractualObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_ContractualObligationDueInFourthYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_ContractualObligationDueInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_ContractualObligationDueInSecondYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_ContractualObligationDueInThirdYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in remainder of current fiscal year. + ReferencesNo definition available. + Details Name: us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 83 R74.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Additional Information) (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Jul. 18, 2024 Sep. 30, 2024 Mar. 31, 2024 Mar. 31, 2023 Sep. 30, 2024 Commitments And Contingencies [Line Items] Â Â Â Â Â Purchase commitment Â Â Â $ 54.7 Â Amendment Implemented Fee Â Â Â 60.0 Â Thermo Fisher Scientific, Inc. [Member] | Supply Agreement [Member] Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Non-cash contract termination cost Â Â Â Â $ 62.7 Research and Development Expense [Member] | Supply Agreement [Member] Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Research and Development Expense Â Â Â Â 29.2 Research and Development Expense [Member] | Thermo Fisher Scientific, Inc. [Member] | Supply Agreement [Member] Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Research and Development Expense $ 55.4 Â Â Â Â Â Research and Development Expense [Member] | Thermo Fisher Scientific, Inc. [Member] | Roche Agreement [Member] Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Research and Development Expense Â $ 36.5 Â Â $ 36.5 First Installments [Member] Â Â Â Â Â Commitments And Contingencies [Line Items] Â Â Â Â Â Amendment Implemented Fee Â Â $ 20.0 $ 20.0 Â Installments Date of implemented fee Â Â Mar. 01, 2024 Â Â X - DefinitionImplemented fee + ReferencesNo definition available. + Details Name: srpt_AmendmentImplementedFee Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommitments and contingencies. + ReferencesNo definition available. + Details Name: srpt_CommitmentsAndContingenciesLineItems Namespace Prefix: srpt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definitioninstallments date + ReferencesNo definition available. + Details Name: srpt_InstallmentsDateOfImplementedFee Namespace Prefix: srpt_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionNon-cash contract termination cost. + ReferencesNo definition available. + Details Name: srpt_NonCashContractTerminationCost Namespace Prefix: srpt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe minimum amount the entity agreed to spend under the long-term purchase commitment. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=srpt_ThermoFisherScientificIncorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=srpt_SupplyAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=srpt_RocheAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=srpt_FirstInstallmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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`N_%C!.+U>RSF%2 M1([@2LFRR+F&FP^\Y'4FT)5QK-#K[S7O\@)^>8-.T/>K"_3ZY1OT$A4U^K:1 MG>)UKLX6&O 8KXML]^P/VV>3B6=?B>8MHL$JX9DXGT%)*=">BMGR MU0L]QTGVLU.=]N>)J@V#64&8NQ,^NN.4E!.^8%^A#366K8/+F21]4@6L=1"9IM10A*6NI%>V2Q%]EG M7G=K:.Q=6]0W)ZTH^UZ4BT:J A)KUBO40L,+=[>)':!P8*U3VPP'!"?8C3W9 M8T^\V/_2&]%"QS[L(2Z0B?WTB(5Q/)IF\5QC$,WQG2/,?5B_"8U+Y^!,;4> M3J*$T2@=@738L3BE="*5.!A(*? "O6Q!I[3ZH9]RTYT:4_63Y;3S=C3S 8N3 M9(3784=(C-E$6O$!B6(OWE[]

(+E&G1*>O.Z\'$U^&"2IA=-A1]*4D0F< \-A M+ZDLO\CZY"Z"U\;V/DYRE1 & O&2&T[G&(:)1-(!W["?H(:(_7T_9VG(PP) MCF,+JVTWT?+Q0$[8ST[;]J\VP'IFWR:>A#(V+BJ'&2O4BG\"Z\!/V$]0V^KW MX+/IAK(T32T"=1F2*&1Q- %Q8"8P'9I$7#,*%6(3KL<)BF$[H&# 2&_?QV(=8"%E .$@QZ6P?ZZ[$J&Q"1L&MT MHK99#),X"/ 8M6W'@A!/K'DR;.O\I'>L>I[" M:A-;E*:A#=9A!PII2@&3@?
B(G_@^/3WW#K[#T*DC: _:=AH3AJ90.M$?\M/=) M7X$FH [$1 M/['9XNBIXG-MS6RXCGW>=&('AB-^AMNVB:<0VM1%*&PT(CH&Z3 , T;H5(,8 M2([X26XEJZK8JN'M"<[C@L@
,WK]16J!*5E]F,C2UCVZM6+A.#X7;]!U].H4B]W/NK0O%W>3N.?2!=ZB?=R _:Q M<2F3A3EZ&;R%A8]!.+;HEI>FD]$Y!T?J0T'$(AW>B/;XE^1OS.E*%"AE!%R M9NG(3BL-%[!\G,FS"7E;PG?
FXHDS9/$PI M _,KZ(.$RIGB>4#P1.N(:78E&B^H:VM7C>?2\-[L0V>[KW3GS'$A#-:) _^5 Z MM\[4L26VTF;;3/0%>G"BZQ<.[.\,$0 3P4&NX'\A9\WMG M(+9*("2TSJ9M]\E-$1V$!'WRR'] -U*\;MO2F)MNG$[@M## A.(C'>R.'8<)22B=V='20$-0O(2Q2[JOR%Z.(MK1<3[G,-EZ'S7&-Q\+[-O.S\S-N;HE:H%&L8&;R-(1'M]OWA]D;+IG\%=RVU MEE5_N1$&PO=V]R:W-
H965T&ULK99=;YLP%(;_BL6F MJ96Z8"'278+4IJJVBTE1HVX7TRX<. E6 3/;)-U^_8Z!LI"2KVI"/DDXH -'E.XE1-K$CK[-JV51!!PE1'9)#BWZJ2W4V.V36*-(7E\$[Y.[/<"V!E-@(V(#! MTQ7)F"1K%N?
0EG;I-2B\S-_&VJ<=2JDSMM?;"1T-:Z!V:]3N>:AE)Q*6ZTA(M_@?"-N32L[?%XI7'#O/QN 9TKX;NO0F:*Y6W _=>@= =U$,1#5*C M#E_5RAD-:7'L()\2V: >U=2C\ZGW=^KH%
<>HUQUYE/9V@%L"O8'G#+T]57;H MOSV-GD]\I&TKRQ.XVR+;P>VM?=E\%'UE'\IA'Z9F-V__MKS_P)02P,$% @ *H!F6:IAY GO M!P %B< !@ !X;"]W;W)K25G,ZH
M#XT_#H]U+B_O/:1T\RR*;~66WDZV4NZN9[-RM>597%Z)'<_AFR=1 M9+&$M\5F5NX*'J^K05DZH[;MS;(XR2?SF^JS^V)^(_8R37)^7UCE/LOBXOL=
M3\7S[81,7C_XE&RV4GTPF]_LX@U_X/++[KZ =[,CRSK)>%XF(K<*_G0[>4^N M(T;5@ KQ->'/YO-A?3NQU17QE*^DHHCASX$O>)HJ)KB._S>D MD^-
OJH&GKU_9_UV)!S&/<V*M]J4463,8KB!+\OIO_-(§XF0 I3T#:#. OG4 :P:PMPYPF@'. M6P>XS8!*^JS67@5N&+)^W?$B5O-:6G&ND!DDY59ERX%;'_*5 MR+AU\;,HRTOKXDL>[]<)
<%Q:4^O+PJ*Z^.G2*K=QP4LKR:W/6[$Q:0:1\9_W4 M>7\SDR!'7=1LU5SZ77WMZ1M.?2F751Y');6A%(6"/CE\CPX'Q,PCC,9;T-99W M=)#P@>^N+&:_LZA-'>1Z%F\?SC Y?
^_7H[_\ZYU@L&-BL8J/]?!]X@>>[WEY MC4UL/=3!AZK:>%WNXA6_G4">E;PX\,G\G_\@GOTO+*ICDBW')(M&(NO$WSG& MWQEBG]\78KU?25AG.9?8'-3#O6JX:B>'N4-#WRV-&&$
M.&%@LRXN,G&^#S#W".N(=8]BW4&QG[_ON"I43=)9OTE_!\6 M@&'*?3G=Q/'NNHGC1YX]\@)+OW%HEN/01'^;IA-_[QA_;Y 7VG0:/XJZ250]
M0L@M>H%WGIE/OF/K66>B*'5"TLZ$Q4RWW.TE#-1GN>[-IYQ_E&Q/YQQ0L8I M.*6ZR&%"Z_'NZ?KR?.)K"V=APA@C ?$UJ2:,4(>YGH:+3%S@>*[;L[Z"H]I@
ML)@O1"FK:>4O.^46*H>C%G5QR1;CDD6C436F8CP.!'AF84&$P&%KHQ3\%,7 M_&65@MO*-U:WL"F66RTMLRD(C74+BA?IJ-%',MZFG MI:B)
(H'GZXLV0F"V1TX2N1,88K=&UAX,S2<(=ERLME6>KF%AIF*G'"QJ+&WC M(J"^.('6K18(CH0.T\O5$L%YMN-ZH:8=PP4D\'N*$3EQ\610_ /LM" -WED; MGH-
73ZL@Q&O8,$#W4V7YP-$X$*2L!+#)U.. X>P@9'H<3!P+61@:<4!PKDU. MS$$F@WZR M:4DKO52C@IFIQ7%"W],UFSCF4L\U9)LX FE-C/:$ EEHGX2HJ[ZUNV38[S9[
M5"B%%VFU$TVJ?2FJWD%/PD-\29L"DGOZ-87P;F>HZ^A"*4+H>J$/=);\TO< MP>[\J_):C=Y&?>7ZT29-!AWBCW;I4=F6H[)%8[%U9Z6UQ&38$W=GI5F-E[W; ML89-
6T+$J,0F;$HH8T92FCA&/4;TI$1^U8<-7D]*MNZ8#-OC_\1);CT5(JN< MBJK$]T4BBD1^5WLT=7[X5>Q7/5L$8II8(PQG(.M+R; QK9N/ MZ*E$J&C$"&();\+PA$=,*I;P"!WU IAU/
*T]9]TV']^.%5M/?(G4?#74,CX MY;4?8Z&@IBUDT$#TAH3 IK!9]#5[L41P06@;H<#H7+"M7D\RT-:-TF$W^N%M MJC&SZ.J:39#O>[KO1%#@8QU#L0FCA)RP=?6VKI,.N\Y?
N.PF/2K7-'V,>43? M:R&PJ6.'3#\00'"^1T)]Q6-T;@:"::8_HUF[2X0/>NK^M.O<"ZB"@H..>N8[M*MMR5+9H++;NO+1&F X;X2]YP>,T^0-V/!OHPE4?2(#+V5U/Z>JQZHAP^I$
MY\FTJ8SZQK(T48YQ9H6 "'#I&8J@3@\7NF%H33$].XXU]0Y5)N1,U@L"H_V8,*A,+M5]"(+S?5>/4(31N8'M MV7WR6_-)_<'*%,5%#HZK?.W%L#.L[T#BA6G0R?
YP81J3;3DJ6S066W=:6E-, MATWQ75PF*W0&ZG'!J7&]8L:R,U%3^\K13R$;6-@A"_3<0[B*[W4>JSJ7K&_WP"FI.!IVGE&+US=JK\S?8$:I"O*\.:?@/K5$V:+U_^(;Q
MF&S+4=FBL=BZ4]LZ=S;LW'O7*#.M<^@RW6XN%9@ __3S0HS-\8SC_"1BA;*;0V'^)Z7SVZI'U^1ZX7!/E\2:ZC^A&MEKY^8NQC7&R4F4SY$_P4
M%!NXUJ)^"*M^(\6N>LKH44@ILNKEEL=K7B@ ?/\DA'Q]HW[@^"C<_$]02P,$ M% @ *H!F6>,";T$J#@ BXL !@ !X;"]W;W)K=?6 D.N*$ M$E62LM/]]0O*JB 5Q I7V=?
$LL&SR5QB(]S< '=/-;-IW99%%WP>56MV]NK M9==MOKN^;N?+8I6WW]:;8JW^Y>7Z MZNYF][NWS=U-O>VJ'L57?WYBU_*C\NN_\7UW-^G1]0%F4JV+=EO4Z:
(K[VZOOH^]D2OL+=B5^*XO']NCGH'^4 M#W7J]?_P>G%[%?9W5%3%O.LA[A MU<-\R-MB6E?_*A?=\O8J00H6Q7V^K;I?ZLD]W-QK\^TVQ^E T M_P%@9GZ8[Q?
J@=0+GU?!V[Q<3%ZO@VF^*=4M^4#%&=#Y?+O:5KMZ_;E;%HVJ MZI7J!I9]^MPH@E?_K-OVZ^#U>EZO"E\<.3S.K+@OYV5W NU:O22'-R4^O"GQ M#IZ>@\AK_+UO
CR3J'/OPU()$T0AW$,&6FT2<4[.4!$J1+ ICP@\%C:HAAZHA@ZKFE7KWVV7> M%(K.(=7D1>W'E._:33XO;J_4V](6S4-Q=??7OT0_#O40)[V-'#I8E3Y3/, MD (33"*!&032
X'42Z#X7#3SLBWZSJ[>]#U &ZA1.Y@_=2MMWZU !%*GSN,X M#5/K-?2&'EE-LT$A!69(B01F,,,.S+!G,_/-OM%!#'G1QS8QYM8]3ZP&AAE0
M8())#"#1GZ@D7MI_*UHNYY"A=PUY;P?HG;4!=MUV8'$>?'&$L<=XDAF]XR8 M 04FF$0",XA+#L0E7N)>M^UV-[8I\H[;9C').S0:#8K6IZC^*8O_+S;:9+]4\ M/]BH 1%B-7&(8'%L#?
I3[QV-[2^'1!28$242F$%7>J K?2FZ?+VH-^C8QI@Z MC"1V)XH93V""220P@]SL0&[F)7>G;B:]CE[TY&Z4?LC[$1%B+',JF4:Q,P'W
MQAO;T@:%%)@A)1*8P484:ND<#FML/]\'A@"5=:_QU@]*+O?NB?JS4@ T^*GN MBC;X+:^V!2B,0Z<">4:(W3BF_KL:R]K J (UJL1",YD[,CVBR[K)IZGE@;GZ
MF+EO@G;ONO,J^IIK#,4A28:)#AVY77(*;/;IO>^1K?-04$%:E")A692 MIZV4R.^EO%\W15Z5_U5$?JF"BJ)FU>J2E,,=\V95?V M#7-=[CN\L\@=ZXU$L4N=9ANQ@P530QZ
HD5TV1.>RB1WT3Y29&P-S&?+$V0 M"]>_F+"()\RA]4U0443J&AR0)68C&CO)/*;)T>6[9N\.7B1!"3&-3>2*$ZH M+<[VY7RF+0#%(AI&SEP0*#BA46:_UE
I&O,LBTY4D'8E(K\M<<*X/5]9J.Y$ MY-H3&5$59EM4D1^5V*,6L3D>L(@(L3^W+>%]V%@IW@S!;5*T!%ZAH@O-7&75KD+L=Q4&3:-B5[5/6!IQ$MM+K*AF 2J:0$63
M6&@F;=I2B/V6PM$0[*[8]$XU/#U]B%U]GW!*F.WT[,MY%\A=*!8SGC)K;!% MP0DGUKJAA$I1FD4I3^$1*#Y*QB6/V"-0.$$=N 1@TJ4-$D M%IK)HQ;H\;!DAR'SY-C5K:"HV)?
SON@N%"PJ@(* J !+^41%K'5P[-?!EXH* M/^SH%]U5E9"H0 TJ4-$D%IK)HU;/\?-3#T > ?F;\LA^Y3'7]F>#8@K4F!(+ MS:1':_?8K]V?FQGBAQ_=W%P-GSIM#57 HZ))++#233"W@8[^
'Y\?X@<<31^0 M)D!M^C C"E0TB85FTJ?=A=CO+HQ9F8Y=#X F[BJG/^+H_G%04($:5&*AF:1H MJR#V6P4OL)(2NUZ!$A'0&+%-+.)M05 $"P E@ ,P"*11DAJ9WM
M"Q2<1*&]I":A8I2R4.F"$S6DQ3VY2-R?KRU4<4(=:_DIEVOJ.(>%4UBH9D\ M'FUD\(O[2S4/<>5TEB;$?N=1E]@'Q12H,246FDF/MA:(WUIXKN;QPX]N;]% M$-
'8;FRH!@,JFL1",]G4!@/Q&PSC18\?<#1_KFE@+_O,4",*5#2)A6;2IPT(MXC<@D%/CB>L@,.:LY_CO:707.B2F0(TIL=!,UK330%YL0X.W9T6U(XAK1R1V M^B=J1(&*)K'03(ZU'4'P[@".
-IZ-BU_HBCV]V@H (UJ,1",TG1=@3YXG8$ M@;88../V]=N8[!?]?*(! ,5(2'EL.PM M0?7^VN\YF&>@T")RXCT_.K/@HCR#\W6%:@)0*,\@L37$##6H0$636&@FC]H&
MH"^39T!=^1XQEMBY-?[HHX?<04$%:E")A682I(4^?=E, S_\Z ;G:O8X=(85 MU%0#5#2)A6:RJ0T BIUJX <U@V"-(K* F=]K)8'XG8Y#UQERC@?#(3GB?^D.-9@/5
MMD!%DV["7\]AY/P* 8B2),FYG 0$%)SR+[%<: M-"2B,,SHB0K2A@2[R) X7UFHA@0## E*G7$<-:A 19-8*:/1TV/EC P HV'@#"KK&&U#(;[PQ[0>PBTX-.%]7]#X @TX-<(TWU* "
M%4UBH9D\:B> ^9T _+W4S-7V=CJN_YY&C\.H/@$JFL1",]G5/@'S^P3#)D_ M880\L@>+J3_4:-)0CS= 19-8:"9IVB9@?IO@Q.(F/&UPU7H4QU&8V.;-ON#Q MV!,YTP$7C+$T38GM;
,%8_4$/[^.#T#!<@(H",@) MJ)173G"M?OE%Z_CG*PMU'9\#Z_B G$ -*E#1)!::R:/6S?QE]A1P5ZF2(S)GH M3[DKH>W5E!-(]NX__W/]12 %?Y\(+.NM03G?@"G^W*5*/_SHMN-*
<6KW,S/4 MD (536*AF6QJ(X00$636&@F?T=?>N W"L8LB' H M%9_;V753?\2Q2F184($:5&*AF:1HU<\';@# .;6;NY(_HE']\(8J^X<%%:A!
M)1::R9O6_S"=?]+S^SVQQO=5[I.0I39.T]10PI4-(F%9M*KE3__XML#."* MB2WHI_[&MTR4=,#!CV!Q(II?D&,-B02A T""? U Y3;/IL_TE@N4-$$*IH\
M5Q\F%]I42"XZJ0#4R8DKW:,P24+N?!^/ZRHX_AD QF@:)<[B#5!P$H7$PI-0 M,4I#PLD)7R'1OD+R[+,*X/I"]142P%=@<6H;:*A!!2]:Q&(S>=2^0O(ROD("
M[16PS]28^H./[HJ&Q!27Q 0-" 0@DQ1M0"0O:T#XX4 B&P#:88:4J"B M22PTDTUM0"38!H0?<#1_K@%AXWYP!$%*IK$0C/IT_Y#\D5/*$@ MX!36^GZ M[VETQSDDID"-*;'03-
:.OG'Q_W)"@3_JZ)8')'CHS%U0DQ-0T206FLFQ-C,2 MO!,*$NBP@"RS3]WS1QS=[@8%%:A!)1::28JV()*!>Q1PG,$$R$^P.4/U'LX' M%*@!)1::^56GVGA(_<;#FW11WI?S7<-
YLOVB))@^I6]-\ZJ"O\H4V - TM3. M5_2"LO,L* "-:C$0C/9T59$^L4W'J2N*4#BQ-XSXK^OT=2A[CL8] 02*Z;) MG#9(4H1M!RF09=^GV=MDH&X[0$43J&CR;(68;&B;(QX\
[>!LCE<*Y$* *7%0 M0=O2 \K *7% 02 E#BCE3XE+M>F0^DV'2U/B_+!CI\2I:S9 *7&H004JFL1" M>^+QNET613?+N_SN9I-_+-[DS<=^(*B*>P4??MNKXZ;\N#Q\Z.K-[97J^S[4
M75>O=C\NBUR)GKZ ^OM]K69<^P_7"O^Q;C[M8MS]#U!+ P04 "]@&99 MKGP29G + #S, & 'AL+W=O.3\H53?JK40-7KX[.K,-(-C,7O4CQ4@\](NW)7EM_TET_9NY-
(Q*Y2&O=!8<_]^)2Y+GN M"7#\T75ZLG^G;CC\O.O]9^,\.'/*W%9YO^66;U^=Y*9/7-^7#/T7G M4*C[2\N\,O^BA\XV.$%I4]7EIFL,"#:R:/_RQRX0@P;0C[L!Z1J0<0,ZT8!V M#>BX
9MHP+H&S$2F=<7$X8K7_.)EVACX F M.VP_!X_V;I&=6Q^(M\-;L3U%-'B+2$"8 \.5RYM3#QRZCS(U_=&I*.L +DT MEZK<()BVBM>R6+5Y+VLIJC-7V-INF;M;71/.JBU/Q;L3F/254/?
BY.+'"W 4 M_.3R^4B='42 [2/ ?+U?_ 8E3!9IN1'H=5Y6U1N7MVT7D>E"%ZS[BSC"B^!\ M?C]TP[::A0F.*-G;'2 ,]PA#[QB]S_X'TZW-^;]$FI:612IS@8HQ=/US^E=' M-#SFB!ZILX-X1?
MX1=X1O1+0:2IY6[Z+#/%-J6KYIWG@\KSM+AR,&XE)M!B- MKFU%:4!"]]C&>ZRQ%^N-R)J69Z!.U6L!PZ?4DQFM3=ET54X_5YHF])>F$HA7
ME:B=U2RV0&)"DK$K#]L@HI';E63O2N*?2&4Q,\DGBUK J-9(/&YU!7?3.Q@ MQBP>P708+?#"C7*Q1[GPHKRMR_3;3!-RAF#F:("3>;&PPT19I,OV 4R7610E
MB1LH#GH"#+Q0WZ>I$8W8-AE<2_:(H R6:4Z-]J N"DM,!"-*.4Q6/@3CN2 M#,;A$/F NO'+4@$2 :1!.Q/3-59@; &)B)T/#K-@ BKIH9*7005XQ4KL MIN&22X7N>=X('?
Q,*'G/M0YTPR<6KB2,PC%ZVPJ#")YPH"=P[&7'BT^;+6 U MB0%(Q1^-K)\&V>(&3#V![-#:)B1.")Z V[,M]M/MK\J3"+(A$W>Z0&AB:F2U MUE"=2-GS2&T3FL243!0*W-
,N]K+4Q2^P.&DYM.*YR8-K)4NEXWLC[O7*X?>R M@>6.<@(GP=NF\QP "DQE1,] 6(_ _ZKGD)EQXA."!D#I(N 8G.7.WD3VYPXHPPOK%+IL,,!(V2JMO?\B?T$^GJ'^@W, MX1[_AA?-
$A1FHV!89TKD9K66B6U9R6Z (890JB9683:)S@@-0V9QEFT8)XL) MKTC/M<3/M<.AT,6SJ$QUY)*')Q)* TQ'@%U&88TPA.3F_3D2OSD.H1:ZHGN
MD8/$9LP97=!D7(I<=B1))A0AZ=F5^-GU:I AF5@*I2 IE(#X-L[T)C9'SFC(M\)A+7791%(=3P>W9E/C9= AX/R6W_$G/Q[?ZB6K @T[80IW*C?&@=)E,;X=E
M\-3I]\VP,TQMW>"TPR#KZ82S/1>3YY>^1OLT6@T?UN7]6M$)W:;<&5G$":5C M[Y#QB(ZM=8@/3D3_Z)XO''1*IX7+')/4=>YQ^KM, H]T1,_T5\W"G1K9<3) M5NGA
W&B,U#KP.V4J"(VO\\626*M#UQV81Q$4]6VEP+$O^H=PN.W7.9Z>LV6 MI9H9I56)%&AD,OGLU>MLH1=<%GR'(69QR(()+4-ZYB9^YO[,-=%UL=ZIP^_W MQ"9I'-
X""PN<1A2%I!H8O>![&Q._&P^' E8MX-"D^" CU$<1(V#H6;M(+OL M,*$3JISV3$W]3'VMRE2(K/K+RIS:Q#P&[S#Q"7/:]E!E7W M[LE9NIS '22=A.%8^KG,<(
9FT@6VK,Y)=]5PM"_2EVP6>U7"=^\6'ZFW MPR@,=LS]NP <6C4*EL)U"E]Y: 1/5V1R=Y!].K_;4I,I &>HOAXV:;ET] M(+,EA?8S$?I?*;YQQM&G &G86.K(8<86>)C0*
[37"]2O%ZZYJB7/H:K5=2YV M6PXIWV[U9AK/X989($T60R]P*"^E?W5WH# M(BUA[BES5)B65?TBR,\O[!TFLPCX=0)RS_;4S_;.ZN&:A$[<-ID[<\>Q0T!H M$$UL_-">\ZF?\X?
6COQMG5%"Y5[.)%MTC4&\=*IK7)J&KM],3!ZP QC"U? M'(:,L)A,U?&>_VGR;"5\F0/N>NA5%]]=#X_4VV$L>@E!_1+B@UC)HM)]$6H M "+.G#[;@H Q%@3CLPF'W2()DV B
5DO')A?.'S4"S,?0F:S/@&91<>ZTF$7 MPKH^F4+8JP.&O5EUTYWL=4=7IK;^K3QC7C7RO7EVK-X.H].K#^;?2S#J0WL^ M#H?3<\=F.RQ0PW&)<-B%#"^FCFQ9KQ*87R7<'
[/2S9KF$W;&.3=:(0BW _)L)M\UV MVPH:\$4?K^5EU2BQFX%&\\((MI>98&JZ)]M=U:.U=MA1'JIP?Q2PTPVO5N+ M,K.C:Q1K6SJ-1NJN'=3\T:TVF$-&X A;(VJ;+<)H*BE[K<'\6N-
Y].T)M1.Y MXW \Q-9M +?9U*$3ZY4%\RN+@U34E^FIREWA%KN#RF?66NRHVN)8O1U&H]<6 MS*\M/I>97,ITSX>0VG0H?SN7+/-)G1AV&N,\+ECA-$6 M2G?PX=J9TW,H;
[)VYW6\U]S>6QEM-SMO[=ABA-*$C7>0'&8P2.%$NH:]9 G] M&QJ_VOO?2E9ZRK67C^YJ+HTV?.']E=#>O" !C<9CYS"+%PF;V%4.>XT1/J,Q MRLT&,JU=JLNJTM'7!4,\=M<#3
[ZEH>A0W@PG(QUA\,L6E :3ZP1PXUQ9[MG2C*&CW\?9 MG2C*&CW\?9>PC6(LLA'4-.I%1>@7%3##)=0 _^2>$OYJXL&-F M2'9PU:OR'JV%]OT\$L2#HXC.(=MLRB$M, Z?]
0;^@D69!KZ!_H"O 0YM^7% M$UISF/%;J!6/$E2&R)_0*X3#TPAM9)YW-\24I2K[$M+*2T,3C5*ZP'0EJ&RO MM'3O^?&'A.#XIPHUN_NR>A>DNVJ;#J_:WO&<%ZE
Y@YOI<,+670'KT&W8EN+ MS1V\;G>3U8P&+/&[I[B]H(I.T5@'Z]ED^FCI6)]WZZ-B<[/QM7R#Y6MGYW>ZX'Q=C?IK(-:M# M_5\IT>Z;Z7!!G]!I6N8Z
*I+]WV07$YV+TVYRJ3DSQ60IAQW1U$F(X>9+W. M%\ &/!-EU_]*4*_4ZHT+ESZXP0W>K,Q->$"BV:J]PKI_NK]M M_I<,1\]_X#/KK#K.3F[=-F_#\.SJS!T_A+M+O3/>TCM?P?XS-
5*0GG+Q1+@ M!:Q!C-*6!YFD+Z/D) MV?0U4]LN/,6KB,L%W>]E<(46B#]GN42QBG"+"884+3L:_=F=^9(O1+\ MBM&&[8R!S.2%D%.L^ M5KF+7%X@0P\D^1V'/.IK;0V$:
GSA#^1S125^;C2+R)4[]@4VA=5P-!SCA) M2UCL((UQ\0_?RONP YBG *LK/ .0'8)6 W!9P2<)H";@FX30&O!+RF0*L$
M6DWO4KL$VDTC=$J@H\JA>'[JX0\AAWZ/D@V@4BW^5PAV]0;8RL_^R!M05^B%G5-O)\^F+LM@@/J:.'P8HFND^9_F9[QM:[* M+FDVO*39Z))FXTN:32YI-
KVDV>Q"9GMU[%1U[)QS]W^(QFB& Y(BOMXMRF.5YWC&OFA88R6<.ONJT;'JUC$Z=FM?-JZ1
M67;'.8@YJ9&YIM=RW7W=]%C7\LS.@=NLSJUM>K95Z8H'H>\IZ#M8'9G=BUJQ/1;M8='?_[(M>4WQJ5S%F($%+$8_N!0B!)0P !@
!X;"]W)W)K'+\DL0TX;88%6[H@2;8/PS[0TDDB(I$J2=G)O]^1 MLA4'4SB0@0\D$D4^SSUWQ[M<%CNI'G6):."IKH1>']4QS448ZK3$FNF1;%#0 M3BY5S0PM51'J1B'+'*BNPB2*IF'-
N A6"_?M3JT6LC45%WBG0+=US=3S%59R MMPSBX/#AGA>EL1_"U:)A!3Z@^:.Y4[0*>Y:,UR@TEP(4YLM@'5]PKFRD?+2+FVP91%815I@:2\'HL<5/6%66B71\VY,&O4T+/'X_L/_L
MG"=G-DSC)UG]Q3-3+H-Y !GFK*W,O=S[@GN')I8OE95VOV'7G1W3X;351M9[M,"FHN>B>[&D?B"/ /'H#D.P!+A!A9\BI_,P,6RV4W(&RIXG-OCA7'9K$<6&S M\F 4[7+"F=4-
Q3=#!5\5R[@H8*T4$P52W(U>A(8LV'-ANF>[ZMB2-]C&<"N% M*35SUVM.,W:(>\ M/8'-,]R(C&]YUK)JR/F.]&R8U-;/A6Y8BLN "D2CVF*P>O\NGD:7'LEGO>0S
M'_OJEAE4G%7P%56M0>9#*1L2[:>],5C#9 2_FY)NP8WHZMS6RP@^M\KRTP[] M*$2HN^2CB3T&Q:@B[(52?GQ/X3;9<(]Q+4B9?ZT8Q8/.DW1"<&$D,)$!RR1A MZ0D[Q8U!
4W%!)!M9TRS"JV#LJ7V@2FI,!PU;3$#7%N:3@&Q:=*]\V<'2R4E MSTK7H!M,>Z73']&8IC] \JR7//,&]PNK M<4B3'S74*#QBYKV8N9?VN(J.8@CKKN,,Z?
03&M6B1]=YK^O<'R0I3K]#FY\T M9Y7VB8NCER$@\C*M#VU"9HC!9/X?_E53\4DZFDMB+^7U4\,5\XOR,_RGC_ET M)2^Z$K^K1:&PL*URO66\8IMJ6%O',G$L=C3>KI(Y=[?
J6J8+^3$&%.4&CT8QLJVXF[19&-FX.W$A# M4Z5[+6F.1V4/T'XNI3DLK('^/X/5OU!+ P04 "]@&99+_(FXE\' "2 M$0 & 'AL+W=OK#"E7DN[>]",K,\ZPP[S<2<FJ>=
M)_KGIX6U44!Y*;T\/[5F*2Q+0QL_!%/#:H!3FH,R]19O%=;Y M_O'WR9W-[]//MW?IS=W5='K:]]B(Q?MQK?2B M4CIZ0>F)N#7:ITYZ7GXL%D*E;DQ!^3R'F++/G/+H,K?0>
[]7'EO'.%C.FL@])P M9!?4.?_YS?!H\/X5M ,966"B_%IY2L+*CT*G9= M<:/CGMCS9DX>\TA9GPKEG5BF)LM6^V:I*4&=1TXE2EIXMRM^?G,\&@W>U_K"
M:/A>&^N@H7GYP>2%U*OZY:]".2%%;/*<;*QDMN\\>$)$RA2I1$7& 8[,6(37 MB9E!Q6!G5'M*6<'A+:17I '-I]:4\S1LER@7FP79E9 Z00TOP$T%F,8+,E
M5M]*$H]WDVTO+2R$0K]E_9PTU5.5!A.\P-,0V!06N4EDICSUZRVU8,[?;.9 MA3L8#H%87$],BB);,6QV9F%- =\!Q*HK4K +/)NHV8PL%BO)N'ASI;592.8V MX2E.M; MVEU##
(T/%F=;KHTAJ!*@KS:7(K)&)O"H1HY@\\:K58R5,S8)YBD=9V7'>INM MN^*CRJ/]N;))M@,K!ZJ!^_&WVTNW!;6*O:;2FG8ES\> ; $9/EV8$IZ&-LK7 M0'I<4HV??W%K3RH='/FY-
^UUQ=6_[^\NOT[%X5#L(1.+3%E'^E<4X)]U6VN0 MK24;>%WQY6L]-Q9[<^1%\N+JM>26<9/;:OK@4.S%TJ$;OZ1@+;G>?HE,%7$ M)*1J'*,5VRIM0_K
.=&JM55<&U,E]*4MYV*2H-FID)YAFPV6N+ZCHC1"VO@/)0)2@^9BH]4S8/A>(KW%@5"*=))=V0A_2!W:!:1D@Z;P0] M0_X0F*J'<8 *@SKW4J.'23
M!'A^^/8]4C0U#G\05S(/I0=^LYA!;S$"OW.#!&E3 KI;E7R6YBN6JOV&Y/6 MK+5B-_#TZ[[8[=.>N.+WK5;%E03>2)B^#9=7#AH)*^M2J^,C=1"T6J)U(>"E
MKE(@*KV88D]+8\>/5EQOV\5Y"&=,1BX0 Y^:9P*@+D&2\;U3 MAG)H2;/.>N0QY^_2\B/ZK---V0%#]L);,OG3-QQ?0+94NWWU;;Y$0K6CZ3 M)ML]:6?VRCP".7F#&+3)BRS,0)
(PU)16K$A:AS@F57]HTSV,=J9WS56M9!V(MQBUL2^;,VG(&IA['75A*A*J"O9,J()N>%>X]X SQDQAVQR>'O6/<0;*LKAQTA+0;?@5] M*Q7\S!@#*1TFK8L8>7E:GE 5F\TH %CK4"IR?
>:JR[Z@W)&,CP> M]<:;\AO:PS((':.-B6^P[35?45$F<)QP]6\#"611#W']+*5WQLEI&N)B8FQ M?E;.E8TBGR*X./T:&[C?E;,9WSR0;^ G,$T2=HY+:T,.%E3U/LY]@*D..4V] MLFY-
SWA84K9@ON'[%D3M+3A)+:.R0:* M.1^^=1"KDCVN9>!-M$/E=A]8 0\H2:,]L:>V^T9U#JMN CBQ]7;=N_H;]V1T MJGGX&L %A[M@=65N9]L/#I/JGKT6K[Y6W.)JH
LHQF6#GIO#SO"5E\ JH$W M1;AU1\C#A\>4P*M6Q; ^YE!$ZD'O$'[&>;\+U!+ P04 "]@&99?+4- M[9H' !7$P &0 'AL+W=O+F#H?#?:"ELRB^R6Q)'+FS6/W=VO]
MG<2.6!8ZT,P5_S9Y7)_W7O543DM=%_.';7ZC)IZ?V%[FBB!_U2:M/3WIJ:P. MT97-9B HC4W_]6.3A\Z&5Z,G-DR:#1/!G1P)RE]UU!=GWFV4Y]6PQC\D5-D-
M<,9R4>;1XZG!OG@QO[^^GM[]1WUXI^97[V^NWEW-ICW+9'ORA.U?U+6S<1W46YM3?KA_")P[L),6[.7D M68-SJ@;]9-17D]'D]!E[)[O@3\3>R1/VIEGF:AN-
7:E;5YC,4%#_G2Y"]"#+ M_XX%G.R='K?'#?0Z5#JC\QXZ))!_H-[%CS^,?QZ]>0;MZ0[MZ7/6_V2IGK<] M&:@_;EY=ZF"'2*FJE+6SBUF;MX.>%VUB8#?4B-QH#R(-U+0H
MX#:2;U*B0"L;M*A10&AQP]&Q(5TZ!,#F#M+3-=?)!Q4&0L K!NI:6T@G)PX+ M N0([O 0F^-:)_2SQCMTW$O42(6SI *M>-]KE9N0N0="^E9]6'B 4%?RN]2V M7@)OS8\$:
[?:26;]KIB9-&I"@$&QJ6B>.2(K1+4$GFX2JEGHTP3)+$#BS,^ M?ODFL+,FDKY"Z93./T']A!*\12O+(ER@,%GM!0%24,.1I8Q"P$!1&%%8M]3&

MJZI+S'WJFJIRYF;D(V96AX/&IAG'6R1[X'AR"B*!6T6=-R2TML;Z8^Q]EJP[MFO75HHX='Q' OM2&MW$,0AI3XF;E?.)V[2N'9/:ERA***TV40-!V@;ZOUU18
MN[K(85#Q0&?,V/.IMFEB"FBNU>\;8G)X*F0!X@$K.!#>NR7M%?$ 4+^B4N6" MO#H9BX2?-*W.=($++L>^4[_FQS0E_4YR @(K'LIJ/'KQCS_DJ@_.:M0 M2,+XF:2]_RUPC+T;=
(Z09.A2O18"7UW/I;7.Q3(AR6P<,30)4&%X>^#2QEMW]M(AS]J"+-&R-?:!69J4J[:R# MSA*6+0KJ@Z(090D]G4C)-SIT B*!FKKF*F9; MM4!//F;$RD)Y=EPQ;FJ<@E""7'PU$-#6G-MV\ !
(%,?+HRTG!YAO.-#JJ@O) M IOO4J';;M\XZIA_OB&8XTSA-&I2CS4R?O)2_45A)?]CB),1?R(=/=F)4"8> M Y@2Q;9U>VS@N=H_Y?1T)$'[O^S_L~_QY'M\'QENAYW7)#O($;?0?@7)V4N)
M3$*88;IPJ">(@&+K^.- AZ<#U V$2DWZ:IX^<4AR?L M^S*P+0//NQJ5/*BP;@YEWrG8P?*NI)/.C*F;4S?/79W=U^-INECR7YY^N1T M#2JBA55!2VP=#5[^U$.CRV>
<=!%=)9].%BZ"0_)SC3J3YP5XOG0H>'/!#G;? MTB[^#U!+ P04 " J@&99TURSL!<* "O'0 &0 'AL+W=O*(F[(B*)*DEYO?WU9V9(2MJ;XP3MBZT+.?SF]LV,JG2A]#>3"6'94Y&7
MYJR765N]'0Q,DHF"FTA5HH0W,Z4+;N%6SP>FTH*GM*G(!^/A\'!0<%GVSD_I MV9T^/U6US64I[C0S=5%PO7POL<]EHH9KW-[MKQ:_"Z_/ 2VIC5>$W X)"ENX_?
)V>,F&L=\P)MSN($)Y MQ2T/]5JP32N!FEX0:K2;@ G2W3*@]7P5L(^>W[S\?+Z\\,UN_A\Q2YO;VXN MWM_>7WSY>/N97?QV?WW]Z?KSEX?3@863K^ 2!L8(X#S/?
C9P4^B"IBDV&?C8?CZ3/R)HW:$Y(WV2'O5L]Y*?_F&!E] M=JE*HW*9N>__C(Z'+Y[1KUIH][T.>D_[=7GI4XB]A+! M[$/$?E>S6<'+_1O.[A40";NQ:<0@CYB%&YMI(!P=0%KD>7#
<'CL\C([#HSXL-Y6@S,^7 M??0D)$5.8Z6=:[5X%&4-6(Q1X%X+0A?29G1B+A,@']%?VX*GJ,I=SD$/C 7V M&C?\^LOQ>#Q\YQ2^"._HZ>C=&R=XIVU>=W[3("915!(D72EL?MJ@,/C.R
MG.>$LHC!FBFXA=R+A/!5)S+N8]R.K]4P+])YMA0VB6;>9\D2J.M5?)"/0A M5;K3)V,6L;_PRFU=4WC57QDW;*YYB5JXAD1X+*TC6%+AI?@]ZH;(&ON(7#LD>2-
DSPMX;!JQ"X.2MF03^O9*)/[I:!OO91S5MF"+#2\X MO ?C#F!'A=/CHVC:,E^NTTJ3$^O^#^J%0-Y&DQO9#W"Y:#$Z'MF!$Q-KPP#.2U!91QO%
M=C0<1:/MU?;GR_V_@WXRC4[6T!]/NNFQ"OXG4W= 8P-4 MJX\E52>=TM/=F=WE(^I]'&-#4=. ">LY1'E5Y/6?AY5Z_^ $;;1;$?LS@SI.F-?7 MN"2C5U @$F%
(?"PP;$HQ5Y;89;./244.'M-DP095!VL#,&BGO.8V@*+LN@!G MMKI"4@"SLZK6T)T8X4RS'R_W5Y_@S"G!1S"CT*P!'%W6,[BHJ>EHBG^G4VF> MK5';[AASZ[U),!1(9Y3_W5@R[3SDC
'C3(9#^R,=G)K!7N?*F#>.PF> 02U0 MLJ7$=A\#Y-]@R]#R^41?;U!_C /?O@KL\X7V=>?1AI@^HZ#NFU>OR0:J-G". M>?/J.T:'K#[J'Y^,D%TF_<.3XU?
W:R[88R?]@]&02F%_>'@($@T5#L,QH^$X M6&>57C:DUQ1FB$SD-%H 3^#8W6UQ M/43,_='1.Q@X1"FL3(B4>25JN'9->1^+ AJNA>SHH C+&B8DWJ#KKSI MM* !B\
7_!O8LL)+JH9-.4+;-FJWPT\8B#JCWLKYH>9Q*GFCT>&JQ$196(6T MZ.,DR$, ,?::*=7U+FJB14L3 =04\#0/=;T9"SIV@2*=IM)-'%A&Y6S%:FAD MP3%65YJ][?9:J#I/7>
<%,1:D(M5A,T'=7C-*.R_OLG#'G5CGYS5$#R2X&QA= MVF_:>(6_FX?XN3$-51TBVF_W0>\/PHD_4 79KRU(_DM!VXF]I/]BV[^WT.>6 MHTX#""CJ:G^F%89_0-S)%=[.UBU5K#%(-
X5\O];Y3K&+R5PE^)X:_^SG)E)_ MTHEP4']+SH0N_@6*1NS*59,?+VYK+DIEBO:R;9+@4Y\&?7BE:0EU;6UH/Y/Q M$-=4N"&N8JK2H*Q*L-D$O!'[U&RX[>3$>JD(U.?
ZN97.HZ4PY(F<)XYZW=0H M+2S'9(R;SU>>?#GF>-GH$%C2HUX)RO)D0/AMP1AWBY@Z%(L6*KK.>/0% +C.^R95O4\ MPV=0?&
5E82VE<1,=R51+*'QVCV/;*7]%;NM\XX.H(JVX2P_[RVD[,ZB!!, M8]\-JEH?RO'KS6:_V<1$XX/PJ:S+KN*)>M9.!?$P XL@^VYZ#"W8E%YL'S(. M/>@2:-,5G):-$&&WYFUO9FBNHC
MX(S^"KNL?KQT#7XS"M.7HBZ+^2E^U([&Z[/I"YCL7QX<7EP17DR?T;:?6 := M']$@YN?T4R$&<5U:]WM:\[3Y-?+"_0C7+G<_97[B>BXA"G,Q@ZW#Z.B@Y[ZH
MA1NK*O1)+E;6JH(N,P'ID,8%\'ZF(/3]#1[0_$9[_G]O2P,$% @ *H!F M68A5&S(!#0 HB@ !D !X;"]W;W)K&ULS5K; M;MPX$GWW5Q>"8"!Y';??(L3 XZ3S XV#@9Q9O9AL0]LB=W-
M21V2,F=WJ_? M4T7JUC?;@P"[0!#K0A:+5:>J#DO]9FGLO9LK58CO69J[MX?SHEB\/CYV\5QE MTO7,0N5X,S4VDP5N[>S8+:R2"4_*TN-AOW]ZG$F='UZ]X6>_VZLWIBQ2G:O?
MK7!EEDF[>]=2LWQ[.#BL'GS1LWE!#XZOWBSD3-VIXH_%[Q9WQ[641&MW8QK/ _[4:NE:UX)V,C'FGFY^2]X>]DDAE:JX(D2?Q[4C4I3 M$@0UO@69A_62-
+%]74G_R'O'7B;2J1N3_D,GQ?SMX?FA2-14EFGQQ2S_IL)^ M3DA>;%+'_XNE'SL:'XJX=(7)PF1HD.G<_Y7?@QU:$\[[.R8,PX0AZ^T78BW? MRT)>O;%F*2R-AC2ZX*WR;"BG>:-ZIR.6-
]JU4ZFM^%.FI1+OM8M3XTJKG/CG]<05 M%N#XU[8]>Y'C[2(I8%ZJA8S5VT-$A%/V01U>_?S3X+1_N4?A<:WP>)_TY[AF MOZ!Q3^R0);
[.E;@QV4+F*S&73L3*%HAD,=6YS&,M4R&=4X43,D]$JN5$I[K0 M,%LQEX605B$P8V/A<8'[*9GX@4V\G.MX#I$/2DR4RD6<0I">:AKHQ"?UH%(Q M@&^%L6($S!=SK%I
FY:,N596VGB^HBF)11)"YQ,_G0^'IY?5ZGP_&%Z*;Z4I('=A=:R\")U@AHZQ?9T# M'24+H(5]D VGM8Y7)-Y'"/2*)*P<20E19[L7273%-)G.7P4R[S BT49_-Y^[.V:D!SK>"DS(>#+2:JV
M&8CF=XTTJHW44J/2;&I-UCP7A8KGN?Y6JI:B$M>#GW02K6W3012 M%$/^IJD/OIH"NZ["LHJE8-B#EZRP*1WVY%X=7+-Q#E!MU"K@3$Q+O!(OQ' 0 M79P,VA<5UNJK
Y@]4Y;MO) +4F,<75R_&N I]_K#IK/6[4SE\4I, M#*U]T>]'X_Z9&(RB\<58G)^?1A>#46M1NS"6?.&'#T>C:#AN%EV[/T#ZQN"9 MCN'$!^4*'^GCZ&PX$B/^OYHYB/K]_L$-
\C8'0J'8R(E:& >'#701#4[/_4.L (>!\#0Z+1QPMK]4Q%)QA]$@]%9!RJ=)QNP'" D1^?]9D;W M?@3MCQSX+9 MZ#P:[(2+?[D59D^8UV93=58/VZ#$*V0[Z9)19L8BG;8IT:,96N=Q6B9:
?8K1L&WI#;<%M9+-E(G/AC ML#19@_<6R\5"47$&K3(+3W)>TE0F0_W+87]P)F[\H!L,/0$ '#/- NB>?!#6(?*0R' MV9]A!4YW@Q-??M?TPH//-+Y2:-V#/\S,GKWLL'1SZDA<;$\#T:
4EP58LEK%\=L .M$D"L_$$4=OD:"%ML6*Y M?, BR1"WK&%*!WIW-#?$(R!.7,0_Z"C9(O0BWD^QY${9B M.5#.S9"R*F7!,"0-V(@8L>1C83 Q7.C(5=B[C[?:>7SV\=:B%@7\)VUJZ"A5
MIO[XX77:0';D4Y6 MNWL<=N BBH>>N'X564A!@(4I M9W"PM#@$S=S3O<$G,]9Q.E7^D%?A:,MW8#0?V.0+_&N@,#@-B0=:;P*$*IP% M22-(K9#[^KVS*O-Y;:OW[/^Z_1
*A:%3&PTQF1(OU?<%(?55)'(.S*PR^D5BDO TX#BIC&*5= M,8 9?H-:$\S-*9Q[/X!6/-YA:64BN8<&+!@6:@<=6,Z-4SOZ+^RM';NU1!1L
MBS9J6G2["8QEGU5#Z86Q#'>=6DFKWF1KN;\64@',^PG16IME44Y2'2.9<]H& M>E1<960:4H>H]K(UHI&["(2AW[N=T^CPM"7B^!/1"+X(B'LOHV4QQ+P/;AO6X M202%M?
4;_]KI6S1'^;8S>.9&BMUGBY(LG=+;6K9H6!:5AU;PYN M&.9D!64;;[4,Q&9,.MV=3NG;H<%(1.W]M;J8>5LIBG(RQ0LQ/.N=U 1LS6R/ M\^<[^ O*7E.I1;!;3C(FON?
^D63:SFX#GP(1B1VE@+@G7@92%H;4%%%.4?1\ MU-6[WO1=)7BK4E!=%XZ;1RL2P3-#?EW;?T5(O5TI#I_@XA&!-9Q5N&7K$W.= MD4,B]8FYE9Q^9'+>EC?C72?
#ZK2W^G$YU<.D9A'@[$0XC%T=50!J:;.0JY!< MC+A=X7#WO73[,%&-J4'A%,!)7)7HR-RD";=!*9I2.DR37$G]622IC+$ IE*4 MO'><'N$;($4!4)3>D=#
(].#O<+G'"Z6\C+X2>GHP95I.E9T*1D,7?$GDYNR. M8E@IWJI_O&U;Q2)3]7*@-F-25,Y,<%!UY4NM4&;AFD+%&W,;6-KUWE>8L87 M+@7$2^CC'JKNT=]KH*_ C@*N-
WI#'E5/01%,WI#!FIL&B(('6$,ER5?$P+'Q M;!+F'RWY>R+>4<3$#!9BYM/4+$,!(E'A0,6]7I090,L+;$EJ*E";"+)#.'>8 M\#4%N'WPO@[Y
]D.&Z!VNZ^]I?.-9'VO4CTWANMJ)N^K#%0AFRX/_H0%W MK05BG(QFRE7GL)I(PN^)"M==/X1SE;=.M='&,/1%A@YGJ-"XQ'EI5H1J+>!Y MT@\'*>MQ'RS['V
M%%$8BY='<.!2VJ32O+N7RI5-B+>[<56@^EVX^D-'\OK@FOW%_Z\W:C_6*T3A M=#I!5@13^5,JC7R)Q],4K M_#VGOUOT"#X*K8A62SLH_&O5.#Q3HK#-;?&$M.;?
N^\:2_EU9@&>S3FHC>J MQD0$V(4_!J:KR,.;/\?6OHEKN^UCE>H[#AWD@$6(IJP"$@N4BX:J=H5#2QJJF:NN#:!O^Q);BHLZ!3\S@4=.ZHY-#
M=R9W\EH$@Z3,U#!P9F76M&\3[;SIN72'3W1M__D5_!?(VM73,NB MM*K#/":*]PWUI U=-S.=XJA)9W&&8#!W7?HWJ8+G3SNH1E6Y?(W&*,)L0M>M MED/R/#
(_[OVU"*%#0!OF%=5OMUISBL=!;U@_8;PT>'HB\'LU,K1F/*\AZ1&S8 MT]4&?7JP4/K?T7_S26&GA$Y/15*R3DT^\\W'AMR8?$WK9W8' XNJ#A^^>>U" M?6JXVW-
[CN0"CC'_7;S;R(PJ3_$&E69VX0' WJE>(ARX8C%%^[Z9\2S3"6:.V&VW:D-C=GJD[IKT]76KS<\=-LE>'<+J3$WM8M?_=63/<_WKO5EK44L!733&U
MWSL[.136_R+.WQ1FP;]"FYBB,!E?SJ&MLC0 [Z<&:H<;6J#^6>+5?P%02P,$ M% @ *H!F6?[U\46+!0 $@X !D
!X;"]W;W)K&ULM5?;;MLX$'WW5Q!NT6T!)M;]DB8!G,1M@VV+;IQV'Q;[0$NT340B M59*.X_WZG:%DUZWM(%UT'RQ30\[MS!E2/%TJ?6?FG%OR4%?2G/7GUC8G@X$I
MYKQFYE@U7,+,5.F:67C5LX%I-&>E4ZJK0>!YR:!F0O;/3YWLDSX_50M;"G#9OQ,;>?FT\:W@8;*Z6HN31"2:+Y M]*P_]$\N(ESO%GP1?&FVQ@0SF2AUAR_7Y5G?PX!XQ0N+%AC\W?-
+7E5H",+X MVMGL;URBXO9X;?V-RQURF3##+U7UIRCM_*R?]4G)IQV1V1NU?,>[?&*T5ZC* MN"=9MFNCO$^*A;&]JI0A@EK(]I\]=#AL*63>
86@4PAJT(3@AL2ACJV%6@)X%DW*3S+ZX_/UE^'[T_CVZ'%^]'9#RZ_'QS?7L]&I\.+'A%W4'1>;AH/00'/.3D@Y)V;LA(EKS\ M7G\ T6Y"#M8A7P2/&ASSYIB$'B6!%T2/V
LW$(3.7G@(F;FA,F2N,'HZT+< MLXI+:\A?PXFQ&HCS][ZT6ZO1?JO83">F804_ZT.W&*[O>?_\Q3,_\5X_$G.T MB3EZS/HO*=NC'O;'"Q^3G_5,;N>
<3%4%W2_DC%@VJ7BW!8A_N"$6IB]5W3"Y M>O$L"_STM2%3(9DL!*L(,X9#(9;"SH'U=]&%%:"DIJ3B!I69)+E'2K8"+:UJ M9ZYDEN.29J&+.70L$;*H%D ^&)
"B\RWB@PR5%I(MBB%A46% J)*TXZ,J@3: M*Z'W*P@*8L=> V]*$\Z*.3I"_89KH4HT5XH"%4YZ0Q>H>_9>.C=J88!HYE4/ M6H*O("-]!_ON= $R\IP$/LUC'P9)2',_[P$L-=<.AX:!?
1+0,/1('-(D\V!6 M-TICJA.%^@'U/)\X#(/7O5ME00UL)C3(ACX?DKC/"?7EHC]]#>0:K$B5L$^ M8\4,+1>: R9$"W.'. F[IS83S$-("S\L,"-+V&*/2MAKM1%3 &PLG@25VU?!C1ZFEVV_!
M.@-'<'Q\4^D*TJ7WFX$53%3(NR,HVI%A2$!>K+FT!(^L:;1Z$&"""5RN8O.?2 M>9Y"%]1NMR_FJ@F;C^7U!(JQWH'=%+?24,*)Y9IN#MSJM7QOBXPW]I@ M.V"R*0A2E>X0E@(# =
CRW6]!8UQ<4@ECR SC5AMSSV9K;OY]88UN(,@2_6 M*VBZ]OF&"?TCJS<[:;V/WGX>TACP>KXFZ7>C;G:7]&%$\SS>K%S_M^+>6P7E MEXX;Z'BV]3KC$NC<-D>69S0-
$N+3U(O(2Q*$Y!5L'!Z-O'2WD*)G%$$B^$ MI7X 2X,PI$$4]RXY0#%UD#FX2@ZTA0Z!YLJS;"?(5MPUX_YR_L!P!Q0-TY1F M68K]2T,/_U^2,(8XW&3F43_.L6":8V]A]3;0[]A':,%:C,#
[/T".\K@WWL^G M'##+L@@\)DF*0*00@ ^[C$?C,.I]/$ U/_.I'^6PB>6HE*$2B-+4^_]P@$KL M=. OXVV81C2-O0.\[69W>>O[(0V38)<3K?RIS&T!#[W C1)7![\K! =[M+7 MA\X-4@\
<9;#:X0^2$(^, ^R-$YH$_DZDK?CGJY:D,00F9T(:^ R:@JIWG,9].*;=#:1] ML:IQ7_T39>$.X89SN+1QC0M@?JJ47;^@@\TU\Q?4$L#!!0 ("J 9EF\ M-?UN"@< &1 5 >&PO=V]R:W-
H965T#7\A" M[4[[?K\=F.6KM<6!X=G)1JSD7-K;S53#V[!#R?)25B97%=%R>=H_IS]<<%SO M%MSER00U62CU!5\^9:=]#PG)0J86$00\[N58%@4" 8VO#6:_.Q(W/I9; M])^=
[J#+0A@Y5L5O>6;7I_VD3S*Y%-O"SM3N%]GH$R)>J@KC_I-=L];KDW1K MK"J;S<"@S*OZ*;XU=GC+!M9L8(YW?9!C>2FL.#O1:D0RRMT MRMQJF,UAGSV;SJXO;\?+H[O_AU
MTLY<7<+@?#*[F\S)S]&3*L9D_W M#T&?3BG6*G7!7@64SM&I4?1\5T^V V(I6G?<@G(_6][)_I)\T?>1]?XRVJ*O=NL\79.\2HMM)DTW
M080Q*LV%E1FDFUT3NY9D^OF:3&L$6%!E9/+KY.[3Y>_ +E50A RN5DNW=JD* MJ&9YM?K0@]K@AF[66LHG4&S:J2LPRY.9'L8E!F= .JGW/J]@M=H:.-O\U'M, MIW=;Y7CZW
)E0]X1YGLT2@*0_%%"O6@$4N1Q&HX2)S'*_; WD\8BX]^4+C(2 M)-3W0L(9]7E(?"^A850_6<)Z-\J*PMG@N14KL"V\-H>W6P\9M 1:C'#^8#(;ZF4B.9[Y'L7
M7(Y_=228!Q!ACP*/6"Q'32_-_P83(^A8E1M1[7\T1R%H6>R;GB(U!2S44AG9 MC2&(L >LEHTQ-E+G*C-.KQ13YS^,_>DQA_7WB$Y8 $XYT@@"ED'S_,,T@ M"V"0X0S#-0Q?SPT:1
4W74)%KT]-QK0 _N)U#D-:T9;^^LHVDDM7>3Q00@- MN2C_9PV-=M#9FJ]W=A#TR MI?N4KE.:K!S*D\N1>E54*K0[CU\5\;_!6W7=X/L_TJ8K5C*1D=G=6<J=31_WB#XW
\W\"U3&RXTE+@F:-@?#SU0 MAUOM,#&R=C?)2AJZE]RPH!\!5-:!OJ^E-,>)7:#]M9C_"U!+ P04 " J M@&990B+7PO4$ &"P &0 'AL+W=OB09+=/2SV0$NT3502M21E)_OK
M]Y%2'*?K>('%7FR*Y,R\F?>&Y.E6Z1]F+82E^ZJLS=EP;6US,AZ;?"TJ;D:J M$356EDI7W.)3K\:FT8(7WJ@JQRP,TW%93V71R MD;C]?L.O4FS-WIA<)@NE?KB/K\79,'2
1"ERZSQP_&W$I2A+YP@P_NQ]#G'^^-'[9Y\[V-VGX1?3X3YR]7I?&_M.WV M9MF0\M985??&0%#)NOOG]WT=]@RFX0L&K#=@'G<7R*.\XI;/3[7:DG:
[X&N!D[4BYM1JK$G9V_OWNRZ<;.K^]_71W>SJV\.CFQWEO?=%9LQ>L9_1- MU79MZ%-=B.*Y_1A(=G#8(YP+=M3AK6A&%(B.'\S:LH#3\>R2W9Y98<_ZOU!VW
MGHYHWP'=K04M58DFE?6*+%^4HN]4%,L0JH,:5@VO']Z\FK(H^VA(^9+E+0I< M6^)=Z7!.D.#YFM32&S5"2U48DG4ARAK;5&O @7DW0'.5 M?
*$T[UH6O'1!M,B%W#A0AEY3F@9)F&# 9D$V30=7B+'AKKT[%)0D0:3L MXZ GFMPA947-ZQRY@0V9PUT4!S%+*8H"-HUV6W/4"WA+CP'D?=A-B'LV&DAVQ2Y$HXRT/U4:
MVI@&$?-Y) $+$U=&7]^D@]^A":B&5%@63++0*2EEX> &==8R=WYS;M;O*9I@ M>=;_#=! B+F2.1!OL!6W$P(GH"D&J1.6'9<:6 TS0GW3M.<%/$YBS,39Y!DM
M!VKWFJ9Q,)G,'$=Q&F191.\].7WU:6X "BE4!1 ',!]X>RV4#/4!H4A >/M@]PQ(W7-[>>02<;#% ;B54' MHU%@V+J^7;;6W17]:\#%]M;4\ -UR6OM&=HZVTZT+S
MK1.GIM9TLRM1NYBD@'[ECVLS.G2IC??>)LAFY5]@0*+:VG;/E-WL[I%WWKUM MGK9W+\1O7*]PR*&(2YB&HVPR)-V]NKH/]QK_TH$^\&[RPS4>]D*[#5A?*C#6 M?[@ NZ?
O_&]02P,$% @ *H!F6;T/\@%C P %@< !D !X;"]W;W)K M&ULC57;CMLV$'WW5PR4($@ =76WY(UMP.NX2![2 M&NND+5#D@99&-A&)5$EJ;>?K.Y2\6C?8-?
HB7F;.X9D9],4<;"1;*;_;Q:=BYOA6$%:8&\O :'C)5:5 M)2(9_YPYG>%("[R/N(YGL3R MY;+2W1<.O6\4.9"WVLCZ#"8%-1?]R([G/%P ,O\%0'@&A)WN_]!.Y0=FV'RJ MY &4]28V.^E"[=
DC@M&E(U19.6$_,/% M@D;U@,[\S:M@[+^_HC<>],;7V/]72:XR/*]O<@,_,\.7/4(I*WJ97.S V#2= MGR?_00DS9%[*NF'B].95%@;I>TJB32 6@$?J"YJ6"W&2KJ1KZW6BM9-'FAM[W
XH6::PL!LZR-;R&P,_< M- RZF>_Z:3):G#7D=/%L">E!B+:D2:ML'+G41D.:N!-_E'DTC4:(%@WE3PA MDE-M V!=;^@12>H&?@HI'1>%3X=0=BF0JKL^E,Y?AHT>%?
MN$L00Q>YX/!E0 MC9(E:MNZR+%$"B0,W#@;0T""9.G@QP4)04K]D5P"XIB02^2FX_'@HN2)589; M>TC8Q Y^Z@_VDA_IR[1&J\:E.D'DAE'P1$"Y9(HJ-
-0L=+,LI&\0!!XL9^.OHBC4W&S]?@-66 #H]\.Z-)I,4GGL, MWD6OJE'MNHZL*9>M,'W;&G:'IK_H>]V3>__'^,S4C@L-%98$]6_2Q '5=^%^ M8633=;ZM--1'N^F>?ERHK /92RG-X\
(>,/P*Y_\"4$L#!!0 ("J 9EE- M1+L<>PD $D; 9 >&PO=V]R:W-H965T X ^YM?OUP!(MD1)M3Z;F1>*!;GQ]X.L&>'Y7JN]Z*X1AJWE6Z(O1UICJU>FI3K8BYWI<5J+ MFW6IC:-0\^"
(W6T,/3B_/*[X17X7YM?JL<'?::DEE+@HMRX(IL;X8746O MWDQIO!WPFQ1WNG/-R))567ZGFYOT8A02(&)Q) &CK];59D&2D"C-^]SE$[
M)0EVKQOM[ZWML&7%M7A;9O^1J=E>C)8CEHHUKS/SI;S[17A[9J0O*3-M?]F= M&QLO1BRIM2ES+PP$N2S1.K;_*(MOFNQ,NQ:ZB0K=:T$^^_52AN%5/C?
D+%.UW18%RV/5[KBB;@8(?^U4++B=/GS M3]$\?/T$TFF+=/J4]F<#\:3T,+8H'+.N6NM4]K8L;H4RI'@5
M+=A;7E4BQ5^6L6^*%YK;I:/9IP)#/;T6^$HI%T\".#IC9"FC+*UX\,*EU#=$7 M:+8(QR$R-,YV5=&%:NF1:%+!5+.H@*BRBM!2N[
M<\Y<1A#4@&F98\WQ0I2USAX")@HC%":7A2E9XFQ(R ;3M>%.FBVFJFEPQ3$= MYH&$H,QE$,3BDKG\0UBS)*Q*+,8*@ HC@3N566V9I*[PXT!;;L(HDK$ K4?' MY#"DLNEZ+
([[']NNAU@*0X*: _'2+B^R!%6)38F)#\+J&8+@25:V2+=B(<2!4 MI@,#$*OAG%06FQZD;WBW+:,4H)FXAW"QL0&+9N%XW@9,#L?LEF<4DG5'(]N* M+&6K!YHT9R@/"$Y7EC^
NZT+7[!XNNS,06/7->*CA3&9:(81^/T9*35YDJC: M.0H.TX8R0!?)EJ689\RND,!PB$9*-%IV[M%/^)P#JIWY$X5$;F*)$(%")R?3P?3[J>3[C>VMSYP &?Q39M)G\] M;9HP'YB:8+FA8+?
Y\!=39Q)-QK,_G3K]-7*8/M..+KWE\&LCY6W_^:=E'"U> M4TSRG :9,OD^F -R!^,_D"L!\.XEP0_%G:\4.6]S%VT7K#EWO)S27!3L'_6 MA7-8T,9+W$MM*#IM-*B[5'0GOA<4YIXDAOX,
[..U8>X K^P46A0(B&O(&<05G7+5D7=@SH MPJ$B/]4%KU-)4P%%BE[27>DRDZE=(LAWX], MWZ[6P#3]#6RSLP^CUR5-46E=5UB4$P4'!WJ)#8LC+5*X?^K9W)09)H[&Z M4_?
\@F=@\:U="KSH&CK ;79FF7 *6=\>;,HT2A[EN 6=X;8=^C0[(3V3K+:= MT-8EH:;\1Z]<-W&CP+OUBT:)&B(P0S,%Y,AGQ%"PT* GTUL;YQ6E>F<41\G M;*FBT!!<0U9BR2J].M3-
]2WJR-*+-9=JOZ+LV1.PM2ISQT$^]ST_>7 4B0,0 M#7OT\R9PJ:#KE88LQTB9F M4J/1 ?J^MYZEUQ7/>)$0*0H;:3(;M$]92A>/Q/00E#5SP$/ MR."9M]HO?0"
M96NQVX<,&M40O+B0*#OHH1"F@?5WEXX#HP+&LQ+EH=-\[JK=G6S[X\&=T)B] MMUVT\H:XXQEW4M(K1QWOIJ+I6CI\, +/$CAH3,>"X>AM+PG-;]9-1_P%GMI M9[G#T4DR3,
(EL2!60>J([2W-W#O"I +<%<+&S#1JD!AQ\VR(2D?HOWV MXZHH:DA\$=21D=OHX(9%X_%AB.!N /^"B5VO8$[*4W M25,[E%"GH!T?=" !O,I^RDQ_7LVCU1-
,@G#A=T2*8+G%YY'(VX4K9 M9K,ET@-7^Y0+9O/0)]HB.#M;'KWO\6_/==&"S)_:/<4T6$XFAX-W'IN$T#>Q M'EO$0;R8>VA]?A^$-5V'2SA-,8%D4GEE>L?GFHX-R*JC[L>>-
;@4_LB+= M(FR/"SR[NQIR,+VK%;/=%B=P-&-IW!;@J+/]P0,?O)9$K<8FCMKQ(>%%$_ W MP5WSA)8@=9X.;33;*VUX-!\O'[5@ MZQWI==IV5\D6[-
BW[+MD:MIU"W9_+Z+M*7Q*RNC3!+9(ZCNJME$\]6>9&-)O M.?\M)Q% PW'5@I%9RT/?XK-C,WGSB;:=<[V0)D*3QM#?_CEK-YM<@?9$ N7 M6DH[OB&[PTSID-9-
,XM;7I_]7/O3643C M9W;W%,6OB6@FBYG_HU?SQU\MNFSI7P;1W+UW&%M_6-Z9-O-/)^"4N7NXG($% MYFSH)/VT\WDC%VIC/^+XDSGWI:-]VGXGNG*?
1W;#W4>F#UQML/I9)M80184N;WG;Y?U!+ P04 M" J@&999A%5)MP& "A$@ &0 'AL+W=O+I7^:A9"6/A6%I4YZR^LK=\-!B9; MB)(;3]6BPC^G@Y++JG]^ZN9N]?FI:FPA*W&K
MP31ER?7J4A1J>=8/^NN]SW*^L#0Q.#^M^5Q,A/VIOM7X--B@Y+(4E9&J BUF M9_V+X-UE3/).X(L42[,U!EK)5*FOJ/ ^/^O[Y) H1&8)@>/?O;@214% Z,;O M'69_8Y(4M=K]^ZM>-
:IMR(*U7\+'.[..N/^I"+&6*^UDM?Q3=>A+"RU1A MW"\L6]DXZD/6&*O*3AD]*&75_O-O71RV%$;^ 86P4PB=WZTAY^4UM_S\5*LE M:))&-!JXI3IM=$Y61,K$:GPK4<^>3^X^7?

WG[>7%Y.8:KCY]N+WY.+FX>__I MX^G (CK)#+(.Z;)%"@\@C>&#]NS"P$V5BWQ7?X!>;5P+UZY=AD\"3D3M0>0S M"/TP?@(OVBPU3(W5F":_[5M\ MBQWOQZ;2>6=JGHFS/M:&$?I>],^_>Q.D_LD3GL<;S^.GT%]%TM-(0>#!(32X M6PB8J0+K5%9SL'Q:B*Y8Y1_"@,775ZJL>;7Z[LTH#(8G!C _LZ_ EUSG!N88 M2XO!Q58!@F<+4#.G5
LM%;Z752XSCA+O>EA1[M7=0@NQDSB M%M13H5VW*\% M/^)"GI#K48Y0HD2P&?7^1?X8^-E5)FJ\\KDW<8M3-;4/ RF+XQ#^ 4GB!2DD MA/L-$WQ,4R^)(J';!SZ]#STHC$$+(@2-AR/<688>NC,9Y*))3.RTP:MJ20: M(S%_3+A!,/22 ! HB4@M"$:>GR!2E 1L/ KA*#AV8B-0[#L#0X;+A*/032>1 MY[_&3<,#@Y=K11]"L*==F&6NRAQ 482PG& M0Q:G/ABJ*X-
]RRZ(:K=15)F 3"'?;>S6]CYPC6GA &ZW32\7$N<)4XN",@2L M^OW7@((VFN9Q^%"O)&NZI\(4$>7#BH M/=0QJ!0"/!3G/L;6R: %[>QD.8E8L,6V0+(P$%/7)1!K*DBHXRO'+K-3/$3*
M+AREWJ9C;"W.NHY \B_*PP6_1_-5L0)JNC(3;Z>NP6=:6FP[W"%1Z$'=H]Y, M-1I6@FLDF IGNU;(NO/J%840N:1-_)"%8?*B2B#@QJ40[50#VU\.SZ4@+?11
MN?!G"L9R/1>6P519UZQ;NX[:-9$4&/+0@R\/";N3GZWS(TMDR2<\3:@K6)._:PUKA3[48AC"UTNY<^YB/=C%8CQDO$;Z0'FL]N[WG
.,#6R[I,5_(4>KPM5FV\T%IOS0]M6GMW5L(8HI3"E,7X MFRWX;!M>=/!+;G#SC2,OP<-Y4;A[!F+@U,@+UE.,**^%NW\4*V_CT\LVVC_G
M4A#%7OK(IR!*O>$AIYXY_#UK=MK5(MA5W?9OG)DU57OYDNL^2[79]=JFX@T2 M[0!Q]54+71E5N'*A$PO^4;ZY9"*K6BSH/H@M'P$5IO=1H8PY?O(\>? $N??,
M>.2<4XW!%9CC1T= .F:Q(!G1 #?M84!$IVR=B]QF$*X0C_ M8MKRPS2 H<\"/^C=E'6A5NAW:^VVP6K$0,.M5AC2$L]ZXR#$WS3%,4ACY+ F0CI1%P^CO7Q;\@-1*2DOU\C[<"-
Y*7]M MWZR4A9*[4U#A[;N%#K8^&Y0"CP+T<81:?U/9]@O"9G;S_>8B>SP(-Y^O,$= M9"ZQ0@HQ0U7?&R9]T.T'D?;!JMI]A,"CAE6E&RX$SX4F 7P_4\JN\C YJO4 M^?\ 4$L#!!0 (
"J 9ED"S!"S(P0 .4(9 >&PO=V]R:W-H965T MC :6W82IY<$:+/>KL#U!]JN M>QCVH-A,+)QL^20EZ>VO'R4G:3HT'?824Q+Y\2-%BAEOE/YN2D0+SY6LS20H MK6W.>CV3EUAQCI6
M*RM%C7<:S*JJN/YY@5)M)D$<[#;NQ;*T;J,W'3=\B0]H?V_N-*UZ>Y1"5%@; MH6K0N)@$Y_'91>KTO<*3P(TYD,%%,E?JNUM<%9,@I3,\E'?
H7WSL%,N<&YPI^8]Y%B=@K'T."Q1%@H21TJ MZB58/I>X;5/Q-^5'^C 4H#ZG1%3=IJ9>CNS$GJ,/U^LXF
MWZ)>H['T6%@HA,G5JK8MPU\@CL)A.G(""T=92D*2ADGL=I)^F$6CSE5MD:[. M[B(;9%(2+XAVC1U(0GCM'69 MLIW#T:#=841JJ[ZO@FT&3O9ICL,LCDCHND0G"2-+RC
+!TGLCH=A0JG^C;L$ M:%6!X=+'?T<%HX7]"?>X=H_XDUKESL^.[[^_<>23T_E&50AT^07.W758*MR5 M,*7/RS%;BC(C'NZ6.H_*))H!!4]V7\4@D@!9\+*:R@YG,OE;-
C43R$&6\:DX=UZ'^H8>2Y=> M+&JD9)^^]9[U#D9/A7KI!ZP!WX'M%-KO[F?X>3NZ7M3;/P#77"]%;4#B@DRC MTV$_ -
T.U79A5>,'V5Q9&HM>+"DDU$Z!SA>*>&\7SL'^G\WT'U!+ P04 M" J@&99N1F78[& "_$ &0 'AL+W=O\WN.A_\ M]?=FUDG(H3ZQ6#@TP65VB>V MI@J_Y-
:5.N#1S0>^=J0S,2J+P7@X?#8HM:EZ9R?R[J,[.[%-*$Q%'YWR35EJ MM[F@PJY.>Z/>]L4G,U\$?C$X.ZGUG*XH?*X_.CP-=BB9*:GRQE;*47[:.Q^]
MN)CR>EGPIZ&5[WQ7[,G,VAM^>)N=]H9,B I* R-H?"SDTM@"G4#C2XO9VVW) MAMWO6_0WXCM\F6E/E[;XRV1A<=H[[JF,MW'H&!P/[S$8MP9CX1TW$I:O=-!G)\ZNE./50.,O
MXJI8@YRI."E7P>%7 [MP]O:/RP_O7ZOK\[]?7YT, A#Y_2!MK2^B]?@>Z^?J MO:W"PJO754;9;?L!F.SHC+=T+L8/ EY1G:C)L*_&P_'T
;S)SKV)X$WN\CEB#@]C,@B>>%KG=)I#RKPY);4.WO\ MR^C9\.4#?*<[OM.'T+^;CH>M1]-$=1'4J\:9:J["@O#7$2E=9:J"E2ICWHCS MIA#U0.6,W"
[TJB]&E[:L=;6!^E+K>*6NE(DA#0AI[>S2B#QMKAZI83)%B1:% MJ T;7<C<7*\?=4'BD2L"LP)2)3G)*(4,*<#,>XI[*A$QU 3%4 #0V,RDW'N/QHD1[3_Q'7B]UT>C8 MZ IT6EVEQ!
["*VY2A !DXC\;L:2!*D-FBNY8&6)B/& ,.XC^S" MA;"$ES/P#QMVW#=PZ\ .J,2JM=R68,O\\2_'X]'12Z^V*-@"SG! A"Z\B#E MKO>IQ;F0$2]9(N>V\2J'H*V[E<2\":QW1^#L=>&9,*V-
ER1M(X[2KZW#B:0R M@XIT[#904!/_H>BP08MR.T-88 /7LBYBIFY)9I,"_-U6KB<#U-T=A M;W,;=X@%"&(1NV4"SWR3YR8U(D*KH BGJPA9490!#Q"B-HUX@_FA>M9S+/#A
M0;>U)/G;CH92E!BKW+V1M+-3*Q,67$LHB 8X.RU >#+PB(K$'35K4,BL W!L M*R+*,\8.CZVX.[[N\+IR0G."=(GE_4U"#\GD0'1B$]P"M78'UO4Y'"N,//S)
M:VBMN769,K;@[$X7$&SWL/U=7)BT^#5C0>"ISR8 L%*[@=O([0+:<2^@/'$L M=MA6\7U1)"//<3Z&15^HT]J;O'C@.]6UC747(%&?ONL[QL&FR+A?8T!34E@S MJ@@@[$_G
.%]*U:"=8(5L]I6==S%^-T1V&\[>2KH"\V-$YF'5K@3&+B/$($' MUR=IQ^KW,5W!!JSXMF;1W LAO _P_3XAC[I&+-:&]T2?>*2.GQ\EP_W!>V_] M7W<$+LVAFU_DTX0V
"))CD8K17RKM9-.=\\IH]67!BO(@9 <5^PGB1P>1)VH\X0'D-T%\HB;8 P]WQY$W'#68;9!MCQ*; MF]CR6UWGB(IZIZN&#YB1N#B.'O)0>MF$>%]\LS.OSE-1X7@X.E)4L$CC%(/%
MMI:H(U/M,-((RH-+-@5[5"2C).QX&Q=OU*QWY"B@PP&V[9A(E)&C7LX.KI(X MQCW]85/<&OE4W]O'-B?,R,;PZ%"^U_-(/6\S4S<.C9A\VPOV%/?'W;([$+33 M8!LV+C_I0X1Q
Q+@MS(1WFH>4H739'1W #[:OSHTQ]X#U#630^O.9"LGYL[V M]E02E5ILMH/E;//=X30Y=',9=*Z5);FY7)T]][TJQ/OE[NWN=GX>+Z7[Y?%]
M_UX[J()/@QRFP^3H:4^Y>%V.#\'60%^SRUFK?:!-]C] MG\79_U!+ P04 " J@&99I;)J MW'M1NJ;&:=,(2\N[P7SZYN&2[:/!/S6MW=9OP9$LC/G&%[^HN\&$ 5%%A6Z!U5%3L"C-
^SST&_)2_<_NUY_48EC%@0AI[>S2B#QMKAZI83)%B1:% MJ T;7<C<7*\?=4'BD2L"LP)2)3G)*(4,*<#,>XI[*A$QU 3%4 #0V,RDW'N/QHD1[3_Q'7B]UT>C8 MZ IT6EVEQ!
["*VY2A !DXC\;L:2!*D-FBNY8&6)B/& ,.XC^S" MA;"$ES/P#QMVW#=PZ\ .J,2JM=R68,O\\2_'X]'12Z^V*-@"SG! A"Z\B#E MKO>IQ;F0$2]9(N>V\2J'H*V[E<2\":QW1^#L=>&9,*V-
ER1M(X[2KZW#B:0R M@XIT[#904!/_H>BP08MR.T-88 /7LBYBIFY)9I,"_-U6KB<#U-T=A M;W,;=X@%"&(1NV4"SWR3YR8U(D*KH BGJPA9490!#Q"B-HUX@_FA>M9S+/#A
M0;>U)/G;CH92E!BKW+V1M+-3*Q,67$LHB 8X.RU >#+PB(K$'35K4,BL W!L M*R+*,\8.CZVX.[[N\+IR0G."=(GE_4U"#\GD0'1B$]P"M78'UO4Y'"N,//S)
M:VBMN769,K;@[$X7$&SWL/U=7)BT^#5C0>"ISR8 L%*[@=O([0+:<2^@/'$L M=MA6\7U1)"//<3Z&15^HT]J;O'C@.]6UC747(%&?ONL[QL&FR+A?8T!34E@S MJ@@@[$_G
.%]*U:"=8(5L]I6==S%^-T1V&\[>2KH"\V-$YF'5K@3&+B/$($' MUR=IQ^KW,5W!!JSXMF;1W LAO _P_3XAC[I&+-:&]T2?>*2.GQ\EP_W!>V_] M7W<$+LVAFU_DTX0V
"))CD8K17RKM9-.=\\IH]67!BO(@9 <5^PGB1P>1)VH\X0'D-T%\HB;8 P]WQY$W'#68;9!MCQ*; MF]CR6UWGB(IZIZN&#YB1N#B.'O)0>MF$>%]\LS.OSE-1X7@X.E)4L$CC%(/%
MMI:H(U/M,-((RH-+-@5[5"2C).QX&Q=OU*QWY"B@PP&V[9A(E)&C7LX.KI(X MQCW]85/<&OE4W]O'-B?,R,;PZ%"^U_-(/6\S4S<.C9A\VPOV%/?'W;([$+33 M8!LV+C_I0X1Q
Q+@MS(1WFH>4H739'1W #[:OSHTQ]X#U#630^O.9"LGYL[V M]E02E5ILMH/E;//=X30Y='_

M5G]P<[%0>R:(]!^+0:O7#NC;#EM!OT^(QKI:&$;S!!2.[*S2>XCIPI!?4Y%< MJZ2(24<-697(O$WJMSO4 3K6)?[01,M3; "-'\XX]]02P,$% @ *H!F6>SU./#G! [PP !D !X;"]W M;W)K&ULK5=;;^(X%'[G5UA,-6JE;,F-2UI HK?9 MD=I55=KNPVH?3'(@5A,[8QN8[J_?8R>$T '4E?8E]K'/W=_Q<89K(=]4"J#) MSSSC:M1.M2XN.AT5IY!3=2X*X+@S%S*G&DFYZ*A" DVL4)YU?-?M=7+*>'L\ MM&N/4_E^!9E8C]I>>[/PQ!:I-@N=\;"@"YB"?BD>)5*= M6DO"I S7H[T9Y6'AL# /2#@5P*^];LT9+V\ MH9J.AU*LB333[T_D=7+_

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|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}(Z!7 OJQ MH-*8'"L2<-*8'BL!],2,(X5&%4"HY; 0'U&8%P)C(_MPZ02F+0$5..YB5.> M9DXI/*B<\L)?S('T_,L?219WE[P\HO"ZOIYX291DL?''<_$KY&0X].[,BY(MNB!WT3*)%E$8))QZ^V%EX55IH?:, MA3JY3A.^8L1*YG3>(>_*Y2563 /IBN.LQUY[&_$J3$N_HYI3HRGNB M*=J ?+DSROR_T@J>_\+[X]/+[XNM' M(4L\3M?L[ZZP+Q4-NA7E>><$9VP0AO>B)A9_1[('VIK_^HAK* [UWQ@8292)B% MA-E(F(.$N4B8AX3Y(%@C7 9UN QD].D?V_4]S?+5562T65 $"'"M?%(S\]_3. MZ(H.*?>UT8&$F4B8A8392)B#A+DE;%C \BW+PU0][S_LNSQ2G0^"-5Q^6+O\ M4.KR7L*IH')"OXM-'*B%S??AIV9UU5),O.&92@V=LV1F4G5O=9YD3#K&/-M M1$@"'7,/S5>'H[,]7D^J?ZH#7S4F>->Y9!PJQ# M\S\HIP.CY4=(E0X2YG8-_VC<\LB.3AJGPU8G? 9!=#7\6+WM_"}^ODL34*1S&7E1Y';B'W;,U;MD!BYI2&-'H+[>$?IW4H];CTZO-C M^@;IE=R:5X<#DF9":1:49D-I#I3F0FD>E..C:,WHTG;1I;U5IE5I0D4.DF9" M:1:49D-I#I3F0FD>E..C:,W(V=4[56E]Z*=2+FB%$THSH30+2K.A-_=*%^>F;^^*DZ}\.KG+N589?8N/6G)[7AT1T+(FE&9!:3:4 MYD!I+I3F06D^BM:,KUTE5!V^6=:%K/S-H#032K.@-!M*DV>XN<'UG,G4%I)I1F06DVE.9 :2Z4YD%!/HK6#*]=E5X=OUG. M!:W!0VDFE&9!:3:4YD!I+I3F06D^BM:,G%TQ7I46+W\JYX*6WZTTJSH#0; M2G.@-!=*\Z TOZ*U5:SO.'HCB5=Y]R.MD?45ERL:S&F6-Q"_+]*4/]WD"NH3L]/_5!+ P04 "J@&99^6@A>!D'M #G. &0 'AL+W=O %O[-RT MRKVX&#S[&Y@9]N'O9?+(^/=T26F&G{(P3L] [RRQ+SOK]U%O2R$U/64)C\WIO<^(V6"RS_$1_.DGAGSE& MT:"P^!K0QW3G,\IOY8&Q[_G!E7_>T_(KHB'ULASABC]K.J-AF)/$=?Q507M; MGWG#W<\;NE/E,Q;^'OC9\KPWZB&? SMU5F-VRQT^TNJ%!SO-8F!;_MH\?*5NLA;Y5F+*H:BRN(@KC\ZSY5@=AI{#C=#7#5 #<;F'L:&%4#XU /9M7 M/-3#H&HP.+2!536PBMB7P2HB;,N9.YUP]HAX;BUH^8 @SBOK+N/B MVT"TRZ:? T^4"45N[".1G=!]8-PMC}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

>BSBZ]4;F3T#" M254?D#0;E$9 :0X43:Z/6G'2U9+33'3P@4AXH8]6XEW=OR?E[*J[?P<5HD!I M=D63)$.S8R8%*C)!T>1,UC*3KA0K_C>]5GT91^<=5&BJ:))$/]3R?\W,@ZI(M4#0Y\ [6.I*N%)-70_E*&U6,^D+Y3I1J29H/2""C-@:+)/]77NAC6WL:8CT$U M-5":#4HCH#0'BB;71ZVI8:4F,Y7ZA-V%G6*UK48>G6K]D)_T0'V2@WPZ4#[E MU-
1R%E;+6GOYXJ.V^UIZ,S!BIU@=((*,V!HLD54 MB M^(WL#L*@VX- :38HC8#2"'B;7!^U*H>!-@FI.4?GMZUQ8=P2N>P.LWS=U9Q^ M=YA9;:7;@;H%.=2U9(;5DIE-
YY1SL5*ZW;]S"+GHDG[SD9#<\>K'.A:I,(O;362 WV9BMQW/U#+N[8QU,L\IH!!Y60#O1* M0+TZ'5X'VOZ UZH/5JL^KYH!M%C452V_U +,,-\L;;R.1QT3=?\6S;C0RS
MW5/\%]H+KK47K-9>Y$WCM]2CP=I]"+OC.&H]1?G^BU8<0861PYP24*=.AU,\ M'NVMWEKOP#^@=^R?)(MO#]I@I_9^],)JGJ T@@HS8&BR9OJ:]7#>".JAP&J M>H#2,%-:
:4Y4#2Y/FK5PU"K'J_=&Z[&'IUNO=4G-H=&4(?D98<.E,,R,?V= M]{ BRA?%&W,I\M@JSLJ79+9GMV_E713OHC7.7^IG,[WCO*V?D?*=NQI?O@)X M[?)%()[@B,Z%*^UT8-**
O'RKKCS(6%*\!?, LHQ%Q<TH-MV6T?5GUPPDE "YC:3K(C]BDXVI>$FS\?>?J@WTF!T*_LPB HQ]I MDK&I%&G>W^HZ6T>08G9#9B2+0L9ADB,)FJLW,V\"T):!8\7L,!]9X1M*4%2'?
Y>!C.-4,J1$DL.:2 HN_ M/.,[''L32@Z(RM6"33X4WB_0PE]Q)A-ER:EX M&PL<]S[%:Q%U0#@+D7!V@E>$XB*$LRT%$"G!&7J/EF4>(,)!,QG:F#^B!228
M0X@X$:_S/'D\0=!;'SB.$_9.8+\N??3VS3OT!L49^A*1'1/"V$3G0GVIA+ZN M5+TK5;6>4-5&]R3C$4-!%D+8@??[\>,>O"[<5OO..OKNSNHE7$)^@VSC%V09
MEM.AS_SY<+O+G)=)#_ZS])8S[#J1[(+/?H^OD3Q[0#-*<;8MN MV*@D\U62!8K(6E%TZB@Z?>S>%\)Q@A9$?(_$MZ/8U+C>U!3VD.V@*S0EJUNP
MRF_3WK.'CF%.]'W3YY>K+,L9#]JK,,M58WOH.NU5P>4JUQT.C'I5R_Q!,?Z@ MU_S2\(MJ]NT>TA70SJ3L);PV*562^2K) B5XD:BX=53'QA.H//K7
(^C1UMVD/KK#K,>X5DE%0G^+1,\X%>=M=(^SW48\[&B<;<7IK"C6O;6K5_2U6:^2 MS%=)%B@B:\5O7,=O_;U:ZPRBBK)?)5D@2*R5A1-XW1-,OZ7@U%%VRPQUG T
M/C\9]4N_UN\=0FW,'8_.ZHIJH6V7-FZ>Y@M+VX(\XJ2X:?Y[+>L7=NTV4,KF M*V4+5+&UTV:=PF:]=D6K-% 52Y5LOE*V0!5;,Y.G.[O9>YGTCANLKX#9E]>Q M@6FK;ND,Z*ON#9
M_)UY.S<[YGW942V:=B?ZLAU[C>DVSAA*8"-$&3=#+,6I@ZI'YSD10MO13@G M:?2D!R@7B_880+0Z:H=@$HPP #2D M 9 >&PO=V]R:W-
H965T;M/CV1JSQ\N9.WO^Q:?LJ]YJ?C&_NMBEM_*SK'[=?2SJG^9'RG6VD=LR MR[=.(6\N9S^YKX6[\)L9^R&_9?*Q/'GM-._E2YY_;7YX=WTY6S0AR;5<50TC MK?
_W()=RO6Y0=2!_'*BSXT&;B:>OG^EO]^^^?C=?TE(N_5_LNOJ[G(6SYQK M>9/>KZM/^>._Y.$=!0UOE:_+_7^=Q\/8Q%[(^#:K2^8?S M4UG*^D6ZO7;>9^F7;)U5F2R?
1UWO_[!,BR)K7E?."><A[+JLT6_J00W!]$)WO MO_O!^<{)DKLO=_E]64\K+'95'7H3P'QU"//-4YC>7X3Y6>Y>.6SQH^,M/-\P M?4E/YW53W?WTYEA.N]_=--TT?_HGCY]7!?K6#/O6#-
OSV.=-?NQLTKUO\5/ M:I M=KB?W33_ARO7"Z*$N1?SA]/L&L:QR$W\4!_'R6AL$P>":8GSCXGSR<0M\VU5 MG\EUSW)6>?WY=2V+M/D$,B7QB12<),>/_,7B+(7M42QVST=Q,BK;!
()@6@*# M8P*#'F?>6O4.4^:"7IEKCS)EC@S'-G,@F):Y\)BYD,SH[G)L'YQV)[5,@2-SGK3&0DMDD#P,2D)<>D)1T?BIN-+%99 MG;F/Z4X69%\B4;8G,1+&D3 !@FGU6*6?75I
=S:PMAY.%@M_$9UWL/:X6OO532PZ;V%0Z8RBZ=E3XMFEU?,R M+W9YD5:R3Z]"*M\EE,;A-(&BZ451NMP-I]6KH-(>2N-0FD#1],(J>>^24K.[M5T5M-NMMKC7+9@\'2E2%1V.=?
+&T-&N$M(NK:3KUW6?NLU6COCC/JN^ M.>^V#[*LGNP>LF\A=?$22N-0FD#1] HIU>XFT^I;4.D/I7$H3:!HNEVGU+]' MBM#.OG68KJ^O-TZCUK4,H\+ .[^\HD.Q]L3&4-
>>4M<>K:Z7LJBRFVQ5-Z[2 MR6\<+G=YF55DNZ*1UG8EDL:A-(&BZ<4Y<:.$G9D-C?6BL$8UUHL?0^I[2^MXP M,_HP7;M\BI(X/N]7[6%|&'KN>.<."JFD434^=4M,>K:.Y+++'M-
G[|)0_8_J0 M G@)I7=$H3:!H>C&4./>":34HJ,"TCB4)E TO;!*X'NT\[9H,+VJ90?>MYY M@X(J;2A-H&AZAI72]FBE_5X^R+7CTA=:4/L;2N-0FD#1]&(HY>[%^IC4,$/
MI7$H3:!H>F&5X/=HG[ZSCR5M\S!QP]:%5GM8F/BM/7]T,-.I&T-2,R6I&2VI M;?;]L,9P/M^ZUCV$TP%9]YD<0U@S):Q9'|NZ8]P;,Y0&H?2!(JFE^ID1_6T'&L&=:RA- ZE"11-
M+ZS2V&R88\W:3K113Z!AF&E3(!V,=>K&4,1,*6)&V]6&]F6U5Y#&6Y_C4(4+ MI0D432^44KAL6A8V@UK84!]'T@2*IA=6"6LVS,)F;6NZ= W6?QA9+]Y.2!_*^CR'VM]0FD#1]*
(IL>]/R_[VH8L#4!]'T@2* MIA=6+0{XP^QOOVU_L_9V0L.HH+V=D_[%.G%CB&]?B6_?SM5N+KU>L,.0/HKU MB0XUOJ$T@:.+I]5+*WY^6\>U#UP2@-_ZE"11-
+ZQ:$_"'&=]^V]%N78)U#N%'M$-8I&T-M!TMI[1-CKM:0VE<2A-H&AZ?92L#]Q)]:H N@X I7$H M3:!H>F'5.D! 6_Y=O8J>;@[/,=8 +&BZ350DCV@)?M3_/{JS(:8?T/
M-NJ_"&=]^V]%N78)U#N%'M$-8I&T-M!TMI[1-CKM:0VE<2A-H&AZ?92L#]Q)]:H N@X I7$H M3:!H>F'5.D! 6_Y=O8J>;@[/,=8 +&BZ350DCV@)?M3_/{JS(:8?T/
MI7$H3:!H>F&5X/=HG[ZSCR5M\S!QP]:%5GM8F/BM/7]T,-.I&T-2,R6I&2VI M;?;]L,9P/M^ZUCV$TP%9]YD<0U@S):Q9'|NZ8]P;,Y0&H?2!(JFE^ID1_6T'&L&=:RA- ZE"11-
M+ZS2V&R88\W:3K113Z!AF&E3(!V,=>K&4,1,*6)&V]6&]F6U5Y#&6Y_C4(4+ MI0D432^44KAL6A8V@UK84!]'T@2*IA=6"6LVS,)F;6NZ= W6?QA9+]Y.2!_*^CR'VM]0FD#1]*
(IL>]/R_[VH8L#4!]'T@2* MIA=6+0{XP^QOOVU_L_9V0L.HH+V=D_[%.G%CB&]?B6_?SM5N+KU>L,.0/HKU MB0XUOJ$T@:.+I]5+*WY^6\>U#UP2@-_ZE"11-
+ZQ:$_"'&=]^V]%N78)U#N%'M$-8I&T-M!TMI[1-CKM:0VE<2A-H&AZ?92L#]Q)]:H N@X I7$H M3:!H>F'5.D! 6_Y=O8J>;@[/,=8 +&BZ350DCV@)?M3_/{JS(:8?T/
M-NJ_"&=]^V]%N78)U#N%'M$-8I&T-M!TMI[1-CKM:0VE<2A-H&AZ?92L#]Q)]:H N@X I7$H M3:!H>F'5.D! 6_Y=O8J>;@[/,=8 +&BZ350DCV@)?M3_/{JS(:8?T/
MI7$H3:!H>F&5X/=HG[ZSCR5M\S!QP]:%5GM8F/BM/7]T,-.I&T-2,R6I&2VI M;?;]L,9P/M^ZUCV$TP%9]YD<0U@S):Q9'|NZ8]P;,Y0&H?2!(JFE^ID1_6T'&L&=:RA- ZE"11-
M+ZS2V&R88\W:3K113Z!AF&E3(!V,=>K&4,1,*6)&V]6&]F6U5Y#&6Y_C4(4+ MI0D432^44KAL6A8V@UK84!]'T@2*IA=6"6LVS,)F;6NZ= W6?QA9+]Y.2!_*^CR'VM]0FD#1]*
(IL>]/R_[VH8L#4!]'T@2* MIA=6+0{XP^QOOVU_L_9V0L.HH+V=D_[%.G%CB&]?B6_?SM5N+KU>L,.0/HKU MB0XUOJ$T@:.+I]5+*WY^6\>U#UP2@-_ZE"11-
+ZQ:$_"'&=]^V]%N78)U#N%'M$-8I&T-M!TMI[1-CKM:0VE<2A-H&AZ?92L#]Q)]:H N@X I7$H M3:!H>F'5.D! 6_Y=O8J>;@[/,=8 +&BZ350DCV@)?M3_/{JS(:8?T/
MI7$H3:!H>F&5X/=HG[ZSCR5M\S!QP]:%5GM8F/BM/7]T,-.I&T-2,R6I&2VI M;?;]L,9P/M^ZUCV$TP%9]YD<0U@S):Q9'|NZ8]P;,Y0&H?2!(JFE^ID1_6T'&L&=:RA- ZE"11-
M+ZS2V&R88\W:3K113Z!AF&E3(!V,=>K&4,1,*6)&V]6&]F6U5Y#&6Y_C4(4+ MI0D432^44KAL6A8V@UK84!]'T@2*IA=6"6LVS,)F;6NZ= W6?QA9+]Y.2!_*^CR'VM]0FD#1]*
(IL>]/R_[VH8L#4!]'T@2* MIA=6+0{XP^QOOVU_L_9V0L.HH+V=D_[%.G%CB&]?B6_?SM5N+KU>L,.0/HKU MB0XUOJ$T@:.+I]5+*WY^6\>U#UP2@-_ZE"11-
+ZQ:$_"'&=]^V]%N78)U#N%'M$-8I&T-M!TMI[1-CKM:0VE<2A-H&AZ?92L#]Q)]:H N@X I7$H M3:!H>F'5.D! 6_Y=O8J>;@[/,=8 +&BZ350DCV@)?M3_/{JS(:8?T/
**M-NJ_"

M"3'6IK@>%[D0>V9R6#DQMAK;ZZ6SP>VO.0,T-"-3F(N\D2435H:)[8:YBWQB-MW0B/$82^)D^FP("0,=/$RC2QW31?%E!LL$080*11U.-"N7@?8ZBL$]NM4P[. M?"6 +*=51>TH^XK&H=#Z?5;6B]TW5U%L=?>]"W(@M'Y!E,]CN_OI*)8]W-2 MDN$[IBF*N",:BI738[O36S44ZR^VB+CN^$QPMVE>L//% >]L:4G5J:)[::Y@W+]CNC!4'OH M>I0+X<@7)*)LD]AM\P^QI+SZ1LO7<69?@-J1]OZRJQ;OJ439+D%O_Z73ZNQ[M%^1 :/V"*(Z7R=?M'CQ\63Z&^W'I'K MWB$W0QCVX(@8$>7%QX:_&KQ) (9WWG"X:C8$C3%69DE>^'R\@WP2W06/O3!P MM2=NB)/RY(fID_)+8O?+E^6S >A^6R<0P>'ZW13FA=%PW>ET]K]RRA?UMF) M:K'8;NNT5]NMQ_-ZPVUP_0*=7FXW$!7,=C_S.N9RJ14@HP\2$IX$LFI\NT6X M/1%L5>^RW3,A6%X?+FD\I[P*D/&PO=V]R:W-H965TU!-#D.6-<#:REUOFU;:MX"1E5ER('CCMS(3.J M<2H7MLHET*0$9P8RXPJ M& KV*TWTI"EO'K3 MYUJ'+4#'?P/@U@#W6(!7 [QC 7X-\(%!#6@#-VN8B^%&U%-H[X4:R*-;*9 M0:E^B4:]4F[J9*HE[]:(T]%$BJ2(-;F"%? "U 7Y ?]"W,2G+1,A6N!Y&V4.Y0DN*I K4 3KE.PSD,]D6A4=$7/R(#I+E+X {'K,B@82P0%5X*E"=4X MOZ6,\AC(U$2BR/D<$W9)R1[G({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}#]JM)C0W\.GRWB0PE^Y@K:RFKYS\[.3+_:?%'4Q7]\7] M"EK3-.4NX4S 9UF=6H=06N.EG%AKN =?%W-H?7Z"EX#EW"?J=(PF9I1:"D: MAQDF-?--Q=Q]AGF%11MZG;? 0[73C!O?YR^YS3,@]\NZ]!O?EY>QG[B%)>-2Q M>]2QZ_%ZS^#=:BP83V'Q0%?>() F\,5FJ&%J#%KS%F:EUB@M?)NNC=5TH_YJ MTJQBB9M97)49FH(E. ZHC!C4.PPF;UY%@\ [')@5]=CR%X'I&[OJ&{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}H3[SXWMH$Y]8>#DOI/U%Q]8V\%"^EXJ7K;,F*%G5_/' M5HB> X[..)#6@3S67(GE=0IMH0V;36E)%LYG@1R2,M8RY/JPVUEMGPRI3QI42 M>I1I/Y5]4CL0Z%9*4!)=H5533<2WJ!E9[(6 2ITL7BU!45:\UJ9?5DOTZL5K M] *Q"MWO^%[2:B-GOM)4)K:?MP1O&P)RAF %]34*@S>(!"1RN"\NNR\AU^[8 MNH=/W7VM12<(Z00A-EYX)MZ=@)JR#?KG4>\4"4@GA?HBO>DD^?=V+970Z__ M5]+--+)%[%K,Y,V1-O=)$?PI!=_X3CXVR7!_Q3LB2!A)TAX*7JF-TA! MUUS09MMI.;B50T . [$#?!3B+W@2-;5!SEARR.(X"?>!#/[&Q%9DF:=Q9/2&. M.N+H(O$2A 8SQP.BHT=*"I#=Q%,6$#/#&5H$;;=*A32ZBG5:7.6 55+3* M 9F"L=RMXF0$@,.0Q -,AQ4F*7:CQAUJ_"S47 ^PG!:V]'I]774=T&P1)W@\ M1B)!."R_PRH@Z1F-DPX\N0A^3Q^O!!14P::_2$_\)BDG]9O4!HWJRNOBF M8[XX3 9\8R.2A&>6+ Y^WV;!LY1DE=P+L[N<]U$PGAM/TP&@PRH,)VS9>DDV%9'58XB*?A&:S?MQZ^>(=D]USI5=><['E[P=G#TWVC MD]&YC>-)E R+[+!+D@1' UJ_]WXQC\>/5#SH"](''MMHON$YTNJ)YCS4-Q6O[M!%ES1I]G.GW[@C(S>WW*N3@WS2NI>Q=DO4$L#!0 ("J 9EDX/)&_ M^00 T0 9 >&PO=V]R:W-H965T04=47.7#\LA0RHQI? MY$E5D&97/-V"*[57/Z^T& M'MAJK:B""%6!L(BC\;N(4T-4@8QS\5:*_V:0SWGW?HR2RH M@EN1_L42O; [JC7HD@24M4OT@MI^A(A08O%BDROXEVVJNVR-QH;3(*F.,(&.\ M_*5/E1![!M[P%0._,O";!H-7# :5P>"M'H:5P?"M'H+*('BKA[R"*WVI5A6 MZ1G5=#]18DNDF8UHYL$NE[5&@1DW.^M12_S*T$Y/_]!KD.1:*="*7)#'$\;)M[4H%.6)FC@:(S/X M3EQ%<5-&X;\2Q2/D?3)PSXGO^L,6\UFW^0QB-/>L^:#%?/YV[PUS!^6L-?5K M37V+-W@%[UY"3EE"[I[P_"L@J G9U_GY4 PWJ-$[+]>@=2^6X*$%-YEW,_5'GA]-G,V^6L>SHJ'O#@]G MS3L#/5&&82W#L%.&+UQ3OF"+%+=8M;$XZ#;&)4ZPSS@* (K?!N&76./0;L^:= M,9W(.*@9!YV,'P#/"HO-.L=4K=NH!D8/*84&@6P]$>$1L&)E,>+ [CB>% M0?/0S#L#.G%S1#7=J)/N+NV:>DH#ISP&8GRP&%I91T>$!F.WF06.)P7#,&RP M[HSK1-:CFO6HD[6]6-KHC8[IA4%S48\G!8,H:-#K#.!$>N.:WKB3WC>A:4J$ MO3WY7BU2)KPVWN.CHS0:!$'CE,Z.9WF#,(J\!O7.X$ZD[IG:^G!DKUIS_B]] MD-^PT@)R*[* <\F>RI@FA>2[%$\;Z&J)G+,;\H!]BL9BFIG9GI@,%2)LX%*=% M@F_X[35I"9KJ%S\?WHU\+_JD2,%ID3 +)2^1RZ40B[1$3*$GL-+VA:'CU3D^)E MK$PQN4 W!.LL#=D"W>U*/7M58_56C585'.F31J(GV$*5&#E()A)%RDM?$2W(M&?M(4M .I'452\#X" +01,*%V2)8;C["#.?+'O\D6+W/9*N->P\[*/;^S709H)^'TI&ULK9=- C]LV$(,_"J$&10(T*U+?VMH&-KL-VD-1(T[: M0]$#+8_60B31)2G;^^\[E&2M5Z(-'WJQ1'+FU3/DD$//#D)^5UL 38Y56:NY ML]5Z=^^Z*MM"Q=6=V$&-([F0%=? 8E,^NVDG@F]:I*EV/TLBM>%$[BUG;MY2+ MF6AT6=2PE$0U5<7ERR_O:@S?-,XGK^?U#^WP6,P.Z[@491_%1N]G3N)0S:0\Z;47\3A5^@# M"HU>)DK5_I)#;TL=DC5*BZIW1H*JJ+LG/_83<>: @=H=O-[!N]7![QW\-M". MK WKB6N^F$EQ(-)8HYIY:>>F]<9HBMHLXTI+'"W03R\>LDPVL&_'#$Q%"CR MD:RZ%24B)Y/1]T^@>5%^0+-OJR?R_MT'\HX4-?FZ%8WB]4;-7(U41MO->H)/ M'8%W@6 %NSOBTY^(1[W XOYXW?T),G1GK;O_UMW%N1@FQ!LFQ&OU_ MZ2_[" MUR6&BM%T\? -2D;\?UDI+S+E_;%HH

[C2KZ(I$S]HGUE:V@HVC%.L@HL/,B2O'SBYTJ' X#@:098%< Z!3@7 M 'B%L-]Z@E,!G+>>X%8]Q3@70!X%46DMV.1 A4NA MA53[,2A^L"S[8Z);D?,O0 M(H\&,L 'I?
C!C_!A.]ZT6@AT(6BMJO6JZLQJ95Q"T4.V\1Y9AN4T.#1_.]QN MTN/W3E_\WNEA.SR 2,!-!;=:M+3K#+45GWW)G2VFT)2A4TIQO@%1Y3A:O:!# MNSO\HI:G>TQC].5?08EN.&3L:U-
VEN<[S>?+RCYD!8Y@K(G2S8 ^@3,Y^R_3 M,_YIBFR79$&79(LNR<*.R(XRPJDSPFECKVK62D4Z.LP(>)9C:(IQR3A0C/)E
M^S1Q{)X{TI\.8]=@U.^9QT;!N9%I.SWOV&K19.7U_&.KL/6>OZBB6ZOHMJKX M4?QL'.'N/E)}(%/Q2\2YIW(.K>(YCG4AW;N0:??]$X.#Z!<91$7.1@J>!#GG"&KNZ7#^P:?;F%;
6TL=RT M\OYLN>F2+.B2;-$E6=@1V5&D_3K2_A]^_?E=9D279$&79(LNR<*.R(XRHE]G M1++^;TME*\[.!9(LZ)^5V(‘O>*>%^-S*%1]UUDE9#_-[+YK?"F .%V5'^IV^[{]O,=TD.4,I MK,5111L\7OM*RYRPGG!2J1UH1+CHN-=R*-AVH-!#[;T+XZT0>4#?^DV]02P,$ M% @ *H!F6<&)L3^!0 R", !D !X;"]W;W)K&ULS5I;;]LV&/TKA%<,+9#$HFZV,\=
8DM=@18UXG9[>X90<;@9P\'3C/MG&7-X8SJ8%VN(5YE^+)157PP9EDV0X9PG) M <4/-X-;>!W:KG0H+?Y(\($=G0,9RIJ0'_+BP^9F8,D9X11'7$(@<==CC.4Y3
MB23F\5<-.FC&E(['YT_H81F\"&:-&)Z3],]DP^.;P7@ -O@![5)^3PZ_XSH@ M3^)%)&7E7W"H;:T!B':,DZQV%C/(DKPZHI]U(HX<7!K!_>Y(WBU@_?<$?S:P2]S7R6KS/0"<32;4G(
5%H+-'E2EJOT%@E. M}[EPR3?23#KGC*3)!G%QL>+B(+J4,SG&YP+3 M$I0!E%?#4!S+'MYC\)$P!MXN,$=)^D[,[>MJ -=Z^>0?> '_)28[)GS8=,A% M2F1@PZ@.?UZ%;Y\)WP&?
2,YC!@(QPXW&/~GWG_3X#T4IFGK83_68V[V *UQ< M <>Z +9ENYKY+)(]NC"~6^CA_]Z}$XRG*8YQ+.#,79$5"C$&*TSW222. M,3%)=T.64$QVI1.63JT+6])9U.RXVF2
MXR4%,)=EB#[>X90<;@9P\'3C/MG&7-X8SJ8%VN(5YE^+)157PP9EDV0X9PG) M <4/-X-;>!W:KG0H+?Y(\($=G0,9RIJ0'_+BP^9F8,D9X11'7$(@<==CC.4Y3
MB23F\5<-.FC&E(['YT_H81F\"&:-&)Z3],]DP^.;P7@ -O@![5)^3PZ_XSH@ M3^)%)&7E7W"H;:T!B':,DZQV%C/(DKPZHI]U(HX<7!K!_>Y(WBU@_?<$?S:P2]S7R6KS/0"<32;4G(
5%H+-'E2EJOT%@E. M}[EPR3?23#KGC*3)!G%QL>+B(+J4,SG&YP+3 M$I0!E%?#4!S+'MYC\)$P!MXN,$=)^D[,[>MJ -=Z^>0?> '_)28[)GS8=,A% M2F1@PZ@.?UZ%;Y\)WP&?
2,YC!@(QPXW&/~GWG_3X#T4IFGK83_68V[V *UQ< M <>Z +9ENYKY+)(]NC"~6^CA_]Z}$XRG*8YQ+.#,79$5"C$&*TSW222. M,3%)=T.64$QVI1.63JT+6])9U.RXVF2
)6$DI5R.B84'!%*+KB5+A^B2M?F/N9ZWB6-1WNC[.NL1I#U2HXM8*. MZZMFH<[,'QV9=5+@-2GP#*1 ,%O-HDES3\MPU6!>)R^NI^9%8S6V?*CDY=1* MYD5R02?
&;O/B]>5GMUERF1A>DKYG^9.(K0>JL3H,\M8+N9.QY M2I :LYX@1TV0HI)K@YZA(1(PE-YUM@4BRE28-=_W8WZ"6U48G@5QZGJOF[M1*
M_=%H<*!G.TIZPSZ@3&34Z.T],UM0D6&2+#3&ZT&J+MCBU'}>:$L-&:V[=@*)0<:,\^%T%$82&/F6P[T]#0<$C[02[']!"0&*A7<+-ZX MLB;1 J-
HH2FT;F5;A0K{):H'M)H3]Z8Y6'-&8C=Z3JGHV9ZT\\5;QKS(3" M/V*U;FY:80O[U:>0:9PF$?\2MF"7)UH5.^\'>G&[FD0+C**%IM"Z)6F%,QR_ M,B(RJKN-H@5&T4)3:-W*MMH;]LI XT0T.>$$!T[LDP71J9D]GJC_'@PT9I.1 MK?X?+M28C2QH03T1V:V$M?LEK+(@6NYH%(L4@66*M.NB?KB7-JU1M, H6F@* MK5N85C_,\'71D6U4>1M%"XRBA:,0NI5ME;?
=J_],TU$]6N?#RP3:"AOIK'Q? M56<:*\]WU2\]&BM7+,7.4)'4K=T[K5JS^]7:._@=+*&4+4\ )X#$&N6SAK/]* MC.579/'K*$1'KS%M/L6'"Q }^[:!.& J8 D'&>+BUX+VT-AT>;!C),M^7V
M#B8@=CFOOF4U=YLM)'?EQ@GE_AQ>+Z#F?@"O0]W]6]N¥#FQ'^\053\JM$\-V M2M4>ET^(;I.<@10_B.E95R/QVJ#5MI'J@1.BW.:P)IR3K#R.,=I@*@W$\P=" M^-.%'*#9O#/[!U!+
P04 "_J@&9949TFK1T% !\$@ &0 'AL+W=O M4HM@2+0=;7VR)_,[E.SPZ/.1P)^0WM6), MH^<*]1-;Z7U^MKSU'S%5% M;S2T8P]R-!0;G?&"/4BD-GE.Y??W+!.[FQ[NO0Q\Y,N5-
@/>:+BF2_;(].?U M@X0WKJ:2\IP5BHL"2;:XZ=WBZQF.C(!%?.%L[_>D:'R),0W\W*7WO1\XQ'+ MV%P;%13^MFS,LLQH C_^J93V:IM&W?22'DK9 M@FXR_5'L?F<5(>0@7&3*_])=A?
5[.+Y16N25,'B0\Z+\I\]5(/8$<'!$@%0" MI"D0'1$(*H&@*1 >$0@K@?"M%])*('JKA;@2B&WLRV#92$^IHJ.A%#LD#1]T MF0>[7%8. LP+DUF/6L(L!SD]^E.OF$1WQ5SD#)W](90ZOT
?(*,OT6.9,$@L MD .%SB9,4YZ=_+SXP2=O3M'[Q OT*>5V"A:I&KH:7#0F/'FE3/CTAERQ)D MW8M"KQ2:%BE+'?+3;OE!A[P'@:FC0UZB,R:="A_9^@H%_@4B/@D=_DS>+AZX
MZ/P_Z{/_;/T@&$&=*H'5%QS1!T$44- DU;Q8UKDP?88:H'$0^GK[I+2$0O&W M:1>S;LZF>UVI-Y^RF!^51,;EE0=']//^8_4+25]!^I,/HCEH:11.5A %NZ)HY4%'BOZ(.^3$FBZF
MI8)HSVX_:E*8M$&#)$@:/-L@0OI1T.#I0 &(N'G&-<_X;3Q9^>FYB,8MPY?A M_#=(3!RHB)#&8DT=*!P,<-S@ZH+%_7[L)MNOR?8[R8Y7M%@RLZTL*)=H2[,-
M,_F=,LFWU#0EZA='-YW:_V*G46JWZ* HR!J!*T-NH0NSF\$8%*HKBA:^9 M8;*GZR!D21VRI#L_\C6$RG[Z$"A3DS5,\OE>27#NS$G+EP:G21MQ">G2_XV:.B!%CA3-
;!EXD%Q(KK^CCVQK3C%?Q :.7M(9"GPRP4]# MIJ:5/.NF;MAO!]IZR)U/\31NVX6IEOF@G87*:\$G(]#1D MYH!R@*./TB6=<@UFQC3+U+X 58H=87@;(]R M(8WI\HX#%%^@=
<;@$(_/0?Z(#1#X06:&<>.7N878CF=V(K#F+P7!.N2M, M:K.T8)#H5Z5EV-L[Z.9,+NV5A$*VORT[Q7]TOO9X;P.[C?$QOIY@Q_C47),X
MQF]Q>#W%H7,F@AE[>O=>72KO9>ZI7/)"H8PMP#W_J@]+*\NKCO)%B[4]FC\) M#0=]^{B"L#%I #"_$!";ZL4BJ"^<1O\"4$L#!!0 ("J 9EFG)-B=!P4 M /D@ 9 >&PO=V]R:W-
H965T,OY3K $D>4GB5$R,M939E6F*Q1H2*BY9!JGZ9,EX0J5ZY"M3 M9!QH6!@EL>E85M],:)0:TW'Q[HY/QVPCXRB%.T[$)DDH?YU!S+83PS;>7MQ' MJ[7,7YC3<497
#R,,OCZLFL*6&40"HBEA(.RX59,5\%=B\W*%K\$<%6[-V3 MO"M/C/W,'V["B6'E4,"YDCJ+=H$;M,S?> MJ(
YB_^,0KF>&$.#A+"DFUC>L^U7[#I4!++A@L2C^DFW9MC@6._8^!4!LZA0?\=@TYET#DT<-XQZ%8&W<^&U*L,>I_UT*\,
M^I\U&%0&@R)9Y;=;I,:EDD['G&T)SULK6GY3Y+>P5AF)TER*#Y*K3R-E)Z?? M0.51D+/K,(QR;="8W*2EPM73.3ES0=(H%N?D"XE2\GW--H*FH1B;4GG/&>:B M\N26GIQW/-
GDEJ5R+R8*2*UV/MZ^Y'&WE2]KKONO'5]YFB!M_25=.P+XEB. M0QX?7'+VY;PEK+F>ISO7 MT5!\/>4!,A6,]6$P@1[CPN+R@V@:&>S4XNT4W,Z[XA4"X((4(KX@+H@%C[)B
MB/OQ3;4E-Q(2\5=+P+,2W&T'Y^/_E_I9DS&O6$!4BPAESZM5SZ_]?TT@?+631IF&!XFS,>$!4BPACA&N3&'XA#*EWDLIAS4-MJ W<-d_A9@%MH@=K8-Z_P>Z4(?Q*G"0*5YJ#0?
E19@T9KB MV*NXV5IQ/*9A)!9LDTHE#0ZD)!E]3=2U50E:UJG31D7;UU7'&APIRT7UZJ'2 M?%1:@$5K.L'9:<'1.N$[I%0)($HRSIXA%P&A<[%AE(SPXZH2H6E8 M;1/BB#Y%
**<20C:*TUZ1V=G%C4B8BJS:MH'XC.1W4:8-&..MG5&VV4@.>97MU'W[VL"

!X;"]W;W)K&UL4$L! A0#% @ M*H!F66&[,A/< P 7PD !D ("!>>< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *H!F6;\AR5QT!@ /3L !D M ("!W (! 'AL+W=O!D' #G. &0 @(&'"0$ >&PO=V]R:W-H M965T&UL4$L! M A0#% @ *H!F6?N!!T2C# -*0 !D ("!'14! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *H!F M6:[TTEE# P 60T !D ("!9BP! 'AL+W=O&PO=V]R:W-H965T*> ($<& 9 " @<0W 0!X;"]W;W)K M&UL4$L! A0#% @ *H!F68'R]SF9! Y1P M !D ("!&PO=V]R:W-H965T&UL4$L! A0#% @ *H!F6;3$%QC+!0 M!T !D M ("!_$@! 'AL+W=O&UL4$L! A0# M% @ *H!F6071$91^ @ 8P8 !D ("!&%4! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ *H!F63@\ MD;_Y! #1 !D ("!JU\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *H!F65U*[^,2! 7A0 !D M ("!-70! 'AL+W=O $ >&PO M=V]R:W-H965T&UL4$L! A0#% @ *H!F68OI.6PX!@ !!L !D ("! M3X(! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ *H!F65&=)JT=!0 ?!(!D ("!P9(! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *H!F60H@4=ME @ D04 !D M ("!V*T! 'AL+W=O*1TG,# #V" &0 @(%TL $ >&PO=V]R M:W-H965T&UL M4$L! A0#% @ *H!F657EFB5" P *!0 T (!?[D! M 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! M A0#% @ *H!F6 XML 85 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none';};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{ display: block; font-weight: bold; } .report table.authRefData p{ margin-top: 0px; } .report table.authRefData .hide{ background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover{ background-color: #2F4497; } .report table.authRefData .body{ height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited{ color: black; text-decoration: none; } /* table */ .report{ background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr{ border: 1px solid #acf; } /* Top labels */ .report th{ background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void{ background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl{ text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a{ cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a{ width: 200px; } .report td.pl a:hover{ background-color: #ffc; } /* Header rows... */ .report tr.rh{ background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc{ background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu{ background-color: #def; } .report .reu td{ border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou{ background-color: white; } .report .rou td{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td{ border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn{ white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump{ text-align: right; white-space: nowrap; } .report .nump{ padding-left: 2em; } .report .nump{ padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text{ text-align: left; white-space: normal; } .report .text .big{ margin-bottom: 1em; width: 17em; } .report .text .more{ display: none; } .report .text .note{ font-style: italic; font-weight: bold; } .report .text .small{ width: 10em; } .report sup{ font-style: italic; } .report .outerFootnotes{ font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 306 325 1 true 69 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Sheet http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Statements 4 false false R5.htm 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995455 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureORGANIZATIONANDNATUREOFBUSINESS ORGANIZATION AND NATURE OF BUSINESS Notes 9 false false R10.htm 995465 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 995475 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLICENSEANDCOLLABORATIONAGREEMENTS LICENSE AND COLLABORATION AGREEMENTS Notes 11 false false R12.htm 995495 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 12 false false R13.htm 995505 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIES CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES Notes 13 false false R14.htm 995515 - Disclosure - PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenues1 PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES Notes 14 false false R15.htm 995525 - Disclosure - INVENTORY Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINVENTORY INVENTORY Notes 15 false false R16.htm 995535 - Disclosure - OTHER ASSETS Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOTHERASSETS OTHER ASSETS Notes 16 false false R17.htm 995545 - Disclosure - ACCRUED EXPENSES Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureACCRUEDEXPENSES ACCRUED EXPENSES Notes 17 false false R18.htm 995555 - Disclosure - INDEBTEDNESS Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINDEBTEDNESS INDEBTEDNESS Notes 18 false false R19.htm 995565 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureSTOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 19 false false R20.htm 995575 - Disclosure - OTHER INCOME (LOSS), NET Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNet OTHER INCOME (LOSS), NET Notes 20 false false R21.htm 995585 - Disclosure - INCOME TAXES Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxes INCOME TAXES Notes 21 false false R22.htm 995595 - Disclosure - LEASES Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLEASES LEASES Notes 22 false false R23.htm 995605 - Disclosure - EARNINGS (LOSS) PER SHARE Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningsLossPerShare EARNINGS (LOSS) PER SHARE Notes 23 false false R24.htm 995615 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 24 false false R25.htm 995635 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 25 false false R26.htm 995645 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables LICENSE AND COLLABORATION AGREEMENTS (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLICENSEANDCOLLABORATIONAGREEMENTS 26 false false R27.htm 995655 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS 27 false false R28.htm 995665 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIES 28 false false R29.htm 995675 - Disclosure - PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTables PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenues1 29 false false R30.htm 995685 - Disclosure - INVENTORY (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINVENTORYTables INVENTORY (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINVENTORY 30 false false R31.htm 995695 - Disclosure - OTHER ASSETS (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOTHERASSETSTables OTHER ASSETS (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOTHERASSETS 31 false false R32.htm 995705 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureACCRUEDEXPENSESTables ACCRUED EXPENSES (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureACCRUEDEXPENSES 32 false false R33.htm 995715 - Disclosure - INDEBTEDNESS (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINDEBTEDNESSTables INDEBTEDNESS (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINDEBTEDNESS 33 false false R34.htm 995725 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureSTOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureSTOCKBASEDCOMPENSATION 34 false false R35.htm 995735 - Disclosure - OTHER INCOME (LOSS), NET (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetTables OTHER INCOME (LOSS), NET (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNet 35 false false R36.htm 995745 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningsLossPerShareTables EARNINGS (LOSS) PER SHARE (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningsLossPerShare 36 false false R37.htm 995755 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES 37 false false R38.htm 995765 - Disclosure - Organization and Nature of Business - Additional Information (Detail) Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail Organization and Nature of Business - Additional Information (Detail) Details 38 false false R39.htm 995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 39 false false R40.htm 995785 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail License and Collaboration Agreements - Additional Information (Detail) Details 40 false false R41.htm 995795 - Disclosure - License and Collaboration Agreements - Summary of Activity Related to Supply Agreement (Details) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails License and Collaboration Agreements - Summary of Activity Related to Supply Agreement (Details) Details 41 false false R42.htm 995815 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured and Carried at Fair Value (Detail) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail Fair Value Measurements - Assets and Liabilities Measured and Carried at Fair Value (Detail) Details 42 false false R43.htm 995825 - Disclosure - Fair Value Measurements - Summary of Fair Value of Level 3 Financial Liabilities (Details) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfLevel3FinancialLiabilitiesDetails Fair Value Measurements - Summary of Fair Value of Level 3 Financial Liabilities (Details) Details 43 false false R44.htm 995835 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 44 false false R45.htm 995845 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Company Financial Assets with Maturities of Less Than 90 Days Included in Cash Equivalents (Detail) Sheet

http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90Days Cash, Cash Equivalents and Marketable Securities - Summary of Company Financial Assets with Maturities of Less Than 90 Days Included in Cash Equivalents (Detail) Details 45 false false R46.htm 995855 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Company Cash, Cash Equivalents and Short-term Investments (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments Cash, Cash Equivalents and Marketable Securities - Summary of Company Cash, Cash Equivalents and Short-term Investments (Detail) Details 46 false false R47.htm 995865 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail) Details 47 false false R48.htm 995875 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Product Revenues (Details) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Product Revenues (Details) Details 48 false false R49.htm 995885 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues (Additional Information) (Details) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues (Additional Information) (Details) Details 49 false false R50.htm 995895 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summarizes the concentration of the three largest customers (Details) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfTheTh Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summarizes the concentration of the three largest customers (Details) Details 50 false false R51.htm 995905 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Change in Reserves for Discounts and Allowances (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisco Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Change in Reserves for Discounts and Allowances (Detail) Details 51 false false R52.htm 995915 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Total Reserves Included in Consolidated Balance Sheets (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfTotalReservesIncludedInC Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Total Reserves Included in Consolidated Balance Sheets (Detail) Details 52 false false R53.htm 995925 - Disclosure - Inventory - Summary of Components of Inventory (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureInventorySummaryOfComponentsOfInventoryDetail Inventory - Summary of Components of Inventory (Detail) Details 53 false false R54.htm 995935 - Disclosure - Inventory - Summarizes the Balance Sheet Classification (Details) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureInventorySummarizesTheBalanceSheetClassificationDetails Inventory - Summarizes the Balance Sheet Classification (Details) Details 54 false false R55.htm 995945 - Disclosure - OTHER ASSETS (Additional Information) (Details) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails OTHER ASSETS (Additional Information) (Details) Details
http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOTHERASSETSTables 55 false false R56.htm 995955 - Disclosure - Other Assets - Summary of Other Current Assets (Detail) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail Other Assets - Summary of Other Current Assets (Detail) Details 56 false false R57.htm 995965 - Disclosure - Other Assets - Summary of Other Non-current Assets (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherNoncurrentAssetsDetail Other Assets - Summary of Other Non-current Assets (Detail) Details 57 false false R58.htm 995975 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail Accrued Expenses - Summary of Accrued Expenses (Detail) Details 58 false false R59.htm 995985 - Disclosure - Indebtedness - Additional Information (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail Indebtedness - Additional Information (Detail) Details 59 false false R60.htm 995995 - Disclosure - Indebtedness - Summary of Debt Facilities (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail Indebtedness - Summary of Debt Facilities (Detail) Details 60 false false R61.htm 996005 - Disclosure - Indebtedness - Summarizes Total Gross Payments Due under Company's Debt Arrangements (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail Indebtedness - Summarizes Total Gross Payments Due under Company's Debt Arrangements (Detail) Details 61 false false R62.htm 996015 - Disclosure - Stock-Based Compensation - Summary of Stock Awards Granted (Detail) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail Stock-Based Compensation - Summary of Stock Awards Granted (Detail) Details 62 false false R63.htm 996025 - Disclosure - Stock-Based Compensation - Summary of Stock Awards Granted (Parenthetical) (Details) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails Stock-Based Compensation - Summary of Stock Awards Granted (Parenthetical) (Details) Details 63 false false R64.htm 996035 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 64 false false R65.htm 996045 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Grant Type Included within Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedConso Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Grant Type Included within Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail) Details 65 false false R66.htm 996055 - Disclosure - Other Income (Loss), Net - Summary of Other Income (Loss) (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail Other Income (Loss), Net - Summary of Other Income (Loss) (Detail) Details 66 false false R67.htm 996075 - Disclosure - Leases (Additional Information) (Details) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails Leases (Additional Information) (Details) Details 67 false false R68.htm 996085 - Disclosure - INCOME TAXES (Additional Information) (Details) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails INCOME TAXES (Additional Information) (Details) Details
http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxes 68 false false R69.htm 996095 - Disclosure - Earning (Loss) Per Share - Basic and Diluted Net Loss Per Share (Detail) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail Earning (Loss) Per Share - Basic and Diluted Net Loss Per Share (Detail) Details 69 false false R70.htm 996105 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Parenthetical) (Detail) Sheet http://www.sarepta.com/20240930/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareParentheticalDetail Net Loss Per Share - Basic and Diluted Net Loss Per Share (Parenthetical) (Detail) Details 70 false false R71.htm 996115 - Disclosure - Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Details) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDiluted Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Details) Details 71 false false R72.htm 996125 - Disclosure - Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Parenthetical) (Details) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDiluted Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Parenthetical) (Details) Details 72 false false R73.htm 996135 - Disclosure - Commitments and Contingencies - Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations (Detail) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactur Commitments and Contingencies - Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations (Detail) Details 73 false false R74.htm 996145 - Disclosure - Commitments and Contingencies (Additional Information) (Details) Sheet
http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies (Additional Information) (Details) Details 74 false false All Reports Book All Reports srpt-20240930.htm srpt-20240930.xsd http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 91 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "srpt-20240930.htm": { "nsprefix": "srpt", "nsuri": "http://www.sarepta.com/20240930", "dts": { "inline": { "local": ["srpt-20240930.htm"] }, "schema": { "local": ["srpt-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 251, "keyCustom": 74, "axisStandard": 21, "axisCustom": 0, "memberStandard": 25, "memberCustom": 39, "hidden": { "total": 16, "http://fasb.org/us-gaap/2024": 11, "http://www.sarepta.com/20240930": 1, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 306, "entityCount": 1, "segmentCount": 69, "elementCount": 696, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 849, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 7, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R3": { "role": "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R4": { "role":

"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "srpt:CostOfGoodsSoldExcludingAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R5": { "role": "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_062445ff-fb82-4c7b-a25f-eb602b3e3f27", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_27ae4127-70f9-4c56-be8f-4e649c3c752c", "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R6": { "role": "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureORGANIZATIONANDNATUREOFBUSINESS", "longName": "995455 - Disclosure - ORGANIZATION AND NATURE OF BUSINESS", "shortName": "ORGANIZATION AND NATURE OF BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1", "longName": "995465 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLICENSEANDCOLLABORATIONAGREEMENTS", "longName": "995475 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS", "shortName": "LICENSE AND COLLABORATION AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS", "longName": "995495 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIES", "longName": "995505 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES", "shortName": "CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenues1", "longName": "995515 - Disclosure - PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES", "shortName": "PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "srpt:ProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "srpt:ProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINVENTORY", "longName": "995525 - Disclosure - INVENTORY", "shortName": "INVENTORY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOTHERASSETS", "longName": "995535 - Disclosure - OTHER ASSETS", "shortName": "OTHER ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureACCRUEDEXPENSES", "longName": "995545 - Disclosure - ACCRUED EXPENSES", "shortName": "ACCRUED EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINDEBTEDNESS", "longName": "995555 - Disclosure - INDEBTEDNESS", "shortName": "INDEBTEDNESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureSTOCKBASEDCOMPENSATION", "longName": "995565 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNet", "longName": "995575 - Disclosure - OTHER INCOME (LOSS), NET", "shortName": "OTHER INCOME (LOSS), NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxes", "longName": "995585 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLEASES", "longName": "995595 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-

4a5d-bd80-77a264c4c2ec", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningsLossPerShare", "longName": "995605 - Disclosure - EARNINGS (LOSS) PER SHARE", "shortName": "EARNINGS (LOSS) PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES", "longName": "995615 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995635 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables", "longName": "995645 - Disclosure - LICENSE AND COLLABORATION AGREEMENTS (Tables)", "shortName": "LICENSE AND COLLABORATION AGREEMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "srpt:ScheduleOfCertainActivityRelatedToRevenueWithSupplyAgreementTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "srpt:ScheduleOfCertainActivityRelatedToRevenueWithSupplyAgreementTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables", "longName": "995655 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables", "longName": "995665 - Disclosure - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables)", "shortName": "CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTables", "longName": "995675 - Disclosure - PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES (Tables)", "shortName": "PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "srpt:ProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "srpt:ProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINVENTORYTables", "longName": "995685 - Disclosure - INVENTORY (Tables)", "shortName": "INVENTORY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "srpt:ScheduleOfInventoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "srpt:ScheduleOfInventoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOTHERASSETSTables", "longName": "995695 - Disclosure - OTHER ASSETS (Tables)", "shortName": "OTHER ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OtherAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OtherAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureACCRUEDEXPENSESTables", "longName": "995705 - Disclosure - ACCRUED EXPENSES (Tables)", "shortName": "ACCRUED EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINDEBTEDNESSTables", "longName": "995715 - Disclosure - INDEBTEDNESS (Tables)", "shortName": "INDEBTEDNESS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureSTOCKBASEDCOMPENSATIONTables", "longName": "995725 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetTables", "longName": "995735 - Disclosure - OTHER INCOME (LOSS), NET (Tables)", "shortName": "OTHER INCOME (LOSS), NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningsLossPerShareTables", "longName": "995745 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)", "shortName": "EARNINGS (LOSS) PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESTables", "longName": "995755 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail", "longName": "995765 - Disclosure - Organization and Nature of Business - Additional Information (Detail)", "shortName": "Organization and Nature of Business - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "srpt:CashCashEquivalentsRestrictedCashAndInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first":

```
true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "srpt:CashCashEquivalentsRestrictedCashAndInvestments",
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-
gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first":
true, "unique": true } }, "R39": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"longName": "995775 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies
- Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef":
"C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF",
"ancestors": [ "span", "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount":
1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-
gaap:NumberOfOperatingSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-
gaap:BasisOfAccountingPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-
20240930.htm", "first": true, "unique": true } }, "R40": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail", "longName": "995785 - Disclosure -
License and Collaboration Agreements - Additional Information (Detail)", "shortName": "License and Collaboration Agreements - Additional Information (Detail)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44",
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p",
"td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-
4ed61eda8b44", "name": "srpt:DevelopmentMilestoneAndSettlementUpfrontFeeRecognizedAsResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang":
null, "decimals": "-6", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R41": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails", "longName":
"995795 - Disclosure - License and Collaboration Agreements - Summary of Activity Related to Supply Agreement (Details)", "shortName": "License and Collaboration
Agreements - Summary of Activity Related to Supply Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "41", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-
gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [
"span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_870bb570-299c-4707-
b4f0-952fb8c94e90", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr",
"table", "ix:continuation", "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique":
true } }, "R42": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail",
"longName": "995815 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured and Carried at Fair Value (Detail)", "shortName": "Fair Value Measurements -
Assets and Liabilities Measured and Carried at Fair Value (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"42", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang":
null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-
20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:AssetsFairValueDisclosure",
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"
], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R43": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfLevel3FinancialLiabilitiesDetails", "longName": "995825 -
Disclosure - Fair Value Measurements - Summary of Fair Value of Level 3 Financial Liabilities (Details)", "shortName": "Fair Value Measurements - Summary of Fair Value of
Level 3 Financial Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": {
"contextRef": "C_eb43281d-22c3-4944-87d8-254abce3abb6", "name": "us-gaap:LiabilitiesFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first":
true }, "uniqueAnchor": { "contextRef": "C_65357d7d-8671-4c15-8537-b2fbe7ccfdde", "name": "us-gaap:LiabilitiesFairValueAdjustment", "unitRef": "U_USD", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div",
"ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R44": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "longName": "995835 - Disclosure - Fair Value
Measurements - Additional Information (Detail)", "shortName": "Fair Value Measurements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-
gaap:EquityMethodInvestmentOtherThanTemporaryImpairment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr",
"table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "div", "body", "html" ],
"reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2dbf3498-ef02-4c0b-8dcc-fd636031043d", "name": "us-
gaap:DebtInstrumentMaturityDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ],
"reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R45": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90Da
"longName": "995845 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Company Financial Assets with Maturities of Less Than 90 Days Included
in Cash Equivalents (Detail)", "shortName": "Cash, Cash Equivalents and Marketable Securities - Summary of Company Financial Assets with Maturities of Less Than 90 Days
Included in Cash Equivalents (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": {
"contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-
gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-
gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } },
"R46": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
"longName": "995855 - Disclosure - Cash, Cash Equivalents and Marketable Securities - Summary of Company Cash, Cash Equivalents and Short-term Investments (Detail)",
"shortName": "Cash, Cash Equivalents and Marketable Securities - Summary of Company Cash, Cash Equivalents and Short-term Investments (Detail)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name":
"srpt:CashAndCashEquivalentsAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-
20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name":
"srpt:CashAndCashEquivalentsAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-
20240930.htm", "first": true, "unique": true } }, "R47": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail", "longName": "995865 - Disclosure -
Cash, Cash Equivalents and Marketable Securities - Additional Information (Detail)", "shortName": "Cash, Cash Equivalents and Marketable Securities - Additional
Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef":
"C_6b6cfa20-4c60-421b-9792-b1b4478022b7", "name": "srpt:WeightedAverageMaturityPeriodOfAvailableForSaleSecurities", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "C_6b6cfa20-4c60-421b-9792-b1b4478022b7", "name": "srpt:WeightedAverageMaturityPeriodOfAvailableForSaleSecurities", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm",
"first": true, "unique": true } }, "R48": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails",
"longName": "995875 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Product Revenues (Details)",
"shortName": "Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Product Revenues (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name":
"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr",
"table", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_6cf8095c-b981-4f44-bf2b-a633195de5a6",
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p",
"td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "srpt:ProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTextBlock",
"div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R49": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"longName": "995885 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues (Additional Information) (Details)", "shortName":
"Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-
gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr",
"table", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eb43281d-22c3-4944-87d8-254abce3abb6",
"name": "us-gaap:BilledContractReceivables", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "body",
"html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R50": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1
"longName": "995895 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summarizes the concentration of the three largest
customers (Details)", "shortName": "Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summarizes the concentration of the three largest
customers (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef":
"C_e7c80fa6-57dc-43e7-a7a7-3174a36e9532", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2",
"ancestors": [ "span", "p", "td", "tr", "table", "srpt:ScheduleOfProductRevenuesConcentrationRiskTableTextBlock", "div", "ix:continuation", "div", "body", "html" ],
"reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc
"longName": "995905 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Change in Reserves for Discounts and
Allowances (Detail)", "shortName": "Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Change in Reserves for Discounts and
Allowances (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef":
"C_eb43281d-22c3-4944-87d8-254abce3abb6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null,
"decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "srpt:SummaryOfChangeInReservesForDiscountsAndAllowancesTableTextBlock", "div", "ix:continuation", "div",
"body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name":
"srpt:ProvisionForReservesForDiscountsAndAllowances", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table",
"srpt:SummaryOfChangeInReservesForDiscountsAndAllowancesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-
20240930.htm", "unique": true } }, "R52": { "role":
```

```
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfTotalReservesIncludedIn(
"longName": "995915 - Disclosure - Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Total Reserves Included in
Consolidated Balance Sheets (Detail)", "shortName": "Product Revenues, Net, Accounts Receivable, Net, and Reserves for Product Revenues - Summary of Total Reserves
Included in Consolidated Balance Sheets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52",
"firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "srpt:ReservesForReductionToAccountsReceivable", "unitRef": "U_USD", "xsiNil": "false",
"lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table",
"srpt:SummaryOfReservesForDiscountsAndAllowancesIncludedInConsolidatedBalanceSheetsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1,
"baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name":
"srpt:ReservesForReductionToAccountsReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table",
"srpt:SummaryOfReservesForDiscountsAndAllowancesIncludedInConsolidatedBalanceSheetsTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1,
"baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R53": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureInventorySummaryOfComponentsOfInventoryDetail", "longName": "995925 - Disclosure - Inventory - Summary of
Components of Inventory (Detail)", "shortName": "Inventory - Summary of Components of Inventory (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-
gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table",
"srpt:ScheduleOfInventoryTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first":
true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef":
"U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "srpt:ScheduleOfInventoryTableTextBlock", "div", "us-
gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R54": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureInventorySummarizesTheBalanceSheetClassificationDetails", "longName": "995935 - Disclosure - Inventory -
Summarizes the Balance Sheet Classification (Details)", "shortName": "Inventory - Summarizes the Balance Sheet Classification (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-
gaap:InventoryNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1,
"baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails", "longName": "995945 - Disclosure - OTHER ASSETS (Additional
Information) (Details)", "shortName": "OTHER ASSETS (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:RestrictedCashNoncurrent", "unitRef":
"U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm",
"first": true }, "uniqueAnchor": null }, "R56": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail",
"longName": "995955 - Disclosure - Other Assets - Summary of Other Current Assets (Detail)", "shortName": "Other Assets - Summary of Other Current Assets (Detail)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-
9859a6c51f4e", "name": "srpt:CollaborationReceivableCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table",
"us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "us-gaap:OtherAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-
20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "srpt:CollaborationReceivableCurrent",
"unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div",
"us-gaap:OtherAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R57": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherNoncurrentAssetsDetail", "longName": "995965 - Disclosure - Other Assets -
Summary of Other Non-current Assets (Detail)", "shortName": "Other Assets - Summary of Other Non-current Assets (Detail)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name":
"srpt:ManufacturingRelatedDepositsAndPrepaidExpenseNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr",
"table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "div", "us-gaap:OtherAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-
20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name":
"srpt:ManufacturingRelatedDepositsAndPrepaidExpenseNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr",
"table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "div", "us-gaap:OtherAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-
20240930.htm", "first": true, "unique": true } }, "R58": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail", "longName": "995975 - Disclosure - Accrued Expenses -
Summary of Accrued Expenses (Detail)", "shortName": "Accrued Expenses - Summary of Accrued Expenses (Detail)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name":
"srpt:AccruedProductRevenueRelatedReserveCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1,
"baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name":
"srpt:AccruedProductRevenueRelatedReserveCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1,
"baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R59": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "longName": "995985 - Disclosure - Indebtedness - Additional
Information (Detail)", "shortName": "Indebtedness - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "59", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "U_USD",
"xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div",
"ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-
4ed61eda8b44", "name": "us-gaap:AmortizationOfFinancingCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p",
"ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R60": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail", "longName": "995995 - Disclosure - Indebtedness - Summary
of Debt Facilities (Detail)", "shortName": "Indebtedness - Summary of Debt Facilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef":
"U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div",
"ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-
9859a6c51f4e", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table",
"us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R61":
{ "role": "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail",
"longName": "996005 - Disclosure - Indebtedness - Summarizes Total Gross Payments Due under Company's Debt Arrangements (Detail)", "shortName": "Indebtedness -
Summarizes Total Gross Payments Due under Company's Debt Arrangements (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "61", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-
gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p",
"td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-
20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-
gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p",
"td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-
20240930.htm", "first": true, "unique": true } }, "R62": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail", "longName": "996015 - Disclosure - Stock-
Based Compensation - Summary of Stock Awards Granted (Detail)", "shortName": "Stock-Based Compensation - Summary of Stock Awards Granted (Detail)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals":
"0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true },
"uniqueAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef":
"U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body",
"html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R63": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails", "longName": "996025 -
Disclosure - Stock-Based Compensation - Summary of Stock Awards Granted (Parenthetical) (Details)", "shortName": "Stock-Based Compensation - Summary of Stock Awards
Granted (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "63", "firstAnchor": {
"contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
"unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-
gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body",
"html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_58c7a010-ed4f-49b3-adc0-eaf602a750fe", "name":
"srpt:RemainingSharesAssociatedWithPerformanceCondition", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "link:footnote", "p",
"us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body",
"html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R64": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "longName": "996035 - Disclosure - Stock-Based
Compensation - Additional Information (Detail)", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-
gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div",
"body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role":
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
"longName": "996045 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Grant Type Included within Condensed Consolidated
Statements of Operations and Comprehensive Loss (Detail)", "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense by Grant Type
Included within Condensed Consolidated Statements of Operations and Comprehensive Loss (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-
gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div",
"body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name":
"srpt:ShareBasedCompensationExpenseIncludedInCostsAndExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr",
"table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div",
"ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R66": { "role":
```

```
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail", "longName": "996055 - Disclosure - Other Income (Loss), Net - Summary of Other Income (Loss) (Detail)", "shortName": "Other Income (Loss), Net - Summary of Other Income (Loss) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "srpt:AmortizationOfDiscountsPremiumsInvestmentsCashEquivalentAndInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "srpt:AmortizationOfDiscountsPremiumsInvestmentsCashEquivalentAndInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "996075 - Disclosure - Leases (Additional Information) (Details)", "shortName": "Leases (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_afaf6f97-0c4c-47d5-83e1-aa459abaa648", "name": "us-gaap:AreaOfLand", "unitRef": "U_sqft", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R68": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "996085 - Disclosure - INCOME TAXES (Additional Information) (Details)", "shortName": "INCOME TAXES (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R69": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail", "longName": "996095 - Disclosure - Earning (Loss) Per Share - Basic and Diluted Net Loss Per Share (Detail)", "shortName": "Earning (Loss) Per Share - Basic and Diluted Net Loss Per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a3ef11d4-85d6-487a-aade-4ed61eda8b44", "name": "us-gaap:InterestOnConvertibleDebtNetOfTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R70": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareParentheticalDetail", "longName": "996105 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Parenthetical) (Detail)", "shortName": "Net Loss Per Share - Basic and Diluted Net Loss Per Share (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": null }, "R71": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDilute "longName": "996115 - Disclosure - Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Details)", "shortName": "Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_423f9b11-26a0-4a5d-bd80-77a264c4c2ec", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c2f84d3f-0a69-4d10-9a80-67caec0ca3cb", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "unique": true } }, "R72": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDilute "longName": "996125 - Disclosure - Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Parenthetical) (Details)", "shortName": "Earning (Loss) Per Share - Summary of Potential Shares of Common Stock that were Excluded from the Computation of Diluted Earnings per Share (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "srpt:DilutiveSecuritiesShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "link:footnote", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "srpt:DilutiveSecuritiesShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "link:footnote", "p", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu "longName": "996135 - Disclosure - Commitments and Contingencies - Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations (Detail)", "shortName": "Commitments and Contingencies - Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c8244e3e-85c3-4f0b-b3b8-9859a6c51f4e", "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "996145 - Disclosure - Commitments and Contingencies (Additional Information) (Details)", "shortName": "Commitments and Contingencies (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C_27ae4127-70f9-4c56-be8f-4e649c3c752c", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_27ae4127-70f9-4c56-be8f-4e649c3c752c", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "srpt-20240930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "srpt_AccountingStandardUpdateTwoThousandAndSixteenToTwoThousandAndEighteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AccountingStandardUpdateTwoThousandAndSixteenToTwoThousandAndEighteenMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Accounting standard update two thousand and sixteen to two thousand and eighteen.", "label": "Accounting Standard Update Two Thousand And Sixteen To Two Thousand And Eighteen [Member]", "terseLabel": "ASU 2020-06" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate202006Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate202006Member", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "ASU 2020-06", "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity." } } }, "auth_ref": [ "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540" ] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc ], "lang": { "en-us": { "role": { "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts Notes And Loans Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r284", "r1041" ] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc ], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "terseLabel": "Other Accruals [Member]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r63", "r69" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureACCRUEDEXPENSES" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED EXPENSES", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r52", "r54", "r58", "r1094" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r52", "r874" ] }, "srpt_AccountsReceivableAndReservesForProductSalesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AccountsReceivableAndReservesForProductSalesTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenues1" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable And Reserves For Product Sales [Text Block]", "documentation": "Accounts receivable and reserves for product sales.", "terseLabel": "PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r799" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [
```

```
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "totalLabel": "Total accounts receivable, net", "terseLabel": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1040" ] }, "srpt_AccountsReceivablePaymentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AccountsReceivablePaymentTerm", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Accounts receivable payment term.", "label": "Accounts Receivable Payment Term", "terseLabel": "Accounts receivable payment term" } } }, "auth_ref": [] }, "srpt_AccountsReceivablePaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AccountsReceivablePaymentTerms", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable Payment Terms", "label": "Accounts Receivable Payment Terms", "terseLabel": "Payment Terms" } } }, "auth_ref": [] }, "srpt_AccretionOfInvestmentDiscountNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AccretionOfInvestmentDiscountNet", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Accretion of Investment Discount, Net", "label": "Accretion of Investment Discount, Net", "terseLabel": "Accretion of investment discount, net" } } }, "auth_ref": [] }, "srpt_AccruedClinicalAndPreclinicalCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AccruedClinicalAndPreclinicalCostsCurrent", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "documentation": "Accrued clinical and preclinical costs current.", "label": "Accrued Clinical And Preclinical Costs Current", "terseLabel": "Accrued clinical and pre-clinical costs" } } }, "auth_ref": [] }, "srpt_AccruedContractManufacturingExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AccruedContractManufacturingExpenseCurrent", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "documentation": "Accrued contract manufacturing expense current.", "label": "Accrued Contract Manufacturing Expense Current", "terseLabel": "Accrued contract manufacturing costs" } } }, "auth_ref": [] }, "srpt_AccruedFixedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AccruedFixedAssets", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "documentation": "Accrued Fixed Assets", "label": "Accrued Fixed Assets", "terseLabel": "Accrued fixed assets" } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxes", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Accrued Income Taxes, Total", "label": "Accrued Income Taxes", "terseLabel": "Accrued income taxes", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes." } } }, "auth_ref": [ "r54", "r58", "r106", "r670" ] }, "srpt_AccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AccruedInterest", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "documentation": "Accrued Interest", "label": "Accrued Interest", "terseLabel": "Accrued interest" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r54" ] }, "srpt_AccruedProductRevenueRelatedReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AccruedProductRevenueRelatedReserveCurrent", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "documentation": "Accrued product revenue related reserve current.", "label": "Accrued Product Revenue Related Reserve Current", "terseLabel": "Product revenue related reserves" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r54" ] }, "srpt_AccruedResearchExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AccruedResearchExpenses", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "documentation": "Accrued research expenses.", "label": "Accrued Research Expenses", "terseLabel": "Accrued research expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r54", "r821" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r186", "r187", "r188", "r190", "r197", "r198", "r1014" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income, net of tax", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r16", "r17", "r70", "r180", "r674", "r706", "r710" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r941" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r64" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r719", "r1026", "r1027", "r1028", "r1030", "r1099", "r1165" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r954" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r954" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r954" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r954" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r165", "r166", "r167", "r168", "r169", "r170", "r226", "r227", "r228", "r229", "r239", "r281", "r282", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r352", "r353", "r362", "r480", "r481", "r482", "r483", "r484", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r501", "r502", "r503", "r505", "r506", "r507", "r508", "r509", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r554", "r555", "r569", "r570", "r571", "r581", "r582", "r583", "r584", "r585", "r586", "r627", "r628", "r629", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement." } } }, "auth_ref": [] }, "srpt_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc
], "lang": { "en-us": { "role": { "documentation": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years", "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years", "terseLabel": "Adjustments relating to prior periods" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to cash flows from operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
```

```
"lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
"terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r987" ] },
"ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous
Compensation Amount" } } }, "auth_ref": [ "r913", "r923", "r933", "r965" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us":
{ "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } },
"auth_ref": [ "r916", "r926", "r936", "r968" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service
Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r988" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r954" ] }, "ecd_AllExecutiveCategoriesMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } },
"auth_ref": [ "r961" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]",
"terseLabel": "All Individuals" } } }, "auth_ref": [ "r917", "r927", "r937", "r961", "r969", "r973", "r981" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading
Arrangements" } } }, "auth_ref": [ "r979" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense", "verboseLabel": "Stock-based
compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r459",
"r464" ] }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense, after Tax", "terseLabel": "Subtotal", "documentation": "Amount, after tax, of expense for
award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfTotalReservesIncludedInt
], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning
balance", "totalLabel": "Total reserves", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r181",
"r285", "r331" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel":
"Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] },
"srpt_AmendmentImplementedFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "AmendmentImplementedFee", "crdr":
"debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": {
"role": { "documentation": "Implemented fee", "label": "Amendment Implemented Fee" } } }, "auth_ref": [] },
"srpt_AmortizationOfDiscountsPremiumsInvestmentsCashEquivalentAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930",
"localname": "AmortizationOfDiscountsPremiumsInvestmentsCashEquivalentAndInvestments", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion
of investment discount, net", "label": "Amortization of Discounts Premiums Investments Cash Equivalent And Investments", "documentation": "Amortization of Discounts
Premiums Investments Cash Equivalent And Investments" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of
Debt Issuance Costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref":
[ "r78", "r403", "r1018", "r1112" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": {
"role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of in-licensed rights", "totalLabel": "Amortization of Intangible Assets, Total",
"documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and
rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or
used in operations using the indirect method." } } }, "auth_ref": [ "r5", "r345", "r351", "r839" ] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDilute
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareParentheticalDetail" ], "lang": { "en-us": { "role": { "label":
"Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total number of potentially issuable common stock", "documentation":
"Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the
future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for
the period presented." } } }, "auth_ref": [ "r259" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDilute
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r27" ] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDilute
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareParentheticalDetail" ], "lang": { "en-us": { "role": { "label":
"Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These
concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain",
"presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDilute
], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not
included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [
"r27" ] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Area of Land", "terseLabel": "Area of
lease", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
"documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r510" ] },
"us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel":
"Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r104", "r120", "r177", "r217", "r263", "r265", "r275",
"r276", "r320", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r512", "r516", "r557", "r669", "r751", "r832", "r833", "r874", "r904", "r1061", "r1062",
"r1117" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]",
"terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent",
"crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": {
"label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } }
}, "auth_ref": [ "r172", "r184", "r217", "r320", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r512", "r516", "r557", "r874", "r1061", "r1062", "r1117" ]
}, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets, Current
[Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail" ], "lang": { "en-us": { "role":
{ "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets", "periodStartLabel": "Fair value, at the beginning of the period", "periodEndLabel": "Fair value, at the
end of the period", "totalLabel": "Assets, Fair Value Disclosure, Total", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } },
"auth_ref": [ "r542", "r543", "r860" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Available for sale debt securities,
Gross unrealized gains", "verboseLabel": "Available for sale debt securities, Gross unrealized losses", "documentation": "Amount, before tax, of unrealized gain in accumulated
other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-
```

```
sale)." } } }, "auth_ref": [ "r292" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Available for sale debt securities, Gross unrealized losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r293" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Available for sale debt securities, Amortized cost", "terseLabel": "Available for sale debt securities, Amortized cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r289", "r337", "r668" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale", "terseLabel": "Available for sale debt securities, Fair value", "totalLabel": "Debt Securities, Available-for-sale, Total", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r290", "r337", "r542", "r660", "r860", "r864", "r1043", "r1103", "r1104", "r1105" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Available for sale debt securities current, Fair value", "totalLabel": "Debt Securities, Available-for-sale, Current, Total", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r287", "r337" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r976" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r977" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r972" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r972" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r972" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r972" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r972" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r972" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r975" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r974" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r973" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r973" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r361", "r1132", "r1133" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r44", "r45", "r361", "r1132", "r1133" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "srpt_BedfordMassachusettsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "BedfordMassachusettsMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Bedford Massachusetts", "label": "Bedford Massachusetts [Member]" } } }, "auth_ref": [] }, "us-gaap_BilledContractReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BilledContractReceivables", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Billed Contracts Receivable", "terseLabel": "Product sales receivable, net of discounts and allowances", "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date." } } }, "auth_ref": [ "r624" ] }, "srpt_BioMarinPharmaceuticalIncorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "BioMarinPharmaceuticalIncorporationMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Bio Marin Pharmaceutical Incorporation.", "label": "Bio Marin Pharmaceutical Incorporation [Member]", "terseLabel": "BioMarin Pharmaceutical, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r346", "r347", "r348", "r349", "r350", "r500", "r852", "r853" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r41", "r42", "r346", "r347", "r348", "r349", "r350", "r500", "r852", "r853" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail", "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration", "verboseLabel": "Contingent consideration", "totalLabel": "Business Combination, Contingent Consideration, Liability, Total", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r43", "r99", "r504", "r544", "r545", "r546" ] }, "srpt_CapitalizedStockBasedCompensationAndDepreciationAsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CapitalizedStockBasedCompensationAndDepreciationAsInventory", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Capitalized stock-based compensation and depreciation as inventory", "label": "Capitalized stock-based compensation and depreciation as inventory", "terseLabel": "Capitalized stock-based compensation and depreciation as inventory" } } }, "auth_ref": [] }, "srpt_CappedCallTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CappedCallTransactionsMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "2022 Capped Call Transactions [Member]", "documentation": "2022 Capped Call Transactions [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "srpt_CashAndCashEquivalentsAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CashAndCashEquivalentsAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents amortized cost basis.", "label": "Cash And Cash Equivalents Amortized Cost Basis", "totalLabel": "Cash and cash equivalents, Amortized cost", "terseLabel": "Cash and cash equivalents, Amortized cost" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
```

"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents, Fair value", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r21", "r174", "r817"] }, "srpt_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CashAndCashEquivalentsGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents, Gross unrealized gains", "label": "Cash And Cash Equivalents Gross Unrealized Gain Before Tax", "documentation": "Cash and cash equivalents gross unrealized gain before tax." } } }, "auth_ref": [] }, "srpt_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CashAndCashEquivalentsGrossUnrealizedLossBeforeTax", "crdr": "debit",
"presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
], "lang": { "en-us": { "documentation": "Cash and cash equivalents gross unrealized loss before tax.", "label": "Cash And Cash Equivalents Gross Unrealized Loss Before Tax", "negatedLabel": "Cash and cash equivalents, Gross unrealized losses" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90Da
], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "srpt_CashCashEquivalentsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.sarepta.com/20240930", "localname": "CashCashEquivalentsAndInvestments", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
], "lang": { "en-us": { "role": { "documentation": "Cash cash equivalents and investments.", "label": "Cash Cash Equivalents And Investments", "terseLabel": "Cash, cash equivalents and investments, Fair value", "totalLabel": "Cash, cash equivalents and investments, Fair value" } } }, "auth_ref": [] },
"srpt_CashCashEquivalentsAndInvestmentsAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"CashCashEquivalentsAndInvestmentsAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
], "lang": { "en-us": { "role": { "totalLabel": "Cash, cash equivalents and investments, Amortized cost", "label": "Cash Cash Equivalents And Investments Amortized Cost Basis", "documentation": "Cash cash equivalents and investments amortized cost basis.", "terseLabel": "Cash, cash equivalents and investments, Amortized cost" } } }, "auth_ref": [] },
"srpt_CashCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"CashCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and investments, Gross unrealized gains", "label": "Cash Cash Equivalents And Investments Gross Unrealized Gain Before Tax", "documentation": "Cash cash equivalents and investments gross unrealized gain before tax.", "totalLabel": "Cash, cash equivalents and investments, Gross unrealized gains" } } }, "auth_ref": [] }, "srpt_CashCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.sarepta.com/20240930", "localname": "CashCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
], "lang": { "en-us": { "role": { "documentation": "Cash cash equivalents and investments gross unrealized loss before tax.", "label": "Cash Cash Equivalents And Investments Gross Unrealized Loss Before Tax", "negatedLabel": "Cash, cash equivalents and investments, Gross unrealized losses", "negatedTotalLabel": "Cash, cash equivalents and investments, Gross unrealized losses" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIES"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": ["r1042"] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label":
"Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash, cash equivalents and investments", "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r1013"] }, "srpt_CashCashEquivalentsRestrictedCashAndInvestments": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndInvestments", "crdr": "debit",
"presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail"], "lang": { "en-us": {
"role": { "documentation": "Cash cash equivalents restricted cash and investments.", "label": "Cash Cash Equivalents Restricted Cash And Investments", "terseLabel": "Cash cash equivalents restricted cash and investments" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit",
"presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"totalLabel": "Total cash, cash equivalents and restricted cash", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } },
"auth_ref": ["r21", "r85", "r214"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:" } } }, "auth_ref": [] },
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr":
"debit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role":
{ "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } },
"auth_ref": ["r21", "r85", "r214"] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract",
"presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": {
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]", "terseLabel": "Cash, cash equivalents and restricted cash:" } } }, "auth_ref": [] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"crdr": "debit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": {
"role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel":
"Decrease in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
} } }, "auth_ref": ["r0", "r85"] }, "srpt_CashDepositsAndMoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930",
"localname": "CashDepositsAndMoneyMarketFundsMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
], "lang": { "en-us": { "role": { "documentation": "Cash deposits and money market funds.", "label": "Cash Deposits And Money Market Funds [Member]", "terseLabel": "Cash and Money Market Funds [Member]" } } }, "auth_ref": [] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90Da

```
], "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents", "totalLabel": "Cash Equivalents, at Carrying Value, Total",
"documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present
insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } },
"auth_ref": { "r1008", "r1130" } }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Flow,
Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental schedule of non-cash activities:" } } }, "auth_ref": [] },
"srpt_CatalentAndThermoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CatalentAndThermoMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
], "lang": { "en-us": { "role": { "documentation": "Catalent and Thermo Member", "label": "Catalent And Thermo [Member]", "terseLabel": "Catalent and Thermo [Member]" }
} }, "auth_ref": [] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CertificatesOfDepositMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail" ], "lang": { "en-us": { "role":
{ "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and
savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of
deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r8", "r898", "r899", "r900", "r901" ] }, "us-
gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Change
in fair value of derivatives*", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "documentation": "Amount of gain (loss) from the increase
(decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement." } } }, "auth_ref": [
"r102" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer
Group, Footnote" } } }, "auth_ref": [ "r952" ] }, "srpt_ChargebacksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"ChargebacksMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc
], "lang": { "en-us": { "role": { "documentation": "Chargebacks.", "label": "Chargebacks [Member]", "terseLabel": "Chargebacks [Member]" } } }, "auth_ref": [] },
"srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Chief Executive
Officer [Member]", "terseLabel": "Chief Executive Officer", "documentation": "Person with designation of chief executive officer." } } }, "auth_ref": [ "r1039" ] },
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year
Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r949" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are
Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } },
"auth_ref": [ "r947" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City
Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure
Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r953" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r953" ] }, "srpt_CollaborationReceivable": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CollaborationReceivable", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Collaboration Receivable.", "label": "Collaboration Receivable", "terseLabel": "Collaboration Receivable" } } }, "auth_ref": [] },
"srpt_CollaborationReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CollaborationReceivableCurrent",
"crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": {
"documentation": "Collaboration receivable current.", "label": "Collaboration Receivable Current", "terseLabel": "Collaboration receivable", "verboseLabel": "Collaboration and
other receivables" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLICENSEANDCOLLABORATIONAGREEMENTS" ], "lang": { "en-us": { "role": { "label": "Collaborative
Arrangement Disclosure [Text Block]", "terseLabel": "LICENSE AND COLLABORATION AGREEMENTS", "documentation": "The entire disclosure for collaborative
arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c)
the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative
arrangement between participants." } } }, "auth_ref": [ "r124", "r126", "r132" ] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement", "documentation": "Contractual arrangement that involves two or more parties that both:
(i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
} } }, "auth_ref": [ "r510" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement
Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r510" ] }, "srpt_CollateralizedLetterOfCreditCashDeposit": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CollateralizedLetterOfCreditCashDeposit", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collateralized Letter of Credit
Cash Deposit", "documentation": "Collateralized Letter of Credit Cash Deposit", "label": "Collateralized Letter of Credit Cash Deposit" } } }, "auth_ref": [] },
"srpt_ColumbusOhioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ColumbusOhioMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Columbus Ohio", "label":
"Columbus Ohio [Member]" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommercialPaperMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90Da
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail" ], "lang": { "en-us": { "role":
{ "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides
institutions with short-term funds." } } }, "auth_ref": [ "r94", "r371", "r898", "r899", "r900", "r901" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and
contingencies (Note 16)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has
entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or,
less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains
from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r59", "r109",
"r671", "r738" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "label": "Commitments and
Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and
contingencies." } } }, "auth_ref": [ "r92", "r364", "r365", "r800", "r1053", "r1058" ] }, "srpt_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://www.sarepta.com/20240930", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments
And Contingencies [Line Items]" } } }, "auth_ref": [] }, "srpt_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.sarepta.com/20240930", "localname": "CommitmentsAndContingenciesTable", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
], "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies [Table]", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments
And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label":
"Common Stock [Member]", "terseLabel": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r894",
"r895", "r896", "r898", "r899", "r900", "r901", "r1026", "r1027", "r1030", "r1099", "r1163", "r1165" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common
Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref":
[ "r62" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized",
```

```
"presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r62", "r739" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation":[
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "totalLabel": "Common Stock, Shares, Issued, Total", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r62" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r10", "r62", "r739", "r757", "r1165", "r1166" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value, 198,000,000 shares authorized; 95,493,005 and 93,731,831 issued and outstanding at September 30, 2024, and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "totalLabel": "Common Stock, Value, Issued, Total", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r62", "r673", "r874" ] },
"ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r958" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r957" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r959" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r956" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r18", "r193", "r195", "r201", "r662", "r684", "r685" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r29", "r30", "r46", "r47", "r280", "r799" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r29", "r30", "r46", "r47", "r280", "r712", "r799" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r29", "r30", "r46", "r47", "r280", "r799", "r995" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r50", "r128" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentration of credit risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r29", "r30", "r46", "r47", "r280" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } },
"auth_ref": [ "r29", "r30", "r46", "r47", "r280", "r799" ] }, "srpt_ContractManufacturingRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ContractManufacturingRevenueMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Manufacturing Revenue [Member]", "label": "Contract Manufacturing Revenue [Member]", "documentation": "Contract Manufacturing Revenue [Member]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "terseLabel": "Deferred Revenue", "totalLabel": "Contract with Customer, Liability, Total", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r414", "r415", "r418" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current portion", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r414", "r415", "r418" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r414", "r415", "r418" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
], "lang": { "en-us": { "role": { "label": "Contractual Obligation", "totalLabel": "Total manufacturing commitments", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r1024" ] }, "us-gaap_ContractualObligationDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligationDueInFourthYear", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligationDueInSecondYear", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligationDueInThirdYear", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
```

```
], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESTables" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Summary of Aggregate Non-Cancelable Contractual Obligations Arising from Manufacturing Obligations", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r1005", "r1025" ] }, "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
], "lang": { "en-us": { "role": { "terseLabel": "2024 (October-December)", "label": "Contractual Obligation, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of contractual obligation to be paid in remainder of current fiscal year." } } }, "auth_ref": [] }, "srpt_ContractualObligationToBePaidAfterYearThreeYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ContractualObligationToBePaidAfterYearThreeYear", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
], "lang": { "en-us": { "role": { "documentation": "Contractual Obligation To Be Paid After Year Three Year", "label": "Contractual Obligation To Be Paid After Year Three Year", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "srpt_ConversionOfSharesExcludedFromComputationOfDilutedEps": { "xbrltype": "sharesItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ConversionOfSharesExcludedFromComputationOfDilutedEps", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareParentheticalDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of shares excluded from computation of diluted EPS", "documentation": "Conversion of shares excluded from computation of diluted EPS", "label": "Conversion of shares excluded from computation of diluted EPS" } } }, "auth_ref": [] }, "srpt_ConvertibleDebtAndTermLoanAndRevolverAndMortgageLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ConvertibleDebtAndTermLoanAndRevolverAndMortgageLoansMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Convertible debt and term loan and revolver and mortgage loans.", "label": "Convertible Debt And Term Loan And Revolver And Mortgage Loans [Member]", "terseLabel": "Convertible Debt, The Term Loan, The Revolver and The Mortgage Loans [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDilute
], "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r1066" ] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90Da
], "lang": { "en-us": { "role": { "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate Bond [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "srpt_CorporateBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CorporateBondsMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "documentation": "Corporate Bonds", "label": "Corporate Bonds [Member]", "terseLabel": "Corporate Bonds [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "totalLabel": "Cost of Goods and Services Sold, Total", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r73", "r74", "r625" ] },
"srpt_CostOfGoodsSoldExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CostOfGoodsSoldExcludingAmortization", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Cost of goods sold excluding amortization.", "label": "Cost Of Goods Sold Excluding Amortization", "terseLabel": "Cost of sales (excluding amortization of in-licensed rights)" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales [Member]", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses", "totalLabel": "Total cost and expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r80" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Cost and expenses:" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureGainFromSaleOfPriorityReviewVoucherAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r158", "r159", "r219", "r220", "r385", "r411", "r587", "r607", "r666", "r825", "r827" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect of Accounting Change [Member]", "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards." } } }, "auth_ref": [ "r161", "r167", "r225", "r232", "r239", "r324", "r330", "r353", "r480", "r481", "r494", "r496", "r521", "r523", "r524", "r526", "r527", "r528", "r533", "r536", "r538", "r539", "r584" ] },
"srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption", "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards." } } }, "auth_ref": [ "r161", "r167", "r225", "r232", "r239", "r324", "r330", "r353", "r480", "r481", "r494", "r496", "r521", "r523", "r524", "r526", "r527", "r528", "r533", "r536", "r538", "r539", "r584" ] },
"srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption", "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards." } } }, "auth_ref": [ "r161", "r167", "r225", "r232", "r239", "r324", "r330", "r353", "r480", "r481", "r494", "r496", "r521", "r523", "r524", "r526", "r527", "r528", "r533", "r536", "r538", "r539", "r584" ] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal tax expense", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r996", "r1022", "r1097" ] },
"dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State tax expense", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } },
"auth_ref": [ "r996", "r1022", "r1097" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r89", "r280" ] }, "srpt_CustomerFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CustomerFourMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Customer Four [Member]", "label": "Customer Four [Member]" } } }, "auth_ref": [] }, "srpt_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CustomerOneMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
```

"documentation": "Customer one.", "label": "Customer One [Member]", "terseLabel": "Customer One [Member]" } } }, "auth_ref": [] }, "srpt_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CustomerThreeMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Customer three.", "label": "Customer Three [Member]", "terseLabel": "Customer Three [Member]" } } }, "auth_ref": [] }, "srpt_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CustomerTwoMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1 "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Customer two.", "label": "Customer Two [Member]", "terseLabel": "Customer Two [Member]" } } }, "auth_ref": [] }, "srpt_CustomersExceedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "CustomersExceedMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Customers Exceed [Member]", "label": "Customers Exceed [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionByUniqueDescriptionAxis", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail"], "lang": { "en-us": { "role": { "label": "Debt Conversion Description [Axis]", "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction." } } } }, "auth_ref": ["r23", "r25"] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Common stock issued for exchange of 2024 Notes", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r23", "r25"] }, "srpt_DebtConversionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "DebtConversionCosts", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Debt Conversion Costs", "label": "Debt Conversion Costs", "terseLabel": "Debt conversion costs for 2024 Notes", "negatedTerseLabel": "Debt conversion costs for 2024 Notes" } } }, "auth_ref": [] }, "us-gaap_DebtConversionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionNameDomain", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail"], "lang": { "en-us": { "role": { "label": "Debt Conversion, Name [Domain]", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r23", "r25"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINDEBTEDNESS"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "INDEBTEDNESS", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r93", "r216", "r356", "r357", "r358", "r359", "r360", "r370", "r371", "r381", "r387", "r388", "r389", "r390", "r391", "r392", "r397", "r404", "r405", "r407", "r567"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareParentheticalDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r15", "r53", "r54", "r105", "r108", "r221", "r382", "r383", "r384", "r385", "r386", "r388", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r840", "r841", "r842", "r843", "r844", "r871", "r1020", "r1054", "r1055", "r1056", "r1111", "r1113"] }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Aggregate principal amount converted into equity", "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion." } } }, "auth_ref": ["r35"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount", "totalLabel": "Total payments", "verboseLabel": "Principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r382", "r567", "r568", "r841", "r842", "r871"] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Total fair value of debt instruments", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt Instrument Fair Value", "totalLabel": "Debt Instrument, Fair Value Disclosure, Total", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": ["r395", "r556", "r841", "r842", "r1102", "r1103", "r1104", "r1105", "r1106"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate per annum", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r56", "r383"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r221", "r382", "r383", "r384", "r385", "r386", "r388", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r406", "r840", "r841", "r842", "r843", "r844", "r871", "r1020", "r1111", "r1113"] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt instrument, maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": ["r179", "r840", "r1104", "r1105"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareParentheticalDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r15", "r221", "r382", "r383", "r384", "r385", "r386", "r388", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r840", "r841", "r842", "r843", "r844", "r871", "r1020", "r1054", "r1055", "r1056", "r1111", "r1113"] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Payment for full settlement of the principal value and accrued interest", "label": "Debt Instrument, Periodic Payment", "totalLabel": "Debt Instrument, Periodic Payment, Total", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": ["r15", "r49"] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Periodic Payment, Principal", "label": "Debt Instrument, Periodic Payment, Principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": ["r15"] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } } }, "auth_ref": ["r116"] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": ["r116"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r15", "r38", "r39", "r48", "r95", "r96", "r221", "r382", "r383", "r384", "r385", "r386", "r388", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r403", "r406", "r840", "r841", "r842", "r843", "r844", "r871", "r1020", "r1111", "r1113"] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized discount - debt issuance costs", "totalLabel": "Debt Issuance Costs, Net, Total", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1064", "r1110", "r1111", "r1113" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue, Current", "terseLabel": "Deferred Revenue, Current", "totalLabel": "Deferred Revenue, Current, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r1010" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r476" ] }, "us-gaap_DepositLiabilitiesAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositLiabilitiesAccruedInterest", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deposit Liabilities, Accrued Interest", "terseLabel": "Eliminated accrued interest", "documentation": "Amount of accrued but unpaid interest on deposit liabilities." } } }, "auth_ref": [ "r107" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r263", "r270", "r276", "r832", "r833" ] }, "srpt_DerivativeAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "DerivativeAssetMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative asset", "label": "Derivative Asset[Member]", "documentation": "DerivativeAsset[Member]" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative asset", "label": "Derivative Asset, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r185" ] }, "srpt_DevelopmentMilestoneAndSettlementUpfrontFeeRecognizedAsResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "DevelopmentMilestoneAndSettlementUpfrontFeeRecognizedAsResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Development milestone and settlement upfront fee recognized as research and development expense.", "label": "Development Milestone And Settlement Upfront Fee Recognized As Research And Development Expense", "terseLabel": "Development Milestone and Upfront Fee Recognized as Research and Development Expense" } } }, "auth_ref": [] }, "srpt_DilutiveSecuritiesShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "DilutiveSecuritiesShares", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDilute" ], "lang": { "en-us": { "role": { "documentation": "Dilutive Securities, Shares", "label": "Dilutive Securities, Shares", "terseLabel": "Dilutive securities" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Michael A", "label": "Director [Member]", "documentation": "Person serving on board of directors." } } }, "auth_ref": [ "r1006", "r1039", "r1164" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of Product Revenues", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1065" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureSTOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r428", "r432", "r461", "r462", "r463", "r855" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A: the filing date, for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r908" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r940" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "verboseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r951" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail", "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings (loss) per common share, basic", "verboseLabel": "Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r202", "r230", "r231", "r232", "r233", "r234", "r235", "r241", "r243", "r256", "r257", "r258", "r262", "r498", "r509", "r539", "r540", "r663", "r686", "r829" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Earnings (loss) per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "terseLabel": "Earnings (loss) per common share, diluted", "verboseLabel": "Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r202", "r230", "r231", "r232", "r233", "r234", "r235", "r243", "r256", "r257", "r258", "r262", "r498", "r509", "r539", "r540", "r663", "r686", "r829" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningsLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS (LOSS) PER SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r240", "r259", "r260", "r261" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r218", "r469", "r485", "r857" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Effective tax rate", "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "terseLabel": "Effective tax rate", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r470", "r471", "r1023", "r1096" ] }, "srpt_ElevidysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ElevidysMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "ELEVIDYS [Member]", "label": "ELEVIDYS [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype":
```

```
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails" ], "lang": { "en-us": { "role": {
"label": "Employee Benefits and Share-Based Compensation", "terseLabel": "Stock-based compensation Grants", "documentation": "Amount of expense for employee benefit
and equity-based compensation." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "label": "Employee-related
Liabilities, Current", "terseLabel": "Accrued employee compensation costs", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the
carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued
salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if
longer)." } } }, "auth_ref": [ "r54" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
"crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Capitalized stock-based compensation costs",
"documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r460" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based
Compensation, Allocation of Recognized Period Costs [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation":
[ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Share-based payment arrangement, Cost not yet recognized, Amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost
Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit
options." } } }, "auth_ref": [ "r1093" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeStockOptionMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option",
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined
price for specified period of time." } } }, "auth_ref": [] }, "srpt_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.sarepta.com/20240930", "localname": "EmployeeStockPurchasePlanMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase
Plan" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine1", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street
Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine2", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } }
}, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown",
"presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address,
City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype":
"stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province",
"terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype":
"centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly
abbreviated as CIK." } } }, "auth_ref": [ "r906" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate
number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related
periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member]
or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype":
"yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status",
"terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been
subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
} } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityEmergingGrowthCompany", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth
company criteria." } } }, "auth_ref": [ "r906" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityFileNumber", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may
contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref":
[] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel":
"Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions
of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related
disclosure." } } }, "auth_ref": [ "r906" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-
character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current",
"terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File
required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files)." } } }, "auth_ref": [ "r990" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityRegistrantName", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is
required by forms filed with the SEC." } } }, "auth_ref": [ "r906" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityShellCompany", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined
in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r906" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntitySmallBusiness", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } },
"auth_ref": [ "r906" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityTaxIdentificationNumber", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as
an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r906" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r945" ] },
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity
Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation
Table" } } }, "auth_ref": [ "r986" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]",
"terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r986" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant
Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r986" ] }, "us-gaap_EquityComponentDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label":
"Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total balance including that which is
allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r167", "r196", "r197", "r198", "r222", "r223", "r224", "r227", "r234", "r236",
```

```
"r238", "r264", "r324", "r330", "r353", "r413", "r480", "r481", "r494", "r495", "r496", "r499", "r508", "r509", "r521", "r523", "r524", "r525", "r526", "r528", "r538", "r558", "r560", "r561", "r562", "r563", "r564", "r570", "r573", "r586", "r682", "r701", "r702", "r703", "r719", "r777" ] }, "srpt_EquityIncentivePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "EquityIncentivePlansMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDilute ], "lang": { "en-us": { "role": { "documentation": "Equity Incentive Plans [Member]", "label": "Equity Incentive Plans [Member]", "terseLabel": "Equity Incentive Plans [Member]" } } }, "auth_ref": [] }, "srpt_EquityInvestmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "EquityInvestmentAgreementMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Investment Agreement [Member]", "label": "Equity Investment Agreement [Member]", "documentation": "Equity investment agreement." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment of strategic investments", "label": "Equity Method Investment, Other-than-Temporary Impairment", "terseLabel": "Impairment of equity investment", "verboseLabel": "Impairment of investment in private companies", "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting." } } }, "auth_ref": [ "r1049" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r955" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r913", "r923", "r933", "r965" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r910", "r920", "r930", "r962" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r961" ] }, "srpt_FDAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "FDAMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureGainFromSaleOfPriorityReviewVoucherAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "FDA Member.", "label": "F D A [Member]", "terseLabel": "F D A" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfLevel3FinancialLiabilitiesDetails", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r542", "r543", "r550", "r860" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r542", "r543", "r550", "r860" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Assets and Liabilities Measured and Carried at Fair Value", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": [ "r860", "r1101", "r1102", "r1107" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Summary of Fair Value of Level 3 Financial Assets", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": [ "r542", "r543" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfLevel3FinancialLiabilitiesDetails", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Level 2 [Member]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r395", "r420", "r421", "r422", "r423", "r424", "r425", "r541", "r543", "r544", "r545", "r546", "r549", "r550", "r552", "r594", "r595", "r596", "r841", "r842", "r849", "r850", "r851", "r860", "r864" ] }, "srpt_FairValueConvertibleNoteExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "FairValueConvertibleNoteExchange", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Fair value convertible note exchange", "label": "Fair value convertible note exchange", "terseLabel": "Fair value convertible note exchange" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r395", "r420", "r425", "r543", "r550", "r594", "r849", "r850", "r851", "r860" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r395", "r420", "r425", "r543", "r544", "r550", "r595", "r841", "r842", "r849", "r850", "r851", "r860" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfLevel3FinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r395", "r420", "r421", "r422", "r423", "r424", "r425", "r543", "r544", "r545", "r546", "r550", "r596", "r841", "r842", "r849", "r850", "r851", "r860", "r864" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Summary of Fair Value of Level 3 Financial Liabilities", "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": [ "r542", "r543" ] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": [ "r103" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfLevel3FinancialLiabilitiesDetails", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r395", "r420", "r421", "r422", "r423", "r424", "r425", "r541", "r543", "r544", "r545", "r546", "r549", "r550", "r552", "r594", "r595", "r596", "r841", "r842", "r849", "r850", "r851", "r860", "r864" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r332", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r406", "r412", "r529", "r553", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r683", "r835", "r860", "r862", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r875", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1045", "r1046", "r1047", "r1048", "r1100", "r1103", "r1104", "r1105", "r1106", "r1108" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherNoncurrentAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Finite-Lived Intangible Assets, Net, Total", "periodStartLabel": "Finite-Lived Intangible Assets,
```

Net, Beginning Balance", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r626", "r1052"] }, "srpt_FirstInstallmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "FirstInstallmentsMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "First installments", "label": "First Installments [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r917", "r927", "r937", "r969"] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r917", "r927", "r937", "r969"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r917", "r927", "r937", "r969"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r917", "r927", "r937", "r969"] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r917", "r927", "r937", "r969"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r950"] }, "srpt_GainFromSaleOfIntangibleAssetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "GainFromSaleOfIntangibleAssetLineItems", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureGainFromSaleOfPriorityReviewVoucherAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Gain from sale of intangible asset.", "label": "Gain From Sale Of Intangible Asset [Line Items]", "terseLabel": "Gain From Sale Of Intangible Asset [Line Items]" } } }, "auth_ref": [] }, "srpt_GainFromSaleOfIntangibleAssetTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "GainFromSaleOfIntangibleAssetTable", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureGainFromSaleOfPriorityReviewVoucherAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Gain from sale of intangible asset.", "label": "Gain From Sale Of Intangible Asset [Table]", "terseLabel": "Gain From Sale Of Intangible Asset [Table]" } } }, "auth_ref": [] }, "srpt_GainLossFromSaleOfIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "GainLossFromSaleOfIntangibleAssetsDisclosureTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureGAINFROMSALEOFPRIORITYREVIEWVOUCHER"], "lang": { "en-us": { "role": { "documentation": "Gain (loss) from sale of intangible assets.", "label": "Gain Loss From Sale Of Intangible Assets Disclosure [Text Block]", "terseLabel": "GAIN FROM SALE OF PRIORITY REVIEW VOUCHER" } } }, "auth_ref": [] }, "us-gaap_GainLossOnContractTermination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnContractTermination", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Non-cash termination charges", "label": "Gain (Loss) on Contract Termination", "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform." } } }, "auth_ref": ["r87"] }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfIntangibleAssets", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Intangible Assets", "terseLabel": "Gain from sale of Priority Review Voucher", "negatedLabel": "Gain from sale of Priority Review Voucher", "documentation": "Amount of gain (loss) on sale or disposal of intangible assets." } } }, "auth_ref": ["r1018"] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Loss on debt extinguishment", "negatedTerseLabel": "Loss on debt extinguishment", "negatedLabel": "Loss on debt extinguishment", "label": "Gain (Loss) on Extinguishment of Debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r5", "r36", "r37"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r5", "r342", "r343", "r344", "r838", "r861"] }, "srpt_HenogenSaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "HenogenSaMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Henogen SA.", "label": "Henogen SA [Member]", "terseLabel": "Henogen SA [Member]" } } }, "auth_ref": [] }, "srpt_ImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ImpairmentLoss", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Impairment Loss", "label": "Impairment Loss", "documentation": "Impairment Loss" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Income (loss) before income tax expense", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income tax expense", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r71", "r114", "r119", "r664", "r679", "r831", "r832", "r1033", "r1035", "r1036", "r1037", "r1038"] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Impairment of equity investments", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": ["r5", "r72", "r113", "r263", "r271", "r276", "r319", "r678"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "terseLabel": "Income Statement Location", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r354", "r361", "r363", "r547", "r548", "r551", "r696", "r698", "r762", "r812", "r863", "r1134"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "terseLabel": "Income Statement Location", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r361", "r363", "r547", "r548", "r551", "r696", "r698", "r762", "r812", "r863", "r1134"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r218", "r467", "r469", "r472", "r473", "r474", "r475", "r477", "r486", "r488", "r489", "r490", "r717", "r857"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit), Total", "verboseLabel": "Income tax expense", "terseLabel": "Provision for Income tax", "negatedLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r121", "r131", "r237", "r238", "r263", "r272", "r276", "r468", "r469", "r487", "r687", "r857"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Income Taxes Paid, Net, Total", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid during the period for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r22", "r213", "r478", "r479"] },
"srpt_IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherLiabilities", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Decrease in accounts payable, accrued expenses, lease liabilities and other liabilities", "documentation": "Increase decrease in accounts payable and accrued expenses and other liabilities.", "label": "Increase Decrease In Accounts Payable And Accrued Expenses And Other Liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Increase in accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount
due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] },
"srpt_IncreaseDecreaseInAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"IncreaseDecreaseInAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Increase decrease in accumulated deficit.", "label": "Increase Decrease In Accumulated Deficit", "negatedLabel": "Decrease in accumulated deficit" } } },
"auth_ref": [] }, "srpt_IncreaseDecreaseInAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"IncreaseDecreaseInAdditionalPaidInCapital", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Increase (decrease) in additional paid in capital.", "label": "Increase Decrease In Additional Paid In Capital", "negatedLabel": "Decrease in additional paid-
in-capital" } } }, "auth_ref": [] }, "srpt_IncreaseDecreaseInConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"IncreaseDecreaseInConvertibleNotes", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Increase (decrease) in carrying amount of convertible notes.", "label": "Increase Decrease In Convertible Notes", "terseLabel": "Increase in convertible
notes" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease
in deferred revenue", "negatedLabel": "Net decrease in deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase
(decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r813"
] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories",
"crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us":
{ "role": { "negatedLabel": "Increase in inventory", "label": "Increase (Decrease) in Inventories", "totalLabel": "Increase (Decrease) in Inventories, Total", "documentation":
"The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are
classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "srpt_IncreaseDecreaseInManufacturingRelatedDepositsAndPrepaids": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.sarepta.com/20240930", "localname": "IncreaseDecreaseInManufacturingRelatedDepositsAndPrepaids", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "
(Increase) decrease in manufacturing-related deposits and prepaids", "documentation": "Increase Decrease In Manufacturing-Related Deposits And Prepaids", "label":
"Increase Decrease In Manufacturing-Related Deposits And Prepaids", "terseLabel": "Net (increase) decrease in manufacturing-related deposits and prepaids" } } },
"auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Increase in other assets", "label": "Increase (Decrease) in Other Operating Assets", "totalLabel": "Increase (Decrease) in Other Operating Assets, Total", "documentation":
"Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-
gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Increase
(Decrease) in Other Operating Assets and Liabilities, Net [Abstract]", "terseLabel": "Changes in operating assets and liabilities, net:" } } }, "auth_ref": [] }, "us-
gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail" ], "lang": { "en-us": { "role": { "label":
"Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Effect of dilutive securities*", "documentation": "Additional shares
included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } } }, "auth_ref": [ "r244",
"r245", "r246", "r258" ] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail" ], "lang": { "en-us": { "role": { "label":
"Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Common stock issuable under the Company's convertible debt",
"negatedLabel": "Common stock issuable under the Company's convertible debt", "documentation": "Additional shares included in the calculation of diluted EPS as a result of
the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": [ "r252", "r253", "r258" ] }, "us-
gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail" ], "lang": { "en-us": { "role": { "label":
"Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Common stock issuable under the Company's equity
incentive plans", "negatedLabel": "Common stock issuable under the Company's equity incentive plans", "documentation": "Additional shares included in the calculation of
diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r244", "r245", "r247",
"r258", "r431" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r917", "r927", "r937",
"r961", "r969", "r973", "r981" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } },
"auth_ref": [ "r979" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies
and Procedures:" } } }, "auth_ref": [ "r909", "r985" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider
Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r909", "r985" ] },
"ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider
Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r909", "r985" ] },
"srpt_InstallmentsDateOfImplementedFee": { "xbrltype": "dateItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "InstallmentsDateOfImplementedFee",
"presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"documentation": "installments date", "label": "Installments Date of implemented fee" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "Interest
Expense, Operating and Nonoperating", "negatedLabel": "Interest expense", "totalLabel": "Interest Expense, Total", "documentation": "Amount of interest expense classified as
operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r263", "r265", "r269", "r273", "r276",
"r566", "r832", "r833" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt",
"crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest expense
debt", "label": "Interest Expense, Debt", "terseLabel": "Interest expense reduced", "totalLabel": "Interest Expense, Debt, Total", "documentation": "Amount of the cost of
borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r78", "r401", "r409", "r843", "r844" ] }, "srpt_InterestMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "InterestMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail" ], "lang": { "en-
us": { "role": { "documentation": "Interest [Member]", "label": "Interest [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestOnConvertibleDebtNetOfTax", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Interest on
Convertible Debt, Net of Tax", "terseLabel": "Add: interest expense, net of tax, on the Company's convertible debt", "negatedLabel": "Add: interest expense, net of tax, on the
Company's convertible debt", "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in
cash." } } }, "auth_ref": [ "r242", "r249", "r258" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest",
"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-
coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable
to accreted interest of debt discount." } } }, "auth_ref": [ "r208", "r211", "r212" ] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InterestReceivable", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Interest Receivable",
"terseLabel": "Interest receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or
accrued interest receivable." } } }, "auth_ref": [ "r1011", "r1167" ] }, "srpt_InventoryCurrentAndNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.sarepta.com/20240930", "localname": "InventoryCurrentAndNoncurrentNet", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureInventorySummarizesTheBalanceSheetClassificationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureInventorySummaryOfComponentsOfInventoryDetail" ], "lang": { "en-us": { "role": { "documentation": "Inventory
current and noncurrent net.", "label": "Inventory Current and Noncurrent Net", "totalLabel": "Total inventory" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InventoryDisclosureTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINVENTORY" ], "lang": { "en-us": { "role": { "label":
"Inventory Disclosure [Text Block]", "terseLabel": "INVENTORY", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating
inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r341" ] }, "us-
gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureInventorySummaryOfComponentsOfInventoryDetail" ], "lang": { "en-us": { "role": { "label": "Inventory, Finished
Goods, Net of Reserves", "terseLabel": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of
merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r91", "r822" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureInventorySummarizesTheBalanceSheetClassificationDetails",
```

```
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory", "verboseLabel": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r182", "r818", "r874" ] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureInventorySummarizesTheBalanceSheetClassificationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Inventory, Noncurrent, Total", "label": "Inventory, Noncurrent", "terseLabel": "Non-current inventory", "verboseLabel": "Other non-current assets", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r1009" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureInventorySummaryOfComponentsOfInventoryDetail" ], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r91", "r824" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureInventorySummaryOfComponentsOfInventoryDetail" ], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in progress", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r91", "r823" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r263", "r268", "r276", "r832", "r1017" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90Da
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "terseLabel": "Investment Type", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r721", "r723", "r724", "r726", "r728", "r780", "r782", "r784", "r787", "r788", "r789", "r791", "r792", "r793", "r794", "r795", "r896" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90Da
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "terseLabel": "Investments", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r721", "r723", "r724", "r726", "r728", "r780", "r782", "r784", "r787", "r788", "r789", "r791", "r792", "r793", "r794", "r795", "r896" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments", "totalLabel": "Investments, Total", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r666", "r667", "r891", "r893" ] }, "srpt_IssuanceOfCommonStockForConversionForNotesShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "IssuanceOfCommonStockForConversionForNotesShares", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Issuance Of Common Stock For Conversion For Notes Shares", "label": "Issuance Of Common Stock For Conversion For Notes Shares", "verboseLabel": "Issuance of common stock for exchange of 2024 Notes, shares", "terseLabel": "Issuance of common stock for exchange of 2024 Notes, shares" } } }, "auth_ref": [] },
"srpt_IssuanceOfCommonStockForConversionOf2024NotesShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "IssuanceOfCommonStockForConversionOf2024NotesShares", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Issuance Of Common Stock For Conversion Of 2024 Notes Shares", "label": "Issuance Of Common Stock For Conversion Of 2024 Notes Shares", "terseLabel": "Issuance of common stock for conversion of 2024 Notes, Shares" } } }, "auth_ref": [] }, "srpt_IssuanceOfCommonStockForConversionOf2024NotesValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "IssuanceOfCommonStockForConversionOf2024NotesValue", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Issuance Of Common Stock For Conversion Of 2024 Notes Value", "label": "Issuance Of Common Stock For Conversion Of 2024 Notes Value", "terseLabel": "Issuance of common stock for conversion of 2024 Notes" } } }, "auth_ref": [] }, "srpt_IssuanceOfCommonStockForExchangeOf2024NotesShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "IssuanceOfCommonStockForExchangeOf2024NotesShares", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Issuance of Common Stock for Exchange of 2024 Notes Shares", "label": "Issuance of Common Stock for Exchange of 2024 Notes Shares", "terseLabel": "Issuance of common stock for exchange of 2024 Notes, shares" } } }, "auth_ref": [ ] }, "srpt_IssuanceOfCommonStockForExchangeOfNotesShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "IssuanceOfCommonStockForExchangeOfNotesShares", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for exchange of notes shares", "label": "Issuance of common stock for exchange of notes shares", "terseLabel": "Issuance of common stock for exchange of 2024 Notes, shares" } } }, "auth_ref": [] }, "srpt_LacertaTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "LacertaTherapeuticsIncMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Lacerta Therapeutics, Inc.", "label": "Lacerta Therapeutics Inc [Member]", "terseLabel": "Lacerta Therapeutics Inc [Member]" } } }, "auth_ref": [] }, "srpt_LeaseholdImprovementReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "LeaseholdImprovementReceivableCurrent", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "documentation": "Leasehold improvement receivable current.", "label": "Leasehold Improvement Receivable Current", "terseLabel": "Leasehold improvement receivable" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r576", "r580" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r576", "r580" ] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease discount rate", "label": "Lessee, Operating Lease, Discount Rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r872" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r580", "r1114" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Leases, term of contract extend", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1115" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r572" ] }, "srpt_LetterOfCreditReduce": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "LetterOfCreditReduce", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit Reduce", "documentation": "Letter of Credit Reduce", "label": "Letter of Credit Reduce" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r15", "r53", "r54", "r55", "r57", "r58", "r59", "r60", "r217", "r320", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r513", "r516", "r517", "r557", "r737", "r830", "r904", "r1061", "r1117", "r1118" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r68", "r110", "r676", "r874", "r1021", "r1050", "r1109" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r55", "r173", "r217", "r320", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r513", "r516", "r517", "r557", "r874", "r1061", "r1117", "r1118" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfLevel3FinancialLiabilitiesDetails",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of derivatives", "label": "Liabilities, Fair Value Adjustment", "terseLabel": "Fair value of contingent consideration liability", "verboseLabel": "Change in the fair value of contingent consideration", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail",
```

```
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfLevel3FinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value at the beginning of the year", "label": "Liabilities, Fair Value Disclosure", "terseLabel": "Total liabilities", "verboseLabel": "Fair value at the beginning of the period", "periodEndLabel": "Fair value at the end of the period", "totalLabel": "Liabilities, Fair Value Disclosure, Total", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r543", "r1101" ] }, "srpt_LiabilitiesTerminated": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "LiabilitiesTerminated", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfLevel3FinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Liabilities Terminated", "label": "Liabilities Terminated", "terseLabel": "Liabilities Terminated" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total carrying value of debt instruments", "terseLabel": "Aggregate long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r15", "r108", "r394", "r408", "r841", "r842", "r871", "r1129" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total carrying value of debt instruments", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r178" ] },
"srpt_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFour", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail" ], "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date.", "label": "Long Term Debt Maturities Repayments Of Principal After Year Four", "terseLabel": "2027" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r221", "r399" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r221", "r399" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r221", "r399" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r221", "r399" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (October-December)", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r1025" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Long-Term Investments, Total", "label": "Long-Term Investments", "terseLabel": "Non-current investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r175" ] }, "us-gaap_LongTermLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLoansPayable", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Loans Payable, Noncurrent", "terseLabel": "Long-term debt", "totalLabel": "Total carrying value of debt facilities", "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r15" ] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Purchase commitment", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r15", "r1054", "r1055", "r1056" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r15", "r34", "r1054", "r1055", "r1056" ] }, "srpt_LysogeneSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "LysogeneSAMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Lysogene S.A. [Member]", "label": "Lysogene S A [Member]", "documentation": "Lysogene S.A." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r280", "r848", "r885", "r889", "r1065", "r1131", "r1135", "r1136", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162" ] }, "srpt_ManufacturingCommitmentsAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ManufacturingCommitmentsAgreementMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu
], "lang": { "en-us": { "role": { "documentation": "Manufacturing commitments agreement Member", "label": "Manufacturing Commitments Agreement [Member]",
"terseLabel": "Manufacturing Commitments Agreement [Member]" } } }, "auth_ref": [] }, "srpt_ManufacturingRelatedDepositsAndPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ManufacturingRelatedDepositsAndPrepaidExpenseCurrent", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "documentation": "Manufacturing-related deposits and prepaid expense current.", "label": "Manufacturing Related Deposits And Prepaid Expense Current", "terseLabel": "Manufacturing-related deposits and prepaids" } } }, "auth_ref": [] }, "srpt_ManufacturingRelatedDepositsAndPrepaidExpenseNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ManufacturingRelatedDepositsAndPrepaidExpenseNonCurrent", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherNoncurrentAssetsDetail" ], "lang": { "en-us": { "role": { "documentation": "Manufacturing related deposits and prepaid expense non current.", "label": "Manufacturing Related Deposits And Prepaid Expense Non Current", "terseLabel": "Manufacturing-related deposits and prepaids" } } }, "auth_ref": [] }, "srpt_ManufacturingRelatedDepositsAndPrepaids": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ManufacturingRelatedDepositsAndPrepaids", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Manufacturing related deposits and prepaids", "label": "Manufacturing related deposits and prepaids", "terseLabel": "Manufacturing-related deposits and prepaids" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
```

```
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Maximum [Member]", "terseLabel": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r133", "r135", "r137", "r138", "r140",
"r163", "r164", "r366", "r367", "r368", "r369", "r426", "r465", "r546", "r623", "r695", "r697", "r711", "r729", "r730", "r781", "r783", "r785", "r786", "r790", "r810", "r811",
"r834", "r845", "r854", "r864", "r865", "r869", "r870", "r886", "r1063", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124" ] }, "ecd_MeasureAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r953" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure
Name", "terseLabel": "Name" } } }, "auth_ref": [ "r953" ] }, "srpt_MilestonePaymentToBePaidByCompanyUponSpecifiedResearchMilestoneAchievement": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "MilestonePaymentToBePaidByCompanyUponSpecifiedResearchMilestoneAchievement",
"crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "documentation": "Milestone payment to be paid by company upon specified research milestone achievement.", "label": "Milestone Payment To Be
Paid By Company Upon Specified Research Milestone Achievement", "terseLabel": "Contingent research milestone payments" } } }, "auth_ref": [] }, "srt_MinimumMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Minimum [Member]", "terseLabel": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r133", "r135", "r137", "r138", "r140",
"r163", "r164", "r366", "r367", "r368", "r369", "r426", "r465", "r546", "r623", "r695", "r697", "r711", "r729", "r730", "r781", "r783", "r785", "r786", "r790", "r810", "r811",
"r834", "r845", "r854", "r864", "r865", "r869", "r886", "r1063", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI
Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r972" ] }, "srpt_ModificationOf2017CappedCalls": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.sarepta.com/20240930", "localname": "ModificationOf2017CappedCalls", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Modification of 2017 Capped Calls", "label": "Modification of 2017 Capped Calls", "documentation": "Modification of 2017 Capped Calls" } } }, "auth_ref": [] },
"srpt_ModificationOfCappedCalls": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ModificationOfCappedCalls", "crdr": "credit",
"presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role":
{ "terseLabel": "Modification of 2017 Capped Calls", "label": "Modification of Capped Calls", "documentation": "Modification of Capped Calls" } } }, "auth_ref": [] }, "us-
gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90Da
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail" ], "lang": { "en-us": { "role":
{ "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for
example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid
securities." } } }, "auth_ref": [ "r1066" ] }, "srpt_MsRodinoKlapacMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"MsRodinoKlapacMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Ms. Rodino Klapac [Member]",
"documentation": "Ms. Rodino Klapac [Member]" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r980" ] },
"srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r280", "r848", "r885", "r889", "r1065", "r1131",
"r1135", "r1136", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154",
"r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r954" ] },
"srpt_NationwideChildrenHospitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"NationwideChildrenHospitalMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Nationwide Children Hospital.", "label": "Nationwide Children Hospital [Member]", "terseLabel": "NationWide Children Hospital [Member]" } } },
"auth_ref": [] }, "srpt_NationwideChildrensHospitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"NationwideChildrensHospitalMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Nationwide children's hospital.", "label": "Nationwide Childrens Hospital [Member]", "terseLabel": "Nationwide Children?s Hospital [Member]" } } },
"auth_ref": [] }, "srpt_NationwideLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"NationwideLicenseAgreementMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Nationwide license agreement.", "label": "Nationwide License Agreement [Member]", "terseLabel": "Nationwide License Agreement [Member]" } } },
"auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash
Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing
activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of,
their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-
term credit." } } }, "auth_ref": [ "r210" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash
Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash
Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing
activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and
property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r210" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash
Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-
gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTotalLabel":
"Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation":
"Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in
value not defined as investing or financing activities." } } }, "auth_ref": [ "r85", "r86", "r87" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash
Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net income (loss)", "documentation": "The portion of profit or
loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r75", "r87", "r115", "r171", "r191", "r194", "r198", "r217", "r226", "r230",
"r231", "r232", "r233", "r234", "r237", "r238", "r254", "r320", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r498", "r509", "r540", "r557", "r681",
"r759", "r775", "r776", "r902", "r1061" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net
income (loss) - diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net Income (Loss) Available to Common Stockholders, Diluted,
Total", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of
issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } } }, "auth_ref": [ "r205", "r242", "r248", "r249",
"r250", "r251", "r255", "r258" ] }, "srpt_NoIndividualMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"NoIndividualMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "label": "No Individual [Member]", "documentation": "No Individual [Member]" } } }, "auth_ref": [] },
"srpt_NonCashChangeInTheFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"NonCashChangeInTheFairValueOfDerivatives", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash
change in the fair value of derivatives", "label": "Non-Cash Change In The Fair Value Of Derivatives", "documentation": "Non-Cash Change In The Fair Value Of Derivatives" }
} }, "auth_ref": [] }, "srpt_NonCashContractTerminationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
```

```
"NonCashContractTerminationCost", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash contract termination cost", "label": "Non-Cash Contract Termination Cost", "documentation": "Non-cash contract termination cost." } } }, "auth_ref": [] },
"srpt_NonCurrentInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "NonCurrentInvestmentsMember",
"presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
], "lang": { "en-us": { "role": { "terseLabel": "Non-current investments [Member]", "label": "Non-current investments [Member]", "documentation": "Non-current investments [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r953" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r917", "r927", "r937", "r961", "r969" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r944" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r943" ] },
"ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r961" ] },
"ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r980" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r980" ] }, "us-gaap_NonUsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Non-US [Member]", "terseLabel": "Outside of U.S. [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1168",
"r1169", "r1170", "r1171" ] }, "srpt_NoncashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"NoncashInterestExpense", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Noncash Interest Expense", "documentation": "Noncash interest expense." } } }, "auth_ref": [] }, "us-
gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Intangible assets and property and equipment included in accounts payable and accrued expenses",
"documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "us-
gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit",
"presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": {
"role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (loss), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r77" ] }, "us-
gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract",
"presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ],
"lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (loss), net:" } } }, "auth_ref": [] }, "us-
gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r833", "r1034" ] },
"us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit",
"presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ],
"lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Operating (loss) income", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r119", "r831", "r1033", "r1035", "r1036", "r1037", "r1038" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label":
"Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } },
"auth_ref": [ "r577", "r873" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Operating lease liability", "totalLabel": "Operating Lease, Liability, Total", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r575" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r575" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r574" ] },
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureORGANIZATIONANDNATUREOFBUSINESS" ], "lang": { "en-us": { "role": { "label":
"Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION AND NATURE OF BUSINESS",
"documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r51", "r100", "r713",
"r714" ] }, "srpt_OtherAccrualsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "OtherAccrualsMember", "presentation":
[
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc
], "lang": { "en-us": { "role": { "documentation": "Other accruals.", "label": "Other Accruals [Member]", "terseLabel": "Other Accruals [Member]" } } }, "auth_ref": [] }, "us-
gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr":
"credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": {
"label": "Other Accrued Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r54" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Assets, Current",
"terseLabel": "Other current assets", "totalLabel": "Total other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r183",
"r874" ] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherAssetsDisclosureTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOTHERASSETS" ], "lang": { "en-us": { "role": { "label":
"Other Assets Disclosure [Text Block]", "terseLabel": "OTHER ASSETS", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherAssetsMiscellaneousCurrent", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Other Assets, Miscellaneous, Current", "terseLabel": "Other", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherAssetsMiscellaneousNoncurrent", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherNoncurrentAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Other Assets, Miscellaneous, Noncurrent", "terseLabel": "Other", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherAssetsNoncurrent", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherNoncurrentAssetsDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets", "totalLabel": "Total other non-current assets", "documentation": "Amount of noncurrent assets classified as other." } }
}, "auth_ref": [ "r176" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Other
```

Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest", "terseLabel": "Unrealized gains from available-for-sale securities, net of tax", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to noncontrolling interest." } } }, "auth_ref": ["r2", "r9", "r101"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r10", "r14", "r192", "r195", "r200", "r234", "r558", "r559", "r564", "r661", "r682", "r1014", "r1015"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains on investments, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r186", "r189", "r318"] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "srpt_OtherInvestingActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "OtherInvestingActivity", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "documentation": "Other investing activity.", "label": "Other Investing Activity", "negatedLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "totalLabel": "Other Liabilities, Current, Total", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r54", "r874"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r58"] }, "srpt_OtherNonCurrentAssetsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "OtherNonCurrentAssetsAmortizedCost", "crdr": "debit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments"], "lang": { "en-us": { "role": { "terseLabel": "Other Non-Current Assets Amortized Cost", "label": "Other Non-Current Assets Amortized Cost", "documentation": "Other Non-Current Assets Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other", "totalLabel": "Other Noncash Income (Expense), Total", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": ["r87"] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNet"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income and Expense [Text Block]", "terseLabel": "OTHER INCOME (LOSS), NET", "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": ["r203", "r204"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "totalLabel": "Other income (expense), net", "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r79"] }, "us-gaap_OtherNonrecurringIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonrecurringIncomeExpense", "crdr": "debit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetSummaryOfOtherIncomeLossDetail"], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Nonrecurring (Income) Expense", "totalLabel": "Other Nonrecurring (Income) Expense, Total", "negatedLabel": "Other, net", "documentation": "Amount of other expense (income) that is infrequent in occurrence or unusual in nature." } } }, "auth_ref": ["r81"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r953"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r915", "r925", "r935", "r967"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r918", "r928", "r938", "r970"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r918", "r928", "r938", "r970"] }, "srpt_PRVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PRVMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureGainFromSaleOfPriorityReviewVoucherAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "PRV", "label": "P R V [Member]", "terseLabel": "P R V" } } }, "auth_ref": [] }, "srpt_PartialSettlementOfCappedCallShareOptionsFor2024Notes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PartialSettlementOfCappedCallShareOptionsFor2024Notes", "crdr": "debit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Partial settlement of capped call", "terseLabel": "Partial settlement of capped call share options for 2024 Notes", "label": "Partial settlement of capped call share options for 2024 Notes", "documentation": "Partial settlement of capped call share options for 2024 Notes" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r942"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "srpt_PaymentForOptionExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PaymentForOptionExercise", "crdr": "debit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Payment for option exercise", "label": "Payment For Option Exercise", "documentation": "Payment for option exercise." } } }, "auth_ref": [] }, "srpt_PaymentsCreditsReservesForDiscountsAndAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PaymentsCreditsReservesForDiscountsAndAllowances", "crdr": "debit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc"], "lang": { "en-us": { "role": { "documentation": "Payments credits reserves for discounts and allowances.", "label": "Payments Credits Reserves For Discounts And Allowances", "negatedLabel": "Payments/credits" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromTenantAllowance", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Payments for (Proceeds from) Tenant Allowance", "verboseLabel": "Tenant improvement allowance", "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy." } } }, "auth_ref": ["r19", "r83"] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Payments for Rent", "terseLabel": "Undiscounted rent payment", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": ["r3"] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchase of available-for-sale securities", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r20", "r206", "r286"] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Intangible Assets", "terseLabel": "Purchase of intangible assets", "negatedLabel": "Purchase of intangible assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": ["r84"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r84"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote"

```
} } }, "auth_ref": [ "r952" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r952" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r944" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r961" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r954" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r943" ] }, "us-gaap_PhantomShareUnitsPSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PhantomShareUnitsPSUsMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Phantom Share Units (PSUs) [Member]", "documentation": "Share-based payment arrangement awarded as phantom share or unit." } } }, "auth_ref": [] }, "srt_PlatformOperatorCryptoAssetTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "PlatformOperatorCryptoAssetTable", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfLevel3FinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto Asset [Table]", "documentation": "Disclosure of information about crypto-asset held for platform user." } } }, "auth_ref": [ "r162", "r355" ] }, "srpt_PmoProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PmoProductsMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation": "PMO Products [Member]", "label": "PMO Products [Member]" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r945" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r989" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r944" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r61", "r410" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r61", "r739" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r61", "r410" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r61", "r739", "r757", "r1165", "r1166" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value, 3,333,333 shares authorized, none issued and outstanding", "totalLabel": "Preferred Stock, Value, Issued, Total", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r61", "r672", "r874" ] }, "srpt_PrepaidClinicalAndPreclinicalExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PrepaidClinicalAndPreclinicalExpensesCurrent", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "documentation": "Prepaid clinical and preclinical expenses current.", "label": "Prepaid Clinical And Preclinical Expenses Current", "terseLabel": "Prepaid clinical and pre-clinical expenses" } } }, "auth_ref": [] }, "srpt_PrepaidCommercial": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PrepaidCommercial", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "documentation": "Prepaid commercial.", "label": "Prepaid Commercial", "terseLabel": "Prepaid commercial expenses" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsNoncurrentAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r819", "r836", "r1051" ] }, "srpt_PrepaidMaintenanceServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PrepaidMaintenanceServices", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherNoncurrentAssetsDetail" ], "lang": { "en-us": { "role": { "documentation": "Prepaid maintenance services", "label": "Prepaid maintenance services", "terseLabel": "Prepaid maintenance services" } } }, "auth_ref": [] }, "srpt_PrepaidMaintenanceServicesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PrepaidMaintenanceServicesCurrent", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "documentation": "Prepaid maintenance services, current.", "label": "Prepaid Maintenance Services Current", "terseLabel": "Prepaid maintenance services" } } }, "auth_ref": [] }, "srpt_PrepaidMedicalAffairsExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PrepaidMedicalAffairsExpenses", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "documentation": "Prepaid medical affairs expenses.", "label": "Prepaid Medical Affairs Expenses", "terseLabel": "Prepaid medical affairs expenses" } } }, "auth_ref": [] }, "srpt_PrepaidResearchExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PrepaidResearchExpensesCurrent", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "documentation": "Prepaid research expenses, current.", "label": "Prepaid Research Expenses Current", "terseLabel": "Prepaid research expenses" } } }, "auth_ref": [] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidTaxes", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Prepaid Taxes", "terseLabel": "Prepaid income tax", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r820", "r837", "r1051" ] }, "srpt_PrincipalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PrincipalMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummarizesTotalGrossPaymentsDueUnderCompanySDebtArrangementsDetail" ], "lang": { "en-us": { "role": { "documentation": "Principal [Member]", "label": "Principal [Member]" } } }, "auth_ref": [] }, "us-gaap_PrincipleTransactionRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrincipleTransactionRevenueLineItems", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1" ], "lang": { "en-us": { "role": { "label": "Principal Transaction Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1126" ] }, "us-gaap_PrincipleTransactionRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrincipleTransactionRevenueTable", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1" ], "lang": { "en-us": { "role": { "label": "Principal Transaction Revenue [Table]", "documentation": "Disclosure of information about revenue from trading for broker-dealer's own account by reporting category or type of financial instrument, including, but not limited to, derivative. Excludes dividend and interest." } } }, "auth_ref": [ "r1126" ] }, "srpt_ProceedsFromExerciseOfStockOptionsNotYetReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ProceedsFromExerciseOfStockOptionsNotYetReceived", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of stock options not yet received", "documentation": "Proceeds from exercise of stock options not yet received" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "terseLabel": "Maturity and sale of available-for-sale securities", "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r206", "r207", "r1044" ] }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of Priority Review Voucher", "label": "Proceeds from Sale of Intangible Assets", "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r82" ] }, "srpt_ProceedsFromSaleOfRarePediatricDiseasePriorityReviewVoucherNetOfCommission": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ProceedsFromSaleOfRarePediatricDiseasePriorityReviewVoucherNetOfCommission", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureGainFromSaleOfPriorityReviewVoucherAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
```

```
"documentation": "Proceeds from sale of rare pediatric disease priority review voucher, Net of commission.", "label": "Proceeds From Sale Of Rare Pediatric Disease Priority Review Voucher Net Of Commission", "terseLabel": "Proceeds from sale of rare pediatric disease priority review voucher, Net of commission" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options and purchase of stock under the Employee Stock Purchase Program", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r1", "r13" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r147", "r160", "r277", "r625", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r814", "r846", "r884", "r886", "r887", "r890", "r892", "r1007", "r1059", "r1060", "r1065", "r1131", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162" ] }, "srpt_ProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenues1" ], "lang": { "en-us": { "role": { "terseLabel": "PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES", "label": "PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES [Text Block]", "documentation": "PRODUCT REVENUES, NET, ACCOUNTS RECEIVABLE, NET, AND RESERVES FOR PRODUCT REVENUES [Text Block]" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r147", "r160", "r277", "r625", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r814", "r846", "r884", "r886", "r887", "r890", "r892", "r1007", "r1059", "r1060", "r1065", "r1131", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "terseLabel": "Net income (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r171", "r191", "r194", "r209", "r217", "r226", "r234", "r237", "r238", "r320", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r498", "r509", "r511", "r514", "r515", "r540", "r557", "r664", "r680", "r718", "r759", "r775", "r776", "r858", "r859", "r903", "r1016", "r1061" ] }, "srpt_PromptPayMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "PromptPayMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc ], "lang": { "en-us": { "role": { "documentation": "Prompt pay.", "label": "Prompt Pay [Member]", "terseLabel": "Prompt Pay [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property, Plant and Equipment, Net, Total", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r579", "r665", "r677", "r874" ] }, "srpt_ProvisionForReservesForDiscountsAndAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ProvisionForReservesForDiscountsAndAllowances", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc ], "lang": { "en-us": { "role": { "documentation": "Provision for reserves for discounts and allowances.", "label": "Provision For Reserves For Discounts And Allowances", "terseLabel": "Provision" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r942" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r942" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r133", "r135", "r137", "r138", "r140", "r163", "r164", "r366", "r367", "r368", "r369", "r419", "r426", "r455", "r456", "r457", "r465", "r546", "r597", "r606", "r623", "r695", "r697", "r711", "r729", "r730", "r781", "r783", "r785", "r786", "r790", "r810", "r811", "r834", "r845", "r854", "r864", "r865", "r869", "r870", "r886", "r896", "r1057", "r1063", "r1104", "r1120", "r1121", "r1122", "r1123", "r1124" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r133", "r135", "r137", "r138", "r140", "r163", "r164", "r366", "r367", "r368", "r369", "r419", "r426", "r455", "r456", "r457", "r465", "r546", "r597", "r606", "r623", "r695", "r697", "r711", "r729", "r730", "r781", "r783", "r785", "r786", "r790", "r810", "r811", "r834", "r845", "r854", "r864", "r865", "r869", "r870", "r886", "r896", "r1057", "r1063", "r1104", "r1120", "r1121", "r1122", "r1123", "r1124" ] }, "srpt_RebatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "RebatesMember", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc ], "lang": { "en-us": { "role": { "documentation": "Rebates.", "label": "Rebates [Member]", "terseLabel": "Rebates [Member]" } } }, "auth_ref": [] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc ], "lang": { "en-us": { "role": { "label": "Receivable [Domain]", "terseLabel": "Receivable", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r63", "r69" ] }, "us-gaap_ReceivablesNetCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrentAbstract", "lang": { "en-us": { "role": { "label": "Receivables, Net, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r910", "r920", "r930", "r962" ] }, "srpt_ReductionInCarryingValueOfConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ReductionInCarryingValueOfConvertibleNotes", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Reduction In Carrying Value Of Convertible Notes", "label": "Reduction In Carrying Value Of Convertible Notes", "terseLabel": "Reduction in carrying value of convertible notes" } } }, "auth_ref": [] }, "srpt_ReductionInTheCarryingAmountsOfTheRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ReductionInTheCarryingAmountsOfTheRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the carrying amounts of the right of use assets.", "label": "Reduction In The Carrying Amounts Of The Right Of Use Assets", "terseLabel": "Reduction in the carrying amounts of the right of use assets" } } }, "auth_ref": [] }, "srpt_ReductionToRightOfUseAssetsAndLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ReductionToRightOfUseAssetsAndLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction to right of use assets and lease liabilities", "label": "Reduction To Right Of Use Assets And Lease Liabilities", "documentation": "Reduction To Right Of Use Assets And Lease Liabilities" } } }, "auth_ref": [] }, "srpt_RemainingExpenseAssociatedInShare": { "xbrltype": "sharesItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "RemainingExpenseAssociatedInShare", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining expense associated", "label": "Remaining expense associated in share", "documentation": "Remaining expense associated in share" } } }, "auth_ref": [] }, "srpt_RemainingSharesAssociatedWithPerformanceCondition": { "xbrltype": "sharesItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "RemainingSharesAssociatedWithPerformanceCondition", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining shares associated with performance condition", "label": "Remaining Shares Associated With Performance Condition", "documentation": "Remaining Shares Associated With Performance Condition" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
```

```
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureGainFromSaleOfPriorityReviewVoucherAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Counterparty Name [Domain]", "terseLabel": "Counterparty Name", "documentation": "Named other party that participates in a financial transaction. Examples include, but
not limited to, the name of the financial institution." } } }, "auth_ref": [ "r158", "r159", "r219", "r220", "r385", "r411", "r587", "r607", "r666", "r826", "r827" ] }, "us-
gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr":
"debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Research and Development Expense", "terseLabel": "Research and development expense", "totalLabel": "Research and Development Expense, Total", "documentation":
"Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of
research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired
in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r466", "r812", "r832", "r1125" ] }, "us-
gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": {
"role": { "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development", "totalLabel": "Research and
Development Expense (Excluding Acquired in Process Cost), Total", "documentation": "Amount of expense for research and development. Excludes cost for computer software
product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture
formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." }
} }, "auth_ref": [ "r1095" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"verboseLabel": "Research and Development Expense [Member]", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development
Expense", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref":
[] }, "srpt_ResearchMilestoneExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ResearchMilestoneExpense", "crdr":
"debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Research milestone expense", "label": "Research Milestone Expense", "documentation": "Research Milestone Expense" } } }, "auth_ref": [] },
"srpt_ResearchOptionAndMilestoneExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"ResearchOptionAndMilestoneExpense", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Research, option and milestone expense.", "label": "Research, Option And Milestone Expense", "terseLabel": "Research, option and milestone expense" } }
}, "auth_ref": [] }, "srpt_ReservesForComponentOfAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname":
"ReservesForComponentOfAccruedExpenses", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfTotalReservesIncludedIn(
], "lang": { "en-us": { "role": { "documentation": "Reserves for component of accrued expenses.", "label": "Reserves For Component Of Accrued Expenses", "terseLabel":
"Component of accrued expenses" } } }, "auth_ref": [] }, "srpt_ReservesForReductionToAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.sarepta.com/20240930", "localname": "ReservesForReductionToAccountsReceivable", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfTotalReservesIncludedIn(
], "lang": { "en-us": { "role": { "documentation": "Reserves for reduction to accounts receivable.", "label": "Reserves For Reduction To Accounts Receivable", "terseLabel":
"Reduction to accounts receivable" } } }, "auth_ref": [] }, "srpt_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930",
"localname": "RestOfWorldMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails"
], "lang": { "en-us": { "role": { "documentation": "Rest of World [Member]", "label": "Rest of World [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r911", "r921", "r931", "r963" ] },
"ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" }
} }, "auth_ref": [ "r912", "r922", "r932", "r964" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r919", "r929",
"r939", "r971" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit",
"presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "totalLabel": "Restricted Cash, Total", "documentation": "Amount of cash restricted as to withdrawal or
usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand
deposits." } } }, "auth_ref": [ "r1008", "r1019", "r1127", "r1130" ] }, "us-gaap_RestrictedCashAndInvestmentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndInvestmentsNoncurrent", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Restricted Cash and Investments, Noncurrent", "terseLabel": "Restricted cash and investments", "totalLabel": "Restricted Cash and Investments, Noncurrent, Total",
"verboseLabel": "Restricted cash", "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may
include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with
regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating
cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet.
Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal." } } }, "auth_ref": [ "r797", "r798" ] }, "us-
gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit",
"presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherNoncurrentAssetsDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel":
"Restricted cash", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash in other assets", "documentation": "Amount of cash restricted as to withdrawal or
usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general
characteristics of demand deposits." } } }, "auth_ref": [ "r123", "r1009", "r1019" ] }, "srpt_RestrictedStockAndRestrictedStockUnitsRSUsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "RestrictedStockAndRestrictedStockUnitsRSUsMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
], "lang": { "en-us": { "role": { "documentation": "Restricted stock and restricted stock units.", "label": "Restricted Stock And Restricted Stock Units R S Us [Member]",
"terseLabel": "Restricted stock units" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails" ], "lang": { "en-us": { "role": {
"label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units [Member]", "documentation": "Share instrument which is convertible to stock or an
equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "srpt_RestrictedStockUnitsVested": {
"xbrltype": "sharesItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "RestrictedStockUnitsVested", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Vest of restricted stock units", "documentation": "Restricted Stock Units Vested", "label": "Restricted Stock Units Vested" } } }, "auth_ref": [] }, "us-
gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit",
"crdr": "credit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": {
"label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
"totalLabel": "Retained Earnings (Accumulated Deficit), Total", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "documentation": "Amount
of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r65", "r97", "r675", "r705", "r710", "r716", "r740", "r874" ] }, "us-gaap_RetainedEarningsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label":
"Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r167",
"r222", "r223", "r224", "r227", "r234", "r236", "r238", "r324", "r330", "r353", "r480", "r481", "r494", "r495", "r496", "r499", "r508", "r509", "r521", "r524", "r525", "r528",
"r538", "r570", "r573", "r701", "r703", "r719", "r1165" ] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr":
"credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": {
"role": { "verboseLabel": "Total Roche supply agreement revenue", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
"terseLabel": "Collaboration and other", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic
606." } } }, "auth_ref": [ "r122", "r1098" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": {
"role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Products, net", "totalLabel": "Revenue from Contract with Customer,
Excluding Assessed Tax, Total", "verboseLabel": "Product revenues, net", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of
performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on
and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r117", "r118", "r263",
"r266", "r267", "r274", "r276", "r277", "r278", "r280", "r416", "r417", "r625" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [
```

```
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": {
"role": { "label": "Revenues", "totalLabel": "Total revenues", "terseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered,
insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest
expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r117", "r118", "r199", "r217", "r263", "r266", "r267", "r274",
"r276", "r277", "r278", "r280", "r320", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r557", "r664", "r832", "r1061" ] }, "us-gaap_RevenuesAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": {
"role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit",
"presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": {
"label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Lease liabilities arising from obtaining right of use assets", "documentation":
"Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r578", "r873" ] }, "srpt_RocheAgreementMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "RocheAgreementMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Roche
Agreement [Member]", "label": "Roche Agreement [Member]", "documentation": "Roche Agreement." } } }, "auth_ref": [] }, "srpt_RocheMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "RocheMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation":
"Roche.", "label": "Roche [Member]", "terseLabel": "Roche Holding A.G. [Member]" } } }, "auth_ref": [] }, "srpt_RoyaltyRevenue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.sarepta.com/20240930", "localname": "RoyaltyRevenue", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Royalty revenue", "label": "Royalty Revenue", "documentation": "Royalty Revenue" } } }, "auth_ref": [] }, "srpt_RoyaltyRevenueMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "RoyaltyRevenueMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Royalty Revenue [Member]", "label": "Royalty Revenue [Member]", "documentation": "Royalty Revenue [Member]" } } }, "auth_ref": [] },
"ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1
Arrangement Adopted" } } }, "auth_ref": [ "r980" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement
Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r980" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummarizesTheConcentrationOfThe1
], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "terseLabel": "Sales Revenue Net [Member]", "documentation": "Revenue from sale of product and
rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r280", "r993" ] }, "us-
gaap_SalesRevenueProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueProductLineMember",
"presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Revenue, Product and Service Benchmark [Member]", "terseLabel": "Product Revenues [Member]", "documentation": "Revenue from specified product or service, when it
serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [ "r994" ]
}, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]",
"terseLabel": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on
historical fact." } } }, "auth_ref": [ "r427", "r1004", "r1029" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to,
pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r161", "r239", "r427", "r991", "r1029" ] }, "us-
gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfChangeInReservesForDisc
], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivables [Table]", "terseLabel": "Schedule Of Accounts Notes Loans And Financing Receivable [Table]",
"documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } }
}, "auth_ref": [ "r63", "r69", "r284", "r1041" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureACCRUEDEXPENSESTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table
Text Block]", "terseLabel": "Summary of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareSummaryOfPotentialSharesOfCommonStockThatWereExcludedFromTheComputationOfDilute
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareParentheticalDetail" ], "lang": { "en-us": { "role": { "label":
"Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share
(EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90Da
], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalent [Table]", "terseLabel": "Schedule Of Cash And Cash Equivalents [Table]", "documentation": "Disclosure of
information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables" ], "lang": { "en-us": { "role": { "label":
"Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Summary of Company Financial Assets with Maturities of Less Than 90 Days Included in Cash
Equivalents", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureCASHCASHEQUIVALENTSANDMARKETABLESECURITIESTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Summary of Company Cash, Cash Equivalents and Short-Term Investments and non-current investments", "label": "Cash, Cash Equivalents and Investments
[Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] },
"srpt_ScheduleOfCertainActivityRelatedToRevenueWithSupplyAgreementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sarepta.com/20240930",
"localname": "ScheduleOfCertainActivityRelatedToRevenueWithSupplyAgreementTableTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Certain
Activity Related to Revenue with Supply Agreement", "label": "Schedule Of Certain Activity Related To Revenue With Supply Agreement [Table Text Block]", "documentation":
"Schedule of certain activity related to revenue with supply agreement." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement
Transactions [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-
generating activity or operations." } } }, "auth_ref": [ "r510" ] }, "us-
gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureSTOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment
Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense by Grant Type Included within Consolidated Statements of
Operations and Comprehensive Loss", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is
not limited to, related tax benefit." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINDEBTEDNESSTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments
[Table Text Block]", "terseLabel": "Summary of Debt Facilities", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification,
terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than
twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r15", "r38", "r39", "r48", "r95", "r96", "r841", "r843",
"r1025", "r1111" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningsLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and
Diluted [Table Text Block]", "terseLabel": "Basic and Diluted Net Loss Per Share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share
calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } },
"auth_ref": [ "r1032" ] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningsLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Diluted, by
Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Summary of Potential Shares of Common Stock that were Excluded from the Computation of
```

Diluted Earnings per Share", "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share." } } }, "auth_ref": ["r26", "r28", "r1031"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r40"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureSTOCKBASEDCOMPENSATIONTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense by Function Included within Condensed Consolidated Statements of Operations and Comprehensive Loss", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r40"] }, "srpt_ScheduleOfInventoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ScheduleOfInventoryTableTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINVENTORYTables"], "lang": { "en-us": { "role": { "documentation": "Schedule Of Inventory Table Text Block", "label": "Schedule Of Inventory Table Text Block", "terseLabel": "Schedule of Components of Inventory" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINDEBTEDNESSTables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Summarizes Total Gross Payments Due under Company's Debt Arrangements", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r7"] }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOTHERASSETSTables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "terseLabel": "Summary of Other Non-current Assets", "documentation": "Tabular disclosure of noncurrent assets." } } }, "auth_ref": ["r1009"] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOTHERASSETSTables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Summary of Other Current Assets", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherIncomeLossNetTables"], "lang": { "en-us": { "role": { "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Summary of Other Income (Loss)", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPrincipalTransactionsRevenueTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Activity Related to Supply Agreement", "label": "Schedule of Principal Transactions Revenue [Table Text Block]", "documentation": "Tabular disclosure of revenue by reporting categories or types of financial instruments, including derivatives but excluding dividends and interests, from trading for own account by broker dealers." } } }, "auth_ref": ["r1126"] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductInformationTable", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "srpt_ScheduleOfProductRevenuesConcentrationRiskTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ScheduleOfProductRevenuesConcentrationRiskTableTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTables"], "lang": { "en-us": { "role": { "documentation": "Schedule of product revenues concentration risk.", "label": "Schedule Of Product Revenues Concentration Risk [Table Text Block]", "terseLabel": "Schedule of Product revenue Concentration risks" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureSTOCKBASEDCOMPENSATIONTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Summary of Stock Awards Granted", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": ["r11", "r12", "r98"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r429", "r430", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r905"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r907"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical", "documentation": "Geographical area." } } }, "auth_ref": ["r134", "r136", "r139", "r141", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r278", "r279", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r722", "r725", "r727", "r782", "r784", "r788", "r791", "r796", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r815", "r847", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r888", "r896", "r1065", "r1131", "r1135", "r1136", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "totalLabel": "Selling, General and Administrative Expense, Total", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r76"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "verboseLabel": "Selling, General and Administrative", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "srpt_SeptemberTwentyTwoThousandTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "SeptemberTwentyTwoThousandTwentyFiveMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "September 20, 2025 [Member]", "label": "September Twenty Two Thousand Twenty Five [Member]", "documentation": "September Twenty Two Thousand Twenty Five [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Share based compensation granted under plan vest period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r855"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Grants, Restricted stock units", "verboseLabel": "Expanded Grants, Stock options", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r447"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date

```
Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Restricted stock units", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r447" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting PSUs", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r448" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r429", "r430", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total", "verboseLabel": "Grants, Stock options", "terseLabel": "Stock options granted to CEO", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r1074" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Stock options", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r450" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedDetail",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Unvested Tranche Member", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] },
"srpt_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseByGrantTypeIncludedWithinCondensedCons
], "lang": { "en-us": { "role": { "documentation": "Share based compensation expense included in costs and expenses.", "label": "Share Based Compensation Expense Included In Costs And Expenses", "terseLabel": "Total stock-based compensation expense included in expenses" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockAwardsGrantedParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized over approximately the next year", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r856" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Short-Term Investments", "terseLabel": "Short-term investments", "totalLabel": "Short-term Investments, Total", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r111", "r112", "r1012" ] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments
], "lang": { "en-us": { "role": { "label": "Short-Term Investments [Member]", "terseLabel": "Short-term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": [ "r793", "r794", "r795", "r816" ] }, "srpt_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "SignificantAccountingPoliciesPolicyTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Significant Accounting Policies [Policy Text Block]", "label": "Significant Accounting Policies [Policy Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "auth_ref": [] },
"us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r88", "r215" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r10", "r62", "r66", "r67", "r167", "r196", "r197", "r198", "r222", "r223", "r224", "r227", "r234", "r236", "r238", "r264", "r324", "r330", "r353", "r413", "r480", "r481", "r494", "r495", "r496", "r499", "r508", "r509", "r521", "r523", "r524", "r525", "r526", "r528", "r538", "r558", "r560", "r561", "r562", "r563", "r564", "r570", "r573", "r586", "r682", "r701", "r702", "r703", "r719", "r777" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r134", "r136", "r139", "r141", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r278", "r279", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r722", "r725", "r727", "r782", "r784", "r788", "r791", "r796", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r815", "r847", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r888", "r896", "r1065", "r1131", "r1135", "r1136", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r222", "r223", "r224", "r264", "r573", "r625", "r715", "r720", "r731", "r732", "r733", "r734", "r735", "r736", "r739", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r752", "r753", "r754", "r755", "r756", "r758", "r760", "r761", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r777", "r897" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] },
"srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r161", "r239", "r427", "r991", "r992", "r1029" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel":
```

```
"Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r222", "r223", "r224", "r264", "r283", "r573", "r625", "r715", "r720", "r731", "r732", "r733", "r734", "r735", "r736", "r739", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r752", "r753", "r754", "r755", "r756", "r758", "r760", "r761", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r897" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r914", "r924", "r934", "r966" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under employee stock purchase plan, shares", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r10", "r61", "r62", "r97" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of options for common stock, shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r10", "r61", "r62", "r97", "r441" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r10", "r61", "r62", "r97" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of options for common stock", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r10", "r62", "r66", "r67", "r97" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r62", "r66", "r67", "r90", "r741", "r757", "r778", "r779", "r874", "r904", "r1021", "r1050", "r1109", "r1165" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "srpt_StrategicEquityInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "StrategicEquityInvestmentsMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Strategic Equity Investments [Member]", "terseLabel": "Strategic Equity Investments [Member]" } } }, "auth_ref": [] }, "srpt_StrategicInvestmentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "StrategicInvestmentsNoncurrent", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherNoncurrentAssetsDetail" ], "lang": { "en-us": { "role": { "documentation": "Strategic investments noncurrent.", "label": "Strategic Investments Noncurrent", "terseLabel": "Strategic investments" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r565", "r589" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r565", "r589" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r565", "r589" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r565", "r589" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r565", "r589" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r588", "r590" ] }, "srpt_SummaryOfChangeInReservesForDiscountsAndAllowancesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "SummaryOfChangeInReservesForDiscountsAndAllowancesTableTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTables" ], "lang": { "en-us": { "role": { "documentation": "Summary of change in reserves for discounts and allowances.", "label": "Summary Of Change In Reserves For Discounts And Allowances Table [Text Block]", "terseLabel": "Summary of Change in Reserves for Discounts and Allowances" } } }, "auth_ref": [] },
"srpt_SummaryOfReservesForDiscountsAndAllowancesIncludedInConsolidatedBalanceSheetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "SummaryOfReservesForDiscountsAndAllowancesIncludedInConsolidatedBalanceSheetsTableTextBlock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesTables" ], "lang": { "en-us": { "role": { "documentation": "Summary of reserves for discounts and allowances included in consolidated balance sheets.", "label": "Summary Of Reserves For Discounts And Allowances Included In Consolidated Balance Sheets Table [Text Block]", "terseLabel": "Summary of Total Reserves Included in Consolidated Balance Sheets" } } }, "auth_ref": [] }, "srpt_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "srpt_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "srpt_Summaryofinventorybalancesheetclassificationtabletextblock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "Summaryofinventorybalancesheetclassificationtabletextblock", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureINVENTORYTables" ], "lang": { "en-us": { "role": { "documentation": "SummaryOfInventoryBalanceSheetClassificationTableTextBlock", "label": "Summary of Inventory Balance Sheet Classification [Table Text Block]", "terseLabel": "Summary of Inventory Balance Sheet Classification" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "srpt_SupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "SupplyAgreementMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Roche Supply Agreement [Member]", "documentation": "Supply agreement.", "label": "Supply Agreement [Member]" } } }, "auth_ref": [] },
"ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [
"r960" ] }, "srpt_ThermoFisherScientificIncorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "ThermoFisherScientificIncorporationMember", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Thermo fisher scientific, inc.", "label": "Thermo Fisher Scientific Incorporation [Member]", "terseLabel": "Thermo Fisher Scientific, Inc. [Member]" } } }, "auth_ref": [] },
"srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": [ "r1039", "r1116" ] },
"srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail",
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Title and Position
```

{Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "srpt_TotalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "TotalMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Total", "label": "Total [Member]", "terseLabel": "Total [Member]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r952"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r959"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r979"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r981"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r406", "r412", "r529", "r553", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r683", "r860", "r862", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r875", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1045", "r1046", "r1047", "r1048", "r1100", "r1103", "r1104", "r1105", "r1106", "r1108"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r982"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r983"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r983"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r981"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r981"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r984"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r982"] }, "srpt_TwoThousandAndNineteenTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "TwoThousandAndNineteenTermLoanMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail"], "lang": { "en-us": { "role": { "documentation": "Two Thousand And Nineteen Term Loan Member", "label": "Two Thousand And Nineteen Term Loan [Member]", "terseLabel": "2019 Term Loan [Member]" } } }, "auth_ref": [] }, "srpt_TwoThousandAndTwentyFourSeniorConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "TwoThousandAndTwentyFourSeniorConvertibleNotesMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareParentheticalDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail"], "lang": { "en-us": { "role": { "documentation": "Two thousand and twenty four senior convertible notes.", "label": "Two Thousand And Twenty Four Senior Convertible Notes [Member]", "terseLabel": "2024 Convertible Notes [Member]" } } }, "auth_ref": [] }, "srpt_TwoThousandAndTwentySevenSeniorConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "TwoThousandAndTwentySevenSeniorConvertibleNotesMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareParentheticalDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessSummaryOfDebtFacilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "2027 Convertible Notes [Member]", "label": "Two Thousand And Twenty Seven Senior Convertible Notes [Member]", "documentation": "Two Thousand And Twenty Seven Senior Convertible Notes [Member]" } } }, "auth_ref": [] }, "srpt_TwoThousandSeventeenCappedCallTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "TwoThousandSeventeenCappedCallTransactionsMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2017 Capped Call Transactions [Member]", "label": "Two Thousand Seventeen Capped Call Transactions [Member]", "documentation": "Two Thousand Seventeen Capped Call Transactions [Member]" } } }, "auth_ref": [] }, "srpt_TwoThousandSeventeenCappedCallsPartialSettlementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "TwoThousandSeventeenCappedCallsPartialSettlementMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2017 Capped Calls Partial Settlement [Member]", "label": "Two Thousand Seventeen Capped Calls Partial Settlement [Member]", "documentation": "Two Thousand Seventeen Capped Calls Partial Settlement [Member]" } } }, "auth_ref": [] }, "srpt_TwoThousandTwentyFourNotesInducedConversionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "TwoThousandTwentyFourNotesInducedConversionMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Four Notes Induced Conversion [Member]", "label": "Two Thousand Twenty Four Notes Induced Conversion [Member]", "terseLabel": "2024 Notes Induced Conversion [Member]" } } }, "auth_ref": [] }, "srpt_TwoThousandTwentyFourNotesRepurchaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "TwoThousandTwentyFourNotesRepurchaseMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2024 Notes Repurchase [Member]", "label": "Two Thousand Twenty Four Notes Repurchase [Member]", "documentation": "Two Thousand Twenty Four Notes Repurchase [Member]" } } }, "auth_ref": [] }, "srpt_TwoThousandTwentySevenNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sarepta.com/20240930", "localname": "TwoThousandTwentySevenNotesMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Seven Notes [Member]", "label": "Two Thousand Twenty Seven Notes [Member]", "terseLabel": "2027 Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureIndebtednessAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update", "documentation": "Amendment to accounting standards." } } }, "auth_ref": ["r165", "r166", "r167", "r168", "r169", "r170", "r226", "r227", "r228", "r229", "r239", "r281", "r282", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r352", "r353", "r362", "r480", "r481", "r482", "r483", "r484", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r501", "r502", "r503", "r505", "r506", "r507", "r508", "r509", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r554", "r555", "r569", "r570", "r571", "r581", "r582", "r583", "r584", "r585", "r586", "r627", "r628", "r629", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfAggregateNoncancelableContractualObligationsArisingFromManufactu "http://www.sarepta.com/20240930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsSummaryOfActivityRelatedToSupplyAgreementDetails", "http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r510"] }, "us-gaap_TypeOfRevenueExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRevenueExtensibleList", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited"], "lang": { "en-us": { "role": { "label": "Revenue, Product and Service [Extensible Enumeration]", "terseLabel": "Type of Revenue [Extensible List]", "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesAdditionalInformationDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureProductRevenuesNetAccountsReceivableNetAndReservesForProductRevenuesSummaryOfProductRevenuesDetails", "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S. [Member]", "verboseLabel": "United States [Member]" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyCashCashEquivalentsAndShorttermInvestments "http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesSummaryOfCompanyFinancialAssetsWithMaturitiesOfLessThan90Da "http://www.sarepta.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAndCarriedAtFairValueDetail"], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "Government and Government Agency Bonds [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or

```
Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": { "r828", "r849", "r1128" } },
"ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent",
"terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r978" ] }, "srpt_UpFrontAndDevelopmentMilestoneExpenses": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.sarepta.com/20240930", "localname": "UpFrontAndDevelopmentMilestoneExpenses", "crdr": "debit", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Up-front and development milestone expenses.", "label": "Up Front And Development Milestone Expenses", "terseLabel": "Up-front and development
milestone expenses" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UseOfEstimates", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": {
"role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Estimates and Uncertainties", "documentation": "Disclosure of accounting policy for the use of
estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r31", "r32", "r33", "r125", "r127",
"r129", "r130" ] }, "us-gaap_ValueAddedTaxReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValueAddedTaxReceivable",
"crdr": "debit", "presentation": [ "http://www.sarepta.com/20240930/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherCurrentAssetsDetail" ], "lang": { "en-us": { "role": {
"label": "Value Added Tax Receivable", "terseLabel": "Tax-related receivables and prepaids", "documentation": "Carrying amount as of the balance sheet date of value added
taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities." } } }, "auth_ref": [ "r1011" ] }, "us-gaap_VestingAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]",
"documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1067", "r1068", "r1069", "r1070", "r1071",
"r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090",
"r1091", "r1092" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]",
"documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073",
"r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092" ] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date
Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } }
}, "auth_ref": [ "r940" ] }, "srpt_WeightedAverageMaturityPeriodOfAvailableForSaleSecurities": { "xbrltype": "durationItemType", "nsuri": "http://www.sarepta.com/20240930",
"localname": "WeightedAverageMaturityPeriodOfAvailableForSaleSecurities", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Weighted average maturity period of available for sale securities.", "label": "Weighted Average Maturity Period Of Available For Sale Securities",
"terseLabel": "Weighted average maturity period of available-for-sale securities" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": {
"role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average common shares outstanding - diluted", "terseLabel": "Diluted",
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the
timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r242", "r258" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/DisclosureEarningLossPerShareBasicAndDilutedNetLossPerShareDetail",
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": {
"role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Weighted-average common shares outstanding - basic", "totalLabel": "Weighted
Average Number of Shares Outstanding, Basic, Total", "terseLabel": "Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable
shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been
outstanding to the total time in that period." } } }, "auth_ref": [ "r241", "r258" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [
"http://www.sarepta.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "lang": { "en-us": {
"role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Weighted average number of shares of common stock used in computing
earnings (loss) per share:" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end
Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r946" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic":
"10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r8": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic":
"718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" },
"r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r19":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r22": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r24":
{ "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-
5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph":
"1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r29": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" },
"r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-
8" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph":
"9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-
5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph":
"4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r38": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
```

Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483613/220-20-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/820/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "FF", "Paragraph": "Question 2", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-
50-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r187": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r190": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-
10-45-1A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r194": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r197": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r199":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r200": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r201": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r202": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r203": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r204": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r205": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r206": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-
45-17" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-
45-25" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r215": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-
45-23" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r226": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r227": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r228": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r229": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r230": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r233": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r235":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r238": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r243": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name":
```

"Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.FF.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476188/405-10-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

```
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r440": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r441": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r442": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r444": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r462": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r463": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r466": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r470": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A",
"Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r471": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r472": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r475": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r478": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-
10-65-8" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r482": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-
65-9" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r486": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r487": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r488": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r489": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-
65-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r493": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-
323-65-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r497": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r498": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r499": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r500": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
```

```
"Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-
65-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r504": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r505": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-
65-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r509": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r512": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-
10-50-1A" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r516": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-
65-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r520": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-
65-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r524": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r525": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r526": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r527": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r528": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r529": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-
40-65-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r533": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r534": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r535": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-
40-65-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r539": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r540": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r544": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r545": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r546": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r547": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r548": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r552": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-
65-13" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r556": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r559": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-
45-20" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r563": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-
45-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r798": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954",
"SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-
50-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r802":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r803": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r804": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r805": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r806": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r807": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r808": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r876": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" },
"r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r881": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r884": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r887": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-
40-55-9C" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r893": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-6" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r903": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b-2" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "d1-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q",
"Number": "240", "Section": "308", "Subsection": "a" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section":
"16", "Subsection": "j", "Paragraph": "a" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection":
"F", "Paragraph": "1", "Subparagraph": "i" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r915": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence":
"D" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph":
"a", "Subparagraph": "1" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "i" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name",
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-
F", "Section": "19", "Paragraph": "b" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "i" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r944": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "i" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "iii" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "v" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r953": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "vi" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "3" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "4" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r958": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "iii" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
```

"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r991": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r992": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Subparagraph": "(a)", "Publisher": "SEC" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "6", "Subsection": "04", "Paragraph": "12", "Subparagraph": "(b)(1)", "Publisher": "SEC" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1097": { "role":

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1098": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r1099": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1100": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1104": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1105": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1106": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-6A" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r1110": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1111": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-
30-45-2" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1114": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-
20-50-3" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1117": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1118": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1119": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1120": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1121": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1122": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1123": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1124": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1125": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479048/940-320-50-1" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-
30-50-2B" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1133": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1134": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1135": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1136": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1137": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1140": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1141": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1142": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1143": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1144": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1145": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1146": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1147": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1148": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1149": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1150": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1151": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1152": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1153": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1154": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1155": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1156": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1157": { "role":
```

*"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 92 0000950170-24-122239-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-122239-xbrl.zip M4$L#!!0 ("J 9EG.@^=" _B/O\+P,CM_]J2^/=+A_?_Z7__/+O_S\/Q@;/'GV_,7@!7X8/$KS MX7M\,IRET62VF.+@A]T_?AP\'X^&8QS\YZ^O?A\\F:3%/H[G S;8F\\/=AX\ M^/#AP_U%T^&YO/O@A_3BHWZ)WC\/;7>R>&_D'=GTS? M/. AA ZM9WCH_>>OPU !. MWJT>T#K.:6IX? #^M_-^_C%\0Y:?#=[7)GSZ8'YX@__H1C9>WOEI5+/A>6.B&8@'__G'!EM#_>_!MG9WZ'HP/_6U&4SQ8 [=_JH;@@?%CV]>&O>8Q>XE1Q>Z+QS?3&-E M=:RS2Z9"WY&,*Z;$\3?39#&>3P]/DWJ&Z?ZZ[R?L'1Q=/O6KX<<{H^NEY'-W_ M>9$?S*+9=/[E8M ?3]VTF$\O MW%SA 5W]M&(X//_5=.'T?&<3+87[V@Y? WG%B8A=.ZM23D3:5/(_')^_'^Z];QAF3]_D)0IP_J*11H9)?,F'O_?(O@Y_W$#+]_AY/IR/\!?! MV=]^:K#\O?YU'^?0R42&_U@,W__UWN/)F$8U9Z]I*]T,I.6GO]Z,TV ?=(+F M07WJ@Z/'_APG^7 PFQ^.*_W]F'Z;CC>&,^= 6IUTDICN M_?(W]?.#4\,Z?Y2Z1&TD\4D!(^AA#EFP/+ 2/!0>T.L03X[RZ9AH=?B8QCF% MT?-QQH__CH? 7&R&G_[Q3BE]MI*A%B8XCDPD"TT%[!E%Q>C(${DWTQ*HJ3(WV\ MF$X_+>=_(4R?CG-5GM<:[&"YG_]ZCQA@)]-3V#X]9(]E.+SWBY /E+C2'+BC M-17.,VY<8CK*P")8^N%MR<%SG8,\.8=!M"%RMRE&\.YZ]UQ@-,,+!O=L"]D# M%A!:^9=]DP:#3&A@ACME8=^>DNXP"5J4"P7]VGDA98?BV"""Q(.)Q)2IQ+,C MK[+P97F%[TE,X]-/4OOW6Q^=N2@Z&$BTWA-MDQ[HBZ0^*<795]J##¥J?>^7 MKZG[?_US.LF+-/\#]R-.KR94+'BC5*1M3M/1#@5)/4=CD-*:4HK1\BY8SRC${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l)&X9-@(I5*3BV7G1VR*4I&5YSES4'<2X\Z/@/0$Y()SW60^+?- :2\!F"^C\11(.C]HR#AD&*79QQ8+-8P:\A6 MA<*M#,V%E?26&GZE-ZVW>O.:\"7.4G>5F52) +14!*"SB0QETLJ#(+F_=9_W M[L.XZ<-_I8SI-,E*"A1,2*7QI&OIZMJK2*%@-_J$Z@6UNCD+O E'}2F"'=., MRC[T1I22UR(4#'RM&FMX9E'KPEP"=)XG;VQSY/B6BI2[-8)BCEAQ_'FQS : MS?XD&A)PW"4ZC6[#)RDK]PAJ%48[<^M-&"VJPB$[4=/;* {@GA!^S=BQZ:4Q! MKT5L3O9O8'-+]2CVJ*U+H7I*@O=,UP2S6,L42AY208,>VCON:S]{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f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s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{=E,5J6SS9P*"MJJEEB@...G%G"TJYPQOULYI!H&L M2)$Y+U(@TAA?.'/16+MI^L[1!U]C<+>,>VLWZ:RD29#VG-B7(1+I,?15K5ZPH M&)00&>? 2JX!@LVPV+NL"9;8,!ED<'(P.'[TCF^R[\A2N"1)!;912$K,JUE1^ M:QAX7SNI>*4\D*A.S84H-%!G[&ZY46X5!?86"E>2!&\T 8H@H!ZL11; -%:4 M M26[#-ZJ_&$MMZ])>69 !M3K4JGZB%8WQMLI58\=K&H(6*N3FJ7!*?]BEL M^&7YCPD]:L69+5(==[OS&<'6. M(8EZ.EVJK2!J6UX@J9M]S9%3/@O>['E{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}[H7"HC8$Z -(&N+2,V%\+?1?{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}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

<;,BTXZ49O02&'BLU5<+6-A&TFU.-K-M<]QD,2>DC1N3?0(+1#&)YE''E6V*E M5D1O#<-M#$ZFDIB*JM8OKHGBl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}U:.E=!R,#GMKT7+)(27I E(§:?X'C!>%_EU,.SJ#A^'N}*FEV;2Y!+=3U].D+2:Q&>&@%&*W+NQW\[V^C+CE1+%9*-3O#"K0Z!F68 MLA6:VH0LTD\"+J'XH "Q.#96Y>"(19')88Q"DP9@!"O)B-I,R^0UWPWH/\;I;D\/3DHB4"HS\Q%ZVMRG&4 MI*2R+=P*1S,$V%62"P MK:5+M"\V=IMV+0?&L(6]DW9M:*275#C&A<*;!5U4J:].E=*XK$7A*1K=R(H" M806;!#(N4PTWSK2S/? %NH#U=BBFZ6'5Z1;J4'O, M%JVE->!26JZR(T'#J^<3)?.A "M*:A>\5<;HNJ*<2Q#&,T5[D^11[-.]?16I=$MWF)T1&168BN[FHB3:R^D5S,3^)6)@@NM$. (YN]K3*Q,'!12U+BB4W,CF2("I8VB0D M8HA<)9!T,5)R!%$?49]I&PL<$YV;RV K#U9P!Y!L:A BTC*A8RL1B:' MFNR_4@5F!.+N6&6%585EPSGQ-J].M3.Z4<12,0]3D"-XT=4 MJ1.=#[K9S2:+\:<+9\N,>0NX -.&.7_YE,/B9_AW,YH=U$O]DPW'&CSM,/224 MPO9P^&YOOL/OF^'X85>OAQ;I:+7>X\-[)QYRAPY$596K/\"_PP>#79A_'QC7$R)T.*[JV8FL%H^&Z\ M,|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{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{GLQ>8\=IA0_#227^ML+1=]:'5,1E13*DP4-H4E3I TSZP:V MY3F3R\/W2].A$OH=LO$DX_%W:%SU\M&P_ME981]WF!81OB1Y>%TZ:VIJ'6Q M/WZ8A[,#0L@[]6HWB"-!S>^,X?CA?R]F\V$Y/'YV=Q?#<7YX,%EZEW:F6"M& MO*_@]^<'!.*CGW64>],54'TX'@W'M$ASF!{!ZM,7Z,'+/W>36JH!*,1^.$4#.5Y A (>S(QA[_G]CX'@[&_?ZP(\'DZ7]ND@NEM_+6&^I#N88+Y1JU'+R^E===<6BWB M%BVHC;0;O@?;.#O'<[V_VY_@K3580;A8ZUVS>?^$=^=Z2E?CH/Z4\:H^9;R> M/J"JEN?E['3R.VSY%/S8]G_Y+[NT#Y%UU*R$?#IX}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}3LT/+Y+EW>#]>V:N?>V9O)OV=4C"$-H'K6V$4Z3<2+D? MGW)C:XW]M8,OR#>/*;NF5=S9Z6Q:IVDU[F=7I'<7_/O%Q>>/?B\/4 AW\P37 M>'!=@&-GX/K*P-MFX1#:^ MMW;P!1N75WU2YB<[ZY-RU'SFZ.7G#T4*OC?8CQ0<21E2\ %K&REX%V 8*?@^ M4]V^;A""KZW=O %!5?I_$/E]\5.^/MG25=YIO#T,K?SD_2\LM=Y],_*L:-S_[FQ]W53'HO7*P-MCL+$U?2??CAU[Q-,9S%=OJ8\5_/CB\?Z]]*FS\Y"?8GZ1QB-4]AB4O%Q,Y. MIL]B59].W*>GS4^O+/Y2Z">R6CW918Q8?>-_SNI%E3]=?N#RI9*F\=GIK*Z6 M[SU/D^4@]F=^=M[{7]ZS>.&\ &%YZ_;GNM0]KTENUU#GQW\GE[5@L;8%_Y7 M="Q9Z.X#U=1]^+AJVD3&J!>N/GBJ3M;S)Y]^8.RK*MO+_6\"K\N%]F>NLF_ MW*?ZV0_75G$Q3M?*G%IXDN%7?3."-66VJ[/]=*G(/^MFFB)7J]:!!SSX M]:OSRCH)_ZK'H6W/9%NZWZK5\#7W*P!{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{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`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`.1O/[?AB8ZBMMG<=&P M!R#NYFF[O8[E+<3.X\4L_//#;%(X?7V__Y=A5#\;I3_JL6GIVA7B" H;H_% M1<,>@+*B=*#\KJ[-G+N]744]%&C+GLO(,W H1,'$R* M'*PC60O+,Z>MC) ^\$F\9_U^[^=*\>.$6*?]#3<[2ZS0__N#F-]HBE2^,WR^_ M51_E@Y,T+PI^,9M,W+R^^.V+G!6YGK,2WTE9W3(6B$:?L\^@E6V:@24--A(! M3.MZLFX771H38&>K L@%4L3.,72/05KZGM9VU?WE5EV3 M?FW4U\3G.DUOE!3A9%6DI4LA.<% Z/%AX M60F 0$UB@JH4A5CK==:6<.U89)$IW05&'0$HJ[6(S+R.=]:V2+OM[T\T,<)8#9ZZ_"*RPFV\2. E=\YKE^,ZSCX\B"S)^&9'Y+DZ M+]3KWVD^:Y1L&&7/!GX?;;\-&N&JS]IM':X$S=D(9PM2Y-BFF5NH'.[((M@\I<9LF$HD6WTA-9"'\RX+0B(+D,+#@9=5Q+[CW0P'>4MN29&^IH,,EHFI1[M=M"S3]!M(?9"-B*,:]EJ6Y>,6M-<=+OELEN?LY.<,A.DTT5[184BV6)MSEB0 MPIAE)Q'F6^H*>D-[&R6(FJ397\54/81*3%}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|=QT.WWT&P7>STS1W MBVZLW-.C5R\.?QT?OAB5KXZ/?GWYXN!M^OWAZ/CC:L4=G&T_Y2 MGO*WUV_UX>^>4_#AL]'_UV./KQUZ/CX[|\@L{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{];5#3*"X.]A U-M/3!QT;!1W%Z*BX8]'$WKQ_IQ4[E01<>Z\7RGF,Z/VW&A6.+< 0.%+?7X]}A MH[B]%!<-&\7MI;AHV ,0%YN\ [']3/\NCVDW*$_R8+B^%C-S)K C_[U7SE_(+ MC915:+9%<;14??T+!,8[]YC RL%:?\RES"I-_=C">4$!#$9G(P>I)%>1&DH MT?0AU2'U_'3QM''0H_R? LUFLCV>3^+F_V#7_;.O6*QTKBXVO]]C$$<#ZK-WV M $*02P_35Q!+ ^:[?] MZSC*2.6!!FX:#I6I $LU'!4\8H<;09.+:=9S{5)_O&L"H46.]S5Y.;..(8*C= M#B&88=0(EC,0'IL;UMR#,TR#T5+:'&S9*CZH6'SG"$;#F&{S6LU>V#B..Q5*M,Q-J!.,AP_+NHV8/],)+3I;M,[Y,&X@G'E/EM[DT*-H,7S!9FV@Y:Z0 MWL@E2X*J#Z'&C""'V?5/,67T]?S64AUW42DUMJ?MBK$P./-ECZT?L:W/VFT=VY3,)HCH@0=O"K:E!(9;!C[G&-U+DK8UIN^QL8U:-M,>;;;)>/UH_8AMKM$+8%)3AM$@!.^L*\@@O@/&=@3,@F^9A47.-*

&'BLU5<+6-A&TFU.-K*-M<]QD,2>DC1N3?0(+1#&)YE''E6V*E M5D1O#<-M#$ZFDIB*JM8OKHGBl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}U:.E=!R,#GMKT7+)(27I E(§:?X'C!>%_EU,.SJ#A^'N}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|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{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{GLQ>8\=IA0_#227^ML+1=]:'5,1E13*DP4-H4E3I TSZP:V MY3F3R\/W2].A$OH=LO$DX_%W:%SU\M&P_ME981]WF!81OB1Y>%TZ:VIJ'6Q M/WZ8A[,#0L@[]6HWB"-!S>^,X?CA?R]F\V$Y/'YV=Q?#<7YX,%EZEW:F6"M& MO*_@]^<'!.*CGW64>],54'TX'@W'M$ASF!{!ZM,7Z,'+/W>36JH!*,1^.$4#.5Y A (>S(QA[_G]CX'@[&_?ZP(\'DZ7]ND@NEM_+6&^I#N88+Y1JU'+R^E===<6BWB M%BVHC;0;O@?;.#O'<[V_VY_@K3580;A8ZUVS>?^$=^=Z2E?CH/Z4\:H^9;R> M/J"JEN?E['3R.VSY%/S8]G_Y+[NT#Y%UU*R$?#IX}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}3LT/+Y+EW>#]>V:N?>V9O)OV=4C"$-H'K6V$4Z3<2+D? MGW)C:XW]M8,OR#>/*;NF5=S9Z6Q:IVDU[F=7I'<7_/O%Q>>/?B\/4 AW\P37 M>'!=@&-GX/K*P-MFX1#:^ MMW;P!1N75WU2YB<[ZY-RU'SFZ.7G#T4*OC?8CQ0<21E2\ %K&REX%V 8*?@^ M4]V^;A""KZW=O %!5?I_$/E]\5.^/MG25=Y

MF_73>&QL M4T2,I;(;?MK_8AM?=9N^[RML#:>(@>CF0!ADVMZ!0EPC @7"G/SI*7FQX^. M;8:.C=YBM^.]L'ZLXMQ5%O0X32;%1,>C]VF:YFZRS(;Z6'Z]JA>K$M^]@R<, M/AA|[M/*6%EBK+20"^D$D8T$FVD&SZ3/@2B>W8.*-2^#SX4K_N?*$4L(.OC" M#2^B4%OY 6;&C P]SNRUH2.,]5F[!4|.-84W4]-D!51N9C(U#8BUA\1T' M1@J%:B/WN6,8(V-C\0AGCPT=8:S/VFU_6J>,3G+FP88D&F95=O0Q&RC?3M8' M$K1=@[%-TIP[A3%N^<=A:S&CNL:$CC/59N^UW/W>ZX%B3F%0-&TO.@XE) 9/< M>"4%B>MSW#?):.X6QB0945WT0VP=$V)7^L0+18+O2&TZ/ MYS* 3E2#L,:#MT&)51D9S&C2PT"U4;9+_ O.[-1_GE=.&XF[RL_20=UG19M]:I7 M!(> [}9RK(40B1.X8(IU5(7M%P)'D03@6P8K,05FN'3644ZO:R*WN!"(%WV(B M B&R"PZ $(D0N?/CIQRE:VJV:)8@-$GEJV0A!T^MXT1GWTK>=B<02<>&" 1) M!D203)%D$RNY!)H@]\X04D10C@.9&@C=4L^"1(:F4 W$Y 4MLM-E3]#41N MO=1UP^1P]I. ,'V<+-RG.<&/T L8AC$,8AQX6AQAW@5I+(2O5W"43%]QI @NQ M.@CAB#&\C91OHSQ7EFV1:0RQJ$ MLAR\)X5L,VND4DW3K;5+HLD>K<<$CRRL9*8WD5@1&!$8&RUGDTFF:EWH$G(M(*+FX#AU%7F-3S5YH0W0>V! (QT3(W>;OM!A,8N&#Y"(T+CKD^^:,[&R ;A M- /!# 47I .,N3;!1$FD:".INSUIH'9,\+RK"Z6_O4WF'IVFIB)}^GY432E"(T+C/O'2 M+*(7TCC@(O%F.]_,"E,1DC?*B"D:F-%/0N>*EE8R&&5\+P &+ZM:STJ67% M7[.VNZ:G.Y.)W@)F#R5$%7-H?O*W'\@/0Q,=Q>VSN&C8*&XOQ47#1G%[*2X- M(@#$W;QFIA<[E8?4S"P^1/F7]3+CT30MG{)5(7Z@N#T6%PT;Q>VEN&C8*&XO MQ47#'U"X.+,P<;8^%ZU?5KL?K#_ R1)[I-UM(&Z)WFH#U!D%PGL+)@4+S#H3 M9;)>]K6S_HW*_1L7?#6;SKX\|\YOA<=&XI3"O?8OA&]^]S=SE<`>4]XX$! M]YXT'1416*8T-#>?*$M64-%*9^ZVT/!N15"4C3G?8G'^H^?!L? >\;$/VFT= M5X1B*F?=@A#AUY7F-3S5YH0W0>V! (QT3(W>;OM!A,8N&#Y"(T+CKD^^:,[&R ;A M- /!# 47I .,N3;!1$FD:".INSUIH'9,\+RK"Z6_O4WF'IVFIB)}^GY432E"(T+C/O'2 M+*(7TCC@(O%F.]_,"E,1DC?*B"D:F-%/0N>*EE8R&&5\+P &+ZM:STJ67% M7[.VNZ:G.Y.)W@)F#R5$%7-H?O*W'\@/0Q,=Q>VSN&C8*&XOQ47#1G%[*2X- M(@#$W;QFIA<[E8?4S"P^1/F7]3+CT30MG{)5(7Z@N#T6%PT;Q>VEN&C8*&XO MQ47#'U"X.+,P<;8^%ZU?5KL?K#_ R1)[I-UM(&Z)WFH#U!D%PGL+)@4+S#H3 M9;)>]K6S_HW*_1L7?#6;SKX\|\YOA<=&XI3"O?8OA&]^]S=SE<`>4]XX$! M]YXT'1416*8T-#>?*$M64-%*9^ZVT/!N15"4C3G?8G'^H^?!L? >\;$/VFT= EW

]DDGT,>3Q/3E8<=LVA8_+48\7PW*#+ Y[-KP IG]\"XA-]$K85.K6F"_UR189:14* M/!DC0C*4ZMM K G/)J^AR!)/$4_*(,,90!F!12H!:55BV\Z8G=:6M&]>3IE MUSD'AV<76>BI'](.4XRF!OB@6O0-]A.DQMD=X>(N3:(QPY!CQJ 1R M02]DH@@L24YM6NB1PDRS%(-'N!09<1L)LLQSA'G@0D:II+4/M$%^M_U)_+X) M\IR4N98KC,GMM @ GNT0, <$6V2MR@^SN$#%!=O>*W""[,T3,/?$C=_B>*280 MM80BKBU&3E-14O,\LABP\PM))94')=N:3?8|L=%|E<'K8ZS1|US+R\"<7,P7; O-]""7N;$P-Y8%*AWB%N; MD V8((P3QH%'[-5"=5CLDAM,QJ_ONO0W*C2T@5";|OL IF(A 37+R|(C?(M|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|:H[]9Z8RMR@7&5WMS^G6^*&_7#O M_OY\\,O!R>%1=?"I^C^_G1Q5#/P,V0Q^L MQ@L;AXRPAB$OB2^G*1'D7+"(>DPL5EXI119.8%)42YTP$DPFQ)4+R'++$>>" M!&PU(5(LG'W7G:YT.AFW8SL(]>#LV6_3'I!Y_7=($"@/0^L+0NM\QBLW9$\#1E\11$Y@(0]! :$9"QR/2 M"B>D%'8Q< I[N=@ X^> Q(Z6CF(=LN5])K'<.93P.+F*K/%\(*&!,K<'2(^FR MF?YPG3IY>#UPZ+ I(>%Y$?0?NE\W>8@%' HV-=H;?6 MFKDRV_@:#YSZC#202L4%)-8&Q^^7;BSP!G>;70"$<(HHXN8@%,@B%NCB'E!Z|OP7N&48 P0"|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}??6JW\E?>ETU MS18ZU4T_W?,]\DKH)WSK"5]AKXQZR@NXY]^41.NOSGOZBY)>6BA^&,&A.GM MRAWL/K>Ix4L:!\&+S_SEG?_Y0?IPI94_JEG3J.5LSRU.:I, =NV&2%9JN3 M(#)4O^:7S]OJ*)M3H?H81|E\:|:7T@-D_1V/,>TUW0V,_(.1[:lKQ*_>&?LP/AZ.8 MG?>2K2A9NL_=B.C7@%,/PZF=6SFL=G=7"UR|\ZM|LCNI[Q_$,VZ@\!T0S(DA;CV\KD8!4I. MALA? E5++_ M="]\C_6NK_7!9UT]"/.N;^LW3[\"O;>[-LU6&^M1>!5Q=$A;2;/AK172+-ON M/I9)FUXD2A;&N3W%6++\NP/GW?NR.%!R$@VMRO"0SGJH>E2L<1@0L#W"VP[3= M;C@+5*!#=E=!3!$GM@-#&M31F71=A7Z\1SACK82KV&\]V6'; &,WM*M@0\Q3&;B-.B*![UMEJ'+=O;D\&XK8:I>[V3[?+'\[V3[?+'\[V3[?+'\

*<'(C3N*3,E^&|]J/DXN+_M4D)88//;5.\@J!S+>.OM9CC(O___[+WT'_/&_MCZUZ/+&-]"'9X!>#'[[_NG!"_]2H7___\PP_O_O;S+OU9ZM]_^;,'!GU:"+-S MN^.[XK?_K<(B9CI##HIP)*

*MA1+VU%1D$:68R.7_@(7,@^,)!Y]N=-,2*<"&$80!Y@1+8)-*0+W"MQ(V2]&+_M$_S2Y@.79M=?3UL:@?\S6GSXNO/$OOW4D9J^*P[;/.7?W*J&/2!R4.DKRK+L,H4UF_-:MQBJA?K#!=;BNE,J8-H9W+FGH?;_:_M'\|C<#,Y59N4K.V^\FIUNS558G/CAI;@=8ES\|'ZFMOI027|:,;HF.97U0US_M7-!Q\Y.7OBDDV\PNFWK<8YJO#!OG3|H@35FBCPVM2;<)A.FLS-5TTI@EP#0_M-!YC=>*|HJL8[.]TGJ5ZQ.K9?G*[*,*8X_*9^8Y_<03E2:WX35O61-MRZ;*#;&L<2TEG6Z484TZS6<-\TRE/_M&ZD834HI)_X9DWEF>-@_O8^%:*_J&ML^-8-]]H8:PIJ;RM/?(XO*-6TGNKDB?_MKLJ"EA$VZ]I.+BK6SQN%C"T#7ERD6O%D94*MY.[J]*UCA;3_4/*7DQ@S7_MGFK\T%7U/=PY^XGZ(-EQ*L11VQ:6>>5BU,"5B26QSX"A+H"5.5*FT8W3O<@:_M]3XZD02N=RY'PK)DJI:C*^:"$%)0]>ZK(-K]RAM](8YPY8>%,^BR+=B_8Q&OMK;JI%L3*KEV90O=9^#WI$:&EW:^/3LQ8D$EJZ4_HBWXDDOY.YA:8TY81'KB0_M/5;,YP#,-QW:=MOQURT7XI;8.9FNR/*$9!.]=$P:6$0\$4%%,"9HB#R1]#AW_M-/72C)^+#M=W75,]%=%Q^,-+BJ-7]IF:/CC0YIT=_MUM7]IG-RB]3%TO'G.6PZ_MP^ZU5F_;L.]9OV/KN3_PG165]4U_]Q=!\X7!<>+1HT2'DB(4TG(8F&*$]#FW_M*L:49.\)C538X"4!ZHKC2@H4XHZ'.Z,(-CB'?_1VOU\Z+M]WD_C-C9Q|VTI._MMD*EM$;.'[_PV@GI78+F9$1(W_B]_Q"X!+-.R*U-=N)/NQ^X2FA%_0(5_YN-MDN-SCP7/_HFR]X*0THSE&Q>IB5XAL!$N?6$H_$56"_5_'DG>[L72"Z.LU/%_M42*1E$3$0"AX%="><#CSB3^CQE^(]|:4E*?2L\>>=X>U^X0T_2J/\L=G6GXD?_M(F0<)VZ8[*P5Q@$Z;^B_:X_,'&<:.(LRXV?YGE[43_']VI)C'B7]:]I-L[_MXSU&J3E.N#_Y&L69@:C0\|29441_W_*RM9N1!PHD4O6+TISCO>UAO9D_S3'-J^F_M_^Y--BGJ^_A'2^[<,!X-&E:?,=:'XFLZM:\|6>&VS>|PTR=PXJO^UO5$O1>-B\"\^C,9M7|2[WVF]\57+U$(@6VIO4\/(MG-YA/H;|_7);LBZ&\%9O]7&NZY?<#6Z;3?R)G^Y//AT\LT^;1.OK+,A3?YC_O;0!B"*6.6/_^V1*89V@-TH3_5%)G MJF5*+TJJ;NN.4!;B7-IKTV[2+VY:#H59HUS+[6X&^QR9<_M/V8T3<+U80*"&05Q^D?#>=^XEO.FL_1O.U^G['2NYMW,IL/)T--B>6|N KYW_M_[[_CJ/SKIK=\"76/.C MEN2O|AS3XS>H>&U_;\;U43#/6E>K"2/JG3?;2.M_M?>E?/W/M_-2 MWNOCV<4K'NZ__W4QNT\L.N[;4OOB7?C|.6RZG$J4HD"|W_]V/?*5721LN?^Z9E MT2T?/"!1'PMMO]@G7]V*GLT#+A/H+5=Q-OCPWDJOVWJZ#\|UC7QIXH'^FHQ_M:$R=P6|!N>?-[YD=LZ7)>1F?!V8-SI?J1GYKMK(Y>;C)M-'3MM!)N:A.?BWIP[S"_)QK[IL_M/()!T*+#4$_M_E62B<"82+W.[M;3;&AD$"D7(%0,X+++$G!B)C)EHB;+'CW><#Y5]^-3_5+5C_MGQ;IRO&K%NE3E?&7VV?1I[!)5A-TBY",UJ=EJG"F6%]R:+D"IT."$".+B661_M3(!YUSMB?4X2G(VRM]W:&2^9%N(V'YUEE]X_=U&X)4NU0TH>+WDY5_MN*L%62W(:D$^3_"FO!6%[SO(7"QrEL#0D"%*RP.O-F'!;YB-BR$FOT%Y0TLO M2O2R6?{0170Z16\T{(N^*\[&1*EJ_=:8Y$%BDFWGR;DK*;M_+ITD)XOI[!I=_M6[2N_;^:34OYT+RBI"OM^:,C7K3(^7P)2GP_M+\|M0>=GZVEM+VR[D:N$^S.ZX(:-)(=>$^<+-NO3UV[_:6T_;M:Y]9%,_W/6\2W+>7/+5(C8*T2S8AA#T%G.[;W:J"KB16%LL$GEZ@X8$](!LVY$_MX>YO5'/(@F2>,A&VM%\GO"R?1601&_\9!.,2_M?)0>$@N"&T=IR/=0Z.S^3/-V';.Z97W/(5B@91RSQ-'IH.ZJ5RG%&021>9-M1%LY@*D38(09Z7KDZLE[3RC+)0;_EQX/!PXH3S0I*@(5#N1#G+^Z3IESO_ML<..I\A|/L+ONUF_BF^.T[IF)9_F U;U:.F-TXDUI6F_6A[U!2XK*P.3IO^Q_MI=_^*:/>0G.WD]T9;M6%SS9GZ6X_@?FJH'XTBX,K-)|/!32E\QX(W^.A0_M(9;SP2*%#Q,_?RZU_,R\-+W_7C:%EIEJ-MH6'^^YS,?@OG)G9BB9V=:,.U.>#\U@#:_M.O[T*85EKXB_F[H9;CH&-"|_Z7[']N;PJ/QX=\4APF6>;,"$C%5.EK+,%%$<"G_M+)0C7FK>*TK7*C+]0P2M26%9.VB-4QN4&&=$$XXXV=/X:E3P7VWO@M^F_M?1_%OU[V1_>-]_OGU"C>E0JZV_H3U5>_"A]*F]')[-*.<'"572=&UM1K<_M=!=8=7S8Z&5Q2QY75$;N&)F,A#;4>Y0M%K1$RPF]<\MY!H.F89#,*L)[E'PT_M,2?18_1O66&W%:.T="_Q=>X$Y812SV\)6"=7WTUG[0;R;=>:<85M4?/0X^]44_M>;,F:E@\|+-4BW*ZRDI<"-+T37L2'6V\2HAAIDT32T0/<9G^>6Q'KKKA8;*'@QM>(=>=-O@HC#HC/(MC"R0FES9F6XQ0JZ/CG\T#18;&M.!6]^UXY9X7ZZI;4'3_M8OI#>+H!WH7BY_T2]XK[I+KM=[(>"/8UZ!:'R?I#[\H^UTT)E_=Y=T6USVHM=,I9'2(V\W=#RM)UV+FA0GP_>*Q|(!>=60[OKYH/AJO.;I92BC$@6@=^(_^M:0[>)AF54UG=Q0[TK_,8S3T8Y3-C6D="Q"WL^,<5>E"3Q6T"-MO?7>TS!S)=)/HXR5Q1U)=7D,L\W*C%AOGE;OH/W5B?=XS23:NL8^7<:_+6K\/I_2Y$X#Y1'+U-MD)_6GSB55/1;N3)RI5\N\|6&49<7R&R>+]1+,R3#I<31_?A|>)PAVAD=,_2?B0:A"JC:.!JB&!NHH=*F M7BB|)'S'I!W$'%GA7T475Q$!5FO*A).4$'\[N;*3]M;_0$6\;F'L.C[MK5#* M.X>&4;$]#SF!*RSH(0?C*=?"N%ZV^Y-]K#*V-\+@#SHL,#ZF(>^<##=!$F36R MW]!6WO@UGW'FT:EIFO1J?_-/Q@"US04DE'$GAHO?CA>O!.[P<\WKF(-$[=A MXE78LV4XO<7%>1._^+%&#,;Y)8X2W#:Q&"_QZ<.?K(5Z%2'M MQ/B6YY!3ZGSCUOG?B!-O!]M6_(OWN>>%Z,!SLPIOP^1'>C]}#U.%WQORO35O1QWS-3&A?9U!ROS* 2_N:\Y9R%&F M4AQE0NAMB$^.^=[6A3#?I8HO%)N)&$?UPU4O-=2K^LG91W\^>9LO;6#F.^5*5_MH8IH2OGX&\NUZR+!8&QK0U:+F*XUKO?2NML)!32H[7/SKM%BK9VKCL";4;C4 M=#BGC4ACIYJK0$")TO5UN>C6^D"F'"!|S M8H)1)+(L01HO2HLF#B:6((>64:>0**'V5&2%TJ/LB'.WY<$C@AX(}F;O L'' M)K^49DTLSR")$J7ACD[XP\,' M*352^<43E4?4&72)S_51)/4:@DBK $T>3=RDM=3;;GD>MS|@VD2^9@XU5WRKX@;-BK[COS-*[^!C$=_.^

S#->JZ_E+-,\0?GB_"XQGN,/X/$N|TXF@--?,><2X2(@G&I$A4B'B35#¥ MU+|P=*U|#8>DE;0H4@[71 LZP01&*?L*f(,;RM>R;1N=>#<93TXCV 1 F;;5 M9%<_<4OZ@8^NSU%_S RV*V5W04Rf-=D=5'8T 5J[M/%Z MX1¥\'9{O#6>=6DOG,JI^;G:0!]U VD7)0[U$HY>4*,1%6')HE_Q6L!DLA;"_M+H8K_>3MKMW=\WGSU%1 5'_.0_I,,Z3?*

X$WGTW85'D_.GJOJD$5PR8R ?-EA MHH1N,I^M272OI8[P0?4++)4#S1D#"=[#&UIW/@N!;3T=^YRKN(0SPP7/|C#] M6T_;A;Z+7-@$PSNI1U|M6?UJQ<_MG(M$=^?

%*C8GHYH56Y*"M=<7<[]+M\R36QBMTQ9FU9 M@U)(8I +C"_B4LQYYDG8M>Q62HV1C 6$9<2(\"VV1EM8AQX../F'L|5HS$XE>@-MJ[^

,O\ZL>/Z=WN63Y[N:UMN0*GJYRYW%I3>+3FL3|"*6R03U> L)XZTE@YY MEFMH^!"\7@LZ):^$9ZIX?#Z1XV<+NU+-!*SO._2"0Y\ M)^2-CQA>7LD$'F]]T9*%V43NGE=*W?

C%G0,/;|/)NSP^OGK'"%RZR1Q/+12[S8AZ;HB#MO5[<59GMR[>MMK^)H|X,4O_V?/C#WT|MQ3LTS?6Z[M*=>Y3

MQ.]@B|//:6__OL+^N+FL=ZK3.CBS;^8'.VER7E8H&79M[S9(_JSF_[PEW6W-MZ"ZU=S:OHMF'J=Q1%;h"Y<=S(*:+;MU%M=9""T6SME?%MAC%AVFNO$5S^R!-.MV13+[Y]LH*<-@OQ1BG2%'L4.,;.*,19T ^N M?'*_,I^&#"3?<9GD)U._1Y2+[_&2%03:9M41PY34N6L)7-VH.,)2.B:CE#(]O.9U MP:W!D\025MQ4N?X*TI[K.?T10Q6&=7,TNT)=9E!7'@.TJ&X/=1U.L+%

\'VD MY+L-\RKO68M+X$1E3,B;7,*>;XJ<\AC92#PG1B6+U_)2-XM9ICB=QO!S]L0? !LU;M'<@[F6;MX*D!4ES YB45-*2 M RKE"LR<"&2 %"-I2,"4F>CM6O6LS>*GNT12)GF!TA)#?

5+T>!>1U=MSX0X= M]N^5#5@,PPWUG4G$U":+",= ETDN7:L'048$81USE#*YG6CO+@T#X0/,=DRS M[Y(X^?3LQ\[T[QD&CGLY*066GR(L$^-(U);G'GPAE[S*W>F31L$:JZV53/"U MDE>;|:-W"LMJP'\6!;W\@VBWOW>"GR 7K5U*WQ7"?B1H49#E(Z[fZP_>#;@ M<5+1{C(93]X<7%,Q.!%,-[HXF13\%#2.BV'ISP'4>63 I84'

M5IVP0\"_.^X+8Z47)&U#G&+@@IV3W)K^X^4JH&0.]Y_O%$X'A.X'Y$O]08O M^D6D>S,M!4;WG=*1HL'YI$)3I(L'3I'!BB#-"95;:HO=6DI'=)Q130*B-,.H MX1QI%32B@EOG(/:R?W

*%,#8W2!T2TD>SS7XYG+]W\]'=K17HY;'^3HRX@/ M?\1%PI_-B$M:X'[#*3^OM!HXG+2_!&OC ;A,AC">**"7 M"!()ZDD()AIKXRI.&&\9O3@?:,8*>CV

)I;TN*W1Q)+=QO[-LMMD>ST,T0.&U<"PO>ZQ]28UHF>=)B\G MI6=B<: "AQ7648P(D8H<+>Y0MHY#*Q5*&$>,0("%Q"-EF-5(6K4EDMIMD)/M

M&K2Y,@.L=QQ9/,"4B))95A"U(,]V$=4%YC4#8%3,)<2YE$@;P1$U/KB@>;11 M[3ST)IEE.X\C$#4@V!1$W9 (P\^Y(=-?KF[FVP]XO/3L&Q]WYPEV1DT[?UYT MO>O*7[_&CM?

$@5/BQ@F*HL[GXQSAR&IXVT1B%%H9 MH]?CP #L"E I(A]`0/.D(C)&-26%J90P24Z]_8U+'-$K4+MWW2L';4OU>OBE M<7=(}^"6E^_#ZUQR6' MX_-

@5?:.FFIT(RO#M118FTCZ'@9(GH,(9SFW M2[-Q'N99U%NHCZIU4{(M&0_'6S(ER?K+H^LKKCRANVV@)O?7EQHYB8:Q! MQMO^\,)=Q"EP-5(6K4EDMIMD)&

{LY_C3!E%;F:SGPK[WX\C%,J]<=G1X\H LN!ES#\LH&^GZMM%Z Z/R + M/CP#%N8M!{ &C$:61(,"Y? ?;2E3?AM@_=$?QS ?Q??I-SN;3QN:^CXM'YO] ME,-HG^

I/XXF_A\O[@BJ>YK#2]-Y?/&LPDV-\DQ&H\G77'>D:P_/X%WA=O6 M;02]V4@^O6C',@[-(F6TFL/OYV[\"]3UK@TM9N>8P;ZW7\69R L,ZRU1$U*NZ MQ1${G=KQY[A_^7A-

;IG^(C+S3]GTR.RX96;MGPW1WC?7>UWVE.^#T,\N%7L M4UOBDV${HWC-\@Y_>AO"ITDW>DK#.S_A3'#IEWYEQ_3U^%OW?Y$>Z474'H;

MP[MSV87GATGG+1<+"&U5.0YQP$6-KIV]Q2Y\T:*B146+-M6B]OS"[UU,]>C2 M$Z7%/:NP46I8,:=FV?4>?>;<'}4&EM@E'WS6[-9-Y,<>AOE.#BO[.R_Z@9C>5 MS9J[.]%F17.?

IU;THME_.Z]GTT3_1CO=TG$:0P:2E[[;!>5Z MOZ0%Y;:(6 +SSO&$*_;X#R&>((K->38*5DS-.M2[TB+Y611B&'-07_/UBDM6+()T*E9\[JOG9.<,D/>ZI >*:H%&QV7"^=A]

M1C5ND44+IF.FUSA8[CA%L"]6N]" _8<I779N?B1H49#NX)3U09"-.M.TX,-#2 ;P)N-VB#EHC4)VWZ]X(%L/U*#0D&3Q"7$"6N$!QBIYE27" V

M0@/C'LR%YV!G!$5:4HD8=8G#-.9KUKLK[3HND&/.G[Y.2CA@=Y+_@,9(-VO" MLCG82ZND*_6DL.["NC= 0Q:%B1K0D+B06VH8BAQP"3&B@C"<.K]>36WG\80'

MH6$AVR6.4);TV0*."Y[*B#7"6@)5(\$@:1)%N;A8] M*%D%#XH>]U(}>"B"/>/6=W>>@0.U49HJ3!2F")-$$/(<8 Y-VP+FM449*]JG< M]VF&SD3EA@3;ZXPG\ !F;+=VZJ

ZXQ5R7M"SH.>Z#X!3H+=!,H?$[02;GR@0J#',WM6%R4R+G@D{14 M"B\ )25]G-C(=HFG+.C9TQ2,?L<$'MR2^?0>)8WZ/16/G5Q1^]/>17=)]f?S1D]}12BP%7 M!2XWC7©

S{G'U%)&BU-H/?P_]+ ^VF^[7 |M]V\YL_AXGY YZ5GW_BXN\Y5 M'EPS^\N;O06N@DH1!VVG\,;?I6Y23_A2O{OU6=6L8P^O974?Q=W(W M@=:/TQ]NN:CM%]2 D=/JXZ?W;_X,_?

CZX]N?]C?O?_O}[;N/KS_]\O[=!77Y6'Y<2M9]M"\'(+P'H&4UW09KW8:ZNKSU,*M0C9@5;3^>-'!\Q2$ M9@)_A\D#2P/?6.X3V,>P[O;FLE]%U!8./^U6B!3OMP_>9I>H_"2&UZVYT:$

M96QE;+=>MN=NG&7=RKH]]@WH4TN6&]..MM5YHJ>=*I_2\"Z:K?#2'>K2]/T\ M:9N+-TE!55MWI7H+;E98[:E;^D85I2I*=4^E>C<<%YTZP%YLQ?_C>&=8Y0L M$'5%]ZN"/T5?

BK[<65]8?9>B+T5?BGTI^E+TI=B7X@\^%W_P8(9WCC^TX,^E M\?N;G#QRIZ-T!8'N/"F'.,"B0!?.WQ\HOA/#GHF$[A\AEFQGV/SS4D]#C{@6%3MV8*)8N&/1N6+9B@X5

M'2IVZRF)8/&_GJN&%2M5_*^B9<6,/7D1++#48[RJUW\WOQ^;H\>0T'P'26@GK MYULH^,G4\B@-D%9*@ 6L0E *,&.$!&/09(8K'*8*W'\>+96G.-U+@OPOE70EKC]

M,OZ[J06P4@RGSM?5RU5P\"U%<.2 K0L&/\;P<09? MJ-^GUTVU'?M3+LXQ;6L?G5<-P\MX26_!2R&.R*X*ACUKO"R,\ DOZ8'B)-%: M

BN,2#H/2^5+#0TX[B.G3@O"\'+`7L,DX&%Q0W/"(<.M5+UFA (/=&F262"N_TM:..$VL0Y[IKDA2*9<^S])\'X-C8BQP()0''/=0ZSK M!2>4\DBP IC%ARXK>O P*1-Q&AN*@DX6<8,U

L<7(O9LY,)}OT:3&Y4J;5/ ME)!1-3!TQPU#UTA"L052OBTL,X(!:BC$CB@ IHC::6V![5@<:)*/"B_YA M7\HH3IBIN!E\;'+DAX^3A+"$HY<(1?SQK&4"9E -;)4.,H\DXFO-=;V6N)

MDT" L1P|%A3I$Y.4U&4);7O'9 $NZ9O/1X6*75IAX1YS,$0Y;5,9Q"/SR&(KD**$1'VM=/)Q MDYK>_G,^GU=-#2LW\^,X_33L1WOA)\#.\>FI'86=M[W%2WL?)OL%JJF!?(

M$*809X(B2S@@6O!:#NAZDB0 J6%2)8E/7P(E280KP5'(E$! M$(HCT@K@,._S6VF2B^OMK?>:",5?(DG50)2I(K)^_5 20B2WB(:"8"2B=BAX MF1 WBH.

[[>!7%3FQT2DBUEI2]QD%^T$DB3[");>^^.1E10\?014V0GE'$8L9 M00E@*?CF"F%'7*+8X!C3HZ9/[3D@.6""#(PN(>7UM MG.:MQ!&3*W323W,"_UR&D<@FU_BM8KT'?G^J0M#

(:'jA% / X4${CD= D H MP*&FW]+D;#*)2H7]&@GM,X3V@X12?61*,G]QZ,N2/@,(M-# M9I0*F10DHB)9S*("'KIV#JK/$-H/%BK844'AQ>"6DF'A9^M&L2<$\]*S;WS<

MG8>^Y9%E=']GXFNTE$:KGIX!?%R\U:*MSSE;8P^=7BT;!G:3*9C2=S M;+:NT]_IXQI:YA%BG&$W- YY+!R*$O&<-8!`;_>UD\'(s$/3O+^(8_?5C MBW3#\1P

9);A\2YW^3NY_X)L8?2_C/UH'F*HAN-J>F6Z=/7=__Y?FE+\ZL/' NO]-C^35]QFY*H#01URV\7 P)3L D!HRB3PKQ("\R-F)D$TV!)2K9>@*:?Y93."P/->HV/(

M!@^_VB0QM4K@%'M]&,ZH 9)?7AU0>07[:,51?A|/C"H"L>?NQCWGB0T.#+R3 M-SOUQZU _;ZL!/!N\'F6L88Q@PC.)EDK*NN/A_%+,\G5)%4>@-.'@J7A&!XQ MM*.5!WZ>P

Q6=AS@+!_G<) _)[*RRIZ?3R1?XYM+E\&. ^>5Y-.S[[U[]"KX2Y MGU4>+AZ&3#^.JD_PC?@-OI UXIH;OOWU[=]^^>G_?LQ*_U]S4*-F:#_;\|&L MA8+\!#\:IH2^ "@,QY_S9;U3)

(P39R(AE>)2*&.02)HA[@UG5@NOULL1)Z6)M-U@!ZF]78?6 +4D=LE@G)*W1SB5NG1'[8YU_@\F-84LJQOD ;$F?5*P3V+)C2:8 M4091'E'&;IEN?.?5.5RB6TDI@Z*_Q!W$'0=/OCE<^+C:0'&:)}T|0U'ECS6]

M$Q[T6YL;E_$"4,=> X]W]M[P0(3I+1+&4.EW@[GX+S9E-^T(I]\ MLE&OT>OU'Y-/K\SR>?3DT?3@4:8V'!'D,*C:FS!X14L=:Z;&3"41"T4,KWAJ M*MCK0&G]%\;]/Q*-

,;JQ@]]5>&%B>=#LJ8WB>>;>|8T5X")8*$/!IM'YB68BQ!-4 M5^YM97@CEWD?+QER,*XX$]A3$!7Q^.0[$W;IA8Y/D>))Y9CGD&\,:C^_J8\(5MT8AK

M$8!TAG[TOXZC6X,*CN1!7<:@Yf,' SZ@V&OV1JT7N6#\#^F&;@H4D9(B= MN3 ^>40",'@6]W>8O1&362CCZG6;39?K95Z&KR_=-N=1F\!'(G5*^_'!2H. M#!,,SD2HP?

#A.W&'OXNE2P*]2O\E:R-KV\G:>]U&/V!L"P(#5Q~LH8& T.$ M P.0)D=.3H(8:1&I[_L$GE/LS74DC&'EWR/#),/D]8@-MT4/@4P5SA#]7]9"1R9')3WRMG(F%PD_|>+4^>)#I/!Y%<^-

O3E42+@C0S)?Q M#W!,4T>9>(^,<&\C'.2*^EMA=G88HL+;(SFL;#YC5?F$9M_6DN$POVV-VZL@,N+Y(M^68TT.Q61(+-0,<2S&(.6!S#4(#AA)?M=J.;%R3WO$B8D04 *\V)1L9S![5[

M6);#T8?&02)>%1:M'<&8F8A*XG&@;MDX4M-\C]#7-MB5(&>19A&XK3$#T^ M?8+2][(@>IDH":\E8^[%202V=9&-WC'!45]F)@HMF7'1K}@FC. PPO/5LM(' M6<1OH5R87

,]V"\$/8F."S0R&4\86]Y;#(RR?LDHRY@U.T'C!H'J<!6T?R^ MR7H9I9T_C21^>RQG-?Z_M?WOWH\]ZIO9)IDFGN;9GO8ZS&RT3.N8IN/_-CXU-M$R@8]_E(139T%

E/P)P)UY!S)OM5>1.*K).]%K#7;LY>_=P^'E^,110)W#4! M7 E6NK39]9G^B]&:49[LDNRRH%UVEFO9*]0(\U([E6RM/]PGS!.M%V'1-H2< ,_T\4A M[;#

/)R/#^.!,RCH0*YDM#]P(M.-83DVD(31NKI+F#"8USN"0SL,P+(!MC6 & MB(NE@DVO>#R9+F:R?L!=- M4091E_1"O/>NP/%A;\+9FB!PWBH'"T3.[32=FX%T;8,5=NB8$5FM2VSZKK&!>

MMH^S,WXM+D+EBZPI+U:$]*?AEKO+B_:5$:LO(V$612]!*LDT7#7-&?=]C'@M-MMXY+V^%TK[7]8*.^_*Q7)CR&99O> 2JO1NH.Q8H1VD7J[!V.^;U/)+L';JV/-M;PAK,_E7-

3>)UF@B!8(Q]TN>Q.IJ]0N0]_W8*-KN8>=CZ-PE#V[Y7%^]^&EA M$FG)F19-DK316,X*[FGSL$I[_@M0#Z"A#?I_R(,EIG^^!|M;S;G;FN!)64UD

M;OL[%NU&\^F)=&1Q9'$%4C<'>8N3TQF7D9TB@^DH-#Z@NL5I6<,!.!;7TLME M0!A_1?F>'^XVROX=Y/8%[=JA\VP%+)#68IC'A//.2Y.TI>MMG*#"@PG MZ.C[-

D,"\0P<)8@FRW^LB^15)&,Y^RKN)'0K-]5XIF5.]PNUFZM<@8E25&2-M%^P]3G8=7.K3<<-U[_L=G(DI2?@Y8Y!W,O5*Y7M7IIR'Y>Z3/Q!US"RLPS[

M0T%9\I6)#=_/U<)"U0V@$*K?MHI LST"7 '-?=8WK6KMF"#B[';S OO9\[X M8FH0:'>8KZSKDM&2T>Z]";67<_X>3979-4&&L@S((@OM?6FO;'I9E .;\S1P

GY/NIFA%K[A2NAX/WO9Y8:&,HB- $2#*PVN9-9DUF=DUN0S$C<|+S>OXXH89&&\|+-6IZ12>PFY!P5.8?J+@&'@%,!X- L ML53L4\%Q^]QR2EY+3,!6B>:AK_]"DY[SMOW#1$^K8_M;

[^LKKQA*9^[U3=S# A?NF3U"KQ-M=IGJ97D"PVA. M@^@3;.7,\X(Z]XU,MI9JK7/?R&1K]=8Z]XU,MI9JK6[?GCYGR$+*.TX\IOK

M38E/N.P[+|,\;CFM33K[@YB,;]LLRQ_AMPPUZVZRMB/ >IYKCB_/9F6A#D8_> MC7[R*>K>+6&<&QU%P -J];PI%S:&]-2:F^VK>N3E1.[81N0O<6=']M=I5\|+=5.Z"9T5U+-

!=#M=@9.MUGIH?MP]E@)99\9IL],NT4&ZK/PP#>N(>^_ MK%HADJ<9V+*8<|$&,08SS?PG:K[31[+E$& M4091'E'&;IEN?.?5.5RB6TDI@Z*_Q!W$'0=/OCE<^+C:0'&:)}T|0U'ECS6]

M$Q[T6YL;E_$"4,=> X]W]M[P0(3I+1+&4.EW@[GX+S9E-^T(I]\ MLE&OT>OU'Y-/K\SR>?3DT?3@4:8V'!'D,*C:FS!X14L=:Z;&3"41"T4,KWAJ M*MCK0&G]%\;]/Q*-

,;JQ@]]5>&%B>=#LJ8WB>>;>|8T5X")8*$/!IM'YB68BQ!-4 M5^YM97@CEWD?+QER,*XX$]A3$!7Q^.0[$W;IA8Y/D>))Y9CGD&\,:C^_J8\(5MT8AK

M$8!TAG[TOXZC6X,*CN1!7<:@Yf,' SZ@V&OV1JT7N6#\#^F&;@H4D9(B= MN3 ^>40",'@6]W>8O1&362CCZG6;39?K95Z&KR_=-N=1F\!'(G5*^_'!2H. M#!,,SD2HP?

#A.W&'OXNE2P*]2O\E:R-KV\G:>]U&/V!L"P(#5Q~LH8& T.$ M P.0)D=.3H(8:1&I[_L$GE/LS74DC&'EWR/#),/D]8@-MT4/@4P5SA#]7]9"1R9')3WRMG(F%PD_|>+4^>)#I/!Y%<^-

O3E42+@C0S)?Q M#W!,4T>9>(^,<&\C'.2*^EMA=G88HL+;(SFL;#YC5?F$9M_6DN$POVV-VZL@,N+Y(M^68TT.Q61(+-0,<2S&(.6!S#4(#AA)?M=J.;%R3WO$B8D04 *\V)1L9S![5[

M6);#T8?&02)>%1:M'<&8F8A*XG&@;MDX4M-\C]#7-MB5(&>19A&XK3$#T^ M?8+2][(@>IDH":\E8^[%202V=9&-WC'!45]F)@HMF7'1K}@FC. PPO/5LM(' M6<1OH5R87

,]V"\$/8F."S0R&4\86]Y;#(RR?LDHRY@U.T'C!H'J<!6T?R^ MR7H9I9T_C21^>RQG-?Z_M?WOWH\]ZIO9)IDFGN;9GO8ZS&RT3.N8IN/_-CXU-M$R@8]_E(139T%

E/P)P)UY!S)OM5>1.*K).]%K#7;LY>_=P^'E^,110)W#4! M7 E6NK39]9G^B]&:49[LDNRRH%UVEFO9*]0(\U([E6RM/]PGS!.M%V'1-H2< ,_T\4A M[;#

/)R/#^.!,RCH0*YDM#]P(M.-83DVD(31NKI+F#"8USN"0SL,P+(!MC6 & MB(NE@DVO>#R9+F:R?L!=- M4091E_1"O/>NP/%A;\+9FB!PWBH'"T3.[32=FX%T;8,5=NB8$5FM2VSZKK&!>

MMH^S,WXM+D+EBZPI+U:$]*?AEKO+B_:5$:LO(V$612]!*LDT7#7-&?=]C'@M-MMXY+V^%TK[7]8*.^_*Q7)CR&99O> 2JO1NH.Q8H1VD7J[!V.^;U/)+L';JV/-M;PAK,_E7-

3>)UF@B!8(Q]TN>Q.IJ]0N0]_W8*-KN8>=CZ-PE#V[Y7%^]^&EA M$FG)F19-DK316,X*[FGSL$I[_@M0#Z"A#?I_R(,EIG^^!|M;S;G;FN!)64UD

M;OL[%NU&\^F)=&1Q9'$%4C<'>8N3TQF7D9TB@^DH-#Z@NL5I6<,!.!;7TLME M0!A_1?F>'^XVROX=Y/8%[=JA\VP%+)#68IC'A//.2Y.TI>MMG*#"@PG MZ.C[-

D,"\0P<)8@FRW^LB^15)&,Y^RKN)'0K-]5XIF5.]PNUFZM<@8E25&2-M%^P]3G8=7.K3<<-U[_L=G(DI2?@Y8Y!W,O5*Y7M7IIR'Y>Z3/Q!US"RLPS[

M0T%9\I6)#=_/U<)"U0V@$*K?MHI LST"7 '-?=8WK6KMF"#B[';S OO9\[X M8FH0:'>8KZSKDM&2T>Z]";67<_X>3979-4&&L@S((@OM?6FO;'I9E .;\S1P

MQ22;JVQ.AC5K+O;9V2Q2-SQ8H5LH^+\2|+#G0L: U_R?,2CE[V6_-W)'H2S\ MM72/1'.[NKJ:JY&]_^ \|$G'|[B#,H#@(GV5H^JK&WK;T$4>%%#.9!K9X0_KTXSC&U;

*MV_.DJE:Y9J479F-F"E2#*W$G(D)[U$U6R;Y9L2 GYLT#Y9 =9$)G|R?S@(U M%X)],U|\R1[]$JGKB$_/?OPXI#;;;IH<-%4/FB2S\G^3/HV4O/O|K__D_ P!IY&U.,?0?8[+@L&2B=[6NNM*

M36DY=+/T(S'}DD9H]X]-_ MZ:O4/\YWC/L-=W(D481LD%N"GBEP$^9,FH6?*4=W#\/KS)<&4F.91GX6CT?O M&%Y1&06EZSU 6&(.[QM!YQ)?',P!G"1<%RK A\4/L'CD,?*

*2Xf%U.=,HAL.N M<54I7#BF^3^O10BM*G0MR0S ;,Y ,KP.6P:S3!H*M*O3> T=0NEK0$@GS{ M,%T@M&XP(PZ3.;$2,+%-L:Y^N|@E#,_#DT@EUQ-3,>YM-/R2$CET388@BCBQ*

*M+)BN+_QOXUN#O3$-N#\@.^Q6L GW;0CM3N(26V#F;,UA?G VQ+WT]BIG_9ZJ M7'N7HH>NZ6Q^,>RO3D87+]TO&IKA#O('B*WD+< #UO)'ZH#3ZPU[&KDNPM M-*

*(*P.6M)>>N0U@6U//#0QGO>?&VH-6SH3;>W&6612]P(U^^M:AB MG8S^ / *)/"W8\'\|8\$A3A!5>;R#1;V#$5":4;KVK9F_7E\/-=""%)77H/^ MA1A3L.@S1REV\PQI,TXK-C.QT3*

*QLV;3=096-Y47^)*F90;>WG*)'(3B@Y)/9N^UV MC:NT!_O2#[[+X=N?5FEP9W=9XW[C."UC'6T*1(@),%?AS\'ZHX MI^&<-@2\+5$E3\6QQ<:>=_G?*

*~;;;,JT#_VX15?)ROEFC"WVF YVX;R$HTP4?= M?UG(:P\=GF0B.[8WN/ Q+,LC67$8ZFS54&=;|CCG_:L.YQ;8B@(]A=+V7&= MK4()FPB(OP)/285[%\%OL/':> +>Q/\DX,B**,#U*8R"*

*($U14##3=)\7_[,(MH:8O/Q2&=)8]%D$2^#A&ZFSA003MS!E8 P4Z3;3+U(M!:\'9'0C'$5A"1+? M1%Z2*$?.X@[FU,.14..O]-*ULJ5GEB&+|!EG(8+OV*Y A$(O[MWQEZ;EY4UK*

*MR5D8[!48&D3FA:,S:]#_07+-^)I@,J,;YA F-Z9@)}G${ABNN:1J7@A_Z7:&^P7G@9GC:.61N+D6F^<(# 0[(§)&<*3 M_,$HS%Z&=1*OI11#WMME6.XC.G(AJ#D=*

|/+/WOM^__W_NOI,/G#[!|_?3^<]?? M/\TA.(&X+%:4X.L7ED)fGK@-]BNVSD[:;?-VR3_$C+3+M=*,PC\9#A-Y- M2:RD?P(SY\58SXW6423,%6QW6!Z/Q"X;=#YTUBL).Y/0>7M:C*

MGS<-]G5%;?D>Y3L$W3E0P4M9A!LBP^SB%9]TMR=CKX)LTD_GK"1P*B& MR>X/M+@U$[E5%?Y0>F) [[RTA246X%1);$;4L()FB^T%\DTLQ/3>T -+ENR2*

M$':X,%D,R<[,]CRSJNIQ\IT:CJSD.:+% M<1W1+8_\BT"I'SBOS%$5/@X-N,]5[!=A6Y'&\|Y;GVJ8F;X)"MR((3&S&"..& M0ZM&)HAE

RUI^&EYUDC:2ERTG&./,$!|-#]F)Z>&:I@o8M1(V/PXWX20,<\H M,)5 W4X84\|V(212M1S=7)LKJ99^:\UV04^JZ((GV1&41%B\C5 M.D/+G(EH%PQ-Y"GW-G1WI;5L@Z->[N'#UJPLM<,

<-3MA<)1FD)FMOABWM7M]-M(]_.4%?#9O!=[D R<(L,@F.V!..9\Q3SM]VGPY\00E-!_ ,'6W^D6$3$+F MP9!IK7@5F9AJ%YKCEV.|SVL#*,T.99A/1C?6G8K-87H:[QQ8?*

HV)?:N0L$E% M,AQC&->F<&0%@!'#O"":LPCC.>EBCTH3D&Q2"6[!7WTW7=)??]?NW5Y6NP-B M;])D^9\FS3;T$1(\;H;/9 ,.P|+T,A]-W-G9F%BM9+$D89<>R.\B M6S^4W[6X1XO?

@N^?+Q2.21^'|$*A*I2*[_M978LLU?6IZ:O3>\OJ,V%.F?M+))^A7Q,7W5G$D_MJG;GN\5E=|=%G5U">,Cl8PY&RY:1K/09^[

*[L]Q$^6319=*&+U@D&^666,&O.#L,$ES0G+]M? MEJ=37*7(W%]IU7&:.X3^!H_\A>F:79YXT*O9OY-FO]H%"]P8JQ*]W#][C(?> M@J^2(>$/D24SI &=12KM'(>!HZNU(FW]*

M%M[6V]^__CNPATRD50TE=X5D^-L\,&LHY7$K877MBY\3#K4YE65NR@C_X0T M^V/C2.WM&5;.1,.C[$"[7/HC7B@!HL.]N!A)\Z>9R808=,-SHJ_PM.D ^P+ M1?[CTY>5EE^9-

\;FI/!0[._!3=P";#-+F%K<|fX0^4+2RQA=;L443\Q=W;_M_^Rl:W/<1K8M^%<0-V)BI B(K:&(<#61F2[MV'@PIV7S7G;#R6NS6F/O'$IUF&Q"4O0W=?Y<||P'OVPXH,===TZ85:*

[@;;C)"MU] TOJNH10#:$*A2*[_M978LLU?6IZ:O3>\OJ,V%.F?M+))^A7Q,7W5G$D_MJG;GN\5E=|=%G5U">,Cl8PY&RY:1K/09^[

*MGD42L/473]M35Z,_@(>'N@^.I$(+;@(5Q;535]9'V>O8E,IC618P_2K66>_C M:+A*X:F1&)$5ZFFS'CE,/?8;A+IOZ*C%AY!F'=:W/L1>\!%8ALK2DGM_L)V(MLC9Z1V;6&)*

[A09YT="Y:W\>\)^G&IBR+ <'!VYPWE7E3N5;SC^HK@A]-W>8D MPH5'&%'R)+5?E#BLP+!/83V72Z3[FC@1:Z)?V:(?)[8=,HYABUFX?6,;XB>. M2]JJ.$!A:_/]PH.O2EO'J

@'3M'AT1)NNC!;4J7"PV"HA0)!,P) MBFDN$*]U^KOL|W+W@>?=?7G:G3D+X7$9 X9.D5H"\)G\N."ON!%O.36U@5

MP)1D!&_L+@*H0..I#XK,/=@"QWP|WR+I'&?)S9[NUB!+LJV\PI>?IH98C)/-_MYQ*<,%%)(+R8YDU19J^?7QJGW+$+L; +Q!#85A6^;(I'-FD\G-O5UR#$"HDZ*

*MQ0[%#1P%#HFJOP&#^R;?-SI2O>=^2M.35A>G);K[W'$>H"D;]N>0_Y"9FN6A M'$*FP8X(U!&G*9NZ@=3W$!33XB\/N8!G9"U M#1_/U2M68<,>DT\[*EO"EZ(#7R[;YD%*

*[CR"0IO.\1$$C\$WUU_1(YE'I'RA MD7_2)F0<;)+\8_PF%ZD6Z &?Y-*R3_^4!)TT:76EYR_=M8$C@,6H7_/-_ 1 M3:AVP&"V9;)+)?3(,/G@H_,4"M})(- 4/YZG0VE@-*

*BY/08CS$TU8]=:.$"KVZ;J M@AN@(O;4))QSO!WO*F%/8+R3;NBD%X*H1()[UL");ZKHD;4MW9?C^)\9JS"M7 [>3*VT+*Y<89PBHOP.7 !?A^1HJ;6=WE'8 U.3P)F6 M-IE5CS52V%$PKKU(<*MW$_?Q#ZZEO77L5Q2-EDOLA&5OX.VDY#Q"#83^77*PA%I8Q'&6QJ2]'ETZ> MC"7K4>&)U&H035_R4/H. 6#U\)Y-8-*%._2U#;_]AO(2A*\;2K4@,<34#?'*

MD4D(;HY^^>2XLW.J,3;1(++>VU<3#1@)X(2?\GY1W=2>4VP1'<,M=ZH:Y)?5> MPJ;.#F?R*+O?1,&]X<S<>B6FE*E'2AJ\7_O1%\)1T[OD38>/K.G]W.I.-+YA/*

*MZ:T%454787HHD'9H:N6X5JG[6/4NNG!9.0KPKM9_[>D'!Z(>!B*MM@P_KQHU-M1KX"SFT^.%B, 8Z_ZGNX05JA407?X"R.^7AH|+W70C+QAJ2_5HIF>)L?^" (*

*M.X@Y35B/B!O%@GCL>@:LUA.>_1^G,HBCO[+=2-;>+11';A9Z>FK%7)QW2R' M$"$Z*R4?&QAF(@_OX9S' 1O\K\'9=>6*@IQO?TY% ;5-OO]J%86G1\^_> _3P*

M^?/OG__PW%A+ ^NHW(:K@8X9;I M&ZWN7J'9[V'W?F>W:,_>1$\F_I_52ZK$%UV6I^:1?H,?=(@B"Z\3A?SOOPRP'P MX=;--0!W#4AZ;I;"NV.%%#A0F*31"$5SE3K3080E9-*

7&7O1L@+,!7M4 $<2. M9:5MLPH)?"];ZQ-A'S%(2!K_I*-R;-YW1GS2K23J!$"TD"\!?02!U P$RJ_ M!283*DQ_XG^M$]Z>U/7@8AP2I(;2)$19.*'PW=EH9Z.]_O&.Q=FQHRO8-J-#*

M$[=4P]D9/C^ZT4Z4OVR?@*CB&MQ/5(O&4G7%&D)$"6,)8'<-2A8XS^%&CK@Q M1$ &48-< (>;DG "36N8)B\E3BGXBG$O\,V@9]3:?QZL*ZW-\)>" 6/E+T\ M M0Z8'&AGA!\?*

*J8[N+]\@ZH)(=82Y*UH7)HA&L4HZLU/|$*7S,H$"'1">C MI[>9>M2'D.+B2:EK .5VXI*#2:SC\?7)SI&W &@%UQ.%: M[+V/LN[*#TY[.G")2!)%)UU/!.3PN'%?2/87Z;!++>W72MS'9&VJF>')$=,) MSJ*5GEE\]FQB :+$5|I,5Q5F'G'K9%("MQY^&V0(Q$H\30TI;,&]F<.12ARB-((YE$7!CP MHK+2A!W(MJMPO2 2XJ2>~W%#88Z-+T_I&9##GH/Z@_3U"6L]F29TF/B>$,*

(!+86NV@4&BP" M-TES#I]l0DV#=M^%V9,HO6+>57-28W`,^RS:.?@I=\,,,.]1(34ZK M.N@RN0)-&/RGNWPD_MRW^"'*1,R 741Y<5G +>%\4$M#F#'T/ESIT.7D/=:,LE*

M+1[:$',%G^,B6,,^2:!QB! (S,I'0)5T2/:U@Z.JV9/1M.36X+X(>VS;[fKL MI&H6\ M3J?5[CY%\D#]D'I'A>#SW+_%A"._]_X74U8U[!.B"<()U(=+L]D7 MK(JHBYWW_&2$" =NU4?

*FOSO'BO.\'\+NNRG7@M.VO"ZX"N*UX;I#@8GPH6C# M)=/$G&YVJP 31E$:&K+N92V,13'OLKJ#JE'$F^KPRWBT#0];6?MV'B1M-1YR;&,5+E _5KDJC,/U?(TZP?*

JVV<'K_2?&TMDQF.;L/QB M[,LB>U=0$2U7H92EGI8C7T"$AI@:9 =!S18>M^]P-_/H(YDHGC/1:61&N9&F MHI.<3VW[-_=O'+2$@^-S*-ZCLY\(AQX]QD$\]?HK M&Y#2U,XB"

*(JGX[>77>H MAJ]I MAO\<(=BC+-EOJ>F'WHT:3-'"/]F*SIH64RCH%82>'AB%V4'@\!//4[X?)LI+. M8]P-_B,1*+956V:VU&:,Q_MZ?5$< .,5UVFX08XM#GL?W)2\OA1YYZK\L)EQ&?*

=D&.3%3$=#52F9RUW>B4WDWEB&'34;(AZ@M2DM.QO%YB6G+DX:WZ@<+#P"=/U*1" M.'?O@#^.+<[^/OO%M,[-]06V04^.]:&&ULS2>MW#=*G=2>;ZD]I\XTTK_6AB@E]I.'*!*

(:+,/1YU(P-,P3&@OF(;Z>I M>.;Z9^99[9I[,/3.WMZ?F'!OEUSO)O ^OHKLM^^OX![>JBBV1>06/#X);> QV-M2CG)DOA>>8"G:)P7@2I)^+@A1?F.1UH#11^A -&#$@0ARUNDUC#F!;

*MEK@H[)QET)Y?2Z*_5160CC2<@?>7^HAT1H\X3NZP+W4<#FZD$@Q,3?HBI_A. MK>IRZY2CK6[0OZ4HJEAN. Z)LDY%L44FP;*&"_!Y#Q8!<{2) M3LG FG?*

*%C#'4*Y#K%JX"RBR>B$^66I:8-EX.TVU^:+?R-.W>X&$KPPM7% M4P=Q<@3>FJ1:CM*MW.;@Z>^X-UVQ 8@194D(4J*1*$&LG88 M!7J48(^$?\RD\VE*

*E)MG[\8'SAM)$ D)QA!2=I3]_UE&&VG<6U-^3ML&R.O M$J!:I_1V^D)EZF.,(XY)SS:(E)%RN&N221?@!I**...05,!N/2_,[5SYR#*T M:L[JLP(K&!(RX78_/'MP06KB%OF"%FZ)^1%B6?*

#N#OV1%V 6VF>5N9I#02E MJH*$!=!J7,MU">%\O!^7W4,B,&\A@DQ@*&]?X",O2DW(_M]$:7D9?7>H0F%'YE2HA:=(HYNJ?JZ&3N0ZKXG+]5C &#:G@>+C.&>^[HY"BG*

*M2XQ9LH>TKEI/NH^WH]0"I4AATU[CIHSL:R$,>(&H>180;,<7[=)/8O7,9AS MF69ZX,$LW']^U>%8OW#M*5Q[42"Y0B621.O)EO E02;:< WR/5PT'>7_,*

*M+.6&%$Z169=#9(P$"O1*IEY-JMW8K.!USLG:DEVTP/;:'D=PW+3\0\R(F?\SWU M0,$Y]$QNFC.]P&@D)A^59[^#TFS*H;WP7=GUZ@Z0PQ99QOA+BY:)*

M(P\LI622T1<;WH5B,E<1!02_B6' \P#O&FMXF=!D(,-LIT2\LUOS,"0D7^.M.]V1\ W^A!"QI#CU=7"D+V#_;PEN=\#,I(:*.]@[C.?.P?,QA@[Q1UH(%[*!]H&Y6VTVN"L, M'!TD)*>XXEI?*

*Q+SS,:+Z5TD5DG@IZ5#CTV0VP=D$KV>"M;IG=HL3"XR!<7 <M9X.,#>[*!A?D:#09:C(:]DECL(XQ#4.IVV93+LH#D4"U@\3&3o5(O9.\1D<[$ M'CF;[*7Z#_^.:^(J*$LSG?&7,VGB1%/*

*1!A;?\@/LT M,2T:==&"E$8D>&6^S*6[:7J-6UD|>5V+8%,V=T7+>&N3@1-:PB&D BO&KDY: M-K >&"#9IR[(3-1$=!)ZB*WD#79#").!=+6424QJ5*UX!RJ\E,ZDWT)Z3#1_*

MKKW#>$+J.1I'=2F*^I3?/ R)HGK;Q:A;0"(:;JZVX"IP&@6+"">"&AZP^=7P M EJ2M^]D&K(!NU%&D/<%R0Z0)MR!Q/9G>%=# M;)CK-*

LV:IW:D7N@1>8.5_I2M"#6Y2"^?/SP|=/HK,$?OSR>Z_)0BG\B]5KV M4XOK+WN%%46P'^RY/CW*WA?CCBXT[;9OZ6YK>/^%=!PP6FF4'VXK+:78>_2A;W@EA7E:VEVLHJV/Z*

MN7!?Z^I3DFW#=5&5NXJZ6,5)4=8^XAPLQ$,N&>6I@HI]BS*L*P5]^\0HH-8RV0Y*21J" ,W M\&F|<"1_X@*IMM"'|,R6E4|M$E7R3[;/BC%3^.B#S\TRMZ!9YNG<+'/[FV7N

*M@#_RVQ ?K(PXJF8:DIDL$H0F?2UT%OP"44=$C?9#/17A2;__MM>_#\,,AQ4JU5X/ |F8%H.?*_].TDQFQ_UB6DKVS5X=PEP83P*C<=UP$W M"M\@SOH;>I6W4O/WUTL1:PYX2PP-*

*9!YX((EZ@#Q4:G"@E"YEZU=33D:SH52.=6)O2Z;JUK1U3=UQ+]SAN+D1 1IP1PV^M&L=4<9@NA0TN MO]"2IE#(P9I" PBE4%S"1L:6JETA*W>"+#QFX##[.^Z5&*

(+H=9?)M.T\DH$9 MP#=G>#!W%QBTXZS<%GP(ZM=3OT894+EGD!FHMMN^AE]8+X$@!06:&,.L#6W[MN[Z%T.,]X?-%.O"#;8?ZBY0Y9L#A)GGD&-

J)UR'06*KS7$O@UZ#C$3"E_< M!:&G0/8S%_WF-735-33))XQ&RFRAG(/6DDC"BZ@ID@X6]J/RP?>$R?LXV^-L-MC]>R1]W3L6=+24,9&B8EYDYX0-*

*F1]O:61',YE4+02LUQE+QB5I5!DUL27OA M,.*S"=^(",;?P]8WX9T$T@_!7$AP ?-4"I_>V).@_5I(2?-LT\- P 3QWTBB MX+19-G@E"_CINNQ&L=%LX+.!7\? 8,?*

*%UC5LER/&0*IVLPTfXIS$&/8 &{3: ML=GE:02A0*]=^+33U\5I>2(,)MO9;&>SO=:.^O$2N>A%O;(D/?35)44/9DVJ4 MT!BFE-.8F@-^.G:N8E#TEK^4_X469R-*

J4{$U>]ZY\6].AP&C7X*7X@5T8K{!MB6,DX2GG(,OU 9F%,Q>89(=.DJ2IA,*&J:=:%VO&G/$DVEB: (;S)S^QHA&C MTV;&\LU+]_I1ZFB5BIEQ.<=[:NH'_F.YVREZZB)R+SZ(M,9E4!.

*(5W4HEGTZ M1>-T(SC 6YEW%SYGX>\,F|&%|?ADTB-E1V!CH|PSYXHI56P5*D9TM)1U*^#9 MQ'? 5'E9KWN"CC"[@$"!V#A);>3*CWTNI|#0+G1L<[GLW'+99OJ2;$XGKZ%*

*MITY#\2*QKAJBGIR8IM>.FV;W1O*@1_$FZ@6U#Z1=4EV!EH5667CBY}DY%%LL^F=Q9; M1M_,+3.Y.,'VW_MLFS:I-*

(2ZBM$21^=9:Y.ZNE@]WNJP}J0#PLP6I#Y3YB;Z"K+ZH/K8O895RD\ M'(K>B9,ZO.?GP4NF(T2O)O/"[#9"DNF'7K]=C82:=#U\@^NR\; B,:+C[A-F8 M] YD% P!@.OOR,'F>+=HE3)

(L9WD_+U(R_B,O?2(^349OERW3!_&H8$!_ MLY>H@W5(L19WR:/L3=,.:!7'2Y4N>RNY80|6CJ0.2_'+})OQ#K*R9E\V@0"RP*'5(U",-P5S""8O0=GE!BH-QW\/=R=1*/KI*

M2K:U%"N^>B.!=$(U-_)+\Z4TDI136N&^LF {O209_ N>Q4C!'+,+5D)AWQ4 M10(.V+|S0RB(I[FEU1"$L"_I'E!;RZ8@T%_;,48<&$\3V6?+8;BQ0|S;A\DE#]MCEEA:L'"A"H&C3:#*

M4I/NU.7)<4-]40D\33U:4ZM'V3^%O|\F6_&C-YE ^]3X?I&"%GD=F=.0CXA MT%&S8P(P_,H[M\K-'D98@V/",,L@!QU@/VP%> ^]9P$,W_LUSLN6KZ_.1G10D;TO$;ONS39^DO*

*MQM_\|_^1 3PY_YM)><%^]55%=,KXQAW*28|K G.+>@*@ZA*VK+U)OG?"'"9T MN4%91^)0D&R\ E >R!GC.%W;DNB*&UM@3;J7'X@$GA* O\#L$^C_|<-'WY'_ MJ.\7E&+-/>7-*

*\3%=WG5N5Y6PT]>ZA{]ZPD# M#S<@J0Z4U*CKIJ?\)_SD?WK8PA_E^(7GG%U]|8\W[W3(=")IZ2EBO*6!5CHZ M>J0/L&^'6OZX(ICEND0=#>(/N."J>7A25L^%E?,"\S"4E*

F#B[>1BPP>_OE1 M#]}UV.$_?N"19@W8=5-5S=F#?D=#\U1E(0(\.%X57FZ'\2UF RCQ2,D2*K * M&[\(N_+YH.E(NA=*--+ ^!6^'NENDT<35)^'ITTY$BU"EQ&)CS#>=>#1L(7-OM

*M(G)/DQ7\#0(N,8PF&*O*]D/L_"SBVU-/)B:>Y[N&HENR'$##$SLMVCT[\'- M&/D%5B68?02K'WM2M.)QJO,H?I)#9*XM#O"H0Y^\E+ ^(<<<76\=EC(EJ4*5H5*

Ml5_R(&B>6^.>7!,9VT8^B_7EDK8J3AWZHG9H&;5>$]E M2R0LZ#;8"O))IZ17.(9 ..")VKCT;.905*;WXF>2SG51)_L@TA6AAYBK,@W^ M=YUF&447/7$9^!P,O65S!],.R[G.GG4VZ<-

>_NH8>[6GP@KBY9&Z3]\GGF& M_<_&>Y.@.[.:R8PU+"WSG5IAS#6T AS5T(&8>1'6#H]&I=I:]8G|9TV1=WJ3QEZ0OJYPN.?=5@8-VCQNVISH^V\I MVX"-

TZ7PXR#/UWLIH'(S(">WK/UO^G8E+0^3|#PFZS6OBWE=_"GK8D4%!ZQI M2Z>P(5R-!->B0LKXU3RV?-@=G|&$M%0F?Y@9?2#AQJ&P8K;TV=+_!$MG?55L MOJ6-_[0DEGG-

*_034+9B&$+"?\.<4TK%JNE-$),+V#/]B*IA>.>I< E'1!3>J[*]1K^ MG-*#4O648K0+KAEL:- Q4]91&3(52VI,N\K]/3X!C:G[A1? EG;S.AG?K^+Q16VN%-MTS[@#*

*MPK'&34.O/AGIW2UBOYFLGC:U" 730%0I4%[2':JWU@TW&H/Y82^=]G1*V9,N M>D'}UMX47ROSYD8P1N3-C2ZY[D#>A[5N.DKGZCUPQ\'>(("X *GWKEL@OC(9 M/_,=]2H,[!?*

L_8C?D!"E8>'Q(/PTB_!R0#8KBRU%B4,W!AA@:AV.FT'CW] MH5EFT@<5V[L8L<[80!.XW:&9PHKT4:?9\))G3'PM#8/KODIG[>+&&C^W M&LRM!I=I-?AN;C7X*[<:W,IC]*

*"8DQ'U0N^.O02T%P8NC_&+AF'EH.XNZ=_N MZW5;@&?7DZI4?HZ/"$=E YZ58?L,@BM2+(SR ,Q=9[L2K" 5?7B'W:+D0#US M{M0"12\4(+A,H_YLXS4%OZRL.1:S^%,!**

<)S>&!!MTF:01X^NP>.,3>.Q5 MXVTYH/+P'/S1%+P-2/Y1O2O ;,1&IB05*X4+3?9BV#:#<0 ^-QN,<2-Z?#Q?SP%7!10XB9>K"#^]WAG>.WM-F\'X^O? M35+!+9 M>#8H<-E6@67?*

MLRT0PN6WX_IECC?ML@]QV\OU!BTT-'DAHN97X.DEN'WB#M M>DO$Y7>C_O7-(=ND/4?%#&F#4=O)PX_/7.AUOX:!20N[$]H"&01=&+9=1SQ M\L[']RJNK'=2'':WR'$P]+%I-*

I$K(:IQ/B#2YI8HL MP'W:E2W'3S!5X&;"&14DU)!T'4J[])9\B=_[MO0K+5"9]0K3>%I2$T4GO?UE M&VD"%8^9$#>%?@'+V "W!C^ ?-5*^O_| M8,=*=^&##6LN+MG5)PA1_$L!8;

M#:D(IM'2G$DKVQ"2FK+$K],8^)CS%E,313Q+V!XXKRTG.0HM& VFP$((T@=M1%]H7[>_^<0F A3U-/IS8(?7,G!XZ#'3=LP">$INQ3CVG5;R#Y0T6<>WS+>'

*MIP9,2FZ.D"1L=SK.VP6![3X5,F$]VON^]+[G'ZU\?VP)% M&Y48*7Q7$KUORM6J<@}>@0M.[4K6HQ=RDI 5.:>[*G2=2E 0C24LT=#' :N% MJ5D&I[A2MIDI,MA/$%VW*%.) M FR5;\|9C5TT$'#SB<"N>6J@UYUU*S M5MR_Y1WZU8_%OT.Q5EF7V,/ST6DE"32,-:>=\8#@W)6Y9T[:YJS;W+2U"$7P>"2FJ92QW;_MV/C(+4-*

*;,EA3X[OV_%3)I=EG*T@VN0ZN(9%\^I'"'F9X^ MFOQ!CC-N,9Q%RJT=N74C@\>FB$/O"PJ6,<+Y)R3L'QI,!!5JIE M8Z)[%-W4\%K7]6U]IQW!UPDY(W?3%IUC9I"."RL4F)+*

<'?5IM&"6$Q8!3=K4 MKE--^N)PU<4*;<&?&#["(W!$];,@AZI=5,)#E6JZGNOIU?QN>]#'0Y%PIV M'@I30RZ!N%9%/8%4R/LM=}$P]W:R..>AD &8F2GF M1P=U>$?

Y;TVIX_ZF&:XYT(Z5LB(R=;UDU(]#R.,J1(K!20M8QPP@.$=RC2 MUL0RW!=T$#-"2JE/IOV;>>U?O!&K+4BBE^R?Z3@2\BM,)0T"(N%^4K^H:7<; M>I"BZY%6@1=0U;#F-*

78/\2>8L>.O8BK:YRAS1@1++F-':*;&L2+:9G^=CF(J) M'=CZIO,(=S@0?MF'9ONZZ)0_T)Q\6Q7[@B G_^XK G&NMRX+8N;PK$,K^P>_MP78?_OC+BU?TKT<_WA^YL/B[18E4O^5RN*

V'=YS\'NN)POC-D4/3HL,_WM'M?<*(3X*T@(fTL=ZH6#&/B)+A^-7*$SE*Y&/;]#E1C$"K .K#$XP.&<+#NYE MO!FJQO(OWQP[E 090E5'T#2=_A%4GD(]#>]E>HWZ>15MK:1UP6[*

M0%SOX7&QM'LFLFT3O7(&&XTG2)G!4NK'RL5BV:TX'30.//UQTQGW$3Y9 _MD(L%R&_&HW@KG&2!I E+"2D6E?AW!,L0#DQL/#-**B+#@ <4A=NWZCJGMVZ*

MZ%&5D473]B9.%%0A=233C!OfDO=QSQV='.5$]UAG>U>TX=C'BNI]-5^MX1P8 M K%S1>8S[A(J4Y:JQT^.LK?3BP16:TGS[2&61?]:D9-.KS;UK00fS9]@<(l7

*MS>%|MA1E^UB30'N#,1],"4Q2C75X94L0X+@+X^R8R6S#!X,_!X>YI%FXZGP M_*]['$4Q|N=&[HR*K14O!]YR5Z4[;GM2H,_4"H)(- 4/YZG0VE@-*

MKR=""5B/K^OE478,__3/"_;%E\1R!@9GU(/5=U=L:J7^^Z/#=W3Z)AQU%#A MHVI&(ZZ"$0:;D9HS4O.\L,W,U\SKS4O)U^M[]Z1M;'.*71]?#@EK?ML*\D M9PM1ZM_Q=*[*%,*

6$F%WQSGTDC$?3?@2OO>GKU=2P M!5$750FK6$NB&=.64_]4G$I-&J4W,#D+;&:B-"T@4G2[*R:Y_JG*F;(!|," MH3(GR!#R?P",7O&YQQG*6|'8)O+W"64\9Y\N% >T]K@U*

QB3PLWR97DH:9E0 M38I:2W0@M_B&,292@0(8)XFG3D55"-G.B7--]Y]<&Z%))?OLZ^Q>>9_2:!$P ME6O(R2W.%%H8 AEON.=Z"@A:784F%F%1LM'R^1%-)EX)Y>F\[62

*8^%F5?,"I2QLBXWB?%Z$]G3:N=6GA6B&9\"TX9**(@0SDV53-G5 M!_3'\$-NLJ2(0)-, BA7]H>5G,2<&\[AXV+>,U8D_(M87F@1]),56VG_11LWO?4@B$?#7_WS,"D[U'H.@ A&"4<-*

-9VN(X_Q51B 1-D=Q%CH<%,C7!O[98\@X2 MF4E]{&P'6"B7#2%2&_ 1.1#F_F#HOVYZ3+@.DBZA85)P?.8^)<_Y0DWN=K@ M1(91.W '2>71TD]R.?*

2I2=Y(.F&E69V!=T6AY2BY974-DNV=3?^1Q#?\|\Y>7 MQWGVTS^4|8YOCH|A6KCG@4HJG/23>(!M$G5]F.PBFGTA R015H<;@&MQR>2&;^MUDKU91?XA!T& RC-9@#*

@7A&]T'#U.R1LC8;&8>?2"&$]^20TI3*?_*0^A. MV:X!O'B8;GJ4!Z^,P$XK(S+&XGB444"$K,1(&65W),. 'Y(K-"V^<:;^$%4: M(8H2."DIM$^)#>-XY>_AK-#/\))W?*

4MHO5&",KD)$!D8AB^[Z)&!AS8W5ES M8)"T=N 6*"89SZU3)V\+&.CV,.Z.L-S'\>,&OTW.Q;OS#P0\|!IV$Z("H,'.Q M7#.IWLR3^,Y-5"=!.]\#,.OP.0ZIAV@?"9ND'T4R;|_@?$U[Bf??

]09.W.Q?>,#"'PZO"?M2 DT)]LVF[0*AG4E2?0'>%(_M_UGVRV"*&M2D*5?@%?9M!*WG6=*Y]f69"3;<;.2P$RS];DKB+SY<=:/4$52 M2V6D41]"9&+IA(T9$8%M M22HXG'+K-*

*:+>9Z-T(_'Y5*6UQRMFDHFRO,=:>:R\|CC 1'QO^(_X0/BHX1;C9 M^Q(6 _= D6OGA/;'M -V7B3S(KFI18(L=+OA(NS#U0%I492'"T=&LM:DH29$J M0PFG>?!|%;;?*

&,V&L8:K=AP4L\D|;_":OY_L=3YG-4E?,Z9TVX0D4 '0>BOB M,%%@#[.FYZF857@\@BU25K$;P_"_,O9E09>8!L=U'RA6Y@4Z+|"K+M >0?O. M.VIX\F+H+$6&G;4Q'3,JF$UX^\(QC?

*$;YB[QD.+%&3'\#):+<+)FG*JBKY<;=\,O+>TM!Z22L0BD? NICO$ ME5]#'MA;P$G&AA+<9$H0?N*2ZO%DVB[1'4@A_'>F93A(1J#I*

M#FU,.KL&^8,$;Q0%$,'G,T3P]D,$YRP_CN1?0Q*T:W,"%D\'-<<&!HB7/1Q@ M-;;Q_//Q:UX*CNG%FU^S1>$&=@6HO46,,.3%^6GAH0Q\0'@VCCN.N/#ML%NB

M1VGFD'2+O#)R644RGA%%&9%KIP255/.ISAO[FX MSA,"G-WRPGI2TW>*1[0 M;8%GZ1J!A51)Z\HE$L;0?D'=UOQKF4DN!\H+6E%'M7(X?U)&=*QS[K,G^;,'M#_%-/#-X.D*VU"-*

*$,YJA5VY.5H"GZG{#K_ZZ,G_Q1U9X0;"7P;^?.SL_M ;M]}BCS'\O=C@YW_NWSR_[T2?@IRRA_UJ^?/@N_/N)%PBP+=(BK)Y!,4J]3E?]Y\1...X1JG)8K6$'P0O#58556ZN>XEF %[S8$%:M= M>^KBZY,!!6KQZ;L_IIN/;M+M=XZ,1%]\P(T M\'N/P>6(KFUZ6&&;-=W1/,TZ4Y(QYLDH]0M;;3,LEDOL4L?WVCKP I>=MA Z M;+>;>%O"$X;J.MYJH,NQL)@< U\1!Y@-FX!F/V18VR8P&X&%_!C4!B,I896XY:9F,"Y& M3P0RL;00AG)H #6$%4C93SH83,Z)\(81H:!HMM!_,XMMH(>X*)LPJ9R%WB7] MA'A(-"(-M\6$0HGFVJ?S"2EVR-R,*4SW^_1\KA4)P5W&\.0 ^.(W"0&-O_7HZ^%+>/;D?!|| M>!ZWW8E/6^^-B/OYX]?2KY M:7+U=DJX-#]>}710D7+]=&\0P_WL,4_DJX-#)?CQA1WJ/CV96+9K5_T,"J;.^I^6;FFP[9X M6(^_]R? $WECZHU=UUQ:KXD?N$#%X MO=(:P-\Q^MC(0? !AK[*IA%=9LE*5N#<^DVY8\/_5]5AB:O>?[K/D_+>P7]] M@KV!Jf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|{'O1M+LCW#?A M5*4LV,0EX3SWA^[$BC.O83&=\L)-024GN"XLC T>%680>)# XM:+9<=_^X ^ M$2*U86Z7Z#2=9;\6']V]X).!CI;,U>]9Z+ "%1W NPU,8NWZM@D?+EAOTR8Q_Q8@/IS32_I[2=X"RNDYI!60FTM=8H]>G0KWJC&$ZAW(*?$N'<9'JJ5O@IGZ@N"'%#K';9'JJ5O@IGZ@N"'=95D4IH,6'Y^V\/Q!=0$GN_B;7!OK D[Q"T<&0]OP+L-QQ-A-[&V15=(0GVB?%:H6[,=6A)]BA2 O:.H#=)(643^?3 MX_D?G =KH-@FEW2U)Y9O7)))-\1>2;ODB>VIV77QY32:CF]$=?2IR/5X%'=#6U!9K^KM#LP/8%7]V4.\F/QBYN&@0&@ZO$M+2(.#ZLF)M19_,/.L3FF<\!=]*_,ER@JY18]R60R'88@!5@9P*$H]%3;FCZP WQW/H.FE9/BXJ4 M.$Z%IRO:<$/DNGTM/KI.8Q&RGD]!V-%87S77MB}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|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

*MA23]QJ@N8DIT9Q@937QI81[-SK=''''*28-3,'^P'X'B3R0L7?&XM6;F64^AOQ M(^ZY/#-8_N1 O<2[2.A4?Q,OB\2-"\(F0OR$Z{O(-K JN5.66/%% L_!>"/GD%(Z MPHLM],2ZNR9,=<'PAG&..M<1$%=FU2=8D&5#]0L+5D(WM:@D/#$)[GHE039& MO"=%+8[.D-9#. ^YIR#V- M(4^S%@=P"PNL@*FHL<;I"J4%!E.++J2]=LKH@N):[+D;!AFAV#)LQ7G<;PWE M@$>5;L?,QMQU("TMA_=P24#< 'WQMW#4W\X%-F!)ZE5RRAX8(G?E0UQ+C#2F M2,U%Z*%Z"/6F,[,9*51>O&_#A=C/D_A\>G1L\?/!XK"X_?/'C_Z_OEW3W!X M_,3H_?G;7-![1T!0-V(N'[5LEO9EF*QLB/]H>?I<;-1D0\/=%'-MQ8,9KKMI3;MTRLG;\N<,0[22R'&10>AH++\. 1[1+@+WI#6Z,2[*MA* ML+X N<4&%=@$BJT<-

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}E/ZIC^U5S}:!U1RE3 PE1$343S MVIX$*B@?RRD& KZ)4QLUY8-G@'6Y\UM@AJ", M$/YJ<\FJO$7N51O$;"L-I M;,3P)2S0_&3*@SKTY$]>YG_^NK4A@'JL:03.VQ'T>U9M!_\SIR>#=/9VI'-_MI2B.PZO%D8>7TS@"_?H203R_Y;F'>[X\E]1O=Q1'0F^;WNM?\P)H!XE96U&=MHE=6MEW)QT$VP>!> MVM%7>U;_>O'#N4AT=UZL8],/S8HM2<':.FYWT9ZJ_BU15F.?\)>'X[E=,E B M-^#55"-F/!BH)"T8*. ^0I)XXI3AUROR=K*K?/5[VQ77/M<23J"A!3#*)N(\& M.9?8&ZHDS]"%/-MGIP(+C>$!)@<$0)))XDV.MO)Z.7(SO^_.\OXAC|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{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|NQL M#26?XL4]OC7HCSRR!H\|5=#OL4-ZKOY9"A\|=O$AU/2SVUXL#*T*/;1!'AAMX MS @#QS18&]6IR_S0BM;R7W;AL54GA0?RV>XY;?#<3?)A\#Y'!'4'=D*OTV_98 M:''+2'TW,-PD#HPHB1S#"FS'M*V(N]E>?+:[A4[RVI+7EI"3D//,.CVI9V5Q M!M#FLA20CB<&BT+/2((=!W?LV([WH?7]]!&8K#G_+!S-Q()UPC7!HMKA[$(M?9=E46:9!D]CV Y[\"GR #$=)PRXO\PLB9U\+&V/81&2Y_9NSR\Q](>?VG7 MZ.-3GGZ>O90T?_+ZO/L_W2&_[(IX,?!E1_8P>D_SKF !%/V#-=8$ MMVO-?)CA<6% (>/EQL%NZWFJFI0*_DZRS1Y@_M#0GJD&G#7S9\ MRFI0+^TZ")TMG_W=IO.KZ[S)X[S(9I_(]+LYB|_84G?]-BD1<%>G6U7LME+5H.?&%3V<< MD_LTQ]0UV[3=I_/,0TK##6$1#RI(YSAA$]TGB99#HG4 '659IZ&DR*89!K^< MTO0ZX/7O =XA8,$N8?5%7FJS<35O6)DV#$JQ'>ZZ#(#GSP0CJ,3!]AK0:?S? M\WQVJ^4E&9;)D!:,F;$1FEF@ M^$D4Q*Z=)7&V5N,QL//039W,;)D?&6Z*YX,L- T_2!A/S(B%2W

[9T2T&|G6F%!\)W1FIRCQKY{HB$R+ M!@"^X9L&OP1^*F91,,K397LYY;!,2'<)S[TM?Y'_#K,;5U6JO-#"'XYLAAYN MP M:0UZI6C19&FB[:$WVM#S0OJZX6GM^HJ3O\?O?-&,

6%1Q^=8FT&$IRC96C$[MJYXA+C/<{%'?#N_*Z:BY@,)2TUB,'L,YN_PVX3@4NT#+,9\'YD 7'&,'K4FP M831H 4I'6[<&@A7*MNB)H@C,!>Z@-&2|\561-3[Y@B7>V:YTVL908Q>F!,M;)*

[M70 MN@G7VP<7<,MVK;JLP991I*<&%HO7UPDK%AHZ*[_AKE/DY@E$SN4#.E(D3K5 MW',T-ZN>T_49Z8\=_9,)))ER+.5CNOU52 MHM&-WGDFD4ZK(+|-80I;*

<84=SB90_<%+C@>}D%X41I*'TX|RH61?6M MIV/$A:G8H?29KB>PHGA:"?B=RP5$#0'!0"HB19/6#$\#OTV/P0$0_LN9W,ZT MQ=I]-

D^5FP1QG"LWKEQ3,!6F\Z4X6(7@4C=^_/(?C=IKK;(@_CT[IEM@-4JK M'RY"<5HG$J=E4YS6*<=I/;E>RE-CN\XZ2$OI+L>WNL-!U-=J6[[!VPG7VK:Z MME4@G0+'/Q"V/-*:K+!,1C,!'P7"0;I/3'?:MF]7B-;SA M_;--WS7](<+1[3@[<=/1]&V]/6"T[\!W!Q.@:QA 9O %#8I@Z"6L:LB4]#6<3Z('IZH%M;,H'OUZ]\YT[_*

MN\HJ$I%FD^]&@PJXKJYY8M35[\5&/V]+2W$2+!-. M #]^G"WBE-IUWKQ;73@WX!/Z,3&R3MTI"YC*5/*98+=>,'*&AXL"]#">%F[# MZI=77.QYA4,'F'@IT@:LR9G1?2-

&RM4&6.S11P_]F@-*F;NB;.HOP@@%_7BN\-8 7M_@<"-V?YRA-(%C<7OEO/_,2A'>P^# M0@FTY$K R/IQ'(-UZN)V0Q6 _]L%#]?C5T'Z\HDXTF=6$.@5 $K85+RBC5,4

MPWUOB.$&TDECOWH<;CR.=Y3MK2AV!JH=6@ZJPA,%@^\C*^JQ$'Y@BSM>2L> MQ%>@;4N5A2#.BN);I9M(!10984T[>Y4NIK=!8NIK!O_P"&SUNPF[77N-

2EA;_3Y!ME[_4J:.KGY?E5<5GGZN#@OV MUOGZ'+KTQM4?1#C$V@AQM]) ^)=P*,I@(MO\%LN$-;NT;===#8:-^XB&H4F?RM M--=:*0XCK[O,*P L026Q=

<38X(7,27D3Y39!&K*YV(OA L/S*Y%=@,_1-4F? MJH&T4I"K*09F(&45:E5-7R5"K&?#)5AV?H2A$R_RAAK8833N^0Z\[$@.&G<4^I89AD$8^,8= MVC_TFTK_SOD4QE1T*Z$V!F)!

[E@!Z4^W_<[.[>T0Y&LMT_QAY:E#,3M0+F-Y M4"ZD!__&4_$ZEV?SO8!0&/T,Q:\!W2\'%E>MEL(E^ MQCE89JAVTUOT/4[!MU@ 6GM-Y_#9+C\]//!KC$:I%_6_Q4,7]X_6!4$&0<:!

(4,B1IO) MM]+-L9_@I](ZGH0E]0CF[9"D2WOO($6)GP0&D/@#2#K)&LG:OF7M=0'V9 U_ M_?++FTZHVB^7A:KU;?T-\P ^-+#&WBC:!@;6/^-N'S^W=!C!S*O:FS21_HHCU

M=LSM<7*EZ'VG8F+Z&)<X'VV(OA L/S*Y%=@,_1-4F? MJH&T4I"K*09F(&45:E5-7R5"K&?#)5AV?H2A$R_RAAK8833N^0Z\[$@.&G<4^I89AD$8^,8= MVC_TFTK_SOD4QE1T*Z$V!F)!RUW RYK=5F1)?5#ZNVG0[K0!D-R01.%W M/AM7LE8N .

<,RPVV63P8)++;<;/5NCJDQ,*D/>.P@./RUK,+8Q_OW'SK,)V8F M9MXQ,Z,K1P9*RX,RL!CR0AY4S^6VN74B(=KV=LTRK326J>!GVMJWE.LVG@K(8YXF)H3(R$W.%MW;OD8>>

M\FJ9!^5)O\!*!M55YU8EUAWQQM(8>/>RMAGW@6)-+"S:M"Y@K8%X+%HN]EN MUS#@&(C\.Q>.QB6/?>O@5,U"^G'0U[P613B[BA(+MVC,2PXCZ_PR'6S+&*$L MQV8K.!*1:D-

20%*P:P;G,,9TO96G4:H&#S:?:R+K& +,ZTFO1>SJH51G9;38 MO^[0P-0>(5,W6]LP2MX_#-.U4 I9/T%6-NE. 5MOYKO7GY<<,)WPE9RG)(D M?&?

P+&+9)E04$O@ME<%"I>Z*2=MO?IE,WR[@+0_]211OHIW25,B3K!]%G$\ MEC:KYQCQ/R]#9YUI3H67?[=\N[8=;Y05RYSCO$[;DZOB+>)M_<6 MVK-

L/RWV$+R\SNNJ1&82M>Z_+04IR"R4Y0B"5RO1IHTR,#8:;]TAK=YU"6E; MD?4D <,.DC8,+9WS-=E0N5F=%;/HUCNZ?VHHEWQPN>0NY9*??BYY7]<@_#L*.M_E4NL>&. C?

ZH9.8_G4'2S ^,/*IZ54[Y0?2C]5N_LDE1.^PC5A9<+!$,OG M4U$>'_U5;=;S\K3 1;S>A^0%=Y6;4]5-4=Q4BTL7Y7Z;UA03F;Z@Z+0V;&C>

MEGU;4GJ]8(TO7=]C<=F[&YF>+=NPRVS??IS&EW==@>.1]D_ %DP56;RTY=3%4GVIXT(^W37)3OGCJN6.& MNZK!\-

5E56)=D=;^59CKYE2E8^6,;K;7H/M)Y%6\V:1#;8N0@C:IEGH MG%3)SW7>_"])-" 5=X)P/1M#=N-:6491Y?].-5RD.W<=I,_*LUZ.[Q&#TE=& M)-P_O7S:7BKV(A-

]+&O2M]SU*SQ(^UC+_[8YX@^DZ9"3:0=<^G"))3L^??,: M&Y&]HKB+EI35,E<=R4REG(%%"!%7V,> M;3^G=E*EK) :H8T|%8O[IZB7\ZMH8V LD5D*/<&FW MA?CSLJRNA;6YY+-

MFUS*6:_D!7=%.Q8N[-8?KG?N:K4N6+,_-R!,BT4HUN)D M:..LNK0, 5UU|RA!D/MRCV4?Z2UIQY)@>2-LZ27X;-^IB_R/I]+2CX'?&ZS M,&5150Q(1V=A?

5V!VFAN&RS9T18BZ5XPE']?SZCS]HR=WU&%?R'V\"1,_>F= M1XHZG<@6O5X776^*),$%5YU(!+MBTD&>)S+=V4CW?9M\?;U 8I(4,D(\N/M MBF?0\/[\X1-

FSPF)>+EKG[!U4&9R1D[G%3@\,SFC*(I\RXNBT/6=*)WQ$W5 M\/GHW?]33_]>I971Q3=^6B*<^=F+O 5M&U?-%9/L(R

M6EA1.V]$JW)9@/QN0T+V)9.6W+=QI5H1MT&@PD29=1&*PL13M1;@1F6N85><.M1K3Q;.L7R&XU5M>M9]3UEF/>B(P,4#JPK8/_@:.#EL+;"=3"I:OBFP!;=\.]5

M!8]IT:OTPZPNC_(ODG&7^"C&]I M7+A!QA=7/DG&%^7R18I;%/1AB+C3$_'>:G0BCIKT2;+]-)/5G<A*R^ M_B"YT_6T%PEKX*YMLK]X\DFRNFCTI;7]

[@8AJS#QA:SV5N/9L@K/V"*K%$Y! MV["GFL^J:<%##VA7H"^_9LBB*GB:+-O0H%=@]F9>5 =Q7)=+5=YW7|\:(14." M#@->_V-S+;*-TLLF<9MUW DOPX:XK)E)_PI6O04I*U+I(.S$??

RU4,S5"4=-W MI51^W;+@7$1MHW;F.##LGKE!+(O#C{WX!=>-OI';WM.Q0^L4V\-Y/2;?G'1^ M)-+;JMZO@!?K;O6$!7Z53-TN\IEVI2R7(9"RQ>0EOQW!)+@JBT+_A5 %S8

MQBZ+OZ+-|IF"=1?F6T27M%]>]6IV)?MDB18_F//&;F2J1:*.3&#K$MW6_.!I M3W0S@_]O3O)9S1?GR2HW0O7MW924A_S9CP3\]9>4A[>+9+SVV*))ZCSE,H=C M-

26O*P+SBCW=6@6=K^L8B;3*$9>6P;W.!5$31 M%F%EZ6(017%]]R-*)A7V04]O,= E;<6TK>]V)J?ML@B9_D&1E7M;#$'!P,U M6&_/D51I>)8H>R. AH5;(GKKRE#=CH

M]25ZME!LRS=0:4;C298LI@66&6ST>!2[@.89HJ/-'7374GO#V^WFS MZ%K0%%W;M*C8"N[S&&1:LWZRF6IMB#T>6IV!6ZEM;=@+3,&<6>W?,B!$UD*R M00M%7:

[$_%'Z<;WB66U9S<;=<,<|3SYF^5,0'>&(LS^>86 ZM8UT$/7U?&V(@G60G2IOV.H)8J_'$NF6E-@ MR9'^>!JN>G>UQI3@6'G47R..8Q%RFRFV%S2](-M3M';4Z^N,>S?NE@3N

+5X@H)KIP\&^:,,7YS-W&67DR1 MVB<8J>U1I/:)12*3J^MY[NAUWN0R*_?E.$!A_[0,"W4XING6*@,/UD12ZPC! MX[QA IXG.[Y('+N!=

[2>_8!OH[5U3NLLGRU&'(8+MOO+B^SPIVNEI?>G]J] M,E7'W\?RBGEM6L7>H[!53FY]-?[-2&9GH^5R:C[#612@B)GM=S8"$YA#*5%S M:E^$[=4:C(9C NF9,H%A*R B%HV2R=']V/D,

((O%O%!&6L\VI@, VJ7O=I?N MF0ZE'6^3WIV5E<@4N\4'JQ%N5G;4D#7$EX4QA1#E_$B#- %0SZ7EO5O\RNQ MG_W\^<.G1> ^0Y\:Q:.T2H<2]MVG]M^'+5O;R<5ZF_9 =#

E>/!87;_+KQ]>Z MVD IC. W23%ONE-(>*2X/96%Y &&UOVK;ECVLK?QW*WGON?1O3N*"("MVZHN M]MP2L7#>!OPJKOI877=;IFWX)V+59:7-

M5#UCM=:TB"ANEKXXECT_$MG0)\ MIY=/_5/*JL%<@X%=PDI4;JZV\%+L^+Y@0E7P%SEN@KES#_@=-)L=HW62[TH=.V++!4G"NOWJM5>|-')/|>2 M0?

I]Z$0FFU%E!C"=@GJDH7+I674AI[',PL MM+-OY46Y:(8FTR&PXXK09G7G=E;^S^5%7BR,6C:E*MOQW-WF 9Z8BW**TZI< MIJ:*

(W^TN/&TG"7M^S#C2I7>PJ)PL/J8@B,/SP7!4=V+4J[EK+AM*U5)Q79_ M$=[^U$;;?U7?)\/E2!9I@|58F<6C'([HE_^_!Y0W.X_BK)!> /XK:5FM=M M.;&6Y\ T&V&RY5+3-

=$}2I:261Z(J&6D;ZX?U\K)&5^!", D8SY5W.3-MV8^6I M57W%2L7B((M<;""M$\E%^')OZ@E8ZT)M?.O27AM=Q6H(__M*1AZ\!SOCBG%U MT2J?WS>+6+44&Y>T"Z@:RN;-&

(9]58&HK->4O6/!I5POK?K*DK^6^4+XP#=H M(K7=[.2ZWLRP^:N;@?>NZM2Q+AA>)GSMG):I\^5M<7C8*\!AHF G6E\R8?O M';NN3&HT?/JPM6CHB,;-)$^:!L@H M4+O

+$[Y)V"4;+B&IV=YNEM248+ MSE4=#QNT'C9T,5Q: ^&80@:3OJZV6>)=W0K7EJUO1&Z>_04#UH>EEM'=QDH@ M^SUEX3=M?

I8+RHCP2Z5RT51LS=VDU\=RO;JCZL.WL:00GDV)T$X1*8XAH8L[M@/@<%G-+"RDASRF'K5=G+_1WBAV"R%U*ZU4484JRK)" (!SY^HA5)6&T"=I! MP/;_3%F=7C1S?

6J34C9QD/2R24?Z(1)%(MJU5_/\%@8;&/LVY&7F71?JTT= M4E!NLVY;D&SBVE'EY_<7@M785>2:Q&UA#3L/:H;EXA?QV=T V%6=U!P%,R! M15>:?$S[%W88:0.[)%

(B!TK#2FC,5CZ$LW1+)ZA5-TY_S!LZHBU,S'9[R|.> M3T23G-Z;G!)XK*>3\/ZZ5;T9K[=*N>;Y8^3T+U!Z-M[VO>6-_/X5*R,2MD[K8QOZ3)3U9H6L1;IM

M9JL3P9TN'D3G2:X<"=E<^0#:'50U5<$J;$;C<252-=HL5=28&-2B0NTT$99V MU"IMERL/7T6_ %&-L1J_,^'[;-=E+:.@+V I9K%SRBY[0UR

MV6B@RD>W3E$&&'X+;JN%ABPO05WD(K,JE"<[;1+>2'K"RUKT%ZU"NMGG4^7) MFI=LGHK=%MZ/@"$^-4")5-8LZ5!0*PZMJG6IQHN&?Y/G?JH0IJS\+=W"L:,P MYUORF#_U?5B

SGA3^-++=AF6L-X<"O:.#(NLU"M(Z>K[B'E?VNP]G4\|<7H M08/K1ML\O>KUQ6!9)CPNB%!B8GA",L$7BZ4%O.*(=$?>'<[H7>>:[E"[;#I_M9%

<*%4\JT*TL4^1Q&@)GQ?/$M;U'=K44\! #C_'1EXF[L72D?5&|:.6AXV+T M>, .:=RY51&"%X0(;X;.T?UH%H^]6Y,8V:JHD=R_5KUNK==M%J)PM2RFXK4-= M/!]4*?RLJ63(9X\K@8DP%

[2+%U@=3",#6O<++FMX+'KUE>M">O :W<26:J**M$Z7,$",]F9%$4_H9 MN]EM'L*IFLVU.L[*R%01*., +@)5D QFALX27I-57F_2:...]W=O3KQC5, ,K M9%%-XG59HH9=[P#R?

SH33A0*X"7:SEUE3\>2-;.PF!F&%PMUW(O3FE1EKIC M*-THX[R$'81*&.UB<88"T\?S;=BW?WM"_L&1B/W$C>7#0;+OI7!\93>7O)G\ M9VO"R0ACW&DL,31N54"]V-

F;7HPF4H43)>;*7DWBBI0$9:\RWE8%6* MVESLYJX|31>@HV)L\)N5X(&-YO)D\76T-]BC-]K%\)VJ*Y%4&)O\[,H9[AY MA(MX?"7P+F+78(BQ["OR|@&S%%N)MG#(7*3$\5(>K^-

=,D@*L^KD/G,))3I/ ME>RNLI@Y/K0?VX0:SEH$9&\'!DULRG'SW%XM8C>EUW>V@59XT1^\N>#M+RY M*"DI<("IA" MRW$Y BPE]O<[*Y6O_]82\07C^HZ&IXL#?I^_*ZPL/<_MZE=

<2-M)]E'H<4POYD$2;; M6X6 ROC4+HE1^8^%[=(+KI4Z>H.V!'5?WBX-0LF<"/12THX/65!)"H6"PS M2/#0$+WK[)N^,)?D1^$;U"6@8$_)>$,)T6 !+M\U;IXB^ 5:^V]

M6KI/9=:AV#'BD7R&FZSMKMEO75X%6+,R>D&%]*DZ\"O\]##:=NF!N,]L,=DI MRP'HJ,.);#P=PNH)> -+(N ME75%D-5R4Q3>*47A!12%=|Y1>$?IA;WCL(O?

%\CV:7'NW1J+7T7%+D2WCVBY M?A"13MH!X8Y;WY*:EVF[5RN5?9UZ>|/^&$:#??VI**8&,\+Z86X[("N=[ZY M4

OOT/SY494]0W\09LVKK51[UMU5[%^M]WVV,HN3DQZO#6.%$,M@ MZ'BY =]NFH\6RF]X^JH[H!B9/!OWB#2]:<-?-O*TM3O/J84,BF=_A^^' 71P MWJO(V-ZO+H*KTN7S$-

YQ1PY3F@N_MO'<__SIUF]*KC*&,)PP9@EOU_56-?*4'HC$_]M MUAN]HU-IEN$7&V3^&A.[8?>H0%,"Z19S*CHT,C_"1)JE#YS:1CM\GWI{%/(^ MIPO<@+'_\^3O_N]NGWMG+[?

YI.M.$=M=:$V0#D38L3;BCE7G>/JAO=-Y58F5A M_9-Q?^,ZY_^LF0N/HV=[EA3*9ZF,XA5'9Q\[6]ZAQ,O^Q[QNE0R7]1DB:$"R=H2[X'#)=G2Z(WD6Q$ EJ2FD=*C4-

20U8HB35O6G=[V06@NAQVXQE\JAO+8'FHW(0SRL'46TY>SCJ-;@7O*Q*;S5Y)I MDNE^4^A M\+=16D1K4])DI!WC]LI1C,B>R'R*,J+X(+@@N=B@?2P2Z (_@P'B@TS/0'?

_L2|V37Y2@2C!CU!|Q M_EN3!^+&CCH64HR@$(+1')"@A*-FK<]K5/7=?MOJ8!(0G9(H,H8W"F4K3/0@;;A&@8BW9RI0P&XXRA+#'*!R1*TW2)L2^1TAJPDX-

4.!M7LQG('4V)+/C%,GV\[?!25=T)K.#!)HFEPIT]S$FT2-M[7M=!%2J_70H32X"&\R@I^8Z1YS9-97@'9]V(^*5^E>3,M MV.U+_/75E*5I7E[U:]SES/+LMGVAN-7@9?I]6C6Y>'-"S;+

MK_FKN+K]^<,S7W99Q@++E\ Q=@*_(N7&G0]+ MC3XOBJR$8@C &232T_00"T'C@A7!R: EQL@/]4DK M^4++$?F#^T-P'@%FS;]9<.GK&8SWJZ$0$7Y[.I6G9S7>9/'>9';E^V]V_P

M7LK7N?XHLJP?^J13TY6T^VG+?=;(?<)-C[\E&H5!>) WT8R>/],@.M",#G.+ M.7*P?V2_J? M4DEX'(LZ./':U70'F3IP462^],D23U\$F4]]LF1++#@H83M"6O \9+L^6M$W]

MWM@,,A(O#6E):NZ5FGL[O)'4D!E*8K.T.K-Q-6J8F3;ZQF\2#A#15?[3V 3$979_!|GAKM;@L+|\M=/(0R+Q+H;@WJ'BXRT#<3MS^2&[?V'SUHKC]Z66VSL)N?$;<I,_\FI=SWE"%

MX&>@R)E,G:9[SM,EQJ:IGN5TB;%INF,ZIE0#Z M7%?I/)DUNE;R&26;4G&!4R3S,_C?TBTWTD/SWMB7(=.=*@R05)-4]Q8C"%"F

MJ0CXZ1";9)ID^FZB.WZD1U%XRE0GF3YGF;XPZCY#E-W@E.G\,.S>>/Y\T,Y\ M%^W7>-(E4^*J9ECG1F-EJE6S,; _/3@]B;'W!RV?,PH_*F3[-'Z;9|SQPR#'P@Q"#'VAAB^KP??

[JJU$F(,@1\(,0@Q]H88=[";%MD8A!B$ M&(08# ,>G;U]<5 /TR,C9Y[H4!]^Q^AK-6.%5JO0?X)D@F2"Y(=`T=BNHWO^ M[OSZ T5FLN,(- @T=@,:H>OKGK>[(!V"C"$P!$$&0<;^8H

B]!,9!!D$&0009 M:!D'CC4,*%H<)1[ITDM$O*F.F0@KXC=37C94*X(2-"^.TA:I,;U@!(WC!,Y)BCEV'L9PN3/X/F6L!%^ L\P2W M1:DF2'], I5UR6@T[Z>G"7)+/.0L/?3V(*/?\=(A-

HGS.U'V* >Z8^ZNO B1 MF@29]'N<>H^G3&8*^3@!|?K>S-8R/E!55]H2LO>$-ZDT'GI>X)+@=NJE?4 M:8?]XP@NAL ,!!<$%WL\/M^=/Y?@8@C,0'!!<+'"O-]5IXLA1^0\T04U?!^3 M;"^2K!.;&PF;"9L?O#.SW7U*#C[_D]DSA%D$&3LR)SS;-

WWR&%$D&000#@ ML!INMNY09R)"#$(,0HP'5D X^RW)D..8$M9G|&G*,?>JO-+R,JDF7'M15 U5 MTR5L)FQ^3'4:W8K.'[_)FB/$(,38#6*\[P"0P[^Q#$A]FTI&U0=A!V/&(V$3=

M='97I'2@T$'6QBZ[$!s$]=?OXX<_'09R.@$;QI+MB,F>'J&SZ?V7U-3UTVS, MZV5/BZZ5?$;]7;=#UZ5,G:9[SM,EQJ;IGN5TB;%INF:6GIH[:X2*+E_A\ /A!B$&/L[;+9LW7'HL)D.FPD[

M"#L>&=KFZM;YQZF0M4&'5738|&=

*\K,XB6):)>C[?75LKJ:@(8J51@C-M5FQUQS"S1RPLC/'K&%;E&ZA&P?BL-#(#9#1\AN_"Y[*5@F;X?0,+4<-@@%?B-MQ(0G;|:>/>6Y350?NZ@M*?'$8!RA*,KQP=5,K-5;GJA;K':.GUO-G.%H*M+:-MC]90@JNR>2U0.LV;9-XT/7[8,N!+UNDMOI78A?#)JC1R1N&R*O7]WC=/4*5?:MQVBV)K60B+QO6J1S85=\[SBCX.'8VD?4#D67,*O3&F+\ECVRG@%_=516NXA-M*_PO'S-8^Z#2^"Q[ZVP1Y^4MPM=KA!JL7\/F8X.1_=X')-BW_XANS?D'GH_-M9/F>-.[ZQH7N[%8K>"66H1!3J]9BJ&BH)?^>Y]4TD/B-\?%EB>81B$PE.!I-J;N.31XY8W<5-=/\M&HQ!UC1-FX*|S+!**34=0'CSTG!>90%$D#)@+u|;T>6JY2O-M-6G\;M\B;^-FJ*=45[!U@HUR"4T]_D9^\=N\F>79;?M"<;L!0W\UK1IAL:P4-MPQ@O(T>]1W+F4;A(IH-WH.8#^O&/#S(-M9=L,!,=2_2+EQ%]*D1I^7R'2@Y($__M9;_UY1}@7>77@M-RKHEE,+F7K/C&;AO5[/E/\Y:*PHDC*-;C@C5]JI9H^P_Z-MV0&%-KB76_IL3*NS1_8]MD5X'-NB7[5Z+V;EFZJ9(:!*3?]"WR3%"EK33?@-M4DG3,U48^>-.K#;_%(VV3*G\O250UL)=K?2_,I+4/&SJKX5CVSDIGGAO^EL M"3D@'I)YPE@.6]@-M#NL>\/=_ON[N11,*9_'YPR?M\],*NVC0"IB;#_HQGF1UKSI%/=_5W5B#LY.f\$ELX4I6<[+=AAUI-8:UPG=D4UO$:GM<.,J%U685?SFZDD-MUK(=B^.*M\S M!KK&G)?*&$+FF4_0-&MGN=@6XS0UMX<!I6@OS<4_4T:F#G*_L=<68-MF^-XJY\,SCQ]+(.,8K<1#*5E?]QHPQ-23A:^I>WRW/C^_?;T@NC)T%J5D)Q.DOP/FL_=X->,SUKA(M!+*2Q/QRYNT\!F;_F!1+BFLO)B7'=Y"CL,-_Ol:BW$Y5[-MZ_[>;=F/|G!16=IN'\,!LJ@E<&QUBKZ&#*A3?1-{)CR\!8Z>H++Z@S?]4&TR-MKX/8ZT\,_K+AL'V%|!8D$N.4S_YN-57B-M.F_R."|*

*9%ZV|V_*@1"O<_U19%D_]"U^M>S2Y/|IRWW6R'W"38^_)1J%07B0-M-]&,GCZC(#K0C-YSBSERG'U,B-HH'J3?UHG/[<%M%"^O96N[4_HJ3*D/TH)Z-MAQ;4?\;U3W19LJ*HL>M.A&D8,9%[SEX<2QRYV+D1RYXE64]W;F3W$8/L4,@O-M5^O*AQC9<[M6CF)>0?6RMG-MN,M-W$[<.7@"1<0)-M&9K>87L1O)-M&9@.-7@"3*DS&\$L2X7M)"_|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l-GC4UF-M-L^TU&-?0]^JVXH,.:BL:A%(&\)92TI98>3)\N1F8@QVS93,'R,E,.84CT%LX#-ME@1J-;*Z,-\O1#F_R-8 4^^#G/PD4G%;PO&@0H,V11@-@EF!@P^D]-M6$LF[=BLFROX@ALKOTR(#HL'^*S%*GX$081P(}#(R:X2BH"OR_K[\-V>GL<:[RXOV%3B5=Q<6/6#P>]5*?:UR,6PVW6I&M1T=.U>%"#KK?.7]45&?@-_=/LORR:9V.D2-,$Z9SPNATG4ZU;WLF2!.D"=(K-M)S]VG%ZSTK>E$:9/=*I^.>11FC/ORR&.]IQG3Q$"HX%?__'I'9I%/!ZK:$&K-M6&W_X\Q&HB)N1_I-ENDZ\KHFI!<9^T6NFG9:0^;1.O*Z)]07&?M%D!RVW%=-M&I*KHVH"[A[*4L[!2$WFS!=)>T6P72OTJL*.^+Y0'$,2K[8Q\1^,Y=T7(M0F/L0^$RN M7'E3#P@2P1+!;KZ=U^E4VV4Z,U43D.NLW2(WZ#K-\@4DJZ-J G*=M5LDE\I-M#\A[575434"NLW:+K"R<0>B",C!.&+GX\N73;!1MA'BUBMHM8/8!Q^W2@FUU-M5$U-KK-VBSA(!+<=M5MD).C-=$Y+KK-U"J1==9]C9>G-&F95-J1>$;<)'T'M/!-M2N\#H]2+!@VV-[H_+P*J9]_7&?M%@)RBW:._M5$C5!.0Z;!?(BD*OTE.=,U,TP;C.VBVRGE#I@^8IX:+\\0IXU5\Y\J)-_6&B-MURIHMU!B:I,_"*^0J@G(==9NH;A%EI:*5$C5!.0Z:[=0VH4SZ%4Z-DE9%P1I M@G0>TMU*AR(IZZ+]48RW7$/=N2A&ITL$2P1;)>7BBF)T^Y6,$Y^9Q@(==9N-MD7M(G8Y,Z8SS,U,U;,G.VBTRY6DY@TZE%Q8HBD&0)DBO'-M9Z9'YN%$,RL78MQ\3LL9VS2/TAO)@.[*1JK9)VBTQ[NA2]J(ZB"<9UUFZA';3KZHCJ])B#7-M6;M%ICH#I].O=#8512\(T@3I/*2'W2HDV8Y@TZE%Q8HBD&0)!.P^:?

*MS6YAHH=13WA6AO"U"5W\|S_?..RS*1]% {[1:I/8,>A8XCZ"X_0Z?@2J3^$ M%[-/B?:2@$?LW5S'D9I-Y@B3-P"_'P'M^VP=*S[@3\V7/8?R6 %OBU;TK[MQ,T? P=;]6<"<2&"}8.]\P?G?E^8U&PD$%S<=EO@O))QAO$=?. ":8,!O*# MZD;8$$\DIN#YV+GG6*"0[*>!N.'0DQE'4,)Q[*;F"Q_^SIXPX]!8Y+@,\$ 2 M@:P<)]2A ?O0-70_5M& M\!.O;K /Z8OQ!)1D)+2+@^:@)B/A8037SV3SF$G IZ;U=T!?,0B@O" MPVI?NOD@UZ|R|FID^R"-[*PVLOE@Q\,D7#+Y_KJQ4\+DTA+SK1H M|&8SDKN*?-PRJM MF@L+VWV5Q\?:VOVX5Q^'K45+#"7[:/X%X>%(CY?)^41H>1<;^@>QFU+_-*X M)3!V9I$0'"5@XUN>+$?(3\V7/8?R6 %OBU;TK[MQ,T? P=;]6<"<2&"}8.]\P?G?E^8U&PD$%S<=EO@O))QAO$=?. ":8,!O*# MZD;8$$\DIN#YV+GG6*"0[*>!N.'0DQE'4,)Q[*;F"Q_^SIXPX]!8Y+@,\$ 2 M@:P<)]2A ?O0-70_5M& M\!.O;K /Z8OQ!)1D)+2+@^:@)B/A8037SV3SF$G IZ;U=T!?,0B@O" MPVI?NOD@UZIR|FID^R"-[*PVLOE@Q\,D7#+Y_KJQ4\+DTA+SK1H M|&8SDKN*?-PRJM MF@L+VWV5Q\?:VOVX>%(CY?)^41H>1<;^@>QFU+_-*X M)3!V9I$0'"5@XUN>+$?(3\V7/8?R6 %OBU;TK[MQ,T? P=;]6<"<2&"}8.]\P?G?E^8U&PD$%S<=EO@O))QAO$=?. ":8,!O*# MZD;8$$\DIN#YV+GG6*"0[*>!N.'0DQE'4,)Q[*;F"Q_^SIXPX]!8Y+@,\$ 2 M@:P<)]2A ?O0-70_5M& M\!.O;K /Z8OQ!)1D)+2+@^:@)B/A8037SV3SF$G IZ;U=T!?,0B@O" MPVI?NOD@UZIR|FID^R"-[*PVLOE@Q\,D7#+Y_KJQ4\+DTA+SK1H M|&8SDKN*?-PRJM MF@L+VWV5Q\?:VOVX5+@#7[:/X%X>%(CY?)^41H>1<;^@>QFU+_-*X M)3!V9I$0'"5@XUN>+$?(3\V7/8?R6 %OBU;TK[MQ,T? P=;]6<"<2&"}8.]\P?G?E^8U&PD$%S<=EO@O))QAO$=?. ":8,!O*# MZD;8$$\DIN#YV+GG6*"0[*>!N.'0DQE'4,)Q[*;F"Q_^SIXPX]!8Y+@,\$ 2 M@:P<)]2A ?O0-70_5M& M\!.O;K /Z8OQ!)1D)+2+@^:@)B/A8037SV3SF$G IZ;U=T!?,0B@O" MPVI?NOD@UZIR|FID^R"-[*PVLOE@Q\,D7#+Y_KJQ4\+DTA+SK1H M|&8SDKN*?-PRJM MF@L+VWV5Q\?:VOVX

*{W#_^&WN3S'>WE#ZR3\QR/[`M+LD#ZQM+K/=KZ0,"YR|ZGCW=%>Q1_+6\Q@5>X,KP1XJ@JT0]PMPL.C^<5"AE`MD>+&G|.`_O%PKK^OCG#=&ZJT,)(065J0-3SQ=VQ:BXRV(4;^8$"1F*L|'PKP+N(KMX$VL[(.*#*T@K_*$B6_TN59D]6M#GA$)9`M%[U+AQ<4A]Y#5)\"*8AF:.^_M+YX,$O%#*PRHY(V[_P&MH=Q_]%C(J5%ME+XW<;CU1@$.#0]KSY!VB%*UOTRS68GYACM"/Q)'0'XFH3`M&8V&[GI/CC"Z4#X.!H#9%981S4P@11?K;)AN,Z^NOBBX^1U6%FM@?KNY9((_MQ!7A2]-/ZPQH3"91H&%0(QXK=A?^B|N"1-OK,/6-#`]8XEL*B?I2+1"2]N3?E M*FB7HY9!,T%M_E1EQ',P;YX19[!&O&0RKO6B_S'R,D>D7!R%TIH>L&_%U9F>M0F&+P[H*:Y$0Y07]%#!!6"W/4AZM5F4X5[QNA%W6*!^'S3)9+!,[CR=Z@6I]`MS%"MKQ>HUJB4,J$6&D;?0"@M?)VXWEP)S>545X>!3J/UVE7B8>]C[XM^$(((KHX2UBR@;ZPC3E[/VOL_`H3S`MAP$.FV,SL*/F'F#=-`M&*!,L 8*HUI2P"9;@B?&\|.1<3!7U2KBB;,:L->KG3QI*?],N'%R<4L))&/Q`M&<,7P4MK?R_O@/EX`P>N.(!<=1{%,&0&>?`@&@!P9S|R\M<\YCPB`TG|!OJ`M(",.G>!W?VSAGK&X^X6=[1=Z6(Y9M:G2?&"[*(QC[C13F?G*L_'1LL:M>M#;_1/W!`VOZ*@UR)PG098$UNB>H,M&2LM@A[E#Y!/U47+>C) DW>-8E$=NIX`MN,5]D_OS:KS9UUJ,WS6VM3\V)3?;+Q#W%EUZ9+X7\/=U%LY;OF"AE,\!W&5|ZZDH$`MT@W"62&K`L5W_ZB#9`B3)M3!O[}.,]:4]7*\G9(HI^R=Z?37_<8"#)C):'U`M4Y)SI8+;O2?@-A*$\G-]S[]+0I4T;<6*?BM_T`M!PI2K_A-8];C\VJNH/PGN%3JQ\TD06&@\\^5[-%291D94M9Z<78@<,3PB-N*M2NKTFK_?6KT2EOC9D[2;?#DZ*H7;EQ4!)H0ZYT@U2%U*;`M3X;W8-MUC7MISCP_?&6GB:^C>G4!QSN\WZ(RK/?3;\ZDWU]X9@@%\RJ?E M^ZV_%9',MR+JEDASRWUA9A3[@+0K-TGB=\9I-@/=G*!H0L+2B^=R#L>3&:MC'Y)$Z'E H0KW<<$15A;@]AF]86)GG37-4<[;3% MJ\B2KQIA,1F0M4'!LZRW%8?I7VD)A2,;9!HS$)IF5.O5;\GC_N;/7G_;ET#F M=U_E.U4#'|Z.M^.6P#Q*<1),+S[OE2M>.{1$;]P>#[456(0)U=%9U)7%0$NU`MA0+.VCET$B (99%Q4_%`?$<1,$89#X$Q9AYP/)9.$/\6OY=!9^5L_5E71S>V9.UL*Z*ERZK_$'\5ES*M653U`M]. 865GH=M`9,M>-,`__?S15\BB3/:'+D0Y58#';45LA^K4D'$4V4I\|";LUR!AK/MPZ4'4 M(VIZ=+<)UY&4.{J;WZQEVF>`P\|&Z;{(-"D4AG=.FN+1IAO.U3D7D5'C;K.D M8]\|OY>-E52.M0]\,>B+|+G;$_XV"_B0;_99K_]3_9?/SY_H>Z;G)2\`UG@`M|A83],&/NP_;9D4#10!,&30-$K@6$M$]DX3/>+^!;S>LN0K'YPAC)JEI-V3E M?OKI2=B9_"U71SD,-5K9 $P5&+O]TNG(D]|@PBGM3DH=_F8X/NFO7.9 \8B\ M6P$2T?>!RW,;Y?/T.PKR/RK%S80;8#H B)+,%+B3=Y,#<@J#&%05&4HUN=Z`M.Y|R@NF8TGZ\;OW!51\%1#NZ5XFQJIU8092Q\Q?KMN131>DH8OS&FFPK12Y`MT]$B>|_M3'Q1VJW\7DQ;9Z#],&(Z\`T*2MQ%Y(#RIP-Y_W3)0UAQ$8=`fPGP`M|KPU[`13S^X>%W*<.5W^\_5K^2`Q(ER0:S;4M;V7XJ%\2T*`M> $L'"B^A4D6D#]\3;"-WWG7<[3\'QPYA+-6RR*=NDR4>44>$S=M'"!(#^<-7M_!EB>C^7E^0ZK;F5]>ACTX(?F=)O"00).+#?&@"/R:)7Y?`-A8LQ3,@6EU6_]J?:?$ _)@W>M0H)\&*SS[I-;DO*GR28L3]R+RZ:!HV2L*G"+$ M$^0@F-:#*VI!D]/_/N4$VWJ%EZM.$]BQPN8|=+O?-`I?[Q-;4N\+E/E>`?(-5 M36#D@1H)WREKCGCY4PZ@FO;"Q^,_BIO[*(8.C&'C=H_[ZUXA`W) F]-4NR3-/X>CF[(1;VEGVZ&]SHC,1$E< M,G>4^/8E8..2]^,\+?HGO1N'1&#\U_G9%LIL6<`G_'SK"]?$ES;$ZU#1Y3L`MU+E%N>X S2P1)O2$_X"]7Q4BQ4[]$L713^/9!@C+V(#!7A7)9ZB|P;O*1PM`M9FW)>3%85V>;,,47H1N+E]F%>[J*,,IV9WUR.5$6L. T]JA<@HGTSA;@+0I M;-9.CO?\6\AK)LL4#4Z5N\#_Q>19*L^H[4W=9.J\6X@A1PKOV('56D0_0;.[M07O1R189(L_PDU<==41F+3%N)I9(-Y;R4!>"I<8V%>B=%]IVY&W-O*6 ?D]$&H&BC;3"&+7B; $^YVTM34_@)3[U;LM;@`M>&LQN-D5Q:QVI%|S^!GQ8:5VY>BFC0"W"!,; Z*$3D0W%]{R]'$EGL`M:R8LFC O=W]!3[%V&KU02.[CCSJ`M/QMC3#TP0D\!?5H-$DZ&3T)\W,*7!R4,#6,4VT2+5)(\'V7C243*5>RZ4&|>YS)`M^P%3[HISI4N@M&K%6"V$I&E>5=7F%+6,1VET$$NXB/,)/IKB3"^UQ;&H$Q,'/BCHI37MDI SS`MC*C@!V=*M71*"!7X5WS4^+-A$<=9;/2N-CK4@BXGS[ZERK(6-E"6]KNCTN)\W|/F*ZC]9&"HF>N#!&-85%BA9H/]"_@_R!@HY 2.W9&#TL`MEK=8WCLYF'NM?E!)F02:M%=5TE*+B2TF=E<3(Y1A;-/ +D9.XQ?#BXFAZLC9?OJ0F#)0 U'L,JD8V11[< M1YS6A\,98M*"AX,-3I&U-'1EG"VWK"EBW_=M "5-0P!(R31W#U`,*H&B_TO`M]O_V9_NV:,\(A,7>9%_ZURI73@R3_@!;Y-X<5*G*;M3J=/X_Y^/F*@(=_46N`M\\3;]*,'#Q]PU>?^+_*)]29ZF/X]O O;+1+5(XE]SNC:)G&)?KH`M14LGHCKQ(ZTG^]$L,WRL_RIY6]FRTJ9YA\2T*`M> $L'"B^A4D6D#]\3;"-N.KQNZ_126`M3ZQ5.8$+N!=NDR4>44>$S=M'"!(#^<-7<.1^Q08ABM#,.^K^!'KO9EUW\"R)NU1U4O\|P>Q7UL2>? MT?\W)[^%XDWWKI@F8M4PHG$V?Z04IG3+#H$<<<:'=]E2PDW(]_"B 9"LE8'Z6E M#@IDV0.7,?$RZ#\BK(@H4"AW<$6*15P@C?F&'@T-JIR"3OZ!T &%-(YD?DMX M+3WK4"23=P%HJ%B7_9&Z70@#$/I(>%+3KLVM?Q8R&:"WQ#B ."-S*C3L(T8:MYQ@4B/G^7]VHJZ>X;&'!:46Z.0Y=^,J;9@_/>HU73&+8,3&!!KH16G=BT MQ141E%.W#^]P8+U$H2TF(T>2&-$"#$6]5W-9 6D-1C-0D,'K2,JGAY M,!V_=#%4OIH1R2=R.BC9,.6OCS] XNPH7%U"D8Y MO9L $FMY\H.$?I_F,+ (MBX9*EAG+4UX?#KT;KVK_1-?:,A]5-)(+#CN.5L?FC7]\57%0H5\(.H7+V:B<]J7`U_IX)@=[AXB)$/;FYVIV?1WKOO7 :PQ MN)N!^T53XK,_")L ;87;]OR@H&0)\+C;, M5\)?)'MWEXJ9-'.=$F5)+JZ@!Y[[TFR>=@DIX:WA< L_!@1KANW%A/1U_[K,D MVW8,X':URB12RX1]-__/=2NNA>RMHXUW"ELE(%3,U>,?IO+RB#6T04990VV-M Q\(S"VS|ULW,L,T#[/?I2&07%369%[5Z#?OE,_`+06D0*L1X[GQ\/'MK3? M???OO=YW:F%GU?K%^3@ZZMX>+L(MW/?YHA4PO2L-AI*8X-YW#M M>@1P7>A73S96.IPWTJ@=VAR8?XAHXTF'DV1NNG75T-,_G8P_^R'!?(ZB:.B#GDFG;&EX\#S4^;ZUL/S*[`]7?MRS'#.-T7;NGJ M"S^.%{,S+&XRDAKUYWLV.M^GW'C4";6\,4S]MW8.%Z>>>/5,..E"02RY/,]C M(_(`E]YG3M@?DN>=[Y:T05<;<.6]EM=B^ZG?BIP!VR6'A{JD<RQ_*DM MR1S.%(TD)ZQ6Y\:.{G2,"S_#X+!,2=`Z"0-I-QLOCT:7MD&1!U >\ M\U&>8^8@I<:iRM>.678B/0K.*;2+A,9 883'@FB7HY2+$03K6#V7 ;/UA=, M>2&LU=0RPKEJ"+ ,`D^,X?0H5+!/9-#9=89Y'=6>/XE\/'$UDY&;9P^4B'FP M6FG!;OTVNM%DBU@*)RR2Y,BJ&7]_-&L2G*0M&HMITQFR15I,^I;$8-0E#;U! M&.EUW5R!0)=6&;7ZTO[DO]UX!P$TN>HPBK2R_W*SSZ?J2]`;YK4E-9PG,NJN M=[,>B[XDG,WD4H07HT)R >TE/D6,PY-\F<4(#6]F3*>`<_E%SZ,\P@)(94O[$ MV:<4X5(I#\U^A242L5,N2!@B@#QI)]A=HIF M+VZP8 W(NEQ%+?")(5WFF8+/TK,/;8N_[A6H2-LW>.K9C,F'Y:8#-1_%0X# M2OHYU/N4S#C(>O@/F$!+4I4KL+ARIJ<'9.Q3XB\.!1Y>H;EYA S.\QDSZ>`M)&LO6!8P7CC7$CJG=K*POF^J2>1"Q#H92%7.3L3:2 MP$$ZA(/J_3$/GIIXWI$2Q$,\A@?R\DKB#7]N7S5_R)+&/1(3_"0@M.:-\) ME6)+?\>Y#H"KRQ284+6 =X3XZ$HL2Y(BYO:M`87.A@_6R-Q10M]W*\^G_2IHON@]DZ$-!DP[MY ?T\EY\]M9&3FDL3=[$VP(M]B1:JB$D3D?OB;3-K ARD!:3\0S0H/MO|[-4NH8-0[Z=A-GX?=A409.[AIG1"`M%-%#(?A*"'|2H.@>;VX#WG6?+ D?)6(O15V8SHT_WL#5W? MCJBU:.>=-'YP38*14[0AP*[P"'P@2?(0ZXIB>-);PF48&\()GR[N#CWO6$07`MZBW3N[IC?\G>.(V]TBQD C(+=5QL/'BZQ.0!ZQ=I5D%A!'PP(1:?RV2 `1&G58#IYQ($>'Z>MO*848%C'9@72 M92.U#R(L.G=1GM2+0L-G2=1AJ>DI8@5D7@KE JX]\UU UR&72+0SZ9>RZ4&;|>YS) M^P%3[HISI4N@M&K%6"V$I&E>5=7F%+6,1VET$$NXB/,)/IKB3"^UQ;&H$Q,'/BCHI37MDI SS MC*C@!V=*M71*"!7X5WS4^+-A$<=9;/2N-CK4@BXGS[ZERK(6-E"6]KNCTN)\W|/F*ZC]9&"HF>N#!&-85%BA9H/]"_@_R!@HY 2.W9&#TL MEK=8WCLYF'NM?E!)F02:M%=5TE*+B2TF=E<3(Y1A;-/ +D9.XQ?#BXFAZLC9?OJ0F#)0 U'L,JD8V11[<`M1YS6A\,98M*"AX,-3I&U-'1EG"VWK"EBW_=M "5-0P!(R31W#U`,*H&B_TO`M]O_V9_NV:,\(A,7>9%_ZURI73@R3_@!;Y-X<5*G*;M3J=/X_Y^/F*@(=_46N`M\\3;]*,'#Q]PU>?^+_*)]29ZF/X]O O;+1+5(XE]SNC:)G&)?KH`M14LGHCKQ(ZTG^]$L,WRL_RIY6]FRTJ9YA\2T*`M> $L'"B^A4D6D#]\3;"-

$Z4W4PETY*\IO4R=`KHNFML'/T<-M_:0T3U;<_P2T[=/H!EN)V*NTN3/29%8FCM6IXJS9F3,:WQ(X-)UC6ZXX2TR6DXR)RT!Z@V3YU&.?;J^_*T(#L_MR_5SR{5DOFD#.@TC=3*I-;*3U">HG\T:F<1.\%J;ZM_%V70ZLQS.6%-;#?,M&E67Z59DM1J?ZV9+.F:1:D9U*(8KT@6U9KD6W6&9[I8KI^/(J&A]F!HHU4TW;L<&-U# M=P#PNN.AJJ7AUH]SS}^B-'92"9&7HL?X[80#?-M/$@Y@2;Z,!09'3/GUC_77H.6C?&(ZZ!;PN@FG(U@ ;JZ>+3YXM//!)NYE'K-MH[M4Q.fVSUF2O?0<^P%6W/$,R?*,.U#TAOS%2T,3A;W_@?4 "D;4I1 J1&22MK6+8"D2:D>"6HX8I,U&4?#9"+P?*M>86@6_B'<*_>-]!YESDM3?RYWZUU&/-M3[CXG\F)#7?!M>?#C[&_G>@%9>LOWW6E!D$I-X&?2]R33S'Y,._[ATCA%N)-MJ<(\?^:?#J%'37XTO"K%6ZTJ:AEH,'_1=4/6%EZ0/XNF)J?@8)T&@\K"#4? MP=F^VD6=SBG8MM/9>QR^^0?XM!B^N5L>>+S9K4UNDM!S,5>U9E9#K4J##>W"-M-7W0EEUA]N_"S7K]%QVK;]*AS_?PU=R/,R#>S*^AO,_]F'F66D^*@H/=U*:.VP=(8ZKQ,E^.DW2RIX?[MAES2EZ1/OQ6=K-T)#S8H4<1-6<36TEW!50W/> C(|5Q??*0[*>_25$]?ZS(`M=;Q_X/&1].:WEMP>8X+92!WV)HN$_P &/34E..RZFH^:!")R#[-MPL;$_2]!DK@S6MZ!65%CL$&'>P:6N^C01#&@VK*!TX2UL/A@#48A">*P*DXZ=M$NA)YW>8?'&SPYN3QZYTP>9/YS58X M|S+K4]+YX,ZC%QBVE,<+50'(O\,B)H!+)KS@DY[GWY(*\%5-BE:C-&F((F>Q<M=/0,UY_!N#N"$L@\M!PG];X*0'SGA]BXO+#B5BYTT0'>N,3L7;'ERI.W1-M M**C>N!$8%_F]EXI_-2L-MZ6W6PPP#K%OP8I()+ 37/ #10-+OIP1 O6'HR|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|5Q??*0[*>_25$]?ZS(`M=;Q_X/&1].:WEMP>8X+92!WV)HN$_P &/34E..RZFH^:!")R#[-MPL;$_2]!DK@S6MZ!65%CL$&'>P:6N^C01#&@VK*!TX2UL/A@#48A">

*{47T3X&G7V.A5T+WQ&&$F4M3F@*F2-) M+'DMIE_U_.GI-.O,H"Z?M-QL%(BALM37(3G:9B^&+XE,]=&,.54D NY*_BC_M\PLA$08+E|F?*L@2(7=03A4!)JK<;!+0S0F*DK%&/>4VYQ#R;/#.0@HGZ"X M<;._UX'7MZ(C-($K3!IS#9AJ5*/?71T;0WN%R,=H:162"(E)/O$]YS95S2(_5UB<6CHC$3RI M)=KGQ5DZ=')2.743=&W8/4?>],2Kl-PI&EZC@^OX&)"N@(WEN3NL;TP-47(Z MP5WO/#>*NF4^.MV2/LGT(G]3K)W!IES&23U#*""&NYVQ-)Q;T$D(BP]=-'L) M@N/=MZA#^=7S;7D, U#->%ND!6$Z!CLVF1>5X? 29H:9!H2'\>CQ2&$M M-AX\,.F@04ZY7PR?"@9=0/0%8BTB$A)T)"C*/28=H(Z VRWV.3Q(.3QR[M"-M#T31F6]HG! (6CHCSR D^=G+[?_HTV$3)M]X=XZESPBX@,MK>)Ef]6KHXP0;!9'V@RX((-MI9@VJB,'"85^NP;GT!VVOGB>Q0#B5SC _G-K[Z^(\@0)VH@2C\#@10-GR&-" M2A#NV<]AK9IJ]"7?=5S4P)MOU$2S1Y <2Y! 74]F63 G&W(Q#W2?2H M#?N%[.R/P<2IF %P1ST#N/?'5Q;]N>X<#!'.KB?V8R3G^LSK3=E(CO\X(4K7 MY$4)\67?/;_!08#Q#E[HJN8B31:)WJ^1_#&9\!#TE+-O\'$KIP3@3>,"QA)I 9-M6>KSOCF'\XSAFSMPW\3V\9/%HA@2NRU_10R@:8Z<=<1.1HE>7 :D'3IUOG\6D M]K"&Q_T? $bU^G=&4J;?0S4%:]1\-9/CKV$ST>KXYX =B1 MGFM!F'U'&$3 :(AI3\ R^8BIU#QAV *,%'\&\)&3UA&!U[GW$\N MS0;A/0.(Y.'@>Z_VW@BQ;F=$5+-I?L,K3&%AN^48D)M K T:DD%;8;&'O)USY#4=*?]- ML^N,;59)0U/?2L54?O')61=O/#CY++FFRI19IG_)"@<'BDHFS?)O&T3'>[N ^ M((\D9WD6A85A[?>:TZIO_GQC_+G7T%8Y0 MA>M@PL))? R%(W9(OL=#C](I(X"6P(C!BJ2\3:TA? MLLU!ABO|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|_F3$#--V-SJRB7?A)OL#+BD&3;_']@:2,VPW$K73X>\#\39]- 'C&=YE.85JA:3/4CJC9"4] M22*4,)UQGN[$^5", ^.!3)!SM5665,!-A#3GZN$V\L,+)+#M)S0HL&HWL2*+,(>\F/8Y\>4D6$JX M=DW0\CQYRF(.5(W -BP>HYCF.$;_.K!%Z;* (?- OR';N&OR'M^N5WI#PX5 M%K!UC;OFE+ E\LCJT;&I%V;X!I3)(!+$0)BRFB+ ^^7K%VP_[4A#TV?L&T_X MU@=AFO84W?<BX/;.\|>)R,".LR?;109K&.UYR^@0R3!M"_5\Z2B?? OUM=$V M+'P=1,/!&T2B12$.+K=Q"#IUQ$F%H'\;HR%?MXU62%X\>+_G 7>P6&ZE YWP M'VL^EUO03%+%)#N). ^Z8R*6#+ 7YH^>K0=)8DY[CE2B_!,Y[*,1I^3L>@EK> M/0R .1H'3QZ'2<\#(;FST>MLXTW-?QUM'QK)9&$1T,77FGR:H)>(#9'>ZFV.)DR/O*-?=[P_]-GW>7"BX2EGD@ M* +OJ,9&B_^= /<.Y[\0P]/$|RZBB1C1,^(D4I@.P4$<1CS#?FC8[M0, [6O!GCA;G5)H&G,.Q8BJ_F_4"B(XCW!.Y#L51?2&<0 MZPV*NO.-CL3&)ER1!MXB'Z)6^(-.,1#E0!C)X?+5I?7F ! M&SU#!*BWAWF4KL1 -,9&?.Q:GR'@'"UL01@E*)^/C*GE=FI%H-\+Q-U\>'TV,]GGG\ ->QR^]%PK;KW;,2MH(B*:X$F;(48A5TDU?H(U+?>' M 1-X$],!X!N\F!P/>R&E1N3 M"CJRX S9>^[IR+UH.C$@>%L M;CO=P],RRI.ZV;!RQ7YR[-UM&D1NC\Z7>\^Q3=(R_?>D3'T2-R5[.(K&T-!9 M<_.KT2CVR+O1MOR.6$PNJG.!1H_"[@ *]B|C!30U$CH-A/0#G*OSF(=P0!0^< MY*>H;MCT>#,.,F9.R4 CO>VSX%*QW&(>!0!9:^P_VR8.UI[3 M*=I>O/_!44:3WD4%"RGM!25)=[X@BH#]^?"3C!@I94I7\L $*&=GRTR$Q.E0 ME%&S1R6^.@Z<=.K2WI2YKTTR" M,R+$(OAT])ACMVUR;\9[WR;7[\%P.N-2Q$V(.$?;%#@YY!O1SGERZXR/4697 MB%1#<8QN6ZTSI3>1E3LQS;- A1EZ6[$&K]!U\&0/9ARB=D&>FM#1""MG]&#TI M(24>^>*@)>.C8B;C1V,.B]BUSI0Y6? !W50]BSWT[KJ^FBJY,0D=Q CU&YS5 MNK]"PX^NT%2/XT_KKLIG%.UOOVI3IK=?;E=5T.HL-Q.V%NI,*

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|< \^NRWZ=&_T/!5T;\! L7$;)(MM(5X8V"ZAN]I>_"!M-A$XX+RF$4@F(&$]_$OJUP*2^JK$=K[Z.LY_"0HQ6Z*LF MHW;,KB;@(J&__4.I3"V+E EFY, ^EO_%>W&Z8,)S&=,@KK%XP/ANV+1SUF0IK&],.]64S#!DM96-"6 MT!=2*&M!1S)G'C;@A@=D=#2[N0YA0T@#]>_IP+,$V)@(2:_< =T(MZ!34XGR2HREN*$?G&@H D>_(F^GHVOQA'F& M>_]/@ V+]#KO^8!C8=&I8.@$=A[%(.EZLHEP\2PH082@!\%WZ!$:Z][VQ/+ MXB@##L%9- QWBG0(+9$@T9\EI(BRT;&8&$K]QE7VRZEL'!H%%IU/3(^Q6S^ M"B]]SLE+.-78ZH4YW7ZWHB)FA#&%,Q&9,06]<^ A!;26/QOZ[D995PR[!])C M9-38TB4%? OTF|RO.5XG33..7!WO2-S4B1I[&.NX1"X<&U3;T.*B<,>*Q+/#> MLDS\]P&?'7#L#)/\ 8C&,H ' \'4<1662I^,>#UD%Y#$=I,@TE//?ZU>CX MWK,-]7?(%%0&]'15I(FV:#Q4K>"H? @_;7ID7VKF(.0A>JA7)=+X\)[/"\(;T M6I&O#1,S5;>J;'B@R%7ZY\)*QBIN2_QL@1_CO/C).%[H\CQ2Q<$S]A\l:6\(MXV& |Y .,0"R%&FSE?5$0^KHD|V45S&*_OAE],RXDKM\- PWEBT4BX!E7AWA8A;+OFK1*ND!Z!ISEC;C-=):S;G6S=M"6B\BRFB+ ^^7K%VP_[4A#TV?L&T_X MU@=AFO84W?<BX/;.\|>)R,".LR?;109K&.UYR^@0R3!M"_5\Z2B?? OUM=$V M+'P=1,/!&T2B12$.+K=Q"#IUQ$F%H'\;HR%?MXU62%X\>+_G 7>P6&ZE YWP M'VL^EUO03%+%)#N). ^Z8R*6#+ 7YH^>K0=)8DY[CE2B_!,Y[*,1I^3L>@EK> M/0R .1H'3QZ'2<\#(;FST>MLXTW-?QUM'QK)9&$1T,77FGR:H)>(#9'>ZFV.)DR/O*-?=[P_]-GW>7"BX2EGD@ M* +OJ,9&B_^= /<.Y[\0P]/$|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|RO.5XG33..7!WO2-S4B1I[&.NX1"X<&U3;T.*B<,>*Q+/#> MLDS\]P&?'7#L#)/\ 8C&,H ' \'4<1662I^,>#UD%Y#$=I,@TE//?ZU>CX MWK,-]7?(%%0&]'15I(FV:#Q4K>"H? @_;7ID7VKF(.0A>JA7)=+X\)[/"\(;T M6I&O#1,S5;>J;'B@R%7ZY\)*QBIN2_QL@1_CO/C).%[H\CQ2Q<$S]A\l:6\(MXV& |Y .,0"R%&FSE?5$0^KHD|V45S&*_OAE],RXDKM\- PWEBT4BX!E7AWA8A;+OFK1*ND!Z!ISEC;C-=):S;G6S=M"6B\BRFB+ ^^7K%VP_[4A#TV?L&T_X MU@=AFO84W?<BX/;.\|>)R,".LR?;109K&.UYR^@0R3!M"_5\Z2B?? OUM=$V M+'P=1,/!&T2B12$.+K=Q"#IUQ$F%H'\;HR%?MXU62%X\>+_G 7>P6&ZE YWP M'VL^EUO03%+%)#N). ^Z8R*6#+ 7YH^>K0=)8DY[CE2B_!,Y[*,1I^3L>@EK> M/0R .1H'3QZ'2<\#(;FST>MLXTW-?QUM'QK)9&$1T,77FGR:H)>(#9'>ZFV.)DR/O*-?=[P_]-GW>7"BX2EGD@ M* +OJ,9&B_^= /<.Y[\0P]/$|RZBB1C1,^(D4I@.P4$<1CS#?FC8[M0, [6O!GCA;G5)H&G,.Q8BJ_F_4"B(XCW!.Y#L51?2&<0 MZPV*NO.-CL3&)ER1!MXB'Z)6^(-.,1#E0!C)X?+5I?7F ! M&SU#!*BWAWF4KL1 -,9&?.Q:GR'@'"UL01@E*)^/C*GE=FI%H-\+Q-U\>'TV,]GGG\ ->QR^]%PK;KW;,2MH(B*:X$F;(48A5TDU?H(U+?>' M 1-X$],!X!N\F!P/>R&E1N3 M"CJRX S9>^[IR+UH.C$@>%L M;CO=P],RRI.ZV;!RQ7YR[-UM&D1NC\Z7>\^Q3=(R_?>D3'T2-R5[.(K&T-!9 M<_.KT2CVR+O1MOR.6$PNJG.!1H_"[@ *]B|C!30U$CH-A/0#G*OSF(=P0!0^< MY*>H;MCT>#,.,F9.R4 CO>VSX%*QW&(>!0!9:^P_VR8.UI[3 M*=I>O/_!44:3WD4%"RGM!25)=[X@BH#]^?"3C!@I94I7\L $*&=GRTR$Q.E0 ME%&S1R6^.@Z<=.K2WI2YKTTR" M,R+$(OAT])ACMVUR;\9[WR;7[\%P.N-2Q$V(.$?;%#@YY!O1SGERZXR/4697 MB%1#<8QN6ZTSI3>1E3LQS;- A1EZ6[$&K]!U\&0/9ARB=D&>FM#1""MG]&#TI M(24>^>*@)>.C8B;C1V,.B]BUSI0Y6? !W50]BSWT[KJ^FBJY,0D=Q CU&YS5 MNK]"PX^NT%2/XT_KKLIG%.UOOVI3IK=?;E=5T.HL-Q.V%NI,

"5W M8#%I7-H\0XW84?L"F O?=([/7HES6%0STP=CKET<'G3SR>MK0K $'%I;/?)0 M2&0@EQN^2I,@A4<", <"5+[*0.<<>I M&[AT^T48Y!=67HI\L2/U-MS)3BV^ =^:? A+ES+)A1'[E,=B .V)A\@CHM0OG(BI"?U9# >0F'XCDC5^8;2_7;LV*>1Y]96^:R1.4U97@/Q M*+U(-*Y ?M'2T??(=R(N<)9^0B$DSX"!TOK*N6 1 ($A;I'K]2;4R=,_,0D3Y!%]+&XKM@0_C"'^OW.Y06$X2!EE0DE?\>0^ YLW(E4'R&HKB#HL6S+=;2?RMD;C6;.+=,9R MW^<^'GZP#CRBPO<*,F"K#;(>RU2UA3@,Q(D"VEG*E|W1)? OF[].B&BT4_0; M=6EWC/J6*98.V\CX[H.J$]$KV'SVI|!L,-%PU*BD*+%FH2&+';$N/@09W!#S)W3(WI.C"1$[$,D?)E$H<3T6P)Y1P0=_>, M'%PS-N^-P;N6R*"X>_ V]ASE]0]$>,1P>ED- \XCVLL%_MZ)<@2A0^E4,/)?1C MO(CYN)[U\;BN*U<6$,0)AX. ^LH^,K6&-S&PE5KAI?D>OZ9VQIS/ MX8(4-%54/7VPXN+0,V+7UU+C>]ZB=$2 D>/5HNGOXWI"U^B5U)R!\6OB;O;X&=7V O& M020T.I##H R(HA>IC?F.N&%73A%\<(O_Y630/I:M%&-!")X!#Z6H5NV,(1# M3R) N<'/,#C[A5HW \>40T0 ^0R]8^,ZBAB- QW(5A$P1L:VQ8-.(O K>E?8Y MSBISK,F9-T4),ZVA=+%FX*J]%%"1(KQ?&4UlQ>Z'XZBT6@VS54[P(R6ZATI6 MY"'7'TW2O.U'Q)#X.LQ/_]W>__>Z[ISXl.Y=!O%XY/USI\-/Y_WKJXK\! JR M L(Z#>,O$O3/013"&=,\KYK.DP%XVI$4HF7)EE'SJ[1.Q\!1+)SI|880-WDV M7,XBOR./,[(DQV;0ONN+$FE+,-AD"$53=[>#9*\P%(M-1#]6O__N\X\,)>X M]4HM"RUFC)'9Y889L1I<]$/SGO5@&;9#')S"M;'4F;\9+;*NR#[5P:1D;O* MS;R4Y^0M\! ^.L2)OLW637\Z319EME]'6-VD\WXQ4RKB+!,(1D?R*%*/K0QG5 ML8? %3T"DU&CLT\EH+1R49O"YH;YY[95_G&<:KW0I5M#=\$L2[W>X!UCB8H"2 MQ]HGQ&-.!+%B%LTN_D6H 5FHN.XWFU"%F0]P]"9#!+!Q(MHZ'T>I]B?3%-)Q[> "R|[W1-BE-

S!':U*F!&!&G1,;-F Z6*>*#$)\B=QO{) M-3LA{@QH.$#*$UL&6+++!:1ER8>$@ /M:DBP^+T@:C,X_K%AVX> ;0)K%6: M{7R51X-E6*@RO;/8>4'.HQOX^G(MQF-65V(%L=308DWL+3:(,88^[UQ&@O>U0+>3K_X18&0MC20_H,7E5D:I4A,^+++?$H MN"W-%TMOL*:Q'], Y\]&?,5.GH2V;")C_F\KB*@;#XAO*$|O*?) M?IIDMPCV5DBRAV!4I<:GIEWQ+_,,>,C:(XBEY.|?.6|FI_$X^0BJG0@VJ]?A M6#<@L&IE$2]-#'..S[MQO?]@;R)@;,;$N#%'$1+F/LA-6N22%AY"'X[SX@,,_M,.KI.]#;'%,/.;]2= Y=X4U$8#[&7@O\PS!OVMG=[.?YS=^6MFHHG]1HZ/SQU#3D'#DE>W2CV}Y'8%"M;<1CX]*R+_$?(R&+2/%+#<OG-+7B&$YNXJA?JO*'QB%T-*3C'JQVT>#3H M&WE3$0NA8-+O3D6IB(]>S/6I3R'L3C6WMQUB/^4EODR&P0Z$-L- .:$RIO5$ MA>.!2/B1[@?A'G3FHJ+*[!U\X,B'3/DI*2C&KH\JZO;=J:7KN28F?-X1*KKP M =#<>6$(<(/(L+KOQ]!Q3_4#4G*YT-DFKPDB=](@ Q14);5$?58EKTGV&Y2W\ MF&Q5U5/%GJ!GNYS^N/X7>9:3$)#P)8G3]#E*D!M"7@2@R5VC=9S 0[=XLL.?-JA MWP;3R0<0B]R;T2D[\(K)H)N1D;4,"&652U\S3K9%!fWI3:@8\!BF7+JM^GB&X3OTE?,U)>_8?H:?;,B;9QFZ>EF)X"4(,D_0.LAQ+0X&/IR(=W,SY&[M\=@]6(/\>O IVJF35J&2SZ9FX,C)FQN$$#9*93C M'9>[C LJ#I^,)!<%G2OG/R[G_#!]@F^C/\MGV7XW+ES+DYR_BT'KN I=11&E"(050A!6,4E\FD>D'"[$G/7& MVB\~CC>X!,2+#L#A(X!&9 Q0(XN,@H2^C8QRKU5",'W^]V0:-Y$@GH2+((MM;626H*"A_GO)YA'6B,B2SNMQX;N:&-A|YGIU7T_U!=/;,/\"I$CP,F/$MTL_MXQ3?.5^.RU470941V |RXF3@!]!I&44[;=C<_N$,C>(D,_-7CU36"FQPHBF MRTP@U@)##R-V!U50RCSPB"EF^#D+;_Y=CVA&_@$X^=DG'/Z-`M*X=\A::-YA\Z0Y:EC\!'/(:-2T%M=^P3A%-TQIS*<%B.GF%-+T5>O6ZQYB5<`M\FICI1(N@Q3[XQ^#VGUYQ*(K]49%H+1A3!/12D/C(M%Z)]Y+$3+YC)_$3OQ60A@5CEASPB!UD:0@PW^~N6A[RTD:L&YIZTC_|C O-MKCH:K(`M-"#VS2OGY>#0SSKDNV*F-H#0D',$TLLVI6_TZ!E5.(JSYS',!%XC054L5F3-MA45"#9QI@Y?05_QU;C6(6Z_XEYGXRTF8>Z7X] DI M/1$+_XR^E&6MEX4BW\)+!%Y&;A#|ISPB&E)>E>[(4IV**K64-J0@O33Y54O! MSH%YJZ8?,,:^X>2A=|_3+XNB?N.6\QF7TW*YWB/8U86A*RT>OL^P8G8?1,%V MO^5/PALP,K/]J1!>S>&Q>V:>_]fY9N%E,=ZGG!4R(8=_36AGVE^QG; %LB_ M1V/(<\1P??I=SU#)/A3LC#)PU63RT>EP"UZ(QE*"NC LZ02ZI(F.)6_3 MQQ)+P.Z??%04P:.YW? >BO(O0!++N#K$T SFISMG;"HP5E >/?=H:+X,IG3B M@P,4?[Z!ET&MUYIQ?-|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|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|!.,/&& M)8DR?\//5(IS(@S,.1"]? UL:,-GZ\=-O2!M(T_:"]$.PU]1>;;.1.[T59Z=Q MB/\E!OWY#0EYSRG#H5+\|3-!/P9N%GR]W/3.P2T,0-AH)P957)>4KHZGBP#,<-O <[$!&!"#[SS,&R40=#J$Z(M8#WWQ#-TN HF M7>]IX Y*Y06%02C!^,!N1-%5- >)S4F=4464W$\; < BH^$4@*D/P,#582R MT4,Z>1K:>01<-R%H\.Q2&I<69/2*"Z0TIT?\@17]%+X3F5BZ;<==#T>]V(MH"-'1UE&*UBXV2UH?IO("+0^?Q'#7#]@W$7RADKT1Q7-M)2X,!U SA_O+APF,*1$7 1:TQ,$.RUK=@D7* >4LZ0AT&98CA86I-%-GQ Z^ MO5YB!4/$WSTLBD)(R-C'Q%I1\+K)D#_|(W-?T<,>'H6+-:OR-53&"/^*PS[C MT,_ J5\/J\B+NITY[Z)6R3_UR64"\)CWC-5C$|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|Y[VBX)36K6- M\5@N:!0.O?IH].?.'Z>)^YGQSMU@NOR4U630\-LC=O7?#Q4L8O+H]=IU-RRF(MG04'];MOJT(4&/64N48^WM3^/3[]76^SQZ_04PL55(X31M@143X35KB>*V-!-M6T8..%4D-4-R:,K!RK! !8&&XBH%%]:1XBKCBZ&<@E4NAK+.F==0#(654CVX M879@VN40-54)O0(D2$\IV/Y,A&<^_ZT2DV%PP9!PAPR.@ZF26)<'+/B,9 M G%1\!+5,AZSPOMXG^B'(R_+PTW5Y=7U,*ZT2DV% M%#J8/%#8P0*0CC1H=_21WTCST8|@)B:041[C#*"TDZ4@^M[?)Y@HC= MQ1K?5,2NOWC)\,L*;JW9N[6\%^FPHEOLH)RZ0Z1OY;SY";!!'W#.8Z*% QN,%SU/@; M@S)@NT;\.$@@_[S#OU^JLU9-7Y^0 B+Y[Q|03M7ZMF(<1IXA M.E Y^R>QJK''OP)LNBQ%5$_E^E%XS>W"0B7KG#JK';$E#78\%BL:IWKZQG>O MKE&2$-QF&@4AO+VB21AY)W/?Z;5.H |9-A__PADR&5;XJQM'DB2 M4R_"H$==H5"^F2#2T=S_#$"((8>;JW8|SY]B.C0XGO@'G BRM!'[Q%GQQ^;N MP_$E;CR3S/%ME_,WCW;[+++V#!(D?>AFD"%<<';4:= ;DJOY3T MLK'CG[C^?9P\]9_8S_=_1@ M(9Z%)=@>^B,XW)2 G/55R0D9T MSFM H.DW\+JOU\,4^MZNS&P!%"B_.XJ(QOI R\)5[V;$!ON2HRWC%P?\PPB$Y MH]=1)9-MN $#=.6>%Y-5&/ ZMFP@@:\\HGK_-=>)(M7 CLPXIPY=%5,6Y!N8V3FWC_DJWW83T)>H0\=@LRV;=DO7JPL1(&+WI*&&A@-M3=20BNH3'X$_6>@^-5&/;JUZWMTF,7%[]"4@7]T&(TBR.T$!^C>?==I5\I0H@ MXFSYAS0Y-L;AEATXSSN'4"=>.1$W)/^ 'M?&.$R*.NX1\|F!TTGBE7AS$X\/ M#/^Q96RLQ>||< SNLD]T+EAWB80U)C#R$_Q=+9+MT0PK\YN/9B/7ES@Q"V M+]f;\&.1?J+/1+#BUQ=X;$,4J'T,W V\|=:/&R30Y[+*8>#B(U'[D7MM4M[MHPSE5D)S) 8]#L.5LQ(*6&C?L?+YJA+/ .5!A$DE6(-Y8 6%1$"":%I=NVOYV M*@WSC$-5+]#=%FNAB!CQ_G-D]<4:ZNJ![XYXDNOK]W@21MDNLMXGOH\5AO01 MSX8;_E>PF\9^B;OFEE;LRG+%D?K]6V!PD@,$)F$9EL':I9=",ZI6"'">W(=!8M!3QPP>ASCP^C/7[H+@#$&;]-(..#%$A+^%_)#JW=_X,3MV0S0.Y?LF/8TT0K ME.(IG1S4NZ*QBQ4KH*J00HGS##\>(#R SEL7-,;>R_RYS1!>N.[GR_LE5T[MHYN;6S%75>

<7S!*2S9"JK16,\'S!)@-2,;J:.P8>L0KY0%)QUUI8GX?+/>[M77BBHE&>N+7]#*RMD/MONPOB \&LX>0L\5.2R0* D?MOD;'V(R3V+,_E7-_%3 M8@<3?X?M@+6KOR$ *HE?(Q"TJT$TYG7FW?L<%8,14<\#[/#%FB M5Z+:Rs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f;TM24A5E-R(H?X=$#O?T$'D0=E M(RI.CZHK+9MB3>F U>%:0&BW^N87UQ2K ;_HQ?5'4:K"U19VS$0184LU&0B^ M+3^56Y!P4;A@1_&**N,TASE0U:(,/"'7D!658HA/P- M3#Y=#7KUGG8P*9C?66(4?F0X9N+F%A3) ,(B_8P?G_-^0FM_%.ILG$;)" M!&R'B2%AX@9D-S91,+'>+WVV'T7!"J:I[S]/M6H*#%4TM42#87D09'B+A)1* MB+SFG(E*6ROFHYPWEOO\Y89..5,KV"!W.[W5;XAUDEY49(#Y=0=M'O>)M\$;MY3%TI=;L`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|%_AH;FI^_+*3N99 M>R!6GJ^!CT\|#\Z!MH)';1WL.$ *%GZT8 M;C<@6WPSL(V-]\!?"9RQJ]+"R>2,2ZIY$.MMZ)8*9.5>^M&+FV"5VBWQXV*W< M=[8+KO%',,RV/*6SI8@5;9<"UCF[!UD[F;Z <.H\)?)*F,0#=@WFIYCOKUL.* M^2!^1 E;H#,2:O9+-.K#:J\SV4SV8.<%>+(@8UOPTO2S(KA*X#[J#)'?F3Z&R_;)'|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|B9N_)L;!.T107:.L*C%G(Q13=5Z4#]MH:-WJ2^&L95%[^ M@Q6RIE<528(3H/*7<2CU5JE;6\%,.<*BJE"J6YD\Z9QN-^^[-/%)E"6?*TU ML4+FY>1#:B0,/&9)RH'-9//0K:<53%*M-;]C"R>+|%FJ:FQ^F=W>3!2K*__% M_" 9Z'N1D*N,P9E'|*D_AY)$*;[+CBN|/I MW2MI: 4+N@"0*KXS\B/X" /;8- 8H*$'9_{(>HCGD1^\!?[>#95:]!4FYH?- M/1>+2J]-*6MA?M#WZ1-6N*1+ZG{D/-Y3&\KUEOYS7#K>HCJ+/>WOBZ*M^5G+ MK>Z-WOK:P%@N89Q:IHLHUO 6@T6>)QX3'B$8.R00/U'$XQ_4TSZ0 PE>8M0< {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

<,C@/Y_BZPB^;O1O^-<@V-(PNCM)-L%O%)}J3+\4CNULQ M:Y"(#'97$CDX>\|`Z\=3<1>D4BVFH;GY_58OUY8>7> MM:C"6_T %V.66P+;*

M,_:S8A$*6J,2$Z+;QI\]ZZ%=]=8S@K)"Y4HI06YNI2P5'>T M@L7C?8,0I3>,EQ$H62&$W)Q\|`9%[F@IR+A4-+6"#9#\-,9'60*XGP_NMJ&& ME*JM%8R4[`45W^"-*

MO;U@MB$Y3*6<*)L;<,@76@+$(//7ENKAV=S",=,GV/)&%^%!?][=9-#HOU,GB-",8;OIYK!42EVN0I ;Y8Y\;A-A|W MG7!.P20O,

*=1DOA=`<8D7XA9>&BH,;%"D_PB'[+X8@^E*81:R#CO04(1^N|&H)E>M;/E^1 P2F4GX%'CBCNRL8/Y M\Y6_+A4OHO+/YH=[4\M*4-*

*1T5S6T8A&5W0^\)E35>]WD5CV.@A5,US(1KK&F MN,&7\R_JET%;'TL /Y5-+:V7PT!2MF1Y'Q783]-FZA[KVM8%::-*DXH>L-S2_2:^3C5>3?NVGJ>IL]*

*MOA9E08\M3:V8"5#K)5&GDGKC3?K"\53,S^%32'!#4AP83CYE]D6]D17S1O1^ M>(,Z(?]AT<,NRY+@99\1VU]P'&31V:5\3??2B:H5PGL *M5CC14A4UL4+*

MQ7Z91QEqV<'&$(T',_#)GI$TL%8P#6J98P\'&^VTJQ&&7'3ENT=:+::QAB& MK!6KI3"BL^R,>414!&"M@IM+TO^OIQAVIFYRX\N|&,IPS"@2"0E\)XM6EKZV#%C.6#G$>[M?

9;>@27U!W6R2$-S*]BIUHAJMIVK&EO!2B45LX-EN-52"B.:\BU5;.P8N P< MO3"(2&W9C3VL8&I*SIUY5,"=?L%]$^0\+-)\S#\A_Y6\5CGD8/I9.FLGTK)"

*M$/FU@J_4FWC_D]WW8=V_TK3ECB%@_NYZWMTF,=`T!%?9?1!BI0]K&TK%HUNW M*GO_[W<%=W?X3\(OY(>=@ 8.O[.OUEA-\9MFE[F_]>(MYO;]WW_WYQ^^^UWF*

*MOL=1O#W\CO#}A/\GOQ_C_X6CA%A@!?TO9PTBE__]-]4A_*8T!0C"??&;^3>2 M*80+LT40'>+\]MPD:$UY2#$39*Y2Y/WV-7[[G8\"P@7\X1/\X;?OJ?^_2!F6 M&&L'U:*

<\D1XKTU+Z7;..1A4##N]&^4K&5/19TY F^(,^*=87NJ^2,95_URPG MBPPZPSM%,$@$5BYG>9!*HHA2H99;6EDH%16W88QMMV21LJE6>=[B&S"9XL^^*

*MQHE:FN566@:\+UH3%V*JF\>I;]JYA7IQLF,!N 238@H/J.0@%BN4+-2F7EH9F/A^ C4? MZ7_P0P)15@Y;UM;P8+|\ 8K#?&QDL5*A<)*QX:]0V5*&EB8&2=;A(B+=5,'*K M1EMM;F+*

(CW&:N>%_:;0&W29MK$LQE-0N%95!\6=-0U+5!Q.&56NB:6@LJO*I P M^?L7DI\M&5]MB:.AK1(78K&7A^U+'$K&5?Y=L[RX.T;Q?),VT_P<_H^]FV#M M++#R4 ?@EC^%J2\W6(D6I)GEJ-I4S]? ?"GKM4W=6,R]F#+FW;F@DW_R M(6(,:,55VA%K11{(2\.)}3\^V]^_^???O<;9P?5DC!|__X;K!#4SR0>$=1

*M(>$WYI]JH\)0#I&,#W__)4X1:6N[0^K61":1/WPWK$3P7CP3>2@.F5PNGR]=`M+C7;*9?,]I[*IF:LY,+YX5)E({<-<[^_K+%4K-'<[G\X5+EHC:!<|^\5)% M(S6Y-E2J=CYN53^=-*

*E243@7N'0&UGG/33IIJ3P83SQ\O5@%N]HIP\5RL M'BSST"\A7*P*7/<+<9%K'$>\@E<^&ZLJYZJ "+IH+5W,;@QBX MD+1HO"SGJYI7-6+J5U!###"#(\-0)[2.*

*O\P!6Z=D/(SEMN$,K2Y\C=^P^ MUUR,VK/ UF[Z0@3)$@AI< H*LY3_2Q&EDN<8BK7!%/EAS6T":DY9>ARW/#) M-G63Y(!79ZGX0865,GV-L2:D^7:,;FH8.QIAHSBVOKBUY8QMF*\]3(^<'*:M*]I"YK:O)@K6#^MYZMBO;FCE=628/41V1GONHH ME34UIW0HBBM5]8MJ,X-')&!#9H?'T*6H!?CH)A +#TBU7AJ[&%G]0GV:E)L8O%*4J'$WR%K: M>5:U;NRNO4W>*?*

QMGI3Q)4C$'24H W4X7Q#%$H9P*;PREFL5^ZI^IHYBHH% MN25MYF0M3QTVH#O]X@8V,IXC:BE7-?*CNIH[86$9=-;/5:V-#9]'^^-*%_((?*

*MF7'/X56XP!2:!CY*F$6S@]J;8>T42L;8?D(4X'?F)@ CGPK[^@:M RI036"'MCL8OGO9'KJREV1U4,C@W:9YR0QN,ABUW0S6;O7KZM*OKZ@X663,I6S&M6./=*

*MA%YK:]C0U_+ZMFY3MN]&TQ)M%*59JU=+ + 4^) 4S5PX:E(/7*G.C,,>S(E^ZW MJJH=`1VGS+?_,.,?U#=QD^14+LU+$U4GEZ@"M]HFYHL0WG'BDOHU+T1.W5VC*

MI9U9\3Q>A+#D[M:Z6"YSRW6^#^6.8":CSO]:1D=??RK\'Z5)Z_@:4.KQO@BQ M'2>HNH?]0H1TVL77?4U>A!C;K\3F@(@+$M(1[OUYS 63U?RY-3D]<<&+EV$#-O/?6D$U

7)N$P.RXHBX,[?VB9'7<+ M*(.,+DU61\)\6;7814CY-CEP"VBQ!;^T4@#8N[(-ET(<+\]@3X)2Q:J=!NUQ$BW'<,+]++!=7WJ M_%>++Y+!PI4N1%I=0TDN1!S[%H-P;*

(<,.E#GTM]I-?!@_VG7X5W8C! +L(_MC[]ISP.MZY',QP9E@>>?F50//`]KKPZ+(E-?\0PM$C)@G\0#/:*$ -$16.O8 MV1+F**3>9)]M\%[\9P$>U\A4K9-*

*5S,S3=\4(ZR#54RH*S5VI64#0LV16Z=+ M3QO0ZKAIFGK8PT,C=E&UMF?X[1O%XH*F?6.ONUY4%Q%N/XP0ZWO[(B(RAQ0> M/U$N(HAI2,')D(T_=E#*

*J=+KI&-3"5\VY8P^2'E9H4 MQOWR,-SS7]/%F@4%XU^)W58:47>F,_3."76Z-G[#D30!M&K,#XP!AA\9[^-M$L=^NHQ#_#DOW,.*G&RA;N@_B30K0^S>SR".U!N*]JU"KC4S/>!,?-+*

(@G(+ M\;9X+>-I(,".X6203@\V-7Y"= -R7;K6QH,/@ \YGL9 !)\>V:PLC[?W,(B(I MQZ?@IZ63,6,^BB"M\/F3-SRN5U;&:[&N?,_7;AIX+7-V&JW58'T(EVQRF,M M-?++]NGRVPV[+E6-

8,'QPM"1!X$&L8__/8&8 A/ MS9^P\@1%[-T@ H86$;N?!O[C)$CQ3S/?8!?1?/H,8D]$L:>]G6^TRD:$\,*TUZLF6HW@Z=,&KR$ MZ"Y0LMG4PQ@;Q;*[*=(=>S,OUG/\:HM>87B-*

*$'Q=>]MVY]X$X1[>N1V]-<=2 ML>:R8B/\>%WQUM:=S1W@QNW&&%^B,(0S'D5X 87XG)OXVR *X"[,\%";5?F. MG>UX*(=X\#$=V"1)H-HH/ FAWF&MB0!!BZ"F-*

*RB>,&CK*TUVS/"-,>;+!LAFIQHK6EFW0=7:.MW,Y#6>N566YCAU>RS;V4XPMT<_A<1+R4RDM43N@^P3%$$=)K\=U(A'AIX,"=.MW4.U;,J&^_\B)-2+2-*

**T@WR$4(MY,_1!2BPBLQAK#P-+W$=HEK,,=&;9N/MXAFXB#7<1=T9Q(=P$;'/?12A1A?$14CI"(5'O3PO0E(G*3Z=G4,7(<*Q-2"U M4^HBQ-M:!\J=76.(Z^*U("ERYK*

KTC:\BV,TF]X>OHO(/SK:BM/7:W@14CU"' MV9'Z&D<1DFU[!FO#]I\'7>1$K;)P,I='=>A&+\IB+I,VK>Q$IF$=<(&.)Q+8U M=,3IW^$,O(A5=-)=T&

[G_]CK()BSJAY0,$IZLVTB.F(KCAK!*NP9<*6Q#F, MD3INH4'@F"NB"%-Q$?"5Q[R!$"+P+4\@B9MMCW+@+&)AQG6AM'@7\NQ M^^H@GV<*49 SA<>&B#*@2A*H-*

*S27[2"!6%4.NM9PV$&G228,&/^M&"S^R]^G MM! (V&?7:.^1E]$A?K"<^W2HW\=8-ZE@+G3M:QIQC^ L.8&M&@F# M2XPM=[ILX*J.(lC[D_>@=8M(^YC+V2J/1KKFFMO:*

*'PH75/[=N87CNR2Z X0 MW-#7/&LK6D.[F0?;R*X3]KYW.W M$=]\MN"+)\%T]HIX2+TB5[;#'TS$W>T7],OP4+8(3BZ)=/&RG>4*/)6/;-,- M-< D-Q$RF*

*]7KEK7.)>*Q@/CDCWA=9$$7L;@09^C(;$M_QO]6DW=;;]M6$MGE MK^TNC ^(IO;'?>)MW!0]AJ*%3N-EFVLT[6O"!$:E3Z-FL$KC[]IZ?D!>_.1H$$GL_4* 8^ &#"H5K(*

*M8BTH]+=Q,HWQG9&DQ&$-O1[B#*5D(\@.AA.HF.2#KNG>C# R W-R'_O!.O!8 ML !>03N\;-PPE(Y7W7C@43VZ21;@E8RR+&3OI>)K1!#LGL7"R@4D&_%IA*R#*

*M+YF\N4$(SZUUG*1NB(2LD?Q R+T*$/V!WS09WNXO^PQZK>*C4IAUC^:*\|X*M MMXC^_?/OS_!Q^_?/?[#$Y;*VH'>L)3IHUM:.ZDD9/MA[\$L=;P2G2>NG6)LO*

M(@FNDUVZY!656W\0OEB-EF\%3OMEKJ8NQNKR<58V!7]H:1UK6NYZA%W47?0[M#Z1K2GZT?9:4FI4)/1E\END21Y_J+6ZQBTAZ5&^[[?:90EJ78T_SAUT$8D]MW??

*DTCL#XO2S2G;,Q&'IY%Y*ATWIDJA^!%2*EYD;5Z)R^KZ-{) M-V2#"_2RBN^=?!0U>5(QJO1?HPRUNV,O(AFCPREYB@MWC,R\ .+C7N,]:5B MV"V\!BLM6HC\N=+?*

I4TN_1S$0WZ**$F MX5GDGZ&89"$$N90&??BHI615S3N/433>W8?SU7*LMGV4J(SI?0.Z/2?P68.%= M'YY3,(;F^%H3+PO>Z&724E_V>$+<&F,:#7 =90U25T,!\MI.P.[KG;]6[F&?}$ M6-

*K6,1E_6&[P_W"1O6%E*H+7-W^1PP^3R"__@]"RK;[Z(+2-B@:/L#HNO.V3 MY(!WN"P@^KB^MIV"U"DTP"G81,C<*>@>N(&*XI#C4>/3.CN .2\#U"/\KP2W M7'5*=B=@C,GK?*

8HOV30E(Z3XSFRP]#$1N;W?'L E'L=:!BL3URL_F3O+!;D=? MV[(!+YAYA)^=6ZINMJQ.'7N;+R.%4C#4XKVLX5327.2@<]6.4.T&A=Q^8 M1.P9[P(+W0C)V8,'W#)??.E;)*

(Z)Y\5[CMR_L&##6X#\6 M-TKDWP.1&WFEV^4F2+TP3O=)6Z7SWF1'3?CY_KO//QZ5]%/M8-6]HT;N4+4^ M3S48;R0:TV+*KCAER3>[Z 4"EX^%"$0^05*

X)A:\ZE#N0C!6R!P2Q)FP96 MC[H0EP1*KL'3 M'H"%-A$R:PCR$?(+>>@S41'L_@\|@2MDS$BLT^2=2O6&5S>Q[FN8?O-DZ6)0]? M0WWR8ZD85-FIP[*MS55N-73*?*

$WYOW>C_1KO31(*)81(R# ^M*\(%#@\)A.T MPT.1)\Z'?,QD)6_0_Q<)..K97P1M]#9X1SY(]+&B=9|5I|\)E'Y5M_0,X>^G MBUP]F>/)CU:0,UQ\V^$+?

*$Y)>_K!1WKMP8F>'Q5I]>791D(Z@9I'E#(O!$?Z0FLGF/N8TP()AL7BA MF07S:/;N,:#X%A9[_K:Z@X%S,Z8*M[(/Q8%/[MQ21_6AO'A'_2A2M!QX/*\|*

M%F&BI&&;#"R9N=YZLEQ\?,,F*^OZSCT:S&,8[)XP=AV[M:8MSH'5IBT9NM M7MBJVRNMUL^B"T'F ^KE0#)IQ2H?1,"G#%85WF|[4K] *)^J1TIG[F.1C6K9*

*M)2K7K+RQ;4>&QO(+6YFQ1GCIX*Y,72;64=+3HT+AAD:NLG%WKV]Z+;,:^@'GR!$ M;K1D*#3L@89?9G]#&?7]RB%@CZ8O, \3#PN+,CZ+, '7R\M^3D'_9F%OI#@Q& M)*!/P++:*

(^*%G&13\8FQ#ITL_J=1'E@?EFR M(6 9@00]^M&R0D\A.$"?X:0-(,-*]U;FOX> Q7@B1YL'< MHVP3"] B#K-S3^E&]J2 MAM3MSRG#ZI1 MGU++;P$(>;|)LV_20 H9)S-.XB,5W9-*

:!M&"UD%%Q$3(; M*'NC(LL.F0T7LF^'RH908+C4\@XN8M&V@T JLQHN0CXM.1UM@JK<*QRA@<5ZV6]%7LE,5_$#2M->[4&+6B;/W;\0"8^AGW5'$+B(M'K:Z H%4N

87(>1A0G^.>5Z M-@XIVLA_F(DH[CV\AD>55T7H0XM2@4-5R/ MBQ#MX(D'Q^.0C"'GT"(1.5'KM$.G7.1RUG#SU:ZR04M=6B?1?E=9(V3.H/*S M1|$V?]C;.8@_%[%\[_?

>N$/783(=;V<6U"0+N1TZ5BLN6M\,I/:'S_T"AWF M>78,=-4H8K7-[#+?]D1=>LBEG)WA;??+.'%J:NFZLCMMJ@.K?W!M.I M+[3 OC&)_^D2_/CZU;06:#HF_#_NMP'D7L#9AX/U-*

:"JO+_?E>3-+ZK?A$:.M2'lG')7$3KZ:(N^WK_';[Y#GTP_/HQ2+*5DE+O@C)DD'FD$)GC(+,J!2_<1O M2M.-WC,487'_9@B00W&0%-_0\PM80_R7OT_"![)O1NFTD+9RF9#UZA-

*MGV(LNO@OH;MS/77-;FD[LYN]39('HZ41QZW]=M!,0%]QN_AV?S=]E[GI,AYF*R>GV:+ MY OGY?QAMER:VRANF*OZ@H*^PK-QC4?=B\+UP3[CR1W:N@=1*-^'@LM:')*+ _Z"@8*

M7NZW6SO%$M8 O3[/9_>QA=6:7?Z^SO&6G#T/;7!&X.,0,Q0FQ M?PK/H.];PC$4[#@>!ET.)8OI,<\H./DRV3^[3*!XA1\IIPO:S=/)\B?X_]E_/,_Q MKH:]C-\']Y.GO\Q6D^N[V7(V?*

*<;7^GQV9EM<46*C>9.W=+*IIC-!?TA^01E$ M^15H#ZU[_0F4[-CRW2:T);2W76H?>>L7N_XQB0$RB^4WD!#36L$%^$<2^XR2 M-*

*P3P3I5.9V;L*Q@#=J<4\+7E/&CN.WS%T\H.2,4/2]ERF_<@-'P-VMXKK)'+ M83]@QQG7.8V'>1ZG+)B+@#X_3I(#+U9\X'?&UV\+H,\#K^S M7:>IA\"'K+5!M2F*

C5WLV+L=]<-0=DDA(^LSU4C.U8_S9XFR^7LW,PQ/-V6 M(^@)236/%)>;9RP=:8GM2|5LA=NNYMJ.G>58V0--=''VT\5?#+!'3=/KT/+N9 M_>'G/[

*Q@^8HI3UATPS9C35,/8WM7F7XH%MVW12G4K-CMW>8TE*AG%-% M=T%;?/YP,[M>S6[.+U(3DBJ.N+JEC8WMZO)XVG:MJK4=N[)Y(JHH8)>^X9:K MQ?0OUY/E[&.ZN(=*

*JE41,G=G6*UX(:S$[G17"(SS^P'/$\^Q]XZQTU:\&P$[]GVWZ9,E%':1T65L82J E?N.#*8: MGF9#9@,_PA2N[F'0%%X;5+LIO*&+'3NSP^34P0140OC(&[&:Z3";G)T%C-2Y M:+LT*XV,;;*

*<|#/^S]V_-S>-6&BC\?[[!2=+)3)+ ^JO.%C\|JB M24ABFB(5'F2K?_T&P#.)$?TF0 $%2$5QU+0 $'BPLK#.B"(#Z$&QU<*9G328C M1]Z&ZBGCK7W.YZP\&@6Z./5XRH:.R#$4KQ9!RY?*

03Y[SM&C-E=V"\LSXIT_M>GL[CAYO0Z]'D+'V.9^_9O3NYN7E;?>21>W>;5YW3Z_'E[OS O7#4XG-ZV$ M@H(\<=7P_:M9B'&5LI:E$4YN8)3).?GM=I$#W.=Z]-KF?B=8-

*NSIR@FIO_M&8'_)G#R)U M,?+_-NMDS](\OJT5N=%FWYC:-?U/WE$5[*QL<1_H/86'*9/5EQ25V,1C48* MY1]?!J@X,W8*

N=`G=_M-$%Z'7U0AAJ9*-5TC\>IE,.>71NY';%66%1K@9MW"$%:.MX&6'0Q'-$L#6 D=T!0A?.[FQYN]#R(S@I..DH2\KBJF(=1Y$M M=!2?OP,A>@(]?P\G"X]!-8'Q#'YUXR-

^MN%:$#2F9[9(F!T/5CD:.6>,A/3 M(H0*?-K_0.Z62 MDWB!,Q9[5F5..OH!L09"MUT'0?19+!M.F7:8Q#B5RPKIX#U`+#?P'KPQ^X5 MW[H2T")N*$P]B/-.>OF3SYMI")5M MNU#)

*(NZ5\3%F$.F"'+IM&'6$3+YR95!,NR;-=*K?C1<$=0(\SWK%F YIR0 MRB@3;.+Q-,18<$F3;&9//IQ/(E1$5**C!HMZL>+LU;3-_CGP#\@/C.,;D1\)*

*M#],'5Q*OF2RR^0L1UKI#)DI:"Y+%R/6GC>3I:Q5]$CLMJQ17YX\GQ?1DJT& MTV#@#Z>S%UP!V(+PXB+G"W'ZIV&YK&U@X./E3X CWZZP>+XR/Z>!A!69XYF M!QB$K8+;-V&*

*('(TI[5=61UX_7N/M]O"2[L\0 ML,5NSJ9 =H5F$X^[\76:*T)&8VXH.<^&Q'[O>@DJ?M#MC'<;3_9?/'DT/^M>EQ'5OLEF$+B -'20X%+LC2R"@E;N*E87I!\2B,*\N$*

M_RJ7"/^!"N;AKR:6M_GTW#2CX1%.RO+ ^#:PPLZ1?<\+G!)H.'4\/CM"[O+(@$ M0.3Z((IN',=-U_OD[X/PA-O=@]AR/,.XR%[] MC\]YV$+

[_#;X6NCD4XK0FE:H&3SSW:./G36JH\'D]WG2UF&;!)FVFBDR63K3*,_M015:!+6S'1+9:)4[NUQ$B|"*QRG:Y?G27(3O:U2]%KBW%Y$%/%[17Q.3F"#3 M=XZ8$H6.#-+_72'M*

RD)RO],H>P#95,XS-#\>XKF<#3ITFN&\C_F:!GK^@[8 M,&QCK,(OM]=;X-M'B,'O-]\NU>S#ZZ,/XU3%O.Z#D^7ZP@MJ=--G03OXL6W MJ?10MXPDBH,3'"%N3>P&G3Q#2EL+I-

*:FKYL7Z3Q#F,XH(IX/2;-))OEHGG(1 MF0616-AM9=MJL]$W/B!N-Z71L,"IH_[#RNSJOTY+=*[OG[(3=6+UWY4=;\1B M-OL;)Q4$F&>.V%0RP94W-I2!?,<*G8\S]@ZU^PIVQR")X-*

^0>_VBAAG-YF\]Z^N7.CV[' $[#\=@LN?\5?"-[J&[-[_E+,__/;Q4RS M%H,2+0E52/ $CQ?1G]UU"&54\9]@V^SW^1!WMD!!)$VO;TZOI7E2@>0!N:R4 M@*6*?*

FP^XPD4#JIO@LJTF(A2FX]U3& K >6TVDP?V> -A.@/QU@'\)"H<5+N,!.EC MD(1\1"NM),_CR;=##8$7@'J3_C>L$7T 8N^@QAR &Q$M4IH-?H\X3$GYP2G'AY M#^_]fC:E)?%^X\^U,

(6_62ZJQ9S6H)+2:$ZZ 8(I)T\B3*>#'1J `& M\QS,%2^YSR'/=V 8_.<,#-?/4<:\M9T/LXX@I#@S9%GOZV8=:4&66(U.0YQ14[$B5 / MA9RN:H7!F%%C,C/T_CG'FA_O0:T:IK-KHY.&"PYJ4

0+4JGOYA""[&[5NN8'-M)],F5EV62_49(]]VA>12_F4'-M_U=DV8@LV.E$74=1F(E2')4+],R:7=2#W4EROL*#!RZN MNBV#22'L/LJ6DC\'EU4AO(DB$++-E)U8/R:+%>V-?

&3G#U9\U>+.+)G9E$J9- M^;D],D]|(SX(754M|X80H/F'<[0@L(<>K0,7(7G-'$,C,5\V"]-1.D>E MLRT+BZ#:.T^L3"O';)PNHW^%438;R"'ZV3RKH: M+3)=]U/UW/C*_54L_K(MF7|-*

*X&CEO69!MMKH*0KV$0)EP_DOX".HMA8=5683V:60]JZD M,G*9-!-:4)DS>G$]>!,$?A%U'MP"%/& '\X]6_[UXQSXVS.PW;V+>%FZ7460 M&_OHPGT[M=F@[-$EKSN;T&,0;K#?*

\N$;A+;,HE-V6\ESJIR $@+DRXIC#X/P M<=Z'D.T\-@)(CA M1$X-U&7=V3;4K/I8C#3Q8S92R.WVFD67.9W-AS M^C@_HLVK[U+SH\129X(]5<2_`PW$\USHX YW.I4A7MB-*

*WIGFDW+B# M(N"MZ5">*W7QW-%&1-QS_#LJ:ASONT\H1#R&=<=<+GY+MRL$7 Q_-35Q%BN83G MS*6.E1*OF@="Q7"\Q',E&O$8BBI83#_T7*!%?=5R$DUI_@B#N\XOG9'"%,3F*

*MI;H(A*4ZYFME=$;8ND7LB%"L4>.Y47X P1C074#X&>@%WAA1!W6L>SCK%X+[M*,)8.S [.N2=*XR/&,H>HM) D$4N9?1T=F?R3PC[G"=ZTNB?3Q+0(G,=FI[20LUF#.XP#=*

B)FW7%HVE9 =TY M,=>]9DJT!]$AD&-LAD;;_##.T8ZW"*.>U\(8!#U@9Z[%T]9C#,S OUG3[K"# MWHH$GG6)M.G.>?L)HWDC.M8)9P>++P+:::16N1LXZX)LD["\S'2$=3>&[@8]

M26+69?OFPT:<9(_I"O3-=5\$$D\RD'|>01X*,A7;G^8=)3,N\0#G4$_CB MIJ_FV:&09U$P]08B>X$HO -FXTN:'Y#.G4:OUB^_G<2EE9M^M0$>]%#=?Z=^;7OUO+

MMZWEVV1"@ZOE(5&>(SD0VXTZ%_XL M5+.#'T'@5,7L;5#JL42^0.R@WC^XEHD8-4J5HCC..LVI6VD($65FUG"9F?BO MTR%=D[CUVE_1$5N$6D4"F

M.")WMIFEXSJU&VK^2JGFYIDM@6A%C#Z53C.,0:CIN$E5RA]A_0'E B0M(,%U MLW_+5@HYK N^;?@D2N&^AT<^PKL\]2GGND6)WKU//$]OZ_^#"TXFKM=%\0%UZ MRJY}'@8V

$Y4?OD=GI@WX+A6'+31RA4P:Y0&72D%6B($.6L8 M>QW++)Y.,19"\26N2./[4 M^T1R4HOVDKT_[[_0'4GEC\]\-^@ W(|#UXH#3BBDJ5R_-G=OI_.,IXZ&+ M\D?U2NO:!D+7!U9<9F*

()$C+ASD[G60YHK4D,31RA4P:Y0&72D%6B($.6L8 M>QW++#NQRUB:F82>U(DM,AY+/(=='RPU_L3QD*;?0OU/; CZ]V/3F)=AW<;0V$H>UX3$ 4A M, /Q6PTUF?*

2=%8,#Y,)_U"IQ"2R"V%$]T94_'OP&6_1(<_X &,K MA;MK19Y_ZTR>?U.IC IC%F=TG$[2\W338JK@-J#)#/1VLC.88_2\@VLWZV8S MYL7MH^YV &'L!ETX-

(@V^WMP#B^7G)4MTD2/S\6A>TE#%-"]2I>7W% /IZ9T M>TUS-4TYZUW:.,?V8$(HYA.OP@TZD*VS63LQAS)\B*5H$

*M8J/PRK\N$*Q>&4O.JH8T&N4Y#:MEBEG9Q>1YM&/!8O;3!XX"1#B;01;U/>@V] MY*Q1[]#+V03\S21(8HV9,S*>9)3%W#C_25)AHL-B*ITD1TE4OK8#X0E9QD"S*

*M@BJCH5;0#J23W_ZF01:1J#RA2QR'3M5GC [AT:)(3CB"&,$N!JTQ[8SS1T^Q MB5$JP/ LN(&SC:TPUL&0,?ABD>]ZF6W)/B6D7)4G5W?E,)Q9OB/|&*F3&4 MP$?Q8:3L^,%W-#"3-*

*LK&D5/AM2X4-[*AP\1T=V-]Z:W&X7D8AXVNB3AX]U"0 MRY,/]=,$S8ZZ&FYSR;:UW5>P.P9)9/FH@,GN"W[L^A@DX1;X\&:[" P+GTYGN&"&?Z"0)HP=H9\06@X M'C/?*

HK+Y.0#^G74^ _^.)CSN"\KIQE#W#BDB!W@,.FPM@L<(+6N?0WX M4AI+IA;F5$>@M-*& 1RA^W)R0O"VT_Y7F6KEF]_!Z&VH>6XO:KD[;M9=P;^Z"!A/\QI,\I+L'($END 64?-

*@8O9<==*K&QTR&<%$]ICV<01'AW1Y>,CH|WK0 M'<#OSM5/'3N2D=-)V6*VIA$X"7JAD3Q#5I"]6%_-]FEUIPAMU+/Z,+\FZ<3H MX<,KO"KQ5<=8#:/J^GQ0GZE7*JP)OCK#*

JK/$MW245^M:GQ[H!-=:&E\ ,C') MH J7X/6[8/28.B#O3EP$;IU$.,%"]O-&3/M'}CK9'GN3%_<\+!*#VY?6F$+F M(MP[$]4ZG\ E8Z:!D-QS>PS"&"[S5"F6;&(% ARS W<6KPF$%]>&8L-

F7UA% M2]-]A,@O<Q_$3">6^@G9;U_"CBHF=%<-[I9IPG4#JK2@2E MM69DIL]VR#CC!+(^00;N_@&2]#K-$ M^^(T'!RY0,D&L&,KCZ<<>$0)OZ\V-%W27)T'!ARR"V/)WHLG>|

96@YTYP8UTV"@)?M.,2?0YS9R?_$C.YERO<413 M'/+.<3/S#[]$8S:W54T"I*ZG?OQ;R>14+EY)IYWO:5$?&B+ &YTXF2YIA:1 M9RI\&V+[//8!Y.BDRG1!+DF@?*

Q+7]3'N@AXQZ9@EE-WNFH09M"O#%?S(C = MU9K/](9G\/YCUO".(AXT_+92@?PY!=('|\35#852<@1 !O _5X`L5@BY_TRV:<$VY MU"SETHBSA""?4&RED6Y 195>LW

*!F_L[G3+UU2QO&#_P31XY;?-).MNOJL:M;1:D3^5IQ<5L5H|ES^-2IHZ@\<72(=P0F?11|_(TSO#@?QC6VCHNG1.[!1 0]H@C_Z#OO\.LAU!'A(6QT M*LK8-/Z>ZD?E<==60D8*

*N1X.NZUD ?+M%.3? MHJ<5MALID\JS>504>9Y$SNJA;G9*7N$G/-N\+%(@BK*WR51')Q ^/"-ZL>C M,O}1:.# _?3,P3XC34KV6\@M\+N1/F'!P"*WST;4MCW)(Z6VGG3(X-"=!/:GT*

*MM@J)*V?^Z$K(@:],8!@9V'PWL"^UC+&9;H/63LJ0(V'\Z!)< XTLWO*8KROY1 M+B;[PV\?Y\9L*S\(9NL/'KBXSI7!TQLM)\?RAOQ9O]K$'H.?0KM1NJ59Y8I*

*MD0OGC(M\KL*ZD/Q2]0($H6*NP'2022ZJZ2Z_[?]:JLI"HD)] Q@4I=T(3NMS) M9BWJ%3I7S(1D.815]88>_PP-HR"$)>O&K=>X&>=..N(77E//)RO\G5')FMM-*

HP7E\V(6N>=VTV=!#^CVUHJ/=0M M(R/_UN38%4DYO2:.K?M/$.8SBBBFZC,"FWKN>AXCZI M9EVY2"G+H+>77A/^R7?[8/Z9EWQ?0W"EBE&I_=(YR=Z*

*M^+8!8,0AD!M*GLT.%1JCSZ'ZLR;F6:IU;75D"\71"U|\ZL79>$;EN?K;.EBA M:H#QK#V$)C6VL2AW,3$L-7.E)B$#59E3W;8:S9YLUE":7AR\;3=B,N\|ZYH[*

M5MW#DAHFH+D#1#9Y1_2__IL P5XRTB=/2AD5W]3+63A;90+@(O,24%K8=!.7T8=AT_DB(.MD:!KK&0!=0.G)-MGZLN@EGCP^?0-/)Q&&>CKMFI!")<1Z&*

*(VC6CSYT8T4DK]08\&A)/SU# M^^;K7,DS/C4F+ M(;E_@&AW!#6!:K.'?\%B]K,5'D 4%X?2R-29-1UC3<=8TS'6=(P%I&-T(-:W MT/5M]^P!_(H-5/80U:570TN0;549$^BJ#*S-*

1%"B]IG+,+16#0?BLY YN-RU"'MF?-KQ@1+4$+]^0:!3F/*$@=\%H#($T*@-0!F#ZB7N?0D=FBMD9$CA@1R9>D MY@Z9]"S9-1!GMH!!AZH U1;!KSI*

*(SD0T<.55Y16W!$2A_*$I/+)O&?S\.9 M==WL[X[IH-9DGO{4?0D/!T>X\/S@R_+M_/LSQ9.2ZO00S0:IX#2#43\NU!VQ8DG_$^\=K$4#R;2EYEIS%6LZ@$*Y)1W+)&89B\)EEC[H[*

*MAW+Z8L|9=!M-@VWDNBV)366;4(_(:?IV;\S7D1H-U)>,H6WRJ?7.GH,/AB@ M&G4_,A0&%S>_"]PED1]Q+B;15W0:0_K,%IP4Q9+UK46T@N^]&\}Y^]Q+]^-?I%%1O M-*IR)=^#!V|HI_[*

LZSWY;TA(^C>P0G)5CF$CRJ>-TSE^LZZ,YZ@:363/((U# MC.Z@Y.BB^[$/@78=0_(;-0$1A/#(AXGE,2B5U&PY@LYQ_ZN)HM15AJTE#W5# M;0PSSOD_]:F-K3#6(;BV?

TIZ7YEM$:FU+)&NM)^U!;U%@"-#8*MGNY' 7@24 M S4G4F)EOUU9!-I]KIX^,OPB,EF%6&1#?5@$,&.=:2,!+@+9WN=WJ\ZYB"QC MH0/=TE@7 4W_BZ.S>BW5V_-

*SBJ);C;1HQVF+=[\E'M5 \^?>|'P6>ZZ 3=VMY:.'V1P#BZ+ZXHUP M-NKCH**.NYSOT3M 6P1QW 7M'26;K07!CC2*

*G.WB3!C[$!PN*80**780^WAL\UM%9A",4V=S;SW(N5ZI'|Z56XL"3#Z|T MR NO9?103EC19E_\;F*D4#GY8K6>%47NWK7-?>Q[;M);^T{E-M%@HL61XLZW;+F*-M)F/?*

%%7^M@HA1(0JA+L'7WOSIG;.U)_6A2!.+IQ'#==UI._#*3N7?E&P3 M)>'7,#WX!Q$+@[SJ,^,[OK M/X[L+++ @U,*L]QWC@=/I(G?TK=[GQ)RS67QF!_&)Y"8 "$7ZPEQHV MP&L]$O3!Z01"V[4\%KYE(X4J-+PFX;7,Q8_04&$)1XS?DP\O572VI-) /Y#*P(' //> 3J=P^""R^4+W5UB'4>Z M X"#F>-^;IEAQ(H!8G=0MND5 >L%BJ@ B@$ ^"!+.1@5U!23^U[M@ R["-O<$%AYXO08-KL+'#^=#64#(%>47X2X<0G\'"^L8B-NLE8"BH#4WWBH]YX-'4PPRSOZ^8L?QE;2TUP^T?*VZL$0(RQ&6*;28'<-4W&(>7;Q;*45PU M#C$46\#)U2UT#E>[> !E+A_\|'=V5]?7W=1,&4>GNAM.1Y?&N#*7,2(QBUV/P M[%Y0RG=L^0<77K 9\-1@5TZG.<86#:&O+;]Y#PZNC>+WLO(MU,F)1)C,A]_-~M>;.^%JZ-V17-)0"'C#HOJL@ZC8N3H-T0_1TZ5.R_>E\,&5_0&6$04]G 8N:&< M4G4LPUDp L>><=TDNWJLC@"'K(E^\&T?L&(M(${HMWZG2&DH'>7/>.=CI_HYQ+ MH?BM39QY.9R^@AS.9]? Z=#TW=FGQH>+]1MH*CQ0><1=$M'"Z MCIU5OE.3$?D>1!'FMX^ MPN<3]H7\^1#K@Q8X;]$A]HG_1Y<+-8|_ &BMQR'[M1_<;,.FMS:#O;]MQYM'T-S,FTVHZSHSRF O&3(HFBHU&Z6R$62RGD^IS(KR_M3DM0(5/S):>R0'#SJNX E)4\NP;XF\UT%66T:D<@^:$Q ;EV'+ZD9R M*ET&?;K7IC5A-]E&*=ZX=26MY<1:MR=B=64@&7$%7<'J:VA+ ".6N#M2I>:T MC&#A;MR)H(M)%RX%TMGX257HM?$P_ ,.^.W:A5)!WQ""=V',A.C%)99#H;G MP#] ^CS=PZ6U7]5IZ/R4QM*KR(@7$,8H-)\"!+1#GX3O6:#WUBY!!\$?|/ MER" ,#!8!X'=N&*^6#QA.KC4F"N/*EL! E=L!__';#A$,*B'ON!?7@8>2\%@Y MO9W.J?|JQL?T-;3 CX[N>1<|\^/ 7(GDU&<$A96 /N,G'S+'!(5)/#A^5>::[* 5^O$9E'4YI*9U.XKV!V#)++@%0HYRA?\ MV/4Q2,(M\%WTUDC!<_!K7'3NU&L<99N!F/YF?^.D-SMQ5:(_!,3 *F?4 84*GX0^-LXL'JG M,OUV.]F)*E#|Q .G=WV%#LB$ /<\"Z&)#A]Y*#YOP6P24QBISM9JTR^:*.MHM_4U!ES)S:=5)N\!=T-@2*$HY-YJ,)XHGQZ>+0H $)?;*9UDQ_ 010F\1.1?O MS>6LZ3%7$9 3#TD3Z/O;HQ628W@ZCS&!TH1QDZ$U\0>::,$<>ONVCY1_@WWMN M!WD V58VZWQ&^3.>ARIV"|\KRC*CL=I/CBSJ.QC=YB#C43NFS1@ OROJG65FU? 4!@BVW^HIR%4H_M0"_0@7Q#%!%2/^0AB)D'E$6V/1.DU)\ M]&9!GFQY6Q#"'E9Q^}{]=239R=K-ST!>4DP",XT-U@&1(E\P$|)R^@TTMIR# M{(SX2^_@G(20*T8,C;- #;TW4~XH4<&>%9\NQW1_#W%1>X2?VK,WNQW1_#W%1>)]);:R!F4EQ?21-H@FF_EBH8C2^!OQ6+F5!SH'R5M1O,/^Y,=T M@*M2(E&C+GF2]!|#,V7@_[!#3A9I]*S5"< M]A(:{]A<&$*|+TE#'>!NNUX"Y_)P)FY(OX$DK^;1A*D8V>%B\-52"HQ2.Q.(?%^RE_R81Q!ES;PQXL1DU>X{)8=] M$>BR0L;fT-*4W[G>'P/RG7(MMAG@MDAZXFM?M.B[152- $5#L>\8!+A"^CMJ^ M0 SB D%LJ:X,]TT0\.C^_/G92G31KJ>06G\V;YP]E8I30V4740Q+F8.P8 MTC&PTO0D92QB]1DFY++G\(E&D'E"R MF78,A P[DD,R=A91F[3/,>4F"BT0.<& !L?'D"2}:CQ5[C8PR38|&MDG_7#>IWR,)\8IDN_#S$L:,/YR48:#R8YB+^M'L58]F$FIL7JQ"%,:5A<%,E8N"__AMAVAQLW^"U|S%=1++(\2\TMNIG2JZ MJ[&K!MT$1_>\"QY\>++:NO*B[/B.H{[/,-L6(/ZZV4#U-9!1CO^!*!D45 MS:FFH0[.'@72R:G!,U<$)HFHK!VYN2-)M#\)).}(VO BZ@"N(>^Z2!!BUNN< M0S+U_450KF:NZ65F!?!DF;K%8NZ/[\"G(Q9HMEFOLO4E$VI#FQ\@.T0I#C6(H M)0?.:P7S6*1*,=^,D?*A%9YSCF;7"FA#DB2E)F^T-D"_8+QZ+=#6SYD%^_:* MI7A$f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|5?#)+I[(IH9JGUD2ZG97#//#DR>YCO'JRSR8(4]&'N6M$?0VE?'("0ODBWA# MI#>$'*%_$6]|| */?VCE/L5!/+1ZF;P9SW"4[C$C#- :5M57"ASC6:DXG#2JX MWP4>G'.01O5473EPOI">;.MS"P 7'T-B1W>G\!:BUTB-_A;? &'-="!G#(|P'RS687YCNXN.#KER"Q-MD?R%G3N@M)C2(W:!.=W-'UD!G$;@AR@H$\-CS7- \>-R[*88DSPCE#U?D^ M*S%;:\"""OO>+)043242+9SI;XQ+|^"2&5>32N5#Z;R)2]7Y&5%J M1+FBO*I)4ZA)@Q669Q!%(*6H>Q@9H8M/'4M!9_587PE<7PF438L\?9C72UTM ME1!8F_VSY=.>.*LT4(BYQ3=*-A1)-AK< @?>?\Z+%<$;_0COZCAF%.9@M%[?-M>*.=]4WN9, [^0Y\|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}KG@G9O7^U M4!X]5?L?,J+>,+1?FJG4&QB"!GM@O4%)^16J:Y&6:]RB\JNDE U9H^K&%3)N MU3K8W?@"=11UIL"&',!B=N2VVDR=? 3'16NLAWO.DMUHYT+]@-M CK3A=\!*2S M11AY>M.4F/BW"'-/%PP41:CV'HTC,,H=G(B'R+\, -)1Y,C[2XBLD)^B3*D MY45$"CTE@FW2!>Y0P0-T>*NB"(%6&7T1!_2$X-469"2+Z5)K!&T9NM@G\#2-_ M!+%K6YZ)!G#$=\MGBJ@%^+C-)=?#V'T%NV.01)"90>QW7_!CU\<@";?AY17 M45A>@Q@P"ESU&D<;5=TXYT19YO3&CUT"1GW LI[_>';)A) ([BCN&CUBG<39 M4WC-I8@]:B#E(^I*V@V,_3.GE)^TX4T%Z..$,KK&02<;6V&T7!4/$ZI0,AI. MP*JWX)\&;R./Y#T,EZE3I(*U52:R"2"AS.Q'E,_@?20%GE"09$3TN^:7DVQ M#8E;]K4YIQH7LF_,6@4;.0:(FA\'&O'@[8ON?F3MV#N*_S;L(K\X8+&*(M@##WNA_CLP)Y.SKWO. K(.W\362BC@^-<_C-_LWR"PAK5E> M9E3?5]RIN Z,5_PI@_PK9J8Z >.R;9E03\S/)AXYK)N1VDZRUI<^'/_DVYK@+ M>/.LGZ%Ji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|-+|PHJ]=&&1[B M[1L%&>W4H%E=@]/ JJT.T7#]B2TZ2Z:I)\MHFTJ#ZM4]>L%7M&;0S#^-#!M(S MVN^W,+BXD,)NKQ\1LA-LS@ I*N ?,NS8O.3L@5T IL= RA8-}[EW8X;SOM) M7;X *AL)_Q^\!:? (]'TD(>=2,_KAQG?]'ZBTY#VV)V5IL="@TI"->4$"#,.K MK1#52!%BWOKJ=Q1\R)^$\L@92=QZM:ZY$VG!/0@'G#*2E>$?$7*= QW"^W4N1K8 MTCROX@,H6^1M$L& [*8KP#*-4]$GDRRY9R.]WQJN1G,;F\ M4BF+RBU6)M9;\2O04 ('$3*FP+-,60FAH_D@'*24 7-T> M'L9GU_IT/S5T5(W@N+%M5)$=?K4V@!"APXX:X? S7O_STCTY15LT.6MT[]-1E6FNMIB_EVE2? MP#E("H<\PDM0^ <\">=@LKP?89"<4:U%>#)PS?0$,!F?A(K^F !!WZDL G@-_M -05";ET;R$XPZF0DR!|#Z:,.^:6]S29$GLOL'Q7Y]- '|!DZFSZ;4Y/Q$ MXWX]1*>.E\D^(7))W!W!+GY-W!/MKLS=_>W<,QWNPA8TZG0K0F=1!ES1E5 M+P2/(=5]^GT85 \KD,$0R4*18^;9*9W M<'>U=0%;$=W.Q%>0;_HT9,XSZK0X,KL1(#%5C%0R9"2'&"7 R01F9#7"%(,'[MZ'8S$@+Z!D<$CJ"X8I4*R,8T/=HN2&.M-SL[Z$^<\$|(<2S)=Q7<; 6HAA\ M&^",VQ<0'X-*OC5#6!;HJ_3X1&AV]Z&AV]$)8D;'5/C)L,MPN^G 4=(G>=N M?B,*"6"BO=56 BS,/XBXV,^2T!NO)>NTJ; C,WNI<[2%X<#T3W"I E?-&#$< M$*EY);6;9F)9&8;#US|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|[ETOB5O/R_%;& PX7G_-.:#N8Y8CL64Z[="=$9LG3241FX=N-/ M@9#SLLR@:;7L2#5XWP?>1;WC#[V?H(D7<"=5D3WE..ZT!XS++#E!N)XL-Q1BR M1AK7$UFD&>R-^|9-WQB_&B)S>>>NFEQNU*@F1N8DAP+#$Y5&0,>,(\7DBU[N, M'Q:&@](0!&@<(H|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|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|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|V (1GW3[^[U:"R^3< 0+-B/I<@!PQ_"$0GB%K4%50&B M&5D.!Z.759;(9$CVF[F_Y9XQ;.;Z>R]U4<<(C$VG5$;C351#*>&8S$*9_KK MW_9BS/U,D4:'L+> [_2)6R\-AV>4 _FWN8$SUH'D&5\-+RG?]>PQ;+V&E^KN M@0/?SFQX(>6>4A'+8&UXE>0>5$(QD<\F2+*H*UG\NMFG-\PCE%]\)U76*C] MXD)+#Y'D%2#TK!@ENVW.2,@.PKOP>HX#1F*70!?UWM\U(@&S1D,"&%%SJ9G@3PH M\3MP]2-OUX,\2Z/-G/P[*HPV<[)"\ZfWU&C6(*-1#$3S,T?@;Q5+(N9'RRZ.L MRKU94,T_Q'YDH[^KOG"KUA(::3)I;&X;;W/0%C)0<9DQ-H=5,-@\SV1QK M0^V^@MTQ2"++1U44=E_PP]?^(FWP(<2TEW@7Y_'"? +^UR"TI'#U'T>VDLW1$2P1D_WQX[^39|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|J49*(@ M^18&3F+'[Z@\> *B5Q#?V#8JS!F] QO E;-7'^_??><=1""$8C/<_4;GHGH!.MX^^IE!DI$S.5Z53D7!IZ(R>]A@7C9GIZ8;$GK-ZF0E$UB$Z9679]\1&RF8]*E M_1]0$\S9;25++>V^G(/&\0>GW4@9T68\X!$RV#LHR866':-.K7=)% V2"]!L]M,. ^54F*Y. M@DKB]+92IAP!^T^\X/)G?.F$UW36V3_*26=_^.UCVYAAY0?))PYJ'A?7N3*. M6Z.%Y._#^S;>[\-H 1$GT*]D;'ZF.!M3=;%J++>BSD(I7T5AW9>Y\,FXJK1> M/%L)Y5[A<9"N!4-77;/&I+#KFM4.(NZYX%ZW^>,9"]0@;>EWJ MO-8>JCE'!VIPQ@;,W-#1WH!M3;.HN!B]:B-AITI+,ZOZ^!GL:G-8W+5)\0D MJM@GGDV*T%"=*2J?"|/N5&^TFB"F+@OFVP!-$E'YNQO]?GN!];Y|/%GA[X52 MD-QN&BTHGQ>S{B.WFSX+0H&LW=92Z:%N&1GYMR;'++L#%Z35Q3,%_@C"?442Q*

*MV1$;33D)|'CD9E^;!=581V\KNRY(-OK&IX6*$!NMAEEC#+.2H|R!031;Z?H M,1/|\G"IR_) E,D@4-9E5[\CMM6'(-Z@V(@/_8!W 3Z(44>TR$A2;?05\+E8V M4@;G;^!_L*L?*
5ENHJWS54M&8GOH3B??,>]N$YB>;P*G*U6DN?1/JAO MUA5K^B!LV2]$>HQT?B*HD0/ <)N2&TJ>S2Z(6=M5_=E8IRW=BE7SU3,.1C]f M) 1\=&^+7IAKKJOYJ5XBA6?
AT1H7@4AG?5_>V#2/;-EBE6OHC(;X=Y/H3V)?#<.!AR;K(CV?BELW-?F@CMIX9"D&_F[!BH=-YW>-ROO*RT!D#&4R/ M,/ T=-%##N!_=DFIX9=),.K2Y%6Ul,KNJ_5?
GE4M@=&3R#]+$$SIAE>*-M%3OQ#!N\H>OOQ@(AG\(6RZ) PR.6M6VHHc*{(7<*H8BT._N;_AN#*TWVVWM-M-4_14|@VAU!{?K<[.%?L$ST;
(4'$,4%K:@.XGX+7=]VSQ[54OA MA84N^W0]K>/>*C4@T%69*YPQ.U;H-[>;/H%(:U3T&A6]1D6O4='SBXHV,#QS MCH''9D7ZCAX@:T8\4Q>!KFJVX,M+6KONULB>-
;)GC>Q9(WOZ52SIQS*G=VXK M9Y?+#O81M2DH=8*OT3!K*(B9YV*'L+C)W<9=H!GF2)ZK(?VZV=|=48GB)[_2 M%'T)#P=!N/&\X,OR[;Q>KS)C>K[$UR &:&+/ =S5491
M8E/95IP<\IMJ6O:OCG[F!4;*\X=Y\'U#C/<-&M)4.OH-7EA6XO4_"+1B MU&%P<=&M#4\A]U0AT5JW :<D3+6\3QHR>SBNI6&\C.H77^DV1/3^'V]B3+6(=_$. M/"=8==@.7l)_|-
B3#_!E9(SK$=-J)\VCB=XS?KRBA3WF@B>P9I\$QT%P+'-M1==""P+M.H;D->!GTB'/"A,H8-.1)#4SUO;>5?XC5X/N*%H9;D,8@EE'>_!D|,A^$1<\<$Z 'RW,-P) X;,-)!\Y\9(?RG3 M+BD!
[^1V:J>*"LJE0ES@1T?WO L>_!C>3=1(^*XCS'MY@_TCDAG9HV6#FQ,2 MMH086:6Y[-*57\'N&"21!64^>'" X,>NCT$2;H$/A9_*T<:")}/&99]QE&T&
MXJV;_8V3RG/;X'MB4]7^4JC);6,(M14ZT[>=T+(RVQ0V]E4!.VG\$7::VUT?H8)6R?92IBM9|<6=1G,+K-0<:C=DR;,0!^5]0[CZ'L]DG=,%$$
MXH@='4YH."j;>75]@&#++9NB7(723RW KU-3/H.0.X2?'#LX@8?C_ CFA>'#MTVE2BH_>+,B3>6\3QCB-3^Q+)|21I >1-CX#>2GD V${$N$79PI9-X'"PI:,7ZNF[A_MG)/*
[Z]LB6^0@.+@A*>%87_;?I"+U(GT,.I4X__X!9(?>I4/GYR?9)}4 MDW3Z{#P@+ ^H5!5M'2(O!(CTNP5#}'=7D>0WB?X/X'=C!P7?_.!7'3CLUV1/O
M,IM\/NHN2P^/"RB\H'CJC7R+BG66G!.9YF|!^LW&OXFBP'.1-)Y\)'&; 4[MC37+|'V)\GOH(7EX\O9!>$1+2OF.2V#;/07R4B)ACS#T|?1/>9@*3("&9XN/LQ^B]D##,\GE M@B=JEC3\T?
8Q01.WDAK^O+MF-U5GZZOA[\j/"+!*U>7"">O/$*P%+V= MVJDBV> =>!B\Z.B>=|&#'T.620S3ZS.",C+++5$9&X%JUA>I,L,BZVW,F>I(M]1XX-/Z.&""EJGK|UTFGl0+EAU-
RHDZL_KN~L0=KM*]Y 74 ,-7>3LXRVFXY(MY2NGE!H1F;O&-0Q4\S#0 M&G?6&2X!?D0T40H0&5E|-Q2, 8,>/G/NC0$/4 ,-RH\!S'6SQBNW_IM%Q^PW2Y?; M4WNEKTFH!Kl,T[*?
6]R#V5@RB7C 8),'>66E,?[&[K?l/Q1 M\E??PL &P(D>X96RM1!MOD->^ 8$;+B|14'IY!%(%T M@O<@LD/WG.'!U =XO92)^.2)L61U5HI5Z#9/Z%ZKMTV'F,;5NT)@;?;/ED\K
MF%11(%G1N@4.Y.[.BQ7!B_$(;Z@X9L1E,EJO19AH_#U+X?$/F&V_ Q]\6=X. MA"M%H=D,W3OO%LQ M6S!@=%.VH/J.A_L4[*SK>@W,0N4VL.G555^SA"K?,#/P$"L
J,#"\S:WVZ'M3AR'D)'4?0 MA'TTIBK$29H-%E*CNY5.!%E:V,MSH+*>]6(S%20M;9AK=;@'M990 7O(+,V. M,Z]'M51 ;$=[8=)65]4!&+KZ8:X=EB5'YP#&,,C;R/5EUD)7RH|\US1D*"3#
M> #)%F5X8*DVTVC;MPP/$)6$3-TX9OBKMSTP(=G7#'|KM@,*#+N>X6_&=@5! MV*|H^+,P/8Y(ROYI^*.NPR!@VC@-?V^UZZ'L:D<=12K36S'E&+[*041OV9UJ MQS4QVNL5Q"A=Y
V$>?],.Z,L8M=+8N T?GV#_^_'1Q"[MN4I?EOWQH]=:|\W2 MO8 ML),0'}&'[S0-CWE 64Q%GJSX,5(O&Y6$IKAYLA%[*&UR"!9.!:Q))' MI'Q$&5CWX#,NGR5G%/(C-
-1DTMPRDM3FDIV3NZ]@=PR2R/(=R$EV7_!CU\;<@ M";? A_SQ+O O((Q=N-VO04PI)-9 "5!?,/HGUFK2L[8$VSS%ER +V.?^0-) MC\= 7XDP?A<@T:K59W?
AP)CK6^PUDK%=7]C5,SB&2TIJO1@H3C!3DV7/U?FXVV06X_VM SO'DV^C$?77"5 M*(;VQVBM&=#"9')I)0_ >M1DQ"Ij!:N-@>BW>/|9L8:OM>0'&, D%L_H!%LG$
MY0J8+RKP>AEK/^)),(NU|_75&5A%''D7L]98B!7M'Q_2YEM$C#&VE9!FEZD)-MF!8WO]!8KJ:ZY9C]1CTALS1JL=_9X(I'AF/21=Z1QR5,-.?A.EIQ7M8+T@4* MN0*^#2$HS'HWAT,
(#E8.4-4O%,'HH7.*K$!C+U9/*M00+F,%OMHV1GG7QI66\!66:H66 NJ M+ZV@^CW8@S $V2MN -]YKX"'^%^36:Z5(HVH4+*IR7A4Q=FU"4DMMN&1FRA!D MDGGKM6*"CC'[.\6$-
;M[S>Z>93ZSKHH]11*2OK'#@[KB!1R-PSLGRZ?X!H%\26]R,,HBA_5/@^ 1^P:8A\QI9_W>+] M4V&(O*3I[ZMV'+'GFT2HWR**R7!SKF!'-9E_XC=\!.H>0@)#_)+(M#[U0+]!F
MJQI6Z3Z6,1>WUP_?_6\"[D%DAR[F!QP3,K^O)DL3LBH3FYN^@,%O(-$>$\A) MFFY&:S8QX=P_^;_PUH+RM'2_*[ZS")FST\>90U#1M+$_%/JL-S M->;K-E2.IX#W$[EUQFH,HZZ
/*XS).*<^(&"%@%XZ0,>XA\;J,4E$QON27[#)4 M9GPVU9).01DL5J2EC,#H(0tH*DKSLM M2$S/ZJ\4SJK@0 =U!*MBUKPL3=(:A-N=:,%O=7LLFF2I-S[^UIPT57\+ RJP96_L(G 15=^2N
M(J(M@^4"DS>^.HCZ,F]67@53?_24E6N234/DC^@+%G67TZU&17I\Y\VS^$Z? M43ZE#+B'T]D+KB#EJAO"$R>-U=/;JKWBH5"[5CBMMOG)M-^G!OLU-6,*OP+W
M<(02P@W48*T#P#^BBC&\0/FI9Z$,]G>HLX>N#2>'S_L'%/"B]^T'DT.P^YA' M.6FYJR M(C%WD ?(8%78&9*UU@B*O8%'DKD[$5TOE T!CN5O5(*<&<3Y)8<^^=.M1K9!+ M?
8,,=]&9<*4(2'1SWP5)=PY'7S/<[:H9+7=6# WWZIH-OS0F8@WF,U\"""7E' M$+NV+YC:V^L=4WMOK&M'0ZK+ZQU>V$NA79PI9-X'"PI:,7ZNF[A_MG)/*
/

U@M4,#5% MY)GF?&D1($SZ+,V ;CV-+3/;TI_ZGHC7GP%X8!5=YP@EB$?< 9^@<*K$'|! M6A5'*1'FN(K;A(P5-\!L^**-2NU@J,8+=LO,;;^5!E(X(!LLMV,3)CCBF)T M@!+3]A7$2(R"84"QPF?%-(R2"Q/>CZD"'&4X3 W<[S*'[,:WZ#;.@;WJ:"?L M-B4&:SN"(+#6_X**X]\1+7&RN.0E84, M6OITFEO)4H:UDWBA?9BJ3 M3V<[EFWKI=<0-
>ND+1!QM<_@ZZOP0RYE1!48[$NJ/H#!-$E MV+=^"KBP/>*2'.SO';P#4SMLR+6QF!S<%B5]E^<*;F6U!_(;C9,,>0\^5^=O M6[)"3C]PJJ.#0V!N88PL399Q>E5V*HP>
[%Y\\7=BEVR!E3YC(%R&[4_9=9# MDJ;0*7(5';Y*[*. 8.OLM-G8WD;.05.693=&`IX#-/(H(-MHI-@Q@DC@R0- M&2=&R2ARL]E'J4(4/"1$XZ($>G_0\%M &XE:DKKO,R239-!F5LJD-
2%>*7 MUQ*"/"'5% ;E)'4 ,"D(QKL34!>'Z>UK(6@,'5ZAT_>";N#NP#8F!VE'@-* M"B@H6WU&;4,?I4JQW,7M!--%9>WL[N_,2"DL.^M^Q@5P%WL#X@]3:#;M:E>8 MFY/;/;\\\2DSE$?
T+Y,7:P)>HC 'DB2J?KV,0G .T*O8%#;CQ@98&B4 H=$ M'@E7;IV'FIV%&JD;A4,N[$$UB/65\?\6VW^!< T]BBQCX [(]E&X1Y- *C
MJ7^<@VV+JKN\O,RR[UT87AJ)ILJOI#<;=%8 8XN_U'H'XIF -G9VKCK/UC M*)0#@P_XC8A\5=,?U+J;WDQ6CW VR/9N3L#.[ )O7L.:"]~6)"K;]^SO?6=4 M=E0Y?
+F)RI82E;V]O&AW7M=;I/&FWO7)2;WU9XFT[\&G^CFI=[OM1M.^VP11 M;^ME-T';-P1!72]_O/ND8+<%OZ)Z$ZS]C,':.G':!FX;Q7X]=E]008=X",G4 MENFD^H$1_Z;@^7C5M%6ZP?
@ AQ6^-/77'U9P[B!5C%SB204CIW\9*K^+/?UK M6W?_.8#9WYQ[?-*^YD3#"M^>VUR7WER7WER7WER7_F&9NKDNO;DNO;DN M_?V\8YW\#\3>?7+\8[];TC^#U!+ P04_"
]@&99.[KU2O\(K+@ M#P '-R<'0M97@S,5\O+FAT;>Ù;!V_,-A/^OK^"6[$A 2S'3IBBD_T6R-IL M"["WW=*\P+]2TLGF(HD;2?G'_OH)1TJVXSB-LZ;=^CH%FD32D7>|>^ZYHZCA
MQ!7YRR_$<$(RQ6\Q=,KE]/+\M^BDW^T/C\(E!(X:B>%(IPAWM2*G_WQ52#-6 M92OD[?27JBT<;)T@TJF]2K'L?BVF@]R55(T(36>N%CT!U]Y+:F:MG,TPI'3
M5=5KGJR\&>DRI3F<70R*%39C@W/*FV54]],#>72]2D-1GH>6?4GZQMDY*) M<-=]AE6K(=.E8Q&*^[W*#8+10=_,\MDH?)%?*4*LN(-S<2E+F39"HZT<[J
MK*.YBV2NQF6<4^98!P!OU\=B?PZ,*_^$^[\;/N43#7M]<8Z)S;>)G/?]O*9R%F MQYVGC^&"\]!^NOC^XDH$3"X=L.,+^L?WJ;W."PD.(/.O><.K\\NKBQ\N7!U=.M7:QJ^ZXJ(<
M&UET1$++&J6PAW$2Z^%&\\^)S=$X?'A$3.25A.*IH1BD\HJSXM98&4,X7XI*8 MJ(4NQ0_:%*+?BWX5.A/OI*'*27$U(9A"M5.)[<"[2,!?C*X MI+&RSH#IPYUT<#C87W\?
=\?WTL++\&>Q$->EGN64C]D3W&Z"LU.-R4KM! ^4 MJA2R7(BZ=*8FF"L=%9B-HR!%@2NC9"XRF>"6$;103C@=Y&X)E)20M=(L6*20 MUR0X5LLY+>ZE.
8]\DKU;Y<$ M">;D#8"A.=-AOX0;58.MSQ?X:8) MF=U0#6-3WUQU6*+.(0"P:34]f/>GD3:B(:YAJ!399-0AG971*6Y(
<8=#HI00XA!"=SY.)+,5NCTO^@3P4K\G"""C4T_?]X>YP94ED;7=N<+N#5AHJL8JGIV&U?BA @/!%]MSE4KG#1U9 ME2I!%"]A=KFN;3DF6K+]<:GCO7%R3.-
M@2#L)'U@RIT02JI<\D$B65Y(U9U M"R-'"%5POWOAK1"R(H&$\I7O.60>C3:SMG/BW(+<[9>R,/*!UJE(F!VEU*9D; MI048N_!X>,>H'M#=*U-\A0\.Q94U:8" M[JPOO4FB3>H-\
W3F$I4U!SPPQ-TW%@/BZ 9#! #_E4%%MQGD"6'XGP]\HG M/4> L@P=BYK"=W9+Y!$JG#O06+CD:W>W";L0K5Q*$S=T MV?U]LABUK:+/$PJN@#T#GGR(<9&"?(+';T>.=U1-
)^&?,>[-' SB'JY=.2M8PI"VT=QO+K(DQF$!ST1AQWSMC$9L 8^V!:Q;>3?7X_R%O%LEY:.M=ACLFDB[K%S),!Z;E'I*&]2YIZ&^\7=\UGV.GO[M#MZ_H4E, M+'=6&
<\$M(ZF5?(S'!Y0;&^U5BO;)/HKIXU=%CA_W,6A7*.Z'T$.]*HH2R0 M*ECH9SD Z,!GEOD2O[G-:W.%_]@5%N#3HBX3OX\\W/-6_0Q[<6YD%/# .QC> M"R6*$,"F."U;YAG);ZXVH9'P]
<:W0/ZM4+LO?Q LFNXV[!^W<(1,,=#2DB+N MAE#3.6$,8(-&IQ-JGD7!LW4!Y\-/?C4-/6]]A;'G],'-]!G*5F:0@!W$ACQI M(+K^35L#@TZ@?%5.=3XEYOU2CIL7AJ;A&2JJ7"\
(3V<3'UADICW?N".R8.5SF!E;AQ!1FQ=S$>?@^;@DU"!MUM>>@!ZJ(YO_#WLI.Z[7<;A#[.YJ,.0UR-G!N=$ M(]#3==>Q_1GQC>Z1OKWO*1?]6.@.^,?_O> .1W(>\-$]!8(?
=>=,1Q[_CY MC8/?+9[?6'"P%(XU?_NIC[\?<*9]_]QELLC_F!4I]2"^2Q^Z#.+\!$|$[_?`M_N_'G_>^3/,-5]>GOUWFS_^'IV_+;!U411)L[GE-3\TE&\#:\/6B|\3*\^Y=I3KOV?Y]K!+^&<
M!3O;6REV^+ZV_TC6]\/|H5I^XEN@K)L^1/=,46E3]D= [O6ON!=^UXW MRVD>A1>#_)$N E07Y2!5ML)>...G[C7GQ$@EY#,9H8L63.+Q7|\^N2VZG4*>.U-_^0966L
MY]H[/*RZ=$U-.4?51&>R*! M=-"O_# *"]D-P[>05A;2N>75<(OW1]DAK[D4ODAS2Q,*4$3DV]?#=[TAZ,> MC7'I[ZE7X'\47U/B_7*(EK6^O,3/*V!15/_P;[E_Q/-IL8I1X#A5<_;?;O\0_C
M6Q8QN5+$@2H8G#W&=K\6,A0 ["BAG=7-[?C]^-WE[?CGZ[WZ2$(3PZD??JZ M>W%^_LTVZV=2S2X?.%0Q?TT/XPX;<\U^[+-(KYZ'BNL,RL%[F2^8+[M-
G490RSKK=MB)+X!]^V!QUA]DPQN82NK[[,N M^X$[U#+]LURR.VWF"L04.E'M-B!,&]Q,&\]H(>;<;UDM?,V!A27>RAQ-K(" M9R4^6 M1)\)F!4EDFDI5W!"N"FU)KW##0F3*X.('3
M,'1P(>)3?)14)>D(\Y[?40380%>T-LER,*A'],<&=$ZMS&%)3NCCCEG_!3 M]B]P* 1J-(3OQ\W=HG2;]T4>)$0AE<49)P?T0=.*DD-Q*6H",N2W$4DTS MU8[R37 =%Y)3B#3&
0J$?6P85&$5)+-:<0J0N*P@Q#IOX8B8!3>3-_XU`2)$ MH^%X$$<O) I#G6+'(&>K. M[;@\UHGS@# 6'W=7(P%4.!!#D(LUS\34?K\(AP1:OJ(&*NCRQ^MD-FE+Q>-G
M$%%!\@Q\B/&A<#@$S7^T'+443651/BR&Q]/B#F4O4R6U98,M)$J=DU;&N=Q M+.T5X60NPYE^CPUW]UWC M.8]7^)O*O-97X/=:X@*"6]0Z"WWDZ9&7ZI?
8BU;A(Q$/U,%0+Y1D0 .VR6E5 M.L^!WU&VB85&R#>A!_]!0FU?_B18-:5M!!WQ @N<*"!#58C8#Z&F*XN4?FHH[";CSOW.(X\O!!Q?0EI[WR! 4SY.7NT_?7G6.!:G
M6>;1PXT!EF%J_2AE;AWYIF0="F=>PZ;4T<2@PXA<0U$GBB^Q.(19UY@RQBY M#/K],O^;=@"N1?'*0>IB?P&M,L+)6YP{G):B +,E3MU.=+ZT=\0(958'44&
M=F\"K]7I.+.^]GBTY\6><8, -^S|^T/&X1]V>U'-"6] SDZ;SE%CR01CUET: M?B;T8L>Z9Y1PL9YJ$(3P^SL.@@\ Z3]D7:/CE1/TO3<==M8 >WWOU'>'YK<6
M'"7ND8RZ.NB/TG4O*I2$-HH^,W/W7(-.+Z_#2>8OMU/3<)DO!#['XB*?ER/$.R[W#_5?7.'%%;Y@5XB2$'Dj/Y:O'CBBR=^P9ZXMT'_$(]CT!'6 M+D&;&I?
K$Y0&0TX_YB+XFSK"OZ5A_K]=2FUO]6:*.T>W>J>0;".@-8-R;5SZ MW;CBFRM0)$!D>[UHKWJ4@-^%=!5VT"E],>\3;]3[4C^\&OR?V%N:\LP#$U MBY<[PZL[P^N;P\4J:#
<22QTN:CO/;./WU947/3.!!^YU?H8&#:F3BQ$]HI=]XSH!03(#-= D\YP MCXHMQ[]3)2/\3<*OOUTY#DEH2BF4]K.M&FL7>WNIUUYJ.F;V5PU;C56*,.M5S+43%#+++U@T47/A
(]H;Z)TPK0'3\!,MZ@MI$I:%&%A MX!/?/<3[8YX5JW91(GD>T#0?_]Z\'PP)E5. MKH"X)@1!^TMF=Z,0@P-,_R0PG/3/QH.7@Y/>>#\)6_/ST;GO=,Q&0^_'I,; MI\5/!.8?
DN%+,G]>V?/>;7_D#=^_Z?}-B=C'&G[?ONN@K07 M')'SYJAYTB0U7D'GP-_?A8>+ W=@:<.GS8-,Y_&V%]^IMB[;1*^+T;=!,FB0 M%Z[<"FK(]$D&)$1]\@:>"S&-X\#KT%
E2;]L"59 M$*^%,"-52FS&R(C]"97,>,,Y8 O2BRV.8$8V8)R"6L8->5=2#3DC%N2,X7L4 M94"3%9:2<<<8@<<%9:'IL&N!LW"9AX]71. M]{1U*EG:4/]SD*IKE*\"(-53, G
M<#.?,$TZX'C,;S]MD+04(!.KO! <()MQF[DI-/M0-9Y2]A,]A"Y:!]SZJ,"9:#0%"3PE)@R MSBZ)?2,ZREU(FAGTJH%J5 @"TT&45(#/I@ W3ZH!,(5I.43P38,/ ^]"!')BY8M%KJ!'1?$
M@.*>H M56IAYSI*HLA+X?M- 7"M +((6AH6&%13 9S48KLVHYG.M(3B@:,^L7 MW/)%|PNPEI,*012R.KO#FK9 MSKK,N71-9X"8-I&, ANZOOX^N"3N"]RN8BJ6&51EU?
1^%XC3W+<76VJ1QL'A3@C!(\N845#YH!*-\>!"W3(B^& MYZ>$;N_7OZZJSWUV6P_,CZ 9!^L>*Y82;]WD'^>LOX62=Z7PGWE7 G*^$M MJ.@:;@X'Y0). MRI\5V?Y550&?
>.B[R8HP)4%&'L!U4=%,, MQ!J5B.4.D$!G.U;=&P;3-# 9$D8I"HD M A=?3!@D&,'+0AFVR0H>79,)K/C2O.(C]U#AR:-YVP_B:%VZ>I9$ ^TTR0D\W M475)#G&N^0Z1PA?
8Q13XAJR2"T2SE&DF8QP!"2H7&"274U*"?;WM|R-X?!@\)YTRCRI$E;G M'F3[VC7]V5I*MC<2V#-W2(A=5,E,DX!*01=A#A:W!"NT0EU9;7/3.!#^S[_8@X%I9^*\-+13[%QG
M0B<=,L.U10DWW$?%EFO=R9*1Y";AU]^N'(!=V]YEZO5?V*!PV%16^BDSE8-Y?\|\;&-8\I%/4L2H2Y#."QFD12*!QD7EYD+H1,]]EX2<56OL3 .G"[" M=G-?J.A#
(%3"9V'0C7*AZKG56*&M<$*KT'#)G+CBT43/ BL^D+^)-@DW 3Y!-M-[VB]!]YJ-IQHYW2.MH[/ M7,"DN%2AY*DC'S2]=C/-A..!+5C,P\+P8&I8$6WXOM$=^]I*Q&5A*EP0HR57
MY.39D\Y!.^JU:.Y1KU7@7Z3/T_@M0S3$^F:,L9;:A$_;_D^T/>)!M6<3+9.O M0<'@W:OAR^$8JIQ<$G%+"CI[GW.[G848 7#S@!P/+@8#T^&Q_WQ\.P4SM]>_MC-[V3|

-1<-8^;4//5Z>ZW=[?QX>.@$UBY\'ESO]M]NHGB M*]76=8?H;3GZ;Y0,&S!D"OYHPL Z7C#5@)@;,))Y XK2V!+?8N TK##'8WKM
M>.8:P"RP1!>,)VOFM1&EHT[!91Q&S$R8XC8XFTD^AW]L:(32L8'C*=EPL*; MDAE,&#F'"TXO4,+!F;QP#.89QZAYZ41L$;:*FX N3K3)H=,.WD"]C??T?KE& MP8W0"7#>.^]Y
])2HEFL\T(*Y&LJ7.:7,/Q]*0S/D23K M(2R#WF&[@'XZ^SO)[C(T'I<&7\:XPF 69TQ=\CJ^SHON\"P(TCP*=@RS]Z)?2TZ)GQ(AEM"U:!I3$K Y3!*)A&S+1"F;7A,J5!,Q?0< M'26^4_
XT*]455 ;Z?%8[,TL?\?CXB[=Q&?K[K;=A&_ZV$3R]:8N(% A-7;1 MHJTB+-1E(70R#R2;Z]+A\C.>1)6K3KO=;# ^M)V M2U98'EHL,>2#",#4WJ^$%\,AA9N'|?
R%$5HE2W:\NP/O;]G^+8*L^[^62[,,Z]QM6O?%_M:>;A?\QF4(L6UB?,%,D))H:S?T+_;T /KC_I/HWIBDZIF,E%XE3)!\TNI]0 V1PL$HZ5(O!&,=YH=
MG/SM*&C9%@S[I_Z=.QH/SONGUW'R/8L'&?K)*N>..?1K|_GS;>-ZZ_E0!@]E M<"_+8####PB2\.!/$7,XQQY=T$=G XXSP5,X6?;R9VF%%:A4AXJY5Y6RLZY
M$5(@)!9,"QZ*@S]H^\,M2.?P.J6MD]Z8BP9_TY7;OY)X^6 3 $]#XY8D$RDK" M$!:F1C@T0CCX>4JZ1ZV!)#"9?YF> QF5,.&X6&'TE2#MA22A]2H.,>]42(F3 MT.M"%2&O-T])2Z.$S:KE-
W08&E]_<E0244QB6),$9=;A+E5<9X.VI_?*)N1D*4TOO#X+,8MKS<4 MR=G,1*^4X0(-2I:$8ZIB(@CYY80A<1!1%MKR=47O\)8]7]5UYI66N$,3GCV9 M[;4[<;1]73U+HMTFC
CI.JL^R3':.%>P0*?Z"AYI&;"0-^4 ,3[GA*]81M&!J M3D'2Z5:B?[.)]R/,]BK,!BP4T56$6SCV^N0-_)&\VZ ,AP70%KL5Z6D.\64AT MP1E+9BU=<%
[R0.F$UI[F'V;YR_]ERVYE*/@L2W"_2:1_E;F*F+R>8AC=97 MJRN.@%"?WI+ ^75H2LVN"?FJ Y#OHF;+QG&!6"A_9XVGI5FHE.I# M2&3UV.]LU5:R%(^)D,DIFUO??2!9:=%%^]*C7\E?
L_P)02P$"%,4 "_] M@&99SH/G0G*O P!*-S@ $0 @ $ /0 #P @ $\,04 #$P7S$N:'1M4$L! A0# M% @ *H!F6?;"A*-*#0 C60 \ (:]CD% '-R<'0M M97@Q,%\R+FAT;5!+ 0(4 Q0 ("_]
9ED[NO7I#@@ "LN / M_" 2%'!0!S+@ -#P @ %<3P4 #,Q7S(N:'1M4$L! M A0#% @ *H!F65X54>76!0 L!\ \ (!H5< '-R M<'0M97@S,E\Q+FAT;5!+ 0(4 Q0 ("_] 9EDK8A@(UP4 &D?-/
M_" :1=!0!S XML 93 srpt-20240930_htm.xml IDEA: XBRL DOCUMENT 0000873303 us-gaap:CommonStockMember 2023-04-012023-06-30 0000873303 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0000873303
srpt:RebatesMember 2023-09-30 0000873303 srpt:ElevidysMembercountry:US 2023-01-012023-09-30 0000873303 us-gaap:CommonStockMember 2024-03-31 0000873303
srpt:SupplyAgreementMember 2024-07-012024-09-30 0000873303 us-gaap:CommonStockMember 2023-06-30 0000873303 srpt:CustomerOneMemberus-
gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000873303 2023-09-30 0000873303 us-
gaap:FairValueInputsLevel3Membersrpt:StrategicEquityInvestmentsMember 2024-09-30 0000873303 srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMemberus-
gaap:FairValueInputsLevel2Member 2024-09-30 0000873303 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-012023-09-30 0000873303
srpt:RoyaltyRevenueMembersrpt:SupplyAgreementMember 2024-01-012024-09-30 0000873303 srpt:ChargebacksMember 2024-01-012024-09-30 0000873303 us-
gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember 2024-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-
31 0000873303 srpt:RebatesMember 2022-12-31 0000873303 2024-04-012024-06-30 0000873303 srpt:PmoProductsMember 2024-01-012024-09-30 0000873303 us-
gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000873303 srpt:ElevidysMember 2024-01-012024-09-30 0000873303
srpt:ChargebacksMember 2023-09-30 0000873303 srpt:NoIndividualMembersrpt-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-
09-30 0000873303 us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember 2024-09-30 0000873303 srpt:RebatesMember 2023-12-31 0000873303 us-
gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0000873303 us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember 2024-09-30 0000873303 us-
gaap:CommonStockMember 2024-07-012024-09-30 0000873303 srpt:ContractManufacturingRevenueMembersrpt:SupplyAgreementMember 2024-01-012024-09-30
0000873303 srpt:CustomerFourMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0000873303 us-
gaap:AdditionalPaidInCapitalMember 2024-06-30 0000873303 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000873303 us-gaap:CommonStockMember 2024-
04-012024-06-30 0000873303 us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember 2023-12-31 0000873303 srpt:SupplyAgreementMember 2024-01-
012024-09-30 0000873303 srpt:CashDepositsAndMoneyMarketFundsMember 2024-09-30 0000873303 srpt:CustomerTwoMemberus-gaap:SalesRevenueNetMemberus-
gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000873303 srpt:CorporateBondsMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel1Member
2023-12-31 0000873303 srpt:RocheMemberus-gaap:CollaborativeArrangementMember 2024-09-30 0000873303 2024-07-012024-09-30 0000873303
srpt:BedfordMassachusettsMember 2024-01-012024-09-30 0000873303 us-gaap:CommonStockMember 2024-09-30 0000873303 srpt:RocheMemberus-
gaap:CollaborativeArrangementMember 2023-07-012023-09-30 0000873303 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000873303 srpt:RebatesMember 2024-09-30
0000873303 srpt:OtherAccrualsMember 2024-01-012024-09-30 0000873303 srpt:MsRodinoKlapacMember 2024-07-012024-09-30 0000873303 us-
gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0000873303 us-gaap:CorporateBondSecuritiesMember 2023-12-31 0000873303 us-
gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000873303 srpt:PmoProductsMembercountry:US 2024-07-012024-
09-30 0000873303 srpt:RocheMembersrpt:ElevidysMemberus-gaap:CollaborativeArrangementMember 2023-07-012023-09-30 0000873303 srpt:BedfordMassachusettsMember
2022-04-22 0000873303 srpt:TwoThousandSeventeenCappedCallsPartialSettlementMember 2022-09-142022-09-14 0000873303 us-
gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-012024-09-30 0000873303 srpt:CashDepositsAndMoneyMarketFundsMember 2023-12-31 0000873303
srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember 2023-12-31 0000873303 srpt:PromptPayMember 2024-09-30 0000873303 srpt:PrincipalMember 2024-09-30
0000873303 srpt:RoyaltyRevenueMembersrpt:SupplyAgreementMember 2024-07-012024-09-30 0000873303 us-
gaap:FairValueInputsLevel3Membersrpt:CorporateBondsMember 2023-12-31 0000873303 srpt:CustomerOneMemberus-gaap:AccountsReceivableMemberus-
gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000873303 us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember
2023-12-31 0000873303 us-gaap:CashAndCashEquivalentsMember 2024-09-30 0000873303 srpt:RocheMemberus-gaap:CollaborativeArrangementMember 2023-01-012023-
09-30 0000873303 srpt:TwoThousandTwentyFourNotesRepurchaseMember 2024-01-012024-09-30 0000873303 us-gaap:ResearchAndDevelopmentExpenseMemberus-
gaap:CollaborativeArrangementMember 2023-01-012023-09-30 0000873303 srpt:EquityIncentivePlansMember 2024-01-012024-09-30 0000873303
srpt:CustomerThreeMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0000873303
srpt:EquityIncentivePlansMember 2023-01-012023-09-30 0000873303 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-012023-09-30 0000873303 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0000873303 srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember 2017-11-14
0000873303 2024-09-30 0000873303 2023-01-012023-09-30 0000873303 us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-
09-30 0000873303 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-012024-09-30 0000873303 us-gaap:FairValueInputsLevel1Membersrpt:CorporateBondsMember 2023-
12-31 0000873303 srpt:PmoProductsMembercountry:US 2023-01-012023-09-30 0000873303 us-gaap:FairValueInputsLevel1Membersrpt:StrategicEquityInvestmentsMember
2024-09-30 0000873303 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000873303 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31
0000873303 srpt:RebatesMember 2024-01-012024-09-30 0000873303 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0000873303 srpt:BedfordMassachusettsMember
2022-05-31 0000873303 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0000873303 us-gaap:MoneyMarketFundsMember 2023-12-31 0000873303
srpt:RocheMembersrpt-gaap:CollaborativeArrangementMember 2024-07-012024-09-30 0000873303 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30

0000873303 srpt:OtherAccrualsMember 2023-09-30 0000873303 us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel3Member 2023-09-30 0000873303 us-gaap:RetainedEarningsMember 2024-06-30 0000873303 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0000873303 srpt:PromptPayMember 2022-12-31 0000873303 srpt:CustomerTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000873303 us-gaap:CertificatesOfDepositMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel3Membersrpt:DerivativeAssetMember 2024-09-30 0000873303 2023-07-012023-09-30 0000873303 srpt:BedfordMassachusettsMember 2022-04-222022-04-22 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0000873303 us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember 2024-09-30 0000873303 srpt:TwoThousandAndTwentySevenSeniorConvertibleNotesMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel2Membersrpt:StrategicEquityInvestmentsMember 2024-09-30 0000873303 srpt:RebatesMember 2023-01-012023-09-30 0000873303 us-gaap:CertificatesOfDepositMember 2023-12-31 0000873303 srpt:OtherAccrualsMember 2024-09-30 0000873303 srpt:NoIndividualMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0000873303 us-gaap:CommonStockMember 2024-06-30 0000873303 srpt:RestrictedStockAndRestrictedStockUnitsRSUsMember 2024-07-012024-09-30 0000873303 srpt:BedfordMassachusettsMember 2024-08-012024-08-31 0000873303 srpt:RocheMembersrpt:ElevidysMemberus-gaap:CollaborativeArrangementMember 2023-01-012023-09-30 0000873303 srpt:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000873303 srpt:TwoThousandSeventeenCappedCallTransactionsMember 2024-01-012024-09-30 0000873303 srpt:RestrictedStockAndRestrictedStockUnitsRSUsMember 2023-01-012023-09-30 0000873303 us-gaap:RestrictedStockUnitsRSUMember 2022-01-012022-12-31 0000873303 srpt:StrategicEquityInvestmentsMember 2023-12-31 0000873303 srpt:PmoProductsMembercountry:US 2024-01-012024-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-04-012023-06-30 0000873303 2023-12-31 0000873303 us-gaap:CollaborativeArrangementMember 2024-07-012024-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-06-30 0000873303 us-gaap:FairValueInputsLevel3Member 2024-09-30 0000873303 us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember 2023-12-31 0000873303 us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember 2023-07-012023-09-30 0000873303 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000873303 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000873303 srpt:CustomerThreeMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000873303 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0000873303 srpt:DerivativeAssetMember 2024-09-30 0000873303 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000873303 us-gaap:CollaborativeArrangementMember 2023-01-012023-09-30 0000873303 srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember 2024-06-30 0000873303 us-gaap:RetainedEarningsMember 2024-09-30 0000873303 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0000873303 us-gaap:ResearchAndDevelopmentExpenseMembersrpt:SupplyAgreementMember 2024-01-012024-09-30 0000873303 srpt:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0000873303 us-gaap:CommonStockMember 2023-12-31 0000873303 srpt:PmoProductsMembersrpt:RestOfWorldMember 2024-07-012024-09-30 0000873303 srpt:ConvertibleDebtAndTermLoanAndRevolverAndMortgageLoansMember 2023-12-31 0000873303 us-gaap:FairValueInputsLevel3Membersrpt:StrategicEquityInvestmentsMember 2023-12-31 0000873303 srpt:CorporateBondsMember 2023-12-31 0000873303 us-gaap:CommercialPaperMember 2023-12-31 0000873303 srpt:StrategicEquityInvestmentsMember 2024-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-06-30 0000873303 us-gaap:CommonStockMember 2023-07-012023-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-09-30 0000873303 srpt:FirstInstallmentsMember 2024-01-012024-03-31 0000873303 srpt:BedfordMassachusettsMember 2024-09-30 0000873303 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0000873303 srpt:PmoProductsMembersrpt:RestOfWorldMember 2024-01-012024-09-30 0000873303 us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember 2023-12-31 0000873303 2024-01-012024-03-31 0000873303 srpt:BedfordMassachusettsMember 2023-05-012023-05-31 0000873303 2022-12-31 0000873303 srpt:NonCurrentInvestmentsMember 2024-09-30 0000873303 us-gaap:RetainedEarningsMember 2022-12-31 0000873303 srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember 2017-11-132017-11-14 0000873303 2023-03-31 0000873303 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000873303 us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember 2023-12-31 0000873303 srpt:PromptPayMember 2023-12-31 0000873303 us-gaap:RetainedEarningsMember 2023-06-30 0000873303 us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember 2023-12-31 0000873303 srpt:InterestMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember 2023-12-31 0000873303 us-gaap:CommonStockMember 2022-12-31 0000873303 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0000873303 us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember 2024-09-30 0000873303 srpt:ChargebacksMember 2022-12-31 0000873303 us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember 2024-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-07-012023-09-30 0000873303 srpt:PmoProductsMembersrpt:RestOfWorldMember 2023-01-012023-09-30 0000873303 srpt:ElevidysMember 2024-07-012024-09-30 0000873303 2023-06-30 0000873303 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000873303 us-gaap:CommercialPaperMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel1Membersrpt:CorporateBondsMember 2024-09-30 0000873303 srpt:PromptPayMember 2023-09-30 0000873303 us-gaap:CommercialPaperMember 2023-12-31 0000873303 srpt:RocheMemberus-gaap:CollaborativeArrangementMember 2023-12-31 0000873303 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012023-09-30 0000873303 us-gaap:CollaborativeArrangementMember 2024-01-012024-09-30 0000873303 us-gaap:RetainedEarningsMember 2023-03-31 0000873303 srpt:ElevidysMembercountry:US 2024-01-012024-09-30 0000873303 srpt:TwoThousandAndTwentySevenSeniorConvertibleNotesMember 2023-12-31 0000873303 srpt:TwoThousandTwentyFourNotesRepurchaseMember 2024-09-30 0000873303 srpt:ConvertibleDebtAndTermLoanAndRevolverAndMortgageLoansMember 2024-09-30 0000873303 srpt:PmoProductsMember 2023-01-012023-09-30 0000873303 us-gaap:CertificatesOfDepositMember 2024-09-30 0000873303 us-gaap:RetainedEarningsMember 2023-12-31 0000873303 srpt:NoIndividualMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-07-012024-09-30 0000873303 2023-01-012023-03-31 0000873303 srpt:ThermoFisherScientificIncorporationMemberus-gaap:ResearchAndDevelopmentExpenseMembersrpt:RocheAgreementMember 2024-07-012024-09-30 0000873303 srpt:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0000873303 srpt:LacertaTherapeuticsIncMember 2023-09-30 0000873303 us-gaap:CommonStockMember 2023-03-31 0000873303 us-gaap:ShortTermInvestmentsMember 2023-12-31 0000873303 us-gaap:FairValueInputsLevel1Member 2024-09-30 0000873303 srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMemberus-gaap:FairValueInputsLevel2Member 2024-01-012024-09-30 0000873303 us-gaap:FairValueInputsLevel3Membersrpt:CorporateBondsMember 2024-09-30 0000873303 srpt:ElevidysMembercountry:US 2023-07-012023-09-30 0000873303 srpt:PmoProductsMember 2023-07-012023-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-012023-03-31 0000873303 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0000873303 us-gaap:ShortTermInvestmentsMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel2Membersrpt:StrategicEquityInvestmentsMember 2023-12-31 0000873303 srpt:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0000873303 us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember 2023-12-31 0000873303 us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember 2023-12-31 0000873303 srpt:FirstInstallmentsMember 2023-01-012023-03-31 0000873303 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000873303 srpt:LacertaTherapeuticsIncMember 2024-09-30 0000873303 srpt:ChargebacksMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel1Membersrpt:StrategicEquityInvestmentsMember 2023-12-31 0000873303 srpt:ThermoFisherScientificIncorporationMemberus-gaap:ResearchAndDevelopmentExpenseMembersrpt:SupplyAgreementMember 2024-07-182024-07-18 0000873303 us-gaap:CorporateBondSecuritiesMember 2024-09-30 0000873303 2024-01-012024-09-30 0000873303 srpt:ThermoFisherScientificIncorporationMembersrpt:SupplyAgreementMember 2024-01-012024-09-30 0000873303 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0000873303 srpt:ElevidysMember 2023-01-012023-09-30 0000873303 srpt:ChargebacksMember 2023-01-012023-09-30 0000873303 srpt:ElevidysMember 2023-07-012023-09-30 0000873303 srpt:PromptPayMember 2023-01-012023-09-30 0000873303 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0000873303 srpt:PmoProductsMembersrpt:RestOfWorldMember 2023-07-012023-09-30 0000873303 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0000873303 us-gaap:FairValueInputsLevel2Membersrpt:CorporateBondsMember 2024-09-30 0000873303 srpt:PromptPayMember 2024-01-012024-09-30 0000873303 us-gaap:FairValueInputsLevel3Member 2023-01-012023-09-30 0000873303 2024-06-30 0000873303 2024-03-31 0000873303 srpt:BedfordMassachusettsMember 2022-05-312022-05-31 0000873303 srpt:ChargebacksMember 2023-12-31 0000873303 us-gaap:FairValueInputsLevel2Membersrpt:CorporateBondsMember 2023-12-31 0000873303 srpt:OtherAccrualsMember 2023-12-31 0000873303 srpt:OtherAccrualsMember 2023-01-012023-09-30 0000873303 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0000873303 srpt:ThermoFisherScientificIncorporationMemberus-gaap:ResearchAndDevelopmentExpenseMembersrpt:RocheAgreementMember 2024-01-012024-09-30 0000873303 srpt:EmployeeStockPurchasePlanMember 2024-01-012024-09-30 0000873303 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000873303 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000873303 us-gaap:FairValueInputsLevel1Membersrpt:DerivativeAssetMember 2024-09-30 0000873303 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000873303 srpt:EmployeeStockPurchasePlanMember 2024-07-012024-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-07-012024-09-30 0000873303 us-gaap:MoneyMarketFundsMember 2024-09-30 0000873303 srpt:MsRodinoKlapacMember 2024-09-30 0000873303 srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel2Membersrpt:DerivativeAssetMember 2024-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-09-30 0000873303 srpt:RestrictedStockAndRestrictedStockUnitsRSUsMember 2023-07-012023-09-30 0000873303 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000873303 us-gaap:CommonStockMember 2024-01-012024-03-31 0000873303 us-gaap:CommonStockMember 2023-01-012023-03-31 0000873303 srpt:PmoProductsMembercountry:US 2023-07-012023-09-30 0000873303 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000873303 srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMemberus-gaap:CommonStockMember 2023-03-022023-03-02 0000873303 us-gaap:CertificatesOfDepositMember 2023-12-31 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-012024-03-31 0000873303 srpt:TwoThousandTwentyFourNotesRepurchaseMember 2022-09-142022-09-14 0000873303 us-gaap:FairValueInputsLevel3Member 2024-01-012024-09-30 0000873303 us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0000873303 2024-11-01 0000873303 srpt:EmployeeStockPurchasePlanMember 2023-07-012023-09-30 0000873303 srpt:CustomersExceedMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000873303 us-gaap:CorporateBondSecuritiesMember 2023-12-31 0000873303 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000873303 srpt:CustomerTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0000873303 us-gaap:CorporateBondSecuritiesMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember 2024-09-30 0000873303 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000873303 srpt:TwoThousandSeventeenCappedCallsPartialSettlementMember 2023-03-022023-03-02 0000873303 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0000873303 srpt:ElevidysMembercountry:US 2024-07-012024-09-30 0000873303 2023-01-012023-12-31 0000873303 srpt:TwoThousandAndTwentyFourSeniorConvertibleNotesMember 2023-03-02 0000873303 us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0000873303 srpt:PmoProductsMember 2024-07-012024-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-04-012024-06-30 0000873303 srpt:TwoThousandTwentyFourNotesRepurchaseMember 2022-09-14 0000873303 us-gaap:CommercialPaperMember 2024-09-30 0000873303 us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember 2023-12-31 0000873303 us-gaap:CommonStockMember 2023-09-30 0000873303 srpt:RestrictedStockAndRestrictedStockUnitsRSUsMember 2024-01-012024-09-30 0000873303 srpt:OtherAccrualsMember 2022-12-31 0000873303 us-gaap:RetainedEarningsMember 2024-03-31 0000873303 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000873303 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000873303 srpt:NoIndividualMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000873303 srpt:CustomerTwoMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000873303 srpt:EmployeeStockPurchasePlanMember 2023-01-012023-09-30 0000873303 srt:MaximumMemberus-gaap:CollaborativeArrangementMember 2024-01-012024-09-30 0000873303 srpt:ContractManufacturingRevenueMembersrpt:SupplyAgreementMember 2024-07-012024-09-30 0000873303 srpt:RocheMemberus-gaap:CollaborativeArrangementMember 2024-01-012024-09-30 0000873303 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-03-31 0000873303 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000873303 srpt:CustomerTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-07-012023-09-30 0000873303 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0000873303 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-012024-09-30 0000873303 us-gaap:RetainedEarningsMember 2023-09-30 0000873303 srpt:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0000873303 2023-04-012023-06-30 pure utr:sqft shares srpt:Segment iso4217:USD shares iso4217:USDQ30000873303--12-31false http://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMemberhttp://fasb.org/us-gaap/2024#ProductMember P7M10-Qtrue2024-09-302024false001-14895SAREPTA THERAPEUTICS, INC.DE93-0797222215 First StreetSuite 415CambridgeMA021426172744000Common Stock, $0.0001 par value per shareSRPTNASDAQYesYesLarge Accelerated

Filerfalsefalsefalse955196501978550004284300001000534000124782000043452400040032700056592400032285900032105500010218100016547700077714000268536900004370023000-44462130001221071000859337000359993400032645760004297710003093220001149803000779805000374010002249500093764000667500004671720003318170001243567208420005640000-29244900011810000-123320003263100017309000001020000000000-38732900011810000-12332000032631000-26802000034006000-33174000890310000-56046900039500077630001284100021163000336110000-4093700076190000-58163200032750004170001327000102600032750004170001327000102600036886000-40520000775170000-5806060000.35-0.460.8-6.560.34-0.460.78-6.56953990008888900094669000886090001004480008888900099572000886090009373290005304623000918000-44462130008593370002071557900015579000461906561000656100045205000452050000-1609000-1609000361190003611900094490900053719680000-691000-44100940009611920004681000399170003991800013155654000556540001941418400014184000-339000-33900064600006460000952831000054817230000-1030000-44036340001077069000118858800085880003953564400056440004899600048996000100010004388700043887000327500032750003361100033611000954931000055888396437002300012210710008795090004296841000-1664000-39102360003849500002672280800022808800039044566933770006933770008064500080645000775229000522900041250000412500001245000124500051675500009314090005140150000-419000-44269910007127490000805861000586100054473770004737700063600063600023940000-23940000932749000519338800010550000-44509310007414110001429873000987300045765532000553200048061000417000417000-40937000935379000525685400063800044918680007643570007619000056816320002726900030250001228900010636000374700039190001346240001366880003447400032847000627470000856500012000000-278210000-38732900001020000001822000-32400034197000104227000235544000-78970002335110005361000039380000288600035415000-66750000-13565000-111223000-297833000-44633600098874000570670009366840001475404000103700100013402650001000000001123900001020000008557000-10144500075815000493030000806450000668700075815000123061000-230575000-42472000044400900098580100021343400056108100019785500054193200015579000191490002134340005610810001161400095690001516900015129000438870000338410style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">1. ORGANIZATION AND NATURE OF BUSINESS Sarepta Therapeutics, Inc. (together with its wholly-owned subsidiaries, “Sarepta” or the “Company”) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying its proprietary, highly-differentiated and innovative technologies, and through collaborations with its strategic partners, the Company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (“Duchenne”) and is developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (“LGMDs”) and other neuromuscular and central nervous system disorders. The Company’s products in the U.S., EXONDYS 51 (eteplirsen) Injection (“EXONDYS 51”), VYONDYS 53 (golodirsen) Injection (“VYONDYS 53”) and AMONDYS 45 (casimersen) Injection (“AMONDYS 45”), were granted accelerated approval by the U.S. Food and Drug Administration (the “FDA”) on September 19, 2016, December 12, 2019 and February 25, 2021, respectively. Indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping, respectively, EXONDYS 51, VYONDYS 53 and AMONDYS 45 (collectively, the “PMO Products”) use the Company’s phosphorodiamidate morpholino oligomer (“PMO”) chemistry and exon-skipping technology to skip exon 51, exon 53 and exon 45 of the dystrophin gene. Exon skipping is intended to promote the production of an internally truncated but functional dystrophin protein. ELEVIDYS (delandistrogene moxeparvovec-rokl), approved by the FDA on June 20, 2024, is an adeno-associated virus-(“AAV”) based gene therapy for the treatment of ambulatory patients at least four years old with Duchenne with a confirmed mutation in the Duchenne gene. ELEVIDYS is also approved for non-ambulatory patients under the accelerated approval pathway. ELEVIDYS was previously granted accelerated approval by the FDA on June 22, 2023 for the treatment of ambulatory patients aged four through five years with Duchenne with a confirmed mutation in the Duchenne gene. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. As of September 30, 2024, the Company had approximately $1,395.8 million of cash, cash equivalents, restricted cash and investments, consisting of $197.9 million of cash and cash equivalents, $1,182.3 million of investments and $15.6 million of restricted cash. The Company believes that its balance of cash, cash equivalents and investments as of the date of the issuance of this report is sufficient to fund its current operational plan for at least the next twelve months, though it may pursue additional cash resources through public or private debt and equity financings, seek funded research and development arrangements and additional government contracts and establish collaborations with or license its technology to other companies. 139580000019790000011823000001560000 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), reflect the accounts of Sarepta and its wholly-owned subsidiaries. All intercompany transactions between and among its consolidated subsidiaries have been eliminated. Management has determined that the Company operates in one segment: discovering, developing, manufacturing and delivering therapies to patients with rare diseases. In the opinion of the Company’s management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with U.S. GAAP, but that is not required for interim reporting purposes, has been omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes for the year ended December 31, 2023 which are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on February 28, 2024. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year. Estimates and Uncertainties The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash held at financial institutions, cash equivalents, investments and accounts receivable, net, from customers. As of September 30, 2024, the Company’s cash was concentrated at three financial institutions, which potentially exposes the Company to credit risks. However, the Company does not believe that there is significant risk of non-performance by the financial institutions. The Company also purchases commercial paper, government and government agency bonds, corporate bonds and certificates of deposit issued by highly rated corporations, financial institutions and governments and limits the amount of credit exposure to any one issuer. These amounts may at times exceed federally insured limits. The Company has not experienced any credit losses related to these financial instruments and does not believe to be exposed to any significant credit risk related to these instruments. As of September 30, 2024, three entities accounted for 37% , 27% and 20% of accounts receivable, net, respectively. As of December 31, 2023, four entities accounted for 40%, 19%, 19% and 12% of accounts receivable, net, respectively. As of September 30, 2024, the Company believes its largest customers are of high credit quality and has not experienced any material credit losses related to such customers. Significant Accounting Policies For details about the Company’s accounting policies, please read Note 2, Summary of Significant Accounting Policies and Recent Accounting Pronouncements

of the Annual Report on Form 10-K for the year ended December 31, 2023. There have not been any material changes to the Company's accounting policies or recent accounting pronouncements that could have a material impact through September 30, 2024. Basis of Presentation The accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"), reflect the accounts of Sarepta and its wholly-owned subsidiaries. All intercompany transactions between and among its consolidated subsidiaries have been eliminated. Management has determined that the Company operates in one segment: discovering, developing, manufacturing and delivering therapies to patients with rare diseases. In the opinion of the Company's management, all adjustments of a normal recurring nature necessary for a fair presentation have been reflected. Certain financial information that is normally included in annual financial statements prepared in accordance with U.S. GAAP, but that is not required for interim reporting purposes, has been omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes for the year ended December 31, 2023 which are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission on February 28, 2024. The results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year. 1 Estimates and Uncertainties The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues, expenses and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash held at financial institutions, cash equivalents, investments and accounts receivable, net, from customers. As of September 30, 2024, the Company's cash was concentrated at three financial institutions, which potentially exposes the Company to credit risks. However, the Company does not believe that there is significant risk of non-performance by the financial institutions. The Company also purchases commercial paper, government and government agency bonds, corporate bonds and certificates of deposit issued by highly rated corporations, financial institutions and governments and limits the amount of credit exposure to any one issuer. These amounts may at times exceed federally insured limits. The Company has not experienced any credit losses related to these financial instruments and does not believe to be exposed to any significant credit risk related to these instruments. As of September 30, 2024, three entities accounted for 37%, 27% and 20% of accounts receivable, net, respectively. As of December 31, 2023, four entities accounted for 40%, 19%, 19% and 12% of accounts receivable, net, respectively. As of September 30, 2024, the Company believes its largest customers are of high credit quality and has not experienced any material credit losses related to such customers. 0.370.270.200.400.190.190.12 Significant Accounting Policies For details about the Company's accounting policies, please read Note 2, Summary of Significant Accounting Policies and Recent Accounting Pronouncements of the Annual Report on Form 10-K for the year ended December 31, 2023. There have not been any material changes to the Company's accounting policies or recent accounting pronouncements that could have a material impact through September 30, 2024. 3. LICENSE AND COLLABORATION AGREEMENTS F. Hoffman-La Roche Ltd. For the three and nine months ended September 30, 2023, the Company recognized $22.5 million and $66.8 million, respectively, of collaboration revenue associated with the license, collaboration and option agreement (the "Roche Agreement") with F. Hoffman-La Roche Ltd. ("Roche") related to the amortization of the single, combined performance obligation, with no such activity for the corresponding periods ended September 30, 2024. Under the Roche Agreement, the Company has granted Roche options to acquire ex-U.S. rights to certain future Duchenne development programs (the "Options") in exchange for separate option exercise payments, milestone and royalty considerations, and cost-sharing provisions. These Options were accounted for as material rights related to individual programs and recorded in deferred revenue at the inception of the Roche Agreement. The value assigned to the material rights is included in deferred revenue until such rights expire or are exercised. On February 12, 2024, Roche declined to exercise its optional rights related to one external, early stage development program, which resulted in the immediate recognition of $48.0 million of collaboration revenue for the nine months ended September 30, 2024. As of September 30, 2024 and December 31, 2023, the Company had total deferred revenue of $452.0 million and $487.4 million, primarily related to the separate material rights for the Options associated with the Roche Agreement, of which $127.0 million and $50.4 million were classified as current, respectively. The costs associated with co-development activities performed under the Roche Agreement are included in operating expenses, with any reimbursement of costs by Roche reflected as a reduction of such expenses when the related expense is incurred. For the three and nine months ended September 30, 2024, costs reimbursable by Roche and reflected as a reduction to operating expenses were $61.5 million and $101.1 million, respectively. For the three and nine months ended September 30, 2023, costs reimbursable by Roche and reflected as a reduction to operating expenses were $34.9 million and $83.4 million, respectively. As of September 30, 2024 and December 31, 2023, there were $66.4 million and $29.8 million, respectively, of collaboration and other receivables included in other current assets on the unaudited condensed consolidated balance sheets. In accordance with the Roche Agreement, the Company agreed to enter into a supply agreement with Roche in order to supply them with clinical and commercial batches of ELEVIDYS (the "Supply Agreement"). While the Supply Agreement is in the process of being negotiated, the Company has delivered

batches of commercial ELEVIDYS supply to Roche that were agreed upon on a purchase order-by-purchase order basis. Contract manufacturing revenue and royalty revenue are included in collaboration and other revenue in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). The following table summarizes certain Roche activity for the three and nine months ended September 30, 2024:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.851%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.523999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.523999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Contract manufacturing revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,891</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 33,698 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Royalty revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,510</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 12,066 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Cost of sales (inventory costs related to products sold to Roche) </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,725</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,379 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> There was no similar activity for the same periods of 2023. Research and Option Agreements The Company has research and option agreements with third parties in order to develop various technologies and biologics that may be used in the administration of the Company's genetic therapeutics. The agreements generally provide for research services related to pre-clinical development programs and options to license the technology for clinical development. Prior to the options under these agreements being executed, the Company may be required to make up to $34.8 million in research milestone payments. Under these agreements, there are $116.8 million in potential option payments to be made by the Company upon the determination to exercise the options. Additionally, if the options for each agreement are executed, the Company would incur additional contingent obligations and may be required to make development, regulatory, and sales milestone payments and royalty payments based on the net sales of the developed products upon commercialization. For the nine months ended September 30, 2023, the Company recognized $7.5 million of up-front payments related to an exercised option as research and development expense, with no similar activity for the three months ended September 30, 2023. For the three and nine months ended September 30, 2023, the Company recognized $3.8 million of research milestone expense as research and development expense. During the three and nine months ended September 30, 2024, the Company did not exercise any options, nor did any additional research milestone payments become probable of occurring. Milestone Obligations The Company has license and collaboration agreements in place for which it could be obligated to pay, in addition to the payment of up-front fees upon execution of the agreements, certain milestone payments as a product candidate proceeds from the submission of an investigational new drug application through approval for commercial sale and beyond. As of September 30, 2024, the Company may be obligated to make up to $2.7 billion of future development, regulatory, commercial and up-front royalty payments associated with its collaboration and license agreements. These obligations exclude potential future option and milestone payments for options that have yet to be exercised within research and option agreements entered into by the Company as of September 30, 2024, which are discussed above. For the three and nine months ended September 30, 2023, the Company recognized up-front, development milestone and other expenses of $3.8 million and $11.9 million, respectively, as research and development expense in the accompanying unaudited condensed consolidated statements of comprehensive income (loss), with no similar activity for the three and nine months ended September 30, 2024.

2250000006680000048000000452000000487400000127000000504000006150000010110000034900000834000006640000029800000The following table summarizes certain Roche activity for the three and nine months ended September 30, 2024:   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.851%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.523999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.523999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Contract manufacturing revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,891</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 33,698 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Royalty revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,510</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 12,066 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Cost of sales (inventory costs related to products sold to Roche) </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,725</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,379 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>
27891000033698000951000012066000137250001537900000348000001168000007500000380000038000000027000000003800000119000000 4. FAIR VALUE MEASUREMENTS The Company has certain financial assets and liabilities that are recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements. • Level 1 — quoted prices for identical instruments in active markets; • Level 2 — quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and • Level 3 — valuations derived from valuation techniques in which one or more significant value drivers are unobservable. During the nine months ended September 30, 2024, there were no transfers into or out of Level 3. The tables below present information about the Company’s financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques it utilizes to determine such fair value: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.744%;box-sizing:content-box;"></td> <td style="width:1.379%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.435%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.379%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.435%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.379%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.435%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.379%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.435%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurement as of September 30, 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-

width:fit-content;">Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,951</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,951 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,995 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Government and government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 900,407 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 886,913 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 233,245 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Strategic investments </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,723 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,723 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,988 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Derivative assets </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 44,622 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 44,622 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,257,931 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">39,168</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,217,763 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liabilities</p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contingent consideration</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 47,400 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">47,400</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 47,400 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">47,400 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurement as of December 31, 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">63,919</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 63,919 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">— </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Government and government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,001,137 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 130,380 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Strategic investments </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,527 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,527 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 56,621 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 56,621 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,371,946 </td> <td style="white-space:nowrap;vertical-

align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">69,446</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,301,500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liabilities</p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contingent consideration</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 38,100 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 38,100 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total liabilities </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38,100</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38,100</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's assets with a fair value categorized as Level 1 within the fair value hierarchy include money market funds, certain government and government agency bonds and the Company's strategic investment in a biotechnology company listed on the Nasdaq Global Market.</p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's assets with a fair value categorized as Level 2 within the fair value hierarchy consist of commercial paper, government and government agency bonds, corporate bonds, certificates of deposit and the derivative assets associated with capped call options (the "2017 Capped Calls") for the Company's $570.0 million aggregate principal amount of senior convertible notes due on November 15, 2024 (the "2024 Notes"). The Company's commercial paper, government and government agency bonds, corporate bonds and certificates of deposit have been initially valued at the transaction price and subsequently valued at the end of each reporting period utilizing third-party pricing services. The Company uses observable market inputs to determine value, which primarily consist of reportable trades. Certain short-term investments with maturities of less than three months at the date of acquisition are presented as cash equivalents on the unaudited condensed consolidated balance sheets as of September 30, 2024.</p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The fair value of the derivative assets related to the 2017 Capped Calls was determined using an option pricing model with Monte Carlo simulations. The significant inputs to the model are the Company's share price, estimated volatility and corresponding risk free rate. At the end of each reporting period, the fair value is adjusted to reflect the most current assumptions through earnings. The fair value of the derivative assets from the effective date of the 2017 Capped Calls modification on September 16, 2024 to September 30, 2024 increased by $0.7 million. The increase was recorded within other income (expense), net in the unaudited condensed consolidated statements of comprehensive income (loss). For additional information related to the 2017 Capped Calls, please refer to Note 10, Indebtedness. </p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's assets with a fair value categorized as Level 3 within the fair value hierarchy consist of a strategic investment in a private biotechnology company whose fair value measurement was based upon significant inputs not observable in the market and therefore represented a Level 3 measurement. At the end of each reporting period, the fair value of the Company's strategic investments that are not publicly traded securities are adjusted if the issuers issue similar or identical securities or when there is a triggering event for impairment. There were no valuation measurement events related to the fair value of the Company's Level 3 strategic investments during the nine months ended September 30, 2024. as no impairment indicators were identified nor were similar securities issued. During the three months ended September 30, 2023, the Company recorded an impairment loss of $27.5 million related to the Company's strategic investment in Series A preferred stock of Lacerta Therapeutics, Inc. ("Lacerta") after comparing the fair value of the Lacerta strategic investment to its carrying value. The impairment loss for the three and nine months ended September 30, 2023 is included in other (expense) income, net within the unaudited condensed consolidated statements of comprehensive income (loss). </p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's contingent consideration liability with a fair value categorized as Level 3 within the fair value hierarchy relates to the regulatory-related contingent payments to Myonexus Therapeutics, Inc. ("Myonexus") selling shareholders as well as to an academic institution under a separate license agreement that meet the definition of a derivative. For more information related to Myonexus, please read Note 3, License and Collaboration Agreements to the financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The contingent consideration liability was estimated using an income approach based on the probability-weighted expected cash flows that incorporated industry-based probability adjusted assumptions relating to the achievement of the milestone and thus the likelihood of making the payments. This fair value measurement was based upon significant inputs not observable in the market and therefore represented a Level 3 measurement. Significant changes, which increase or decrease the probabilities of achieving the milestone or shorten or lengthen the time required to achieve the milestone, would result in a corresponding increase or decrease in the fair value of the liability. At the end of each reporting period, the fair value is adjusted to reflect the most current assumptions through earnings.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;">The following table represents a roll-forward of the fair value of Level 3 financial liabilities for the periods indicated:</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.74%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of
September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of
September 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fair value, as of beginning of year</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38,100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36,900</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Change in estimated fair value</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,500</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr

style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Liabilities terminated </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (200 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (800 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Fair value, as of end of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">47,400</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 38,100 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> For the three and nine months ended September 30, 2024, the Company recorded a net decrease of $0.8 million and a net increase of $9.3 million, respectively, to account for the change in fair value of the Company's existing contingent consideration liabilities and any liabilities terminated. These changes, which are recorded through earnings, were a result of updates made to certain inputs and assumptions impacting the probability-weighted expected cash flows, principally the probability of success of the underlying programs and the discount rate utilized to determine the present value of future payments to be made, partially offset by the termination of a license agreement with an academic institution that included an embedded derivative during the three months ended September 30, 2024. For the three and nine months ended September 30, 2023, net increases of $2.0 million and $1.2 million were recorded to account for the change in fair value and a termination of one of the Company's license agreements with an existing contingent consideration liability. As of September 30, 2024, the contingent consideration was recorded as a long-term liability on the Company's unaudited condensed consolidated balance sheets. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, net and accounts payable approximated fair value because of the immediate or short-term maturity of these financial instruments. For fair value information related to the Company's debt facilities, please read Note 10, Indebtedness. The tables below present information about the Company's financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques it utilizes to determine such fair value: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.744%;box-sizing:content-box;"></td> <td style="width:1.379%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.435%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.379%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.435%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.379%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.435%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.379%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.435%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Measurement as of September 30, 2024 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,951</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,951 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,995 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,995 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Government and government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 900,407 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,494 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 886,913 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 233,245 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 233,245 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Strategic investments </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:right;">4,723 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,723 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,988 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,988 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Derivative assets </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 44,622 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 44,622 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,257,931</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 39,168 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,217,763</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Liabilities </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;">

solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">63,919</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 63,919 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,001,137 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 130,380 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 130,380 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Strategic investments </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,527 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,527 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 56,621 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 56,621 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 56,621 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-

align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Liabilities </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Contingent consideration </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38,100</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38,100</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> 38,100 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 38,100 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Fair value, as of beginning of year </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38,100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36,900 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Change in estimated fair value </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Liabilities terminated </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (200 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (800 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Fair value, as of end of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">47,400</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 38,100 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table>3810000036900000950000020000000-200000-8000004740000038100000800000930000020000001200000 5. CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES The following table summarizes the Company's financial assets with maturities of less than 90 days from the date of purchase included in cash equivalents in the unaudited condensed consolidated balance sheets for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.727%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="6" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,951</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 63,919 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 2,330 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 53,680 </td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,001 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">26,282</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 117,599 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> It is the Company’s policy to mitigate credit risk in its financial assets by maintaining a well-diversified portfolio that limits the amount of exposure as to maturity and investment type. The weighted average maturity of the Company’s available-for-sale securities was approximately seven and five months as of September 30, 2024 and December 31, 2023, respectively. The following tables summarize the Company’s cash, cash equivalents, short-term investments and non-current investments for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.96%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Market
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Cash and money market funds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">193,524</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">193,524 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,995 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 34,995 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Government and government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 898,726 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,704 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (23 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 900,407 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 232,654 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 603 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 233,245 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 17,988 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 17,988 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total cash, cash equivalents and investments </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,377,887</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,307 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,380,159</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">As reported:</p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 197,854 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 197,855 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Short-term investments </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 998,884 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,667 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (17 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000,534 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Non-current investments </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 181,149 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 639 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">

</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (18 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 181,770 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total cash, cash equivalents and investments </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,377,887</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,307 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(35</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,380,159 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> As of December 31, 2023 </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Market
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Cash and money market funds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">374,750</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 374,750 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;">Commercial paper </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 113,362 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Government and government agency bonds </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000,302 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,006 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (171 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 1,001,137 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Corporate bonds </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 130,270 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 118 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 130,380 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Certificates of deposit </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 56,621 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 56,621 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">1,675,305 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,124</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 179 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="vertical-align:middle;"> As reported: </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="text-indent:10pt;vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Cash and cash equivalents </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">428,430</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 428,430 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Short-term investments </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,246,875 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (179 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,247,820 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total cash, cash equivalents and investments </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,675,305</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(179</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,676,250 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table summarizes the Company's financial assets with maturities of less than 90 days from the date of purchase included in cash equivalents in the unaudited condensed consolidated balance sheets for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.727%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="6" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,951</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 63,919 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 2,330 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 53,680 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,001 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">26,282</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 117,599 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   2195100063919000233000053680000200100002628200011759900OP5M The following tables summarize the Company's cash, cash equivalents, short-term investments and non-current investments for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.96%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Market
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td>
</tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Cash and money market funds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">193,524</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 193,524 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Commercial paper </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,995 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,995 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Government and government agency bonds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 898,726 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,704 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (23 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 900,407 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-

left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 232,654 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 603 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (12 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 233,245 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 17,988 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 17,988 </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total cash, cash equivalents and investments </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,377,887</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2,307</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,380,159 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> As reported. </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="text-indent:10pt;vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Cash and cash equivalents </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 197,854 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-

align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">197,855</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Short-term investments</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">998,884</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,667</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(17</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,000,534</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#fffffd;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Non-current investments</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">181,149</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffffd03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">639</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffffd03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(18</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffffd03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,377,887 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,307</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (35 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,380,159 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#fffffd;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> As of December 31, 2023 </td> <td style="vertical-

align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair
Market
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td colspan="14" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Cash and money market funds </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">374,750</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> 374,750 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Commercial paper </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 113,362 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Government and government agency bonds </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000,302 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,006 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (171 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 1,001,137 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Corporate bonds </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 130,270 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 118 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 130,380 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Certificates of deposit </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 56,621 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 56,621 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total cash, cash equivalents and investments </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,675,305</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (179 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,676,250</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">As reported:</p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="text-indent:10pt;vertical-align:bottom;text-align:center;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 420,430 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times

*New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 428,430 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> Short-term investments </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,246,875 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (179 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,247,820 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total cash, cash equivalents and investments </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,675,305</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(179</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,676,250 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>193524000193524000349950003499500089872600017040002300090040700023265400060300012000233245000179880001798800013778870002307000350001380100000000000

bottom:0;text-align:center;">2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> PMO Products </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> United States </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">210,683</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,069 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">604,598</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 602,415 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Rest of World </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 38,105 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 42,145 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 108,565 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 108,282 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total PMO product revenues, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">248,788</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 240,214 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">713,163</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 710,697 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> ELEVIDYS </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> United States </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 180,983 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 69,108 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 436,640 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 69,108 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total ELEVIDYS product revenue, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">180,983</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 69,108 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">436,640</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 69,108 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Total product revenues, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">429,771</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 309,322 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,149,803</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 779,805 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> For the three and nine months ended September 30, 2024 and 2023, no individual country outside the U.S. exceeded 10% of total net product revenues.   The following table summarizes the Company's net product revenues, by customer, for those customers that exceeded 10% for the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td

style="width:9.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Product revenues, net </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Customer 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 40 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 45 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Customer 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> As of September 30, 2024 and December 31, 2023, the Company's accounts receivable, net were $434.5 million and $<span style="font-size:10pt;font-family:Times New

Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">400.3 million, respectively, both of which were related to product sales, net of discounts and allowances. As of September 30, 2024, the majority of the Company's accounts receivable arose from product sales in the U.S. and all customers have standard payment terms that generally require payment within 65 to 90 days. Outside of the U.S., the majority of the Company's customers have payment terms ranging between 90 and 150 days. PIease refer to Note 2, Summary of Significant Accounting Policies for discussion of the credit risk associated with accounts receivable, net. The following tables summarize an analysis of the change in reserves for discounts and allowances for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:34.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Chargebacks </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Rebates </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Prompt Pay </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Other Accruals </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Balance, as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,486</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 98,194 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,831</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,261 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 164,772 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Provision </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 72,832 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 118,228 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,442 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,674 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 258,176 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Adjustments relating to prior periods </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 783 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8,716 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (88 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8,021 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Payments/credits </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (77,808 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (100,693 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (12,191 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (58,741 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (249,433 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Balance, as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,293</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 107,013 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">30,106</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 165,494 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:34.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td

style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Chargebacks </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Rebates </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Prompt Pay </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Other Accruals </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="18" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Balance, as of December 31, 2022 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">417</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 67,493 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,343</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,445 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 94,698 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Provision </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,191 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 94,025 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,251 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 52,500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 175,967 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Adjustments relating to prior periods </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 110 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,154 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;">

 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,044 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Payments/credits </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (9,386 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (73,317 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (10,586 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (40,048 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (133,337 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Balance, as of September 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,332</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 84,047 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,008</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 35,897 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 133,284 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table summarizes the total reserves above included in the Company's unaudited condensed consolidated balance sheets for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.727%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Reduction to accounts receivable, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,773</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 64,697 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Component of accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 108,721 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 100,075 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total reserves </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">165,494</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 164,772 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Net product revenues, which includes revenues associated with the PMO Products and ELEVIDYS, consisted of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.96%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> PMO Products </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> United States </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">210,683</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,069 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">604,598</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 602,415 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Rest of World </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 38,105 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 42,145 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 108,565 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 108,282 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total PMO product revenues, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">248,788</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 240,214 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">713,163</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 710,697 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> ELEVIDYS </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> United States </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 180,983 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">

69,108 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 436,640 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 69,108 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Total ELEVIDYS product revenue, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">180,983</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 69,108 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">436,640</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 69,108 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Total product revenues, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">429,771</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 309,322 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,149,803</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 779,805 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
2106830001980690006045980006024150003810500042145000108565000108282000248788000240214000713163000710697000180983000691080004366400006910806 style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the Company's net product revenues, by customer, for those customers that exceeded 10% for the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.76%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">

</td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Product revenues, net </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Customer 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 40 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 45 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Customer 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table>0.100.280.400.330.450.190.230.200.2943450000040030000OAs of September 30, 2024, the majority of the Company's accounts receivable arose from product sales in the U.S. and all customers have standard payment terms that generally require payment within 65 to 90 days. Outside of the U.S., the majority of the Company's customers have payment terms ranging between 90 and 150 days. The following tables summarize an analysis of the change in reserves for discounts and allowances for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:34.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Chargebacks </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Rebates </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Prompt Pay </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Other Accruals </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:center;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="18" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Balance, as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,486</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 98,194 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,831</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,261 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 164,772 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Provision </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 72,832 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 118,228 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,442 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,674 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 258,176 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Adjustments relating to prior periods </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 783 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8,716 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (88 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8,021 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Payments/credits </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (77,808 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> <span style="min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (100,693 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (12,191 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (58,741 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (249,433 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Balance, as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,293</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 107,013 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,082</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 30,106 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">165,494</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:34.96%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Chargebacks</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Rebates</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Prompt Pay</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Other Accruals</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="18" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance, as of December 31, 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 417 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td>

<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 67,493 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,343</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,445 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 94,698 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Provision </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,191 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 94,025 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,251 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 52,500 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 175,967 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Adjustments relating to prior periods </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 110 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,154 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,044 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Payments/credits </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (9,386 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (73,317 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (40,048 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (133,337 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Balance, as of September 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,332</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 84,047 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,088</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 35,897 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 133,284 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>27486000981940003831000352610001647720007283200011822800013442000536740002581760000783000-87160000-88000-80210007780800010069300012191000587410002494330002329300010701300050820003010600016549400041700067493000334300023445000946980001819100094025000415400000-40440009386000733170001058600040048000133337000933200084047000400800035897000133284000 The following table summarizes the total reserves above included in the Company's unaudited condensed consolidated balance sheets for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.727%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.537%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Reduction to accounts receivable, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">56,773</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 64,697 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Component of accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 108,721 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 100,075 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total reserves </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">165,494</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 164,772 </td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table>5677300064697000108721000100075000165494000164772000 7. INVENTORY The following table summarizes the components of the Company's inventory for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Raw materials </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">208,320</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 133,963 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Work in progress </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 482,171 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 318,458 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Finished goods </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 77,983 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 61,806 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total inventory </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">768,474</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 514,227 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> No material inventory reserves existed as of September 30, 2024 or December 31, 2023. The Company classifies inventory associated with its PMO Products as non-current inventory when consumption of the inventory is expected beyond the Company's normal PMO Product inventory operating cycle of two years. Non-current inventory consists of raw materials and work in progress associated with the PMO Products. The following table summarizes the balance sheet classification of the Company's inventory for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.351%;box-sizing:content-box;"></td> <td style="width:2.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.163999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.163999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Balance sheet classification </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Inventory </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">565,924</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 322,859 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Non-current inventory </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 202,550 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 191,368 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total inventory </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">768,474</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 514,227 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table summarizes the components of the Company's inventory for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:64%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Raw materials </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">208,320</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 133,963 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Work in progress </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 482,171 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 318,458 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> <span style="color:#000000;white-space:pre-wrap;min-

width:fit-content;">Finished goods </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 77,983 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 61,806 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total inventory </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">768,474</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 514,227 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
20832000013396300048217100031845800077983000618060007684740005142270000 The following table summarizes the balance sheet classification of the Company's inventory for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:53.351%;box-sizing:content-box;"></td> <td style="width:2.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.163999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.163999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Balance sheet classification </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Inventory </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">565,924</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 322,859 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Non-current inventory </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 202,550 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 191,368 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total inventory </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">768,474</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 514,227 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>56592400032285900020255000019136800076847400051422700 8. OTHER ASSETS The

following table summarizes the Company's other current assets for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.36%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Collaboration and other receivables </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">66,404</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,786 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Derivative asset </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,622 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid maintenance services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,326 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,281 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid clinical and pre-clinical expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,034 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,280 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Tax-related receivables and prepaids </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,422 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,862 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid commercial expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,982 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,729 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Interest receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">

3,637 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,731 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid insurance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,198 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,352 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,852 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 10,693 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total other current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">165,477</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 77,714 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table summarizes the Company's other non-current assets for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Manufacturing-related deposits and prepaids </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,127</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 74,204 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Intangible assets, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 27,570 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,620 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Restricted cash* </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,579 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,579 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Strategic investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,723 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid maintenance services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,907 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,466 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,653 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,375 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total other non-current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">83,559</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 136,771 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> *The Company had approximately $15.6 million in restricted cash included in other non-current assets on the Company's unaudited condensed consolidated balance sheets as of both September 30, 2024 and December 31, 2023. Restricted cash for both periods relates to (i) letters of credit established under the Company's various property leases that serve as security for potential future default of lease payments, (ii) a letter of credit established under a certain commercial supply agreement and (iii) collateralized cash for the Company's credit cards. The restricted cash is unavailable for withdrawal or use for general obligations.</p></div><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the Company's other current assets for each of the periods indicated:</p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.36%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of
September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of
December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Collaboration and other receivables</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 66,404 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,786 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Derivative asset </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,622 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid maintenance services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,326 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,281 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid clinical and pre-clinical expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,034 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,280 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Tax-related receivables and prepaids </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,422 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,862 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid commercial expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,982 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,729 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Interest receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,637 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,731 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid insurance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,198 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,352 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,852 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;border-bottom:0.5pt solid #000000;text-align:center;"> 10,693 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total other current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">165,477</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 77,714 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>6640400029786000446220000133260001128100012034000102800001142200068620003982000272900036370002731000219800033520007852000106930001654770
style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;">The following table summarizes the Company's other non-current assets for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.4%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Manufacturing-related deposits and prepaids </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,127</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 74,204 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Intangible assets, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 27,570 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,620 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Restricted cash* </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,579 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,579 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Strategic investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,723 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,527 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Prepaid maintenance services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,907 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,466 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,653 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,375 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total other non-current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">83,559</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 136,771 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> *The Company had approximately $15.6 million in restricted cash included in other non-current assets on the Company's unaudited condensed consolidated balance sheets as of both September 30, 2024 and December 31, 2023. Restricted cash for both periods relates to (i) letters of credit established under the Company's various property leases that serve as security for potential future default of lease payments, (ii) a letter of credit established under a certain commercial supply agreement and (iii) collateralized cash for the Company's credit cards. The restricted cash is unavailable for withdrawal or use for general obligations.
2812700074204000275700002962000015579000155790004723006527000390700054660003653000537500083559000136771000156000001560000 9. ACCRUED EXPENSES The following table summarizes the Company's accrued expenses for each of the periods indicated.   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td>
</tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Product revenue related reserves </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">108,721</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100,075 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued contract manufacturing costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 75,909 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,024 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued employee compensation costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 57,107 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 78,732 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued clinical and pre-clinical costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 40,514 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,669 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued professional fees </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,486 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,696 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,766 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued royalties </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,185 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,070 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued fixed assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,821 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,231 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued research expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,882 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,441 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,118 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,395 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,391 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,407 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> <span

style="color:#000000;min-width:fit-content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">344,830</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 314,997 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table summarizes the Company's accrued expenses for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Product revenue related reserves </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">108,721</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100,075 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued contract manufacturing costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 75,909 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,024 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued employee compensation costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 57,107 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 78,732 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued clinical and pre-clinical costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 40,514 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34,669 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued professional fees </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,486 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,696 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,766 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued royalties </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,185 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,070 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued fixed assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,821 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,231 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued research expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,882 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,441 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accrued interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,118 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,395 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,391 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,407 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">344,830</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 314,997 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>10872100010007500075909000330240005710700078732000405140003466900021486000171870001469600013766000121850001207000048210003231000288200026

style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">10. INDEBTEDNESS 2024 Convertible Notes and 2017 Capped Call Transactions On November 14, 2017, the Company issued $570.0 million aggregate principal amount of senior convertible notes due on November 15, 2024 and, simultaneously, entered into capped call transactions with counterparties intended to minimize the impact of potential dilution upon conversion of the 2024 Notes.
On September 14, 2022, the Company entered into separate, privately negotiated transactions to repurchase a portion of the outstanding 2024 Notes. The holders exchanged $150.6 million in aggregate principal value of 2024 Notes held by them for an aggregate payment of $248.6 million for full settlement of the principal value and accrued interest on such date. As a result of the repurchases, the Company entered into agreements with the 2017 Capped Calls counterparties to terminate a corresponding portion of the 2017 Capped Calls and received $<span

*style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.3 million in cash. On March 2, 2023, the Company entered into separate, privately negotiated exchange agreements with certain holders of the outstanding 2024 Notes. The holders exchanged $313.5 million in aggregate principal value of the 2024 Notes held by them for 4.5 million shares of the Company's common stock. As a result of the exchange, the Company entered into agreements with the counterparties to the 2017 Capped Calls to terminate a portion of the 2017 Capped Calls and received approximately $80.6 million in cash. In June 2024, certain existing holders elected to convert $14.2 million in aggregate principal amount of the 2024 Notes into approximately 0.2 million shares of the Company's common stock. As the conversions were completed under the original terms of the 2024 Notes, there is no gain or loss impact on the accompanying unaudited condensed consolidated statements of comprehensive income (loss). The capped call options related to the shares underlying the conversion are required to be settled at the scheduled maturity date of the 2024 Notes. In May 2024, the Company informed holders of the 2024 Notes of its election to settle the 2024 Notes in shares, which, pursuant to the terms of the 2017 Capped Call agreements, would require the Company to settle the 2017 Capped Calls in shares. On September 16, 2024 (the "Effective Date"), the Company entered into supplements with each of the counterparties to modify the terms of each of the 2017 Capped Calls to require settlement in cash rather than in shares. As a result of the modification, the Company reassessed the classification of the 2017 Capped Calls and concluded that these instruments, which were initially classified within equity, should be reclassified as derivative assets. Accordingly, the Company reclassified the fair value of the 2017 Capped Calls, from stockholders' equity to derivative assets on the Effective Date, with subsequent changes in fair value recorded to earnings through the settlement date. The fair value on the Effective Date of $43.9 million was reclassified from stockholders' equity (additional paid-in capital) to derivative assets and recorded to other current assets on the unaudited condensed consolidated balance sheets. The increase in the fair value of the derivative assets from the Effective Date to September 30, 2024 was $0.7 million and recorded to other income (expense), net in the unaudited condensed consolidated statements of comprehensive income (loss). The derivative assets, along with the 2024 Notes, will settle on November 15, 2024. For further information related to the fair value determination of the derivative assets, please read Note 4, Fair Value Measurements. For additional details about the 2024 Notes, please read Note 13, Indebtedness to the financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Total Debt Obligations As of September 30, 2024 and December 31, 2023, the Company recorded approximately $1,227.6 million and $1,238.0 million as debt on the unaudited condensed consolidated balance sheets, respectively, with the 2024 Notes balance recorded as a current liability for both periods.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:9.8%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the Company's debt instruments for each of the periods indicated:</p><p style="margin-left:9.8%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.419999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.419999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of
September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of
December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Principal amount of the 2024 Notes</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 91,640 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 105,847 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Principal amount of the 2027 Notes </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,150,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,150,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Unamortized discount - debt issuance costs of 2024 Notes </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (45 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (364 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Unamortized discount - debt issuance costs of 2027 Notes </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times*

New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (14,035 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (17,485 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total carrying value of debt instruments </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,227,560</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,237,998 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#fffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Fair value of 2024 Notes </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">171,154</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 144,833 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Fair value of 2027 Notes </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,307,930 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,172,276 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total fair value of debt instruments </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,479,084</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,317,109 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> For both of the three months ended September 30, 2024 and 2023, interest expense from debt instruments was $5.2 million, inclusive of $1.2 million of amortization of debt discounts. For the nine months ended September 30, 2024 and 2023, interest expense from debt facilities was $15.7 million and $16.8 million, inclusive of $3.7 million and $3.9 million of amortization of debt discounts, respectively. The fair value of the 1.25% convertible senior notes due on September 15, 2027 (“2027 Notes”) and the 2024 Notes is based on open market trades and is classified as Level 1 in the fair value hierarchy. The following table summarizes the total principal and contractual interest payments due under the Company’s debt arrangements: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:30.46%;box-sizing:content-box;"></td> <td style="width:2.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Principal </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">

 </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Interest </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total Payments </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> 2024 (October-December) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">91,640</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 711 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">92,351</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,375</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,375</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right,"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,375</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,375</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,150,000</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,375</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,164,375</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,">Total payments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,241,640 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 43,836 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,285,476</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div>5700000002024-11-151506000002486000002630000031350000045000008060000014200000200000439000007000001227600000123800000<p style="margin-left:9.8%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the Company's debt instruments for each of the periods indicated:</p><p style="margin-left:9.8%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.419999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.419999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of
September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of
December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Principal amount of the 2024 Notes</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 91,640 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">105,847</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Principal amount of the 2027 Notes</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,150,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,150,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unamortized discount - debt issuance costs of 2024 Notes</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(45</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(364</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unamortized discount - debt issuance costs of 2027 Notes</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(14,035</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(17,485</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total carrying value of debt instruments</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,227,560 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,237,998</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fair value of 2024 Notes</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 171,154 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">144,833</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Fair value of 2027 Notes</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,307,930</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,172,276</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total fair value of debt instruments</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,479,084 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,317,109 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>916400001058470001150000000115000000045000364000140350001748500012275600001237998000171154000144833000130793000011722760001479084000131

style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the total principal and contractual interest payments due under the Company's debt arrangements: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:30.46%;box-sizing:content-box;"></td> <td style="width:2.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Principal </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Interest </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total Payments </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:middle;text-align:left;"> (in thousands) </td> <td style="vertical-align:middle;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> 2024 (October-December) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">91,640</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 711 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 92,351 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 14,375 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 14,375 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 14,375 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 14,375 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:middle;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 1,150,000 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 14,375 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 1,164,375 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,241,640</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 43,836 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,285,476 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>916400007110009235100001437500014375000014375000143750001150000000143750001164375000124164000043836000128547600 11. STOCK-BASED COMPENSATION The following table summarizes the Company's stock awards granted for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:20%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Grants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant
Date Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Grants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant
Date Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Grants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant
Date Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Grants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant
Date Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Grants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant
Date Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Grants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant
Date Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Grants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant
Date Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 6,442 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">55.16</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,875</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 66.53 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 327,920 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">67.39</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,135,799</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 72.23 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 135,092 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">127.51</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,539</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 118.05 </td>

<td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 1,351,982 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> (1) </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">128.90</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,137,202</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(2)</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 153.02 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> </table> (1) Included in restricted stock units (“RSUs”) for the nine months ended September 30, 2024 are 97,460 shares with performance conditions (“March 2024 PSUs”) which are related to the achievement of certain financial performance goals and regulatory approval of certain of the Company's product candidates. The expanded regulatory approval of ELEVIDYS in June 2024 resulted in the cliff-vesting of 44,300 of the 97,460 shares of the March 2024 PSUs during the nine months ended September 30, 2024. As of September 30, 2024, none of the performance conditions for the remaining 53,160 shares were probable of being achieved. Stock options and the remaining RSUs granted during the three and nine months ended September 30, 2024 have only service-based criteria and vest over four years. (2) Included in the RSUs for the nine months ended September 30, 2023 are 502,225 shares with performance conditions (the “March 2023 PSUs”), which are related to regulatory approval of ELEVIDYS and achievement of a certain financial performance target, both of which were achieved in 2023. Vesting of the March 2023 PSUs is contingent on the fulfillment of remaining service conditions. During the year ended December 31, 2022, the Company granted 38,500 RSUs with performance conditions (the “March 2022 PSUs”), which are related to regulatory approval of certain of the Company's product candidates. As a result of the expanded regulatory approval of ELEVIDYS in June 2024, a portion of the March 2022 PSUs became eligible for vesting. Vesting of the March 2022 PSUs is contingent on the fulfillment of remaining service conditions. As of September 30, 2024, none of the remaining performance conditions were probable of being achieved. Stock-based Compensation Expense For the three months ended September 30, 2024 and 2023, total stock-based compensation expense was $43.5 million and $48.1 million, respectively. For the nine months ended September 30, 2024 and 2023, total stock-based compensation expense was $134.6 million and <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$136.7 million, respectively. The following table summarizes stock-based compensation expense by grant type and by function included within the unaudited condensed consolidated statements of comprehensive income (loss):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.36%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">

 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td colspan="15" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15,158</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 17,471 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46,954</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 62,436 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 31,926 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 28,924 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 97,261 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 70,101 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Employee Stock Purchase Program </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,912</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,666</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,640</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,151</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Subtotal</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 48,996 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">48,061</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">149,855 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">136,688</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Capitalized stock-based compensation costs*</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(5,546</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(15,231</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total stock-based compensation expense included in expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 43,450 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">48,061</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 134,624 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 136,688 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 18,034 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 22,325 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 54,113 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 60,315 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Selling, general and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 25,416 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 25,736 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 80,511 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 76,373 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#eff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total stock-based compensation expense included in expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,450</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">48,061</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 134,624 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 136,688 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   *Prior to the nine months ended September 30, 2024, capitalized stock-based compensation costs were not material. The following table summarizes the Company’s stock awards granted for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:20%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Grants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant
Date Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Grants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant
Date Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Grants </td> <td style="vertical-align:bottom;border-bottom:0.5pt

solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant
Date Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Grants </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant
Date Fair
Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 6,442 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">55.16</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,875</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 66.53 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 327,920 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">67.39</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,135,799</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 72.23 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 135,092 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">127.51</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">27,539</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 118.05 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 1,351,982 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> (1) </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">128.90</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,137,202</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(2)</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 153.02 </td> <td style="white-space:nowrap;vertical-align:middle;"> <span

style="min-width:fit-content;"> </td> </tr> </table> (1) Included in restricted stock units (“RSUs”) for the nine months ended September 30, 2024 are 97,460 shares with performance conditions (“March 2024 PSUs”) which are related to the achievement of certain financial performance goals and regulatory approval of certain of the Company’s product candidates. The expanded regulatory approval of ELEVIDYS in June 2024 resulted in the cliff-vesting of 44,300 of the 97,460 shares of the March 2024 PSUs during the nine months ended September 30, 2024. As of September 30, 2024, none of the performance conditions for the remaining 53,160 shares were probable of being achieved. Stock options and the remaining RSUs granted during the three and nine months ended September 30, 2024 have only service-based criteria and vest over four years. (2) Included in the RSUs for the nine months ended September 30, 2023 are 502,225 shares with performance conditions (the “March 2023 PSUs”), which are related to regulatory approval of ELEVIDYS and achievement of a certain financial performance target, both of which were achieved in 2023. Vesting of the March 2023 PSUs is contingent on the fulfillment of remaining service conditions.

644255.1650875665332792067.39113579972.23135092127.5127539118.051351982128.91137202153.029746044300974605316050222538500435000004810000013460(style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes stock-based compensation expense by grant type and by function included within the unaudited condensed consolidated statements of comprehensive income (loss): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:43.36%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.38%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.72%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;"> </td> <td colspan="15" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15,158</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 17,471 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46,954</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 62,436 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">31,926 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 28,924 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 97,261 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 70,101 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Employee Stock Purchase Program </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 1,912 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 1,666 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 5,640 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 4,151 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Subtotal </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">48,996</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 48,061 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">149,855</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> (5,546 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (15,231 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total stock-based compensation expense included in expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 43,450 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">48,061</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 134,624 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">136,688</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,034</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,325</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54,113</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,315</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Selling, general and administrative</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25,416</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25,736</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">80,511</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">76,373</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total stock-based compensation expense included in expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 43,450 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">134,624</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 136,688 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
  *Prior to the nine months ended September 30, 2024, capitalized stock-based compensation costs were not material. 151580001747100046954000624360003192600028924000972610007010100019120001666000564000041510004899600048061000149855000136688000-55460000-152310000434500004806100013462400013668800018034000223250005411300060315000254160002573600080511000763730004345000048061000134624000136688000 12. OTHER INCOME (LOSS), NET The following table summarizes other income (loss), net for each of the periods indicated: <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.603%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.929%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.929%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.929%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.929%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="15" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accretion of investment discount, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,749</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,984 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">34,319</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,809 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffffe;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Interest income </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,584 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,838 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22,753 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 27,532 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Interest expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,918 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (5,229 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (13,916 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (16,776 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Change in fair value of derivatives* </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,535 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8,565 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,200 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Impairment of strategic investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (27,500 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (27,821 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#fffffe;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3,140 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,960 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (235 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other income (expense), net </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,810</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (12,332 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-

align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 32,631 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,309</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Gain from sale of Priority Review Voucher</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">102,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Loss on debt extinguishment</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(387,329</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total other income (loss), net</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,810 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,332</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 32,631 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (268,020 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr>
</table> *Related to the change in fair value of the contingent consideration derivative liabilities and the 2017 Capped Calls derivative assets. For more information, please read Note 4, Fair Value Measurements and Note 10, Indebtedness. The following table summarizes other income (loss), net for each of the periods indicated: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.603%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.929%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.929%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.929%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-

space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="15" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Accretion of investment discount, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,749</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,984 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">34,319</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,809 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Interest income </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,584 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,838 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22,753 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,918 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (5,229 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (13,916 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(16,776 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Change in fair value of derivatives* </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,535 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8,565 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,200 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Impairment of strategic investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (27,500 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (27,821 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Other, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3,140 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (425 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,960 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (235 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other income (expense), net </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,810</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (12,332 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">32,631</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> <span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">17,309 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Gain from sale of Priority Review Voucher </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 102,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Loss on debt extinguishment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (387,329 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total other income (loss), net </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,810</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (12,332 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">32,631</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (268,020 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr></table> *Related to the change in fair value of the contingent consideration derivative liabilities and the 2017 Capped Calls derivative assets. For more information, please read Note 4, Fair Value Measurements andNote 10, Indebtedness. 1074900012984000343190003580900075840009838000227530002753200049180005229000139160001677600015350002000000856500012000000275000000278210003140000-425000-1960000-235000118100001233200032631000173090000001020000000000-387329000118100001233200032631000-2680200000 13. LEASES The Company has real estate operating leases in Cambridge, Andover, Burlington and Bedford, Massachusetts, Dublin and Columbus, Ohio, and Durham, North Carolina that provide for scheduled annual rent increases over the lease term. The Company has also identified leases embedded in certain of its manufacturing and supply agreements as the Company determined that it controls the use of the facilities and related equipment therein. For more information related to the lease embedded in manufacturing and supply agreements with Catalent, Inc. (“Catalent”), please refer to Note 21, Commitments and Contingenciesof the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Bedford, Massachusetts On April 22, 2022, the Company entered into a lease agreement (the “Bedford Lease”) for <span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-

space:pre-wrap;min-width:fit-content;">288,000 square feet of to-be-constructed research and development and manufacturing space in Bedford, Massachusetts. The term of the Bedford Lease commences upon the landlord's completion of the initial construction of the core and shell of the building, at which time the Company will obtain control of the premises and commence internal construction activities. The Company has two options to extend the lease for a period of ten years each, exercisable under certain conditions and at a market rate determined in accordance with the lease agreement. In May 2022, in connection with the execution of the Bedford Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $8.4 million, which was included in the other non-current assets of the Company's unaudited condensed consolidated balance sheets. Such letter of credit shall be reduced to approximately $5.6 million at the commencement of the fourth rent year, provided certain conditions set forth in the Bedford Lease are satisfied. Undiscounted minimum rent payments due over the term of the lease aggregate to $307.4 million. Additionally, the Company is responsible for reimbursing the landlord for the Company's share of the property's operating expenses and property taxes. The Bedford Lease also provides for a tenant improvement allowance from the landlord of up to $72.0 million to be used towards costs incurred by the Company in the design and construction of the premises. The Company recorded the $72.0 million tenant improvement allowance as a reduction to right-of-use ("ROU") assets and lease liabilities in May 2023 as the Company obtained control of the premises. In August 2024, the Company entered into an amendment to the Bedford Lease to extend the term in which the tenant improvement allowance could be reimbursed from the landlord (the "Bedford Amendment"). The Bedford Amendment extended the reimbursement period associated with the tenant improvement allowance through December 2, 2025. The Company also agreed to reimburse the landlord for certain costs incurred in order to fund the extension of the reimbursement period associated with the tenant improvement allowance, totaling $2.9 million. The Bedford Amendment was accounted for as a modification to the Bedford Lease. As of September 30, 2024, the Company had a lease liability and ROU asset of $131.7 million and $92.0 million, respectively, on its unaudited condensed consolidated balance sheets related to the Bedford Lease. Tenant improvement costs incurred by the Company that had been reimbursed by the landlord totaled $29.5 million through September 30, 2024 and were recorded as an increase to lease liabilities when received within the Company's unaudited condensed consolidated balance sheets.
288000P10Y8400000560000030740000072000000720000002900000131700000920000002950000 14. INCOME TAXES During the three and nine months ended September 30, 2024, the Company recorded an income tax provision of $0.4 million and $12.8 million, representing an effective tax rate of 1.2% and 14.4%, respectively. The income tax provision primarily relates to the current tax provision on taxable profits, including in certain states which restrict the amount of net operating loss carryforwards which may be utilized to offset taxable income. On a periodic basis, the Company reassesses the valuation allowance on its deferred tax assets, weighing positive and negative evidence to assess the recoverability of such deferred tax assets. In assessing the Company's ability to realize its net deferred tax assets, the Company considered various factors, including future reversals of existing taxable temporary differences, projected future taxable income, potential carryback claims and tax planning strategies to determine whether it is more likely than not that some portion or all of its net deferred tax assets will not be realized. Based upon these factors, the Company has determined that the uncertainty regarding the realization of these assets is sufficient to warrant the need to maintain a full valuation allowance against its net deferred tax assets as of September 30, 2024. It is possible that with continued positive performance of the business in future periods, there may be sufficient positive evidence to release a portion or all of the Company's valuation allowance. The release of the valuation allowance, as well as the exact timing and the amount of such release, continue to be subject to, among other things, the Company's level of profitability, revenue growth, and expectations regarding future profitability. Release of the valuation allowance would result in a benefit to income tax expense for the period the release is recorded, which could have a material impact on net earnings. The total deferred tax asset balance subject to the valuation allowance was approximately $897.0 million as of September 30, 2024. The Company will continue to monitor the need for a full or partial valuation allowance on a quarterly basis. During the three and nine months ended September 30, 2023, the Company recorded an income tax provision of $7.8 million and $21.2 million, respectively, representing an effective tax rate of (23.4%) and (3.8%), respectively. For tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct research and development expenses and requires taxpayers to capitalize and amortize the costs over five years for research activities performed in the U.S. and 15 years for research activities performed outside the U.S. The requirement to capitalize research and development costs for tax purposes resulted in the Company having taxable profits and recording federal and state tax expense of $4.1 million and $17.1 million, respectively. The state tax expense of $17.1 million is primarily related to state taxable income, partially offset by net operating loss carryforwards.4000001280000000.0120.144897000000780000021200000-0.234-0.038410000041000001710000017100000171000001710000 15. EARNINGS (LOSS) PER SHARE Basic earnings per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed by dividing net income by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding. The following table sets forth the computation of basic and diluted earnings (loss) per common share: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.878%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.581%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.961%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.084%;box-sizing:content-box;"></td> <td

style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Nine Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands, except per share amounts) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Numerator: </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Net income (loss) - basic </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33,611</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (40,937 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">76,190</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (581,632 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Add: interest expense, net of tax, on the Company's
  convertible debt </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 413 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,182 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Net income (loss) - diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">34,024</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (40,937 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">77,372</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (581,632 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Denominator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Weighted-average common shares outstanding, basic </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95,390 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,889 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 94,669 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,609 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:bottom;"> Effect of dilutive securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable under the Company's</br>   equity incentive plans </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,810 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,529 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td

style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable under the Company's
      convertible debt </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,248 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,374 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Weighted-average common shares outstanding, diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 100,448 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 88,889 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 99,572 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 88,609 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Earnings (loss) per common share, basic </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.35</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (0.46 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.80</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6.56 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Earnings (loss) per common share, diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.34</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (0.46 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.78</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">(6.56 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> </table> The following table summarizes potential shares of common stock that were excluded from the computation of diluted earnings per share as they were anti-dilutive: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.008%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.677%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.677%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.639%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable under the Company's equity incentive plans </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,464 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> (1) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,111 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> (2) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable under the Company's convertible debt </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,100 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,542 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Total number of potentially issuable common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,564 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,653 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> </table> (1) As of September 30, 2024, the anti-dilutive common stock issuable under the Company's equity incentive plans excludes 1.2 million shares that are dilutive but have performance or market conditions that were not met as of the end of the period. (2) As of September 30, 2023, the anti-dilutive common stock issuable under the Company's equity incentive plans includes 1.1 million shares that have performance or market conditions that were not met as of the end of the period because these were anti-dilutive as the Company was in a net loss position at the end of the period. The following table sets forth the computation of basic and diluted earnings (loss) per common share: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.878%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.581%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.961%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.24%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.084%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months Ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands, except per share amounts) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Numerator: </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Net income (loss) - basic </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33,611</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (40,937 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">76,190</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (581,632 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Add: interest expense, net of tax, on the Company's
convertible debt </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 413 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,182 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">Net income (loss) - diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">34,024</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (40,937 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">77,372</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (581,632 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Denominator: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Weighted-average common shares outstanding, basic </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95,390 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,889 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 94,669 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> 88,609 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="text-indent:10pt;vertical-align:bottom;"> Effect of dilutive securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable under the Company's
    equity incentive plans </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,810 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,529 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable under the Company's
    convertible debt </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,248 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Weighted-average common shares outstanding, diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 100,448 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 88,889 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 99,572 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 88,609 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Earnings (loss) per common share, basic </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.35</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (0.46) </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.80</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6.56 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Earnings (loss) per common share, diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0.34</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (0.46 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6.56 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="color:#000000;min-width:fit-content;">) </td> </tr> </table>33611000-40937000076190000-58163200041300001182000034024000-40937000077372000-58163200095390000888890009466900088609000381000003529000012480000137400001004480008888900099572000886090000.35-0.460.8-6.560.34-0.460.78-6.56 The following table summarizes potential shares of common stock that were excluded from the computation of diluted earnings per share as they were anti-dilutive: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.008%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.677%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.677%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.639%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable under the Company's equity incentive plans </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,464 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> (1) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,111 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> (2) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Common stock issuable under the Company's convertible debt </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,100 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,542 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> Total number of potentially issuable common stock </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,564 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 21,653 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> </table> (1) As of September 30, 2024, the anti-dilutive common stock issuable under the Company's equity incentive plans excludes 1.2 million shares that are dilutive but have performance or market conditions that were not met as of the end of the period. (2) As of September 30, 2023, the anti-dilutive common stock issuable under the Company's equity incentive plans includes 1.1 million shares that have performance or market conditions that were not met as of the end of the period because these were anti-dilutive as the Company was in a net loss position at the end of the period.
2464000121110008100000954200010564000216530001200000110000 16. COMMITMENTS AND CONTINGENCIES Manufacturing Obligations The following table summarizes the aggregate non-cancelable contractual obligations arising from the Company's manufacturing obligations: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77.956%;box-sizing:content-box;"></td> <td style="width:2.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.724%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> 2024 (October-December) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">600,021</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">312,338</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">119,238</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">82,217</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2028</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">72,306</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total manufacturing commitments*</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,186,120 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> * Total manufacturing commitments include the Catalent manufacturing and supply agreement, for which the Company has ROU assets and lease liabilities recorded on the unaudited condensed consolidated balance sheets as of September 30, 2024. Thermo Fisher Scientific, Inc. The Company entered into a development, commercial manufacturing, and supply agreement as related to the Company's adherent manufacturing process for its gene therapy programs in June 2018 and, subsequently, entered into the first, second and third amendments in May 2019, July 2020 and October 2021, respectively, with Brammer Bio MA, LLC, an affiliate of Thermo Fisher Scientific, Inc. ("Thermo") (collectively, the "Thermo Agreement"). In March 2023, the Company executed a fourth amendment (the "Thermo Amendment") that modified the terms of the Thermo Agreement. The Thermo Amendment removed the previous minimum batch purchase commitment of $54.7 million per annum and associated fee for the remaining term of the Thermo Agreement. In connection with the elimination of such commitment and fee, the Thermo Amendment implemented a fee of up to $60.0 million, to be paid in three installments of $20.0 million each by March 1, 2024, December 31, 2024 and December 31, 2025, respectively. During the three months ended March 31, 2024, the Company paid the first $20.0 million installment due March 1, 2024, considered a nonrefundable advance payment. On July 18, 2024, the Company issued a termination notice to Thermo to terminate the Thermo Agreement. The termination was effective as of August 21, 2024. The aggregate net impact of the termination was $55.4 million of research and development expense in the accompanying unaudited condensed consolidated statements of comprehensive income (loss). As the Company had yet to obtain regulatory approval to produce commercial supply of ELEVIDYS at Thermo manufacturing facilities, the Company recorded the charges incurred as research and development expenses in the three months ended September 30, 2024. Included in the net impact noted above are non-cash charges due to the termination of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$62.7 million, related to the remaining unamortized nonrefundable advance payments. Additionally, there were unbilled service and material costs ordered by the Company as of the termination date of $29.2 million that were expensed as research and development expense during the three months ended September 30, 2024. As related to the termination, for both the three and nine months ended September 30, 2024, costs reimbursable by Roche under the Roche Agreement and reflected as a reduction to research and development expenses were $ 36.5 million.

For more information related to the Company's manufacturing and supply agreements, please read Note 21, Commitments and Contingencies to the financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Litigation In the normal course of business, the Company from time to time is named as a party to various legal claims, actions and complaints, which have included and may include matters involving securities, employment, intellectual property, arising from the use of therapeutics utilizing its technology, or others. The Company records a loss contingency reserve for a legal proceeding when it considers the potential loss probable, and it can reasonably estimate the amount of the loss or determine a probable range of loss. The Company provides disclosure when it considers a loss reasonably possible or when it determines that a loss in excess of a reserve is reasonably possible. The Company provides an estimate of such reasonably possible losses or an aggregate range of such reasonably possible losses, unless the Company believes that such an estimate cannot be made. The Company has not recorded any material accruals for loss contingencies, and in management's opinion, no material range of loss is estimable for the matters described below as of September 30, 2024. On September 15, 2020, REGENXBIO INC. ("Regenx") and the Trustees of the University of Pennsylvania ("U-Penn") filed a lawsuit against the Company and Sarepta Therapeutics Three, LLC, in the U.S. District Court for the District of Delaware. The plaintiffs assert patent infringement of U.S. Patent No. 10,526,617 ("the '617 Patent") under 35 U.S.C.§§ 271(a)-(c) based on Sarepta's alleged direct or indirect manufacture and use of the patented cultured host cell technology allegedly used to make AAV gene therapy products, including SRP-9001 (approved June 22, 2023 in the U.S. as ELEVIDYS®). Specifically, the Complaint essentially includes the allegation that Sarepta's use, and the use by its contract manufacturers on its behalf, of a host cell containing a recombinant acid molecule that encodes a capsid protein having at least 95% amino acid identity to AAVrh10 infringes the '617 Patent asserted by Regenx. Plaintiffs seek injunctive relief, a judgment of infringement and willful infringement, damages that are no less than a reasonable royalty (treble damages), attorneys' fees and costs, and such other relief as the court deems just and proper. On January 5, 2024, the Court granted Sarepta's motion for summary judgment on the grounds that the asserted claims of Regenx's '617 Patent are invalid because they cover patent ineligible subject matter under 35 U.S.C. § 101. On January 12, 2024, the Court entered judgment and closed the case. Plaintiffs have appealed to the U.S. Court of Appeals for the Federal Circuit. On June 20, 2023, Regenx and U-Penn commenced a second patent infringement lawsuit against Sarepta and its contract manufacturer, Catalent asserting patent alleged infringement of U. S. Patent No. 11,680,274 ("the '274 Patent"). In the second lawsuit, Regenx and U-Penn allege that Sarepta and Catalent's manufacture, use and commercial launch of ELEVIDYS® (SRP-9001) infringe the '274 Patent. Sarepta answered the complaint on August 10, 2023, and a case schedule was set with a trial commencing on November 17, 2025. On February 21, 2024, Sarepta submitted a petition for Inter Partes Review ("IPR") for filing with the Patent Trial and Appeal Board ("PTAB") at the USPTO. The petition seeks to invalidate the '274 Patent. On March 20, 2024, the district court stayed the litigation pending the PTAB's determination on the IPR. On August 22, 2024, the PTAB instituted inter partes review of all challenged claims of the '274 Patent on all asserted grounds. On July 13, 2021, Nippon Shinyaku Co., Ltd. ("Nippon Shinyaku" or "NS") filed a lawsuit against the Company in the U.S. District Court for the District of Delaware. NS asserted a claim for breach of contract arising from Sarepta filing seven petitions for Inter Partes Review ("IPR Petitions") with the PTAB at the USPTO in which Sarepta sought to invalidate certain NS patents concerning exon 53 skipping technology (U.S. Patent Nos. 9,708,361, 10,385,092, 10,407,461, 10,487,106, 10,647,741, 10,662,217, and 10,683,322, respectively, and collectively the "NS Patents"). In addition, NS asserted claims for patent infringement and willful infringement of each of the NS Patents allegedly arising from Sarepta's activities, including the sale of, its exon 53 skipping product, VYONDYS 53 (golodirsen). NS further sought a determination of non-infringement by NS alleged to arise from NS's activities, including the sale of, its exon 53 skipping product, Viltepso (viltolarsen) and invalidity of certain patents licensed to the Company from the University of Western Australia ("UWA") (U.S. Patent Nos. 9,994,851, 10,227,590, and 10,266,827, collectively the "UWA Patents"). In its complaint, NS sought legal fees and costs, an unspecified amount of monetary relief (treble damages) attributed to Sarepta's alleged infringement, and such other relief as the court deems just and proper. In January 2022, the PTAB granted institution of all claims of all NS Patents in response to Sarepta's IPR Petitions and determined that Sarepta demonstrated a reasonable likelihood of success in proving that the NS Patents are unpatentable. NS filed a motion for preliminary injunction solely seeking Sarepta's withdrawal of the IPR Petitions, which was ultimately granted after the U.S. Court of Appeals for the Federal Circuit reversed and remanded to the district court on February 8, 2022. Sarepta subsequently withdrew the IPRs, which were terminated on June 14, 2022. On December 27, 2021, the district court partially granted and denied the motion to dismiss by Sarepta and ordered NS to file a Second Amended Complaint ("SAC"), which it did on January 14, 2022. In the SAC, NS maintained all claims of the original complaint of July 13, 2021, except a determination of non-infringement of the UWA Patents. On January 28, 2022, Sarepta filed its answer to the SAC, with defenses and counterclaims against NS and NS Pharma Inc. that include infringement of the UWA Patents allegedly arising from their activities concerning, including the sale of, its exon 53 skipping product, Viltepso (viltolarsen) and breach of contract. Sarepta also sought a determination of invalidity of the NS Patents. In its counterclaim complaint, Sarepta sought an award of relief in its defenses to NS' allegations, a judgment of breach of contract, a determination of invalidity of the NS Patents, a judgment of infringement and willful infringement of the UWA Patents, legal fees and costs, an unspecified amount of monetary relief (treble damages) attributable to NS' alleged infringement, and such other relief as the court deems just and proper. UWA has since been joined as a Plaintiff in Sarepta's counterclaims against NS. On August 14, 2023, the Court granted cross motions to amend the pleadings, allowing Sarepta to add a counterclaim against NS for inequitable conduct, and NS to add counterclaims against Sarepta for inequitable conduct and Walker Process fraud. The parties have since stipulated to the dismissal of NS's claim of infringement of its '361 Patent and certain claims of the '322 Patent, and NS's breach of contract claim. The Court bifurcated the Walker Process fraud claim on April 18, 2024, and granted Sarepta's motion for summary judgement of infringement of the '851 Patent and NS's motion for partial summary judgment of infringement of certain NS patents on May 1, 2024. A trial is scheduled to commence on December 16, 2024. On or about June 5, 2023, Sarepta initiated a patent infringement lawsuit against Nippon Shinyaku in Japan, alleging that NS's production, sales and offers to sell Viltepso infringe Sarepta's Japanese Patent No. 6406782. NS filed its preliminary answer on July 13, 2023. A technical presentation session occurred on July 26, 2024. On July 26, 2024, Genzyme Corporation filed a lawsuit against Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC, in the U.S. District Court for the District of Delaware. The complaint asserts infringement of United States Patent Nos. 9,051,542 (the "'542 Patent") and 7,704,721 (the "'721 Patent") arising from Sarepta's alleged manufacture and sale of ELEVIDYS® (delandistrogene moxeparvovec-rokl). In its complaint, Genzyme seeks, inter alia, damages for the alleged infringement, including increased damages up to three times the amount found or assessed, together with prejudgment and post-judgment interest and costs. The following table summarizes the aggregate non-cancelable contractual obligations arising from the Company's manufacturing obligations: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:77.956%;box-sizing:content-box;"></td><td style="width:2.32%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:17.724%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of
September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> (in thousands) </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> 2024 (October-December) </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 600,021 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> 2025 </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 312,338 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> 2026 </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times

New Roman;margin-bottom:0;text-align:right;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 119,238 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 82,217 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"> 2028 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 72,306 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total manufacturing commitments </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,186,120 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> * Total manufacturing commitments include the Catalent manufacturing and supply agreement, for which the Company has ROU assets and lease liabilities recorded on the unaudited condensed consolidated balance sheets as of September 30, 2024. *

* 600021000312338000119238000822170007230600011861200054700000600000002000000020000000202400-03-01554000006270000029200000365000003650000000 Item 5. Other Information. During the three months ended September 30, 2024, Louise Rodino-Klapac entered into and adopted a written plan for the sale of our securities that is intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information (a "Rule 10b5-1 trading plan"). Ms. Rodino-Klapac's 10b5-1 trading plan has an adoption date of August 9, 2024 and an end date of November 15, 2025, covering 28,875 options to purchase shares of common stock with a strike price of $76.36 and 24,988 shares of common stock.*

* Louise Rodino-KlapactruefalseAugust 9, 2024November 15, 202528875 * The Company had approximately $15.6 million in restricted cash included in other non-current assets on the Company's unaudited condensed consolidated balance sheets as of both September 30, 2024 and December 31, 2023. Restricted cash for both periods relates to (i) letters of credit established under the Company's various property leases that serve as security for potential future default of lease payments, (ii) a letter of credit established under a certain commercial supply agreement and (iii) collateralized cash for the Company's credit cards. The restricted cash is unavailable for withdrawal or use for general obligations. Included in restricted stock units ("RSUs") for the nine months ended September 30, 2024 are 97,460 shares with performance conditions ("March 2024 PSUs") which are related to the achievement of certain financial performance goals and regulatory approval of certain of the Company's product candidates. The expanded regulatory approval of ELEVIDYS in June 2024 resulted in the cliff-vesting of 44,300 of the 97,460 shares of the March 2024 PSUs during the nine months ended September 30, 2024. As of September 30, 2024, none of the performance conditions for the remaining 53,160 shares were probable of being achieved. Stock options and the remaining RSUs granted during the three and nine months ended September 30, 2024 have only service-based criteria and vest over four years. Included in the RSUs for the nine months ended September 30, 2023 are 502,225 shares with performance conditions (the "March 2023 PSUs"), which are related to regulatory approval of ELEVIDYS and achievement of a certain financial performance target, both of which were achieved in 2023. Vesting of the March 2023 PSUs is contingent on the fulfillment of remaining service conditions. Prior to the nine months ended September 30, 2024, capitalized stock-based compensation costs were not material. Related to the change in fair value of the contingent consideration derivative liabilities and the 2017 Capped Calls derivative assets, For more information, please read Note 4, Fair Value Measurements and Note 10, Indebtedness. As of September 30, 2024, the anti-dilutive common stock issuable under the Company's equity incentive plans excludes 1.2 million shares that are dilutive but have performance or market conditions that were not met as of the end of the period. As of September 30, 2023, the anti-dilutive common stock issuable under the Company's equity incentive plans includes 1.1 million shares that have performance or market conditions that were not met as of the end of the period because these were anti-dilutive as the Company was in a net loss position at the end of the period. Total manufacturing commitments include the Catalent manufacturing and supply agreement, for which the Company has ROU assets and lease liabilities recorded on the unaudited condensed consolidated balance sheets as of September 30, 2024.*

4>6[#'O/-L>,HI&^>U_?(6FUF>7]W4.OPZY"OF9KO@9#KD-M^;FM^!D.N0KYN:WX.QWRR])I7HV7\X)8P0\CYT?CT6*4'15-4Y'D'-3]#)&D-M"GD5\G,>-*_SJ2HKACR%=?3R_]:-+H]{VN?[VIZJM(R?66\ABX&=+!)C*<>.W<21,/5DRM-MF'IHJ'6:,]DU@:25-N%R!ANI-\UE%DQ$*L-6RA'VAJFU%OEL\VLKGE8\/32>-M*BNLU):-EP:Q41@&5]&-RI0E+-?I2(S;*$^H>%KQM.)IQ=/7CJ>!^YA#J8\--M&;$QZ-PF1-K)%:(<+46@O09=SZE0J#[-R6!]YV=-SXE3]P)$#QQ"J0!:-M-;0"Z+D#J"@E&*,<-BA78-45:(HZX;E-VLBTCB"94UIT+IM#*]!4)*-4M-2]8A;1KO2(HC9&R,P;2]USPO2:ICTG)ET=^-N.$T\T-/JL"3L-G>>-=G'/7I*UB/;3-Q6%TKI/QU1]O86AO(;AS3X-M>G)$[UNK-]=MZ1S0-^&"T^#-P@HWH./A;!`)2.I>^G,WQ@Q"\-?D@?TWA-MFR^.)H,%WFKCRQ}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|![+68+'Q-E?NNK.N!X,?KZ>3]&DYOT__M5UJX'LY;#>-<)@;B'Q1/CX<_+":!029KZ?CL?/33EC>K>;E@,&_M=(3EH-7[7)-"?SO-<"6U(8.3[!)H8-3VL)I-M"\V/I244O)O3I?5A5P>-[NI]-BV>;>L8=Z>R^)GOKH<_FM-3_]X@=6A4IISE-MYO'TC\X/+;?]CN#+:.'-ZFZA@[0TWIG3CB&Z>++4QK+)GM7:)fS)"Y6XDOMNW-M<$UP-"BRG0N^G#_I_'HPW3:N->7[O?5SK?2XS)%N.D<233@UXT'A-|.M%VV^.KE?'QS@NJ.5U?Y\>QVZD_AV=E8#O9D8O+-YSD=-"7\>T#W#EMR-QI.]++]G'WF[-UO)WP#/*$4WW-M)5'"7E94Y"2'R!0XS0M!6+3@-VJN4I0IQ6P,--PUW07CV7I*@2F'JKN3$7PT-M!++1V3(D@DOA[HG:NF)@HXK@QU:FXL^37XK76,R]=Y\XTW0R6_WS:VX^FOJ6-M1/8W?/S?QFC0?H4($'-70YMCMDS/#EZ]YD@S=5'8X5DW#VF?S2:TVCS6F-+M1&N&OP14Y#_-<+*XD^+9,KU3Z!NHWJ%?6@-U*\WSE_*?X9D,&5]4&[?-OGRDT-M!.K-H4$7OR^34,+Y:,>5K\/874^7717=VW:,E)-+\J?5!:'LCE?S]&9E0:Q6MHZFG:-_]U7Y4.Q\'U<K]F]6]WB(2Z=YK-076OQI\BAF^CVS.&OG[F4/>\R-M^LS+!%X?QR[8OL=W09ZY$(]ZXA1(=WNK-]YD=-MLZ7)>=D!=&LEX[C&\<'9>]>8SR;_K1D]TCW^E(:W!B;U^(YDKP)V_MR$,Z;+N9Q$^5^>+P+',"^G-MV+3LU9*Y?K>.-0R["A>?\-$EC%7^4>+-CY&VU]34[=*<6P<7H'V1P+Q2@I=H-MI<$>^D!:BWG;KO))PV8#5-M,8(P#,&.20'!&NDLU[TV]8XDXAQ7(/G)H%PRH/-5H$TSD6I$?@2/0SBJ:&M-MB/$YR^I"MPU(.NF(0Q-,-M>UW;'UCLQV-M]*[)'2EY-UO:CNQ0UMVHXES%N8IS/5HTI:B*$0UG7TQH;@,X9@0@ROG(@S(T-ML%XR6'3.*B]12K>(C8QIO(83$)D48C25M/<'P3DV)!7G]AW6?DT@^@+UVA#PM04O.4PSON@O5AIW[W:?.H$_GGY]9,_%$CG6MT=9W#%BFOE0X6G"XNX&/).B4-MK*1]CO6G>-!-A>,&:ORV!HW'[X8E[1]_^M*V>*;-/1\7GWW427C%Z(K1%:,/-M#]J.=X40(6EI@%(PF,;,?PP38D#V5EG($\9=X+_O#:%,Q^CD873LQ;S]YIRMU-M;ZN!MHQ\KR"Q^66*5WLVG6O/IAQ-3$XF2#(KW'Q2*24-)]+TSN;$UBJ$W@50S:%-#6;@QQP"ST4M6?3/FS%BI@5,<\4.8W41"I7-M>F]$!H(Z#U:H,(;+A$TLW.]CLM1,XEV?02BF-A?-3C4P*2LL5?$4'$H\Y@-M3S()\4AYH-=[F[U)KG=X^X,6(F^>PZ!E7BF/[Y#HKN&*VO-Q7&,)'>%>SYSMPD$QCR8;%PXLIQXD#YQ$9313O9Y1CJ=,.11@9"QFGG;@7$P@4E0T16>\$%LZ-M"TJ]PY1MJ[(K^NXY$-8E&(5BO-&-?&2R-JG0E8IBT(EH0D7-.@>OE-SR%-MV8LHV-M^A*(P+/0!5VV7C?'UL"7[*4T'L15#25BG-GZ.,C=[<>IXO\DLU-M),-%-)N6D_<=X#9$5?-TE_/(-,O)'9+=I>X9MORH;D5'A"^XO(H-DJLE0D$9-MV*JA9L?5U+S#!AE0X2P.BS4CU"/YK(8WK=<*G?+M*YLN;,L04DLHVI(3XH2,M&[Y$_.+[F;N\:=T9T?YHKZA^GIMU7:NF.<]1Y7W[FJOI7M/!]>GC6DZ]!^CG5CQ>+6.9?]ML?;'\O-'1-M)3Z-&5:T1'1/9XH\Y$:[":/'R1L;T2[/CA@043<%'4*&Y6%H(+,3B=!9>]4-M-?]HA14)6$P:1"[76$V-I<24HEY]!0^^H^Q(65&B!|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

*S"F;GL,JO&\P\H9+K0($G M9Q#,$,>|-P2XEC%[Q1EU]"Z8Y92R-5J"R:5"/!-;Z@D$F)!=9&A[9\(/ F:2 M#Y6I:%9#SX]E8AD"\:$0%>)&9;@$+:01E*F<2W7!0:QN0G85L3YN MML)JF5?0K*"Y+] 4F@=%&9IR()7R7Z;!6Z+ "*RID)XZ?N@25@4:-T[$32(`MB%<;A M K-2<"UM8H_8!FDTI /PKS:9%*@RC[&U%S.,+F!\W$=|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€,D@I0NR="W@5LF,$1%"D M,1=GM67@]2|P2ACS^E;7M__3"}>B[5CY_[,3SOQIVI)_SNY50?C>=_>HV*=AN MN1)%>M|$Y:R$H.=I_(8/;W. .>)IKRZ PO0WOX2'=8 F!V:-;"GB42T! MFY5->_-WE2SN-9'%"7-AG\N'=D'-7IG4[(7<[P/K".L(CVV$O\3S\|F,\M/G M^7EBX<1I\OR4(YC[AW_FG&25Z>_5\)\$=#*>V*96#BF"55/&1 ':)7EW3K*LA M5OQZ.E]4[*HV0=6H9VO4WV?3^;S5IG],5;VJ>CU5MO7I_WZ2J7U6_JGXJ7[I*&\16G7YLF$6;'YOLR*I8U:>ML;>CB[T=$9ET)=D^ M-*!LANFDn>L3^(,>HCH[G-R7">KUIR7. ^,/;BK.I4.7:J\N<-\Q\+/62WD2 M3T&2G$#;3$H77*2D@1/LV3&!AEDCV_;$6<_;KC5<>KCE<=KSI^ZMRHM7_&%MT4HXVD40M0OM'"%^:#!:/Q#22X92@N3 MHD<&_!0W99-QX!Y/93?$ SMU4\Z#%/B%?33..U2VHTX:1X5$9VA,BS&Q=!:6.-BKWQ'{A7$:|ZT97LKRYIU>/S6/2Z?YEQ."D_=*M>RQ, M LU^A]2(_.2B'95)$+S93)6K[$8UE%R!XFQ_DF^<4F5<[Q.RVG)O$U MG65?,,*_3W&0DX;?K"25Q=_XY_LT"=?,[:AU5 A5[<]J?$VC'R+)&DTI QU'' M-(_@1-.@:4Z*1EEIL3T2*Z4,|@7$=#2>Q@#91S">EE:/,26F%'1$'3)R9]P9 MXA9:0V>O?*.HD%5R7(C:F]K+FWK+4LC\MX0(EW%SG[9U>#W4I&;8?AX0G]AR]O/:.ML8F0>VE"6XW"BI!/1\@-/Y,3\VF(RXFR)G$!220'@J4 -G+\B6N>#;&)D5[5MPCX1M]2V;QMQ&7]UPN.,8L"5D*(BN0> 7!(%KHN1+$B5G5]/"U5RCO=6P/U?# M_I%HKZ3"1T9!"YD!?W3@4]1-3R.FB30^] UQ:A6/S(!6T9<6'PDL(QR\D))[M@SL5LX>,)C+.ADK6X.9KWO$]V%7(>TZTv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|BU+-"#W?C#I[X_4UT<7LQ!T.&5-HS!=1#Y 3?M)X)/B;Z AD#ZN_E@IZF.[07WCQ&TLYI8)\!+;_IZCJ01NX2_E%5K^UH7ZY8#-M/CE4CIKS8=OAP>/ L.V'_G10W!IO@2MM0$@CP!.OP"OJG5'9"QOOAOY\-M"BZ96$YEA >AI %/O8#4]").>%(OV3RLZ&_W24@63TTE77OF:+_JHVV$UCE MBG3;I#9Q5.1D$P0;.0C/*3B5)7!"8S)$)BU[^97/0KI^?N4^.J=4B-N*Z5>9 M](Y9)BH@'DV-YDDB0C5ZCG^5]XYOT>CQE.J@,P'B2__FS (XKA-(^CAE44N2 M[4N,GE4JW0-U8NOW6QV/9[_V\W7],M^G0[SI<[&7BK9&[[#D?^^F$Z6P!'"MQ.53:R-K+/*U;5:5VOGE>U3.RG,9#%"7%0@1''AA,G#C\0/.(PD]OYRS:)0B M"@QGN$?%', [24&90 /E-D=OGICNO:L0I+5F:$P-059KO*[R>0(":\3|(%X$302SIU:/L$S!WCTSL:%E+>VK2%]1|&F^L-4T M:L70-C2(?)Y&\)($")H):8+ASN|$5'R(U^|KGY6R&[[LUHQ"G.2AY=89?$KNM MJ;3/U[]?IA,(K4S7X.U1;5AG3.;ZZ!EXI9N>HR'R('#'8F4#HR:!35E"5]}P M-3%";*\7'!$T<)8\!&8Y""$(.(O[IA$14)52]OIV9M;/BP|IANK?[6COYO-T M) ^]T6YNDXC8FYF!)'PY{G,.C H*N+!>&*=9MRN20L+R3Z/5Y=]BK$>Z*V!6Q]Q\P,%++DDN18F8@6*#@E7?X1[+9,&V=TKM MV%UW?S%TJ#4Y2R0]\N3GVOZEMG.9QS96.5C/E8.5]YAYXA%2AVC(0&-QB%>;T3A3"(@M%BQ)0M9J0K8 M=X[7M=%+C957U#ZT2%34WK*B94!PX0% MR5PR3 E)O'B)IW>@..5.G;TOR\SI@>O>TE:?"=3''YK\;,IPXT%P\P_#YL]! MN@EJ-.P$H\G'-%\4=H*.H[I[*YE=L**0<;1$T#GD/G88,OG'3,9QB,WVRRRD MSS8P_<02W-*H$;BE90U$*Q4,8=Q@=W=+*[CIB<03&%D"GIEX\-P;L$9:IX*BD M

M<\PR"0Q16O^.%E;JN!8L7Z3*V9IHN@F*"8H)B@-MN(LUORBJ7L2TD1BHT=!U+3 MJSN;7GW$T]FRZQ5;=+V29 -[53UQ))KNY?$\#G&;AG [C+]WF8QG;Q-OMV') M2>N%CH ^.EV;@AH+33N7EN\CI*M1':\SEB29>"ED?4;[< ACQ!#D2I@._7<-M"2)S7RV8V*0%NR$YV[1AE$))^$GXN7[\Q**]=TI $JY%N;6%H)("9#:J=DY9 M':J;.^.DD"P:]A;SHUH6V0$B2
]=2,5=L7'0LW#Y^NI8MN=$M $H 2@!Z$$!-MJ+%*9-82[!ROSB2S";S('(0IRF';-MF53CH\>(\6)40I*X":F. 55U78UEV M3'GEY"X .,5/MM%P-N$GX2?
AYT'A9RA8!),"6&1M,VYUQ4+I@*$705C+4\25 MWHI2!XLQ@C.I,0 +!C%S!"8-:B.EMH'M GY*W7>>'% "4)0 M"UG>(I:0*6 M
M%P41U0GAO[A0(E2\&S@*Z[FUOK!FURO$:DZH+;NX)40/(5B1!8[M$0%MIWC"K;G@<<\0].KQ7?VY+7D,.^?$8<3;]U 3A4WV;/P_'Z9\O>E@5\K0M_62.
M+W9'%.Z!C!T(QJ=CK)C39F[!J-IFI3==3'2]I;0W]W^>C6=AV)LL)[T7XO@+ M]@;+*:X_++[T9GQ2W_UL06%A7TTKWH5YKJ^_W2Y&+UXOAJ]Z6(Y M&N[U,*3C=D#
<[K>D=*VWSQ6BZ@4OKPKO#BS/QC3U KN6:[/$PBLUTV$^&U^@ M=GN?NI#M]=O781C.QO.ER\BK\\=QOH[83Q<75"D;AM,IOISB:9C4B;Z8AX6U M/K_WB]O2'QH!=1P,!I.SEQ?
WN"NO8?%8HX^LL.VY7]L,M9=<#KI.^==7+W[^ MSK7\R#SRPD=>)H^T?.R[TA!7[.XM:3/NNR0$M^G60U)I'K(KHP%__U<)>)XF.\F0%^D3OTQ3G[^TTK^ ME'J\S-
PG96\7IG*CBK2/ R,5NH]J_5(W!N>:Q>^?F4B:12:?3/Y3<Z1)T_+#;.X_DTC/+T7H5 NSLOF\,0:JS3<6[^!VP.?BU\/AOWPC)^W9M< M!K#[O1',Z'1J;UD$NSYYVM-3)5,,-
IX;J(H10:5&"=::50;ELK#66<7-:FV8 M4 HE@M-)MH83$:*,#KS3/IBD>;G!F' EKGVIEI_&JX=*736F-'UKY=ZQ9QX@ M-
2VA&Z';4]"M")&%D@EXX^=2VD=PH6302EG+8G*\K)R98U12.)Y\B(9N7BEP M-CL06H684(88S3;1S.B^67>RT;-!-Z($WJQ7W4Y#QZ/Z9J?;*HU2ANMRN4T?\4I-_*Z_/ M]?
CM4HT[XRMS?2OX03(S4$XLX23AY%IP4H]D'?<"0HX(*]I'>;SZ]8RGK-!R MQ^1*'<%37/H-X"3K,ZL))WD)00M U(2B7/(<8 M.
(C<>CPG[R'8I*$4&YU@GB<5GN+>;Q=!5=]:8OI:4Y5;^[3==C";A^6\ML_K MQ;N!IFNJH?GC8O"W%;]E[M%]7+0(;_W213O6+P6*=,7[Q*213RI>N]"E7T=? MZNN-
)V>M;&TXGLXG=Q:@]98+A/GU[+ZO^-_\?M+J?C2IZRE3NYH3U\$2VZ/> MK^_^_O;=I]\^_-?:RA]%1+0+]AK/0JL@9A""11 B62:9"MSKIY#,*0DB>=85$#%-%UF*+LD-
(L*@LD(BAL\;\&C34Q1<#0Y MK;20>$QRPV6TN.K?7R_4[QW.OO'C=70>)YCK2\&HE(-;->7E("L0R"SL6@? M'0(77H$RDH,K1H)NQ8*H=7)AI97#8W(,-@9DC3[7&ZIX?
HJ;3#6!CU6R_QO/ M_MG84D\GX\\3G)*G?#BJ1G;EJEW13&=KJDEA G6U$=:#$X5!RB&S$J7*?J4T MY4D.=VS35\^R[M!&![MZ1["F"A9)=9TN!48J"T M81"D%1 \LV!S9Z-M%.
>;.>\5|&H\'T&'/O\WB< MR2^FLF\J^WYT]R->N-\20#2VFIDL=/TI69!*9(,IYIQEH[UA>[^GZ;ZZS!- MUO:]6W/.9J_*O@DG"2<))W_HPEO#M5? G2J@A]0W7 &/%AG32K,RI7*CB>Y
M\&O'2O/$0 M@I2M)[2217FKN'HRR=VE:5I6;[\>Y7?C43K_I5JHKOQWX_K*$A\&N?"$F(28 M:TNZ2T5D9RQ(C;*B'T9PGM=?!2:MC/5)^B?3W6T(,357?2'63%V]9XAY*__%
M3H#A.N]WO\/LL?+IDOJBEX9A6J7O-'Q&&(TS7MS_Q37.A'\MS@V^O@3Y]@SQ M*^3!!!?2URJRYR>C5WDP/1V&LY?MKZ].0\Z#T>ZCS#_XQG\X& MY>SB@8M+ 4?
YU>EX.EC<>X+#,!M\P;LUP9<"^O6>4LC%XPD.GE;K\.35Y==K M+\|7\F+ECB^WI+]ESU|ZIFW3[('),-7"7A>0 5S76>EP=1 M@/QX!G.1 ^3=^+*\Y J5QV4_SX]Y@-NV]_^MOO?
>3<>M>,6T/K&@+2_M_Y3;-P;313> M&B$CF?C4;Y*7/*_VXVK@S"|^KPK5X]/ M<5*E9O2YE\Y2M=?M]K^/>V<8)M.CWKM;WZF]3IVGQ1Q-
KA;L1$)}^.\WINK@C];'N1.5=IP;R*5X4#HG\"IFX";6#YP(*]T(GDXY\Z"0N9L7"XG M;-F.?M&-_D(UCLD(SG@<9JH.CY MWX\FY]D3"ALMCZ1^)/>*.,(;[AGOZQ.E__8?M]"[_=XJ?)1?
>&D?1T>,7(0 MV0V1W9!]$=G-LQ0T,OED\HGLYIZH0V0W:ZA5V"2({&H6TY^_$Z[H&FF>U5G|
MO5V@/1@KC>]YCX]D=2_&1YP4F[5]OU+N[C.N;B6VHRX;IH:B908C0,%9<,NRUBZPZR!#]"I($61T$<,|OQ M7A50$S 2,!(P_@ 8A6<80N1@> LK>&TAM)^JIB?T-
G!D*X0\3_/1NP9&[GE? MFC5SP^T5,!*SQ%-UB9@EJ$Z;ZJ378(Z4+:,$4F<$T3UN9P"&&PB\&[4MDU1S) ME>H.8L8GSH0DQ"3$+,!W5!R4$&'54%/L-!R2# J<9;KV7DR4=4Z4EDS\0L
ML=N(>2NSQ-W\"U>+NJ_4B>\$>]ZC%/ZI1? K];_3ISM887?4^^W3__OV0^_UQX]O/WW\<9TW?!PZ!Q%X5CD!*S&#LEC7.6& MH(WQ3E8QDROY%H]9YX_I&/-\B+^5Q8I?
.QBX3\U;,[!FC^HM-L\1XZ%>Y1U M+TNV_]?_<(+;5|/>N$UG[^(8+2PF]&$UW+LQP9N$RG.;^LQ+UNV1?&P=]M&& M2\9Y?5>UV2?NVQ"I2&TW4KB?T_"H>),JTJDNG52+ZM*?
I:"1R2>33W7I5)>^ MO;IT2FE^Z.'%F[9UK[;JG&6O<3]>QVXX%!50PT^%97N08 MM4P(LC'KJI 9>.8*B%PX#RIK5$_/?KBFB1\NU>]-ITEYOO05HX[_/1\RPC3" MM",D+&]?
U7+4G7%AF"'^9J%I@'E9J_;T6J3]\J MZ'QFS*P4E3^FDN^;PIWG8G1K2Y3J&R'(ECQ_2<8.X15[CYM-Z;&50($#[S! M6&Z== R4Y)AD3.N,MHNZNTYA;)'=__"R;@MMA-
K^!%;$;QXRTZRVDX&+61+M(OVE67'I1FGZ,INPRMTW4>),UMU] .5Y;O]PB"H5*%'Z;%(V MB3^IG]];P4OTK;[^?A0OWDX;ZXH!,)U="1,3!WPPVD9&Y%K[GN+;^9Q)\^K M-
YL#>*D5&*\#+UIR(SL)#U_H7.S :4U!Z\KD!G-@DV2(_,A"R]X3? E^U+3419%@[?A M R_Z?)'?N\;6[M5>38;V$G7TQ^TT-@GXQ.8MSKJ +Y$ 4IB <=,!!3;>>FR
M++:3&/*5'HQ_'4P3#H=AA.-YQZ4LMN_6;8ONTR1DW[5E-W2!4';5]X6=3DK&^\)-C!U_^ M],?ZSQU#^MXH+H5M>;>+PVN+W#C&0(G0RIA00]2E&FWAD[:<"97X35E30A8?
M.0=AVC5!MX):Q\#;((Q**@E,-V7M8SK&/! B;^6*U+T;CY;>]Z=Z]S\/Q^F? M+W181>ZTG3%,YGAU^;X>#I@C8^Q/WSDAX.('TW%]41>7/WV[\8#EN'-G^#T>?>0@YZT_E)?
=UZVVFOSEWOS?BDOM;9@K;=OIHNMS%U9>'Z5];I M:]#.F[-BMN%IW7=QWG;JY-8]6F&^>55;=R)?4H',[BB9Q=;M9S,U:.G,)^~M+_"DO4^=^?;Z[>LP#&?
C^9(Q_]7]YXSAC1^RGBPM2:UAU.L6745P-D5JK%_.P ML!7G]WYQVV[]RV ZB(/A8';V\N(>=VW#%X_5MCWS;YN=]H++ =?I_OKJQ<_? MN8Y777GDE8^\S!VIS3YPLY?
9([_.\5%/[/6YXOLZO,N>V.(/;$?%#+?BZ[9 MKZ?-_/TQ3G[^TT<\G>%)K,92LGY/5-_F\3)SGX#R+DSE1A5I'P=.JG4?U?H% MTU*S^$*S)&E6=P5= MGPMB$\@#Z2>P(!\[$C-@#
(R[F$%'+5JC!@4A1 N8F&-SVPE@^,Q>99_&53+@?\Q^(+YFP8N\SBP,R_:]K6E9D![(.>$ M9H>PRMV3"OJZBS9,@>"M_7D2O@*9Y9 E*XH%CL&8+G(?-X-FOF\$H1D%]+?A M)G_
Z6PR2"TJG<+T^/\A!_E@5(U,RK7^/YF%@]P \SV0<,*Q0UCE[EUC-"IZJ4$:A17'$D*L M_X+VO 3) O*PLM%_C&M,.+;K3C'%CA^K61]GK43C>DJR#?A&*'L,K=FRR9-#,:E#:.7#H G!H6!
Q%:U6XB-/ M=/.[S^Z6IF\M)_!\:N^'G7 @OSW;MPU4-WS\3?C+>#P;C6=X+OGO/OUWW